doi	section	n_itc	study_number	questions	answer
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Medical Condition of Interest Name	thyroid eye disease
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Countries of first author affiliations	usa
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Countries of last author affiliations	canada
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Private Data Analysis Company
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	primary_outcome_name	change from baseline in proptosis in mm
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	outcome_short_name	proptosis change
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Treatment name 1	teprotumumab
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Treatment name 2	intravenous methylprednisolone
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	paitc_type	MAIC
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	anchored_yn	No
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	prognostic_factors_yn	Yes
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	weights_model_yn	No
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	scale_choice_yn	No
10.1001/jamaophthalmol.2021.6284	results	1	NA	contrast	Means difference
10.1001/jamaophthalmol.2021.6284	results	1	NA	direction_benefit	inferior
10.1001/jamaophthalmol.2021.6284	results	1	NA	n_nonipd_ttt	419
10.1001/jamaophthalmol.2021.6284	results	1	NA	n_ipd_ttt	79
10.1001/jamaophthalmol.2021.6284	results	1	NA	ess_ttt	56
10.1001/jamaophthalmol.2021.6284	results	1	NA	weights_evaluation_yn	Not mentioned
10.1001/jamaophthalmol.2021.6284	results	1	NA	list_covariates_yn	Yes
10.1001/jamaophthalmol.2021.6284	results	1	NA	n_covariates	3
10.1001/jamaophthalmol.2021.6284	results	1	NA	list_covariates	Age, Sex, Other(s)
10.1001/jamaophthalmol.2021.6284	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1001/jamaophthalmol.2021.6284	results	1	NA	unadjusted_effect	-2.38
10.1001/jamaophthalmol.2021.6284	results	1	NA	unadjusted_pval_char	[-3.49;-1.27]
10.1001/jamaophthalmol.2021.6284	results	1	NA	adjusted_effect	-2.31
10.1001/jamaophthalmol.2021.6284	results	1	NA	adjusted_pval_char	[-3.45;-1.17]
10.1001/jamaophthalmol.2021.6284	results	1	NA	geographical region	No
10.1001/jamaophthalmol.2021.6284	results	1	NA	n_ipd_total	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	ess_total	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	n_nonipd_total	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	n_nonipd_anchor	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	n_ipd_anchor	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	ess_anchor	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	effect_cutoff	0
10.1001/jamaophthalmol.2021.6284	results	1	NA	unadjusted_lb_ci	-3.49
10.1001/jamaophthalmol.2021.6284	results	1	NA	unadjusted_ub_ci	-1.27
10.1001/jamaophthalmol.2021.6284	results	1	NA	unadjusted_significant	TRUE
10.1001/jamaophthalmol.2021.6284	results	1	NA	adjusted_lb_ci	-3.45
10.1001/jamaophthalmol.2021.6284	results	1	NA	adjusted_ub_ci	-1.17
10.1001/jamaophthalmol.2021.6284	results	1	NA	adjusted_significant	TRUE
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Patient-level data used	Yes
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Clinical Trial	Yes
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01868997
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Patient-level data used	Yes
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Clinical Trial	Yes
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03298867
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Patient-level data used	No
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Clinical Trial	No
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	meta-analysis of clinical trials from 12 articles
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1002/edm2.259	general_information	NA	NA	Medical Condition of Interest Name	type 2 diabetes
10.1002/edm2.259	general_information	NA	NA	Countries of first author affiliations	uk
10.1002/edm2.259	general_information	NA	NA	Countries of last author affiliations	denmark
10.1002/edm2.259	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1002/edm2.259	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1002/edm2.259	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1002/edm2.259	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1002/edm2.259	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1002/edm2.259	methodology	1	NA	primary_outcome_name	3 point mace (cardiovascular death, non-fatal myocardial infraction, non-fatal stroke)
10.1002/edm2.259	methodology	1	NA	outcome_short_name	3-point MACE
10.1002/edm2.259	methodology	1	NA	primary_outcome_type	Time-to-event
10.1002/edm2.259	methodology	1	NA	Treatment name 1	semaglutide 0.5  +  1 mg
10.1002/edm2.259	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1002/edm2.259	methodology	1	NA	Treatment name 2	dulaglutide 1.5 mg
10.1002/edm2.259	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1002/edm2.259	methodology	1	NA	paitc_type	MAIC
10.1002/edm2.259	methodology	1	NA	anchored_yn	Yes
10.1002/edm2.259	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1002/edm2.259	methodology	1	NA	primary_outcome_yn	Yes
10.1002/edm2.259	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1002/edm2.259	methodology	1	NA	prognostic_factors_yn	No
10.1002/edm2.259	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1002/edm2.259	methodology	1	NA	weights_model_yn	No
10.1002/edm2.259	methodology	1	NA	scale_choice_yn	No
10.1002/edm2.259	results	1	NA	contrast	HR
10.1002/edm2.259	results	1	NA	direction_benefit	inferior
10.1002/edm2.259	results	1	NA	n_nonipd_ttt	NA
10.1002/edm2.259	results	1	NA	n_ipd_ttt	NA
10.1002/edm2.259	results	1	NA	ess_ttt	NA
10.1002/edm2.259	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1002/edm2.259	results	1	NA	list_covariates_yn	Yes
10.1002/edm2.259	results	1	NA	n_covariates	6
10.1002/edm2.259	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1002/edm2.259	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1002/edm2.259	results	1	NA	unadjusted_effect	NA
10.1002/edm2.259	results	1	NA	unadjusted_pval_char	NA
10.1002/edm2.259	results	1	NA	adjusted_effect	0.74
10.1002/edm2.259	results	1	NA	adjusted_pval_char	0.06
10.1002/edm2.259	results	1	NA	geographical region	NA
10.1002/edm2.259	results	1	NA	n_ipd_total	3297
10.1002/edm2.259	results	1	NA	ess_total	2633
10.1002/edm2.259	results	1	NA	n_nonipd_total	9901
10.1002/edm2.259	results	1	NA	n_nonipd_anchor	NA
10.1002/edm2.259	results	1	NA	n_ipd_anchor	NA
10.1002/edm2.259	results	1	NA	ess_anchor	NA
10.1002/edm2.259	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1002/edm2.259	results	1	NA	effect_cutoff	1
10.1002/edm2.259	results	1	NA	adjusted_pval	0.06
10.1002/edm2.259	results	1	NA	adjusted_num_pval	0.06
10.1002/edm2.259	results	1	NA	adjusted_significant	FALSE
10.1002/edm2.259	study_information	NA	1	Patient-level data used	Yes
10.1002/edm2.259	study_information	NA	1	Clinical Trial	Yes
10.1002/edm2.259	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01720446
10.1002/edm2.259	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1002/edm2.259	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1002/edm2.259	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1002/edm2.259	study_information	NA	2	Patient-level data used	No
10.1002/edm2.259	study_information	NA	2	Clinical Trial	Yes
10.1002/edm2.259	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01394952
10.1002/edm2.259	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1002/edm2.259	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1002/edm2.259	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/bf03261873	general_information	NA	NA	Medical Condition of Interest Name	attention-deficit/hyperactivity disorder
10.1007/bf03261873	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/bf03261873	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/bf03261873	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1007/bf03261873	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/bf03261873	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/bf03261873	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/bf03261873	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/bf03261873	methodology	1	NA	primary_outcome_name	change in the adhd-rs-iv total score from baseline to end-point
10.1007/bf03261873	methodology	1	NA	outcome_short_name	ADHD-RS-IV score
10.1007/bf03261873	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1007/bf03261873	methodology	1	NA	Treatment name 1	guanfacine extended-release low dose
10.1007/bf03261873	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1007/bf03261873	methodology	1	NA	Treatment name 2	atomoxetine
10.1007/bf03261873	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.1007/bf03261873	methodology	1	NA	paitc_type	MAIC
10.1007/bf03261873	methodology	1	NA	anchored_yn	No
10.1007/bf03261873	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/bf03261873	methodology	1	NA	primary_outcome_yn	Yes
10.1007/bf03261873	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1007/bf03261873	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/bf03261873	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/bf03261873	methodology	1	NA	weights_model_yn	Yes
10.1007/bf03261873	methodology	1	NA	scale_choice_yn	No
10.1007/bf03261873	methodology	2	NA	primary_outcome_name	change in the adhd-rs-iv total score from baseline to end-point
10.1007/bf03261873	methodology	2	NA	outcome_short_name	ADHD-RS-IV score
10.1007/bf03261873	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1007/bf03261873	methodology	2	NA	Treatment name 1	guanfacine extended-release mid dose
10.1007/bf03261873	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.1007/bf03261873	methodology	2	NA	Treatment name 2	atomoxetine
10.1007/bf03261873	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1007/bf03261873	methodology	2	NA	paitc_type	MAIC
10.1007/bf03261873	methodology	2	NA	anchored_yn	No
10.1007/bf03261873	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/bf03261873	methodology	2	NA	primary_outcome_yn	Yes
10.1007/bf03261873	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.1007/bf03261873	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/bf03261873	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/bf03261873	methodology	2	NA	weights_model_yn	Yes
10.1007/bf03261873	methodology	2	NA	scale_choice_yn	No
10.1007/bf03261873	methodology	3	NA	primary_outcome_name	change in the adhd-rs-iv total score from baseline to end-point
10.1007/bf03261873	methodology	3	NA	outcome_short_name	ADHD-RS-IV score
10.1007/bf03261873	methodology	3	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1007/bf03261873	methodology	3	NA	Treatment name 1	guanfacine extended-release high dose
10.1007/bf03261873	methodology	3	NA	Study 'number(s)' for treatment 1	1;2
10.1007/bf03261873	methodology	3	NA	Treatment name 2	atomoxetine
10.1007/bf03261873	methodology	3	NA	Study 'number(s)' for treatment 2	3
10.1007/bf03261873	methodology	3	NA	paitc_type	MAIC
10.1007/bf03261873	methodology	3	NA	anchored_yn	No
10.1007/bf03261873	methodology	3	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/bf03261873	methodology	3	NA	primary_outcome_yn	Yes
10.1007/bf03261873	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.1007/bf03261873	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/bf03261873	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/bf03261873	methodology	3	NA	weights_model_yn	Yes
10.1007/bf03261873	methodology	3	NA	scale_choice_yn	No
10.1007/bf03261873	results	1	NA	contrast	Means difference
10.1007/bf03261873	results	1	NA	direction_benefit	inferior
10.1007/bf03261873	results	1	NA	n_nonipd_ttt	84
10.1007/bf03261873	results	1	NA	n_ipd_ttt	147
10.1007/bf03261873	results	1	NA	ess_ttt	49
10.1007/bf03261873	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/bf03261873	results	1	NA	list_covariates_yn	Yes
10.1007/bf03261873	results	1	NA	n_covariates	6
10.1007/bf03261873	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1007/bf03261873	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/bf03261873	results	1	NA	unadjusted_effect	NA
10.1007/bf03261873	results	1	NA	unadjusted_pval_char	NA
10.1007/bf03261873	results	1	NA	adjusted_effect	-3.7
10.1007/bf03261873	results	1	NA	adjusted_pval_char	0.07
10.1007/bf03261873	results	1	NA	geographical region	No
10.1007/bf03261873	results	1	NA	n_ipd_total	NA
10.1007/bf03261873	results	1	NA	ess_total	NA
10.1007/bf03261873	results	1	NA	n_nonipd_total	NA
10.1007/bf03261873	results	1	NA	n_nonipd_anchor	NA
10.1007/bf03261873	results	1	NA	n_ipd_anchor	NA
10.1007/bf03261873	results	1	NA	ess_anchor	NA
10.1007/bf03261873	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/bf03261873	results	1	NA	effect_cutoff	0
10.1007/bf03261873	results	1	NA	adjusted_pval	0.07
10.1007/bf03261873	results	1	NA	adjusted_num_pval	0.07
10.1007/bf03261873	results	1	NA	adjusted_significant	FALSE
10.1007/bf03261873	results	2	NA	contrast	Means difference
10.1007/bf03261873	results	2	NA	direction_benefit	inferior
10.1007/bf03261873	results	2	NA	n_nonipd_ttt	84
10.1007/bf03261873	results	2	NA	n_ipd_ttt	46
10.1007/bf03261873	results	2	NA	ess_ttt	16
10.1007/bf03261873	results	2	NA	weights_evaluation_yn	Not mentioned
10.1007/bf03261873	results	2	NA	list_covariates_yn	Yes
10.1007/bf03261873	results	2	NA	n_covariates	6
10.1007/bf03261873	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1007/bf03261873	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/bf03261873	results	2	NA	unadjusted_effect	NA
10.1007/bf03261873	results	2	NA	unadjusted_pval_char	NA
10.1007/bf03261873	results	2	NA	adjusted_effect	-6
10.1007/bf03261873	results	2	NA	adjusted_pval_char	0.02
10.1007/bf03261873	results	2	NA	geographical region	No
10.1007/bf03261873	results	2	NA	n_ipd_total	NA
10.1007/bf03261873	results	2	NA	ess_total	NA
10.1007/bf03261873	results	2	NA	n_nonipd_total	NA
10.1007/bf03261873	results	2	NA	n_nonipd_anchor	NA
10.1007/bf03261873	results	2	NA	n_ipd_anchor	NA
10.1007/bf03261873	results	2	NA	ess_anchor	NA
10.1007/bf03261873	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/bf03261873	results	2	NA	effect_cutoff	0
10.1007/bf03261873	results	2	NA	adjusted_pval	0.02
10.1007/bf03261873	results	2	NA	adjusted_num_pval	0.02
10.1007/bf03261873	results	2	NA	adjusted_significant	TRUE
10.1007/bf03261873	results	3	NA	contrast	Means difference
10.1007/bf03261873	results	3	NA	direction_benefit	inferior
10.1007/bf03261873	results	3	NA	n_nonipd_ttt	84
10.1007/bf03261873	results	3	NA	n_ipd_ttt	82
10.1007/bf03261873	results	3	NA	ess_ttt	38
10.1007/bf03261873	results	3	NA	weights_evaluation_yn	Not mentioned
10.1007/bf03261873	results	3	NA	list_covariates_yn	Yes
10.1007/bf03261873	results	3	NA	n_covariates	6
10.1007/bf03261873	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1007/bf03261873	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/bf03261873	results	3	NA	unadjusted_effect	NA
10.1007/bf03261873	results	3	NA	unadjusted_pval_char	NA
10.1007/bf03261873	results	3	NA	adjusted_effect	-7
10.1007/bf03261873	results	3	NA	adjusted_pval_char	<0.01
10.1007/bf03261873	results	3	NA	geographical region	No
10.1007/bf03261873	results	3	NA	n_ipd_total	NA
10.1007/bf03261873	results	3	NA	ess_total	NA
10.1007/bf03261873	results	3	NA	n_nonipd_total	NA
10.1007/bf03261873	results	3	NA	n_nonipd_anchor	NA
10.1007/bf03261873	results	3	NA	n_ipd_anchor	NA
10.1007/bf03261873	results	3	NA	ess_anchor	NA
10.1007/bf03261873	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/bf03261873	results	3	NA	effect_cutoff	0
10.1007/bf03261873	results	3	NA	adjusted_pval	<0.01
10.1007/bf03261873	results	3	NA	adjusted_significant	TRUE
10.1007/bf03261873	study_information	NA	1	Patient-level data used	Yes
10.1007/bf03261873	study_information	NA	1	Clinical Trial	Yes
10.1007/bf03261873	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00152009
10.1007/bf03261873	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/bf03261873	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/bf03261873	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1007/bf03261873	study_information	NA	2	Patient-level data used	Yes
10.1007/bf03261873	study_information	NA	2	Clinical Trial	Yes
10.1007/bf03261873	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00150618
10.1007/bf03261873	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/bf03261873	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/bf03261873	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	sallee et al. (2009)
10.1007/bf03261873	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/bf03261873	study_information	NA	3	Patient-level data used	No
10.1007/bf03261873	study_information	NA	3	Clinical Trial	Yes
10.1007/bf03261873	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	michelson et al. (2001)
10.1007/bf03261873	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/bf03261873	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s00432-021-03602-w	general_information	NA	NA	Medical Condition of Interest Name	unresectable hepatocellular carcinoma
10.1007/s00432-021-03602-w	general_information	NA	NA	Countries of first author affiliations	italy
10.1007/s00432-021-03602-w	general_information	NA	NA	Countries of last author affiliations	italy
10.1007/s00432-021-03602-w	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic
10.1007/s00432-021-03602-w	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s00432-021-03602-w	general_information	NA	NA	Mentioned sources of funding	No fundings
10.1007/s00432-021-03602-w	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s00432-021-03602-w	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s00432-021-03602-w	methodology	1	NA	primary_outcome_name	overall survival
10.1007/s00432-021-03602-w	methodology	1	NA	outcome_short_name	Overall Survival
10.1007/s00432-021-03602-w	methodology	1	NA	primary_outcome_type	Time-to-event
10.1007/s00432-021-03602-w	methodology	1	NA	Treatment name 1	regorafenib
10.1007/s00432-021-03602-w	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s00432-021-03602-w	methodology	1	NA	Treatment name 2	cabozantinib
10.1007/s00432-021-03602-w	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s00432-021-03602-w	methodology	1	NA	paitc_type	MAIC
10.1007/s00432-021-03602-w	methodology	1	NA	anchored_yn	No
10.1007/s00432-021-03602-w	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s00432-021-03602-w	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s00432-021-03602-w	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1007/s00432-021-03602-w	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s00432-021-03602-w	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s00432-021-03602-w	methodology	1	NA	weights_model_yn	No
10.1007/s00432-021-03602-w	methodology	1	NA	scale_choice_yn	No
10.1007/s00432-021-03602-w	results	1	NA	contrast	HR
10.1007/s00432-021-03602-w	results	1	NA	direction_benefit	inferior
10.1007/s00432-021-03602-w	results	1	NA	n_nonipd_ttt	331
10.1007/s00432-021-03602-w	results	1	NA	n_ipd_ttt	278
10.1007/s00432-021-03602-w	results	1	NA	ess_ttt	NA
10.1007/s00432-021-03602-w	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s00432-021-03602-w	results	1	NA	list_covariates_yn	No
10.1007/s00432-021-03602-w	results	1	NA	n_covariates	NA
10.1007/s00432-021-03602-w	results	1	NA	list_covariates	NA
10.1007/s00432-021-03602-w	results	1	NA	effect_direction	Denominator if ratio, or rightside if difference
10.1007/s00432-021-03602-w	results	1	NA	unadjusted_effect	0.8
10.1007/s00432-021-03602-w	results	1	NA	unadjusted_pval_char	[0.66;0.97]
10.1007/s00432-021-03602-w	results	1	NA	adjusted_effect	0.83
10.1007/s00432-021-03602-w	results	1	NA	adjusted_pval_char	[0.62;1.09]
10.1007/s00432-021-03602-w	results	1	NA	geographical region	NA
10.1007/s00432-021-03602-w	results	1	NA	n_ipd_total	NA
10.1007/s00432-021-03602-w	results	1	NA	ess_total	NA
10.1007/s00432-021-03602-w	results	1	NA	n_nonipd_total	NA
10.1007/s00432-021-03602-w	results	1	NA	n_nonipd_anchor	NA
10.1007/s00432-021-03602-w	results	1	NA	n_ipd_anchor	NA
10.1007/s00432-021-03602-w	results	1	NA	ess_anchor	NA
10.1007/s00432-021-03602-w	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s00432-021-03602-w	results	1	NA	effect_cutoff	1
10.1007/s00432-021-03602-w	results	1	NA	unadjusted_lb_ci	0.66
10.1007/s00432-021-03602-w	results	1	NA	unadjusted_ub_ci	0.97
10.1007/s00432-021-03602-w	results	1	NA	unadjusted_significant	TRUE
10.1007/s00432-021-03602-w	results	1	NA	adjusted_lb_ci	0.62
10.1007/s00432-021-03602-w	results	1	NA	adjusted_ub_ci	1.09
10.1007/s00432-021-03602-w	results	1	NA	adjusted_significant	FALSE
10.1007/s00432-021-03602-w	study_information	NA	1	Patient-level data used	Yes
10.1007/s00432-021-03602-w	study_information	NA	1	Clinical Trial	No
10.1007/s00432-021-03602-w	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	real-world data from unknown origin
10.1007/s00432-021-03602-w	study_information	NA	2	Patient-level data used	No
10.1007/s00432-021-03602-w	study_information	NA	2	Clinical Trial	Yes
10.1007/s00432-021-03602-w	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01908426
10.1007/s00432-021-03602-w	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s00432-021-03602-w	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s00432-021-03602-w	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s11523-021-00803-8	general_information	NA	NA	Medical Condition of Interest Name	hepatocellular carcinoma
10.1007/s11523-021-00803-8	general_information	NA	NA	Countries of first author affiliations	italy
10.1007/s11523-021-00803-8	general_information	NA	NA	Countries of last author affiliations	italy
10.1007/s11523-021-00803-8	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic
10.1007/s11523-021-00803-8	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1007/s11523-021-00803-8	general_information	NA	NA	Mentioned sources of funding	No fundings
10.1007/s11523-021-00803-8	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s11523-021-00803-8	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s11523-021-00803-8	methodology	1	NA	primary_outcome_name	overall survival
10.1007/s11523-021-00803-8	methodology	1	NA	outcome_short_name	Overall Survival
10.1007/s11523-021-00803-8	methodology	1	NA	primary_outcome_type	Time-to-event
10.1007/s11523-021-00803-8	methodology	1	NA	Treatment name 1	lenvatinib
10.1007/s11523-021-00803-8	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s11523-021-00803-8	methodology	1	NA	Treatment name 2	atezolizumab + bevacizumab
10.1007/s11523-021-00803-8	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s11523-021-00803-8	methodology	1	NA	paitc_type	MAIC
10.1007/s11523-021-00803-8	methodology	1	NA	anchored_yn	No
10.1007/s11523-021-00803-8	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s11523-021-00803-8	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s11523-021-00803-8	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1007/s11523-021-00803-8	methodology	1	NA	prognostic_factors_yn	No
10.1007/s11523-021-00803-8	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s11523-021-00803-8	methodology	1	NA	weights_model_yn	No
10.1007/s11523-021-00803-8	methodology	1	NA	scale_choice_yn	No
10.1007/s11523-021-00803-8	results	1	NA	contrast	HR
10.1007/s11523-021-00803-8	results	1	NA	direction_benefit	inferior
10.1007/s11523-021-00803-8	results	1	NA	n_nonipd_ttt	336
10.1007/s11523-021-00803-8	results	1	NA	n_ipd_ttt	455
10.1007/s11523-021-00803-8	results	1	NA	ess_ttt	NA
10.1007/s11523-021-00803-8	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s11523-021-00803-8	results	1	NA	list_covariates_yn	Yes
10.1007/s11523-021-00803-8	results	1	NA	n_covariates	12
10.1007/s11523-021-00803-8	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1007/s11523-021-00803-8	results	1	NA	effect_direction	Denominator if ratio, or rightside if difference
10.1007/s11523-021-00803-8	results	1	NA	unadjusted_effect	NA
10.1007/s11523-021-00803-8	results	1	NA	unadjusted_pval_char	NA
10.1007/s11523-021-00803-8	results	1	NA	adjusted_effect	0.59
10.1007/s11523-021-00803-8	results	1	NA	adjusted_pval_char	[0.46;0.75]
10.1007/s11523-021-00803-8	results	1	NA	geographical region	NA
10.1007/s11523-021-00803-8	results	1	NA	n_ipd_total	NA
10.1007/s11523-021-00803-8	results	1	NA	ess_total	NA
10.1007/s11523-021-00803-8	results	1	NA	n_nonipd_total	NA
10.1007/s11523-021-00803-8	results	1	NA	n_nonipd_anchor	NA
10.1007/s11523-021-00803-8	results	1	NA	n_ipd_anchor	NA
10.1007/s11523-021-00803-8	results	1	NA	ess_anchor	NA
10.1007/s11523-021-00803-8	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s11523-021-00803-8	results	1	NA	effect_cutoff	1
10.1007/s11523-021-00803-8	results	1	NA	adjusted_lb_ci	0.46
10.1007/s11523-021-00803-8	results	1	NA	adjusted_ub_ci	0.75
10.1007/s11523-021-00803-8	results	1	NA	adjusted_significant	TRUE
10.1007/s11523-021-00803-8	study_information	NA	1	Patient-level data used	Yes
10.1007/s11523-021-00803-8	study_information	NA	1	Clinical Trial	No
10.1007/s11523-021-00803-8	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	real-world data from 12 japanese centers from march 2018 to may 2020
10.1007/s11523-021-00803-8	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.1007/s11523-021-00803-8	study_information	NA	2	Patient-level data used	No
10.1007/s11523-021-00803-8	study_information	NA	2	Clinical Trial	Yes
10.1007/s11523-021-00803-8	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03434379
10.1007/s11523-021-00803-8	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s11523-021-00803-8	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s11523-021-00803-8	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-014-0167-z	general_information	NA	NA	Medical Condition of Interest Name	relapsing-remitting multiple sclerosis
10.1007/s12325-014-0167-z	general_information	NA	NA	Countries of first author affiliations	switzerland
10.1007/s12325-014-0167-z	general_information	NA	NA	Countries of last author affiliations	uk
10.1007/s12325-014-0167-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1007/s12325-014-0167-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-014-0167-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-014-0167-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-014-0167-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-014-0167-z	methodology	1	NA	primary_outcome_name	no evidence of disease activity (neda)
10.1007/s12325-014-0167-z	methodology	1	NA	outcome_short_name	No evidence of disease activity
10.1007/s12325-014-0167-z	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1007/s12325-014-0167-z	methodology	1	NA	Treatment name 1	fingolimod
10.1007/s12325-014-0167-z	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1007/s12325-014-0167-z	methodology	1	NA	Treatment name 2	dimethyl fumarate
10.1007/s12325-014-0167-z	methodology	1	NA	Study 'number(s)' for treatment 2	3;4
10.1007/s12325-014-0167-z	methodology	1	NA	paitc_type	STC
10.1007/s12325-014-0167-z	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-014-0167-z	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-014-0167-z	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-014-0167-z	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-014-0167-z	methodology	1	NA	prognostic_factors_yn	No
10.1007/s12325-014-0167-z	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-014-0167-z	methodology	1	NA	weights_model_yn	Yes
10.1007/s12325-014-0167-z	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-014-0167-z	methodology	2	NA	primary_outcome_name	no evidence of disease activity (neda)
10.1007/s12325-014-0167-z	methodology	2	NA	outcome_short_name	No evidence of disease activity
10.1007/s12325-014-0167-z	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1007/s12325-014-0167-z	methodology	2	NA	Treatment name 1	fingolimod
10.1007/s12325-014-0167-z	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.1007/s12325-014-0167-z	methodology	2	NA	Treatment name 2	teriflunomide 7 mg
10.1007/s12325-014-0167-z	methodology	2	NA	Study 'number(s)' for treatment 2	5
10.1007/s12325-014-0167-z	methodology	2	NA	paitc_type	STC
10.1007/s12325-014-0167-z	methodology	2	NA	anchored_yn	Yes
10.1007/s12325-014-0167-z	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-014-0167-z	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-014-0167-z	methodology	2	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-014-0167-z	methodology	2	NA	prognostic_factors_yn	No
10.1007/s12325-014-0167-z	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-014-0167-z	methodology	2	NA	weights_model_yn	Yes
10.1007/s12325-014-0167-z	methodology	2	NA	scale_choice_yn	No
10.1007/s12325-014-0167-z	methodology	3	NA	primary_outcome_name	no evidence of disease activity (neda)
10.1007/s12325-014-0167-z	methodology	3	NA	outcome_short_name	No evidence of disease activity
10.1007/s12325-014-0167-z	methodology	3	NA	primary_outcome_type	Binary (eg rates)
10.1007/s12325-014-0167-z	methodology	3	NA	Treatment name 1	fingolimod
10.1007/s12325-014-0167-z	methodology	3	NA	Study 'number(s)' for treatment 1	1;2
10.1007/s12325-014-0167-z	methodology	3	NA	Treatment name 2	teriflunomide 14 mg
10.1007/s12325-014-0167-z	methodology	3	NA	Study 'number(s)' for treatment 2	5
10.1007/s12325-014-0167-z	methodology	3	NA	paitc_type	STC
10.1007/s12325-014-0167-z	methodology	3	NA	anchored_yn	Yes
10.1007/s12325-014-0167-z	methodology	3	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-014-0167-z	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-014-0167-z	methodology	3	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-014-0167-z	methodology	3	NA	prognostic_factors_yn	No
10.1007/s12325-014-0167-z	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-014-0167-z	methodology	3	NA	weights_model_yn	Yes
10.1007/s12325-014-0167-z	methodology	3	NA	scale_choice_yn	No
10.1007/s12325-014-0167-z	results	1	NA	contrast	RR
10.1007/s12325-014-0167-z	results	1	NA	direction_benefit	superior
10.1007/s12325-014-0167-z	results	1	NA	n_nonipd_ttt	769
10.1007/s12325-014-0167-z	results	1	NA	n_ipd_ttt	783
10.1007/s12325-014-0167-z	results	1	NA	ess_ttt	783
10.1007/s12325-014-0167-z	results	1	NA	weights_evaluation_yn	NA
10.1007/s12325-014-0167-z	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-014-0167-z	results	1	NA	n_covariates	2
10.1007/s12325-014-0167-z	results	1	NA	list_covariates	Age, Past treatments for the disease of interest
10.1007/s12325-014-0167-z	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-014-0167-z	results	1	NA	unadjusted_effect	1.58
10.1007/s12325-014-0167-z	results	1	NA	unadjusted_pval_char	[1.00;2.50]
10.1007/s12325-014-0167-z	results	1	NA	adjusted_effect	1.67
10.1007/s12325-014-0167-z	results	1	NA	adjusted_pval_char	[1.08;2.57]
10.1007/s12325-014-0167-z	results	1	NA	geographical region	NA
10.1007/s12325-014-0167-z	results	1	NA	n_ipd_total	NA
10.1007/s12325-014-0167-z	results	1	NA	ess_total	NA
10.1007/s12325-014-0167-z	results	1	NA	n_nonipd_total	NA
10.1007/s12325-014-0167-z	results	1	NA	n_nonipd_anchor	771
10.1007/s12325-014-0167-z	results	1	NA	n_ipd_anchor	773
10.1007/s12325-014-0167-z	results	1	NA	ess_anchor	773
10.1007/s12325-014-0167-z	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-014-0167-z	results	1	NA	effect_cutoff	1
10.1007/s12325-014-0167-z	results	1	NA	unadjusted_lb_ci	1
10.1007/s12325-014-0167-z	results	1	NA	unadjusted_ub_ci	2.5
10.1007/s12325-014-0167-z	results	1	NA	unadjusted_significant	FALSE
10.1007/s12325-014-0167-z	results	1	NA	adjusted_lb_ci	1.08
10.1007/s12325-014-0167-z	results	1	NA	adjusted_ub_ci	2.57
10.1007/s12325-014-0167-z	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-014-0167-z	results	2	NA	contrast	RR
10.1007/s12325-014-0167-z	results	2	NA	direction_benefit	superior
10.1007/s12325-014-0167-z	results	2	NA	n_nonipd_ttt	365
10.1007/s12325-014-0167-z	results	2	NA	n_ipd_ttt	783
10.1007/s12325-014-0167-z	results	2	NA	ess_ttt	783
10.1007/s12325-014-0167-z	results	2	NA	weights_evaluation_yn	NA
10.1007/s12325-014-0167-z	results	2	NA	list_covariates_yn	Yes
10.1007/s12325-014-0167-z	results	2	NA	n_covariates	1
10.1007/s12325-014-0167-z	results	2	NA	list_covariates	Age
10.1007/s12325-014-0167-z	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-014-0167-z	results	2	NA	unadjusted_effect	2.18
10.1007/s12325-014-0167-z	results	2	NA	unadjusted_pval_char	[1.46;3.25]
10.1007/s12325-014-0167-z	results	2	NA	adjusted_effect	2.01
10.1007/s12325-014-0167-z	results	2	NA	adjusted_pval_char	[1.38;2.93]
10.1007/s12325-014-0167-z	results	2	NA	geographical region	NA
10.1007/s12325-014-0167-z	results	2	NA	n_ipd_total	NA
10.1007/s12325-014-0167-z	results	2	NA	ess_total	NA
10.1007/s12325-014-0167-z	results	2	NA	n_nonipd_total	NA
10.1007/s12325-014-0167-z	results	2	NA	n_nonipd_anchor	363
10.1007/s12325-014-0167-z	results	2	NA	n_ipd_anchor	773
10.1007/s12325-014-0167-z	results	2	NA	ess_anchor	773
10.1007/s12325-014-0167-z	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-014-0167-z	results	2	NA	effect_cutoff	1
10.1007/s12325-014-0167-z	results	2	NA	unadjusted_lb_ci	1.46
10.1007/s12325-014-0167-z	results	2	NA	unadjusted_ub_ci	3.25
10.1007/s12325-014-0167-z	results	2	NA	unadjusted_significant	TRUE
10.1007/s12325-014-0167-z	results	2	NA	adjusted_lb_ci	1.38
10.1007/s12325-014-0167-z	results	2	NA	adjusted_ub_ci	2.93
10.1007/s12325-014-0167-z	results	2	NA	adjusted_significant	TRUE
10.1007/s12325-014-0167-z	results	3	NA	contrast	RR
10.1007/s12325-014-0167-z	results	3	NA	direction_benefit	superior
10.1007/s12325-014-0167-z	results	3	NA	n_nonipd_ttt	358
10.1007/s12325-014-0167-z	results	3	NA	n_ipd_ttt	783
10.1007/s12325-014-0167-z	results	3	NA	ess_ttt	783
10.1007/s12325-014-0167-z	results	3	NA	weights_evaluation_yn	NA
10.1007/s12325-014-0167-z	results	3	NA	list_covariates_yn	Yes
10.1007/s12325-014-0167-z	results	3	NA	n_covariates	1
10.1007/s12325-014-0167-z	results	3	NA	list_covariates	Age
10.1007/s12325-014-0167-z	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-014-0167-z	results	3	NA	unadjusted_effect	1.75
10.1007/s12325-014-0167-z	results	3	NA	unadjusted_pval_char	[1.18;2.57]
10.1007/s12325-014-0167-z	results	3	NA	adjusted_effect	1.61
10.1007/s12325-014-0167-z	results	3	NA	adjusted_pval_char	[1.12;2.31]
10.1007/s12325-014-0167-z	results	3	NA	geographical region	NA
10.1007/s12325-014-0167-z	results	3	NA	n_ipd_total	NA
10.1007/s12325-014-0167-z	results	3	NA	ess_total	NA
10.1007/s12325-014-0167-z	results	3	NA	n_nonipd_total	NA
10.1007/s12325-014-0167-z	results	3	NA	n_nonipd_anchor	363
10.1007/s12325-014-0167-z	results	3	NA	n_ipd_anchor	773
10.1007/s12325-014-0167-z	results	3	NA	ess_anchor	773
10.1007/s12325-014-0167-z	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-014-0167-z	results	3	NA	effect_cutoff	1
10.1007/s12325-014-0167-z	results	3	NA	unadjusted_lb_ci	1.18
10.1007/s12325-014-0167-z	results	3	NA	unadjusted_ub_ci	2.57
10.1007/s12325-014-0167-z	results	3	NA	unadjusted_significant	TRUE
10.1007/s12325-014-0167-z	results	3	NA	adjusted_lb_ci	1.12
10.1007/s12325-014-0167-z	results	3	NA	adjusted_ub_ci	2.31
10.1007/s12325-014-0167-z	results	3	NA	adjusted_significant	TRUE
10.1007/s12325-014-0167-z	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-014-0167-z	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-014-0167-z	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00289978
10.1007/s12325-014-0167-z	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-014-0167-z	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-014-0167-z	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-014-0167-z	study_information	NA	2	Patient-level data used	Yes
10.1007/s12325-014-0167-z	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-014-0167-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00355134
10.1007/s12325-014-0167-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-014-0167-z	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-014-0167-z	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-014-0167-z	study_information	NA	3	Patient-level data used	No
10.1007/s12325-014-0167-z	study_information	NA	3	Clinical Trial	Yes
10.1007/s12325-014-0167-z	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212
10.1007/s12325-014-0167-z	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-014-0167-z	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-014-0167-z	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-014-0167-z	study_information	NA	4	Patient-level data used	No
10.1007/s12325-014-0167-z	study_information	NA	4	Clinical Trial	Yes
10.1007/s12325-014-0167-z	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451
10.1007/s12325-014-0167-z	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-014-0167-z	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-014-0167-z	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-014-0167-z	study_information	NA	5	Patient-level data used	No
10.1007/s12325-014-0167-z	study_information	NA	5	Clinical Trial	Yes
10.1007/s12325-014-0167-z	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00134563
10.1007/s12325-014-0167-z	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-014-0167-z	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-014-0167-z	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-017-0564-1	general_information	NA	NA	Medical Condition of Interest Name	chronic lymphocytic leukemia
10.1007/s12325-017-0564-1	general_information	NA	NA	Countries of first author affiliations	belgium
10.1007/s12325-017-0564-1	general_information	NA	NA	Countries of last author affiliations	uk
10.1007/s12325-017-0564-1	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry
10.1007/s12325-017-0564-1	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1007/s12325-017-0564-1	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-017-0564-1	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-017-0564-1	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-017-0564-1	methodology	1	NA	primary_outcome_name	progression-free survival
10.1007/s12325-017-0564-1	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1007/s12325-017-0564-1	methodology	1	NA	primary_outcome_type	Time-to-event
10.1007/s12325-017-0564-1	methodology	1	NA	Treatment name 1	ibrutinib
10.1007/s12325-017-0564-1	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-017-0564-1	methodology	1	NA	Treatment name 2	obinutuzumab + chlorambucil
10.1007/s12325-017-0564-1	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-017-0564-1	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-017-0564-1	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-017-0564-1	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-017-0564-1	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-017-0564-1	methodology	1	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-017-0564-1	methodology	1	NA	prognostic_factors_yn	Yes
10.1007/s12325-017-0564-1	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-017-0564-1	methodology	1	NA	weights_model_yn	No
10.1007/s12325-017-0564-1	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-017-0564-1	results	1	NA	contrast	HR
10.1007/s12325-017-0564-1	results	1	NA	direction_benefit	inferior
10.1007/s12325-017-0564-1	results	1	NA	n_nonipd_ttt	589
10.1007/s12325-017-0564-1	results	1	NA	n_ipd_ttt	115
10.1007/s12325-017-0564-1	results	1	NA	ess_ttt	35
10.1007/s12325-017-0564-1	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-017-0564-1	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-017-0564-1	results	1	NA	n_covariates	9
10.1007/s12325-017-0564-1	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1007/s12325-017-0564-1	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-017-0564-1	results	1	NA	unadjusted_effect	0.5
10.1007/s12325-017-0564-1	results	1	NA	unadjusted_pval_char	[0.22;1.15]
10.1007/s12325-017-0564-1	results	1	NA	adjusted_effect	0.24
10.1007/s12325-017-0564-1	results	1	NA	adjusted_pval_char	[0.04;1.35]
10.1007/s12325-017-0564-1	results	1	NA	geographical region	NA
10.1007/s12325-017-0564-1	results	1	NA	n_ipd_total	115
10.1007/s12325-017-0564-1	results	1	NA	ess_total	35
10.1007/s12325-017-0564-1	results	1	NA	n_nonipd_total	589
10.1007/s12325-017-0564-1	results	1	NA	n_nonipd_anchor	NA
10.1007/s12325-017-0564-1	results	1	NA	n_ipd_anchor	NA
10.1007/s12325-017-0564-1	results	1	NA	ess_anchor	NA
10.1007/s12325-017-0564-1	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-017-0564-1	results	1	NA	effect_cutoff	1
10.1007/s12325-017-0564-1	results	1	NA	unadjusted_lb_ci	0.22
10.1007/s12325-017-0564-1	results	1	NA	unadjusted_ub_ci	1.15
10.1007/s12325-017-0564-1	results	1	NA	unadjusted_significant	FALSE
10.1007/s12325-017-0564-1	results	1	NA	adjusted_lb_ci	0.04
10.1007/s12325-017-0564-1	results	1	NA	adjusted_ub_ci	1.35
10.1007/s12325-017-0564-1	results	1	NA	adjusted_significant	FALSE
10.1007/s12325-017-0564-1	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-017-0564-1	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-017-0564-1	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01722487
10.1007/s12325-017-0564-1	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-017-0564-1	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-017-0564-1	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-017-0564-1	study_information	NA	2	Patient-level data used	No
10.1007/s12325-017-0564-1	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-017-0564-1	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01010061
10.1007/s12325-017-0564-1	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-017-0564-1	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-017-0564-1	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-018-0734-9	general_information	NA	NA	Medical Condition of Interest Name	advanced or metastatic non-small-cell lung cancer
10.1007/s12325-018-0734-9	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s12325-018-0734-9	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s12325-018-0734-9	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-018-0734-9	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-018-0734-9	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-018-0734-9	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-018-0734-9	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-018-0734-9	methodology	1	NA	primary_outcome_name	overall response rate
10.1007/s12325-018-0734-9	methodology	1	NA	outcome_short_name	Overall Response Rate
10.1007/s12325-018-0734-9	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1007/s12325-018-0734-9	methodology	1	NA	Treatment name 1	dabrafenib + trametinib
10.1007/s12325-018-0734-9	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-018-0734-9	methodology	1	NA	Treatment name 2	nivolumab
10.1007/s12325-018-0734-9	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-018-0734-9	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-018-0734-9	methodology	1	NA	anchored_yn	No
10.1007/s12325-018-0734-9	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-018-0734-9	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-018-0734-9	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-018-0734-9	methodology	1	NA	prognostic_factors_yn	Yes
10.1007/s12325-018-0734-9	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-018-0734-9	methodology	1	NA	weights_model_yn	No
10.1007/s12325-018-0734-9	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-018-0734-9	results	1	NA	contrast	NA
10.1007/s12325-018-0734-9	results	1	NA	direction_benefit	superior
10.1007/s12325-018-0734-9	results	1	NA	n_nonipd_ttt	290
10.1007/s12325-018-0734-9	results	1	NA	n_ipd_ttt	57
10.1007/s12325-018-0734-9	results	1	NA	ess_ttt	34
10.1007/s12325-018-0734-9	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-018-0734-9	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-018-0734-9	results	1	NA	n_covariates	10
10.1007/s12325-018-0734-9	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1007/s12325-018-0734-9	results	1	NA	effect_direction	NA
10.1007/s12325-018-0734-9	results	1	NA	unadjusted_effect	NA
10.1007/s12325-018-0734-9	results	1	NA	unadjusted_pval_char	NA
10.1007/s12325-018-0734-9	results	1	NA	adjusted_effect	NA
10.1007/s12325-018-0734-9	results	1	NA	adjusted_pval_char	NA
10.1007/s12325-018-0734-9	results	1	NA	geographical region	No
10.1007/s12325-018-0734-9	results	1	NA	n_ipd_total	57
10.1007/s12325-018-0734-9	results	1	NA	ess_total	34
10.1007/s12325-018-0734-9	results	1	NA	n_nonipd_total	290
10.1007/s12325-018-0734-9	results	1	NA	n_nonipd_anchor	NA
10.1007/s12325-018-0734-9	results	1	NA	n_ipd_anchor	NA
10.1007/s12325-018-0734-9	results	1	NA	ess_anchor	NA
10.1007/s12325-018-0734-9	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-018-0734-9	results	1	NA	effect_cutoff	NA
10.1007/s12325-018-0734-9	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-018-0734-9	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-018-0734-9	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01336634
10.1007/s12325-018-0734-9	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-018-0734-9	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1007/s12325-018-0734-9	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-018-0734-9	study_information	NA	2	Patient-level data used	No
10.1007/s12325-018-0734-9	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-018-0734-9	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01673867
10.1007/s12325-018-0734-9	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-018-0734-9	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-018-0734-9	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-00991-w	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory acute lymphoblastic leukemia
10.1007/s12325-019-00991-w	general_information	NA	NA	Countries of first author affiliations	canada
10.1007/s12325-019-00991-w	general_information	NA	NA	Countries of last author affiliations	germany
10.1007/s12325-019-00991-w	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-00991-w	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-019-00991-w	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-019-00991-w	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-019-00991-w	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-019-00991-w	methodology	1	NA	primary_outcome_name	complete response rate
10.1007/s12325-019-00991-w	methodology	1	NA	outcome_short_name	Complete Response Rate
10.1007/s12325-019-00991-w	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1007/s12325-019-00991-w	methodology	1	NA	Treatment name 1	inotuzumab ozogamicin
10.1007/s12325-019-00991-w	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-019-00991-w	methodology	1	NA	Treatment name 2	blinatumomab
10.1007/s12325-019-00991-w	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-019-00991-w	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-019-00991-w	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-019-00991-w	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-00991-w	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-00991-w	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-019-00991-w	methodology	1	NA	prognostic_factors_yn	No
10.1007/s12325-019-00991-w	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-019-00991-w	methodology	1	NA	weights_model_yn	No
10.1007/s12325-019-00991-w	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-019-00991-w	methodology	2	NA	primary_outcome_name	complete remission rate
10.1007/s12325-019-00991-w	methodology	2	NA	outcome_short_name	Complete Remission Rate
10.1007/s12325-019-00991-w	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1007/s12325-019-00991-w	methodology	2	NA	Treatment name 1	inotuzumab ozogamicin
10.1007/s12325-019-00991-w	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-019-00991-w	methodology	2	NA	Treatment name 2	blinatumomab
10.1007/s12325-019-00991-w	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-019-00991-w	methodology	2	NA	paitc_type	STC
10.1007/s12325-019-00991-w	methodology	2	NA	anchored_yn	Yes
10.1007/s12325-019-00991-w	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-00991-w	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-00991-w	methodology	2	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-019-00991-w	methodology	2	NA	prognostic_factors_yn	No
10.1007/s12325-019-00991-w	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-019-00991-w	methodology	2	NA	weights_model_yn	No
10.1007/s12325-019-00991-w	methodology	2	NA	scale_choice_yn	No
10.1007/s12325-019-00991-w	results	1	NA	contrast	OR
10.1007/s12325-019-00991-w	results	1	NA	direction_benefit	superior
10.1007/s12325-019-00991-w	results	1	NA	n_nonipd_ttt	271
10.1007/s12325-019-00991-w	results	1	NA	n_ipd_ttt	164
10.1007/s12325-019-00991-w	results	1	NA	ess_ttt	70
10.1007/s12325-019-00991-w	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-019-00991-w	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-019-00991-w	results	1	NA	n_covariates	6
10.1007/s12325-019-00991-w	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1007/s12325-019-00991-w	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-019-00991-w	results	1	NA	unadjusted_effect	2.63
10.1007/s12325-019-00991-w	results	1	NA	unadjusted_pval_char	[1.35;5.12]
10.1007/s12325-019-00991-w	results	1	NA	adjusted_effect	2.81
10.1007/s12325-019-00991-w	results	1	NA	adjusted_pval_char	[1.12;7.05]
10.1007/s12325-019-00991-w	results	1	NA	geographical region	No
10.1007/s12325-019-00991-w	results	1	NA	n_ipd_total	NA
10.1007/s12325-019-00991-w	results	1	NA	ess_total	NA
10.1007/s12325-019-00991-w	results	1	NA	n_nonipd_total	NA
10.1007/s12325-019-00991-w	results	1	NA	n_nonipd_anchor	134
10.1007/s12325-019-00991-w	results	1	NA	n_ipd_anchor	162
10.1007/s12325-019-00991-w	results	1	NA	ess_anchor	53
10.1007/s12325-019-00991-w	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-019-00991-w	results	1	NA	effect_cutoff	1
10.1007/s12325-019-00991-w	results	1	NA	unadjusted_lb_ci	1.35
10.1007/s12325-019-00991-w	results	1	NA	unadjusted_ub_ci	5.12
10.1007/s12325-019-00991-w	results	1	NA	unadjusted_significant	TRUE
10.1007/s12325-019-00991-w	results	1	NA	adjusted_lb_ci	1.12
10.1007/s12325-019-00991-w	results	1	NA	adjusted_ub_ci	7.05
10.1007/s12325-019-00991-w	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-019-00991-w	results	2	NA	contrast	OR
10.1007/s12325-019-00991-w	results	2	NA	direction_benefit	superior
10.1007/s12325-019-00991-w	results	2	NA	n_nonipd_ttt	271
10.1007/s12325-019-00991-w	results	2	NA	n_ipd_ttt	164
10.1007/s12325-019-00991-w	results	2	NA	ess_ttt	138
10.1007/s12325-019-00991-w	results	2	NA	weights_evaluation_yn	NA
10.1007/s12325-019-00991-w	results	2	NA	list_covariates_yn	Yes
10.1007/s12325-019-00991-w	results	2	NA	n_covariates	6
10.1007/s12325-019-00991-w	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1007/s12325-019-00991-w	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-019-00991-w	results	2	NA	unadjusted_effect	2.63
10.1007/s12325-019-00991-w	results	2	NA	unadjusted_pval_char	[1.35;5.12]
10.1007/s12325-019-00991-w	results	2	NA	adjusted_effect	3.91
10.1007/s12325-019-00991-w	results	2	NA	adjusted_pval_char	[1.53;9.99]
10.1007/s12325-019-00991-w	results	2	NA	geographical region	No
10.1007/s12325-019-00991-w	results	2	NA	n_ipd_total	NA
10.1007/s12325-019-00991-w	results	2	NA	ess_total	NA
10.1007/s12325-019-00991-w	results	2	NA	n_nonipd_total	NA
10.1007/s12325-019-00991-w	results	2	NA	n_nonipd_anchor	134
10.1007/s12325-019-00991-w	results	2	NA	n_ipd_anchor	162
10.1007/s12325-019-00991-w	results	2	NA	ess_anchor	133
10.1007/s12325-019-00991-w	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-019-00991-w	results	2	NA	effect_cutoff	1
10.1007/s12325-019-00991-w	results	2	NA	unadjusted_lb_ci	1.35
10.1007/s12325-019-00991-w	results	2	NA	unadjusted_ub_ci	5.12
10.1007/s12325-019-00991-w	results	2	NA	unadjusted_significant	TRUE
10.1007/s12325-019-00991-w	results	2	NA	adjusted_lb_ci	1.53
10.1007/s12325-019-00991-w	results	2	NA	adjusted_ub_ci	9.99
10.1007/s12325-019-00991-w	results	2	NA	adjusted_significant	TRUE
10.1007/s12325-019-00991-w	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-019-00991-w	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-019-00991-w	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01564784
10.1007/s12325-019-00991-w	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-00991-w	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-00991-w	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-00991-w	study_information	NA	2	Patient-level data used	No
10.1007/s12325-019-00991-w	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-019-00991-w	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02013167
10.1007/s12325-019-00991-w	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-00991-w	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-00991-w	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-01156-5	general_information	NA	NA	Medical Condition of Interest Name	non-metastatic castration-resistant prostate cancer
10.1007/s12325-019-01156-5	general_information	NA	NA	Countries of first author affiliations	uk
10.1007/s12325-019-01156-5	general_information	NA	NA	Countries of last author affiliations	germany
10.1007/s12325-019-01156-5	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-01156-5	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-019-01156-5	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-019-01156-5	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-019-01156-5	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-019-01156-5	methodology	1	NA	primary_outcome_name	metastasis-free survival
10.1007/s12325-019-01156-5	methodology	1	NA	outcome_short_name	Metastasis-free Survival
10.1007/s12325-019-01156-5	methodology	1	NA	primary_outcome_type	Time-to-event
10.1007/s12325-019-01156-5	methodology	1	NA	Treatment name 1	apalutamide
10.1007/s12325-019-01156-5	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-019-01156-5	methodology	1	NA	Treatment name 2	enzalutamide
10.1007/s12325-019-01156-5	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-019-01156-5	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-019-01156-5	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-019-01156-5	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-01156-5	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-01156-5	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-019-01156-5	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-019-01156-5	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-019-01156-5	methodology	1	NA	weights_model_yn	No
10.1007/s12325-019-01156-5	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-019-01156-5	results	1	NA	contrast	HR
10.1007/s12325-019-01156-5	results	1	NA	direction_benefit	inferior
10.1007/s12325-019-01156-5	results	1	NA	n_nonipd_ttt	933
10.1007/s12325-019-01156-5	results	1	NA	n_ipd_ttt	806
10.1007/s12325-019-01156-5	results	1	NA	ess_ttt	NA
10.1007/s12325-019-01156-5	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-019-01156-5	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-019-01156-5	results	1	NA	n_covariates	7
10.1007/s12325-019-01156-5	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-019-01156-5	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-019-01156-5	results	1	NA	unadjusted_effect	NA
10.1007/s12325-019-01156-5	results	1	NA	unadjusted_pval_char	NA
10.1007/s12325-019-01156-5	results	1	NA	adjusted_effect	0.91
10.1007/s12325-019-01156-5	results	1	NA	adjusted_pval_char	0.736
10.1007/s12325-019-01156-5	results	1	NA	geographical region	NA
10.1007/s12325-019-01156-5	results	1	NA	n_ipd_total	1207
10.1007/s12325-019-01156-5	results	1	NA	ess_total	1171
10.1007/s12325-019-01156-5	results	1	NA	n_nonipd_total	1401
10.1007/s12325-019-01156-5	results	1	NA	n_nonipd_anchor	468
10.1007/s12325-019-01156-5	results	1	NA	n_ipd_anchor	401
10.1007/s12325-019-01156-5	results	1	NA	ess_anchor	NA
10.1007/s12325-019-01156-5	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-019-01156-5	results	1	NA	effect_cutoff	1
10.1007/s12325-019-01156-5	results	1	NA	adjusted_pval	0.736
10.1007/s12325-019-01156-5	results	1	NA	adjusted_num_pval	0.736
10.1007/s12325-019-01156-5	results	1	NA	adjusted_significant	FALSE
10.1007/s12325-019-01156-5	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-019-01156-5	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-019-01156-5	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204
10.1007/s12325-019-01156-5	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-01156-5	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-01156-5	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-01156-5	study_information	NA	2	Patient-level data used	No
10.1007/s12325-019-01156-5	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-019-01156-5	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02003924
10.1007/s12325-019-01156-5	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-01156-5	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-01156-5	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-01157-4	general_information	NA	NA	Medical Condition of Interest Name	non-metastatic castration-resistant prostate cancer
10.1007/s12325-019-01157-4	general_information	NA	NA	Countries of first author affiliations	uk
10.1007/s12325-019-01157-4	general_information	NA	NA	Countries of last author affiliations	germany
10.1007/s12325-019-01157-4	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-01157-4	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-019-01157-4	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-019-01157-4	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-019-01157-4	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-019-01157-4	methodology	1	NA	primary_outcome_name	fatigue occurrence
10.1007/s12325-019-01157-4	methodology	1	NA	outcome_short_name	Fatigue occurence
10.1007/s12325-019-01157-4	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1007/s12325-019-01157-4	methodology	1	NA	Treatment name 1	apalutamide
10.1007/s12325-019-01157-4	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-019-01157-4	methodology	1	NA	Treatment name 2	enzalutamide
10.1007/s12325-019-01157-4	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-019-01157-4	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-019-01157-4	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-019-01157-4	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-01157-4	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-01157-4	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-019-01157-4	methodology	1	NA	prognostic_factors_yn	No
10.1007/s12325-019-01157-4	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-019-01157-4	methodology	1	NA	weights_model_yn	No
10.1007/s12325-019-01157-4	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-019-01157-4	results	1	NA	contrast	OR
10.1007/s12325-019-01157-4	results	1	NA	direction_benefit	inferior
10.1007/s12325-019-01157-4	results	1	NA	n_nonipd_ttt	933
10.1007/s12325-019-01157-4	results	1	NA	n_ipd_ttt	806
10.1007/s12325-019-01157-4	results	1	NA	ess_ttt	NA
10.1007/s12325-019-01157-4	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-019-01157-4	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-019-01157-4	results	1	NA	n_covariates	7
10.1007/s12325-019-01157-4	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-019-01157-4	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-019-01157-4	results	1	NA	unadjusted_effect	NA
10.1007/s12325-019-01157-4	results	1	NA	unadjusted_pval_char	NA
10.1007/s12325-019-01157-4	results	1	NA	adjusted_effect	0.57
10.1007/s12325-019-01157-4	results	1	NA	adjusted_pval_char	[0.37;0.88]
10.1007/s12325-019-01157-4	results	1	NA	geographical region	NA
10.1007/s12325-019-01157-4	results	1	NA	n_ipd_total	1207
10.1007/s12325-019-01157-4	results	1	NA	ess_total	1171
10.1007/s12325-019-01157-4	results	1	NA	n_nonipd_total	1401
10.1007/s12325-019-01157-4	results	1	NA	n_nonipd_anchor	468
10.1007/s12325-019-01157-4	results	1	NA	n_ipd_anchor	401
10.1007/s12325-019-01157-4	results	1	NA	ess_anchor	NA
10.1007/s12325-019-01157-4	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-019-01157-4	results	1	NA	effect_cutoff	1
10.1007/s12325-019-01157-4	results	1	NA	adjusted_lb_ci	0.37
10.1007/s12325-019-01157-4	results	1	NA	adjusted_ub_ci	0.88
10.1007/s12325-019-01157-4	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-019-01157-4	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-019-01157-4	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-019-01157-4	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204
10.1007/s12325-019-01157-4	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-01157-4	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-01157-4	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-01157-4	study_information	NA	2	Patient-level data used	No
10.1007/s12325-019-01157-4	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-019-01157-4	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02003924
10.1007/s12325-019-01157-4	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-01157-4	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-01157-4	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-01173-4	general_information	NA	NA	Medical Condition of Interest Name	atrial fibrillation
10.1007/s12325-019-01173-4	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s12325-019-01173-4	general_information	NA	NA	Countries of last author affiliations	italy
10.1007/s12325-019-01173-4	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-01173-4	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-019-01173-4	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-019-01173-4	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-019-01173-4	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-019-01173-4	methodology	1	NA	primary_outcome_name	arrhythmia recurrence
10.1007/s12325-019-01173-4	methodology	1	NA	outcome_short_name	Arrhythmia recurrence
10.1007/s12325-019-01173-4	methodology	1	NA	primary_outcome_type	Time-to-event
10.1007/s12325-019-01173-4	methodology	1	NA	Treatment name 1	ratiofrequency catheter ablation with ablation index
10.1007/s12325-019-01173-4	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-019-01173-4	methodology	1	NA	Treatment name 2	ratiofrequency catheter ablation with cryoballoon
10.1007/s12325-019-01173-4	methodology	1	NA	Study 'number(s)' for treatment 2	2;3;4
10.1007/s12325-019-01173-4	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-019-01173-4	methodology	1	NA	anchored_yn	No
10.1007/s12325-019-01173-4	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-019-01173-4	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s12325-019-01173-4	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-019-01173-4	methodology	1	NA	prognostic_factors_yn	Yes
10.1007/s12325-019-01173-4	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-019-01173-4	methodology	1	NA	weights_model_yn	No
10.1007/s12325-019-01173-4	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-019-01173-4	results	1	NA	contrast	HR
10.1007/s12325-019-01173-4	results	1	NA	direction_benefit	inferior
10.1007/s12325-019-01173-4	results	1	NA	n_nonipd_ttt	155
10.1007/s12325-019-01173-4	results	1	NA	n_ipd_ttt	132
10.1007/s12325-019-01173-4	results	1	NA	ess_ttt	125
10.1007/s12325-019-01173-4	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s12325-019-01173-4	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-019-01173-4	results	1	NA	n_covariates	1
10.1007/s12325-019-01173-4	results	1	NA	list_covariates	Age
10.1007/s12325-019-01173-4	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-019-01173-4	results	1	NA	unadjusted_effect	0.42
10.1007/s12325-019-01173-4	results	1	NA	unadjusted_pval_char	[0.21;0.86]
10.1007/s12325-019-01173-4	results	1	NA	adjusted_effect	0.41
10.1007/s12325-019-01173-4	results	1	NA	adjusted_pval_char	[0.20;0.85]
10.1007/s12325-019-01173-4	results	1	NA	geographical region	NA
10.1007/s12325-019-01173-4	results	1	NA	n_ipd_total	NA
10.1007/s12325-019-01173-4	results	1	NA	ess_total	NA
10.1007/s12325-019-01173-4	results	1	NA	n_nonipd_total	NA
10.1007/s12325-019-01173-4	results	1	NA	n_nonipd_anchor	NA
10.1007/s12325-019-01173-4	results	1	NA	n_ipd_anchor	NA
10.1007/s12325-019-01173-4	results	1	NA	ess_anchor	NA
10.1007/s12325-019-01173-4	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-019-01173-4	results	1	NA	effect_cutoff	1
10.1007/s12325-019-01173-4	results	1	NA	unadjusted_lb_ci	0.21
10.1007/s12325-019-01173-4	results	1	NA	unadjusted_ub_ci	0.86
10.1007/s12325-019-01173-4	results	1	NA	unadjusted_significant	TRUE
10.1007/s12325-019-01173-4	results	1	NA	adjusted_lb_ci	0.2
10.1007/s12325-019-01173-4	results	1	NA	adjusted_ub_ci	0.85
10.1007/s12325-019-01173-4	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-019-01173-4	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-019-01173-4	study_information	NA	1	Clinical Trial	No
10.1007/s12325-019-01173-4	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	solimene et al. doi: 10.1007/s10840-018-0420-5
10.1007/s12325-019-01173-4	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1007/s12325-019-01173-4	study_information	NA	2	Patient-level data used	No
10.1007/s12325-019-01173-4	study_information	NA	2	Clinical Trial	No
10.1007/s12325-019-01173-4	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	jourda et al.
10.1007/s12325-019-01173-4	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.1007/s12325-019-01173-4	study_information	NA	3	Patient-level data used	No
10.1007/s12325-019-01173-4	study_information	NA	3	Clinical Trial	No
10.1007/s12325-019-01173-4	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	giovanni et al. 10.1111/jce.12409
10.1007/s12325-019-01173-4	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	belgium
10.1007/s12325-019-01173-4	study_information	NA	4	Patient-level data used	No
10.1007/s12325-019-01173-4	study_information	NA	4	Clinical Trial	No
10.1007/s12325-019-01173-4	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	zhao et al. doi: 10.1016/j.acvd.2017.01.015
10.1007/s12325-019-01173-4	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.1007/s12325-019-0873-7	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory acute lymphoblastic leukemia
10.1007/s12325-019-0873-7	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s12325-019-0873-7	general_information	NA	NA	Countries of last author affiliations	uk
10.1007/s12325-019-0873-7	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-0873-7	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-019-0873-7	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-019-0873-7	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-019-0873-7	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-019-0873-7	methodology	1	NA	primary_outcome_name	restricted mean survival time
10.1007/s12325-019-0873-7	methodology	1	NA	outcome_short_name	Restricted Mean Survival Time
10.1007/s12325-019-0873-7	methodology	1	NA	primary_outcome_type	Time-to-event
10.1007/s12325-019-0873-7	methodology	1	NA	Treatment name 1	blinatumomab
10.1007/s12325-019-0873-7	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-019-0873-7	methodology	1	NA	Treatment name 2	inotuzumab ozogamicin
10.1007/s12325-019-0873-7	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-019-0873-7	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-019-0873-7	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-019-0873-7	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-0873-7	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-0873-7	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1007/s12325-019-0873-7	methodology	1	NA	prognostic_factors_yn	No
10.1007/s12325-019-0873-7	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-019-0873-7	methodology	1	NA	weights_model_yn	No
10.1007/s12325-019-0873-7	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-019-0873-7	methodology	2	NA	primary_outcome_name	restricted mean survival time
10.1007/s12325-019-0873-7	methodology	2	NA	outcome_short_name	Restricted Mean Survival Time
10.1007/s12325-019-0873-7	methodology	2	NA	primary_outcome_type	Time-to-event
10.1007/s12325-019-0873-7	methodology	2	NA	Treatment name 1	blinatumomab
10.1007/s12325-019-0873-7	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-019-0873-7	methodology	2	NA	Treatment name 2	inotuzumab ozogamicin
10.1007/s12325-019-0873-7	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-019-0873-7	methodology	2	NA	paitc_type	MAIC
10.1007/s12325-019-0873-7	methodology	2	NA	anchored_yn	No
10.1007/s12325-019-0873-7	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-0873-7	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-0873-7	methodology	2	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1007/s12325-019-0873-7	methodology	2	NA	prognostic_factors_yn	No
10.1007/s12325-019-0873-7	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-019-0873-7	methodology	2	NA	weights_model_yn	No
10.1007/s12325-019-0873-7	methodology	2	NA	scale_choice_yn	No
10.1007/s12325-019-0873-7	results	1	NA	contrast	Means difference
10.1007/s12325-019-0873-7	results	1	NA	direction_benefit	superior
10.1007/s12325-019-0873-7	results	1	NA	n_nonipd_ttt	164
10.1007/s12325-019-0873-7	results	1	NA	n_ipd_ttt	203
10.1007/s12325-019-0873-7	results	1	NA	ess_ttt	107
10.1007/s12325-019-0873-7	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-019-0873-7	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-019-0873-7	results	1	NA	n_covariates	9
10.1007/s12325-019-0873-7	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-019-0873-7	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-019-0873-7	results	1	NA	unadjusted_effect	1.02
10.1007/s12325-019-0873-7	results	1	NA	unadjusted_pval_char	0.16
10.1007/s12325-019-0873-7	results	1	NA	adjusted_effect	1.62
10.1007/s12325-019-0873-7	results	1	NA	adjusted_pval_char	0.04
10.1007/s12325-019-0873-7	results	1	NA	geographical region	NA
10.1007/s12325-019-0873-7	results	1	NA	n_ipd_total	NA
10.1007/s12325-019-0873-7	results	1	NA	ess_total	NA
10.1007/s12325-019-0873-7	results	1	NA	n_nonipd_total	NA
10.1007/s12325-019-0873-7	results	1	NA	n_nonipd_anchor	162
10.1007/s12325-019-0873-7	results	1	NA	n_ipd_anchor	107
10.1007/s12325-019-0873-7	results	1	NA	ess_anchor	NA
10.1007/s12325-019-0873-7	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-019-0873-7	results	1	NA	effect_cutoff	0
10.1007/s12325-019-0873-7	results	1	NA	unadjusted_pval	0.16
10.1007/s12325-019-0873-7	results	1	NA	unadjusted_num_pval	0.16
10.1007/s12325-019-0873-7	results	1	NA	unadjusted_significant	FALSE
10.1007/s12325-019-0873-7	results	1	NA	adjusted_pval	0.04
10.1007/s12325-019-0873-7	results	1	NA	adjusted_num_pval	0.04
10.1007/s12325-019-0873-7	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-019-0873-7	results	2	NA	contrast	Means difference
10.1007/s12325-019-0873-7	results	2	NA	direction_benefit	superior
10.1007/s12325-019-0873-7	results	2	NA	n_nonipd_ttt	164
10.1007/s12325-019-0873-7	results	2	NA	n_ipd_ttt	203
10.1007/s12325-019-0873-7	results	2	NA	ess_ttt	NA
10.1007/s12325-019-0873-7	results	2	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-019-0873-7	results	2	NA	list_covariates_yn	Yes
10.1007/s12325-019-0873-7	results	2	NA	n_covariates	9
10.1007/s12325-019-0873-7	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-019-0873-7	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-019-0873-7	results	2	NA	unadjusted_effect	-0.18
10.1007/s12325-019-0873-7	results	2	NA	unadjusted_pval_char	0.69
10.1007/s12325-019-0873-7	results	2	NA	adjusted_effect	0.15
10.1007/s12325-019-0873-7	results	2	NA	adjusted_pval_char	0.76
10.1007/s12325-019-0873-7	results	2	NA	geographical region	NA
10.1007/s12325-019-0873-7	results	2	NA	n_ipd_total	NA
10.1007/s12325-019-0873-7	results	2	NA	ess_total	NA
10.1007/s12325-019-0873-7	results	2	NA	n_nonipd_total	NA
10.1007/s12325-019-0873-7	results	2	NA	n_nonipd_anchor	NA
10.1007/s12325-019-0873-7	results	2	NA	n_ipd_anchor	NA
10.1007/s12325-019-0873-7	results	2	NA	ess_anchor	NA
10.1007/s12325-019-0873-7	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-019-0873-7	results	2	NA	effect_cutoff	0
10.1007/s12325-019-0873-7	results	2	NA	unadjusted_pval	0.69
10.1007/s12325-019-0873-7	results	2	NA	unadjusted_num_pval	0.69
10.1007/s12325-019-0873-7	results	2	NA	unadjusted_significant	FALSE
10.1007/s12325-019-0873-7	results	2	NA	adjusted_pval	0.76
10.1007/s12325-019-0873-7	results	2	NA	adjusted_num_pval	0.76
10.1007/s12325-019-0873-7	results	2	NA	adjusted_significant	FALSE
10.1007/s12325-019-0873-7	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-019-0873-7	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-019-0873-7	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02013167
10.1007/s12325-019-0873-7	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-0873-7	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-0873-7	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-0873-7	study_information	NA	2	Patient-level data used	No
10.1007/s12325-019-0873-7	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-019-0873-7	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01564784
10.1007/s12325-019-0873-7	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-0873-7	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-0873-7	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-020-01298-x	general_information	NA	NA	Medical Condition of Interest Name	age-related macular degeneration
10.1007/s12325-020-01298-x	general_information	NA	NA	Countries of first author affiliations	japan
10.1007/s12325-020-01298-x	general_information	NA	NA	Countries of last author affiliations	germany
10.1007/s12325-020-01298-x	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-020-01298-x	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-020-01298-x	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-020-01298-x	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-020-01298-x	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-020-01298-x	methodology	1	NA	primary_outcome_name	number of etdrs (early treatment diabetic retinopathy study) letters gained vs baseline after 2 years
10.1007/s12325-020-01298-x	methodology	1	NA	outcome_short_name	ETDRS letters gained
10.1007/s12325-020-01298-x	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1007/s12325-020-01298-x	methodology	1	NA	Treatment name 1	intravitreally administered aflibercept (ivt-afl) with 2 weeks adjustment
10.1007/s12325-020-01298-x	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-020-01298-x	methodology	1	NA	Treatment name 2	intravitreally administered aflibercept (ivt-afl) : one injection every 8 weeks in the first year followed by prorenata regimen in the second year
10.1007/s12325-020-01298-x	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1007/s12325-020-01298-x	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-020-01298-x	methodology	1	NA	anchored_yn	No
10.1007/s12325-020-01298-x	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-020-01298-x	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01298-x	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1007/s12325-020-01298-x	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01298-x	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01298-x	methodology	1	NA	weights_model_yn	No
10.1007/s12325-020-01298-x	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-020-01298-x	results	1	NA	contrast	Median difference
10.1007/s12325-020-01298-x	results	1	NA	direction_benefit	superior
10.1007/s12325-020-01298-x	results	1	NA	n_nonipd_ttt	607
10.1007/s12325-020-01298-x	results	1	NA	n_ipd_ttt	124
10.1007/s12325-020-01298-x	results	1	NA	ess_ttt	NA
10.1007/s12325-020-01298-x	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-020-01298-x	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-020-01298-x	results	1	NA	n_covariates	3
10.1007/s12325-020-01298-x	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1007/s12325-020-01298-x	results	1	NA	effect_direction	Denominator if ratio, or rightside if difference
10.1007/s12325-020-01298-x	results	1	NA	unadjusted_effect	NA
10.1007/s12325-020-01298-x	results	1	NA	unadjusted_pval_char	NA
10.1007/s12325-020-01298-x	results	1	NA	adjusted_effect	-0.99
10.1007/s12325-020-01298-x	results	1	NA	adjusted_pval_char	[-3.90;1.93]
10.1007/s12325-020-01298-x	results	1	NA	geographical region	NA
10.1007/s12325-020-01298-x	results	1	NA	n_ipd_total	NA
10.1007/s12325-020-01298-x	results	1	NA	ess_total	NA
10.1007/s12325-020-01298-x	results	1	NA	n_nonipd_total	NA
10.1007/s12325-020-01298-x	results	1	NA	n_nonipd_anchor	NA
10.1007/s12325-020-01298-x	results	1	NA	n_ipd_anchor	NA
10.1007/s12325-020-01298-x	results	1	NA	ess_anchor	NA
10.1007/s12325-020-01298-x	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-020-01298-x	results	1	NA	effect_cutoff	0
10.1007/s12325-020-01298-x	results	1	NA	adjusted_lb_ci	-3.9
10.1007/s12325-020-01298-x	results	1	NA	adjusted_ub_ci	1.93
10.1007/s12325-020-01298-x	results	1	NA	adjusted_significant	FALSE
10.1007/s12325-020-01298-x	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-020-01298-x	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-020-01298-x	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02305238
10.1007/s12325-020-01298-x	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.1007/s12325-020-01298-x	study_information	NA	1	Phase of the clinical trial (clinical trial only)	4
10.1007/s12325-020-01298-x	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1007/s12325-020-01298-x	study_information	NA	2	Patient-level data used	No
10.1007/s12325-020-01298-x	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-020-01298-x	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00509795
10.1007/s12325-020-01298-x	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-020-01298-x	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-020-01298-x	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-020-01298-x	study_information	NA	3	Patient-level data used	No
10.1007/s12325-020-01298-x	study_information	NA	3	Clinical Trial	Yes
10.1007/s12325-020-01298-x	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00637377
10.1007/s12325-020-01298-x	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-020-01298-x	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-020-01298-x	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-020-01378-y	general_information	NA	NA	Medical Condition of Interest Name	advanced hepatocellular carcinoma
10.1007/s12325-020-01378-y	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s12325-020-01378-y	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s12325-020-01378-y	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-020-01378-y	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-020-01378-y	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-020-01378-y	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-020-01378-y	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-020-01378-y	methodology	1	NA	primary_outcome_name	overall survival
10.1007/s12325-020-01378-y	methodology	1	NA	outcome_short_name	Overall Survival
10.1007/s12325-020-01378-y	methodology	1	NA	primary_outcome_type	Time-to-event
10.1007/s12325-020-01378-y	methodology	1	NA	Treatment name 1	cabozantinib
10.1007/s12325-020-01378-y	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-020-01378-y	methodology	1	NA	Treatment name 2	regorafenib
10.1007/s12325-020-01378-y	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-020-01378-y	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-020-01378-y	methodology	1	NA	anchored_yn	No
10.1007/s12325-020-01378-y	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01378-y	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01378-y	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-020-01378-y	methodology	1	NA	prognostic_factors_yn	No
10.1007/s12325-020-01378-y	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-020-01378-y	methodology	1	NA	weights_model_yn	No
10.1007/s12325-020-01378-y	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-020-01378-y	results	1	NA	contrast	Median difference
10.1007/s12325-020-01378-y	results	1	NA	direction_benefit	superior
10.1007/s12325-020-01378-y	results	1	NA	n_nonipd_ttt	379
10.1007/s12325-020-01378-y	results	1	NA	n_ipd_ttt	326
10.1007/s12325-020-01378-y	results	1	NA	ess_ttt	187
10.1007/s12325-020-01378-y	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-020-01378-y	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-020-01378-y	results	1	NA	n_covariates	11
10.1007/s12325-020-01378-y	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1007/s12325-020-01378-y	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-020-01378-y	results	1	NA	unadjusted_effect	NA
10.1007/s12325-020-01378-y	results	1	NA	unadjusted_pval_char	NA
10.1007/s12325-020-01378-y	results	1	NA	adjusted_effect	0.8
10.1007/s12325-020-01378-y	results	1	NA	adjusted_pval_char	0.3474
10.1007/s12325-020-01378-y	results	1	NA	geographical region	Yes
10.1007/s12325-020-01378-y	results	1	NA	n_ipd_total	NA
10.1007/s12325-020-01378-y	results	1	NA	ess_total	NA
10.1007/s12325-020-01378-y	results	1	NA	n_nonipd_total	NA
10.1007/s12325-020-01378-y	results	1	NA	n_nonipd_anchor	NA
10.1007/s12325-020-01378-y	results	1	NA	n_ipd_anchor	NA
10.1007/s12325-020-01378-y	results	1	NA	ess_anchor	NA
10.1007/s12325-020-01378-y	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-020-01378-y	results	1	NA	effect_cutoff	0
10.1007/s12325-020-01378-y	results	1	NA	adjusted_pval	0.3474
10.1007/s12325-020-01378-y	results	1	NA	adjusted_num_pval	0.3474
10.1007/s12325-020-01378-y	results	1	NA	adjusted_significant	FALSE
10.1007/s12325-020-01378-y	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-020-01378-y	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-020-01378-y	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01908426
10.1007/s12325-020-01378-y	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-020-01378-y	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-020-01378-y	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-020-01378-y	study_information	NA	2	Patient-level data used	No
10.1007/s12325-020-01378-y	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-020-01378-y	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01774344
10.1007/s12325-020-01378-y	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-020-01378-y	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-020-01378-y	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-020-01599-1	general_information	NA	NA	Medical Condition of Interest Name	haemophilia a
10.1007/s12325-020-01599-1	general_information	NA	NA	Countries of first author affiliations	sweden
10.1007/s12325-020-01599-1	general_information	NA	NA	Countries of last author affiliations	sweden
10.1007/s12325-020-01599-1	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1007/s12325-020-01599-1	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1007/s12325-020-01599-1	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-020-01599-1	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-020-01599-1	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-020-01599-1	methodology	1	NA	primary_outcome_name	mean annualized bleeding rates
10.1007/s12325-020-01599-1	methodology	1	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.1007/s12325-020-01599-1	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1007/s12325-020-01599-1	methodology	1	NA	Treatment name 1	recombinant fviiifc
10.1007/s12325-020-01599-1	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-020-01599-1	methodology	1	NA	Treatment name 2	damoctocog alfa pegol (pooled prophylaxis)
10.1007/s12325-020-01599-1	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-020-01599-1	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-020-01599-1	methodology	1	NA	anchored_yn	No
10.1007/s12325-020-01599-1	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01599-1	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01599-1	methodology	1	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-020-01599-1	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01599-1	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01599-1	methodology	1	NA	weights_model_yn	Yes
10.1007/s12325-020-01599-1	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-020-01599-1	methodology	2	NA	primary_outcome_name	mean annualised bleeding rate
10.1007/s12325-020-01599-1	methodology	2	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.1007/s12325-020-01599-1	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1007/s12325-020-01599-1	methodology	2	NA	Treatment name 1	recombinant fviiifc
10.1007/s12325-020-01599-1	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-020-01599-1	methodology	2	NA	Treatment name 2	damoctocog alfa pegol twice weekly
10.1007/s12325-020-01599-1	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-020-01599-1	methodology	2	NA	paitc_type	MAIC
10.1007/s12325-020-01599-1	methodology	2	NA	anchored_yn	No
10.1007/s12325-020-01599-1	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01599-1	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01599-1	methodology	2	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-020-01599-1	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01599-1	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01599-1	methodology	2	NA	weights_model_yn	Yes
10.1007/s12325-020-01599-1	methodology	2	NA	scale_choice_yn	No
10.1007/s12325-020-01599-1	methodology	3	NA	primary_outcome_name	mean annualised bleeding rate
10.1007/s12325-020-01599-1	methodology	3	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.1007/s12325-020-01599-1	methodology	3	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1007/s12325-020-01599-1	methodology	3	NA	Treatment name 1	recombinant fviiifc
10.1007/s12325-020-01599-1	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-020-01599-1	methodology	3	NA	Treatment name 2	damoctocog alfa pegol q5d
10.1007/s12325-020-01599-1	methodology	3	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-020-01599-1	methodology	3	NA	paitc_type	MAIC
10.1007/s12325-020-01599-1	methodology	3	NA	anchored_yn	No
10.1007/s12325-020-01599-1	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01599-1	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01599-1	methodology	3	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-020-01599-1	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01599-1	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01599-1	methodology	3	NA	weights_model_yn	Yes
10.1007/s12325-020-01599-1	methodology	3	NA	scale_choice_yn	No
10.1007/s12325-020-01599-1	methodology	4	NA	primary_outcome_name	mean annualised bleeding rate
10.1007/s12325-020-01599-1	methodology	4	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.1007/s12325-020-01599-1	methodology	4	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1007/s12325-020-01599-1	methodology	4	NA	Treatment name 1	recombinant fviiifc
10.1007/s12325-020-01599-1	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-020-01599-1	methodology	4	NA	Treatment name 2	damoctocog alfa pegol q7d
10.1007/s12325-020-01599-1	methodology	4	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-020-01599-1	methodology	4	NA	paitc_type	MAIC
10.1007/s12325-020-01599-1	methodology	4	NA	anchored_yn	No
10.1007/s12325-020-01599-1	methodology	4	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01599-1	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01599-1	methodology	4	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-020-01599-1	methodology	4	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01599-1	methodology	4	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01599-1	methodology	4	NA	weights_model_yn	Yes
10.1007/s12325-020-01599-1	methodology	4	NA	scale_choice_yn	No
10.1007/s12325-020-01599-1	results	1	NA	contrast	Means difference
10.1007/s12325-020-01599-1	results	1	NA	direction_benefit	inferior
10.1007/s12325-020-01599-1	results	1	NA	n_nonipd_ttt	110
10.1007/s12325-020-01599-1	results	1	NA	n_ipd_ttt	117
10.1007/s12325-020-01599-1	results	1	NA	ess_ttt	81
10.1007/s12325-020-01599-1	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-020-01599-1	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-020-01599-1	results	1	NA	n_covariates	6
10.1007/s12325-020-01599-1	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s12325-020-01599-1	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-020-01599-1	results	1	NA	unadjusted_effect	-2
10.1007/s12325-020-01599-1	results	1	NA	unadjusted_pval_char	[-3.5;-0.4]
10.1007/s12325-020-01599-1	results	1	NA	adjusted_effect	-1.9
10.1007/s12325-020-01599-1	results	1	NA	adjusted_pval_char	[-3.5;-0.4]
10.1007/s12325-020-01599-1	results	1	NA	geographical region	No
10.1007/s12325-020-01599-1	results	1	NA	n_ipd_total	NA
10.1007/s12325-020-01599-1	results	1	NA	ess_total	NA
10.1007/s12325-020-01599-1	results	1	NA	n_nonipd_total	NA
10.1007/s12325-020-01599-1	results	1	NA	n_nonipd_anchor	NA
10.1007/s12325-020-01599-1	results	1	NA	n_ipd_anchor	NA
10.1007/s12325-020-01599-1	results	1	NA	ess_anchor	NA
10.1007/s12325-020-01599-1	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-020-01599-1	results	1	NA	effect_cutoff	0
10.1007/s12325-020-01599-1	results	1	NA	unadjusted_lb_ci	-3.5
10.1007/s12325-020-01599-1	results	1	NA	unadjusted_ub_ci	-0.4
10.1007/s12325-020-01599-1	results	1	NA	unadjusted_significant	TRUE
10.1007/s12325-020-01599-1	results	1	NA	adjusted_lb_ci	-3.5
10.1007/s12325-020-01599-1	results	1	NA	adjusted_ub_ci	-0.4
10.1007/s12325-020-01599-1	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-020-01599-1	results	2	NA	contrast	Means difference
10.1007/s12325-020-01599-1	results	2	NA	direction_benefit	inferior
10.1007/s12325-020-01599-1	results	2	NA	n_nonipd_ttt	24
10.1007/s12325-020-01599-1	results	2	NA	n_ipd_ttt	117
10.1007/s12325-020-01599-1	results	2	NA	ess_ttt	62
10.1007/s12325-020-01599-1	results	2	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-020-01599-1	results	2	NA	list_covariates_yn	Yes
10.1007/s12325-020-01599-1	results	2	NA	n_covariates	6
10.1007/s12325-020-01599-1	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s12325-020-01599-1	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-020-01599-1	results	2	NA	unadjusted_effect	-2
10.1007/s12325-020-01599-1	results	2	NA	unadjusted_pval_char	[-4.6;0.6]
10.1007/s12325-020-01599-1	results	2	NA	adjusted_effect	-1.6
10.1007/s12325-020-01599-1	results	2	NA	adjusted_pval_char	[-4.2;1.1]
10.1007/s12325-020-01599-1	results	2	NA	geographical region	No
10.1007/s12325-020-01599-1	results	2	NA	n_ipd_total	NA
10.1007/s12325-020-01599-1	results	2	NA	ess_total	NA
10.1007/s12325-020-01599-1	results	2	NA	n_nonipd_total	NA
10.1007/s12325-020-01599-1	results	2	NA	n_nonipd_anchor	NA
10.1007/s12325-020-01599-1	results	2	NA	n_ipd_anchor	NA
10.1007/s12325-020-01599-1	results	2	NA	ess_anchor	NA
10.1007/s12325-020-01599-1	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-020-01599-1	results	2	NA	effect_cutoff	0
10.1007/s12325-020-01599-1	results	2	NA	unadjusted_lb_ci	-4.6
10.1007/s12325-020-01599-1	results	2	NA	unadjusted_ub_ci	0.6
10.1007/s12325-020-01599-1	results	2	NA	unadjusted_significant	FALSE
10.1007/s12325-020-01599-1	results	2	NA	adjusted_lb_ci	-4.2
10.1007/s12325-020-01599-1	results	2	NA	adjusted_ub_ci	1.1
10.1007/s12325-020-01599-1	results	2	NA	adjusted_significant	FALSE
10.1007/s12325-020-01599-1	results	3	NA	contrast	Means difference
10.1007/s12325-020-01599-1	results	3	NA	direction_benefit	inferior
10.1007/s12325-020-01599-1	results	3	NA	n_nonipd_ttt	43
10.1007/s12325-020-01599-1	results	3	NA	n_ipd_ttt	117
10.1007/s12325-020-01599-1	results	3	NA	ess_ttt	79
10.1007/s12325-020-01599-1	results	3	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-020-01599-1	results	3	NA	list_covariates_yn	Yes
10.1007/s12325-020-01599-1	results	3	NA	n_covariates	6
10.1007/s12325-020-01599-1	results	3	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s12325-020-01599-1	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-020-01599-1	results	3	NA	unadjusted_effect	-0.4
10.1007/s12325-020-01599-1	results	3	NA	unadjusted_pval_char	[-1.9;1.1]
10.1007/s12325-020-01599-1	results	3	NA	adjusted_effect	-0.6
10.1007/s12325-020-01599-1	results	3	NA	adjusted_pval_char	[-2.0;0.8]
10.1007/s12325-020-01599-1	results	3	NA	geographical region	No
10.1007/s12325-020-01599-1	results	3	NA	n_ipd_total	NA
10.1007/s12325-020-01599-1	results	3	NA	ess_total	NA
10.1007/s12325-020-01599-1	results	3	NA	n_nonipd_total	NA
10.1007/s12325-020-01599-1	results	3	NA	n_nonipd_anchor	NA
10.1007/s12325-020-01599-1	results	3	NA	n_ipd_anchor	NA
10.1007/s12325-020-01599-1	results	3	NA	ess_anchor	NA
10.1007/s12325-020-01599-1	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-020-01599-1	results	3	NA	effect_cutoff	0
10.1007/s12325-020-01599-1	results	3	NA	unadjusted_lb_ci	-1.9
10.1007/s12325-020-01599-1	results	3	NA	unadjusted_ub_ci	1.1
10.1007/s12325-020-01599-1	results	3	NA	unadjusted_significant	FALSE
10.1007/s12325-020-01599-1	results	3	NA	adjusted_lb_ci	-2
10.1007/s12325-020-01599-1	results	3	NA	adjusted_ub_ci	0.8
10.1007/s12325-020-01599-1	results	3	NA	adjusted_significant	FALSE
10.1007/s12325-020-01599-1	results	4	NA	contrast	Means difference
10.1007/s12325-020-01599-1	results	4	NA	direction_benefit	inferior
10.1007/s12325-020-01599-1	results	4	NA	n_nonipd_ttt	43
10.1007/s12325-020-01599-1	results	4	NA	n_ipd_ttt	117
10.1007/s12325-020-01599-1	results	4	NA	ess_ttt	45
10.1007/s12325-020-01599-1	results	4	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-020-01599-1	results	4	NA	list_covariates_yn	Yes
10.1007/s12325-020-01599-1	results	4	NA	n_covariates	6
10.1007/s12325-020-01599-1	results	4	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s12325-020-01599-1	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-020-01599-1	results	4	NA	unadjusted_effect	-3.5
10.1007/s12325-020-01599-1	results	4	NA	unadjusted_pval_char	[-6.6;-0.4]
10.1007/s12325-020-01599-1	results	4	NA	adjusted_effect	-3.3
10.1007/s12325-020-01599-1	results	4	NA	adjusted_pval_char	[-6.4;-0.2]
10.1007/s12325-020-01599-1	results	4	NA	geographical region	No
10.1007/s12325-020-01599-1	results	4	NA	n_ipd_total	NA
10.1007/s12325-020-01599-1	results	4	NA	ess_total	NA
10.1007/s12325-020-01599-1	results	4	NA	n_nonipd_total	NA
10.1007/s12325-020-01599-1	results	4	NA	n_nonipd_anchor	NA
10.1007/s12325-020-01599-1	results	4	NA	n_ipd_anchor	NA
10.1007/s12325-020-01599-1	results	4	NA	ess_anchor	NA
10.1007/s12325-020-01599-1	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-020-01599-1	results	4	NA	effect_cutoff	0
10.1007/s12325-020-01599-1	results	4	NA	unadjusted_lb_ci	-6.6
10.1007/s12325-020-01599-1	results	4	NA	unadjusted_ub_ci	-0.4
10.1007/s12325-020-01599-1	results	4	NA	unadjusted_significant	TRUE
10.1007/s12325-020-01599-1	results	4	NA	adjusted_lb_ci	-6.4
10.1007/s12325-020-01599-1	results	4	NA	adjusted_ub_ci	-0.2
10.1007/s12325-020-01599-1	results	4	NA	adjusted_significant	TRUE
10.1007/s12325-020-01599-1	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-020-01599-1	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-020-01599-1	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01181128
10.1007/s12325-020-01599-1	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-020-01599-1	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-020-01599-1	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1007/s12325-020-01599-1	study_information	NA	2	Patient-level data used	No
10.1007/s12325-020-01599-1	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-020-01599-1	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01580293
10.1007/s12325-020-01599-1	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-020-01599-1	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3
10.1007/s12325-020-01599-1	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-021-01700-2	general_information	NA	NA	Medical Condition of Interest Name	hepatocellular carcinoma
10.1007/s12325-021-01700-2	general_information	NA	NA	Countries of first author affiliations	germany
10.1007/s12325-021-01700-2	general_information	NA	NA	Countries of last author affiliations	germany
10.1007/s12325-021-01700-2	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01700-2	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-021-01700-2	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-021-01700-2	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-021-01700-2	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-021-01700-2	methodology	1	NA	primary_outcome_name	overall survival
10.1007/s12325-021-01700-2	methodology	1	NA	outcome_short_name	Overall Survival
10.1007/s12325-021-01700-2	methodology	1	NA	primary_outcome_type	Time-to-event
10.1007/s12325-021-01700-2	methodology	1	NA	Treatment name 1	cabozantinib
10.1007/s12325-021-01700-2	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-021-01700-2	methodology	1	NA	Treatment name 2	ramucirumab
10.1007/s12325-021-01700-2	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-021-01700-2	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-021-01700-2	methodology	1	NA	anchored_yn	No
10.1007/s12325-021-01700-2	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01700-2	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01700-2	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-021-01700-2	methodology	1	NA	prognostic_factors_yn	No
10.1007/s12325-021-01700-2	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-021-01700-2	methodology	1	NA	weights_model_yn	No
10.1007/s12325-021-01700-2	methodology	1	NA	scale_choice_yn	Yes
10.1007/s12325-021-01700-2	results	1	NA	contrast	Median difference
10.1007/s12325-021-01700-2	results	1	NA	direction_benefit	superior
10.1007/s12325-021-01700-2	results	1	NA	n_nonipd_ttt	197
10.1007/s12325-021-01700-2	results	1	NA	n_ipd_ttt	114
10.1007/s12325-021-01700-2	results	1	NA	ess_ttt	63
10.1007/s12325-021-01700-2	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s12325-021-01700-2	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-021-01700-2	results	1	NA	n_covariates	9
10.1007/s12325-021-01700-2	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1007/s12325-021-01700-2	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01700-2	results	1	NA	unadjusted_effect	NA
10.1007/s12325-021-01700-2	results	1	NA	unadjusted_pval_char	NA
10.1007/s12325-021-01700-2	results	1	NA	adjusted_effect	1.9
10.1007/s12325-021-01700-2	results	1	NA	adjusted_pval_char	0.104
10.1007/s12325-021-01700-2	results	1	NA	geographical region	NA
10.1007/s12325-021-01700-2	results	1	NA	n_ipd_total	NA
10.1007/s12325-021-01700-2	results	1	NA	ess_total	NA
10.1007/s12325-021-01700-2	results	1	NA	n_nonipd_total	NA
10.1007/s12325-021-01700-2	results	1	NA	n_nonipd_anchor	NA
10.1007/s12325-021-01700-2	results	1	NA	n_ipd_anchor	NA
10.1007/s12325-021-01700-2	results	1	NA	ess_anchor	NA
10.1007/s12325-021-01700-2	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-021-01700-2	results	1	NA	effect_cutoff	0
10.1007/s12325-021-01700-2	results	1	NA	adjusted_pval	0.104
10.1007/s12325-021-01700-2	results	1	NA	adjusted_num_pval	0.104
10.1007/s12325-021-01700-2	results	1	NA	adjusted_significant	FALSE
10.1007/s12325-021-01700-2	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-021-01700-2	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-021-01700-2	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01908426
10.1007/s12325-021-01700-2	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01700-2	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-021-01700-2	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-021-01700-2	study_information	NA	2	Patient-level data used	No
10.1007/s12325-021-01700-2	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-021-01700-2	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02435433
10.1007/s12325-021-01700-2	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01700-2	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-021-01700-2	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-021-01756-0	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory diffuse large b-cell lymphoma
10.1007/s12325-021-01756-0	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s12325-021-01756-0	general_information	NA	NA	Countries of last author affiliations	switzerland
10.1007/s12325-021-01756-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01756-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-021-01756-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-021-01756-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-021-01756-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-021-01756-0	methodology	1	NA	primary_outcome_name	objective response rate (orr)
10.1007/s12325-021-01756-0	methodology	1	NA	outcome_short_name	Objective Response Rate
10.1007/s12325-021-01756-0	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1007/s12325-021-01756-0	methodology	1	NA	Treatment name 1	lisocabtagene maraleucel
10.1007/s12325-021-01756-0	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-021-01756-0	methodology	1	NA	Treatment name 2	salvage chemotherapy
10.1007/s12325-021-01756-0	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-021-01756-0	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-021-01756-0	methodology	1	NA	anchored_yn	No
10.1007/s12325-021-01756-0	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01756-0	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01756-0	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1007/s12325-021-01756-0	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-021-01756-0	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-021-01756-0	methodology	1	NA	weights_model_yn	No
10.1007/s12325-021-01756-0	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-021-01756-0	results	1	NA	contrast	OR
10.1007/s12325-021-01756-0	results	1	NA	direction_benefit	superior
10.1007/s12325-021-01756-0	results	1	NA	n_nonipd_ttt	523
10.1007/s12325-021-01756-0	results	1	NA	n_ipd_ttt	248
10.1007/s12325-021-01756-0	results	1	NA	ess_ttt	142
10.1007/s12325-021-01756-0	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-021-01756-0	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-021-01756-0	results	1	NA	n_covariates	7
10.1007/s12325-021-01756-0	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1007/s12325-021-01756-0	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01756-0	results	1	NA	unadjusted_effect	7.7
10.1007/s12325-021-01756-0	results	1	NA	unadjusted_pval_char	<0.001
10.1007/s12325-021-01756-0	results	1	NA	adjusted_effect	7
10.1007/s12325-021-01756-0	results	1	NA	adjusted_pval_char	<0.001
10.1007/s12325-021-01756-0	results	1	NA	geographical region	NA
10.1007/s12325-021-01756-0	results	1	NA	n_ipd_total	NA
10.1007/s12325-021-01756-0	results	1	NA	ess_total	NA
10.1007/s12325-021-01756-0	results	1	NA	n_nonipd_total	NA
10.1007/s12325-021-01756-0	results	1	NA	n_nonipd_anchor	NA
10.1007/s12325-021-01756-0	results	1	NA	n_ipd_anchor	NA
10.1007/s12325-021-01756-0	results	1	NA	ess_anchor	NA
10.1007/s12325-021-01756-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-021-01756-0	results	1	NA	effect_cutoff	1
10.1007/s12325-021-01756-0	results	1	NA	unadjusted_pval	<0.001
10.1007/s12325-021-01756-0	results	1	NA	unadjusted_significant	TRUE
10.1007/s12325-021-01756-0	results	1	NA	adjusted_pval	<0.001
10.1007/s12325-021-01756-0	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-021-01756-0	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-021-01756-0	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-021-01756-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02631044
10.1007/s12325-021-01756-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s12325-021-01756-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.1007/s12325-021-01756-0	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1007/s12325-021-01756-0	study_information	NA	2	Patient-level data used	No
10.1007/s12325-021-01756-0	study_information	NA	2	Clinical Trial	No
10.1007/s12325-021-01756-0	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	scholar-1
10.1007/s12325-021-01756-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01846-z	general_information	NA	NA	Medical Condition of Interest Name	persistent atrial fibrillation
10.1007/s12325-021-01846-z	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s12325-021-01846-z	general_information	NA	NA	Countries of last author affiliations	uk
10.1007/s12325-021-01846-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01846-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-021-01846-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-021-01846-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-021-01846-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-021-01846-z	methodology	1	NA	primary_outcome_name	arrhythmia recurrence
10.1007/s12325-021-01846-z	methodology	1	NA	outcome_short_name	Arrhythmia recurrence
10.1007/s12325-021-01846-z	methodology	1	NA	primary_outcome_type	Time-to-event
10.1007/s12325-021-01846-z	methodology	1	NA	Treatment name 1	thermocool smarttouch /thermocool smarttouch sf catheter with ai (stai)
10.1007/s12325-021-01846-z	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3;4
10.1007/s12325-021-01846-z	methodology	1	NA	Treatment name 2	second-generation cryoballoon (cb)
10.1007/s12325-021-01846-z	methodology	1	NA	Study 'number(s)' for treatment 2	5;6;7;8
10.1007/s12325-021-01846-z	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-021-01846-z	methodology	1	NA	anchored_yn	No
10.1007/s12325-021-01846-z	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-021-01846-z	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s12325-021-01846-z	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-021-01846-z	methodology	1	NA	prognostic_factors_yn	Yes
10.1007/s12325-021-01846-z	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-021-01846-z	methodology	1	NA	weights_model_yn	No
10.1007/s12325-021-01846-z	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-021-01846-z	results	1	NA	contrast	HR
10.1007/s12325-021-01846-z	results	1	NA	direction_benefit	inferior
10.1007/s12325-021-01846-z	results	1	NA	n_nonipd_ttt	389
10.1007/s12325-021-01846-z	results	1	NA	n_ipd_ttt	191
10.1007/s12325-021-01846-z	results	1	NA	ess_ttt	156
10.1007/s12325-021-01846-z	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s12325-021-01846-z	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-021-01846-z	results	1	NA	n_covariates	4
10.1007/s12325-021-01846-z	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1007/s12325-021-01846-z	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01846-z	results	1	NA	unadjusted_effect	0.39
10.1007/s12325-021-01846-z	results	1	NA	unadjusted_pval_char	[0.27;0.56]
10.1007/s12325-021-01846-z	results	1	NA	adjusted_effect	0.35
10.1007/s12325-021-01846-z	results	1	NA	adjusted_pval_char	[0.23;0.52]
10.1007/s12325-021-01846-z	results	1	NA	geographical region	NA
10.1007/s12325-021-01846-z	results	1	NA	n_ipd_total	NA
10.1007/s12325-021-01846-z	results	1	NA	ess_total	NA
10.1007/s12325-021-01846-z	results	1	NA	n_nonipd_total	NA
10.1007/s12325-021-01846-z	results	1	NA	n_nonipd_anchor	NA
10.1007/s12325-021-01846-z	results	1	NA	n_ipd_anchor	NA
10.1007/s12325-021-01846-z	results	1	NA	ess_anchor	NA
10.1007/s12325-021-01846-z	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-021-01846-z	results	1	NA	effect_cutoff	1
10.1007/s12325-021-01846-z	results	1	NA	unadjusted_lb_ci	0.27
10.1007/s12325-021-01846-z	results	1	NA	unadjusted_ub_ci	0.56
10.1007/s12325-021-01846-z	results	1	NA	unadjusted_significant	TRUE
10.1007/s12325-021-01846-z	results	1	NA	adjusted_lb_ci	0.23
10.1007/s12325-021-01846-z	results	1	NA	adjusted_ub_ci	0.52
10.1007/s12325-021-01846-z	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-021-01846-z	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-021-01846-z	study_information	NA	1	Clinical Trial	No
10.1007/s12325-021-01846-z	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	hussein et al. (2017)
10.1007/s12325-021-01846-z	study_information	NA	2	Patient-level data used	Yes
10.1007/s12325-021-01846-z	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-021-01846-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02628730
10.1007/s12325-021-01846-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01846-z	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-021-01846-z	study_information	NA	3	Patient-level data used	Yes
10.1007/s12325-021-01846-z	study_information	NA	3	Clinical Trial	No
10.1007/s12325-021-01846-z	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	solimene et al. (2019)
10.1007/s12325-021-01846-z	study_information	NA	4	Patient-level data used	Yes
10.1007/s12325-021-01846-z	study_information	NA	4	Clinical Trial	No
10.1007/s12325-021-01846-z	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03277976
10.1007/s12325-021-01846-z	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.1007/s12325-021-01846-z	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	stabile et al. (2020)
10.1007/s12325-021-01846-z	study_information	NA	5	Patient-level data used	No
10.1007/s12325-021-01846-z	study_information	NA	5	Clinical Trial	No
10.1007/s12325-021-01846-z	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	gramlich et al. (2019)
10.1007/s12325-021-01846-z	study_information	NA	6	Patient-level data used	No
10.1007/s12325-021-01846-z	study_information	NA	6	Clinical Trial	Yes
10.1007/s12325-021-01846-z	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02213731
10.1007/s12325-021-01846-z	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01846-z	study_information	NA	6	Number of treatment arms (clinical trial only)	1
10.1007/s12325-021-01846-z	study_information	NA	7	Patient-level data used	No
10.1007/s12325-021-01846-z	study_information	NA	7	Clinical Trial	No
10.1007/s12325-021-01846-z	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	circonte et al. (2015)
10.1007/s12325-021-01846-z	study_information	NA	8	Patient-level data used	No
10.1007/s12325-021-01846-z	study_information	NA	8	Clinical Trial	Yes
10.1007/s12325-021-01846-z	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03012841
10.1007/s12325-021-01846-z	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01846-z	study_information	NA	8	Number of treatment arms (clinical trial only)	1
10.1007/s12325-021-01853-0	general_information	NA	NA	Medical Condition of Interest Name	severe haemophilia a
10.1007/s12325-021-01853-0	general_information	NA	NA	Countries of first author affiliations	spain
10.1007/s12325-021-01853-0	general_information	NA	NA	Countries of last author affiliations	portugal
10.1007/s12325-021-01853-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01853-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-021-01853-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-021-01853-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-021-01853-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-021-01853-0	methodology	1	NA	primary_outcome_name	annualized bleeding rate (abr),
10.1007/s12325-021-01853-0	methodology	1	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.1007/s12325-021-01853-0	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1007/s12325-021-01853-0	methodology	1	NA	Treatment name 1	rviii-singlechain
10.1007/s12325-021-01853-0	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-021-01853-0	methodology	1	NA	Treatment name 2	rahf-pfm
10.1007/s12325-021-01853-0	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-021-01853-0	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-021-01853-0	methodology	1	NA	anchored_yn	No
10.1007/s12325-021-01853-0	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01853-0	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01853-0	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1007/s12325-021-01853-0	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-021-01853-0	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-021-01853-0	methodology	1	NA	weights_model_yn	No
10.1007/s12325-021-01853-0	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-021-01853-0	methodology	2	NA	primary_outcome_name	annualized bleeding rate (abr)
10.1007/s12325-021-01853-0	methodology	2	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.1007/s12325-021-01853-0	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1007/s12325-021-01853-0	methodology	2	NA	Treatment name 1	rviii-singlechain
10.1007/s12325-021-01853-0	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-021-01853-0	methodology	2	NA	Treatment name 2	rahf-pfm
10.1007/s12325-021-01853-0	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1007/s12325-021-01853-0	methodology	2	NA	paitc_type	MAIC
10.1007/s12325-021-01853-0	methodology	2	NA	anchored_yn	No
10.1007/s12325-021-01853-0	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01853-0	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01853-0	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.1007/s12325-021-01853-0	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-021-01853-0	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-021-01853-0	methodology	2	NA	weights_model_yn	No
10.1007/s12325-021-01853-0	methodology	2	NA	scale_choice_yn	No
10.1007/s12325-021-01853-0	methodology	3	NA	primary_outcome_name	annualized bleeding rate (abr)
10.1007/s12325-021-01853-0	methodology	3	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.1007/s12325-021-01853-0	methodology	3	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1007/s12325-021-01853-0	methodology	3	NA	Treatment name 1	rviii-singlechain
10.1007/s12325-021-01853-0	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-021-01853-0	methodology	3	NA	Treatment name 2	rfviiifc
10.1007/s12325-021-01853-0	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.1007/s12325-021-01853-0	methodology	3	NA	paitc_type	MAIC
10.1007/s12325-021-01853-0	methodology	3	NA	anchored_yn	No
10.1007/s12325-021-01853-0	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01853-0	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01853-0	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.1007/s12325-021-01853-0	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-021-01853-0	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-021-01853-0	methodology	3	NA	weights_model_yn	No
10.1007/s12325-021-01853-0	methodology	3	NA	scale_choice_yn	No
10.1007/s12325-021-01853-0	results	1	NA	contrast	RR
10.1007/s12325-021-01853-0	results	1	NA	direction_benefit	inferior
10.1007/s12325-021-01853-0	results	1	NA	n_nonipd_ttt	111
10.1007/s12325-021-01853-0	results	1	NA	n_ipd_ttt	146
10.1007/s12325-021-01853-0	results	1	NA	ess_ttt	25.1
10.1007/s12325-021-01853-0	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-021-01853-0	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-021-01853-0	results	1	NA	n_covariates	4
10.1007/s12325-021-01853-0	results	1	NA	list_covariates	Age, Race/ethnicity, Other(s)
10.1007/s12325-021-01853-0	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01853-0	results	1	NA	unadjusted_effect	0.55
10.1007/s12325-021-01853-0	results	1	NA	unadjusted_pval_char	[0.17;3.12]
10.1007/s12325-021-01853-0	results	1	NA	adjusted_effect	0.74
10.1007/s12325-021-01853-0	results	1	NA	adjusted_pval_char	[0.16;3.48]
10.1007/s12325-021-01853-0	results	1	NA	geographical region	No
10.1007/s12325-021-01853-0	results	1	NA	n_ipd_total	NA
10.1007/s12325-021-01853-0	results	1	NA	ess_total	NA
10.1007/s12325-021-01853-0	results	1	NA	n_nonipd_total	NA
10.1007/s12325-021-01853-0	results	1	NA	n_nonipd_anchor	NA
10.1007/s12325-021-01853-0	results	1	NA	n_ipd_anchor	NA
10.1007/s12325-021-01853-0	results	1	NA	ess_anchor	NA
10.1007/s12325-021-01853-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-021-01853-0	results	1	NA	effect_cutoff	1
10.1007/s12325-021-01853-0	results	1	NA	unadjusted_lb_ci	0.17
10.1007/s12325-021-01853-0	results	1	NA	unadjusted_ub_ci	3.12
10.1007/s12325-021-01853-0	results	1	NA	unadjusted_significant	FALSE
10.1007/s12325-021-01853-0	results	1	NA	adjusted_lb_ci	0.16
10.1007/s12325-021-01853-0	results	1	NA	adjusted_ub_ci	3.48
10.1007/s12325-021-01853-0	results	1	NA	adjusted_significant	FALSE
10.1007/s12325-021-01853-0	results	2	NA	contrast	RR
10.1007/s12325-021-01853-0	results	2	NA	direction_benefit	inferior
10.1007/s12325-021-01853-0	results	2	NA	n_nonipd_ttt	32
10.1007/s12325-021-01853-0	results	2	NA	n_ipd_ttt	146
10.1007/s12325-021-01853-0	results	2	NA	ess_ttt	79
10.1007/s12325-021-01853-0	results	2	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-021-01853-0	results	2	NA	list_covariates_yn	Yes
10.1007/s12325-021-01853-0	results	2	NA	n_covariates	2
10.1007/s12325-021-01853-0	results	2	NA	list_covariates	Age, Race/ethnicity
10.1007/s12325-021-01853-0	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01853-0	results	2	NA	unadjusted_effect	0.07
10.1007/s12325-021-01853-0	results	2	NA	unadjusted_pval_char	[-3.09;3.23]
10.1007/s12325-021-01853-0	results	2	NA	adjusted_effect	0.01
10.1007/s12325-021-01853-0	results	2	NA	adjusted_pval_char	[-2.36;2.37]
10.1007/s12325-021-01853-0	results	2	NA	geographical region	NA
10.1007/s12325-021-01853-0	results	2	NA	n_ipd_total	NA
10.1007/s12325-021-01853-0	results	2	NA	ess_total	NA
10.1007/s12325-021-01853-0	results	2	NA	n_nonipd_total	NA
10.1007/s12325-021-01853-0	results	2	NA	n_nonipd_anchor	NA
10.1007/s12325-021-01853-0	results	2	NA	n_ipd_anchor	NA
10.1007/s12325-021-01853-0	results	2	NA	ess_anchor	NA
10.1007/s12325-021-01853-0	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-021-01853-0	results	2	NA	effect_cutoff	1
10.1007/s12325-021-01853-0	results	2	NA	unadjusted_lb_ci	-3.09
10.1007/s12325-021-01853-0	results	2	NA	unadjusted_ub_ci	3.23
10.1007/s12325-021-01853-0	results	2	NA	unadjusted_significant	FALSE
10.1007/s12325-021-01853-0	results	2	NA	adjusted_lb_ci	-2.36
10.1007/s12325-021-01853-0	results	2	NA	adjusted_ub_ci	2.37
10.1007/s12325-021-01853-0	results	2	NA	adjusted_significant	FALSE
10.1007/s12325-021-01853-0	results	3	NA	contrast	RR
10.1007/s12325-021-01853-0	results	3	NA	direction_benefit	inferior
10.1007/s12325-021-01853-0	results	3	NA	n_nonipd_ttt	118
10.1007/s12325-021-01853-0	results	3	NA	n_ipd_ttt	146
10.1007/s12325-021-01853-0	results	3	NA	ess_ttt	123.6
10.1007/s12325-021-01853-0	results	3	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-021-01853-0	results	3	NA	list_covariates_yn	Yes
10.1007/s12325-021-01853-0	results	3	NA	n_covariates	4
10.1007/s12325-021-01853-0	results	3	NA	list_covariates	Age, Race/ethnicity, Other(s)
10.1007/s12325-021-01853-0	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01853-0	results	3	NA	unadjusted_effect	1.14
10.1007/s12325-021-01853-0	results	3	NA	unadjusted_pval_char	[0.82;1.57]
10.1007/s12325-021-01853-0	results	3	NA	adjusted_effect	1.18
10.1007/s12325-021-01853-0	results	3	NA	adjusted_pval_char	[0.85;1.65]
10.1007/s12325-021-01853-0	results	3	NA	geographical region	Yes
10.1007/s12325-021-01853-0	results	3	NA	n_ipd_total	NA
10.1007/s12325-021-01853-0	results	3	NA	ess_total	NA
10.1007/s12325-021-01853-0	results	3	NA	n_nonipd_total	NA
10.1007/s12325-021-01853-0	results	3	NA	n_nonipd_anchor	NA
10.1007/s12325-021-01853-0	results	3	NA	n_ipd_anchor	NA
10.1007/s12325-021-01853-0	results	3	NA	ess_anchor	NA
10.1007/s12325-021-01853-0	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-021-01853-0	results	3	NA	effect_cutoff	1
10.1007/s12325-021-01853-0	results	3	NA	unadjusted_lb_ci	0.82
10.1007/s12325-021-01853-0	results	3	NA	unadjusted_ub_ci	1.57
10.1007/s12325-021-01853-0	results	3	NA	unadjusted_significant	FALSE
10.1007/s12325-021-01853-0	results	3	NA	adjusted_lb_ci	0.85
10.1007/s12325-021-01853-0	results	3	NA	adjusted_ub_ci	1.65
10.1007/s12325-021-01853-0	results	3	NA	adjusted_significant	FALSE
10.1007/s12325-021-01853-0	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-021-01853-0	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-021-01853-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01486927
10.1007/s12325-021-01853-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01853-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 3
10.1007/s12325-021-01853-0	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1007/s12325-021-01853-0	study_information	NA	2	Patient-level data used	No
10.1007/s12325-021-01853-0	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-021-01853-0	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	rahf-pfm-2004 - part 2 10.1111/j.1365-2516.2004.00932.x
10.1007/s12325-021-01853-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01853-0	study_information	NA	2	Number of treatment arms (clinical trial only)	??
10.1007/s12325-021-01853-0	study_information	NA	3	Patient-level data used	No
10.1007/s12325-021-01853-0	study_information	NA	3	Clinical Trial	Yes
10.1007/s12325-021-01853-0	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00243386
10.1007/s12325-021-01853-0	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01853-0	study_information	NA	3	Phase of the clinical trial (clinical trial only)	4
10.1007/s12325-021-01853-0	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-021-01853-0	study_information	NA	4	Patient-level data used	No
10.1007/s12325-021-01853-0	study_information	NA	4	Clinical Trial	Yes
10.1007/s12325-021-01853-0	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01181128
10.1007/s12325-021-01853-0	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01853-0	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-021-01853-0	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-021-01884-7	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory multiple myeloma
10.1007/s12325-021-01884-7	general_information	NA	NA	Countries of first author affiliations	france
10.1007/s12325-021-01884-7	general_information	NA	NA	Countries of last author affiliations	uk
10.1007/s12325-021-01884-7	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01884-7	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-021-01884-7	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-021-01884-7	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-021-01884-7	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-021-01884-7	methodology	1	NA	primary_outcome_name	overall survival
10.1007/s12325-021-01884-7	methodology	1	NA	outcome_short_name	Overall Survival
10.1007/s12325-021-01884-7	methodology	1	NA	primary_outcome_type	Time-to-event
10.1007/s12325-021-01884-7	methodology	1	NA	Treatment name 1	belantamab mafodotin
10.1007/s12325-021-01884-7	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-021-01884-7	methodology	1	NA	Treatment name 2	selinexor + dexamethasone
10.1007/s12325-021-01884-7	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-021-01884-7	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-021-01884-7	methodology	1	NA	anchored_yn	No
10.1007/s12325-021-01884-7	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01884-7	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01884-7	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-021-01884-7	methodology	1	NA	prognostic_factors_yn	Yes
10.1007/s12325-021-01884-7	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-021-01884-7	methodology	1	NA	weights_model_yn	No
10.1007/s12325-021-01884-7	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-021-01884-7	results	1	NA	contrast	HR
10.1007/s12325-021-01884-7	results	1	NA	direction_benefit	inferior
10.1007/s12325-021-01884-7	results	1	NA	n_nonipd_ttt	122
10.1007/s12325-021-01884-7	results	1	NA	n_ipd_ttt	95
10.1007/s12325-021-01884-7	results	1	NA	ess_ttt	63.46
10.1007/s12325-021-01884-7	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1007/s12325-021-01884-7	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-021-01884-7	results	1	NA	n_covariates	8
10.1007/s12325-021-01884-7	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1007/s12325-021-01884-7	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01884-7	results	1	NA	unadjusted_effect	0.6
10.1007/s12325-021-01884-7	results	1	NA	unadjusted_pval_char	0.01
10.1007/s12325-021-01884-7	results	1	NA	adjusted_effect	0.53
10.1007/s12325-021-01884-7	results	1	NA	adjusted_pval_char	0.005
10.1007/s12325-021-01884-7	results	1	NA	geographical region	NA
10.1007/s12325-021-01884-7	results	1	NA	n_ipd_total	NA
10.1007/s12325-021-01884-7	results	1	NA	ess_total	NA
10.1007/s12325-021-01884-7	results	1	NA	n_nonipd_total	NA
10.1007/s12325-021-01884-7	results	1	NA	n_nonipd_anchor	NA
10.1007/s12325-021-01884-7	results	1	NA	n_ipd_anchor	NA
10.1007/s12325-021-01884-7	results	1	NA	ess_anchor	NA
10.1007/s12325-021-01884-7	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-021-01884-7	results	1	NA	effect_cutoff	1
10.1007/s12325-021-01884-7	results	1	NA	unadjusted_pval	0.01
10.1007/s12325-021-01884-7	results	1	NA	unadjusted_num_pval	0.01
10.1007/s12325-021-01884-7	results	1	NA	unadjusted_significant	TRUE
10.1007/s12325-021-01884-7	results	1	NA	adjusted_pval	0.005
10.1007/s12325-021-01884-7	results	1	NA	adjusted_num_pval	0.005
10.1007/s12325-021-01884-7	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-021-01884-7	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-021-01884-7	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-021-01884-7	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03525678
10.1007/s12325-021-01884-7	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01884-7	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1007/s12325-021-01884-7	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1007/s12325-021-01884-7	study_information	NA	2	Patient-level data used	No
10.1007/s12325-021-01884-7	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-021-01884-7	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02336815
10.1007/s12325-021-01884-7	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01884-7	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1007/s12325-021-01884-7	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1007/s12325-021-01885-6	general_information	NA	NA	Medical Condition of Interest Name	non-metastatic castration-resistant prostate cancer
10.1007/s12325-021-01885-6	general_information	NA	NA	Countries of first author affiliations	uk
10.1007/s12325-021-01885-6	general_information	NA	NA	Countries of last author affiliations	germany
10.1007/s12325-021-01885-6	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1007/s12325-021-01885-6	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1007/s12325-021-01885-6	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-021-01885-6	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-021-01885-6	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-021-01885-6	methodology	1	NA	primary_outcome_name	metastasis-free survival
10.1007/s12325-021-01885-6	methodology	1	NA	outcome_short_name	Metastasis-free Survival
10.1007/s12325-021-01885-6	methodology	1	NA	primary_outcome_type	Time-to-event
10.1007/s12325-021-01885-6	methodology	1	NA	Treatment name 1	apalutamide + adt
10.1007/s12325-021-01885-6	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-021-01885-6	methodology	1	NA	Treatment name 2	darolutamide + adt
10.1007/s12325-021-01885-6	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-021-01885-6	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-021-01885-6	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-021-01885-6	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01885-6	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s12325-021-01885-6	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1007/s12325-021-01885-6	methodology	1	NA	prognostic_factors_yn	No
10.1007/s12325-021-01885-6	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-021-01885-6	methodology	1	NA	weights_model_yn	No
10.1007/s12325-021-01885-6	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-021-01885-6	results	1	NA	contrast	HR
10.1007/s12325-021-01885-6	results	1	NA	direction_benefit	inferior
10.1007/s12325-021-01885-6	results	1	NA	n_nonipd_ttt	955
10.1007/s12325-021-01885-6	results	1	NA	n_ipd_ttt	NA
10.1007/s12325-021-01885-6	results	1	NA	ess_ttt	NA
10.1007/s12325-021-01885-6	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-021-01885-6	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-021-01885-6	results	1	NA	n_covariates	9
10.1007/s12325-021-01885-6	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1007/s12325-021-01885-6	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01885-6	results	1	NA	unadjusted_effect	NA
10.1007/s12325-021-01885-6	results	1	NA	unadjusted_pval_char	NA
10.1007/s12325-021-01885-6	results	1	NA	adjusted_effect	0.7
10.1007/s12325-021-01885-6	results	1	NA	adjusted_pval_char	[0.51;0.98]
10.1007/s12325-021-01885-6	results	1	NA	geographical region	Yes
10.1007/s12325-021-01885-6	results	1	NA	n_ipd_total	1150
10.1007/s12325-021-01885-6	results	1	NA	ess_total	455
10.1007/s12325-021-01885-6	results	1	NA	n_nonipd_total	1509
10.1007/s12325-021-01885-6	results	1	NA	n_nonipd_anchor	554
10.1007/s12325-021-01885-6	results	1	NA	n_ipd_anchor	NA
10.1007/s12325-021-01885-6	results	1	NA	ess_anchor	NA
10.1007/s12325-021-01885-6	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-021-01885-6	results	1	NA	effect_cutoff	1
10.1007/s12325-021-01885-6	results	1	NA	adjusted_lb_ci	0.51
10.1007/s12325-021-01885-6	results	1	NA	adjusted_ub_ci	0.98
10.1007/s12325-021-01885-6	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-021-01885-6	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-021-01885-6	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-021-01885-6	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204
10.1007/s12325-021-01885-6	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01885-6	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-021-01885-6	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-021-01885-6	study_information	NA	2	Patient-level data used	No
10.1007/s12325-021-01885-6	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-021-01885-6	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02200614
10.1007/s12325-021-01885-6	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01885-6	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-021-01885-6	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-022-02054-z	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory follicular lymphoma
10.1007/s12325-022-02054-z	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s12325-022-02054-z	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s12325-022-02054-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-022-02054-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-022-02054-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-022-02054-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-022-02054-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-022-02054-z	methodology	1	NA	primary_outcome_name	grade >= 3 treatment emergent adverse event
10.1007/s12325-022-02054-z	methodology	1	NA	outcome_short_name	Adverse Event
10.1007/s12325-022-02054-z	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1007/s12325-022-02054-z	methodology	1	NA	Treatment name 1	tazemetostat
10.1007/s12325-022-02054-z	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-022-02054-z	methodology	1	NA	Treatment name 2	idelalisib
10.1007/s12325-022-02054-z	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-022-02054-z	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-022-02054-z	methodology	1	NA	anchored_yn	No
10.1007/s12325-022-02054-z	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02054-z	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-022-02054-z	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-022-02054-z	methodology	1	NA	prognostic_factors_yn	Yes
10.1007/s12325-022-02054-z	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-022-02054-z	methodology	1	NA	weights_model_yn	No
10.1007/s12325-022-02054-z	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-022-02054-z	methodology	2	NA	primary_outcome_name	grade >= 3 treatment emergent adverse event
10.1007/s12325-022-02054-z	methodology	2	NA	outcome_short_name	Adverse Event
10.1007/s12325-022-02054-z	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1007/s12325-022-02054-z	methodology	2	NA	Treatment name 1	tazemetostat
10.1007/s12325-022-02054-z	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-022-02054-z	methodology	2	NA	Treatment name 2	duvelisib
10.1007/s12325-022-02054-z	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1007/s12325-022-02054-z	methodology	2	NA	paitc_type	MAIC
10.1007/s12325-022-02054-z	methodology	2	NA	anchored_yn	No
10.1007/s12325-022-02054-z	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02054-z	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-022-02054-z	methodology	2	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-022-02054-z	methodology	2	NA	prognostic_factors_yn	Yes
10.1007/s12325-022-02054-z	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-022-02054-z	methodology	2	NA	weights_model_yn	No
10.1007/s12325-022-02054-z	methodology	2	NA	scale_choice_yn	No
10.1007/s12325-022-02054-z	methodology	3	NA	primary_outcome_name	grade >= 3 treatment emergent adverse event
10.1007/s12325-022-02054-z	methodology	3	NA	outcome_short_name	Adverse Event
10.1007/s12325-022-02054-z	methodology	3	NA	primary_outcome_type	Binary (eg rates)
10.1007/s12325-022-02054-z	methodology	3	NA	Treatment name 1	tazemetostat
10.1007/s12325-022-02054-z	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-022-02054-z	methodology	3	NA	Treatment name 2	copanlisib
10.1007/s12325-022-02054-z	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.1007/s12325-022-02054-z	methodology	3	NA	paitc_type	MAIC
10.1007/s12325-022-02054-z	methodology	3	NA	anchored_yn	No
10.1007/s12325-022-02054-z	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02054-z	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-022-02054-z	methodology	3	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-022-02054-z	methodology	3	NA	prognostic_factors_yn	Yes
10.1007/s12325-022-02054-z	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-022-02054-z	methodology	3	NA	weights_model_yn	No
10.1007/s12325-022-02054-z	methodology	3	NA	scale_choice_yn	No
10.1007/s12325-022-02054-z	methodology	4	NA	primary_outcome_name	grade >= 3 treatment emergent adverse event
10.1007/s12325-022-02054-z	methodology	4	NA	outcome_short_name	Adverse Event
10.1007/s12325-022-02054-z	methodology	4	NA	primary_outcome_type	Binary (eg rates)
10.1007/s12325-022-02054-z	methodology	4	NA	Treatment name 1	tazemetostat
10.1007/s12325-022-02054-z	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-022-02054-z	methodology	4	NA	Treatment name 2	umbralisib
10.1007/s12325-022-02054-z	methodology	4	NA	Study 'number(s)' for treatment 2	5
10.1007/s12325-022-02054-z	methodology	4	NA	paitc_type	MAIC
10.1007/s12325-022-02054-z	methodology	4	NA	anchored_yn	No
10.1007/s12325-022-02054-z	methodology	4	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02054-z	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-022-02054-z	methodology	4	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-022-02054-z	methodology	4	NA	prognostic_factors_yn	Yes
10.1007/s12325-022-02054-z	methodology	4	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-022-02054-z	methodology	4	NA	weights_model_yn	No
10.1007/s12325-022-02054-z	methodology	4	NA	scale_choice_yn	No
10.1007/s12325-022-02054-z	results	1	NA	contrast	RR
10.1007/s12325-022-02054-z	results	1	NA	direction_benefit	inferior
10.1007/s12325-022-02054-z	results	1	NA	n_nonipd_ttt	72
10.1007/s12325-022-02054-z	results	1	NA	n_ipd_ttt	99
10.1007/s12325-022-02054-z	results	1	NA	ess_ttt	36
10.1007/s12325-022-02054-z	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-022-02054-z	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-022-02054-z	results	1	NA	n_covariates	8
10.1007/s12325-022-02054-z	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-022-02054-z	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-022-02054-z	results	1	NA	unadjusted_effect	0.59
10.1007/s12325-022-02054-z	results	1	NA	unadjusted_pval_char	<0.001
10.1007/s12325-022-02054-z	results	1	NA	adjusted_effect	0.45
10.1007/s12325-022-02054-z	results	1	NA	adjusted_pval_char	<0.001
10.1007/s12325-022-02054-z	results	1	NA	geographical region	No
10.1007/s12325-022-02054-z	results	1	NA	n_ipd_total	NA
10.1007/s12325-022-02054-z	results	1	NA	ess_total	NA
10.1007/s12325-022-02054-z	results	1	NA	n_nonipd_total	NA
10.1007/s12325-022-02054-z	results	1	NA	n_nonipd_anchor	NA
10.1007/s12325-022-02054-z	results	1	NA	n_ipd_anchor	NA
10.1007/s12325-022-02054-z	results	1	NA	ess_anchor	NA
10.1007/s12325-022-02054-z	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-022-02054-z	results	1	NA	effect_cutoff	1
10.1007/s12325-022-02054-z	results	1	NA	unadjusted_pval	<0.001
10.1007/s12325-022-02054-z	results	1	NA	unadjusted_significant	TRUE
10.1007/s12325-022-02054-z	results	1	NA	adjusted_pval	<0.001
10.1007/s12325-022-02054-z	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-022-02054-z	results	2	NA	contrast	RR
10.1007/s12325-022-02054-z	results	2	NA	direction_benefit	inferior
10.1007/s12325-022-02054-z	results	2	NA	n_nonipd_ttt	129
10.1007/s12325-022-02054-z	results	2	NA	n_ipd_ttt	99
10.1007/s12325-022-02054-z	results	2	NA	ess_ttt	24
10.1007/s12325-022-02054-z	results	2	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-022-02054-z	results	2	NA	list_covariates_yn	Yes
10.1007/s12325-022-02054-z	results	2	NA	n_covariates	8
10.1007/s12325-022-02054-z	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-022-02054-z	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-022-02054-z	results	2	NA	unadjusted_effect	0.45
10.1007/s12325-022-02054-z	results	2	NA	unadjusted_pval_char	<0.001
10.1007/s12325-022-02054-z	results	2	NA	adjusted_effect	0.35
10.1007/s12325-022-02054-z	results	2	NA	adjusted_pval_char	<0.001
10.1007/s12325-022-02054-z	results	2	NA	geographical region	No
10.1007/s12325-022-02054-z	results	2	NA	n_ipd_total	NA
10.1007/s12325-022-02054-z	results	2	NA	ess_total	NA
10.1007/s12325-022-02054-z	results	2	NA	n_nonipd_total	NA
10.1007/s12325-022-02054-z	results	2	NA	n_nonipd_anchor	NA
10.1007/s12325-022-02054-z	results	2	NA	n_ipd_anchor	NA
10.1007/s12325-022-02054-z	results	2	NA	ess_anchor	NA
10.1007/s12325-022-02054-z	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-022-02054-z	results	2	NA	effect_cutoff	1
10.1007/s12325-022-02054-z	results	2	NA	unadjusted_pval	<0.001
10.1007/s12325-022-02054-z	results	2	NA	unadjusted_significant	TRUE
10.1007/s12325-022-02054-z	results	2	NA	adjusted_pval	<0.001
10.1007/s12325-022-02054-z	results	2	NA	adjusted_significant	TRUE
10.1007/s12325-022-02054-z	results	3	NA	contrast	RR
10.1007/s12325-022-02054-z	results	3	NA	direction_benefit	inferior
10.1007/s12325-022-02054-z	results	3	NA	n_nonipd_ttt	142
10.1007/s12325-022-02054-z	results	3	NA	n_ipd_ttt	99
10.1007/s12325-022-02054-z	results	3	NA	ess_ttt	66
10.1007/s12325-022-02054-z	results	3	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-022-02054-z	results	3	NA	list_covariates_yn	Yes
10.1007/s12325-022-02054-z	results	3	NA	n_covariates	7
10.1007/s12325-022-02054-z	results	3	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-022-02054-z	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-022-02054-z	results	3	NA	unadjusted_effect	0.47
10.1007/s12325-022-02054-z	results	3	NA	unadjusted_pval_char	<0.001
10.1007/s12325-022-02054-z	results	3	NA	adjusted_effect	0.37
10.1007/s12325-022-02054-z	results	3	NA	adjusted_pval_char	<0.001
10.1007/s12325-022-02054-z	results	3	NA	geographical region	No
10.1007/s12325-022-02054-z	results	3	NA	n_ipd_total	NA
10.1007/s12325-022-02054-z	results	3	NA	ess_total	NA
10.1007/s12325-022-02054-z	results	3	NA	n_nonipd_total	NA
10.1007/s12325-022-02054-z	results	3	NA	n_nonipd_anchor	NA
10.1007/s12325-022-02054-z	results	3	NA	n_ipd_anchor	NA
10.1007/s12325-022-02054-z	results	3	NA	ess_anchor	NA
10.1007/s12325-022-02054-z	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-022-02054-z	results	3	NA	effect_cutoff	1
10.1007/s12325-022-02054-z	results	3	NA	unadjusted_pval	<0.001
10.1007/s12325-022-02054-z	results	3	NA	unadjusted_significant	TRUE
10.1007/s12325-022-02054-z	results	3	NA	adjusted_pval	<0.001
10.1007/s12325-022-02054-z	results	3	NA	adjusted_significant	TRUE
10.1007/s12325-022-02054-z	results	4	NA	contrast	RR
10.1007/s12325-022-02054-z	results	4	NA	direction_benefit	inferior
10.1007/s12325-022-02054-z	results	4	NA	n_nonipd_ttt	208
10.1007/s12325-022-02054-z	results	4	NA	n_ipd_ttt	99
10.1007/s12325-022-02054-z	results	4	NA	ess_ttt	60
10.1007/s12325-022-02054-z	results	4	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-022-02054-z	results	4	NA	list_covariates_yn	Yes
10.1007/s12325-022-02054-z	results	4	NA	n_covariates	6
10.1007/s12325-022-02054-z	results	4	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-022-02054-z	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-022-02054-z	results	4	NA	unadjusted_effect	0.74
10.1007/s12325-022-02054-z	results	4	NA	unadjusted_pval_char	<0.05
10.1007/s12325-022-02054-z	results	4	NA	adjusted_effect	0.65
10.1007/s12325-022-02054-z	results	4	NA	adjusted_pval_char	<0.01
10.1007/s12325-022-02054-z	results	4	NA	geographical region	No
10.1007/s12325-022-02054-z	results	4	NA	n_ipd_total	NA
10.1007/s12325-022-02054-z	results	4	NA	ess_total	NA
10.1007/s12325-022-02054-z	results	4	NA	n_nonipd_total	NA
10.1007/s12325-022-02054-z	results	4	NA	n_nonipd_anchor	NA
10.1007/s12325-022-02054-z	results	4	NA	n_ipd_anchor	NA
10.1007/s12325-022-02054-z	results	4	NA	ess_anchor	NA
10.1007/s12325-022-02054-z	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-022-02054-z	results	4	NA	effect_cutoff	1
10.1007/s12325-022-02054-z	results	4	NA	unadjusted_pval	<0.05
10.1007/s12325-022-02054-z	results	4	NA	unadjusted_significant	TRUE
10.1007/s12325-022-02054-z	results	4	NA	adjusted_pval	<0.01
10.1007/s12325-022-02054-z	results	4	NA	adjusted_significant	TRUE
10.1007/s12325-022-02054-z	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-022-02054-z	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-022-02054-z	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01897571
10.1007/s12325-022-02054-z	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-022-02054-z	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.1007/s12325-022-02054-z	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1007/s12325-022-02054-z	study_information	NA	2	Patient-level data used	No
10.1007/s12325-022-02054-z	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-022-02054-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01282424
10.1007/s12325-022-02054-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-022-02054-z	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1007/s12325-022-02054-z	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1007/s12325-022-02054-z	study_information	NA	3	Patient-level data used	No
10.1007/s12325-022-02054-z	study_information	NA	3	Clinical Trial	Yes
10.1007/s12325-022-02054-z	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-022-02054-z	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.1007/s12325-022-02054-z	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1007/s12325-022-02054-z	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01882803
10.1007/s12325-022-02054-z	study_information	NA	4	Patient-level data used	No
10.1007/s12325-022-02054-z	study_information	NA	4	Clinical Trial	Yes
10.1007/s12325-022-02054-z	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01660451
10.1007/s12325-022-02054-z	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-022-02054-z	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.1007/s12325-022-02054-z	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.1007/s12325-022-02054-z	study_information	NA	5	Patient-level data used	No
10.1007/s12325-022-02054-z	study_information	NA	5	Clinical Trial	Yes
10.1007/s12325-022-02054-z	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02793583
10.1007/s12325-022-02054-z	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-022-02054-z	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2
10.1007/s12325-022-02054-z	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-022-02099-0	general_information	NA	NA	Medical Condition of Interest Name	unresectable hepatocellular carcinoma
10.1007/s12325-022-02099-0	general_information	NA	NA	Countries of first author affiliations	germany
10.1007/s12325-022-02099-0	general_information	NA	NA	Countries of last author affiliations	france
10.1007/s12325-022-02099-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1007/s12325-022-02099-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-022-02099-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-022-02099-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-022-02099-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-022-02099-0	methodology	1	NA	primary_outcome_name	time to deterioration in quality of life
10.1007/s12325-022-02099-0	methodology	1	NA	outcome_short_name	Time-to-deterioration in quality of life
10.1007/s12325-022-02099-0	methodology	1	NA	primary_outcome_type	Time-to-event
10.1007/s12325-022-02099-0	methodology	1	NA	Treatment name 1	transarterial radioembolization
10.1007/s12325-022-02099-0	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-022-02099-0	methodology	1	NA	Treatment name 2	atezolizumab + bevacizumab
10.1007/s12325-022-02099-0	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-022-02099-0	methodology	1	NA	paitc_type	MAIC
10.1007/s12325-022-02099-0	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-022-02099-0	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02099-0	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s12325-022-02099-0	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-022-02099-0	methodology	1	NA	prognostic_factors_yn	No
10.1007/s12325-022-02099-0	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s12325-022-02099-0	methodology	1	NA	weights_model_yn	No
10.1007/s12325-022-02099-0	methodology	1	NA	scale_choice_yn	Yes
10.1007/s12325-022-02099-0	results	1	NA	contrast	HR
10.1007/s12325-022-02099-0	results	1	NA	direction_benefit	inferior
10.1007/s12325-022-02099-0	results	1	NA	n_nonipd_ttt	336
10.1007/s12325-022-02099-0	results	1	NA	n_ipd_ttt	94
10.1007/s12325-022-02099-0	results	1	NA	ess_ttt	53
10.1007/s12325-022-02099-0	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s12325-022-02099-0	results	1	NA	list_covariates_yn	Yes
10.1007/s12325-022-02099-0	results	1	NA	n_covariates	4
10.1007/s12325-022-02099-0	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score
10.1007/s12325-022-02099-0	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-022-02099-0	results	1	NA	unadjusted_effect	NA
10.1007/s12325-022-02099-0	results	1	NA	unadjusted_pval_char	NA
10.1007/s12325-022-02099-0	results	1	NA	adjusted_effect	1.06
10.1007/s12325-022-02099-0	results	1	NA	adjusted_pval_char	0.725
10.1007/s12325-022-02099-0	results	1	NA	geographical region	NA
10.1007/s12325-022-02099-0	results	1	NA	n_ipd_total	NA
10.1007/s12325-022-02099-0	results	1	NA	ess_total	NA
10.1007/s12325-022-02099-0	results	1	NA	n_nonipd_total	NA
10.1007/s12325-022-02099-0	results	1	NA	n_nonipd_anchor	165
10.1007/s12325-022-02099-0	results	1	NA	n_ipd_anchor	123
10.1007/s12325-022-02099-0	results	1	NA	ess_anchor	78
10.1007/s12325-022-02099-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s12325-022-02099-0	results	1	NA	effect_cutoff	1
10.1007/s12325-022-02099-0	results	1	NA	adjusted_pval	0.725
10.1007/s12325-022-02099-0	results	1	NA	adjusted_num_pval	0.725
10.1007/s12325-022-02099-0	results	1	NA	adjusted_significant	FALSE
10.1007/s12325-022-02099-0	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-022-02099-0	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-022-02099-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01482442
10.1007/s12325-022-02099-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.1007/s12325-022-02099-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-022-02099-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-022-02099-0	study_information	NA	2	Patient-level data used	No
10.1007/s12325-022-02099-0	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-022-02099-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03434379
10.1007/s12325-022-02099-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-022-02099-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-022-02099-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	general_information	NA	NA	Medical Condition of Interest Name	mild-to-moderate atopic dermatitis
10.1007/s13555-021-00646-1	general_information	NA	NA	Countries of first author affiliations	uk
10.1007/s13555-021-00646-1	general_information	NA	NA	Countries of last author affiliations	denmark
10.1007/s13555-021-00646-1	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s13555-021-00646-1	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s13555-021-00646-1	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s13555-021-00646-1	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s13555-021-00646-1	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	primary_outcome_name	investigators static global assessment improvement score of 01
10.1007/s13555-021-00646-1	methodology	1	NA	outcome_short_name	ISGA improvement
10.1007/s13555-021-00646-1	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1007/s13555-021-00646-1	methodology	1	NA	Treatment name 1	crisaborole ointment 2
10.1007/s13555-021-00646-1	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1007/s13555-021-00646-1	methodology	1	NA	Treatment name 2	pimecrolimus 1
10.1007/s13555-021-00646-1	methodology	1	NA	Study 'number(s)' for treatment 2	4;5;6;7
10.1007/s13555-021-00646-1	methodology	1	NA	paitc_type	MAIC
10.1007/s13555-021-00646-1	methodology	1	NA	anchored_yn	No
10.1007/s13555-021-00646-1	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s13555-021-00646-1	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s13555-021-00646-1	methodology	1	NA	prognostic_factors_yn	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	weights_model_yn	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	scale_choice_yn	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	primary_outcome_name	investigators static global assessment improvement score of 01
10.1007/s13555-021-00646-1	methodology	2	NA	outcome_short_name	ISGA improvement
10.1007/s13555-021-00646-1	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1007/s13555-021-00646-1	methodology	2	NA	Treatment name 1	crisaborole
10.1007/s13555-021-00646-1	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.1007/s13555-021-00646-1	methodology	2	NA	Treatment name 2	tacrolimus 0.03
10.1007/s13555-021-00646-1	methodology	2	NA	Study 'number(s)' for treatment 2	3;4;5;8;9
10.1007/s13555-021-00646-1	methodology	2	NA	paitc_type	MAIC
10.1007/s13555-021-00646-1	methodology	2	NA	anchored_yn	No
10.1007/s13555-021-00646-1	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s13555-021-00646-1	methodology	2	NA	primary_outcome_yn	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s13555-021-00646-1	methodology	2	NA	prognostic_factors_yn	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	weights_model_yn	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	scale_choice_yn	No
10.1007/s13555-021-00646-1	results	1	NA	contrast	OR
10.1007/s13555-021-00646-1	results	1	NA	direction_benefit	superior
10.1007/s13555-021-00646-1	results	1	NA	n_nonipd_ttt	NA
10.1007/s13555-021-00646-1	results	1	NA	n_ipd_ttt	1021
10.1007/s13555-021-00646-1	results	1	NA	ess_ttt	627
10.1007/s13555-021-00646-1	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s13555-021-00646-1	results	1	NA	list_covariates_yn	Yes
10.1007/s13555-021-00646-1	results	1	NA	n_covariates	7
10.1007/s13555-021-00646-1	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.1007/s13555-021-00646-1	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s13555-021-00646-1	results	1	NA	unadjusted_effect	2.04
10.1007/s13555-021-00646-1	results	1	NA	unadjusted_pval_char	[1.47;2.82]
10.1007/s13555-021-00646-1	results	1	NA	adjusted_effect	2.03
10.1007/s13555-021-00646-1	results	1	NA	adjusted_pval_char	[1.45;2.85]
10.1007/s13555-021-00646-1	results	1	NA	geographical region	NA
10.1007/s13555-021-00646-1	results	1	NA	n_ipd_total	NA
10.1007/s13555-021-00646-1	results	1	NA	ess_total	NA
10.1007/s13555-021-00646-1	results	1	NA	n_nonipd_total	NA
10.1007/s13555-021-00646-1	results	1	NA	n_nonipd_anchor	NA
10.1007/s13555-021-00646-1	results	1	NA	n_ipd_anchor	NA
10.1007/s13555-021-00646-1	results	1	NA	ess_anchor	NA
10.1007/s13555-021-00646-1	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s13555-021-00646-1	results	1	NA	effect_cutoff	1
10.1007/s13555-021-00646-1	results	1	NA	unadjusted_lb_ci	1.47
10.1007/s13555-021-00646-1	results	1	NA	unadjusted_ub_ci	2.82
10.1007/s13555-021-00646-1	results	1	NA	unadjusted_significant	TRUE
10.1007/s13555-021-00646-1	results	1	NA	adjusted_lb_ci	1.45
10.1007/s13555-021-00646-1	results	1	NA	adjusted_ub_ci	2.85
10.1007/s13555-021-00646-1	results	1	NA	adjusted_significant	TRUE
10.1007/s13555-021-00646-1	results	2	NA	contrast	OR
10.1007/s13555-021-00646-1	results	2	NA	direction_benefit	superior
10.1007/s13555-021-00646-1	results	2	NA	n_nonipd_ttt	NA
10.1007/s13555-021-00646-1	results	2	NA	n_ipd_ttt	1021
10.1007/s13555-021-00646-1	results	2	NA	ess_ttt	311
10.1007/s13555-021-00646-1	results	2	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s13555-021-00646-1	results	2	NA	list_covariates_yn	Yes
10.1007/s13555-021-00646-1	results	2	NA	n_covariates	7
10.1007/s13555-021-00646-1	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.1007/s13555-021-00646-1	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s13555-021-00646-1	results	2	NA	unadjusted_effect	1.31
10.1007/s13555-021-00646-1	results	2	NA	unadjusted_pval_char	[1.02;1.69]
10.1007/s13555-021-00646-1	results	2	NA	adjusted_effect	1.5
10.1007/s13555-021-00646-1	results	2	NA	adjusted_pval_char	[1.09;2.05]
10.1007/s13555-021-00646-1	results	2	NA	geographical region	NA
10.1007/s13555-021-00646-1	results	2	NA	n_ipd_total	NA
10.1007/s13555-021-00646-1	results	2	NA	ess_total	NA
10.1007/s13555-021-00646-1	results	2	NA	n_nonipd_total	NA
10.1007/s13555-021-00646-1	results	2	NA	n_nonipd_anchor	NA
10.1007/s13555-021-00646-1	results	2	NA	n_ipd_anchor	NA
10.1007/s13555-021-00646-1	results	2	NA	ess_anchor	NA
10.1007/s13555-021-00646-1	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s13555-021-00646-1	results	2	NA	effect_cutoff	1
10.1007/s13555-021-00646-1	results	2	NA	unadjusted_lb_ci	1.02
10.1007/s13555-021-00646-1	results	2	NA	unadjusted_ub_ci	1.69
10.1007/s13555-021-00646-1	results	2	NA	unadjusted_significant	TRUE
10.1007/s13555-021-00646-1	results	2	NA	adjusted_lb_ci	1.09
10.1007/s13555-021-00646-1	results	2	NA	adjusted_ub_ci	2.05
10.1007/s13555-021-00646-1	results	2	NA	adjusted_significant	TRUE
10.1007/s13555-021-00646-1	study_information	NA	1	Patient-level data used	Yes
10.1007/s13555-021-00646-1	study_information	NA	1	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02118766
10.1007/s13555-021-00646-1	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s13555-021-00646-1	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s13555-021-00646-1	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	2	Patient-level data used	Yes
10.1007/s13555-021-00646-1	study_information	NA	2	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02118792
10.1007/s13555-021-00646-1	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s13555-021-00646-1	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s13555-021-00646-1	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	3	Patient-level data used	No
10.1007/s13555-021-00646-1	study_information	NA	3	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	schachner et al. (2005)
10.1007/s13555-021-00646-1	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s13555-021-00646-1	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	4	Patient-level data used	No
10.1007/s13555-021-00646-1	study_information	NA	4	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	kempers et al. (2004)
10.1007/s13555-021-00646-1	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s13555-021-00646-1	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	5	Patient-level data used	No
10.1007/s13555-021-00646-1	study_information	NA	5	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00667160
10.1007/s13555-021-00646-1	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s13555-021-00646-1	study_information	NA	5	Phase of the clinical trial (clinical trial only)	4
10.1007/s13555-021-00646-1	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	6	Patient-level data used	No
10.1007/s13555-021-00646-1	study_information	NA	6	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1007/s13555-021-00646-1	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	abramovits et al. (2008)
10.1007/s13555-021-00646-1	study_information	NA	7	Patient-level data used	No
10.1007/s13555-021-00646-1	study_information	NA	7	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	eichenfield et al. (2002)
10.1007/s13555-021-00646-1	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1007/s13555-021-00646-1	study_information	NA	8	Patient-level data used	No
10.1007/s13555-021-00646-1	study_information	NA	8	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	8	Data source name (only if observational study or clinical trial without NCT)	chapman et al. (2005)
10.1007/s13555-021-00646-1	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s13555-021-00646-1	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	9	Patient-level data used	No
10.1007/s13555-021-00646-1	study_information	NA	9	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	9	Data source name (only if observational study or clinical trial without NCT)	levy et al. (2005)
10.1007/s40258-016-0271-0	general_information	NA	NA	Medical Condition of Interest Name	relapsed and/or refractory multiple myeloma
10.1007/s40258-016-0271-0	general_information	NA	NA	Countries of first author affiliations	the netherlands
10.1007/s40258-016-0271-0	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s40258-016-0271-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40258-016-0271-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40258-016-0271-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40258-016-0271-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40258-016-0271-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40258-016-0271-0	methodology	1	NA	primary_outcome_name	progression-free survival
10.1007/s40258-016-0271-0	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1007/s40258-016-0271-0	methodology	1	NA	primary_outcome_type	Time-to-event
10.1007/s40258-016-0271-0	methodology	1	NA	Treatment name 1	panobinostat + bortezomib + dexamethasone
10.1007/s40258-016-0271-0	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s40258-016-0271-0	methodology	1	NA	Treatment name 2	lenalidomide + dexamethasone
10.1007/s40258-016-0271-0	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1007/s40258-016-0271-0	methodology	1	NA	paitc_type	MAIC
10.1007/s40258-016-0271-0	methodology	1	NA	anchored_yn	No
10.1007/s40258-016-0271-0	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40258-016-0271-0	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40258-016-0271-0	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s40258-016-0271-0	methodology	1	NA	prognostic_factors_yn	Yes
10.1007/s40258-016-0271-0	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40258-016-0271-0	methodology	1	NA	weights_model_yn	No
10.1007/s40258-016-0271-0	methodology	1	NA	scale_choice_yn	No
10.1007/s40258-016-0271-0	results	1	NA	contrast	HR
10.1007/s40258-016-0271-0	results	1	NA	direction_benefit	inferior
10.1007/s40258-016-0271-0	results	1	NA	n_nonipd_ttt	220
10.1007/s40258-016-0271-0	results	1	NA	n_ipd_ttt	142
10.1007/s40258-016-0271-0	results	1	NA	ess_ttt	138
10.1007/s40258-016-0271-0	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s40258-016-0271-0	results	1	NA	list_covariates_yn	Yes
10.1007/s40258-016-0271-0	results	1	NA	n_covariates	4
10.1007/s40258-016-0271-0	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1007/s40258-016-0271-0	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s40258-016-0271-0	results	1	NA	unadjusted_effect	NA
10.1007/s40258-016-0271-0	results	1	NA	unadjusted_pval_char	NA
10.1007/s40258-016-0271-0	results	1	NA	adjusted_effect	0.96
10.1007/s40258-016-0271-0	results	1	NA	adjusted_pval_char	[0.72;1.28]
10.1007/s40258-016-0271-0	results	1	NA	geographical region	NA
10.1007/s40258-016-0271-0	results	1	NA	n_ipd_total	NA
10.1007/s40258-016-0271-0	results	1	NA	ess_total	NA
10.1007/s40258-016-0271-0	results	1	NA	n_nonipd_total	NA
10.1007/s40258-016-0271-0	results	1	NA	n_nonipd_anchor	NA
10.1007/s40258-016-0271-0	results	1	NA	n_ipd_anchor	NA
10.1007/s40258-016-0271-0	results	1	NA	ess_anchor	NA
10.1007/s40258-016-0271-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s40258-016-0271-0	results	1	NA	effect_cutoff	1
10.1007/s40258-016-0271-0	results	1	NA	adjusted_lb_ci	0.72
10.1007/s40258-016-0271-0	results	1	NA	adjusted_ub_ci	1.28
10.1007/s40258-016-0271-0	results	1	NA	adjusted_significant	FALSE
10.1007/s40258-016-0271-0	study_information	NA	1	Patient-level data used	Yes
10.1007/s40258-016-0271-0	study_information	NA	1	Clinical Trial	Yes
10.1007/s40258-016-0271-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01023308
10.1007/s40258-016-0271-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40258-016-0271-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s40258-016-0271-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40258-016-0271-0	study_information	NA	2	Patient-level data used	No
10.1007/s40258-016-0271-0	study_information	NA	2	Clinical Trial	Yes
10.1007/s40258-016-0271-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00056160
10.1007/s40258-016-0271-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40258-016-0271-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40258-016-0271-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40258-016-0271-0	study_information	NA	3	Patient-level data used	No
10.1007/s40258-016-0271-0	study_information	NA	3	Clinical Trial	Yes
10.1007/s40258-016-0271-0	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00424047
10.1007/s40258-016-0271-0	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40258-016-0271-0	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s40258-016-0271-0	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-013-0102-x	general_information	NA	NA	Medical Condition of Interest Name	attention-deficit/hyperactivity disorder in children and adolescents
10.1007/s40263-013-0102-x	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s40263-013-0102-x	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s40263-013-0102-x	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40263-013-0102-x	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40263-013-0102-x	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40263-013-0102-x	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40263-013-0102-x	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40263-013-0102-x	methodology	1	NA	primary_outcome_name	the mean change from baseline in the adhd-rs-iv total score at the final on-treatment assessment prior to down-titration
10.1007/s40263-013-0102-x	methodology	1	NA	outcome_short_name	ADHD-RS-IV score
10.1007/s40263-013-0102-x	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1007/s40263-013-0102-x	methodology	1	NA	Treatment name 1	guanfacine extended release
10.1007/s40263-013-0102-x	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1007/s40263-013-0102-x	methodology	1	NA	Treatment name 2	atomoxetine
10.1007/s40263-013-0102-x	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.1007/s40263-013-0102-x	methodology	1	NA	paitc_type	MAIC
10.1007/s40263-013-0102-x	methodology	1	NA	anchored_yn	Yes
10.1007/s40263-013-0102-x	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s40263-013-0102-x	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s40263-013-0102-x	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1007/s40263-013-0102-x	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40263-013-0102-x	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40263-013-0102-x	methodology	1	NA	weights_model_yn	Yes
10.1007/s40263-013-0102-x	methodology	1	NA	scale_choice_yn	No
10.1007/s40263-013-0102-x	results	1	NA	contrast	Means difference
10.1007/s40263-013-0102-x	results	1	NA	direction_benefit	inferior
10.1007/s40263-013-0102-x	results	1	NA	n_nonipd_ttt	84
10.1007/s40263-013-0102-x	results	1	NA	n_ipd_ttt	82
10.1007/s40263-013-0102-x	results	1	NA	ess_ttt	NA
10.1007/s40263-013-0102-x	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s40263-013-0102-x	results	1	NA	list_covariates_yn	Yes
10.1007/s40263-013-0102-x	results	1	NA	n_covariates	8
10.1007/s40263-013-0102-x	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s40263-013-0102-x	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s40263-013-0102-x	results	1	NA	unadjusted_effect	-9.2
10.1007/s40263-013-0102-x	results	1	NA	unadjusted_pval_char	<0.01
10.1007/s40263-013-0102-x	results	1	NA	adjusted_effect	-7
10.1007/s40263-013-0102-x	results	1	NA	adjusted_pval_char	<0.01
10.1007/s40263-013-0102-x	results	1	NA	geographical region	No
10.1007/s40263-013-0102-x	results	1	NA	n_ipd_total	NA
10.1007/s40263-013-0102-x	results	1	NA	ess_total	NA
10.1007/s40263-013-0102-x	results	1	NA	n_nonipd_total	NA
10.1007/s40263-013-0102-x	results	1	NA	n_nonipd_anchor	83
10.1007/s40263-013-0102-x	results	1	NA	n_ipd_anchor	136
10.1007/s40263-013-0102-x	results	1	NA	ess_anchor	NA
10.1007/s40263-013-0102-x	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s40263-013-0102-x	results	1	NA	effect_cutoff	0
10.1007/s40263-013-0102-x	results	1	NA	unadjusted_pval	<0.01
10.1007/s40263-013-0102-x	results	1	NA	unadjusted_significant	TRUE
10.1007/s40263-013-0102-x	results	1	NA	adjusted_pval	<0.01
10.1007/s40263-013-0102-x	results	1	NA	adjusted_significant	TRUE
10.1007/s40263-013-0102-x	study_information	NA	1	Patient-level data used	Yes
10.1007/s40263-013-0102-x	study_information	NA	1	Clinical Trial	Yes
10.1007/s40263-013-0102-x	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00152009
10.1007/s40263-013-0102-x	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-013-0102-x	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-013-0102-x	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1007/s40263-013-0102-x	study_information	NA	2	Patient-level data used	Yes
10.1007/s40263-013-0102-x	study_information	NA	2	Clinical Trial	Yes
10.1007/s40263-013-0102-x	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00150618
10.1007/s40263-013-0102-x	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-013-0102-x	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-013-0102-x	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	sallee et al. (2009)
10.1007/s40263-013-0102-x	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s40263-013-0102-x	study_information	NA	3	Patient-level data used	No
10.1007/s40263-013-0102-x	study_information	NA	3	Clinical Trial	Yes
10.1007/s40263-013-0102-x	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	spencer et al. (2002)
10.1007/s40263-013-0102-x	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-019-00672-w	general_information	NA	NA	Medical Condition of Interest Name	postpartum depression
10.1007/s40263-019-00672-w	general_information	NA	NA	Countries of first author affiliations	uk
10.1007/s40263-019-00672-w	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s40263-019-00672-w	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40263-019-00672-w	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40263-019-00672-w	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40263-019-00672-w	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40263-019-00672-w	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40263-019-00672-w	methodology	1	NA	primary_outcome_name	change from baseline for the hamilton rating scale for depression
10.1007/s40263-019-00672-w	methodology	1	NA	outcome_short_name	Hamilton rating scale change
10.1007/s40263-019-00672-w	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1007/s40263-019-00672-w	methodology	1	NA	Treatment name 1	brexanolone
10.1007/s40263-019-00672-w	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3
10.1007/s40263-019-00672-w	methodology	1	NA	Treatment name 2	placebo
10.1007/s40263-019-00672-w	methodology	1	NA	Study 'number(s)' for treatment 2	4
10.1007/s40263-019-00672-w	methodology	1	NA	paitc_type	MAIC
10.1007/s40263-019-00672-w	methodology	1	NA	anchored_yn	No
10.1007/s40263-019-00672-w	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40263-019-00672-w	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40263-019-00672-w	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1007/s40263-019-00672-w	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40263-019-00672-w	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40263-019-00672-w	methodology	1	NA	weights_model_yn	Yes
10.1007/s40263-019-00672-w	methodology	1	NA	scale_choice_yn	No
10.1007/s40263-019-00672-w	results	1	NA	contrast	Means difference
10.1007/s40263-019-00672-w	results	1	NA	direction_benefit	superior
10.1007/s40263-019-00672-w	results	1	NA	n_nonipd_ttt	30
10.1007/s40263-019-00672-w	results	1	NA	n_ipd_ttt	NA
10.1007/s40263-019-00672-w	results	1	NA	ess_ttt	63.2
10.1007/s40263-019-00672-w	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s40263-019-00672-w	results	1	NA	list_covariates_yn	Yes
10.1007/s40263-019-00672-w	results	1	NA	n_covariates	3
10.1007/s40263-019-00672-w	results	1	NA	list_covariates	Age, Race/ethnicity, Past treatments for the disease of interest
10.1007/s40263-019-00672-w	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s40263-019-00672-w	results	1	NA	unadjusted_effect	3.8
10.1007/s40263-019-00672-w	results	1	NA	unadjusted_pval_char	[1.86;5.74]
10.1007/s40263-019-00672-w	results	1	NA	adjusted_effect	13.9
10.1007/s40263-019-00672-w	results	1	NA	adjusted_pval_char	[9.84;17.10]
10.1007/s40263-019-00672-w	results	1	NA	geographical region	NA
10.1007/s40263-019-00672-w	results	1	NA	n_ipd_total	NA
10.1007/s40263-019-00672-w	results	1	NA	ess_total	NA
10.1007/s40263-019-00672-w	results	1	NA	n_nonipd_total	NA
10.1007/s40263-019-00672-w	results	1	NA	n_nonipd_anchor	NA
10.1007/s40263-019-00672-w	results	1	NA	n_ipd_anchor	NA
10.1007/s40263-019-00672-w	results	1	NA	ess_anchor	NA
10.1007/s40263-019-00672-w	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s40263-019-00672-w	results	1	NA	effect_cutoff	0
10.1007/s40263-019-00672-w	results	1	NA	unadjusted_lb_ci	1.86
10.1007/s40263-019-00672-w	results	1	NA	unadjusted_ub_ci	5.74
10.1007/s40263-019-00672-w	results	1	NA	unadjusted_significant	TRUE
10.1007/s40263-019-00672-w	results	1	NA	adjusted_lb_ci	9.84
10.1007/s40263-019-00672-w	results	1	NA	adjusted_ub_ci	17.1
10.1007/s40263-019-00672-w	results	1	NA	adjusted_significant	TRUE
10.1007/s40263-019-00672-w	study_information	NA	1	Patient-level data used	Yes
10.1007/s40263-019-00672-w	study_information	NA	1	Clinical Trial	Yes
10.1007/s40263-019-00672-w	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02614547
10.1007/s40263-019-00672-w	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s40263-019-00672-w	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1007/s40263-019-00672-w	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-019-00672-w	study_information	NA	2	Patient-level data used	Yes
10.1007/s40263-019-00672-w	study_information	NA	2	Clinical Trial	Yes
10.1007/s40263-019-00672-w	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02942004
10.1007/s40263-019-00672-w	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s40263-019-00672-w	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-019-00672-w	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-019-00672-w	study_information	NA	3	Patient-level data used	Yes
10.1007/s40263-019-00672-w	study_information	NA	3	Clinical Trial	Yes
10.1007/s40263-019-00672-w	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02942017
10.1007/s40263-019-00672-w	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s40263-019-00672-w	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-019-00672-w	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-019-00672-w	study_information	NA	4	Patient-level data used	No
10.1007/s40263-019-00672-w	study_information	NA	4	Clinical Trial	Yes
10.1007/s40263-019-00672-w	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	yonkers et al. (2008)
10.1007/s40263-019-00672-w	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s40263-019-00672-w	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-021-00805-0	general_information	NA	NA	Medical Condition of Interest Name	relapsing-remitting multiple sclerosis
10.1007/s40263-021-00805-0	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s40263-021-00805-0	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s40263-021-00805-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40263-021-00805-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40263-021-00805-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40263-021-00805-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40263-021-00805-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40263-021-00805-0	methodology	1	NA	primary_outcome_name	annualized relapse rate
10.1007/s40263-021-00805-0	methodology	1	NA	outcome_short_name	Annualized Relapse Rate
10.1007/s40263-021-00805-0	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1007/s40263-021-00805-0	methodology	1	NA	Treatment name 1	ozanimod
10.1007/s40263-021-00805-0	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1007/s40263-021-00805-0	methodology	1	NA	Treatment name 2	dimethyl fumarate
10.1007/s40263-021-00805-0	methodology	1	NA	Study 'number(s)' for treatment 2	3;4
10.1007/s40263-021-00805-0	methodology	1	NA	paitc_type	MAIC
10.1007/s40263-021-00805-0	methodology	1	NA	anchored_yn	No
10.1007/s40263-021-00805-0	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40263-021-00805-0	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40263-021-00805-0	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s40263-021-00805-0	methodology	1	NA	prognostic_factors_yn	Yes
10.1007/s40263-021-00805-0	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s40263-021-00805-0	methodology	1	NA	weights_model_yn	Yes
10.1007/s40263-021-00805-0	methodology	1	NA	scale_choice_yn	No
10.1007/s40263-021-00805-0	results	1	NA	contrast	RR
10.1007/s40263-021-00805-0	results	1	NA	direction_benefit	inferior
10.1007/s40263-021-00805-0	results	1	NA	n_nonipd_ttt	769
10.1007/s40263-021-00805-0	results	1	NA	n_ipd_ttt	880
10.1007/s40263-021-00805-0	results	1	NA	ess_ttt	744
10.1007/s40263-021-00805-0	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1007/s40263-021-00805-0	results	1	NA	list_covariates_yn	Yes
10.1007/s40263-021-00805-0	results	1	NA	n_covariates	7
10.1007/s40263-021-00805-0	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1007/s40263-021-00805-0	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s40263-021-00805-0	results	1	NA	unadjusted_effect	NA
10.1007/s40263-021-00805-0	results	1	NA	unadjusted_pval_char	NA
10.1007/s40263-021-00805-0	results	1	NA	adjusted_effect	0.8
10.1007/s40263-021-00805-0	results	1	NA	adjusted_pval_char	[0.67;0.97]
10.1007/s40263-021-00805-0	results	1	NA	geographical region	NA
10.1007/s40263-021-00805-0	results	1	NA	n_ipd_total	NA
10.1007/s40263-021-00805-0	results	1	NA	ess_total	NA
10.1007/s40263-021-00805-0	results	1	NA	n_nonipd_total	NA
10.1007/s40263-021-00805-0	results	1	NA	n_nonipd_anchor	NA
10.1007/s40263-021-00805-0	results	1	NA	n_ipd_anchor	NA
10.1007/s40263-021-00805-0	results	1	NA	ess_anchor	NA
10.1007/s40263-021-00805-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s40263-021-00805-0	results	1	NA	effect_cutoff	1
10.1007/s40263-021-00805-0	results	1	NA	adjusted_lb_ci	0.67
10.1007/s40263-021-00805-0	results	1	NA	adjusted_ub_ci	0.97
10.1007/s40263-021-00805-0	results	1	NA	adjusted_significant	TRUE
10.1007/s40263-021-00805-0	study_information	NA	1	Patient-level data used	Yes
10.1007/s40263-021-00805-0	study_information	NA	1	Clinical Trial	Yes
10.1007/s40263-021-00805-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02294058
10.1007/s40263-021-00805-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40263-021-00805-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-021-00805-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-021-00805-0	study_information	NA	2	Patient-level data used	Yes
10.1007/s40263-021-00805-0	study_information	NA	2	Clinical Trial	Yes
10.1007/s40263-021-00805-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02047734
10.1007/s40263-021-00805-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40263-021-00805-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-021-00805-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-021-00805-0	study_information	NA	3	Patient-level data used	No
10.1007/s40263-021-00805-0	study_information	NA	3	Clinical Trial	Yes
10.1007/s40263-021-00805-0	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451
10.1007/s40263-021-00805-0	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40263-021-00805-0	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-021-00805-0	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-021-00805-0	study_information	NA	4	Patient-level data used	No
10.1007/s40263-021-00805-0	study_information	NA	4	Clinical Trial	Yes
10.1007/s40263-021-00805-0	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212
10.1007/s40263-021-00805-0	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40263-021-00805-0	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-021-00805-0	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40273-021-01015-8	general_information	NA	NA	Medical Condition of Interest Name	anaplastic lymphoma kinase (alk)-positive non-small-cell lung cancer
10.1007/s40273-021-01015-8	general_information	NA	NA	Countries of first author affiliations	sweden
10.1007/s40273-021-01015-8	general_information	NA	NA	Countries of last author affiliations	uk
10.1007/s40273-021-01015-8	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40273-021-01015-8	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40273-021-01015-8	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40273-021-01015-8	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40273-021-01015-8	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40273-021-01015-8	methodology	1	NA	primary_outcome_name	progression-free survival
10.1007/s40273-021-01015-8	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1007/s40273-021-01015-8	methodology	1	NA	primary_outcome_type	Time-to-event
10.1007/s40273-021-01015-8	methodology	1	NA	Treatment name 1	lorlatinib
10.1007/s40273-021-01015-8	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s40273-021-01015-8	methodology	1	NA	Treatment name 2	pemetrexed or docetaxel
10.1007/s40273-021-01015-8	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1007/s40273-021-01015-8	methodology	1	NA	paitc_type	MAIC
10.1007/s40273-021-01015-8	methodology	1	NA	anchored_yn	No
10.1007/s40273-021-01015-8	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40273-021-01015-8	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40273-021-01015-8	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s40273-021-01015-8	methodology	1	NA	prognostic_factors_yn	Yes
10.1007/s40273-021-01015-8	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s40273-021-01015-8	methodology	1	NA	weights_model_yn	No
10.1007/s40273-021-01015-8	methodology	1	NA	scale_choice_yn	No
10.1007/s40273-021-01015-8	methodology	2	NA	primary_outcome_name	overall survival
10.1007/s40273-021-01015-8	methodology	2	NA	outcome_short_name	Overall Survival
10.1007/s40273-021-01015-8	methodology	2	NA	primary_outcome_type	Time-to-event
10.1007/s40273-021-01015-8	methodology	2	NA	Treatment name 1	lorlatinib
10.1007/s40273-021-01015-8	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s40273-021-01015-8	methodology	2	NA	Treatment name 2	systemic therapy
10.1007/s40273-021-01015-8	methodology	2	NA	Study 'number(s)' for treatment 2	4;5
10.1007/s40273-021-01015-8	methodology	2	NA	paitc_type	MAIC
10.1007/s40273-021-01015-8	methodology	2	NA	anchored_yn	No
10.1007/s40273-021-01015-8	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40273-021-01015-8	methodology	2	NA	primary_outcome_yn	Yes
10.1007/s40273-021-01015-8	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.1007/s40273-021-01015-8	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40273-021-01015-8	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40273-021-01015-8	methodology	2	NA	weights_model_yn	No
10.1007/s40273-021-01015-8	methodology	2	NA	scale_choice_yn	No
10.1007/s40273-021-01015-8	results	1	NA	contrast	HR
10.1007/s40273-021-01015-8	results	1	NA	direction_benefit	inferior
10.1007/s40273-021-01015-8	results	1	NA	n_nonipd_ttt	151
10.1007/s40273-021-01015-8	results	1	NA	n_ipd_ttt	59
10.1007/s40273-021-01015-8	results	1	NA	ess_ttt	53.4
10.1007/s40273-021-01015-8	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s40273-021-01015-8	results	1	NA	list_covariates_yn	Yes
10.1007/s40273-021-01015-8	results	1	NA	n_covariates	4
10.1007/s40273-021-01015-8	results	1	NA	list_covariates	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1007/s40273-021-01015-8	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s40273-021-01015-8	results	1	NA	unadjusted_effect	NA
10.1007/s40273-021-01015-8	results	1	NA	unadjusted_pval_char	NA
10.1007/s40273-021-01015-8	results	1	NA	adjusted_effect	0.224
10.1007/s40273-021-01015-8	results	1	NA	adjusted_pval_char	[0.154;0.312]
10.1007/s40273-021-01015-8	results	1	NA	geographical region	NA
10.1007/s40273-021-01015-8	results	1	NA	n_ipd_total	NA
10.1007/s40273-021-01015-8	results	1	NA	ess_total	NA
10.1007/s40273-021-01015-8	results	1	NA	n_nonipd_total	NA
10.1007/s40273-021-01015-8	results	1	NA	n_nonipd_anchor	NA
10.1007/s40273-021-01015-8	results	1	NA	n_ipd_anchor	NA
10.1007/s40273-021-01015-8	results	1	NA	ess_anchor	NA
10.1007/s40273-021-01015-8	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s40273-021-01015-8	results	1	NA	effect_cutoff	1
10.1007/s40273-021-01015-8	results	1	NA	adjusted_lb_ci	0.154
10.1007/s40273-021-01015-8	results	1	NA	adjusted_ub_ci	0.312
10.1007/s40273-021-01015-8	results	1	NA	adjusted_significant	TRUE
10.1007/s40273-021-01015-8	results	2	NA	contrast	HR
10.1007/s40273-021-01015-8	results	2	NA	direction_benefit	inferior
10.1007/s40273-021-01015-8	results	2	NA	n_nonipd_ttt	37
10.1007/s40273-021-01015-8	results	2	NA	n_ipd_ttt	59
10.1007/s40273-021-01015-8	results	2	NA	ess_ttt	24.5
10.1007/s40273-021-01015-8	results	2	NA	weights_evaluation_yn	Not mentioned
10.1007/s40273-021-01015-8	results	2	NA	list_covariates_yn	Yes
10.1007/s40273-021-01015-8	results	2	NA	n_covariates	4
10.1007/s40273-021-01015-8	results	2	NA	list_covariates	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1007/s40273-021-01015-8	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s40273-021-01015-8	results	2	NA	unadjusted_effect	NA
10.1007/s40273-021-01015-8	results	2	NA	unadjusted_pval_char	NA
10.1007/s40273-021-01015-8	results	2	NA	adjusted_effect	0.159
10.1007/s40273-021-01015-8	results	2	NA	adjusted_pval_char	[0.052;0.356]
10.1007/s40273-021-01015-8	results	2	NA	geographical region	NA
10.1007/s40273-021-01015-8	results	2	NA	n_ipd_total	NA
10.1007/s40273-021-01015-8	results	2	NA	ess_total	NA
10.1007/s40273-021-01015-8	results	2	NA	n_nonipd_total	NA
10.1007/s40273-021-01015-8	results	2	NA	n_nonipd_anchor	NA
10.1007/s40273-021-01015-8	results	2	NA	n_ipd_anchor	NA
10.1007/s40273-021-01015-8	results	2	NA	ess_anchor	NA
10.1007/s40273-021-01015-8	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s40273-021-01015-8	results	2	NA	effect_cutoff	1
10.1007/s40273-021-01015-8	results	2	NA	adjusted_lb_ci	0.052
10.1007/s40273-021-01015-8	results	2	NA	adjusted_ub_ci	0.356
10.1007/s40273-021-01015-8	results	2	NA	adjusted_significant	TRUE
10.1007/s40273-021-01015-8	study_information	NA	1	Patient-level data used	Yes
10.1007/s40273-021-01015-8	study_information	NA	1	Clinical Trial	Yes
10.1007/s40273-021-01015-8	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01970865
10.1007/s40273-021-01015-8	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40273-021-01015-8	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.1007/s40273-021-01015-8	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1007/s40273-021-01015-8	study_information	NA	2	Patient-level data used	No
10.1007/s40273-021-01015-8	study_information	NA	2	Clinical Trial	Yes
10.1007/s40273-021-01015-8	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02604342
10.1007/s40273-021-01015-8	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40273-021-01015-8	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40273-021-01015-8	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40273-021-01015-8	study_information	NA	3	Patient-level data used	No
10.1007/s40273-021-01015-8	study_information	NA	3	Clinical Trial	Yes
10.1007/s40273-021-01015-8	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01828112
10.1007/s40273-021-01015-8	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40273-021-01015-8	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s40273-021-01015-8	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40273-021-01015-8	study_information	NA	4	Patient-level data used	No
10.1007/s40273-021-01015-8	study_information	NA	4	Clinical Trial	Yes
10.1007/s40273-021-01015-8	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00585195
10.1007/s40273-021-01015-8	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40273-021-01015-8	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1
10.1007/s40273-021-01015-8	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.1007/s40273-021-01015-8	study_information	NA	5	Patient-level data used	No
10.1007/s40273-021-01015-8	study_information	NA	5	Clinical Trial	Yes
10.1007/s40273-021-01015-8	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00932451
10.1007/s40273-021-01015-8	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40273-021-01015-8	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2
10.1007/s40273-021-01015-8	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.1007/s40744-017-0070-6	general_information	NA	NA	Medical Condition of Interest Name	active psoriatic arthritis
10.1007/s40744-017-0070-6	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s40744-017-0070-6	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s40744-017-0070-6	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40744-017-0070-6	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40744-017-0070-6	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40744-017-0070-6	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40744-017-0070-6	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40744-017-0070-6	methodology	1	NA	primary_outcome_name	response rates for acr 20 (american college of rheumatology) at week 24
10.1007/s40744-017-0070-6	methodology	1	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-017-0070-6	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1007/s40744-017-0070-6	methodology	1	NA	Treatment name 1	adalimumab
10.1007/s40744-017-0070-6	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s40744-017-0070-6	methodology	1	NA	Treatment name 2	secukinumab 150 mg
10.1007/s40744-017-0070-6	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1007/s40744-017-0070-6	methodology	1	NA	paitc_type	MAIC
10.1007/s40744-017-0070-6	methodology	1	NA	anchored_yn	Yes
10.1007/s40744-017-0070-6	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40744-017-0070-6	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-017-0070-6	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-017-0070-6	methodology	1	NA	prognostic_factors_yn	Yes
10.1007/s40744-017-0070-6	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s40744-017-0070-6	methodology	1	NA	weights_model_yn	No
10.1007/s40744-017-0070-6	methodology	1	NA	scale_choice_yn	No
10.1007/s40744-017-0070-6	methodology	2	NA	primary_outcome_name	response rates for acr 20 (american college of rheumatology) at week 24
10.1007/s40744-017-0070-6	methodology	2	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-017-0070-6	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1007/s40744-017-0070-6	methodology	2	NA	Treatment name 1	adalimumab
10.1007/s40744-017-0070-6	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s40744-017-0070-6	methodology	2	NA	Treatment name 2	secukinumab 300 mg
10.1007/s40744-017-0070-6	methodology	2	NA	Study 'number(s)' for treatment 2	2;3
10.1007/s40744-017-0070-6	methodology	2	NA	paitc_type	MAIC
10.1007/s40744-017-0070-6	methodology	2	NA	anchored_yn	Yes
10.1007/s40744-017-0070-6	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40744-017-0070-6	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-017-0070-6	methodology	2	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-017-0070-6	methodology	2	NA	prognostic_factors_yn	Yes
10.1007/s40744-017-0070-6	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1007/s40744-017-0070-6	methodology	2	NA	weights_model_yn	No
10.1007/s40744-017-0070-6	methodology	2	NA	scale_choice_yn	No
10.1007/s40744-017-0070-6	results	1	NA	contrast	Rate difference
10.1007/s40744-017-0070-6	results	1	NA	direction_benefit	superior
10.1007/s40744-017-0070-6	results	1	NA	n_nonipd_ttt	302
10.1007/s40744-017-0070-6	results	1	NA	n_ipd_ttt	134
10.1007/s40744-017-0070-6	results	1	NA	ess_ttt	49
10.1007/s40744-017-0070-6	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s40744-017-0070-6	results	1	NA	list_covariates_yn	Yes
10.1007/s40744-017-0070-6	results	1	NA	n_covariates	10
10.1007/s40744-017-0070-6	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-017-0070-6	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-017-0070-6	results	1	NA	unadjusted_effect	NA
10.1007/s40744-017-0070-6	results	1	NA	unadjusted_pval_char	NA
10.1007/s40744-017-0070-6	results	1	NA	adjusted_effect	9.50
10.1007/s40744-017-0070-6	results	1	NA	adjusted_pval_char	0.176
10.1007/s40744-017-0070-6	results	1	NA	geographical region	No
10.1007/s40744-017-0070-6	results	1	NA	n_ipd_total	NA
10.1007/s40744-017-0070-6	results	1	NA	ess_total	NA
10.1007/s40744-017-0070-6	results	1	NA	n_nonipd_total	NA
10.1007/s40744-017-0070-6	results	1	NA	n_nonipd_anchor	300
10.1007/s40744-017-0070-6	results	1	NA	n_ipd_anchor	147
10.1007/s40744-017-0070-6	results	1	NA	ess_anchor	79
10.1007/s40744-017-0070-6	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s40744-017-0070-6	results	1	NA	effect_cutoff	0
10.1007/s40744-017-0070-6	results	1	NA	adjusted_pval	0.176
10.1007/s40744-017-0070-6	results	1	NA	adjusted_num_pval	0.176
10.1007/s40744-017-0070-6	results	1	NA	adjusted_significant	FALSE
10.1007/s40744-017-0070-6	results	2	NA	contrast	Rate difference
10.1007/s40744-017-0070-6	results	2	NA	direction_benefit	superior
10.1007/s40744-017-0070-6	results	2	NA	n_nonipd_ttt	100
10.1007/s40744-017-0070-6	results	2	NA	n_ipd_ttt	134
10.1007/s40744-017-0070-6	results	2	NA	ess_ttt	76
10.1007/s40744-017-0070-6	results	2	NA	weights_evaluation_yn	Not mentioned
10.1007/s40744-017-0070-6	results	2	NA	list_covariates_yn	Yes
10.1007/s40744-017-0070-6	results	2	NA	n_covariates	10
10.1007/s40744-017-0070-6	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-017-0070-6	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-017-0070-6	results	2	NA	unadjusted_effect	NA
10.1007/s40744-017-0070-6	results	2	NA	unadjusted_pval_char	NA
10.1007/s40744-017-0070-6	results	2	NA	adjusted_effect	5.30
10.1007/s40744-017-0070-6	results	2	NA	adjusted_pval_char	0.507
10.1007/s40744-017-0070-6	results	2	NA	geographical region	No
10.1007/s40744-017-0070-6	results	2	NA	n_ipd_total	NA
10.1007/s40744-017-0070-6	results	2	NA	ess_total	NA
10.1007/s40744-017-0070-6	results	2	NA	n_nonipd_total	NA
10.1007/s40744-017-0070-6	results	2	NA	n_nonipd_anchor	300
10.1007/s40744-017-0070-6	results	2	NA	n_ipd_anchor	147
10.1007/s40744-017-0070-6	results	2	NA	ess_anchor	79
10.1007/s40744-017-0070-6	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s40744-017-0070-6	results	2	NA	effect_cutoff	0
10.1007/s40744-017-0070-6	results	2	NA	adjusted_pval	0.507
10.1007/s40744-017-0070-6	results	2	NA	adjusted_num_pval	0.507
10.1007/s40744-017-0070-6	results	2	NA	adjusted_significant	FALSE
10.1007/s40744-017-0070-6	study_information	NA	1	Patient-level data used	Yes
10.1007/s40744-017-0070-6	study_information	NA	1	Clinical Trial	Yes
10.1007/s40744-017-0070-6	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00195689
10.1007/s40744-017-0070-6	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s40744-017-0070-6	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-017-0070-6	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-017-0070-6	study_information	NA	2	Patient-level data used	No
10.1007/s40744-017-0070-6	study_information	NA	2	Clinical Trial	Yes
10.1007/s40744-017-0070-6	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01392326
10.1007/s40744-017-0070-6	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40744-017-0070-6	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-017-0070-6	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-017-0070-6	study_information	NA	3	Patient-level data used	No
10.1007/s40744-017-0070-6	study_information	NA	3	Clinical Trial	Yes
10.1007/s40744-017-0070-6	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01752634
10.1007/s40744-017-0070-6	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40744-017-0070-6	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-017-0070-6	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-018-0106-6	general_information	NA	NA	Medical Condition of Interest Name	active psoriatic arthritis
10.1007/s40744-018-0106-6	general_information	NA	NA	Countries of first author affiliations	australia
10.1007/s40744-018-0106-6	general_information	NA	NA	Countries of last author affiliations	switzerland
10.1007/s40744-018-0106-6	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40744-018-0106-6	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40744-018-0106-6	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40744-018-0106-6	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40744-018-0106-6	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	primary_outcome_name	acr 20 response rate at week 12
10.1007/s40744-018-0106-6	methodology	1	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-018-0106-6	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1007/s40744-018-0106-6	methodology	1	NA	Treatment name 1	secukinumab 150 mg
10.1007/s40744-018-0106-6	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s40744-018-0106-6	methodology	1	NA	Treatment name 2	adalimumab
10.1007/s40744-018-0106-6	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s40744-018-0106-6	methodology	1	NA	paitc_type	MAIC
10.1007/s40744-018-0106-6	methodology	1	NA	anchored_yn	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-018-0106-6	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-018-0106-6	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-018-0106-6	methodology	1	NA	prognostic_factors_yn	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	weights_model_yn	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	scale_choice_yn	No
10.1007/s40744-018-0106-6	methodology	2	NA	primary_outcome_name	acr 20 response rate at week 12
10.1007/s40744-018-0106-6	methodology	2	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-018-0106-6	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1007/s40744-018-0106-6	methodology	2	NA	Treatment name 1	secukinumab 300 mg
10.1007/s40744-018-0106-6	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s40744-018-0106-6	methodology	2	NA	Treatment name 2	adalimumab
10.1007/s40744-018-0106-6	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1007/s40744-018-0106-6	methodology	2	NA	paitc_type	MAIC
10.1007/s40744-018-0106-6	methodology	2	NA	anchored_yn	Yes
10.1007/s40744-018-0106-6	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-018-0106-6	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-018-0106-6	methodology	2	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-018-0106-6	methodology	2	NA	prognostic_factors_yn	Yes
10.1007/s40744-018-0106-6	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1007/s40744-018-0106-6	methodology	2	NA	weights_model_yn	Yes
10.1007/s40744-018-0106-6	methodology	2	NA	scale_choice_yn	No
10.1007/s40744-018-0106-6	methodology	3	NA	primary_outcome_name	acr 20 response rate at week 16
10.1007/s40744-018-0106-6	methodology	3	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-018-0106-6	methodology	3	NA	primary_outcome_type	Binary (eg rates)
10.1007/s40744-018-0106-6	methodology	3	NA	Treatment name 1	secukinumab 150 mg
10.1007/s40744-018-0106-6	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1007/s40744-018-0106-6	methodology	3	NA	Treatment name 2	adalimumab
10.1007/s40744-018-0106-6	methodology	3	NA	Study 'number(s)' for treatment 2	2
10.1007/s40744-018-0106-6	methodology	3	NA	paitc_type	MAIC
10.1007/s40744-018-0106-6	methodology	3	NA	anchored_yn	No
10.1007/s40744-018-0106-6	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-018-0106-6	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-018-0106-6	methodology	3	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-018-0106-6	methodology	3	NA	prognostic_factors_yn	Yes
10.1007/s40744-018-0106-6	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.1007/s40744-018-0106-6	methodology	3	NA	weights_model_yn	Yes
10.1007/s40744-018-0106-6	methodology	3	NA	scale_choice_yn	No
10.1007/s40744-018-0106-6	methodology	4	NA	primary_outcome_name	acr 20 response rate at week 16
10.1007/s40744-018-0106-6	methodology	4	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-018-0106-6	methodology	4	NA	primary_outcome_type	Binary (eg rates)
10.1007/s40744-018-0106-6	methodology	4	NA	Treatment name 1	secukinumab 300 mg
10.1007/s40744-018-0106-6	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1007/s40744-018-0106-6	methodology	4	NA	Treatment name 2	adalimumab
10.1007/s40744-018-0106-6	methodology	4	NA	Study 'number(s)' for treatment 2	2
10.1007/s40744-018-0106-6	methodology	4	NA	paitc_type	MAIC
10.1007/s40744-018-0106-6	methodology	4	NA	anchored_yn	No
10.1007/s40744-018-0106-6	methodology	4	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-018-0106-6	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-018-0106-6	methodology	4	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-018-0106-6	methodology	4	NA	prognostic_factors_yn	Yes
10.1007/s40744-018-0106-6	methodology	4	NA	ttt_effect_modifiers_yn	Yes
10.1007/s40744-018-0106-6	methodology	4	NA	weights_model_yn	Yes
10.1007/s40744-018-0106-6	methodology	4	NA	scale_choice_yn	No
10.1007/s40744-018-0106-6	results	1	NA	contrast	RR
10.1007/s40744-018-0106-6	results	1	NA	direction_benefit	superior
10.1007/s40744-018-0106-6	results	1	NA	n_nonipd_ttt	151
10.1007/s40744-018-0106-6	results	1	NA	n_ipd_ttt	100
10.1007/s40744-018-0106-6	results	1	NA	ess_ttt	36
10.1007/s40744-018-0106-6	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s40744-018-0106-6	results	1	NA	list_covariates_yn	Yes
10.1007/s40744-018-0106-6	results	1	NA	n_covariates	11
10.1007/s40744-018-0106-6	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-018-0106-6	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-018-0106-6	results	1	NA	unadjusted_effect	NA
10.1007/s40744-018-0106-6	results	1	NA	unadjusted_pval_char	NA
10.1007/s40744-018-0106-6	results	1	NA	adjusted_effect	0.69
10.1007/s40744-018-0106-6	results	1	NA	adjusted_pval_char	[0.34;1.43]
10.1007/s40744-018-0106-6	results	1	NA	geographical region	No
10.1007/s40744-018-0106-6	results	1	NA	n_ipd_total	NA
10.1007/s40744-018-0106-6	results	1	NA	ess_total	NA
10.1007/s40744-018-0106-6	results	1	NA	n_nonipd_total	NA
10.1007/s40744-018-0106-6	results	1	NA	n_nonipd_anchor	162
10.1007/s40744-018-0106-6	results	1	NA	n_ipd_anchor	98
10.1007/s40744-018-0106-6	results	1	NA	ess_anchor	27
10.1007/s40744-018-0106-6	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s40744-018-0106-6	results	1	NA	effect_cutoff	1
10.1007/s40744-018-0106-6	results	1	NA	adjusted_lb_ci	0.34
10.1007/s40744-018-0106-6	results	1	NA	adjusted_ub_ci	1.43
10.1007/s40744-018-0106-6	results	1	NA	adjusted_significant	FALSE
10.1007/s40744-018-0106-6	results	2	NA	contrast	RR
10.1007/s40744-018-0106-6	results	2	NA	direction_benefit	superior
10.1007/s40744-018-0106-6	results	2	NA	n_nonipd_ttt	151
10.1007/s40744-018-0106-6	results	2	NA	n_ipd_ttt	100
10.1007/s40744-018-0106-6	results	2	NA	ess_ttt	38
10.1007/s40744-018-0106-6	results	2	NA	weights_evaluation_yn	Not mentioned
10.1007/s40744-018-0106-6	results	2	NA	list_covariates_yn	Yes
10.1007/s40744-018-0106-6	results	2	NA	n_covariates	11
10.1007/s40744-018-0106-6	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-018-0106-6	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-018-0106-6	results	2	NA	unadjusted_effect	NA
10.1007/s40744-018-0106-6	results	2	NA	unadjusted_pval_char	NA
10.1007/s40744-018-0106-6	results	2	NA	adjusted_effect	0.61
10.1007/s40744-018-0106-6	results	2	NA	adjusted_pval_char	[0.29;1.27]
10.1007/s40744-018-0106-6	results	2	NA	geographical region	No
10.1007/s40744-018-0106-6	results	2	NA	n_ipd_total	NA
10.1007/s40744-018-0106-6	results	2	NA	ess_total	NA
10.1007/s40744-018-0106-6	results	2	NA	n_nonipd_total	NA
10.1007/s40744-018-0106-6	results	2	NA	n_nonipd_anchor	162
10.1007/s40744-018-0106-6	results	2	NA	n_ipd_anchor	98
10.1007/s40744-018-0106-6	results	2	NA	ess_anchor	27
10.1007/s40744-018-0106-6	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s40744-018-0106-6	results	2	NA	effect_cutoff	1
10.1007/s40744-018-0106-6	results	2	NA	adjusted_lb_ci	0.29
10.1007/s40744-018-0106-6	results	2	NA	adjusted_ub_ci	1.27
10.1007/s40744-018-0106-6	results	2	NA	adjusted_significant	FALSE
10.1007/s40744-018-0106-6	results	3	NA	contrast	RR
10.1007/s40744-018-0106-6	results	3	NA	direction_benefit	superior
10.1007/s40744-018-0106-6	results	3	NA	n_nonipd_ttt	151
10.1007/s40744-018-0106-6	results	3	NA	n_ipd_ttt	100
10.1007/s40744-018-0106-6	results	3	NA	ess_ttt	36
10.1007/s40744-018-0106-6	results	3	NA	weights_evaluation_yn	Not mentioned
10.1007/s40744-018-0106-6	results	3	NA	list_covariates_yn	Yes
10.1007/s40744-018-0106-6	results	3	NA	n_covariates	11
10.1007/s40744-018-0106-6	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-018-0106-6	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-018-0106-6	results	3	NA	unadjusted_effect	NA
10.1007/s40744-018-0106-6	results	3	NA	unadjusted_pval_char	NA
10.1007/s40744-018-0106-6	results	3	NA	adjusted_effect	1.34
10.1007/s40744-018-0106-6	results	3	NA	adjusted_pval_char	[1.05;1.70]
10.1007/s40744-018-0106-6	results	3	NA	geographical region	No
10.1007/s40744-018-0106-6	results	3	NA	n_ipd_total	NA
10.1007/s40744-018-0106-6	results	3	NA	ess_total	NA
10.1007/s40744-018-0106-6	results	3	NA	n_nonipd_total	NA
10.1007/s40744-018-0106-6	results	3	NA	n_nonipd_anchor	NA
10.1007/s40744-018-0106-6	results	3	NA	n_ipd_anchor	NA
10.1007/s40744-018-0106-6	results	3	NA	ess_anchor	NA
10.1007/s40744-018-0106-6	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s40744-018-0106-6	results	3	NA	effect_cutoff	1
10.1007/s40744-018-0106-6	results	3	NA	adjusted_lb_ci	1.05
10.1007/s40744-018-0106-6	results	3	NA	adjusted_ub_ci	1.7
10.1007/s40744-018-0106-6	results	3	NA	adjusted_significant	TRUE
10.1007/s40744-018-0106-6	results	4	NA	contrast	RR
10.1007/s40744-018-0106-6	results	4	NA	direction_benefit	superior
10.1007/s40744-018-0106-6	results	4	NA	n_nonipd_ttt	151
10.1007/s40744-018-0106-6	results	4	NA	n_ipd_ttt	100
10.1007/s40744-018-0106-6	results	4	NA	ess_ttt	38
10.1007/s40744-018-0106-6	results	4	NA	weights_evaluation_yn	Not mentioned
10.1007/s40744-018-0106-6	results	4	NA	list_covariates_yn	Yes
10.1007/s40744-018-0106-6	results	4	NA	n_covariates	11
10.1007/s40744-018-0106-6	results	4	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-018-0106-6	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-018-0106-6	results	4	NA	unadjusted_effect	NA
10.1007/s40744-018-0106-6	results	4	NA	unadjusted_pval_char	NA
10.1007/s40744-018-0106-6	results	4	NA	adjusted_effect	1.18
10.1007/s40744-018-0106-6	results	4	NA	adjusted_pval_char	[0.90;1.54]
10.1007/s40744-018-0106-6	results	4	NA	geographical region	NA
10.1007/s40744-018-0106-6	results	4	NA	n_ipd_total	NA
10.1007/s40744-018-0106-6	results	4	NA	ess_total	NA
10.1007/s40744-018-0106-6	results	4	NA	n_nonipd_total	NA
10.1007/s40744-018-0106-6	results	4	NA	n_nonipd_anchor	NA
10.1007/s40744-018-0106-6	results	4	NA	n_ipd_anchor	NA
10.1007/s40744-018-0106-6	results	4	NA	ess_anchor	NA
10.1007/s40744-018-0106-6	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s40744-018-0106-6	results	4	NA	effect_cutoff	1
10.1007/s40744-018-0106-6	results	4	NA	adjusted_lb_ci	0.9
10.1007/s40744-018-0106-6	results	4	NA	adjusted_ub_ci	1.54
10.1007/s40744-018-0106-6	results	4	NA	adjusted_significant	FALSE
10.1007/s40744-018-0106-6	study_information	NA	1	Patient-level data used	Yes
10.1007/s40744-018-0106-6	study_information	NA	1	Clinical Trial	Yes
10.1007/s40744-018-0106-6	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01752634
10.1007/s40744-018-0106-6	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40744-018-0106-6	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-018-0106-6	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-018-0106-6	study_information	NA	2	Patient-level data used	No
10.1007/s40744-018-0106-6	study_information	NA	2	Clinical Trial	Yes
10.1007/s40744-018-0106-6	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00195689
10.1007/s40744-018-0106-6	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s40744-018-0106-6	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-018-0106-6	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-020-00257-w	general_information	NA	NA	Medical Condition of Interest Name	moderate-to-severe rheumatoid arthritis
10.1007/s40744-020-00257-w	general_information	NA	NA	Countries of first author affiliations	uk
10.1007/s40744-020-00257-w	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s40744-020-00257-w	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40744-020-00257-w	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40744-020-00257-w	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40744-020-00257-w	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40744-020-00257-w	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40744-020-00257-w	methodology	1	NA	primary_outcome_name	proportions of patients achieving 70 improvement in the acr criteria (acr70) at month 3
10.1007/s40744-020-00257-w	methodology	1	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-020-00257-w	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1007/s40744-020-00257-w	methodology	1	NA	Treatment name 1	upadacitinib monotherapy
10.1007/s40744-020-00257-w	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s40744-020-00257-w	methodology	1	NA	Treatment name 2	tofacitinib + methotrexate
10.1007/s40744-020-00257-w	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.1007/s40744-020-00257-w	methodology	1	NA	paitc_type	MAIC
10.1007/s40744-020-00257-w	methodology	1	NA	anchored_yn	Yes
10.1007/s40744-020-00257-w	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-020-00257-w	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-020-00257-w	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-020-00257-w	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40744-020-00257-w	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40744-020-00257-w	methodology	1	NA	weights_model_yn	No
10.1007/s40744-020-00257-w	methodology	1	NA	scale_choice_yn	No
10.1007/s40744-020-00257-w	methodology	2	NA	primary_outcome_name	proportions of patients achieving 50 improvement in the acr criteria (acr50)at month 3,
10.1007/s40744-020-00257-w	methodology	2	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-020-00257-w	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1007/s40744-020-00257-w	methodology	2	NA	Treatment name 1	upadacitinib + methotrexate
10.1007/s40744-020-00257-w	methodology	2	NA	Study 'number(s)' for treatment 1	2
10.1007/s40744-020-00257-w	methodology	2	NA	Treatment name 2	tofacitinib + methotrexate
10.1007/s40744-020-00257-w	methodology	2	NA	Study 'number(s)' for treatment 2	4
10.1007/s40744-020-00257-w	methodology	2	NA	paitc_type	MAIC
10.1007/s40744-020-00257-w	methodology	2	NA	anchored_yn	Yes
10.1007/s40744-020-00257-w	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-020-00257-w	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-020-00257-w	methodology	2	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-020-00257-w	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40744-020-00257-w	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40744-020-00257-w	methodology	2	NA	weights_model_yn	No
10.1007/s40744-020-00257-w	methodology	2	NA	scale_choice_yn	No
10.1007/s40744-020-00257-w	results	1	NA	contrast	Proportion difference
10.1007/s40744-020-00257-w	results	1	NA	direction_benefit	superior
10.1007/s40744-020-00257-w	results	1	NA	n_nonipd_ttt	204
10.1007/s40744-020-00257-w	results	1	NA	n_ipd_ttt	217
10.1007/s40744-020-00257-w	results	1	NA	ess_ttt	173
10.1007/s40744-020-00257-w	results	1	NA	weights_evaluation_yn	Not mentioned
10.1007/s40744-020-00257-w	results	1	NA	list_covariates_yn	Yes
10.1007/s40744-020-00257-w	results	1	NA	n_covariates	7
10.1007/s40744-020-00257-w	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1007/s40744-020-00257-w	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-020-00257-w	results	1	NA	unadjusted_effect	9.60
10.1007/s40744-020-00257-w	results	1	NA	unadjusted_pval_char	0.018
10.1007/s40744-020-00257-w	results	1	NA	adjusted_effect	9.90
10.1007/s40744-020-00257-w	results	1	NA	adjusted_pval_char	0.019
10.1007/s40744-020-00257-w	results	1	NA	geographical region	NA
10.1007/s40744-020-00257-w	results	1	NA	n_ipd_total	NA
10.1007/s40744-020-00257-w	results	1	NA	ess_total	NA
10.1007/s40744-020-00257-w	results	1	NA	n_nonipd_total	NA
10.1007/s40744-020-00257-w	results	1	NA	n_nonipd_anchor	108
10.1007/s40744-020-00257-w	results	1	NA	n_ipd_anchor	216
10.1007/s40744-020-00257-w	results	1	NA	ess_anchor	158
10.1007/s40744-020-00257-w	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s40744-020-00257-w	results	1	NA	effect_cutoff	0
10.1007/s40744-020-00257-w	results	1	NA	unadjusted_pval	0.018
10.1007/s40744-020-00257-w	results	1	NA	unadjusted_num_pval	0.018
10.1007/s40744-020-00257-w	results	1	NA	unadjusted_significant	TRUE
10.1007/s40744-020-00257-w	results	1	NA	adjusted_pval	0.019
10.1007/s40744-020-00257-w	results	1	NA	adjusted_num_pval	0.019
10.1007/s40744-020-00257-w	results	1	NA	adjusted_significant	TRUE
10.1007/s40744-020-00257-w	results	2	NA	contrast	Proportion difference
10.1007/s40744-020-00257-w	results	2	NA	direction_benefit	superior
10.1007/s40744-020-00257-w	results	2	NA	n_nonipd_ttt	376
10.1007/s40744-020-00257-w	results	2	NA	n_ipd_ttt	647
10.1007/s40744-020-00257-w	results	2	NA	ess_ttt	480
10.1007/s40744-020-00257-w	results	2	NA	weights_evaluation_yn	Not mentioned
10.1007/s40744-020-00257-w	results	2	NA	list_covariates_yn	Yes
10.1007/s40744-020-00257-w	results	2	NA	n_covariates	7
10.1007/s40744-020-00257-w	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1007/s40744-020-00257-w	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-020-00257-w	results	2	NA	unadjusted_effect	12.70
10.1007/s40744-020-00257-w	results	2	NA	unadjusted_pval_char	0.008
10.1007/s40744-020-00257-w	results	2	NA	adjusted_effect	12.90
10.1007/s40744-020-00257-w	results	2	NA	adjusted_pval_char	0.011
10.1007/s40744-020-00257-w	results	2	NA	geographical region	NA
10.1007/s40744-020-00257-w	results	2	NA	n_ipd_total	NA
10.1007/s40744-020-00257-w	results	2	NA	ess_total	NA
10.1007/s40744-020-00257-w	results	2	NA	n_nonipd_total	NA
10.1007/s40744-020-00257-w	results	2	NA	n_nonipd_anchor	386
10.1007/s40744-020-00257-w	results	2	NA	n_ipd_anchor	324
10.1007/s40744-020-00257-w	results	2	NA	ess_anchor	228
10.1007/s40744-020-00257-w	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1007/s40744-020-00257-w	results	2	NA	effect_cutoff	0
10.1007/s40744-020-00257-w	results	2	NA	unadjusted_pval	0.008
10.1007/s40744-020-00257-w	results	2	NA	unadjusted_num_pval	0.008
10.1007/s40744-020-00257-w	results	2	NA	unadjusted_significant	TRUE
10.1007/s40744-020-00257-w	results	2	NA	adjusted_pval	0.011
10.1007/s40744-020-00257-w	results	2	NA	adjusted_num_pval	0.011
10.1007/s40744-020-00257-w	results	2	NA	adjusted_significant	TRUE
10.1007/s40744-020-00257-w	study_information	NA	1	Patient-level data used	Yes
10.1007/s40744-020-00257-w	study_information	NA	1	Clinical Trial	Yes
10.1007/s40744-020-00257-w	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02706951
10.1007/s40744-020-00257-w	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40744-020-00257-w	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-020-00257-w	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-020-00257-w	study_information	NA	2	Patient-level data used	Yes
10.1007/s40744-020-00257-w	study_information	NA	2	Clinical Trial	Yes
10.1007/s40744-020-00257-w	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02629159
10.1007/s40744-020-00257-w	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40744-020-00257-w	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-020-00257-w	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-020-00257-w	study_information	NA	3	Patient-level data used	No
10.1007/s40744-020-00257-w	study_information	NA	3	Clinical Trial	Yes
10.1007/s40744-020-00257-w	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00853385
10.1007/s40744-020-00257-w	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40744-020-00257-w	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-020-00257-w	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-020-00257-w	study_information	NA	4	Patient-level data used	No
10.1007/s40744-020-00257-w	study_information	NA	4	Clinical Trial	Yes
10.1007/s40744-020-00257-w	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02187055
10.1007/s40744-020-00257-w	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40744-020-00257-w	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3, 4
10.1007/s40744-020-00257-w	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory large b cell lymphoma
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1016/j.bbmt.2020.06.008	methodology	1	NA	primary_outcome_name	Overall Survival
10.1016/j.bbmt.2020.06.008	methodology	1	NA	outcome_short_name	Overall Survival
10.1016/j.bbmt.2020.06.008	methodology	1	NA	primary_outcome_type	Time-to-event
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Treatment name 1	axicabtagene ciloleucel
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Treatment name 2	tisagenlecleucel
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1016/j.bbmt.2020.06.008	methodology	1	NA	paitc_type	MAIC
10.1016/j.bbmt.2020.06.008	methodology	1	NA	anchored_yn	No
10.1016/j.bbmt.2020.06.008	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.bbmt.2020.06.008	methodology	1	NA	primary_outcome_yn	Yes
10.1016/j.bbmt.2020.06.008	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.bbmt.2020.06.008	methodology	1	NA	prognostic_factors_yn	Yes
10.1016/j.bbmt.2020.06.008	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1016/j.bbmt.2020.06.008	methodology	1	NA	weights_model_yn	No
10.1016/j.bbmt.2020.06.008	methodology	1	NA	scale_choice_yn	No
10.1016/j.bbmt.2020.06.008	results	1	NA	contrast	HR
10.1016/j.bbmt.2020.06.008	results	1	NA	direction_benefit	inferior
10.1016/j.bbmt.2020.06.008	results	1	NA	n_nonipd_ttt	115
10.1016/j.bbmt.2020.06.008	results	1	NA	n_ipd_ttt	101
10.1016/j.bbmt.2020.06.008	results	1	NA	ess_ttt	39.59
10.1016/j.bbmt.2020.06.008	results	1	NA	weights_evaluation_yn	Not mentioned
10.1016/j.bbmt.2020.06.008	results	1	NA	list_covariates_yn	Yes
10.1016/j.bbmt.2020.06.008	results	1	NA	n_covariates	7
10.1016/j.bbmt.2020.06.008	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.bbmt.2020.06.008	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.bbmt.2020.06.008	results	1	NA	unadjusted_effect	0.68
10.1016/j.bbmt.2020.06.008	results	1	NA	unadjusted_pval_char	[0.47;0.98]
10.1016/j.bbmt.2020.06.008	results	1	NA	adjusted_effect	0.51
10.1016/j.bbmt.2020.06.008	results	1	NA	adjusted_pval_char	[0.31;0.83]
10.1016/j.bbmt.2020.06.008	results	1	NA	geographical region	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	n_ipd_total	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	ess_total	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	n_nonipd_total	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	n_nonipd_anchor	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	n_ipd_anchor	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	ess_anchor	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	effect_cutoff	1
10.1016/j.bbmt.2020.06.008	results	1	NA	unadjusted_lb_ci	0.47
10.1016/j.bbmt.2020.06.008	results	1	NA	unadjusted_ub_ci	0.98
10.1016/j.bbmt.2020.06.008	results	1	NA	unadjusted_significant	TRUE
10.1016/j.bbmt.2020.06.008	results	1	NA	adjusted_lb_ci	0.31
10.1016/j.bbmt.2020.06.008	results	1	NA	adjusted_ub_ci	0.83
10.1016/j.bbmt.2020.06.008	results	1	NA	adjusted_significant	TRUE
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Patient-level data used	Yes
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Clinical Trial	Yes
10.1016/j.bbmt.2020.06.008	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02348216
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Patient-level data used	No
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Clinical Trial	Yes
10.1016/j.bbmt.2020.06.008	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02445248
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Medical Condition of Interest Name	locally advanced or metastatic urothelial carcinoma
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Countries of first author affiliations	uk
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clgc.2020.07.006	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1016/j.clgc.2020.07.006	methodology	1	NA	primary_outcome_name	overall survival
10.1016/j.clgc.2020.07.006	methodology	1	NA	outcome_short_name	Overall Survival
10.1016/j.clgc.2020.07.006	methodology	1	NA	primary_outcome_type	Time-to-event
10.1016/j.clgc.2020.07.006	methodology	1	NA	Treatment name 1	pembrolizumab
10.1016/j.clgc.2020.07.006	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clgc.2020.07.006	methodology	1	NA	Treatment name 2	carboplatin + gemcitabine
10.1016/j.clgc.2020.07.006	methodology	1	NA	Study 'number(s)' for treatment 2	2;3;4;5
10.1016/j.clgc.2020.07.006	methodology	1	NA	paitc_type	STC
10.1016/j.clgc.2020.07.006	methodology	1	NA	anchored_yn	No
10.1016/j.clgc.2020.07.006	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clgc.2020.07.006	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clgc.2020.07.006	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1016/j.clgc.2020.07.006	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clgc.2020.07.006	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clgc.2020.07.006	methodology	1	NA	weights_model_yn	No
10.1016/j.clgc.2020.07.006	methodology	1	NA	scale_choice_yn	No
10.1016/j.clgc.2020.07.006	results	1	NA	contrast	HR
10.1016/j.clgc.2020.07.006	results	1	NA	direction_benefit	inferior
10.1016/j.clgc.2020.07.006	results	1	NA	n_nonipd_ttt	NA
10.1016/j.clgc.2020.07.006	results	1	NA	n_ipd_ttt	NA
10.1016/j.clgc.2020.07.006	results	1	NA	ess_ttt	NA
10.1016/j.clgc.2020.07.006	results	1	NA	weights_evaluation_yn	NA
10.1016/j.clgc.2020.07.006	results	1	NA	list_covariates_yn	No
10.1016/j.clgc.2020.07.006	results	1	NA	n_covariates	NA
10.1016/j.clgc.2020.07.006	results	1	NA	list_covariates	NA
10.1016/j.clgc.2020.07.006	results	1	NA	effect_direction	Denominator if ratio, or rightside if difference
10.1016/j.clgc.2020.07.006	results	1	NA	unadjusted_effect	NA
10.1016/j.clgc.2020.07.006	results	1	NA	unadjusted_pval_char	NA
10.1016/j.clgc.2020.07.006	results	1	NA	adjusted_effect	2.34
10.1016/j.clgc.2020.07.006	results	1	NA	adjusted_pval_char	[1.92;2.85]
10.1016/j.clgc.2020.07.006	results	1	NA	geographical region	NA
10.1016/j.clgc.2020.07.006	results	1	NA	n_ipd_total	NA
10.1016/j.clgc.2020.07.006	results	1	NA	ess_total	NA
10.1016/j.clgc.2020.07.006	results	1	NA	n_nonipd_total	NA
10.1016/j.clgc.2020.07.006	results	1	NA	n_nonipd_anchor	NA
10.1016/j.clgc.2020.07.006	results	1	NA	n_ipd_anchor	NA
10.1016/j.clgc.2020.07.006	results	1	NA	ess_anchor	NA
10.1016/j.clgc.2020.07.006	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.clgc.2020.07.006	results	1	NA	effect_cutoff	1
10.1016/j.clgc.2020.07.006	results	1	NA	adjusted_lb_ci	1.92
10.1016/j.clgc.2020.07.006	results	1	NA	adjusted_ub_ci	2.85
10.1016/j.clgc.2020.07.006	results	1	NA	adjusted_significant	TRUE
10.1016/j.clgc.2020.07.006	study_information	NA	1	Patient-level data used	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	1	Clinical Trial	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02335424
10.1016/j.clgc.2020.07.006	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clgc.2020.07.006	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clgc.2020.07.006	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1016/j.clgc.2020.07.006	study_information	NA	2	Patient-level data used	No
10.1016/j.clgc.2020.07.006	study_information	NA	2	Clinical Trial	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	bamias et al. (2007)
10.1016/j.clgc.2020.07.006	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1016/j.clgc.2020.07.006	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1016/j.clgc.2020.07.006	study_information	NA	3	Patient-level data used	No
10.1016/j.clgc.2020.07.006	study_information	NA	3	Clinical Trial	No
10.1016/j.clgc.2020.07.006	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	carles et al. (2000)
10.1016/j.clgc.2020.07.006	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	spain
10.1016/j.clgc.2020.07.006	study_information	NA	4	Patient-level data used	No
10.1016/j.clgc.2020.07.006	study_information	NA	4	Clinical Trial	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00014274
10.1016/j.clgc.2020.07.006	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clgc.2020.07.006	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2, 3
10.1016/j.clgc.2020.07.006	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.clgc.2020.07.006	study_information	NA	5	Patient-level data used	No
10.1016/j.clgc.2020.07.006	study_information	NA	5	Clinical Trial	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	linardou et al. (2004)
10.1016/j.clgc.2020.07.006	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	greece
10.1016/j.clgc.2020.07.006	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clgc.2020.07.006	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Medical Condition of Interest Name	metastatic advanced renal cell carcinoma
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1016/j.clinthera.2015.09.013	methodology	1	NA	primary_outcome_name	progression-free survival
10.1016/j.clinthera.2015.09.013	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1016/j.clinthera.2015.09.013	methodology	1	NA	primary_outcome_type	Time-to-event
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Treatment name 1	everolimus
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Treatment name 2	axitinib
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1016/j.clinthera.2015.09.013	methodology	1	NA	paitc_type	MAIC
10.1016/j.clinthera.2015.09.013	methodology	1	NA	anchored_yn	No
10.1016/j.clinthera.2015.09.013	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2015.09.013	methodology	1	NA	primary_outcome_yn	Yes
10.1016/j.clinthera.2015.09.013	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.clinthera.2015.09.013	methodology	1	NA	prognostic_factors_yn	Yes
10.1016/j.clinthera.2015.09.013	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2015.09.013	methodology	1	NA	weights_model_yn	Yes
10.1016/j.clinthera.2015.09.013	methodology	1	NA	scale_choice_yn	No
10.1016/j.clinthera.2015.09.013	results	1	NA	contrast	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	direction_benefit	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	n_nonipd_ttt	194
10.1016/j.clinthera.2015.09.013	results	1	NA	n_ipd_ttt	43
10.1016/j.clinthera.2015.09.013	results	1	NA	ess_ttt	43
10.1016/j.clinthera.2015.09.013	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.clinthera.2015.09.013	results	1	NA	list_covariates_yn	Yes
10.1016/j.clinthera.2015.09.013	results	1	NA	n_covariates	3
10.1016/j.clinthera.2015.09.013	results	1	NA	list_covariates	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1016/j.clinthera.2015.09.013	results	1	NA	effect_direction	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	unadjusted_effect	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	unadjusted_pval_char	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	adjusted_effect	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	adjusted_pval_char	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	geographical region	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	n_ipd_total	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	ess_total	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	n_nonipd_total	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	n_nonipd_anchor	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	n_ipd_anchor	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	ess_anchor	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	effect_cutoff	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Patient-level data used	Yes
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Clinical Trial	Yes
10.1016/j.clinthera.2015.09.013	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00410124
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Patient-level data used	No
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Clinical Trial	Yes
10.1016/j.clinthera.2015.09.013	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00678392
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Medical Condition of Interest Name	chronic hepatitis c coinfected with hiv
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1016/j.clinthera.2015.12.017	methodology	1	NA	primary_outcome_name	sustained virologic response at week 12 post-treatment
10.1016/j.clinthera.2015.12.017	methodology	1	NA	outcome_short_name	SVR rate
10.1016/j.clinthera.2015.12.017	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Treatment name 1	daclatasvir + sofosbuvir
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Treatment name 2	sofosbuvir + ribavirin
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1016/j.clinthera.2015.12.017	methodology	1	NA	paitc_type	MAIC
10.1016/j.clinthera.2015.12.017	methodology	1	NA	anchored_yn	No
10.1016/j.clinthera.2015.12.017	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clinthera.2015.12.017	methodology	1	NA	primary_outcome_yn	Yes
10.1016/j.clinthera.2015.12.017	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1016/j.clinthera.2015.12.017	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2015.12.017	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2015.12.017	methodology	1	NA	weights_model_yn	No
10.1016/j.clinthera.2015.12.017	methodology	1	NA	scale_choice_yn	No
10.1016/j.clinthera.2015.12.017	results	1	NA	contrast	Rate difference
10.1016/j.clinthera.2015.12.017	results	1	NA	direction_benefit	superior
10.1016/j.clinthera.2015.12.017	results	1	NA	n_nonipd_ttt	455
10.1016/j.clinthera.2015.12.017	results	1	NA	n_ipd_ttt	91
10.1016/j.clinthera.2015.12.017	results	1	NA	ess_ttt	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	weights_evaluation_yn	Not mentioned
10.1016/j.clinthera.2015.12.017	results	1	NA	list_covariates_yn	Yes
10.1016/j.clinthera.2015.12.017	results	1	NA	n_covariates	11
10.1016/j.clinthera.2015.12.017	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1016/j.clinthera.2015.12.017	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2015.12.017	results	1	NA	unadjusted_effect	0.12
10.1016/j.clinthera.2015.12.017	results	1	NA	unadjusted_pval_char	0.002
10.1016/j.clinthera.2015.12.017	results	1	NA	adjusted_effect	0.15
10.1016/j.clinthera.2015.12.017	results	1	NA	adjusted_pval_char	<0.001
10.1016/j.clinthera.2015.12.017	results	1	NA	geographical region	No
10.1016/j.clinthera.2015.12.017	results	1	NA	n_ipd_total	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	ess_total	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	n_nonipd_total	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	n_nonipd_anchor	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	n_ipd_anchor	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	ess_anchor	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	effect_cutoff	0
10.1016/j.clinthera.2015.12.017	results	1	NA	unadjusted_pval	0.002
10.1016/j.clinthera.2015.12.017	results	1	NA	unadjusted_num_pval	0.002
10.1016/j.clinthera.2015.12.017	results	1	NA	unadjusted_significant	TRUE
10.1016/j.clinthera.2015.12.017	results	1	NA	adjusted_pval	<0.001
10.1016/j.clinthera.2015.12.017	results	1	NA	adjusted_significant	TRUE
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Patient-level data used	Yes
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Clinical Trial	Yes
10.1016/j.clinthera.2015.12.017	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02032888
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Patient-level data used	No
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Clinical Trial	Yes
10.1016/j.clinthera.2015.12.017	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01667731
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Patient-level data used	No
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Clinical Trial	Yes
10.1016/j.clinthera.2015.12.017	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01783678
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Medical Condition of Interest Name	relapsed-refractory multiple myeloma
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1016/j.clinthera.2017.08.010	methodology	1	NA	primary_outcome_name	progression-free survival
10.1016/j.clinthera.2017.08.010	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1016/j.clinthera.2017.08.010	methodology	1	NA	primary_outcome_type	Time-to-event
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Treatment name 1	pomalidomide + dexamethasone
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Treatment name 2	daratumumab
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1016/j.clinthera.2017.08.010	methodology	1	NA	paitc_type	MAIC
10.1016/j.clinthera.2017.08.010	methodology	1	NA	anchored_yn	No
10.1016/j.clinthera.2017.08.010	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2017.08.010	methodology	1	NA	primary_outcome_yn	Yes
10.1016/j.clinthera.2017.08.010	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.clinthera.2017.08.010	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2017.08.010	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2017.08.010	methodology	1	NA	weights_model_yn	No
10.1016/j.clinthera.2017.08.010	methodology	1	NA	scale_choice_yn	No
10.1016/j.clinthera.2017.08.010	methodology	2	NA	primary_outcome_name	progression-free survival
10.1016/j.clinthera.2017.08.010	methodology	2	NA	outcome_short_name	Progression-free Survival
10.1016/j.clinthera.2017.08.010	methodology	2	NA	primary_outcome_type	Time-to-event
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Treatment name 1	pomalidomide + dexamethasone
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Treatment name 2	carfilzomib
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1016/j.clinthera.2017.08.010	methodology	2	NA	paitc_type	MAIC
10.1016/j.clinthera.2017.08.010	methodology	2	NA	anchored_yn	No
10.1016/j.clinthera.2017.08.010	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2017.08.010	methodology	2	NA	primary_outcome_yn	Yes
10.1016/j.clinthera.2017.08.010	methodology	2	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.clinthera.2017.08.010	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2017.08.010	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2017.08.010	methodology	2	NA	weights_model_yn	No
10.1016/j.clinthera.2017.08.010	methodology	2	NA	scale_choice_yn	No
10.1016/j.clinthera.2017.08.010	results	1	NA	contrast	HR
10.1016/j.clinthera.2017.08.010	results	1	NA	direction_benefit	inferior
10.1016/j.clinthera.2017.08.010	results	1	NA	n_nonipd_ttt	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	n_ipd_ttt	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	ess_ttt	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	weights_evaluation_yn	Not mentioned
10.1016/j.clinthera.2017.08.010	results	1	NA	list_covariates_yn	Yes
10.1016/j.clinthera.2017.08.010	results	1	NA	n_covariates	8
10.1016/j.clinthera.2017.08.010	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1016/j.clinthera.2017.08.010	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2017.08.010	results	1	NA	unadjusted_effect	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	unadjusted_pval_char	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	adjusted_effect	0.945
10.1016/j.clinthera.2017.08.010	results	1	NA	adjusted_pval_char	0.749
10.1016/j.clinthera.2017.08.010	results	1	NA	geographical region	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	n_ipd_total	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	ess_total	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	n_nonipd_total	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	n_nonipd_anchor	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	n_ipd_anchor	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	ess_anchor	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	effect_cutoff	1
10.1016/j.clinthera.2017.08.010	results	1	NA	adjusted_pval	0.749
10.1016/j.clinthera.2017.08.010	results	1	NA	adjusted_num_pval	0.749
10.1016/j.clinthera.2017.08.010	results	1	NA	adjusted_significant	FALSE
10.1016/j.clinthera.2017.08.010	results	2	NA	contrast	HR
10.1016/j.clinthera.2017.08.010	results	2	NA	direction_benefit	inferior
10.1016/j.clinthera.2017.08.010	results	2	NA	n_nonipd_ttt	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	n_ipd_ttt	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	ess_ttt	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	weights_evaluation_yn	Not mentioned
10.1016/j.clinthera.2017.08.010	results	2	NA	list_covariates_yn	Yes
10.1016/j.clinthera.2017.08.010	results	2	NA	n_covariates	8
10.1016/j.clinthera.2017.08.010	results	2	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1016/j.clinthera.2017.08.010	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2017.08.010	results	2	NA	unadjusted_effect	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	unadjusted_pval_char	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	adjusted_effect	0.833
10.1016/j.clinthera.2017.08.010	results	2	NA	adjusted_pval_char	0.238
10.1016/j.clinthera.2017.08.010	results	2	NA	geographical region	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	n_ipd_total	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	ess_total	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	n_nonipd_total	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	n_nonipd_anchor	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	n_ipd_anchor	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	ess_anchor	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	effect_cutoff	1
10.1016/j.clinthera.2017.08.010	results	2	NA	adjusted_pval	0.238
10.1016/j.clinthera.2017.08.010	results	2	NA	adjusted_num_pval	0.238
10.1016/j.clinthera.2017.08.010	results	2	NA	adjusted_significant	FALSE
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Patient-level data used	Yes
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Clinical Trial	Yes
10.1016/j.clinthera.2017.08.010	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00833833
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Patient-level data used	No
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Clinical Trial	Yes
10.1016/j.clinthera.2017.08.010	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01985126
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Patient-level data used	No
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Clinical Trial	Yes
10.1016/j.clinthera.2017.08.010	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00511238
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory mantle cell lymphoma
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1016/j.clinthera.2019.09.012	methodology	1	NA	primary_outcome_name	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	1	NA	outcome_short_name	Overall Response Rate
10.1016/j.clinthera.2019.09.012	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Treatment name 1	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Treatment name 2	ibrutinib
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Study 'number(s)' for treatment 2	2;3;4
10.1016/j.clinthera.2019.09.012	methodology	1	NA	paitc_type	MAIC
10.1016/j.clinthera.2019.09.012	methodology	1	NA	anchored_yn	No
10.1016/j.clinthera.2019.09.012	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clinthera.2019.09.012	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	1	NA	weights_model_yn	No
10.1016/j.clinthera.2019.09.012	methodology	1	NA	scale_choice_yn	No
10.1016/j.clinthera.2019.09.012	methodology	2	NA	primary_outcome_name	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	2	NA	outcome_short_name	Overall Response Rate
10.1016/j.clinthera.2019.09.012	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Treatment name 1	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Treatment name 2	bortezomib
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Study 'number(s)' for treatment 2	5
10.1016/j.clinthera.2019.09.012	methodology	2	NA	paitc_type	MAIC
10.1016/j.clinthera.2019.09.012	methodology	2	NA	anchored_yn	No
10.1016/j.clinthera.2019.09.012	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2019.09.012	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	2	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	2	NA	weights_model_yn	No
10.1016/j.clinthera.2019.09.012	methodology	2	NA	scale_choice_yn	No
10.1016/j.clinthera.2019.09.012	methodology	3	NA	primary_outcome_name	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	3	NA	outcome_short_name	Overall Response Rate
10.1016/j.clinthera.2019.09.012	methodology	3	NA	primary_outcome_type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Treatment name 1	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Treatment name 2	lenalidomide
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Study 'number(s)' for treatment 2	6;7
10.1016/j.clinthera.2019.09.012	methodology	3	NA	paitc_type	MAIC
10.1016/j.clinthera.2019.09.012	methodology	3	NA	anchored_yn	No
10.1016/j.clinthera.2019.09.012	methodology	3	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clinthera.2019.09.012	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	3	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	3	NA	weights_model_yn	No
10.1016/j.clinthera.2019.09.012	methodology	3	NA	scale_choice_yn	No
10.1016/j.clinthera.2019.09.012	methodology	4	NA	primary_outcome_name	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	4	NA	outcome_short_name	Overall Response Rate
10.1016/j.clinthera.2019.09.012	methodology	4	NA	primary_outcome_type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Treatment name 1	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Treatment name 2	temsirolimus
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Study 'number(s)' for treatment 2	2;8;9
10.1016/j.clinthera.2019.09.012	methodology	4	NA	paitc_type	MAIC
10.1016/j.clinthera.2019.09.012	methodology	4	NA	anchored_yn	No
10.1016/j.clinthera.2019.09.012	methodology	4	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clinthera.2019.09.012	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	4	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	4	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	4	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	4	NA	weights_model_yn	No
10.1016/j.clinthera.2019.09.012	methodology	4	NA	scale_choice_yn	No
10.1016/j.clinthera.2019.09.012	methodology	5	NA	primary_outcome_name	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	5	NA	outcome_short_name	Overall Response Rate
10.1016/j.clinthera.2019.09.012	methodology	5	NA	primary_outcome_type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Treatment name 1	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Treatment name 2	ibrutinib + rituximab
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Study 'number(s)' for treatment 2	10
10.1016/j.clinthera.2019.09.012	methodology	5	NA	paitc_type	MAIC
10.1016/j.clinthera.2019.09.012	methodology	5	NA	anchored_yn	No
10.1016/j.clinthera.2019.09.012	methodology	5	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2019.09.012	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	5	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	5	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	5	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	5	NA	weights_model_yn	No
10.1016/j.clinthera.2019.09.012	methodology	5	NA	scale_choice_yn	No
10.1016/j.clinthera.2019.09.012	methodology	6	NA	primary_outcome_name	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	6	NA	outcome_short_name	Overall Response Rate
10.1016/j.clinthera.2019.09.012	methodology	6	NA	primary_outcome_type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Treatment name 1	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Treatment name 2	bendamustine + rituximab
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Study 'number(s)' for treatment 2	11
10.1016/j.clinthera.2019.09.012	methodology	6	NA	paitc_type	MAIC
10.1016/j.clinthera.2019.09.012	methodology	6	NA	anchored_yn	No
10.1016/j.clinthera.2019.09.012	methodology	6	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2019.09.012	methodology	6	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	6	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	6	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	6	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	6	NA	weights_model_yn	No
10.1016/j.clinthera.2019.09.012	methodology	6	NA	scale_choice_yn	No
10.1016/j.clinthera.2019.09.012	methodology	7	NA	primary_outcome_name	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	7	NA	outcome_short_name	Overall Response Rate
10.1016/j.clinthera.2019.09.012	methodology	7	NA	primary_outcome_type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Treatment name 1	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Treatment name 2	lenalidomide + rituximab
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Study 'number(s)' for treatment 2	12
10.1016/j.clinthera.2019.09.012	methodology	7	NA	paitc_type	MAIC
10.1016/j.clinthera.2019.09.012	methodology	7	NA	anchored_yn	No
10.1016/j.clinthera.2019.09.012	methodology	7	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2019.09.012	methodology	7	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	7	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	7	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	7	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	7	NA	weights_model_yn	No
10.1016/j.clinthera.2019.09.012	methodology	7	NA	scale_choice_yn	No
10.1016/j.clinthera.2019.09.012	results	1	NA	contrast	Rate difference
10.1016/j.clinthera.2019.09.012	results	1	NA	direction_benefit	superior
10.1016/j.clinthera.2019.09.012	results	1	NA	n_nonipd_ttt	370
10.1016/j.clinthera.2019.09.012	results	1	NA	n_ipd_ttt	123
10.1016/j.clinthera.2019.09.012	results	1	NA	ess_ttt	45
10.1016/j.clinthera.2019.09.012	results	1	NA	weights_evaluation_yn	Not mentioned
10.1016/j.clinthera.2019.09.012	results	1	NA	list_covariates_yn	Yes
10.1016/j.clinthera.2019.09.012	results	1	NA	n_covariates	10
10.1016/j.clinthera.2019.09.012	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	1	NA	unadjusted_effect	10.2
10.1016/j.clinthera.2019.09.012	results	1	NA	unadjusted_pval_char	<0.05
10.1016/j.clinthera.2019.09.012	results	1	NA	adjusted_effect	9.3
10.1016/j.clinthera.2019.09.012	results	1	NA	adjusted_pval_char	<0.05
10.1016/j.clinthera.2019.09.012	results	1	NA	geographical region	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	n_ipd_total	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	ess_total	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	n_nonipd_total	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	n_nonipd_anchor	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	n_ipd_anchor	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	ess_anchor	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	effect_cutoff	0
10.1016/j.clinthera.2019.09.012	results	1	NA	unadjusted_pval	<0.05
10.1016/j.clinthera.2019.09.012	results	1	NA	unadjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	1	NA	adjusted_pval	<0.05
10.1016/j.clinthera.2019.09.012	results	1	NA	adjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	2	NA	contrast	Rate difference
10.1016/j.clinthera.2019.09.012	results	2	NA	direction_benefit	superior
10.1016/j.clinthera.2019.09.012	results	2	NA	n_nonipd_ttt	155
10.1016/j.clinthera.2019.09.012	results	2	NA	n_ipd_ttt	124
10.1016/j.clinthera.2019.09.012	results	2	NA	ess_ttt	61
10.1016/j.clinthera.2019.09.012	results	2	NA	weights_evaluation_yn	Not mentioned
10.1016/j.clinthera.2019.09.012	results	2	NA	list_covariates_yn	Yes
10.1016/j.clinthera.2019.09.012	results	2	NA	n_covariates	9
10.1016/j.clinthera.2019.09.012	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	2	NA	unadjusted_effect	46
10.1016/j.clinthera.2019.09.012	results	2	NA	unadjusted_pval_char	<0.001
10.1016/j.clinthera.2019.09.012	results	2	NA	adjusted_effect	50.6
10.1016/j.clinthera.2019.09.012	results	2	NA	adjusted_pval_char	<0.001
10.1016/j.clinthera.2019.09.012	results	2	NA	geographical region	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	n_ipd_total	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	ess_total	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	n_nonipd_total	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	n_nonipd_anchor	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	n_ipd_anchor	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	ess_anchor	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	effect_cutoff	0
10.1016/j.clinthera.2019.09.012	results	2	NA	unadjusted_pval	<0.001
10.1016/j.clinthera.2019.09.012	results	2	NA	unadjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	2	NA	adjusted_pval	<0.001
10.1016/j.clinthera.2019.09.012	results	2	NA	adjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	3	NA	contrast	Rate difference
10.1016/j.clinthera.2019.09.012	results	3	NA	direction_benefit	superior
10.1016/j.clinthera.2019.09.012	results	3	NA	n_nonipd_ttt	304
10.1016/j.clinthera.2019.09.012	results	3	NA	n_ipd_ttt	122
10.1016/j.clinthera.2019.09.012	results	3	NA	ess_ttt	28
10.1016/j.clinthera.2019.09.012	results	3	NA	weights_evaluation_yn	Not mentioned
10.1016/j.clinthera.2019.09.012	results	3	NA	list_covariates_yn	Yes
10.1016/j.clinthera.2019.09.012	results	3	NA	n_covariates	12
10.1016/j.clinthera.2019.09.012	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	3	NA	unadjusted_effect	39.7
10.1016/j.clinthera.2019.09.012	results	3	NA	unadjusted_pval_char	<0.001
10.1016/j.clinthera.2019.09.012	results	3	NA	adjusted_effect	38.1
10.1016/j.clinthera.2019.09.012	results	3	NA	adjusted_pval_char	<0.001
10.1016/j.clinthera.2019.09.012	results	3	NA	geographical region	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	n_ipd_total	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	ess_total	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	n_nonipd_total	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	n_nonipd_anchor	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	n_ipd_anchor	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	ess_anchor	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	effect_cutoff	0
10.1016/j.clinthera.2019.09.012	results	3	NA	unadjusted_pval	<0.001
10.1016/j.clinthera.2019.09.012	results	3	NA	unadjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	3	NA	adjusted_pval	<0.001
10.1016/j.clinthera.2019.09.012	results	3	NA	adjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	4	NA	contrast	Rate difference
10.1016/j.clinthera.2019.09.012	results	4	NA	direction_benefit	superior
10.1016/j.clinthera.2019.09.012	results	4	NA	n_nonipd_ttt	242
10.1016/j.clinthera.2019.09.012	results	4	NA	n_ipd_ttt	123
10.1016/j.clinthera.2019.09.012	results	4	NA	ess_ttt	120
10.1016/j.clinthera.2019.09.012	results	4	NA	weights_evaluation_yn	Not mentioned
10.1016/j.clinthera.2019.09.012	results	4	NA	list_covariates_yn	Yes
10.1016/j.clinthera.2019.09.012	results	4	NA	n_covariates	3
10.1016/j.clinthera.2019.09.012	results	4	NA	list_covariates	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.clinthera.2019.09.012	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	4	NA	unadjusted_effect	40.9
10.1016/j.clinthera.2019.09.012	results	4	NA	unadjusted_pval_char	<0.001
10.1016/j.clinthera.2019.09.012	results	4	NA	adjusted_effect	40.7
10.1016/j.clinthera.2019.09.012	results	4	NA	adjusted_pval_char	<0.001
10.1016/j.clinthera.2019.09.012	results	4	NA	geographical region	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	n_ipd_total	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	ess_total	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	n_nonipd_total	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	n_nonipd_anchor	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	n_ipd_anchor	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	ess_anchor	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	effect_cutoff	0
10.1016/j.clinthera.2019.09.012	results	4	NA	unadjusted_pval	<0.001
10.1016/j.clinthera.2019.09.012	results	4	NA	unadjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	4	NA	adjusted_pval	<0.001
10.1016/j.clinthera.2019.09.012	results	4	NA	adjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	5	NA	contrast	Rate difference
10.1016/j.clinthera.2019.09.012	results	5	NA	direction_benefit	superior
10.1016/j.clinthera.2019.09.012	results	5	NA	n_nonipd_ttt	50
10.1016/j.clinthera.2019.09.012	results	5	NA	n_ipd_ttt	84
10.1016/j.clinthera.2019.09.012	results	5	NA	ess_ttt	16
10.1016/j.clinthera.2019.09.012	results	5	NA	weights_evaluation_yn	Not mentioned
10.1016/j.clinthera.2019.09.012	results	5	NA	list_covariates_yn	Yes
10.1016/j.clinthera.2019.09.012	results	5	NA	n_covariates	8
10.1016/j.clinthera.2019.09.012	results	5	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	5	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	5	NA	unadjusted_effect	-14.2
10.1016/j.clinthera.2019.09.012	results	5	NA	unadjusted_pval_char	<0.05
10.1016/j.clinthera.2019.09.012	results	5	NA	adjusted_effect	-10.6
10.1016/j.clinthera.2019.09.012	results	5	NA	adjusted_pval_char	0.09
10.1016/j.clinthera.2019.09.012	results	5	NA	geographical region	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	n_ipd_total	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	ess_total	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	n_nonipd_total	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	n_nonipd_anchor	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	n_ipd_anchor	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	ess_anchor	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	effect_cutoff	0
10.1016/j.clinthera.2019.09.012	results	5	NA	unadjusted_pval	<0.05
10.1016/j.clinthera.2019.09.012	results	5	NA	unadjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	5	NA	adjusted_pval	0.09
10.1016/j.clinthera.2019.09.012	results	5	NA	adjusted_num_pval	0.09
10.1016/j.clinthera.2019.09.012	results	5	NA	adjusted_significant	FALSE
10.1016/j.clinthera.2019.09.012	results	6	NA	contrast	Rate difference
10.1016/j.clinthera.2019.09.012	results	6	NA	direction_benefit	superior
10.1016/j.clinthera.2019.09.012	results	6	NA	n_nonipd_ttt	45
10.1016/j.clinthera.2019.09.012	results	6	NA	n_ipd_ttt	121
10.1016/j.clinthera.2019.09.012	results	6	NA	ess_ttt	56
10.1016/j.clinthera.2019.09.012	results	6	NA	weights_evaluation_yn	Not mentioned
10.1016/j.clinthera.2019.09.012	results	6	NA	list_covariates_yn	Yes
10.1016/j.clinthera.2019.09.012	results	6	NA	n_covariates	5
10.1016/j.clinthera.2019.09.012	results	6	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1016/j.clinthera.2019.09.012	results	6	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	6	NA	unadjusted_effect	-7
10.1016/j.clinthera.2019.09.012	results	6	NA	unadjusted_pval_char	0.31
10.1016/j.clinthera.2019.09.012	results	6	NA	adjusted_effect	-9.8
10.1016/j.clinthera.2019.09.012	results	6	NA	adjusted_pval_char	0.22
10.1016/j.clinthera.2019.09.012	results	6	NA	geographical region	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	n_ipd_total	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	ess_total	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	n_nonipd_total	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	n_nonipd_anchor	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	n_ipd_anchor	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	ess_anchor	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	effect_cutoff	0
10.1016/j.clinthera.2019.09.012	results	6	NA	unadjusted_pval	0.31
10.1016/j.clinthera.2019.09.012	results	6	NA	unadjusted_num_pval	0.31
10.1016/j.clinthera.2019.09.012	results	6	NA	unadjusted_significant	FALSE
10.1016/j.clinthera.2019.09.012	results	6	NA	adjusted_pval	0.22
10.1016/j.clinthera.2019.09.012	results	6	NA	adjusted_num_pval	0.22
10.1016/j.clinthera.2019.09.012	results	6	NA	adjusted_significant	FALSE
10.1016/j.clinthera.2019.09.012	results	7	NA	contrast	Rate difference
10.1016/j.clinthera.2019.09.012	results	7	NA	direction_benefit	superior
10.1016/j.clinthera.2019.09.012	results	7	NA	n_nonipd_ttt	44
10.1016/j.clinthera.2019.09.012	results	7	NA	n_ipd_ttt	93
10.1016/j.clinthera.2019.09.012	results	7	NA	ess_ttt	64
10.1016/j.clinthera.2019.09.012	results	7	NA	weights_evaluation_yn	Not mentioned
10.1016/j.clinthera.2019.09.012	results	7	NA	list_covariates_yn	Yes
10.1016/j.clinthera.2019.09.012	results	7	NA	n_covariates	7
10.1016/j.clinthera.2019.09.012	results	7	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	7	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	7	NA	unadjusted_effect	16.3
10.1016/j.clinthera.2019.09.012	results	7	NA	unadjusted_pval_char	0.06
10.1016/j.clinthera.2019.09.012	results	7	NA	adjusted_effect	14.1
10.1016/j.clinthera.2019.09.012	results	7	NA	adjusted_pval_char	0.13
10.1016/j.clinthera.2019.09.012	results	7	NA	geographical region	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	n_ipd_total	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	ess_total	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	n_nonipd_total	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	n_nonipd_anchor	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	n_ipd_anchor	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	ess_anchor	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	effect_cutoff	0
10.1016/j.clinthera.2019.09.012	results	7	NA	unadjusted_pval	0.06
10.1016/j.clinthera.2019.09.012	results	7	NA	unadjusted_num_pval	0.06
10.1016/j.clinthera.2019.09.012	results	7	NA	unadjusted_significant	FALSE
10.1016/j.clinthera.2019.09.012	results	7	NA	adjusted_pval	0.13
10.1016/j.clinthera.2019.09.012	results	7	NA	adjusted_num_pval	0.13
10.1016/j.clinthera.2019.09.012	results	7	NA	adjusted_significant	FALSE
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Patient-level data used	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02213926
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	10	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01880567
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Patient-level data used	no
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Clinical Trial	yes
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Data source name (only if observational study or clinical trial without NCT)	czuczman 2015
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Patient-level data used	no
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Clinical Trial	yes
10.1016/j.clinthera.2019.09.012	study_information	NA	12	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00294632
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Phase of the clinical trial (clinical trial only)	1, 2
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01646021
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01236391
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01599949
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	pinnacle
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00875667
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00737529
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00117598
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01180049
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Phase of the clinical trial (clinical trial only)	4
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Medical Condition of Interest Name	advanced, unresectable gastroenteropancreatic neuroendocrine tumours
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Countries of first author affiliations	uk
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Countries of last author affiliations	germany
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Private Data Analysis Company
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	primary_outcome_name	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	primary_outcome_type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Treatment name 1	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Treatment name 2	everolimus
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	paitc_type	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	anchored_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	prognostic_factors_yn	Yes
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	weights_model_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	scale_choice_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	primary_outcome_name	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	outcome_short_name	Progression-free Survival
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	primary_outcome_type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Treatment name 1	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Treatment name 2	best supportive care (bsc)
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	paitc_type	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	anchored_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	prognostic_factors_yn	Yes
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	weights_model_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	scale_choice_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	primary_outcome_name	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	outcome_short_name	Progression-free Survival
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	primary_outcome_type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Treatment name 1	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Treatment name 2	sunitinib
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	paitc_type	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	anchored_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	prognostic_factors_yn	Yes
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	weights_model_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	scale_choice_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	primary_outcome_name	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	outcome_short_name	Progression-free Survival
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	primary_outcome_type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Treatment name 1	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Treatment name 2	best supportive care
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Study 'number(s)' for treatment 2	4
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	paitc_type	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	anchored_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	prognostic_factors_yn	Yes
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	weights_model_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	scale_choice_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	primary_outcome_name	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	outcome_short_name	Progression-free Survival
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	primary_outcome_type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Treatment name 1	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Treatment name 2	everolimus
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Study 'number(s)' for treatment 2	3
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	paitc_type	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	anchored_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	prognostic_factors_yn	Yes
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	weights_model_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	scale_choice_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	primary_outcome_name	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	outcome_short_name	Progression-free Survival
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	primary_outcome_type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Treatment name 1	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Study 'number(s)' for treatment 1	1
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Treatment name 2	best supportive care
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Study 'number(s)' for treatment 2	3
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	paitc_type	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	anchored_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	prognostic_factors_yn	Yes
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	weights_model_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	scale_choice_yn	No
10.1016/j.ejcsup.2021.06.002	results	1	NA	contrast	HR
10.1016/j.ejcsup.2021.06.002	results	1	NA	direction_benefit	inferior
10.1016/j.ejcsup.2021.06.002	results	1	NA	n_nonipd_ttt	118
10.1016/j.ejcsup.2021.06.002	results	1	NA	n_ipd_ttt	111
10.1016/j.ejcsup.2021.06.002	results	1	NA	ess_ttt	105
10.1016/j.ejcsup.2021.06.002	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	1	NA	list_covariates_yn	Yes
10.1016/j.ejcsup.2021.06.002	results	1	NA	n_covariates	1
10.1016/j.ejcsup.2021.06.002	results	1	NA	list_covariates	Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.ejcsup.2021.06.002	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	1	NA	unadjusted_effect	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	unadjusted_pval_char	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	adjusted_effect	0.38
10.1016/j.ejcsup.2021.06.002	results	1	NA	adjusted_pval_char	[0.25;0.58]
10.1016/j.ejcsup.2021.06.002	results	1	NA	geographical region	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	n_ipd_total	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	ess_total	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	n_nonipd_total	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	n_nonipd_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	n_ipd_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	ess_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	effect_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	1	NA	adjusted_lb_ci	0.25
10.1016/j.ejcsup.2021.06.002	results	1	NA	adjusted_ub_ci	0.58
10.1016/j.ejcsup.2021.06.002	results	1	NA	adjusted_significant	TRUE
10.1016/j.ejcsup.2021.06.002	results	2	NA	contrast	HR
10.1016/j.ejcsup.2021.06.002	results	2	NA	direction_benefit	inferior
10.1016/j.ejcsup.2021.06.002	results	2	NA	n_nonipd_ttt	57
10.1016/j.ejcsup.2021.06.002	results	2	NA	n_ipd_ttt	111
10.1016/j.ejcsup.2021.06.002	results	2	NA	ess_ttt	95
10.1016/j.ejcsup.2021.06.002	results	2	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	2	NA	list_covariates_yn	Yes
10.1016/j.ejcsup.2021.06.002	results	2	NA	n_covariates	1
10.1016/j.ejcsup.2021.06.002	results	2	NA	list_covariates	Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.ejcsup.2021.06.002	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	2	NA	unadjusted_effect	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	unadjusted_pval_char	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	adjusted_effect	0.35
10.1016/j.ejcsup.2021.06.002	results	2	NA	adjusted_pval_char	[0.21;0.59]
10.1016/j.ejcsup.2021.06.002	results	2	NA	geographical region	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	n_ipd_total	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	ess_total	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	n_nonipd_total	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	n_nonipd_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	n_ipd_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	ess_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	effect_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	2	NA	adjusted_lb_ci	0.21
10.1016/j.ejcsup.2021.06.002	results	2	NA	adjusted_ub_ci	0.59
10.1016/j.ejcsup.2021.06.002	results	2	NA	adjusted_significant	TRUE
10.1016/j.ejcsup.2021.06.002	results	3	NA	contrast	HR
10.1016/j.ejcsup.2021.06.002	results	3	NA	direction_benefit	inferior
10.1016/j.ejcsup.2021.06.002	results	3	NA	n_nonipd_ttt	86
10.1016/j.ejcsup.2021.06.002	results	3	NA	n_ipd_ttt	62
10.1016/j.ejcsup.2021.06.002	results	3	NA	ess_ttt	48
10.1016/j.ejcsup.2021.06.002	results	3	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	3	NA	list_covariates_yn	Yes
10.1016/j.ejcsup.2021.06.002	results	3	NA	n_covariates	4
10.1016/j.ejcsup.2021.06.002	results	3	NA	list_covariates	Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.ejcsup.2021.06.002	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	3	NA	unadjusted_effect	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	unadjusted_pval_char	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	adjusted_effect	0.36
10.1016/j.ejcsup.2021.06.002	results	3	NA	adjusted_pval_char	[0.18;0.70]
10.1016/j.ejcsup.2021.06.002	results	3	NA	geographical region	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	n_ipd_total	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	ess_total	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	n_nonipd_total	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	n_nonipd_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	n_ipd_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	ess_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	effect_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	3	NA	adjusted_lb_ci	0.18
10.1016/j.ejcsup.2021.06.002	results	3	NA	adjusted_ub_ci	0.7
10.1016/j.ejcsup.2021.06.002	results	3	NA	adjusted_significant	TRUE
10.1016/j.ejcsup.2021.06.002	results	4	NA	contrast	HR
10.1016/j.ejcsup.2021.06.002	results	4	NA	direction_benefit	inferior
10.1016/j.ejcsup.2021.06.002	results	4	NA	n_nonipd_ttt	85
10.1016/j.ejcsup.2021.06.002	results	4	NA	n_ipd_ttt	62
10.1016/j.ejcsup.2021.06.002	results	4	NA	ess_ttt	35
10.1016/j.ejcsup.2021.06.002	results	4	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	4	NA	list_covariates_yn	Yes
10.1016/j.ejcsup.2021.06.002	results	4	NA	n_covariates	4
10.1016/j.ejcsup.2021.06.002	results	4	NA	list_covariates	Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.ejcsup.2021.06.002	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	4	NA	unadjusted_effect	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	unadjusted_pval_char	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	adjusted_effect	0.13
10.1016/j.ejcsup.2021.06.002	results	4	NA	adjusted_pval_char	[0.08;0.22]
10.1016/j.ejcsup.2021.06.002	results	4	NA	geographical region	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	n_ipd_total	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	ess_total	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	n_nonipd_total	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	n_nonipd_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	n_ipd_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	ess_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	effect_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	4	NA	adjusted_lb_ci	0.08
10.1016/j.ejcsup.2021.06.002	results	4	NA	adjusted_ub_ci	0.22
10.1016/j.ejcsup.2021.06.002	results	4	NA	adjusted_significant	TRUE
10.1016/j.ejcsup.2021.06.002	results	5	NA	contrast	HR
10.1016/j.ejcsup.2021.06.002	results	5	NA	direction_benefit	inferior
10.1016/j.ejcsup.2021.06.002	results	5	NA	n_nonipd_ttt	207
10.1016/j.ejcsup.2021.06.002	results	5	NA	n_ipd_ttt	62
10.1016/j.ejcsup.2021.06.002	results	5	NA	ess_ttt	22
10.1016/j.ejcsup.2021.06.002	results	5	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	5	NA	list_covariates_yn	Yes
10.1016/j.ejcsup.2021.06.002	results	5	NA	n_covariates	4
10.1016/j.ejcsup.2021.06.002	results	5	NA	list_covariates	Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.ejcsup.2021.06.002	results	5	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	5	NA	unadjusted_effect	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	unadjusted_pval_char	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	adjusted_effect	0.46
10.1016/j.ejcsup.2021.06.002	results	5	NA	adjusted_pval_char	[0.30;0.71]
10.1016/j.ejcsup.2021.06.002	results	5	NA	geographical region	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	n_ipd_total	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	ess_total	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	n_nonipd_total	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	n_nonipd_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	n_ipd_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	ess_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	effect_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	5	NA	adjusted_lb_ci	0.3
10.1016/j.ejcsup.2021.06.002	results	5	NA	adjusted_ub_ci	0.71
10.1016/j.ejcsup.2021.06.002	results	5	NA	adjusted_significant	TRUE
10.1016/j.ejcsup.2021.06.002	results	6	NA	contrast	HR
10.1016/j.ejcsup.2021.06.002	results	6	NA	direction_benefit	inferior
10.1016/j.ejcsup.2021.06.002	results	6	NA	n_nonipd_ttt	203
10.1016/j.ejcsup.2021.06.002	results	6	NA	n_ipd_ttt	62
10.1016/j.ejcsup.2021.06.002	results	6	NA	ess_ttt	18
10.1016/j.ejcsup.2021.06.002	results	6	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	6	NA	list_covariates_yn	Yes
10.1016/j.ejcsup.2021.06.002	results	6	NA	n_covariates	4
10.1016/j.ejcsup.2021.06.002	results	6	NA	list_covariates	Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.ejcsup.2021.06.002	results	6	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	6	NA	unadjusted_effect	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	unadjusted_pval_char	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	adjusted_effect	0.21
10.1016/j.ejcsup.2021.06.002	results	6	NA	adjusted_pval_char	[0.13;0.32]
10.1016/j.ejcsup.2021.06.002	results	6	NA	geographical region	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	n_ipd_total	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	ess_total	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	n_nonipd_total	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	n_nonipd_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	n_ipd_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	ess_anchor	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	effect_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	6	NA	adjusted_lb_ci	0.13
10.1016/j.ejcsup.2021.06.002	results	6	NA	adjusted_ub_ci	0.32
10.1016/j.ejcsup.2021.06.002	results	6	NA	adjusted_significant	TRUE
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Patient-level data used	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Clinical Trial	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	erasmus study
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	the netherlands
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Patient-level data used	No
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Clinical Trial	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01524783
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Patient-level data used	No
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Clinical Trial	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00510068
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Patient-level data used	No
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Clinical Trial	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00428597
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Medical Condition of Interest Name	braf-mutant advanced melanoma
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.esmoop.2021.100050	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1016/j.esmoop.2021.100050	methodology	1	NA	primary_outcome_name	overall survival
10.1016/j.esmoop.2021.100050	methodology	1	NA	outcome_short_name	Overall Survival
10.1016/j.esmoop.2021.100050	methodology	1	NA	primary_outcome_type	Time-to-event
10.1016/j.esmoop.2021.100050	methodology	1	NA	Treatment name 1	nivolumab + ipilimumab
10.1016/j.esmoop.2021.100050	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.esmoop.2021.100050	methodology	1	NA	Treatment name 2	dabrafenib + trametinib
10.1016/j.esmoop.2021.100050	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1016/j.esmoop.2021.100050	methodology	1	NA	paitc_type	MAIC
10.1016/j.esmoop.2021.100050	methodology	1	NA	anchored_yn	No
10.1016/j.esmoop.2021.100050	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.esmoop.2021.100050	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.esmoop.2021.100050	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1016/j.esmoop.2021.100050	methodology	1	NA	prognostic_factors_yn	No
10.1016/j.esmoop.2021.100050	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1016/j.esmoop.2021.100050	methodology	1	NA	weights_model_yn	No
10.1016/j.esmoop.2021.100050	methodology	1	NA	scale_choice_yn	No
10.1016/j.esmoop.2021.100050	methodology	2	NA	primary_outcome_name	overall survival
10.1016/j.esmoop.2021.100050	methodology	2	NA	outcome_short_name	Overall Survival
10.1016/j.esmoop.2021.100050	methodology	2	NA	primary_outcome_type	Time-to-event
10.1016/j.esmoop.2021.100050	methodology	2	NA	Treatment name 1	nivolumab + ipilimumab
10.1016/j.esmoop.2021.100050	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1016/j.esmoop.2021.100050	methodology	2	NA	Treatment name 2	encorafenib + binimetinib
10.1016/j.esmoop.2021.100050	methodology	2	NA	Study 'number(s)' for treatment 2	4
10.1016/j.esmoop.2021.100050	methodology	2	NA	paitc_type	MAIC
10.1016/j.esmoop.2021.100050	methodology	2	NA	anchored_yn	No
10.1016/j.esmoop.2021.100050	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.esmoop.2021.100050	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.esmoop.2021.100050	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.1016/j.esmoop.2021.100050	methodology	2	NA	prognostic_factors_yn	No
10.1016/j.esmoop.2021.100050	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1016/j.esmoop.2021.100050	methodology	2	NA	weights_model_yn	No
10.1016/j.esmoop.2021.100050	methodology	2	NA	scale_choice_yn	No
10.1016/j.esmoop.2021.100050	methodology	3	NA	primary_outcome_name	overall survival
10.1016/j.esmoop.2021.100050	methodology	3	NA	outcome_short_name	Overall Survival
10.1016/j.esmoop.2021.100050	methodology	3	NA	primary_outcome_type	Time-to-event
10.1016/j.esmoop.2021.100050	methodology	3	NA	Treatment name 1	nivolumab + ipilimumab
10.1016/j.esmoop.2021.100050	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1016/j.esmoop.2021.100050	methodology	3	NA	Treatment name 2	vemurafenib + cobimetinib
10.1016/j.esmoop.2021.100050	methodology	3	NA	Study 'number(s)' for treatment 2	5
10.1016/j.esmoop.2021.100050	methodology	3	NA	paitc_type	MAIC
10.1016/j.esmoop.2021.100050	methodology	3	NA	anchored_yn	No
10.1016/j.esmoop.2021.100050	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.esmoop.2021.100050	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.esmoop.2021.100050	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.1016/j.esmoop.2021.100050	methodology	3	NA	prognostic_factors_yn	No
10.1016/j.esmoop.2021.100050	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.1016/j.esmoop.2021.100050	methodology	3	NA	weights_model_yn	No
10.1016/j.esmoop.2021.100050	methodology	3	NA	scale_choice_yn	No
10.1016/j.esmoop.2021.100050	results	1	NA	contrast	HR
10.1016/j.esmoop.2021.100050	results	1	NA	direction_benefit	inferior
10.1016/j.esmoop.2021.100050	results	1	NA	n_nonipd_ttt	563
10.1016/j.esmoop.2021.100050	results	1	NA	n_ipd_ttt	103
10.1016/j.esmoop.2021.100050	results	1	NA	ess_ttt	91.68
10.1016/j.esmoop.2021.100050	results	1	NA	weights_evaluation_yn	Not mentioned
10.1016/j.esmoop.2021.100050	results	1	NA	list_covariates_yn	Yes
10.1016/j.esmoop.2021.100050	results	1	NA	n_covariates	5
10.1016/j.esmoop.2021.100050	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.esmoop.2021.100050	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.esmoop.2021.100050	results	1	NA	unadjusted_effect	NA
10.1016/j.esmoop.2021.100050	results	1	NA	unadjusted_pval_char	NA
10.1016/j.esmoop.2021.100050	results	1	NA	adjusted_effect	0.53
10.1016/j.esmoop.2021.100050	results	1	NA	adjusted_pval_char	[0.39;0.73]
10.1016/j.esmoop.2021.100050	results	1	NA	geographical region	NA
10.1016/j.esmoop.2021.100050	results	1	NA	n_ipd_total	NA
10.1016/j.esmoop.2021.100050	results	1	NA	ess_total	NA
10.1016/j.esmoop.2021.100050	results	1	NA	n_nonipd_total	NA
10.1016/j.esmoop.2021.100050	results	1	NA	n_nonipd_anchor	NA
10.1016/j.esmoop.2021.100050	results	1	NA	n_ipd_anchor	NA
10.1016/j.esmoop.2021.100050	results	1	NA	ess_anchor	NA
10.1016/j.esmoop.2021.100050	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.esmoop.2021.100050	results	1	NA	effect_cutoff	1
10.1016/j.esmoop.2021.100050	results	1	NA	adjusted_lb_ci	0.39
10.1016/j.esmoop.2021.100050	results	1	NA	adjusted_ub_ci	0.73
10.1016/j.esmoop.2021.100050	results	1	NA	adjusted_significant	TRUE
10.1016/j.esmoop.2021.100050	results	2	NA	contrast	HR
10.1016/j.esmoop.2021.100050	results	2	NA	direction_benefit	inferior
10.1016/j.esmoop.2021.100050	results	2	NA	n_nonipd_ttt	192
10.1016/j.esmoop.2021.100050	results	2	NA	n_ipd_ttt	103
10.1016/j.esmoop.2021.100050	results	2	NA	ess_ttt	93.81
10.1016/j.esmoop.2021.100050	results	2	NA	weights_evaluation_yn	Not mentioned
10.1016/j.esmoop.2021.100050	results	2	NA	list_covariates_yn	Yes
10.1016/j.esmoop.2021.100050	results	2	NA	n_covariates	5
10.1016/j.esmoop.2021.100050	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.esmoop.2021.100050	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.esmoop.2021.100050	results	2	NA	unadjusted_effect	NA
10.1016/j.esmoop.2021.100050	results	2	NA	unadjusted_pval_char	NA
10.1016/j.esmoop.2021.100050	results	2	NA	adjusted_effect	0.6
10.1016/j.esmoop.2021.100050	results	2	NA	adjusted_pval_char	[0.42;0.85]
10.1016/j.esmoop.2021.100050	results	2	NA	geographical region	NA
10.1016/j.esmoop.2021.100050	results	2	NA	n_ipd_total	NA
10.1016/j.esmoop.2021.100050	results	2	NA	ess_total	NA
10.1016/j.esmoop.2021.100050	results	2	NA	n_nonipd_total	NA
10.1016/j.esmoop.2021.100050	results	2	NA	n_nonipd_anchor	NA
10.1016/j.esmoop.2021.100050	results	2	NA	n_ipd_anchor	NA
10.1016/j.esmoop.2021.100050	results	2	NA	ess_anchor	NA
10.1016/j.esmoop.2021.100050	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.esmoop.2021.100050	results	2	NA	effect_cutoff	1
10.1016/j.esmoop.2021.100050	results	2	NA	adjusted_lb_ci	0.42
10.1016/j.esmoop.2021.100050	results	2	NA	adjusted_ub_ci	0.85
10.1016/j.esmoop.2021.100050	results	2	NA	adjusted_significant	TRUE
10.1016/j.esmoop.2021.100050	results	3	NA	contrast	HR
10.1016/j.esmoop.2021.100050	results	3	NA	direction_benefit	inferior
10.1016/j.esmoop.2021.100050	results	3	NA	n_nonipd_ttt	247
10.1016/j.esmoop.2021.100050	results	3	NA	n_ipd_ttt	103
10.1016/j.esmoop.2021.100050	results	3	NA	ess_ttt	91.69
10.1016/j.esmoop.2021.100050	results	3	NA	weights_evaluation_yn	Not mentioned
10.1016/j.esmoop.2021.100050	results	3	NA	list_covariates_yn	Yes
10.1016/j.esmoop.2021.100050	results	3	NA	n_covariates	5
10.1016/j.esmoop.2021.100050	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.esmoop.2021.100050	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.esmoop.2021.100050	results	3	NA	unadjusted_effect	NA
10.1016/j.esmoop.2021.100050	results	3	NA	unadjusted_pval_char	NA
10.1016/j.esmoop.2021.100050	results	3	NA	adjusted_effect	0.5
10.1016/j.esmoop.2021.100050	results	3	NA	adjusted_pval_char	[0.36;0.70]
10.1016/j.esmoop.2021.100050	results	3	NA	geographical region	NA
10.1016/j.esmoop.2021.100050	results	3	NA	n_ipd_total	NA
10.1016/j.esmoop.2021.100050	results	3	NA	ess_total	NA
10.1016/j.esmoop.2021.100050	results	3	NA	n_nonipd_total	NA
10.1016/j.esmoop.2021.100050	results	3	NA	n_nonipd_anchor	NA
10.1016/j.esmoop.2021.100050	results	3	NA	n_ipd_anchor	NA
10.1016/j.esmoop.2021.100050	results	3	NA	ess_anchor	NA
10.1016/j.esmoop.2021.100050	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.esmoop.2021.100050	results	3	NA	effect_cutoff	1
10.1016/j.esmoop.2021.100050	results	3	NA	adjusted_lb_ci	0.36
10.1016/j.esmoop.2021.100050	results	3	NA	adjusted_ub_ci	0.7
10.1016/j.esmoop.2021.100050	results	3	NA	adjusted_significant	TRUE
10.1016/j.esmoop.2021.100050	study_information	NA	1	Patient-level data used	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	1	Clinical Trial	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01844505
10.1016/j.esmoop.2021.100050	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.esmoop.2021.100050	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1016/j.esmoop.2021.100050	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.esmoop.2021.100050	study_information	NA	2	Patient-level data used	No
10.1016/j.esmoop.2021.100050	study_information	NA	2	Clinical Trial	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01584648
10.1016/j.esmoop.2021.100050	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.esmoop.2021.100050	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1016/j.esmoop.2021.100050	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.esmoop.2021.100050	study_information	NA	3	Patient-level data used	No
10.1016/j.esmoop.2021.100050	study_information	NA	3	Clinical Trial	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01597908
10.1016/j.esmoop.2021.100050	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.esmoop.2021.100050	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1016/j.esmoop.2021.100050	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.esmoop.2021.100050	study_information	NA	4	Patient-level data used	No
10.1016/j.esmoop.2021.100050	study_information	NA	4	Clinical Trial	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01909453
10.1016/j.esmoop.2021.100050	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.esmoop.2021.100050	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1016/j.esmoop.2021.100050	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.esmoop.2021.100050	study_information	NA	5	Patient-level data used	No
10.1016/j.esmoop.2021.100050	study_information	NA	5	Clinical Trial	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01689519
10.1016/j.esmoop.2021.100050	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.esmoop.2021.100050	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1016/j.esmoop.2021.100050	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.euo.2018.09.009	general_information	NA	NA	Medical Condition of Interest Name	advanced, unresectable, or metastatic urothelial cancer
10.1016/j.euo.2018.09.009	general_information	NA	NA	Countries of first author affiliations	uk
10.1016/j.euo.2018.09.009	general_information	NA	NA	Countries of last author affiliations	the netherlands
10.1016/j.euo.2018.09.009	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.euo.2018.09.009	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.euo.2018.09.009	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.euo.2018.09.009	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.euo.2018.09.009	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1016/j.euo.2018.09.009	methodology	1	NA	primary_outcome_name	overall survival
10.1016/j.euo.2018.09.009	methodology	1	NA	outcome_short_name	Overall Survival
10.1016/j.euo.2018.09.009	methodology	1	NA	primary_outcome_type	Time-to-event
10.1016/j.euo.2018.09.009	methodology	1	NA	Treatment name 1	pembrolizumab
10.1016/j.euo.2018.09.009	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.euo.2018.09.009	methodology	1	NA	Treatment name 2	carboplatin + gemcitabine
10.1016/j.euo.2018.09.009	methodology	1	NA	Study 'number(s)' for treatment 2	2;4;5;6
10.1016/j.euo.2018.09.009	methodology	1	NA	paitc_type	STC
10.1016/j.euo.2018.09.009	methodology	1	NA	anchored_yn	No
10.1016/j.euo.2018.09.009	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.euo.2018.09.009	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.euo.2018.09.009	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1016/j.euo.2018.09.009	methodology	1	NA	prognostic_factors_yn	Yes
10.1016/j.euo.2018.09.009	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.euo.2018.09.009	methodology	1	NA	weights_model_yn	No
10.1016/j.euo.2018.09.009	methodology	1	NA	scale_choice_yn	No
10.1016/j.euo.2018.09.009	methodology	2	NA	primary_outcome_name	overall survival
10.1016/j.euo.2018.09.009	methodology	2	NA	outcome_short_name	Overall Survival
10.1016/j.euo.2018.09.009	methodology	2	NA	primary_outcome_type	Time-to-event
10.1016/j.euo.2018.09.009	methodology	2	NA	Treatment name 1	pembrolizumab
10.1016/j.euo.2018.09.009	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1016/j.euo.2018.09.009	methodology	2	NA	Treatment name 2	gemcitabine
10.1016/j.euo.2018.09.009	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1016/j.euo.2018.09.009	methodology	2	NA	paitc_type	STC
10.1016/j.euo.2018.09.009	methodology	2	NA	anchored_yn	No
10.1016/j.euo.2018.09.009	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.euo.2018.09.009	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.euo.2018.09.009	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.1016/j.euo.2018.09.009	methodology	2	NA	prognostic_factors_yn	Yes
10.1016/j.euo.2018.09.009	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.euo.2018.09.009	methodology	2	NA	weights_model_yn	No
10.1016/j.euo.2018.09.009	methodology	2	NA	scale_choice_yn	No
10.1016/j.euo.2018.09.009	results	1	NA	contrast	HR
10.1016/j.euo.2018.09.009	results	1	NA	direction_benefit	inferior
10.1016/j.euo.2018.09.009	results	1	NA	n_nonipd_ttt	NA
10.1016/j.euo.2018.09.009	results	1	NA	n_ipd_ttt	NA
10.1016/j.euo.2018.09.009	results	1	NA	ess_ttt	NA
10.1016/j.euo.2018.09.009	results	1	NA	weights_evaluation_yn	NA
10.1016/j.euo.2018.09.009	results	1	NA	list_covariates_yn	Yes
10.1016/j.euo.2018.09.009	results	1	NA	n_covariates	3
10.1016/j.euo.2018.09.009	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1016/j.euo.2018.09.009	results	1	NA	effect_direction	Denominator if ratio, or rightside if difference
10.1016/j.euo.2018.09.009	results	1	NA	unadjusted_effect	NA
10.1016/j.euo.2018.09.009	results	1	NA	unadjusted_pval_char	NA
10.1016/j.euo.2018.09.009	results	1	NA	adjusted_effect	2.78
10.1016/j.euo.2018.09.009	results	1	NA	adjusted_pval_char	[2.29;3.38]
10.1016/j.euo.2018.09.009	results	1	NA	geographical region	NA
10.1016/j.euo.2018.09.009	results	1	NA	n_ipd_total	NA
10.1016/j.euo.2018.09.009	results	1	NA	ess_total	NA
10.1016/j.euo.2018.09.009	results	1	NA	n_nonipd_total	NA
10.1016/j.euo.2018.09.009	results	1	NA	n_nonipd_anchor	NA
10.1016/j.euo.2018.09.009	results	1	NA	n_ipd_anchor	NA
10.1016/j.euo.2018.09.009	results	1	NA	ess_anchor	NA
10.1016/j.euo.2018.09.009	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.euo.2018.09.009	results	1	NA	effect_cutoff	1
10.1016/j.euo.2018.09.009	results	1	NA	adjusted_lb_ci	2.29
10.1016/j.euo.2018.09.009	results	1	NA	adjusted_ub_ci	3.38
10.1016/j.euo.2018.09.009	results	1	NA	adjusted_significant	TRUE
10.1016/j.euo.2018.09.009	results	2	NA	contrast	HR
10.1016/j.euo.2018.09.009	results	2	NA	direction_benefit	inferior
10.1016/j.euo.2018.09.009	results	2	NA	n_nonipd_ttt	NA
10.1016/j.euo.2018.09.009	results	2	NA	n_ipd_ttt	NA
10.1016/j.euo.2018.09.009	results	2	NA	ess_ttt	NA
10.1016/j.euo.2018.09.009	results	2	NA	weights_evaluation_yn	NA
10.1016/j.euo.2018.09.009	results	2	NA	list_covariates_yn	Yes
10.1016/j.euo.2018.09.009	results	2	NA	n_covariates	3
10.1016/j.euo.2018.09.009	results	2	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1016/j.euo.2018.09.009	results	2	NA	effect_direction	Denominator if ratio, or rightside if difference
10.1016/j.euo.2018.09.009	results	2	NA	unadjusted_effect	NA
10.1016/j.euo.2018.09.009	results	2	NA	unadjusted_pval_char	NA
10.1016/j.euo.2018.09.009	results	2	NA	adjusted_effect	2.94
10.1016/j.euo.2018.09.009	results	2	NA	adjusted_pval_char	[2.42;3.57]
10.1016/j.euo.2018.09.009	results	2	NA	geographical region	NA
10.1016/j.euo.2018.09.009	results	2	NA	n_ipd_total	NA
10.1016/j.euo.2018.09.009	results	2	NA	ess_total	NA
10.1016/j.euo.2018.09.009	results	2	NA	n_nonipd_total	NA
10.1016/j.euo.2018.09.009	results	2	NA	n_nonipd_anchor	NA
10.1016/j.euo.2018.09.009	results	2	NA	n_ipd_anchor	NA
10.1016/j.euo.2018.09.009	results	2	NA	ess_anchor	NA
10.1016/j.euo.2018.09.009	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.euo.2018.09.009	results	2	NA	effect_cutoff	1
10.1016/j.euo.2018.09.009	results	2	NA	adjusted_lb_ci	2.42
10.1016/j.euo.2018.09.009	results	2	NA	adjusted_ub_ci	3.57
10.1016/j.euo.2018.09.009	results	2	NA	adjusted_significant	TRUE
10.1016/j.euo.2018.09.009	study_information	NA	1	Patient-level data used	Yes
10.1016/j.euo.2018.09.009	study_information	NA	1	Clinical Trial	Yes
10.1016/j.euo.2018.09.009	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02335424
10.1016/j.euo.2018.09.009	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1016/j.euo.2018.09.009	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1016/j.euo.2018.09.009	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1016/j.euo.2018.09.009	study_information	NA	2	Patient-level data used	No
10.1016/j.euo.2018.09.009	study_information	NA	2	Clinical Trial	Yes
10.1016/j.euo.2018.09.009	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00014274
10.1016/j.euo.2018.09.009	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.euo.2018.09.009	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3
10.1016/j.euo.2018.09.009	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.euo.2018.09.009	study_information	NA	3	Patient-level data used	No
10.1016/j.euo.2018.09.009	study_information	NA	3	Clinical Trial	Yes
10.1016/j.euo.2018.09.009	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	getug v01
10.1016/j.euo.2018.09.009	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.1016/j.euo.2018.09.009	study_information	NA	3	Phase of the clinical trial (clinical trial only)	1, 2
10.1016/j.euo.2018.09.009	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.euo.2018.09.009	study_information	NA	4	Patient-level data used	No
10.1016/j.euo.2018.09.009	study_information	NA	4	Clinical Trial	Yes
10.1016/j.euo.2018.09.009	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	bamias et al. (2007)
10.1016/j.euo.2018.09.009	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	greece
10.1016/j.euo.2018.09.009	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.1016/j.euo.2018.09.009	study_information	NA	5	Patient-level data used	No
10.1016/j.euo.2018.09.009	study_information	NA	5	Clinical Trial	Yes
10.1016/j.euo.2018.09.009	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	carles et al. (2000)
10.1016/j.euo.2018.09.009	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	spain
10.1016/j.euo.2018.09.009	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.1016/j.euo.2018.09.009	study_information	NA	6	Patient-level data used	No
10.1016/j.euo.2018.09.009	study_information	NA	6	Clinical Trial	Yes
10.1016/j.euo.2018.09.009	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	linardou et al. (2003)
10.1016/j.euo.2018.09.009	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	greece
10.1016/j.euo.2018.09.009	study_information	NA	6	Phase of the clinical trial (clinical trial only)	2
10.1016/j.euo.2018.09.009	study_information	NA	6	Number of treatment arms (clinical trial only)	1
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Medical Condition of Interest Name	advanced or metastatic non-small cell lung cancer
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Countries of first author affiliations	singapore
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Countries of last author affiliations	canada
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.jtho.2016.05.029	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1016/j.jtho.2016.05.029	methodology	1	NA	primary_outcome_name	overall survival
10.1016/j.jtho.2016.05.029	methodology	1	NA	outcome_short_name	Overall Survival
10.1016/j.jtho.2016.05.029	methodology	1	NA	primary_outcome_type	Time-to-event
10.1016/j.jtho.2016.05.029	methodology	1	NA	Treatment name 1	ceritinib
10.1016/j.jtho.2016.05.029	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1016/j.jtho.2016.05.029	methodology	1	NA	Treatment name 2	crizotinib
10.1016/j.jtho.2016.05.029	methodology	1	NA	Study 'number(s)' for treatment 2	3;4;5
10.1016/j.jtho.2016.05.029	methodology	1	NA	paitc_type	MAIC
10.1016/j.jtho.2016.05.029	methodology	1	NA	anchored_yn	No
10.1016/j.jtho.2016.05.029	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.jtho.2016.05.029	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.jtho.2016.05.029	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1016/j.jtho.2016.05.029	methodology	1	NA	prognostic_factors_yn	Yes
10.1016/j.jtho.2016.05.029	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1016/j.jtho.2016.05.029	methodology	1	NA	weights_model_yn	No
10.1016/j.jtho.2016.05.029	methodology	1	NA	scale_choice_yn	No
10.1016/j.jtho.2016.05.029	results	1	NA	contrast	HR
10.1016/j.jtho.2016.05.029	results	1	NA	direction_benefit	inferior
10.1016/j.jtho.2016.05.029	results	1	NA	n_nonipd_ttt	557
10.1016/j.jtho.2016.05.029	results	1	NA	n_ipd_ttt	189
10.1016/j.jtho.2016.05.029	results	1	NA	ess_ttt	143
10.1016/j.jtho.2016.05.029	results	1	NA	weights_evaluation_yn	Not mentioned
10.1016/j.jtho.2016.05.029	results	1	NA	list_covariates_yn	Yes
10.1016/j.jtho.2016.05.029	results	1	NA	n_covariates	6
10.1016/j.jtho.2016.05.029	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.jtho.2016.05.029	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.jtho.2016.05.029	results	1	NA	unadjusted_effect	0.49
10.1016/j.jtho.2016.05.029	results	1	NA	unadjusted_pval_char	[0.33;0.74]
10.1016/j.jtho.2016.05.029	results	1	NA	adjusted_effect	0.59
10.1016/j.jtho.2016.05.029	results	1	NA	adjusted_pval_char	[0.46;0.75]
10.1016/j.jtho.2016.05.029	results	1	NA	geographical region	NA
10.1016/j.jtho.2016.05.029	results	1	NA	n_ipd_total	NA
10.1016/j.jtho.2016.05.029	results	1	NA	ess_total	NA
10.1016/j.jtho.2016.05.029	results	1	NA	n_nonipd_total	NA
10.1016/j.jtho.2016.05.029	results	1	NA	n_nonipd_anchor	NA
10.1016/j.jtho.2016.05.029	results	1	NA	n_ipd_anchor	NA
10.1016/j.jtho.2016.05.029	results	1	NA	ess_anchor	NA
10.1016/j.jtho.2016.05.029	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.jtho.2016.05.029	results	1	NA	effect_cutoff	1
10.1016/j.jtho.2016.05.029	results	1	NA	unadjusted_lb_ci	0.33
10.1016/j.jtho.2016.05.029	results	1	NA	unadjusted_ub_ci	0.74
10.1016/j.jtho.2016.05.029	results	1	NA	unadjusted_significant	TRUE
10.1016/j.jtho.2016.05.029	results	1	NA	adjusted_lb_ci	0.46
10.1016/j.jtho.2016.05.029	results	1	NA	adjusted_ub_ci	0.75
10.1016/j.jtho.2016.05.029	results	1	NA	adjusted_significant	TRUE
10.1016/j.jtho.2016.05.029	study_information	NA	1	Patient-level data used	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	1	Clinical Trial	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01283516
10.1016/j.jtho.2016.05.029	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.jtho.2016.05.029	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.1016/j.jtho.2016.05.029	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1016/j.jtho.2016.05.029	study_information	NA	2	Patient-level data used	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	2	Clinical Trial	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01685138
10.1016/j.jtho.2016.05.029	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.jtho.2016.05.029	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1016/j.jtho.2016.05.029	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1016/j.jtho.2016.05.029	study_information	NA	3	Patient-level data used	No
10.1016/j.jtho.2016.05.029	study_information	NA	3	Clinical Trial	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00585195
10.1016/j.jtho.2016.05.029	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.jtho.2016.05.029	study_information	NA	3	Phase of the clinical trial (clinical trial only)	1
10.1016/j.jtho.2016.05.029	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1016/j.jtho.2016.05.029	study_information	NA	4	Patient-level data used	No
10.1016/j.jtho.2016.05.029	study_information	NA	4	Clinical Trial	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00932451
10.1016/j.jtho.2016.05.029	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.jtho.2016.05.029	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.1016/j.jtho.2016.05.029	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.1016/j.jtho.2016.05.029	study_information	NA	5	Patient-level data used	No
10.1016/j.jtho.2016.05.029	study_information	NA	5	Clinical Trial	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00932893
10.1016/j.jtho.2016.05.029	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.jtho.2016.05.029	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1016/j.jtho.2016.05.029	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.jval.2018.03.015	general_information	NA	NA	Medical Condition of Interest Name	tremor
10.1016/j.jval.2018.03.015	general_information	NA	NA	Countries of first author affiliations	uk
10.1016/j.jval.2018.03.015	general_information	NA	NA	Countries of last author affiliations	israel
10.1016/j.jval.2018.03.015	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.jval.2018.03.015	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.jval.2018.03.015	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.jval.2018.03.015	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.jval.2018.03.015	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1016/j.jval.2018.03.015	methodology	1	NA	primary_outcome_name	clinical rating scale for tremor part c at 1 month
10.1016/j.jval.2018.03.015	methodology	1	NA	outcome_short_name	Clinical Rating Scale for Tremor
10.1016/j.jval.2018.03.015	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1016/j.jval.2018.03.015	methodology	1	NA	Treatment name 1	magnetic resonance-guided focused ultrasound
10.1016/j.jval.2018.03.015	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.jval.2018.03.015	methodology	1	NA	Treatment name 2	unilateral deep brain stimulation
10.1016/j.jval.2018.03.015	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1016/j.jval.2018.03.015	methodology	1	NA	paitc_type	MAIC
10.1016/j.jval.2018.03.015	methodology	1	NA	anchored_yn	No
10.1016/j.jval.2018.03.015	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.jval.2018.03.015	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.jval.2018.03.015	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.jval.2018.03.015	methodology	1	NA	prognostic_factors_yn	Yes
10.1016/j.jval.2018.03.015	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.jval.2018.03.015	methodology	1	NA	weights_model_yn	No
10.1016/j.jval.2018.03.015	methodology	1	NA	scale_choice_yn	No
10.1016/j.jval.2018.03.015	methodology	2	NA	primary_outcome_name	clinical rating scale for tremor part c at 1 month
10.1016/j.jval.2018.03.015	methodology	2	NA	outcome_short_name	Clinical Rating Scale for Tremor
10.1016/j.jval.2018.03.015	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1016/j.jval.2018.03.015	methodology	2	NA	Treatment name 1	magnetic resonance-guided focused ultrasound
10.1016/j.jval.2018.03.015	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1016/j.jval.2018.03.015	methodology	2	NA	Treatment name 2	unilateral deep brain stimulation (dbs)
10.1016/j.jval.2018.03.015	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1016/j.jval.2018.03.015	methodology	2	NA	paitc_type	STC
10.1016/j.jval.2018.03.015	methodology	2	NA	anchored_yn	No
10.1016/j.jval.2018.03.015	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.jval.2018.03.015	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.jval.2018.03.015	methodology	2	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.jval.2018.03.015	methodology	2	NA	prognostic_factors_yn	Yes
10.1016/j.jval.2018.03.015	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.jval.2018.03.015	methodology	2	NA	weights_model_yn	Yes
10.1016/j.jval.2018.03.015	methodology	2	NA	scale_choice_yn	No
10.1016/j.jval.2018.03.015	results	1	NA	contrast	Means difference
10.1016/j.jval.2018.03.015	results	1	NA	direction_benefit	inferior
10.1016/j.jval.2018.03.015	results	1	NA	n_nonipd_ttt	22
10.1016/j.jval.2018.03.015	results	1	NA	n_ipd_ttt	56
10.1016/j.jval.2018.03.015	results	1	NA	ess_ttt	35.8
10.1016/j.jval.2018.03.015	results	1	NA	weights_evaluation_yn	Not mentioned
10.1016/j.jval.2018.03.015	results	1	NA	list_covariates_yn	Yes
10.1016/j.jval.2018.03.015	results	1	NA	n_covariates	3
10.1016/j.jval.2018.03.015	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1016/j.jval.2018.03.015	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.jval.2018.03.015	results	1	NA	unadjusted_effect	0.35
10.1016/j.jval.2018.03.015	results	1	NA	unadjusted_pval_char	[-2.17;2.87]
10.1016/j.jval.2018.03.015	results	1	NA	adjusted_effect	1.92
10.1016/j.jval.2018.03.015	results	1	NA	adjusted_pval_char	[-0.94;4.79]
10.1016/j.jval.2018.03.015	results	1	NA	geographical region	NA
10.1016/j.jval.2018.03.015	results	1	NA	n_ipd_total	NA
10.1016/j.jval.2018.03.015	results	1	NA	ess_total	NA
10.1016/j.jval.2018.03.015	results	1	NA	n_nonipd_total	NA
10.1016/j.jval.2018.03.015	results	1	NA	n_nonipd_anchor	NA
10.1016/j.jval.2018.03.015	results	1	NA	n_ipd_anchor	NA
10.1016/j.jval.2018.03.015	results	1	NA	ess_anchor	NA
10.1016/j.jval.2018.03.015	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.jval.2018.03.015	results	1	NA	effect_cutoff	0
10.1016/j.jval.2018.03.015	results	1	NA	unadjusted_lb_ci	-2.17
10.1016/j.jval.2018.03.015	results	1	NA	unadjusted_ub_ci	2.87
10.1016/j.jval.2018.03.015	results	1	NA	unadjusted_significant	FALSE
10.1016/j.jval.2018.03.015	results	1	NA	adjusted_lb_ci	-0.94
10.1016/j.jval.2018.03.015	results	1	NA	adjusted_ub_ci	4.79
10.1016/j.jval.2018.03.015	results	1	NA	adjusted_significant	FALSE
10.1016/j.jval.2018.03.015	results	2	NA	contrast	Means difference
10.1016/j.jval.2018.03.015	results	2	NA	direction_benefit	inferior
10.1016/j.jval.2018.03.015	results	2	NA	n_nonipd_ttt	22
10.1016/j.jval.2018.03.015	results	2	NA	n_ipd_ttt	56
10.1016/j.jval.2018.03.015	results	2	NA	ess_ttt	56
10.1016/j.jval.2018.03.015	results	2	NA	weights_evaluation_yn	NA
10.1016/j.jval.2018.03.015	results	2	NA	list_covariates_yn	Yes
10.1016/j.jval.2018.03.015	results	2	NA	n_covariates	3
10.1016/j.jval.2018.03.015	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1016/j.jval.2018.03.015	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.jval.2018.03.015	results	2	NA	unadjusted_effect	0.35
10.1016/j.jval.2018.03.015	results	2	NA	unadjusted_pval_char	[-2.17;2.87]
10.1016/j.jval.2018.03.015	results	2	NA	adjusted_effect	1.67
10.1016/j.jval.2018.03.015	results	2	NA	adjusted_pval_char	[-0.74;4.08]
10.1016/j.jval.2018.03.015	results	2	NA	geographical region	NA
10.1016/j.jval.2018.03.015	results	2	NA	n_ipd_total	NA
10.1016/j.jval.2018.03.015	results	2	NA	ess_total	NA
10.1016/j.jval.2018.03.015	results	2	NA	n_nonipd_total	NA
10.1016/j.jval.2018.03.015	results	2	NA	n_nonipd_anchor	NA
10.1016/j.jval.2018.03.015	results	2	NA	n_ipd_anchor	NA
10.1016/j.jval.2018.03.015	results	2	NA	ess_anchor	NA
10.1016/j.jval.2018.03.015	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.jval.2018.03.015	results	2	NA	effect_cutoff	0
10.1016/j.jval.2018.03.015	results	2	NA	unadjusted_lb_ci	-2.17
10.1016/j.jval.2018.03.015	results	2	NA	unadjusted_ub_ci	2.87
10.1016/j.jval.2018.03.015	results	2	NA	unadjusted_significant	FALSE
10.1016/j.jval.2018.03.015	results	2	NA	adjusted_lb_ci	-0.74
10.1016/j.jval.2018.03.015	results	2	NA	adjusted_ub_ci	4.08
10.1016/j.jval.2018.03.015	results	2	NA	adjusted_significant	FALSE
10.1016/j.jval.2018.03.015	study_information	NA	1	Patient-level data used	Yes
10.1016/j.jval.2018.03.015	study_information	NA	1	Clinical Trial	Yes
10.1016/j.jval.2018.03.015	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01827904
10.1016/j.jval.2018.03.015	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.jval.2018.03.015	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.jval.2018.03.015	study_information	NA	2	Patient-level data used	No
10.1016/j.jval.2018.03.015	study_information	NA	2	Clinical Trial	No
10.1016/j.jval.2018.03.015	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	putzke et al. (2005)
10.1016/j.jval.2018.03.015	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Medical Condition of Interest Name	non-squamous non-small cell lung cancer
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1016/j.lungcan.2021.03.020	methodology	1	NA	primary_outcome_name	overall survival
10.1016/j.lungcan.2021.03.020	methodology	1	NA	outcome_short_name	Overall Survival
10.1016/j.lungcan.2021.03.020	methodology	1	NA	primary_outcome_type	Time-to-event
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Treatment name 1	pembrolizumab + chemotherapy
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Treatment name 2	atezolizumab + chemotherapy
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Study 'number(s)' for treatment 2	3;4
10.1016/j.lungcan.2021.03.020	methodology	1	NA	paitc_type	MAIC
10.1016/j.lungcan.2021.03.020	methodology	1	NA	anchored_yn	No
10.1016/j.lungcan.2021.03.020	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.lungcan.2021.03.020	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.lungcan.2021.03.020	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1016/j.lungcan.2021.03.020	methodology	1	NA	prognostic_factors_yn	Yes
10.1016/j.lungcan.2021.03.020	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1016/j.lungcan.2021.03.020	methodology	1	NA	weights_model_yn	No
10.1016/j.lungcan.2021.03.020	methodology	1	NA	scale_choice_yn	No
10.1016/j.lungcan.2021.03.020	methodology	2	NA	primary_outcome_name	overall survival
10.1016/j.lungcan.2021.03.020	methodology	2	NA	outcome_short_name	Overall Survival
10.1016/j.lungcan.2021.03.020	methodology	2	NA	primary_outcome_type	Time-to-event
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Treatment name 1	pembrolizumab + chemotherapy
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Treatment name 2	atezolizumab + bevacizumab + chemotherapy
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Study 'number(s)' for treatment 2	4
10.1016/j.lungcan.2021.03.020	methodology	2	NA	paitc_type	MAIC
10.1016/j.lungcan.2021.03.020	methodology	2	NA	anchored_yn	No
10.1016/j.lungcan.2021.03.020	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.lungcan.2021.03.020	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.lungcan.2021.03.020	methodology	2	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1016/j.lungcan.2021.03.020	methodology	2	NA	prognostic_factors_yn	Yes
10.1016/j.lungcan.2021.03.020	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1016/j.lungcan.2021.03.020	methodology	2	NA	weights_model_yn	No
10.1016/j.lungcan.2021.03.020	methodology	2	NA	scale_choice_yn	No
10.1016/j.lungcan.2021.03.020	results	1	NA	contrast	HR
10.1016/j.lungcan.2021.03.020	results	1	NA	direction_benefit	inferior
10.1016/j.lungcan.2021.03.020	results	1	NA	n_nonipd_ttt	451
10.1016/j.lungcan.2021.03.020	results	1	NA	n_ipd_ttt	469
10.1016/j.lungcan.2021.03.020	results	1	NA	ess_ttt	428
10.1016/j.lungcan.2021.03.020	results	1	NA	weights_evaluation_yn	Not mentioned
10.1016/j.lungcan.2021.03.020	results	1	NA	list_covariates_yn	Yes
10.1016/j.lungcan.2021.03.020	results	1	NA	n_covariates	6
10.1016/j.lungcan.2021.03.020	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.1016/j.lungcan.2021.03.020	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.lungcan.2021.03.020	results	1	NA	unadjusted_effect	0.8
10.1016/j.lungcan.2021.03.020	results	1	NA	unadjusted_pval_char	0.009
10.1016/j.lungcan.2021.03.020	results	1	NA	adjusted_effect	0.8
10.1016/j.lungcan.2021.03.020	results	1	NA	adjusted_pval_char	0.012
10.1016/j.lungcan.2021.03.020	results	1	NA	geographical region	No
10.1016/j.lungcan.2021.03.020	results	1	NA	n_ipd_total	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	ess_total	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	n_nonipd_total	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	n_nonipd_anchor	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	n_ipd_anchor	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	ess_anchor	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	effect_cutoff	1
10.1016/j.lungcan.2021.03.020	results	1	NA	unadjusted_pval	0.009
10.1016/j.lungcan.2021.03.020	results	1	NA	unadjusted_num_pval	0.009
10.1016/j.lungcan.2021.03.020	results	1	NA	unadjusted_significant	TRUE
10.1016/j.lungcan.2021.03.020	results	1	NA	adjusted_pval	0.012
10.1016/j.lungcan.2021.03.020	results	1	NA	adjusted_num_pval	0.012
10.1016/j.lungcan.2021.03.020	results	1	NA	adjusted_significant	TRUE
10.1016/j.lungcan.2021.03.020	results	2	NA	contrast	HR
10.1016/j.lungcan.2021.03.020	results	2	NA	direction_benefit	inferior
10.1016/j.lungcan.2021.03.020	results	2	NA	n_nonipd_ttt	356
10.1016/j.lungcan.2021.03.020	results	2	NA	n_ipd_ttt	469
10.1016/j.lungcan.2021.03.020	results	2	NA	ess_ttt	389
10.1016/j.lungcan.2021.03.020	results	2	NA	weights_evaluation_yn	Not mentioned
10.1016/j.lungcan.2021.03.020	results	2	NA	list_covariates_yn	Yes
10.1016/j.lungcan.2021.03.020	results	2	NA	n_covariates	6
10.1016/j.lungcan.2021.03.020	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.1016/j.lungcan.2021.03.020	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.lungcan.2021.03.020	results	2	NA	unadjusted_effect	0.84
10.1016/j.lungcan.2021.03.020	results	2	NA	unadjusted_pval_char	0.04
10.1016/j.lungcan.2021.03.020	results	2	NA	adjusted_effect	0.86
10.1016/j.lungcan.2021.03.020	results	2	NA	adjusted_pval_char	0.099
10.1016/j.lungcan.2021.03.020	results	2	NA	geographical region	No
10.1016/j.lungcan.2021.03.020	results	2	NA	n_ipd_total	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	ess_total	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	n_nonipd_total	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	n_nonipd_anchor	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	n_ipd_anchor	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	ess_anchor	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	effect_cutoff	1
10.1016/j.lungcan.2021.03.020	results	2	NA	unadjusted_pval	0.04
10.1016/j.lungcan.2021.03.020	results	2	NA	unadjusted_num_pval	0.04
10.1016/j.lungcan.2021.03.020	results	2	NA	unadjusted_significant	TRUE
10.1016/j.lungcan.2021.03.020	results	2	NA	adjusted_pval	0.099
10.1016/j.lungcan.2021.03.020	results	2	NA	adjusted_num_pval	0.099
10.1016/j.lungcan.2021.03.020	results	2	NA	adjusted_significant	FALSE
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Patient-level data used	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Clinical Trial	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02039674
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	International
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Patient-level data used	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Clinical Trial	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02578680
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Patient-level data used	No
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Clinical Trial	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02367781
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Patient-level data used	No
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Clinical Trial	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02366143
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	general_information	NA	NA	Medical Condition of Interest Name	relapsing multiple sclerosis
10.1016/j.msard.2021.102972	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.msard.2021.102972	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.msard.2021.102972	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.msard.2021.102972	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.msard.2021.102972	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.msard.2021.102972	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.msard.2021.102972	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1016/j.msard.2021.102972	methodology	1	NA	primary_outcome_name	annualized relapse rate
10.1016/j.msard.2021.102972	methodology	1	NA	outcome_short_name	Annualized Relapse Rate
10.1016/j.msard.2021.102972	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1016/j.msard.2021.102972	methodology	1	NA	Treatment name 1	ozanimod
10.1016/j.msard.2021.102972	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1016/j.msard.2021.102972	methodology	1	NA	Treatment name 2	teriflunomide
10.1016/j.msard.2021.102972	methodology	1	NA	Study 'number(s)' for treatment 2	3;4;5;6;7;8
10.1016/j.msard.2021.102972	methodology	1	NA	paitc_type	MAIC
10.1016/j.msard.2021.102972	methodology	1	NA	anchored_yn	No
10.1016/j.msard.2021.102972	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.msard.2021.102972	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.msard.2021.102972	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1016/j.msard.2021.102972	methodology	1	NA	prognostic_factors_yn	Yes
10.1016/j.msard.2021.102972	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1016/j.msard.2021.102972	methodology	1	NA	weights_model_yn	No
10.1016/j.msard.2021.102972	methodology	1	NA	scale_choice_yn	No
10.1016/j.msard.2021.102972	results	1	NA	contrast	OR
10.1016/j.msard.2021.102972	results	1	NA	direction_benefit	inferior
10.1016/j.msard.2021.102972	results	1	NA	n_nonipd_ttt	2290
10.1016/j.msard.2021.102972	results	1	NA	n_ipd_ttt	880
10.1016/j.msard.2021.102972	results	1	NA	ess_ttt	663.53
10.1016/j.msard.2021.102972	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1016/j.msard.2021.102972	results	1	NA	list_covariates_yn	Yes
10.1016/j.msard.2021.102972	results	1	NA	n_covariates	9
10.1016/j.msard.2021.102972	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1016/j.msard.2021.102972	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1016/j.msard.2021.102972	results	1	NA	unadjusted_effect	NA
10.1016/j.msard.2021.102972	results	1	NA	unadjusted_pval_char	NA
10.1016/j.msard.2021.102972	results	1	NA	adjusted_effect	0.73
10.1016/j.msard.2021.102972	results	1	NA	adjusted_pval_char	[0.62;0.84]
10.1016/j.msard.2021.102972	results	1	NA	geographical region	No
10.1016/j.msard.2021.102972	results	1	NA	n_ipd_total	NA
10.1016/j.msard.2021.102972	results	1	NA	ess_total	NA
10.1016/j.msard.2021.102972	results	1	NA	n_nonipd_total	NA
10.1016/j.msard.2021.102972	results	1	NA	n_nonipd_anchor	NA
10.1016/j.msard.2021.102972	results	1	NA	n_ipd_anchor	NA
10.1016/j.msard.2021.102972	results	1	NA	ess_anchor	NA
10.1016/j.msard.2021.102972	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1016/j.msard.2021.102972	results	1	NA	effect_cutoff	1
10.1016/j.msard.2021.102972	results	1	NA	adjusted_lb_ci	0.62
10.1016/j.msard.2021.102972	results	1	NA	adjusted_ub_ci	0.84
10.1016/j.msard.2021.102972	results	1	NA	adjusted_significant	TRUE
10.1016/j.msard.2021.102972	study_information	NA	1	Patient-level data used	Yes
10.1016/j.msard.2021.102972	study_information	NA	1	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02047734
10.1016/j.msard.2021.102972	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	study_information	NA	2	Patient-level data used	Yes
10.1016/j.msard.2021.102972	study_information	NA	2	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02294058
10.1016/j.msard.2021.102972	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	study_information	NA	3	Patient-level data used	No
10.1016/j.msard.2021.102972	study_information	NA	3	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02792218
10.1016/j.msard.2021.102972	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	study_information	NA	4	Patient-level data used	No
10.1016/j.msard.2021.102972	study_information	NA	4	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02792231
10.1016/j.msard.2021.102972	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	study_information	NA	5	Patient-level data used	No
10.1016/j.msard.2021.102972	study_information	NA	5	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00751881
10.1016/j.msard.2021.102972	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	study_information	NA	6	Patient-level data used	No
10.1016/j.msard.2021.102972	study_information	NA	6	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02425644
10.1016/j.msard.2021.102972	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	study_information	NA	7	Patient-level data used	No
10.1016/j.msard.2021.102972	study_information	NA	7	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00134563
10.1016/j.msard.2021.102972	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	7	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	study_information	NA	8	Patient-level data used	No
10.1016/j.msard.2021.102972	study_information	NA	8	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00883337
10.1016/j.msard.2021.102972	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2016.1248380	general_information	NA	NA	Medical Condition of Interest Name	multiple sclerosis
10.1080/03007995.2016.1248380	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/03007995.2016.1248380	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/03007995.2016.1248380	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1080/03007995.2016.1248380	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1080/03007995.2016.1248380	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2016.1248380	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2016.1248380	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/03007995.2016.1248380	methodology	1	NA	primary_outcome_name	annualized relapse rate
10.1080/03007995.2016.1248380	methodology	1	NA	outcome_short_name	Annualized Relapse Rate
10.1080/03007995.2016.1248380	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1080/03007995.2016.1248380	methodology	1	NA	Treatment name 1	dimethyl fumarate
10.1080/03007995.2016.1248380	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1080/03007995.2016.1248380	methodology	1	NA	Treatment name 2	fingolimod
10.1080/03007995.2016.1248380	methodology	1	NA	Study 'number(s)' for treatment 2	3;4
10.1080/03007995.2016.1248380	methodology	1	NA	paitc_type	MAIC
10.1080/03007995.2016.1248380	methodology	1	NA	anchored_yn	Yes
10.1080/03007995.2016.1248380	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/03007995.2016.1248380	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2016.1248380	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1080/03007995.2016.1248380	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2016.1248380	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2016.1248380	methodology	1	NA	weights_model_yn	No
10.1080/03007995.2016.1248380	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2016.1248380	results	1	NA	contrast	RR
10.1080/03007995.2016.1248380	results	1	NA	direction_benefit	inferior
10.1080/03007995.2016.1248380	results	1	NA	n_nonipd_ttt	783
10.1080/03007995.2016.1248380	results	1	NA	n_ipd_ttt	769
10.1080/03007995.2016.1248380	results	1	NA	ess_ttt	587
10.1080/03007995.2016.1248380	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2016.1248380	results	1	NA	list_covariates_yn	Yes
10.1080/03007995.2016.1248380	results	1	NA	n_covariates	6
10.1080/03007995.2016.1248380	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2016.1248380	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2016.1248380	results	1	NA	unadjusted_effect	1.07
10.1080/03007995.2016.1248380	results	1	NA	unadjusted_pval_char	0.5501
10.1080/03007995.2016.1248380	results	1	NA	adjusted_effect	1.11
10.1080/03007995.2016.1248380	results	1	NA	adjusted_pval_char	0.3893
10.1080/03007995.2016.1248380	results	1	NA	geographical region	NA
10.1080/03007995.2016.1248380	results	1	NA	n_ipd_total	NA
10.1080/03007995.2016.1248380	results	1	NA	ess_total	NA
10.1080/03007995.2016.1248380	results	1	NA	n_nonipd_total	NA
10.1080/03007995.2016.1248380	results	1	NA	n_nonipd_anchor	773
10.1080/03007995.2016.1248380	results	1	NA	n_ipd_anchor	771
10.1080/03007995.2016.1248380	results	1	NA	ess_anchor	599
10.1080/03007995.2016.1248380	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2016.1248380	results	1	NA	effect_cutoff	1
10.1080/03007995.2016.1248380	results	1	NA	unadjusted_pval	0.5501
10.1080/03007995.2016.1248380	results	1	NA	unadjusted_num_pval	0.5501
10.1080/03007995.2016.1248380	results	1	NA	unadjusted_significant	FALSE
10.1080/03007995.2016.1248380	results	1	NA	adjusted_pval	0.3893
10.1080/03007995.2016.1248380	results	1	NA	adjusted_num_pval	0.3893
10.1080/03007995.2016.1248380	results	1	NA	adjusted_significant	FALSE
10.1080/03007995.2016.1248380	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2016.1248380	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2016.1248380	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212
10.1080/03007995.2016.1248380	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2016.1248380	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2016.1248380	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2016.1248380	study_information	NA	2	Patient-level data used	Yes
10.1080/03007995.2016.1248380	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2016.1248380	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451
10.1080/03007995.2016.1248380	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2016.1248380	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2016.1248380	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2016.1248380	study_information	NA	3	Patient-level data used	No
10.1080/03007995.2016.1248380	study_information	NA	3	Clinical Trial	Yes
10.1080/03007995.2016.1248380	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00289978
10.1080/03007995.2016.1248380	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2016.1248380	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2016.1248380	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2016.1248380	study_information	NA	4	Patient-level data used	No
10.1080/03007995.2016.1248380	study_information	NA	4	Clinical Trial	Yes
10.1080/03007995.2016.1248380	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00355134
10.1080/03007995.2016.1248380	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2016.1248380	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2016.1248380	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2018.1510225	general_information	NA	NA	Medical Condition of Interest Name	chronic phase chronic myeloid leukemia
10.1080/03007995.2018.1510225	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/03007995.2018.1510225	general_information	NA	NA	Countries of last author affiliations	italy
10.1080/03007995.2018.1510225	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2018.1510225	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2018.1510225	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2018.1510225	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2018.1510225	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/03007995.2018.1510225	methodology	1	NA	primary_outcome_name	cytogenetic response rate
10.1080/03007995.2018.1510225	methodology	1	NA	outcome_short_name	Cytogenetic Response Rate
10.1080/03007995.2018.1510225	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1080/03007995.2018.1510225	methodology	1	NA	Treatment name 1	ponatinib
10.1080/03007995.2018.1510225	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2018.1510225	methodology	1	NA	Treatment name 2	bosutinib
10.1080/03007995.2018.1510225	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2018.1510225	methodology	1	NA	paitc_type	MAIC
10.1080/03007995.2018.1510225	methodology	1	NA	anchored_yn	No
10.1080/03007995.2018.1510225	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1510225	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1510225	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1080/03007995.2018.1510225	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2018.1510225	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2018.1510225	methodology	1	NA	weights_model_yn	No
10.1080/03007995.2018.1510225	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2018.1510225	results	1	NA	contrast	NA
10.1080/03007995.2018.1510225	results	1	NA	direction_benefit	superior
10.1080/03007995.2018.1510225	results	1	NA	n_nonipd_ttt	119
10.1080/03007995.2018.1510225	results	1	NA	n_ipd_ttt	97
10.1080/03007995.2018.1510225	results	1	NA	ess_ttt	70
10.1080/03007995.2018.1510225	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2018.1510225	results	1	NA	list_covariates_yn	Yes
10.1080/03007995.2018.1510225	results	1	NA	n_covariates	6
10.1080/03007995.2018.1510225	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1080/03007995.2018.1510225	results	1	NA	effect_direction	NA
10.1080/03007995.2018.1510225	results	1	NA	unadjusted_effect	NA
10.1080/03007995.2018.1510225	results	1	NA	unadjusted_pval_char	NA
10.1080/03007995.2018.1510225	results	1	NA	adjusted_effect	NA
10.1080/03007995.2018.1510225	results	1	NA	adjusted_pval_char	NA
10.1080/03007995.2018.1510225	results	1	NA	geographical region	NA
10.1080/03007995.2018.1510225	results	1	NA	n_ipd_total	NA
10.1080/03007995.2018.1510225	results	1	NA	ess_total	NA
10.1080/03007995.2018.1510225	results	1	NA	n_nonipd_total	NA
10.1080/03007995.2018.1510225	results	1	NA	n_nonipd_anchor	NA
10.1080/03007995.2018.1510225	results	1	NA	n_ipd_anchor	NA
10.1080/03007995.2018.1510225	results	1	NA	ess_anchor	NA
10.1080/03007995.2018.1510225	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2018.1510225	results	1	NA	effect_cutoff	NA
10.1080/03007995.2018.1510225	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2018.1510225	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2018.1510225	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01207440
10.1080/03007995.2018.1510225	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1510225	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1080/03007995.2018.1510225	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2018.1510225	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2018.1510225	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2018.1510225	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00261846
10.1080/03007995.2018.1510225	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1510225	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1, 2
10.1080/03007995.2018.1510225	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2018.1520696	general_information	NA	NA	Medical Condition of Interest Name	anaplastic lymphoma kinase-positive non-small cell lung cancer
10.1080/03007995.2018.1520696	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/03007995.2018.1520696	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/03007995.2018.1520696	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2018.1520696	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2018.1520696	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2018.1520696	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2018.1520696	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/03007995.2018.1520696	methodology	1	NA	primary_outcome_name	objective response rate
10.1080/03007995.2018.1520696	methodology	1	NA	outcome_short_name	Objective Response Rate
10.1080/03007995.2018.1520696	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1080/03007995.2018.1520696	methodology	1	NA	Treatment name 1	brigatinib
10.1080/03007995.2018.1520696	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2018.1520696	methodology	1	NA	Treatment name 2	ceritinib
10.1080/03007995.2018.1520696	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2018.1520696	methodology	1	NA	paitc_type	MAIC
10.1080/03007995.2018.1520696	methodology	1	NA	anchored_yn	No
10.1080/03007995.2018.1520696	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1520696	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1520696	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2018.1520696	methodology	1	NA	prognostic_factors_yn	Yes
10.1080/03007995.2018.1520696	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2018.1520696	methodology	1	NA	weights_model_yn	No
10.1080/03007995.2018.1520696	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2018.1520696	methodology	2	NA	primary_outcome_name	objective response rate
10.1080/03007995.2018.1520696	methodology	2	NA	outcome_short_name	Objective Response Rate
10.1080/03007995.2018.1520696	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1080/03007995.2018.1520696	methodology	2	NA	Treatment name 1	brigatinib
10.1080/03007995.2018.1520696	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2018.1520696	methodology	2	NA	Treatment name 2	ceritinib
10.1080/03007995.2018.1520696	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1080/03007995.2018.1520696	methodology	2	NA	paitc_type	MAIC
10.1080/03007995.2018.1520696	methodology	2	NA	anchored_yn	No
10.1080/03007995.2018.1520696	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1520696	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1520696	methodology	2	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2018.1520696	methodology	2	NA	prognostic_factors_yn	Yes
10.1080/03007995.2018.1520696	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2018.1520696	methodology	2	NA	weights_model_yn	No
10.1080/03007995.2018.1520696	methodology	2	NA	scale_choice_yn	No
10.1080/03007995.2018.1520696	methodology	3	NA	primary_outcome_name	objective response rate
10.1080/03007995.2018.1520696	methodology	3	NA	outcome_short_name	Objective Response Rate
10.1080/03007995.2018.1520696	methodology	3	NA	primary_outcome_type	Binary (eg rates)
10.1080/03007995.2018.1520696	methodology	3	NA	Treatment name 1	brigatinib
10.1080/03007995.2018.1520696	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2018.1520696	methodology	3	NA	Treatment name 2	alectinib
10.1080/03007995.2018.1520696	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.1080/03007995.2018.1520696	methodology	3	NA	paitc_type	MAIC
10.1080/03007995.2018.1520696	methodology	3	NA	anchored_yn	No
10.1080/03007995.2018.1520696	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1520696	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1520696	methodology	3	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2018.1520696	methodology	3	NA	prognostic_factors_yn	Yes
10.1080/03007995.2018.1520696	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2018.1520696	methodology	3	NA	weights_model_yn	No
10.1080/03007995.2018.1520696	methodology	3	NA	scale_choice_yn	No
10.1080/03007995.2018.1520696	methodology	4	NA	primary_outcome_name	objective response rate
10.1080/03007995.2018.1520696	methodology	4	NA	outcome_short_name	Objective Response Rate
10.1080/03007995.2018.1520696	methodology	4	NA	primary_outcome_type	Binary (eg rates)
10.1080/03007995.2018.1520696	methodology	4	NA	Treatment name 1	brigatinib
10.1080/03007995.2018.1520696	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2018.1520696	methodology	4	NA	Treatment name 2	alectinib
10.1080/03007995.2018.1520696	methodology	4	NA	Study 'number(s)' for treatment 2	5
10.1080/03007995.2018.1520696	methodology	4	NA	paitc_type	MAIC
10.1080/03007995.2018.1520696	methodology	4	NA	anchored_yn	No
10.1080/03007995.2018.1520696	methodology	4	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1520696	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1520696	methodology	4	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2018.1520696	methodology	4	NA	prognostic_factors_yn	Yes
10.1080/03007995.2018.1520696	methodology	4	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2018.1520696	methodology	4	NA	weights_model_yn	No
10.1080/03007995.2018.1520696	methodology	4	NA	scale_choice_yn	No
10.1080/03007995.2018.1520696	results	1	NA	contrast	OR
10.1080/03007995.2018.1520696	results	1	NA	direction_benefit	superior
10.1080/03007995.2018.1520696	results	1	NA	n_nonipd_ttt	163
10.1080/03007995.2018.1520696	results	1	NA	n_ipd_ttt	110
10.1080/03007995.2018.1520696	results	1	NA	ess_ttt	75.8
10.1080/03007995.2018.1520696	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2018.1520696	results	1	NA	list_covariates_yn	Yes
10.1080/03007995.2018.1520696	results	1	NA	n_covariates	7
10.1080/03007995.2018.1520696	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1080/03007995.2018.1520696	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1520696	results	1	NA	unadjusted_effect	0.96
10.1080/03007995.2018.1520696	results	1	NA	unadjusted_pval_char	0.872
10.1080/03007995.2018.1520696	results	1	NA	adjusted_effect	0.88
10.1080/03007995.2018.1520696	results	1	NA	adjusted_pval_char	0.659
10.1080/03007995.2018.1520696	results	1	NA	geographical region	No
10.1080/03007995.2018.1520696	results	1	NA	n_ipd_total	NA
10.1080/03007995.2018.1520696	results	1	NA	ess_total	NA
10.1080/03007995.2018.1520696	results	1	NA	n_nonipd_total	NA
10.1080/03007995.2018.1520696	results	1	NA	n_nonipd_anchor	NA
10.1080/03007995.2018.1520696	results	1	NA	n_ipd_anchor	NA
10.1080/03007995.2018.1520696	results	1	NA	ess_anchor	NA
10.1080/03007995.2018.1520696	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2018.1520696	results	1	NA	effect_cutoff	1
10.1080/03007995.2018.1520696	results	1	NA	unadjusted_pval	0.872
10.1080/03007995.2018.1520696	results	1	NA	unadjusted_num_pval	0.872
10.1080/03007995.2018.1520696	results	1	NA	unadjusted_significant	FALSE
10.1080/03007995.2018.1520696	results	1	NA	adjusted_pval	0.659
10.1080/03007995.2018.1520696	results	1	NA	adjusted_num_pval	0.659
10.1080/03007995.2018.1520696	results	1	NA	adjusted_significant	FALSE
10.1080/03007995.2018.1520696	results	2	NA	contrast	OR
10.1080/03007995.2018.1520696	results	2	NA	direction_benefit	superior
10.1080/03007995.2018.1520696	results	2	NA	n_nonipd_ttt	140
10.1080/03007995.2018.1520696	results	2	NA	n_ipd_ttt	110
10.1080/03007995.2018.1520696	results	2	NA	ess_ttt	50.8
10.1080/03007995.2018.1520696	results	2	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2018.1520696	results	2	NA	list_covariates_yn	Yes
10.1080/03007995.2018.1520696	results	2	NA	n_covariates	7
10.1080/03007995.2018.1520696	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1080/03007995.2018.1520696	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1520696	results	2	NA	unadjusted_effect	2.16
10.1080/03007995.2018.1520696	results	2	NA	unadjusted_pval_char	0.003
10.1080/03007995.2018.1520696	results	2	NA	adjusted_effect	2.17
10.1080/03007995.2018.1520696	results	2	NA	adjusted_pval_char	0.02
10.1080/03007995.2018.1520696	results	2	NA	geographical region	NA
10.1080/03007995.2018.1520696	results	2	NA	n_ipd_total	NA
10.1080/03007995.2018.1520696	results	2	NA	ess_total	NA
10.1080/03007995.2018.1520696	results	2	NA	n_nonipd_total	NA
10.1080/03007995.2018.1520696	results	2	NA	n_nonipd_anchor	NA
10.1080/03007995.2018.1520696	results	2	NA	n_ipd_anchor	NA
10.1080/03007995.2018.1520696	results	2	NA	ess_anchor	NA
10.1080/03007995.2018.1520696	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2018.1520696	results	2	NA	effect_cutoff	1
10.1080/03007995.2018.1520696	results	2	NA	unadjusted_pval	0.003
10.1080/03007995.2018.1520696	results	2	NA	unadjusted_num_pval	0.003
10.1080/03007995.2018.1520696	results	2	NA	unadjusted_significant	TRUE
10.1080/03007995.2018.1520696	results	2	NA	adjusted_pval	0.02
10.1080/03007995.2018.1520696	results	2	NA	adjusted_num_pval	0.02
10.1080/03007995.2018.1520696	results	2	NA	adjusted_significant	TRUE
10.1080/03007995.2018.1520696	results	3	NA	contrast	OR
10.1080/03007995.2018.1520696	results	3	NA	direction_benefit	superior
10.1080/03007995.2018.1520696	results	3	NA	n_nonipd_ttt	87
10.1080/03007995.2018.1520696	results	3	NA	n_ipd_ttt	110
10.1080/03007995.2018.1520696	results	3	NA	ess_ttt	77.5
10.1080/03007995.2018.1520696	results	3	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2018.1520696	results	3	NA	list_covariates_yn	Yes
10.1080/03007995.2018.1520696	results	3	NA	n_covariates	7
10.1080/03007995.2018.1520696	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1080/03007995.2018.1520696	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1520696	results	3	NA	unadjusted_effect	1.78
10.1080/03007995.2018.1520696	results	3	NA	unadjusted_pval_char	0.047
10.1080/03007995.2018.1520696	results	3	NA	adjusted_effect	1.69
10.1080/03007995.2018.1520696	results	3	NA	adjusted_pval_char	0.096
10.1080/03007995.2018.1520696	results	3	NA	geographical region	No
10.1080/03007995.2018.1520696	results	3	NA	n_ipd_total	NA
10.1080/03007995.2018.1520696	results	3	NA	ess_total	NA
10.1080/03007995.2018.1520696	results	3	NA	n_nonipd_total	NA
10.1080/03007995.2018.1520696	results	3	NA	n_nonipd_anchor	NA
10.1080/03007995.2018.1520696	results	3	NA	n_ipd_anchor	NA
10.1080/03007995.2018.1520696	results	3	NA	ess_anchor	NA
10.1080/03007995.2018.1520696	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2018.1520696	results	3	NA	effect_cutoff	1
10.1080/03007995.2018.1520696	results	3	NA	unadjusted_pval	0.047
10.1080/03007995.2018.1520696	results	3	NA	unadjusted_num_pval	0.047
10.1080/03007995.2018.1520696	results	3	NA	unadjusted_significant	TRUE
10.1080/03007995.2018.1520696	results	3	NA	adjusted_pval	0.096
10.1080/03007995.2018.1520696	results	3	NA	adjusted_num_pval	0.096
10.1080/03007995.2018.1520696	results	3	NA	adjusted_significant	FALSE
10.1080/03007995.2018.1520696	results	4	NA	contrast	OR
10.1080/03007995.2018.1520696	results	4	NA	direction_benefit	superior
10.1080/03007995.2018.1520696	results	4	NA	n_nonipd_ttt	138
10.1080/03007995.2018.1520696	results	4	NA	n_ipd_ttt	110
10.1080/03007995.2018.1520696	results	4	NA	ess_ttt	70.7
10.1080/03007995.2018.1520696	results	4	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2018.1520696	results	4	NA	list_covariates_yn	Yes
10.1080/03007995.2018.1520696	results	4	NA	n_covariates	8
10.1080/03007995.2018.1520696	results	4	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1080/03007995.2018.1520696	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1520696	results	4	NA	unadjusted_effect	1.47
10.1080/03007995.2018.1520696	results	4	NA	unadjusted_pval_char	0.133
10.1080/03007995.2018.1520696	results	4	NA	adjusted_effect	1.44
10.1080/03007995.2018.1520696	results	4	NA	adjusted_pval_char	0.212
10.1080/03007995.2018.1520696	results	4	NA	geographical region	No
10.1080/03007995.2018.1520696	results	4	NA	n_ipd_total	NA
10.1080/03007995.2018.1520696	results	4	NA	ess_total	NA
10.1080/03007995.2018.1520696	results	4	NA	n_nonipd_total	NA
10.1080/03007995.2018.1520696	results	4	NA	n_nonipd_anchor	NA
10.1080/03007995.2018.1520696	results	4	NA	n_ipd_anchor	NA
10.1080/03007995.2018.1520696	results	4	NA	ess_anchor	NA
10.1080/03007995.2018.1520696	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2018.1520696	results	4	NA	effect_cutoff	1
10.1080/03007995.2018.1520696	results	4	NA	unadjusted_pval	0.133
10.1080/03007995.2018.1520696	results	4	NA	unadjusted_num_pval	0.133
10.1080/03007995.2018.1520696	results	4	NA	unadjusted_significant	FALSE
10.1080/03007995.2018.1520696	results	4	NA	adjusted_pval	0.212
10.1080/03007995.2018.1520696	results	4	NA	adjusted_num_pval	0.212
10.1080/03007995.2018.1520696	results	4	NA	adjusted_significant	FALSE
10.1080/03007995.2018.1520696	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2018.1520696	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2018.1520696	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02094573
10.1080/03007995.2018.1520696	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1520696	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1080/03007995.2018.1520696	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2018.1520696	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2018.1520696	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2018.1520696	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01283516
10.1080/03007995.2018.1520696	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1520696	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1
10.1080/03007995.2018.1520696	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2018.1520696	study_information	NA	3	Patient-level data used	No
10.1080/03007995.2018.1520696	study_information	NA	3	Clinical Trial	Yes
10.1080/03007995.2018.1520696	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01685060
10.1080/03007995.2018.1520696	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1520696	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.1080/03007995.2018.1520696	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2018.1520696	study_information	NA	4	Patient-level data used	No
10.1080/03007995.2018.1520696	study_information	NA	4	Clinical Trial	Yes
10.1080/03007995.2018.1520696	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01871805
10.1080/03007995.2018.1520696	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1520696	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1, 2
10.1080/03007995.2018.1520696	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2018.1520696	study_information	NA	5	Patient-level data used	No
10.1080/03007995.2018.1520696	study_information	NA	5	Clinical Trial	Yes
10.1080/03007995.2018.1520696	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01801111
10.1080/03007995.2018.1520696	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1520696	study_information	NA	5	Phase of the clinical trial (clinical trial only)	1, 2
10.1080/03007995.2018.1520696	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2018.1541443	general_information	NA	NA	Medical Condition of Interest Name	advanced anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer
10.1080/03007995.2018.1541443	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/03007995.2018.1541443	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/03007995.2018.1541443	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2018.1541443	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2018.1541443	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2018.1541443	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2018.1541443	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/03007995.2018.1541443	methodology	1	NA	primary_outcome_name	progression-free survival
10.1080/03007995.2018.1541443	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1080/03007995.2018.1541443	methodology	1	NA	primary_outcome_type	Time-to-event
10.1080/03007995.2018.1541443	methodology	1	NA	Treatment name 1	ceritinib
10.1080/03007995.2018.1541443	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2018.1541443	methodology	1	NA	Treatment name 2	crizotinib
10.1080/03007995.2018.1541443	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2018.1541443	methodology	1	NA	paitc_type	MAIC
10.1080/03007995.2018.1541443	methodology	1	NA	anchored_yn	No
10.1080/03007995.2018.1541443	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1541443	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1541443	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1080/03007995.2018.1541443	methodology	1	NA	prognostic_factors_yn	Yes
10.1080/03007995.2018.1541443	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2018.1541443	methodology	1	NA	weights_model_yn	No
10.1080/03007995.2018.1541443	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2018.1541443	results	1	NA	contrast	HR
10.1080/03007995.2018.1541443	results	1	NA	direction_benefit	inferior
10.1080/03007995.2018.1541443	results	1	NA	n_nonipd_ttt	172
10.1080/03007995.2018.1541443	results	1	NA	n_ipd_ttt	189
10.1080/03007995.2018.1541443	results	1	NA	ess_ttt	NA
10.1080/03007995.2018.1541443	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1080/03007995.2018.1541443	results	1	NA	list_covariates_yn	Yes
10.1080/03007995.2018.1541443	results	1	NA	n_covariates	8
10.1080/03007995.2018.1541443	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/03007995.2018.1541443	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1541443	results	1	NA	unadjusted_effect	0.68
10.1080/03007995.2018.1541443	results	1	NA	unadjusted_pval_char	0.01
10.1080/03007995.2018.1541443	results	1	NA	adjusted_effect	0.64
10.1080/03007995.2018.1541443	results	1	NA	adjusted_pval_char	0.004
10.1080/03007995.2018.1541443	results	1	NA	geographical region	NA
10.1080/03007995.2018.1541443	results	1	NA	n_ipd_total	NA
10.1080/03007995.2018.1541443	results	1	NA	ess_total	NA
10.1080/03007995.2018.1541443	results	1	NA	n_nonipd_total	NA
10.1080/03007995.2018.1541443	results	1	NA	n_nonipd_anchor	NA
10.1080/03007995.2018.1541443	results	1	NA	n_ipd_anchor	NA
10.1080/03007995.2018.1541443	results	1	NA	ess_anchor	NA
10.1080/03007995.2018.1541443	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2018.1541443	results	1	NA	effect_cutoff	1
10.1080/03007995.2018.1541443	results	1	NA	unadjusted_pval	0.01
10.1080/03007995.2018.1541443	results	1	NA	unadjusted_num_pval	0.01
10.1080/03007995.2018.1541443	results	1	NA	unadjusted_significant	TRUE
10.1080/03007995.2018.1541443	results	1	NA	adjusted_pval	0.004
10.1080/03007995.2018.1541443	results	1	NA	adjusted_num_pval	0.004
10.1080/03007995.2018.1541443	results	1	NA	adjusted_significant	TRUE
10.1080/03007995.2018.1541443	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2018.1541443	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2018.1541443	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01828099
10.1080/03007995.2018.1541443	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1541443	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2018.1541443	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2018.1541443	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2018.1541443	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2018.1541443	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01154140
10.1080/03007995.2018.1541443	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1541443	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2018.1541443	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2019.1585779	general_information	NA	NA	Medical Condition of Interest Name	active relapsing-remitting multiple sclerosis
10.1080/03007995.2019.1585779	general_information	NA	NA	Countries of first author affiliations	uk
10.1080/03007995.2019.1585779	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/03007995.2019.1585779	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2019.1585779	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2019.1585779	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2019.1585779	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2019.1585779	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/03007995.2019.1585779	methodology	1	NA	primary_outcome_name	confirmed disability progression
10.1080/03007995.2019.1585779	methodology	1	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2019.1585779	methodology	1	NA	primary_outcome_type	Time-to-event
10.1080/03007995.2019.1585779	methodology	1	NA	Treatment name 1	cladribine
10.1080/03007995.2019.1585779	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2019.1585779	methodology	1	NA	Treatment name 2	alemtuzumab
10.1080/03007995.2019.1585779	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2019.1585779	methodology	1	NA	paitc_type	MAIC
10.1080/03007995.2019.1585779	methodology	1	NA	anchored_yn	No
10.1080/03007995.2019.1585779	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2019.1585779	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2019.1585779	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1080/03007995.2019.1585779	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2019.1585779	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2019.1585779	methodology	1	NA	weights_model_yn	No
10.1080/03007995.2019.1585779	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2019.1585779	results	1	NA	contrast	HR
10.1080/03007995.2019.1585779	results	1	NA	direction_benefit	inferior
10.1080/03007995.2019.1585779	results	1	NA	n_nonipd_ttt	426
10.1080/03007995.2019.1585779	results	1	NA	n_ipd_ttt	113
10.1080/03007995.2019.1585779	results	1	NA	ess_ttt	41
10.1080/03007995.2019.1585779	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2019.1585779	results	1	NA	list_covariates_yn	Yes
10.1080/03007995.2019.1585779	results	1	NA	n_covariates	6
10.1080/03007995.2019.1585779	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2019.1585779	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2019.1585779	results	1	NA	unadjusted_effect	0.96
10.1080/03007995.2019.1585779	results	1	NA	unadjusted_pval_char	[0.51;1.80]
10.1080/03007995.2019.1585779	results	1	NA	adjusted_effect	1
10.1080/03007995.2019.1585779	results	1	NA	adjusted_pval_char	[0.44;2.27]
10.1080/03007995.2019.1585779	results	1	NA	geographical region	NA
10.1080/03007995.2019.1585779	results	1	NA	n_ipd_total	NA
10.1080/03007995.2019.1585779	results	1	NA	ess_total	NA
10.1080/03007995.2019.1585779	results	1	NA	n_nonipd_total	NA
10.1080/03007995.2019.1585779	results	1	NA	n_nonipd_anchor	NA
10.1080/03007995.2019.1585779	results	1	NA	n_ipd_anchor	NA
10.1080/03007995.2019.1585779	results	1	NA	ess_anchor	NA
10.1080/03007995.2019.1585779	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2019.1585779	results	1	NA	effect_cutoff	1
10.1080/03007995.2019.1585779	results	1	NA	unadjusted_lb_ci	0.51
10.1080/03007995.2019.1585779	results	1	NA	unadjusted_ub_ci	1.8
10.1080/03007995.2019.1585779	results	1	NA	unadjusted_significant	FALSE
10.1080/03007995.2019.1585779	results	1	NA	adjusted_lb_ci	0.44
10.1080/03007995.2019.1585779	results	1	NA	adjusted_ub_ci	2.27
10.1080/03007995.2019.1585779	results	1	NA	adjusted_significant	FALSE
10.1080/03007995.2019.1585779	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2019.1585779	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2019.1585779	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00213135
10.1080/03007995.2019.1585779	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2019.1585779	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2019.1585779	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2019.1585779	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2019.1585779	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2019.1585779	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00548405
10.1080/03007995.2019.1585779	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2019.1585779	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2019.1585779	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2019.1605239	general_information	NA	NA	Medical Condition of Interest Name	chronic phase chronic myeloid leukemia
10.1080/03007995.2019.1605239	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/03007995.2019.1605239	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/03007995.2019.1605239	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2019.1605239	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2019.1605239	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2019.1605239	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2019.1605239	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/03007995.2019.1605239	methodology	1	NA	primary_outcome_name	overall survival
10.1080/03007995.2019.1605239	methodology	1	NA	outcome_short_name	Overall Survival
10.1080/03007995.2019.1605239	methodology	1	NA	primary_outcome_type	Time-to-event
10.1080/03007995.2019.1605239	methodology	1	NA	Treatment name 1	bosutinib
10.1080/03007995.2019.1605239	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2019.1605239	methodology	1	NA	Treatment name 2	dasatinib
10.1080/03007995.2019.1605239	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2019.1605239	methodology	1	NA	paitc_type	MAIC
10.1080/03007995.2019.1605239	methodology	1	NA	anchored_yn	No
10.1080/03007995.2019.1605239	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2019.1605239	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2019.1605239	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1080/03007995.2019.1605239	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2019.1605239	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2019.1605239	methodology	1	NA	weights_model_yn	No
10.1080/03007995.2019.1605239	methodology	1	NA	scale_choice_yn	Yes
10.1080/03007995.2019.1605239	methodology	2	NA	primary_outcome_name	overall survival
10.1080/03007995.2019.1605239	methodology	2	NA	outcome_short_name	Overall Survival
10.1080/03007995.2019.1605239	methodology	2	NA	primary_outcome_type	Time-to-event
10.1080/03007995.2019.1605239	methodology	2	NA	Treatment name 1	bosutinib
10.1080/03007995.2019.1605239	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2019.1605239	methodology	2	NA	Treatment name 2	nilotinib
10.1080/03007995.2019.1605239	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1080/03007995.2019.1605239	methodology	2	NA	paitc_type	MAIC
10.1080/03007995.2019.1605239	methodology	2	NA	anchored_yn	No
10.1080/03007995.2019.1605239	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2019.1605239	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2019.1605239	methodology	2	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1080/03007995.2019.1605239	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2019.1605239	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2019.1605239	methodology	2	NA	weights_model_yn	No
10.1080/03007995.2019.1605239	methodology	2	NA	scale_choice_yn	Yes
10.1080/03007995.2019.1605239	results	1	NA	contrast	HR
10.1080/03007995.2019.1605239	results	1	NA	direction_benefit	inferior
10.1080/03007995.2019.1605239	results	1	NA	n_nonipd_ttt	167
10.1080/03007995.2019.1605239	results	1	NA	n_ipd_ttt	283
10.1080/03007995.2019.1605239	results	1	NA	ess_ttt	NA
10.1080/03007995.2019.1605239	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2019.1605239	results	1	NA	list_covariates_yn	Yes
10.1080/03007995.2019.1605239	results	1	NA	n_covariates	4
10.1080/03007995.2019.1605239	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2019.1605239	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2019.1605239	results	1	NA	unadjusted_effect	NA
10.1080/03007995.2019.1605239	results	1	NA	unadjusted_pval_char	NA
10.1080/03007995.2019.1605239	results	1	NA	adjusted_effect	0.82
10.1080/03007995.2019.1605239	results	1	NA	adjusted_pval_char	0.37
10.1080/03007995.2019.1605239	results	1	NA	geographical region	No
10.1080/03007995.2019.1605239	results	1	NA	n_ipd_total	NA
10.1080/03007995.2019.1605239	results	1	NA	ess_total	NA
10.1080/03007995.2019.1605239	results	1	NA	n_nonipd_total	NA
10.1080/03007995.2019.1605239	results	1	NA	n_nonipd_anchor	NA
10.1080/03007995.2019.1605239	results	1	NA	n_ipd_anchor	NA
10.1080/03007995.2019.1605239	results	1	NA	ess_anchor	NA
10.1080/03007995.2019.1605239	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2019.1605239	results	1	NA	effect_cutoff	1
10.1080/03007995.2019.1605239	results	1	NA	adjusted_pval	0.37
10.1080/03007995.2019.1605239	results	1	NA	adjusted_num_pval	0.37
10.1080/03007995.2019.1605239	results	1	NA	adjusted_significant	FALSE
10.1080/03007995.2019.1605239	results	2	NA	contrast	HR
10.1080/03007995.2019.1605239	results	2	NA	direction_benefit	inferior
10.1080/03007995.2019.1605239	results	2	NA	n_nonipd_ttt	321
10.1080/03007995.2019.1605239	results	2	NA	n_ipd_ttt	283
10.1080/03007995.2019.1605239	results	2	NA	ess_ttt	NA
10.1080/03007995.2019.1605239	results	2	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2019.1605239	results	2	NA	list_covariates_yn	Yes
10.1080/03007995.2019.1605239	results	2	NA	n_covariates	3
10.1080/03007995.2019.1605239	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2019.1605239	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2019.1605239	results	2	NA	unadjusted_effect	NA
10.1080/03007995.2019.1605239	results	2	NA	unadjusted_pval_char	NA
10.1080/03007995.2019.1605239	results	2	NA	adjusted_effect	0.72
10.1080/03007995.2019.1605239	results	2	NA	adjusted_pval_char	0.16
10.1080/03007995.2019.1605239	results	2	NA	geographical region	No
10.1080/03007995.2019.1605239	results	2	NA	n_ipd_total	NA
10.1080/03007995.2019.1605239	results	2	NA	ess_total	NA
10.1080/03007995.2019.1605239	results	2	NA	n_nonipd_total	NA
10.1080/03007995.2019.1605239	results	2	NA	n_nonipd_anchor	NA
10.1080/03007995.2019.1605239	results	2	NA	n_ipd_anchor	NA
10.1080/03007995.2019.1605239	results	2	NA	ess_anchor	NA
10.1080/03007995.2019.1605239	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2019.1605239	results	2	NA	effect_cutoff	1
10.1080/03007995.2019.1605239	results	2	NA	adjusted_pval	0.16
10.1080/03007995.2019.1605239	results	2	NA	adjusted_num_pval	0.16
10.1080/03007995.2019.1605239	results	2	NA	adjusted_significant	FALSE
10.1080/03007995.2019.1605239	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2019.1605239	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2019.1605239	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00261846
10.1080/03007995.2019.1605239	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2019.1605239	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.1080/03007995.2019.1605239	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2019.1605239	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2019.1605239	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2019.1605239	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00123474
10.1080/03007995.2019.1605239	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2019.1605239	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2019.1605239	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2019.1605239	study_information	NA	3	Patient-level data used	No
10.1080/03007995.2019.1605239	study_information	NA	3	Clinical Trial	Yes
10.1080/03007995.2019.1605239	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00109707
10.1080/03007995.2019.1605239	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2019.1605239	study_information	NA	3	Phase of the clinical trial (clinical trial only)	1, 2
10.1080/03007995.2019.1605239	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2020.1747999	general_information	NA	NA	Medical Condition of Interest Name	secondary progressive multiple sclerosis
10.1080/03007995.2020.1747999	general_information	NA	NA	Countries of first author affiliations	canada
10.1080/03007995.2020.1747999	general_information	NA	NA	Countries of last author affiliations	switzerland
10.1080/03007995.2020.1747999	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2020.1747999	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2020.1747999	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2020.1747999	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2020.1747999	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/03007995.2020.1747999	methodology	1	NA	primary_outcome_name	time to confirmed disability progression at six months (cdp-6)
10.1080/03007995.2020.1747999	methodology	1	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2020.1747999	methodology	1	NA	primary_outcome_type	Time-to-event
10.1080/03007995.2020.1747999	methodology	1	NA	Treatment name 1	siponimod
10.1080/03007995.2020.1747999	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2020.1747999	methodology	1	NA	Treatment name 2	ifn-1b 250 g once every other day (q2d)
10.1080/03007995.2020.1747999	methodology	1	NA	Study 'number(s)' for treatment 2	4
10.1080/03007995.2020.1747999	methodology	1	NA	paitc_type	MAIC
10.1080/03007995.2020.1747999	methodology	1	NA	anchored_yn	Yes
10.1080/03007995.2020.1747999	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	1	NA	prognostic_factors_yn	No
10.1080/03007995.2020.1747999	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2020.1747999	methodology	1	NA	weights_model_yn	No
10.1080/03007995.2020.1747999	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2020.1747999	methodology	2	NA	primary_outcome_name	time to confirmed disability progression at six months (cdp-6)
10.1080/03007995.2020.1747999	methodology	2	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2020.1747999	methodology	2	NA	primary_outcome_type	Time-to-event
10.1080/03007995.2020.1747999	methodology	2	NA	Treatment name 1	siponimod
10.1080/03007995.2020.1747999	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2020.1747999	methodology	2	NA	Treatment name 2	ifn-1a 22 g once weekly (qw)
10.1080/03007995.2020.1747999	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1080/03007995.2020.1747999	methodology	2	NA	paitc_type	MAIC
10.1080/03007995.2020.1747999	methodology	2	NA	anchored_yn	Yes
10.1080/03007995.2020.1747999	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	2	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	2	NA	prognostic_factors_yn	No
10.1080/03007995.2020.1747999	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2020.1747999	methodology	2	NA	weights_model_yn	No
10.1080/03007995.2020.1747999	methodology	2	NA	scale_choice_yn	No
10.1080/03007995.2020.1747999	methodology	3	NA	primary_outcome_name	the proportion of patients who experienced cdp-6 (confirmed disability progression at six months) by 96 weeks based on an increase in edss alone
10.1080/03007995.2020.1747999	methodology	3	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2020.1747999	methodology	3	NA	primary_outcome_type	Binary (eg rates)
10.1080/03007995.2020.1747999	methodology	3	NA	Treatment name 1	siponimod
10.1080/03007995.2020.1747999	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2020.1747999	methodology	3	NA	Treatment name 2	natalizumab
10.1080/03007995.2020.1747999	methodology	3	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2020.1747999	methodology	3	NA	paitc_type	MAIC
10.1080/03007995.2020.1747999	methodology	3	NA	anchored_yn	Yes
10.1080/03007995.2020.1747999	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	3	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	3	NA	prognostic_factors_yn	No
10.1080/03007995.2020.1747999	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2020.1747999	methodology	3	NA	weights_model_yn	No
10.1080/03007995.2020.1747999	methodology	3	NA	scale_choice_yn	No
10.1080/03007995.2020.1747999	methodology	4	NA	primary_outcome_name	time to confirmed disability progression at three months (cdp-3)
10.1080/03007995.2020.1747999	methodology	4	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2020.1747999	methodology	4	NA	primary_outcome_type	Time-to-event
10.1080/03007995.2020.1747999	methodology	4	NA	Treatment name 1	siponimod
10.1080/03007995.2020.1747999	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2020.1747999	methodology	4	NA	Treatment name 2	sc ifn-1a 22 g three times weekly
10.1080/03007995.2020.1747999	methodology	4	NA	Study 'number(s)' for treatment 2	6
10.1080/03007995.2020.1747999	methodology	4	NA	paitc_type	MAIC
10.1080/03007995.2020.1747999	methodology	4	NA	anchored_yn	Yes
10.1080/03007995.2020.1747999	methodology	4	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	4	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	4	NA	prognostic_factors_yn	No
10.1080/03007995.2020.1747999	methodology	4	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2020.1747999	methodology	4	NA	weights_model_yn	No
10.1080/03007995.2020.1747999	methodology	4	NA	scale_choice_yn	No
10.1080/03007995.2020.1747999	methodology	5	NA	primary_outcome_name	time to confirmed disability progression at three months (cdp-3)
10.1080/03007995.2020.1747999	methodology	5	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2020.1747999	methodology	5	NA	primary_outcome_type	Time-to-event
10.1080/03007995.2020.1747999	methodology	5	NA	Treatment name 1	siponimod
10.1080/03007995.2020.1747999	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2020.1747999	methodology	5	NA	Treatment name 2	sc ifn-1a 44 g three times weekly
10.1080/03007995.2020.1747999	methodology	5	NA	Study 'number(s)' for treatment 2	6
10.1080/03007995.2020.1747999	methodology	5	NA	paitc_type	MAIC
10.1080/03007995.2020.1747999	methodology	5	NA	anchored_yn	Yes
10.1080/03007995.2020.1747999	methodology	5	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	5	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	5	NA	prognostic_factors_yn	No
10.1080/03007995.2020.1747999	methodology	5	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2020.1747999	methodology	5	NA	weights_model_yn	No
10.1080/03007995.2020.1747999	methodology	5	NA	scale_choice_yn	No
10.1080/03007995.2020.1747999	methodology	6	NA	primary_outcome_name	time to confirmed disability progression at three months (cdp-3)
10.1080/03007995.2020.1747999	methodology	6	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2020.1747999	methodology	6	NA	primary_outcome_type	Time-to-event
10.1080/03007995.2020.1747999	methodology	6	NA	Treatment name 1	siponimod
10.1080/03007995.2020.1747999	methodology	6	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2020.1747999	methodology	6	NA	Treatment name 2	ifn-1b 8 miu once every other day
10.1080/03007995.2020.1747999	methodology	6	NA	Study 'number(s)' for treatment 2	7
10.1080/03007995.2020.1747999	methodology	6	NA	paitc_type	MAIC
10.1080/03007995.2020.1747999	methodology	6	NA	anchored_yn	Yes
10.1080/03007995.2020.1747999	methodology	6	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	6	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	6	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	6	NA	prognostic_factors_yn	No
10.1080/03007995.2020.1747999	methodology	6	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2020.1747999	methodology	6	NA	weights_model_yn	No
10.1080/03007995.2020.1747999	methodology	6	NA	scale_choice_yn	No
10.1080/03007995.2020.1747999	methodology	7	NA	primary_outcome_name	time to confirmed disability progression at three months (cdp-3)
10.1080/03007995.2020.1747999	methodology	7	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2020.1747999	methodology	7	NA	primary_outcome_type	Time-to-event
10.1080/03007995.2020.1747999	methodology	7	NA	Treatment name 1	siponimod
10.1080/03007995.2020.1747999	methodology	7	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2020.1747999	methodology	7	NA	Treatment name 2	im ifn-1a 60 g once weekly
10.1080/03007995.2020.1747999	methodology	7	NA	Study 'number(s)' for treatment 2	5
10.1080/03007995.2020.1747999	methodology	7	NA	paitc_type	MAIC
10.1080/03007995.2020.1747999	methodology	7	NA	anchored_yn	Yes
10.1080/03007995.2020.1747999	methodology	7	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	7	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	7	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	7	NA	prognostic_factors_yn	No
10.1080/03007995.2020.1747999	methodology	7	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2020.1747999	methodology	7	NA	weights_model_yn	No
10.1080/03007995.2020.1747999	methodology	7	NA	scale_choice_yn	No
10.1080/03007995.2020.1747999	results	1	NA	contrast	HR
10.1080/03007995.2020.1747999	results	1	NA	direction_benefit	inferior
10.1080/03007995.2020.1747999	results	1	NA	n_nonipd_ttt	NA
10.1080/03007995.2020.1747999	results	1	NA	n_ipd_ttt	NA
10.1080/03007995.2020.1747999	results	1	NA	ess_ttt	NA
10.1080/03007995.2020.1747999	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2020.1747999	results	1	NA	list_covariates_yn	Yes
10.1080/03007995.2020.1747999	results	1	NA	n_covariates	10
10.1080/03007995.2020.1747999	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	1	NA	unadjusted_effect	NA
10.1080/03007995.2020.1747999	results	1	NA	unadjusted_pval_char	NA
10.1080/03007995.2020.1747999	results	1	NA	adjusted_effect	0.55
10.1080/03007995.2020.1747999	results	1	NA	adjusted_pval_char	[0.33;0.91]
10.1080/03007995.2020.1747999	results	1	NA	geographical region	NA
10.1080/03007995.2020.1747999	results	1	NA	n_ipd_total	543
10.1080/03007995.2020.1747999	results	1	NA	ess_total	410
10.1080/03007995.2020.1747999	results	1	NA	n_nonipd_total	939
10.1080/03007995.2020.1747999	results	1	NA	n_nonipd_anchor	NA
10.1080/03007995.2020.1747999	results	1	NA	n_ipd_anchor	NA
10.1080/03007995.2020.1747999	results	1	NA	ess_anchor	NA
10.1080/03007995.2020.1747999	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2020.1747999	results	1	NA	effect_cutoff	1
10.1080/03007995.2020.1747999	results	1	NA	adjusted_lb_ci	0.33
10.1080/03007995.2020.1747999	results	1	NA	adjusted_ub_ci	0.91
10.1080/03007995.2020.1747999	results	1	NA	adjusted_significant	TRUE
10.1080/03007995.2020.1747999	results	2	NA	contrast	HR
10.1080/03007995.2020.1747999	results	2	NA	direction_benefit	inferior
10.1080/03007995.2020.1747999	results	2	NA	n_nonipd_ttt	NA
10.1080/03007995.2020.1747999	results	2	NA	n_ipd_ttt	NA
10.1080/03007995.2020.1747999	results	2	NA	ess_ttt	NA
10.1080/03007995.2020.1747999	results	2	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2020.1747999	results	2	NA	list_covariates_yn	Yes
10.1080/03007995.2020.1747999	results	2	NA	n_covariates	10
10.1080/03007995.2020.1747999	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	2	NA	unadjusted_effect	NA
10.1080/03007995.2020.1747999	results	2	NA	unadjusted_pval_char	NA
10.1080/03007995.2020.1747999	results	2	NA	adjusted_effect	0.43
10.1080/03007995.2020.1747999	results	2	NA	adjusted_pval_char	[0.20;0.93]
10.1080/03007995.2020.1747999	results	2	NA	geographical region	NA
10.1080/03007995.2020.1747999	results	2	NA	n_ipd_total	578
10.1080/03007995.2020.1747999	results	2	NA	ess_total	157
10.1080/03007995.2020.1747999	results	2	NA	n_nonipd_total	364
10.1080/03007995.2020.1747999	results	2	NA	n_nonipd_anchor	NA
10.1080/03007995.2020.1747999	results	2	NA	n_ipd_anchor	NA
10.1080/03007995.2020.1747999	results	2	NA	ess_anchor	NA
10.1080/03007995.2020.1747999	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2020.1747999	results	2	NA	effect_cutoff	1
10.1080/03007995.2020.1747999	results	2	NA	adjusted_lb_ci	0.2
10.1080/03007995.2020.1747999	results	2	NA	adjusted_ub_ci	0.93
10.1080/03007995.2020.1747999	results	2	NA	adjusted_significant	TRUE
10.1080/03007995.2020.1747999	results	3	NA	contrast	OR
10.1080/03007995.2020.1747999	results	3	NA	direction_benefit	inferior
10.1080/03007995.2020.1747999	results	3	NA	n_nonipd_ttt	NA
10.1080/03007995.2020.1747999	results	3	NA	n_ipd_ttt	NA
10.1080/03007995.2020.1747999	results	3	NA	ess_ttt	NA
10.1080/03007995.2020.1747999	results	3	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2020.1747999	results	3	NA	list_covariates_yn	Yes
10.1080/03007995.2020.1747999	results	3	NA	n_covariates	10
10.1080/03007995.2020.1747999	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	3	NA	unadjusted_effect	NA
10.1080/03007995.2020.1747999	results	3	NA	unadjusted_pval_char	NA
10.1080/03007995.2020.1747999	results	3	NA	adjusted_effect	0.76
10.1080/03007995.2020.1747999	results	3	NA	adjusted_pval_char	[0.44;1.30]
10.1080/03007995.2020.1747999	results	3	NA	geographical region	No
10.1080/03007995.2020.1747999	results	3	NA	n_ipd_total	608
10.1080/03007995.2020.1747999	results	3	NA	ess_total	516
10.1080/03007995.2020.1747999	results	3	NA	n_nonipd_total	887
10.1080/03007995.2020.1747999	results	3	NA	n_nonipd_anchor	NA
10.1080/03007995.2020.1747999	results	3	NA	n_ipd_anchor	NA
10.1080/03007995.2020.1747999	results	3	NA	ess_anchor	NA
10.1080/03007995.2020.1747999	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2020.1747999	results	3	NA	effect_cutoff	1
10.1080/03007995.2020.1747999	results	3	NA	adjusted_lb_ci	0.44
10.1080/03007995.2020.1747999	results	3	NA	adjusted_ub_ci	1.3
10.1080/03007995.2020.1747999	results	3	NA	adjusted_significant	FALSE
10.1080/03007995.2020.1747999	results	4	NA	contrast	HR
10.1080/03007995.2020.1747999	results	4	NA	direction_benefit	inferior
10.1080/03007995.2020.1747999	results	4	NA	n_nonipd_ttt	NA
10.1080/03007995.2020.1747999	results	4	NA	n_ipd_ttt	NA
10.1080/03007995.2020.1747999	results	4	NA	ess_ttt	NA
10.1080/03007995.2020.1747999	results	4	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2020.1747999	results	4	NA	list_covariates_yn	Yes
10.1080/03007995.2020.1747999	results	4	NA	n_covariates	10
10.1080/03007995.2020.1747999	results	4	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	4	NA	unadjusted_effect	NA
10.1080/03007995.2020.1747999	results	4	NA	unadjusted_pval_char	NA
10.1080/03007995.2020.1747999	results	4	NA	adjusted_effect	0.8
10.1080/03007995.2020.1747999	results	4	NA	adjusted_pval_char	[0.46;1.38]
10.1080/03007995.2020.1747999	results	4	NA	geographical region	NA
10.1080/03007995.2020.1747999	results	4	NA	n_ipd_total	455
10.1080/03007995.2020.1747999	results	4	NA	ess_total	237
10.1080/03007995.2020.1747999	results	4	NA	n_nonipd_total	618
10.1080/03007995.2020.1747999	results	4	NA	n_nonipd_anchor	NA
10.1080/03007995.2020.1747999	results	4	NA	n_ipd_anchor	NA
10.1080/03007995.2020.1747999	results	4	NA	ess_anchor	NA
10.1080/03007995.2020.1747999	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2020.1747999	results	4	NA	effect_cutoff	1
10.1080/03007995.2020.1747999	results	4	NA	adjusted_lb_ci	0.46
10.1080/03007995.2020.1747999	results	4	NA	adjusted_ub_ci	1.38
10.1080/03007995.2020.1747999	results	4	NA	adjusted_significant	FALSE
10.1080/03007995.2020.1747999	results	5	NA	contrast	HR
10.1080/03007995.2020.1747999	results	5	NA	direction_benefit	inferior
10.1080/03007995.2020.1747999	results	5	NA	n_nonipd_ttt	NA
10.1080/03007995.2020.1747999	results	5	NA	n_ipd_ttt	NA
10.1080/03007995.2020.1747999	results	5	NA	ess_ttt	NA
10.1080/03007995.2020.1747999	results	5	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2020.1747999	results	5	NA	list_covariates_yn	Yes
10.1080/03007995.2020.1747999	results	5	NA	n_covariates	10
10.1080/03007995.2020.1747999	results	5	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	5	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	5	NA	unadjusted_effect	NA
10.1080/03007995.2020.1747999	results	5	NA	unadjusted_pval_char	NA
10.1080/03007995.2020.1747999	results	5	NA	adjusted_effect	0.84
10.1080/03007995.2020.1747999	results	5	NA	adjusted_pval_char	[0.49;1.47]
10.1080/03007995.2020.1747999	results	5	NA	geographical region	NA
10.1080/03007995.2020.1747999	results	5	NA	n_ipd_total	455
10.1080/03007995.2020.1747999	results	5	NA	ess_total	237
10.1080/03007995.2020.1747999	results	5	NA	n_nonipd_total	618
10.1080/03007995.2020.1747999	results	5	NA	n_nonipd_anchor	NA
10.1080/03007995.2020.1747999	results	5	NA	n_ipd_anchor	NA
10.1080/03007995.2020.1747999	results	5	NA	ess_anchor	NA
10.1080/03007995.2020.1747999	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2020.1747999	results	5	NA	effect_cutoff	1
10.1080/03007995.2020.1747999	results	5	NA	adjusted_lb_ci	0.49
10.1080/03007995.2020.1747999	results	5	NA	adjusted_ub_ci	1.47
10.1080/03007995.2020.1747999	results	5	NA	adjusted_significant	FALSE
10.1080/03007995.2020.1747999	results	6	NA	contrast	HR
10.1080/03007995.2020.1747999	results	6	NA	direction_benefit	inferior
10.1080/03007995.2020.1747999	results	6	NA	n_nonipd_ttt	NA
10.1080/03007995.2020.1747999	results	6	NA	n_ipd_ttt	NA
10.1080/03007995.2020.1747999	results	6	NA	ess_ttt	NA
10.1080/03007995.2020.1747999	results	6	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2020.1747999	results	6	NA	list_covariates_yn	Yes
10.1080/03007995.2020.1747999	results	6	NA	n_covariates	10
10.1080/03007995.2020.1747999	results	6	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	6	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	6	NA	unadjusted_effect	NA
10.1080/03007995.2020.1747999	results	6	NA	unadjusted_pval_char	NA
10.1080/03007995.2020.1747999	results	6	NA	adjusted_effect	0.82
10.1080/03007995.2020.1747999	results	6	NA	adjusted_pval_char	[0.42;1.63]
10.1080/03007995.2020.1747999	results	6	NA	geographical region	NA
10.1080/03007995.2020.1747999	results	6	NA	n_ipd_total	455
10.1080/03007995.2020.1747999	results	6	NA	ess_total	140
10.1080/03007995.2020.1747999	results	6	NA	n_nonipd_total	718
10.1080/03007995.2020.1747999	results	6	NA	n_nonipd_anchor	NA
10.1080/03007995.2020.1747999	results	6	NA	n_ipd_anchor	NA
10.1080/03007995.2020.1747999	results	6	NA	ess_anchor	NA
10.1080/03007995.2020.1747999	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2020.1747999	results	6	NA	effect_cutoff	1
10.1080/03007995.2020.1747999	results	6	NA	adjusted_lb_ci	0.42
10.1080/03007995.2020.1747999	results	6	NA	adjusted_ub_ci	1.63
10.1080/03007995.2020.1747999	results	6	NA	adjusted_significant	FALSE
10.1080/03007995.2020.1747999	results	7	NA	contrast	HR
10.1080/03007995.2020.1747999	results	7	NA	direction_benefit	inferior
10.1080/03007995.2020.1747999	results	7	NA	n_nonipd_ttt	NA
10.1080/03007995.2020.1747999	results	7	NA	n_ipd_ttt	NA
10.1080/03007995.2020.1747999	results	7	NA	ess_ttt	NA
10.1080/03007995.2020.1747999	results	7	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2020.1747999	results	7	NA	list_covariates_yn	Yes
10.1080/03007995.2020.1747999	results	7	NA	n_covariates	10
10.1080/03007995.2020.1747999	results	7	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	7	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	7	NA	unadjusted_effect	NA
10.1080/03007995.2020.1747999	results	7	NA	unadjusted_pval_char	NA
10.1080/03007995.2020.1747999	results	7	NA	adjusted_effect	0.42
10.1080/03007995.2020.1747999	results	7	NA	adjusted_pval_char	[0.20;0.88]
10.1080/03007995.2020.1747999	results	7	NA	geographical region	NA
10.1080/03007995.2020.1747999	results	7	NA	n_ipd_total	563
10.1080/03007995.2020.1747999	results	7	NA	ess_total	113
10.1080/03007995.2020.1747999	results	7	NA	n_nonipd_total	436
10.1080/03007995.2020.1747999	results	7	NA	n_nonipd_anchor	NA
10.1080/03007995.2020.1747999	results	7	NA	n_ipd_anchor	NA
10.1080/03007995.2020.1747999	results	7	NA	ess_anchor	NA
10.1080/03007995.2020.1747999	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2020.1747999	results	7	NA	effect_cutoff	1
10.1080/03007995.2020.1747999	results	7	NA	adjusted_lb_ci	0.2
10.1080/03007995.2020.1747999	results	7	NA	adjusted_ub_ci	0.88
10.1080/03007995.2020.1747999	results	7	NA	adjusted_significant	TRUE
10.1080/03007995.2020.1747999	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2020.1747999	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2020.1747999	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01665144
10.1080/03007995.2020.1747999	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2020.1747999	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2020.1747999	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2020.1747999	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2020.1747999	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2020.1747999	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01416181
10.1080/03007995.2020.1747999	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2020.1747999	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2020.1747999	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2020.1747999	study_information	NA	3	Patient-level data used	No
10.1080/03007995.2020.1747999	study_information	NA	3	Clinical Trial	Yes
10.1080/03007995.2020.1747999	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	nordic spms study
10.1080/03007995.2020.1747999	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2020.1747999	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2020.1747999	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2020.1747999	study_information	NA	4	Patient-level data used	No
10.1080/03007995.2020.1747999	study_information	NA	4	Clinical Trial	Yes
10.1080/03007995.2020.1747999	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	panitch et al. (2004) (north american study)
10.1080/03007995.2020.1747999	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2020.1747999	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2020.1747999	study_information	NA	5	Patient-level data used	No
10.1080/03007995.2020.1747999	study_information	NA	5	Clinical Trial	Yes
10.1080/03007995.2020.1747999	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	cohen et al. (2002) (impact)
10.1080/03007995.2020.1747999	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2020.1747999	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2020.1747999	study_information	NA	6	Patient-level data used	No
10.1080/03007995.2020.1747999	study_information	NA	6	Clinical Trial	Yes
10.1080/03007995.2020.1747999	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	spectrims study group (2001) li et al. (2001)
10.1080/03007995.2020.1747999	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2020.1747999	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2020.1747999	study_information	NA	7	Patient-level data used	No
10.1080/03007995.2020.1747999	study_information	NA	7	Clinical Trial	Yes
10.1080/03007995.2020.1747999	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	european study group (1998) kappos et al. (2001)
10.1080/03007995.2020.1747999	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2020.1747999	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2021.1896489	general_information	NA	NA	Medical Condition of Interest Name	chronic phase chronic myeloid leukemia
10.1080/03007995.2021.1896489	general_information	NA	NA	Countries of first author affiliations	the netherlands
10.1080/03007995.2021.1896489	general_information	NA	NA	Countries of last author affiliations	the netherlands
10.1080/03007995.2021.1896489	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2021.1896489	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2021.1896489	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2021.1896489	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2021.1896489	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/03007995.2021.1896489	methodology	1	NA	primary_outcome_name	major molecular response at 24 months
10.1080/03007995.2021.1896489	methodology	1	NA	outcome_short_name	Major Molecular Response
10.1080/03007995.2021.1896489	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1080/03007995.2021.1896489	methodology	1	NA	Treatment name 1	bosutinib
10.1080/03007995.2021.1896489	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2021.1896489	methodology	1	NA	Treatment name 2	nilotinib
10.1080/03007995.2021.1896489	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2021.1896489	methodology	1	NA	paitc_type	MAIC
10.1080/03007995.2021.1896489	methodology	1	NA	anchored_yn	No
10.1080/03007995.2021.1896489	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2021.1896489	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1896489	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1080/03007995.2021.1896489	methodology	1	NA	prognostic_factors_yn	Yes
10.1080/03007995.2021.1896489	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2021.1896489	methodology	1	NA	weights_model_yn	No
10.1080/03007995.2021.1896489	methodology	1	NA	scale_choice_yn	Yes
10.1080/03007995.2021.1896489	methodology	2	NA	primary_outcome_name	major molecular response by 24 months
10.1080/03007995.2021.1896489	methodology	2	NA	outcome_short_name	Major Molecular Response
10.1080/03007995.2021.1896489	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1080/03007995.2021.1896489	methodology	2	NA	Treatment name 1	bosutinib
10.1080/03007995.2021.1896489	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2021.1896489	methodology	2	NA	Treatment name 2	dasatinib
10.1080/03007995.2021.1896489	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1080/03007995.2021.1896489	methodology	2	NA	paitc_type	MAIC
10.1080/03007995.2021.1896489	methodology	2	NA	anchored_yn	No
10.1080/03007995.2021.1896489	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2021.1896489	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1896489	methodology	2	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1080/03007995.2021.1896489	methodology	2	NA	prognostic_factors_yn	Yes
10.1080/03007995.2021.1896489	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2021.1896489	methodology	2	NA	weights_model_yn	No
10.1080/03007995.2021.1896489	methodology	2	NA	scale_choice_yn	Yes
10.1080/03007995.2021.1896489	results	1	NA	contrast	OR
10.1080/03007995.2021.1896489	results	1	NA	direction_benefit	superior
10.1080/03007995.2021.1896489	results	1	NA	n_nonipd_ttt	282
10.1080/03007995.2021.1896489	results	1	NA	n_ipd_ttt	248
10.1080/03007995.2021.1896489	results	1	NA	ess_ttt	190
10.1080/03007995.2021.1896489	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2021.1896489	results	1	NA	list_covariates_yn	Yes
10.1080/03007995.2021.1896489	results	1	NA	n_covariates	3
10.1080/03007995.2021.1896489	results	1	NA	list_covariates	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1080/03007995.2021.1896489	results	1	NA	effect_direction	Denominator if ratio, or rightside if difference
10.1080/03007995.2021.1896489	results	1	NA	unadjusted_effect	NA
10.1080/03007995.2021.1896489	results	1	NA	unadjusted_pval_char	NA
10.1080/03007995.2021.1896489	results	1	NA	adjusted_effect	1.01
10.1080/03007995.2021.1896489	results	1	NA	adjusted_pval_char	[0.70;1.45]
10.1080/03007995.2021.1896489	results	1	NA	geographical region	NA
10.1080/03007995.2021.1896489	results	1	NA	n_ipd_total	NA
10.1080/03007995.2021.1896489	results	1	NA	ess_total	NA
10.1080/03007995.2021.1896489	results	1	NA	n_nonipd_total	NA
10.1080/03007995.2021.1896489	results	1	NA	n_nonipd_anchor	NA
10.1080/03007995.2021.1896489	results	1	NA	n_ipd_anchor	NA
10.1080/03007995.2021.1896489	results	1	NA	ess_anchor	NA
10.1080/03007995.2021.1896489	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2021.1896489	results	1	NA	effect_cutoff	1
10.1080/03007995.2021.1896489	results	1	NA	adjusted_lb_ci	0.7
10.1080/03007995.2021.1896489	results	1	NA	adjusted_ub_ci	1.45
10.1080/03007995.2021.1896489	results	1	NA	adjusted_significant	FALSE
10.1080/03007995.2021.1896489	results	2	NA	contrast	OR
10.1080/03007995.2021.1896489	results	2	NA	direction_benefit	superior
10.1080/03007995.2021.1896489	results	2	NA	n_nonipd_ttt	259
10.1080/03007995.2021.1896489	results	2	NA	n_ipd_ttt	244
10.1080/03007995.2021.1896489	results	2	NA	ess_ttt	118
10.1080/03007995.2021.1896489	results	2	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2021.1896489	results	2	NA	list_covariates_yn	Yes
10.1080/03007995.2021.1896489	results	2	NA	n_covariates	5
10.1080/03007995.2021.1896489	results	2	NA	list_covariates	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1080/03007995.2021.1896489	results	2	NA	effect_direction	Denominator if ratio, or rightside if difference
10.1080/03007995.2021.1896489	results	2	NA	unadjusted_effect	NA
10.1080/03007995.2021.1896489	results	2	NA	unadjusted_pval_char	NA
10.1080/03007995.2021.1896489	results	2	NA	adjusted_effect	0.81
10.1080/03007995.2021.1896489	results	2	NA	adjusted_pval_char	[0.54;1.22]
10.1080/03007995.2021.1896489	results	2	NA	geographical region	NA
10.1080/03007995.2021.1896489	results	2	NA	n_ipd_total	NA
10.1080/03007995.2021.1896489	results	2	NA	ess_total	NA
10.1080/03007995.2021.1896489	results	2	NA	n_nonipd_total	NA
10.1080/03007995.2021.1896489	results	2	NA	n_nonipd_anchor	NA
10.1080/03007995.2021.1896489	results	2	NA	n_ipd_anchor	NA
10.1080/03007995.2021.1896489	results	2	NA	ess_anchor	NA
10.1080/03007995.2021.1896489	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2021.1896489	results	2	NA	effect_cutoff	1
10.1080/03007995.2021.1896489	results	2	NA	adjusted_lb_ci	0.54
10.1080/03007995.2021.1896489	results	2	NA	adjusted_ub_ci	1.22
10.1080/03007995.2021.1896489	results	2	NA	adjusted_significant	FALSE
10.1080/03007995.2021.1896489	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2021.1896489	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2021.1896489	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02130557
10.1080/03007995.2021.1896489	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1896489	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2021.1896489	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2021.1896489	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2021.1896489	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2021.1896489	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00471497
10.1080/03007995.2021.1896489	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1896489	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2021.1896489	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2021.1896489	study_information	NA	3	Patient-level data used	No
10.1080/03007995.2021.1896489	study_information	NA	3	Clinical Trial	Yes
10.1080/03007995.2021.1896489	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00481247
10.1080/03007995.2021.1896489	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1896489	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2021.1896489	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2021.1947216	general_information	NA	NA	Medical Condition of Interest Name	spinal muscular atrophy type 1
10.1080/03007995.2021.1947216	general_information	NA	NA	Countries of first author affiliations	switzerland
10.1080/03007995.2021.1947216	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/03007995.2021.1947216	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2021.1947216	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2021.1947216	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2021.1947216	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2021.1947216	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/03007995.2021.1947216	methodology	1	NA	primary_outcome_name	event-free survival
10.1080/03007995.2021.1947216	methodology	1	NA	outcome_short_name	Event-free Survival
10.1080/03007995.2021.1947216	methodology	1	NA	primary_outcome_type	Time-to-event
10.1080/03007995.2021.1947216	methodology	1	NA	Treatment name 1	onasemnogene abeparvovec
10.1080/03007995.2021.1947216	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1080/03007995.2021.1947216	methodology	1	NA	Treatment name 2	nusinersen
10.1080/03007995.2021.1947216	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.1080/03007995.2021.1947216	methodology	1	NA	paitc_type	MAIC
10.1080/03007995.2021.1947216	methodology	1	NA	anchored_yn	No
10.1080/03007995.2021.1947216	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/03007995.2021.1947216	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1947216	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2021.1947216	methodology	1	NA	prognostic_factors_yn	Yes
10.1080/03007995.2021.1947216	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2021.1947216	methodology	1	NA	weights_model_yn	Yes
10.1080/03007995.2021.1947216	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2021.1947216	results	1	NA	contrast	HR
10.1080/03007995.2021.1947216	results	1	NA	direction_benefit	inferior
10.1080/03007995.2021.1947216	results	1	NA	n_nonipd_ttt	81
10.1080/03007995.2021.1947216	results	1	NA	n_ipd_ttt	34
10.1080/03007995.2021.1947216	results	1	NA	ess_ttt	24.6
10.1080/03007995.2021.1947216	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2021.1947216	results	1	NA	list_covariates_yn	Yes
10.1080/03007995.2021.1947216	results	1	NA	n_covariates	2
10.1080/03007995.2021.1947216	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1080/03007995.2021.1947216	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2021.1947216	results	1	NA	unadjusted_effect	NA
10.1080/03007995.2021.1947216	results	1	NA	unadjusted_pval_char	NA
10.1080/03007995.2021.1947216	results	1	NA	adjusted_effect	0.19
10.1080/03007995.2021.1947216	results	1	NA	adjusted_pval_char	[0.07;0.54]
10.1080/03007995.2021.1947216	results	1	NA	geographical region	NA
10.1080/03007995.2021.1947216	results	1	NA	n_ipd_total	NA
10.1080/03007995.2021.1947216	results	1	NA	ess_total	NA
10.1080/03007995.2021.1947216	results	1	NA	n_nonipd_total	NA
10.1080/03007995.2021.1947216	results	1	NA	n_nonipd_anchor	NA
10.1080/03007995.2021.1947216	results	1	NA	n_ipd_anchor	NA
10.1080/03007995.2021.1947216	results	1	NA	ess_anchor	NA
10.1080/03007995.2021.1947216	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2021.1947216	results	1	NA	effect_cutoff	1
10.1080/03007995.2021.1947216	results	1	NA	adjusted_lb_ci	0.07
10.1080/03007995.2021.1947216	results	1	NA	adjusted_ub_ci	0.54
10.1080/03007995.2021.1947216	results	1	NA	adjusted_significant	TRUE
10.1080/03007995.2021.1947216	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2021.1947216	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2021.1947216	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02122952
10.1080/03007995.2021.1947216	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/03007995.2021.1947216	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.1080/03007995.2021.1947216	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2021.1947216	study_information	NA	2	Patient-level data used	Yes
10.1080/03007995.2021.1947216	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2021.1947216	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03306277
10.1080/03007995.2021.1947216	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/03007995.2021.1947216	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2021.1947216	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2021.1947216	study_information	NA	3	Patient-level data used	No
10.1080/03007995.2021.1947216	study_information	NA	3	Clinical Trial	Yes
10.1080/03007995.2021.1947216	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02594124
10.1080/03007995.2021.1947216	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1947216	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2021.1947216	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2021.1953456	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory multiple myeloma
10.1080/03007995.2021.1953456	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/03007995.2021.1953456	general_information	NA	NA	Countries of last author affiliations	canada
10.1080/03007995.2021.1953456	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2021.1953456	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2021.1953456	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2021.1953456	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2021.1953456	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/03007995.2021.1953456	methodology	1	NA	primary_outcome_name	overall response rate
10.1080/03007995.2021.1953456	methodology	1	NA	outcome_short_name	Overall Response Rate
10.1080/03007995.2021.1953456	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1080/03007995.2021.1953456	methodology	1	NA	Treatment name 1	ciltacabtagene autoleucel
10.1080/03007995.2021.1953456	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2021.1953456	methodology	1	NA	Treatment name 2	idecabtagene vicleucel
10.1080/03007995.2021.1953456	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2021.1953456	methodology	1	NA	paitc_type	MAIC
10.1080/03007995.2021.1953456	methodology	1	NA	anchored_yn	No
10.1080/03007995.2021.1953456	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2021.1953456	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1953456	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2021.1953456	methodology	1	NA	prognostic_factors_yn	Yes
10.1080/03007995.2021.1953456	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2021.1953456	methodology	1	NA	weights_model_yn	No
10.1080/03007995.2021.1953456	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2021.1953456	results	1	NA	contrast	OR
10.1080/03007995.2021.1953456	results	1	NA	direction_benefit	superior
10.1080/03007995.2021.1953456	results	1	NA	n_nonipd_ttt	124
10.1080/03007995.2021.1953456	results	1	NA	n_ipd_ttt	97
10.1080/03007995.2021.1953456	results	1	NA	ess_ttt	52
10.1080/03007995.2021.1953456	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1080/03007995.2021.1953456	results	1	NA	list_covariates_yn	Yes
10.1080/03007995.2021.1953456	results	1	NA	n_covariates	4
10.1080/03007995.2021.1953456	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1080/03007995.2021.1953456	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2021.1953456	results	1	NA	unadjusted_effect	16.52
10.1080/03007995.2021.1953456	results	1	NA	unadjusted_pval_char	0.0002
10.1080/03007995.2021.1953456	results	1	NA	adjusted_effect	94.93
10.1080/03007995.2021.1953456	results	1	NA	adjusted_pval_char	<0.0001
10.1080/03007995.2021.1953456	results	1	NA	geographical region	NA
10.1080/03007995.2021.1953456	results	1	NA	n_ipd_total	NA
10.1080/03007995.2021.1953456	results	1	NA	ess_total	NA
10.1080/03007995.2021.1953456	results	1	NA	n_nonipd_total	NA
10.1080/03007995.2021.1953456	results	1	NA	n_nonipd_anchor	NA
10.1080/03007995.2021.1953456	results	1	NA	n_ipd_anchor	NA
10.1080/03007995.2021.1953456	results	1	NA	ess_anchor	NA
10.1080/03007995.2021.1953456	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2021.1953456	results	1	NA	effect_cutoff	1
10.1080/03007995.2021.1953456	results	1	NA	unadjusted_pval	0.0002
10.1080/03007995.2021.1953456	results	1	NA	unadjusted_num_pval	2e-04
10.1080/03007995.2021.1953456	results	1	NA	unadjusted_significant	TRUE
10.1080/03007995.2021.1953456	results	1	NA	adjusted_pval	<0.0001
10.1080/03007995.2021.1953456	results	1	NA	adjusted_significant	TRUE
10.1080/03007995.2021.1953456	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2021.1953456	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2021.1953456	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03548207
10.1080/03007995.2021.1953456	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1953456	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.1080/03007995.2021.1953456	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2021.1953456	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2021.1953456	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2021.1953456	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03361748
10.1080/03007995.2021.1953456	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1953456	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1080/03007995.2021.1953456	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2021.1971182	general_information	NA	NA	Medical Condition of Interest Name	paroxysmal nocturnal hemoglobinuria
10.1080/03007995.2021.1971182	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/03007995.2021.1971182	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/03007995.2021.1971182	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2021.1971182	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2021.1971182	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2021.1971182	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2021.1971182	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/03007995.2021.1971182	methodology	1	NA	primary_outcome_name	proportion of patients with transfusion avoidance
10.1080/03007995.2021.1971182	methodology	1	NA	outcome_short_name	Transfusion avoidance
10.1080/03007995.2021.1971182	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1080/03007995.2021.1971182	methodology	1	NA	Treatment name 1	pegcetacoplan
10.1080/03007995.2021.1971182	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2021.1971182	methodology	1	NA	Treatment name 2	ravulizumab
10.1080/03007995.2021.1971182	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2021.1971182	methodology	1	NA	paitc_type	MAIC
10.1080/03007995.2021.1971182	methodology	1	NA	anchored_yn	Yes
10.1080/03007995.2021.1971182	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2021.1971182	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1971182	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2021.1971182	methodology	1	NA	prognostic_factors_yn	No
10.1080/03007995.2021.1971182	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2021.1971182	methodology	1	NA	weights_model_yn	No
10.1080/03007995.2021.1971182	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2021.1971182	results	1	NA	contrast	Proportions difference
10.1080/03007995.2021.1971182	results	1	NA	direction_benefit	superior
10.1080/03007995.2021.1971182	results	1	NA	n_nonipd_ttt	97
10.1080/03007995.2021.1971182	results	1	NA	n_ipd_ttt	36
10.1080/03007995.2021.1971182	results	1	NA	ess_ttt	24
10.1080/03007995.2021.1971182	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2021.1971182	results	1	NA	list_covariates_yn	Yes
10.1080/03007995.2021.1971182	results	1	NA	n_covariates	5
10.1080/03007995.2021.1971182	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1080/03007995.2021.1971182	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2021.1971182	results	1	NA	unadjusted_effect	NA
10.1080/03007995.2021.1971182	results	1	NA	unadjusted_pval_char	NA
10.1080/03007995.2021.1971182	results	1	NA	adjusted_effect	0.714
10.1080/03007995.2021.1971182	results	1	NA	adjusted_pval_char	<0.0001
10.1080/03007995.2021.1971182	results	1	NA	geographical region	NA
10.1080/03007995.2021.1971182	results	1	NA	n_ipd_total	NA
10.1080/03007995.2021.1971182	results	1	NA	ess_total	NA
10.1080/03007995.2021.1971182	results	1	NA	n_nonipd_total	NA
10.1080/03007995.2021.1971182	results	1	NA	n_nonipd_anchor	98
10.1080/03007995.2021.1971182	results	1	NA	n_ipd_anchor	32
10.1080/03007995.2021.1971182	results	1	NA	ess_anchor	12
10.1080/03007995.2021.1971182	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2021.1971182	results	1	NA	effect_cutoff	0
10.1080/03007995.2021.1971182	results	1	NA	adjusted_pval	<0.0001
10.1080/03007995.2021.1971182	results	1	NA	adjusted_significant	TRUE
10.1080/03007995.2021.1971182	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2021.1971182	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2021.1971182	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03500549
10.1080/03007995.2021.1971182	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1971182	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2021.1971182	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2021.1971182	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2021.1971182	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2021.1971182	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03056040
10.1080/03007995.2021.1971182	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1971182	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2021.1971182	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2022.2030112	general_information	NA	NA	Medical Condition of Interest Name	uncontrolled hypertension
10.1080/03007995.2022.2030112	general_information	NA	NA	Countries of first author affiliations	germany
10.1080/03007995.2022.2030112	general_information	NA	NA	Countries of last author affiliations	germany
10.1080/03007995.2022.2030112	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry
10.1080/03007995.2022.2030112	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2022.2030112	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2022.2030112	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2022.2030112	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/03007995.2022.2030112	methodology	1	NA	primary_outcome_name	change in systolic blood pressures from baseline to following 8 weeks of treatment
10.1080/03007995.2022.2030112	methodology	1	NA	outcome_short_name	Systolic blood pressure change
10.1080/03007995.2022.2030112	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1080/03007995.2022.2030112	methodology	1	NA	Treatment name 1	amlodipine 5 mg + bisoprolol 5 mg
10.1080/03007995.2022.2030112	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2022.2030112	methodology	1	NA	Treatment name 2	amlodipine 10mg,
10.1080/03007995.2022.2030112	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2022.2030112	methodology	1	NA	paitc_type	STC
10.1080/03007995.2022.2030112	methodology	1	NA	anchored_yn	Yes
10.1080/03007995.2022.2030112	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2022.2030112	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2022.2030112	methodology	1	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2022.2030112	methodology	1	NA	prognostic_factors_yn	Yes
10.1080/03007995.2022.2030112	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1080/03007995.2022.2030112	methodology	1	NA	weights_model_yn	No
10.1080/03007995.2022.2030112	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2022.2030112	results	1	NA	contrast	Means difference
10.1080/03007995.2022.2030112	results	1	NA	direction_benefit	inferior
10.1080/03007995.2022.2030112	results	1	NA	n_nonipd_ttt	261
10.1080/03007995.2022.2030112	results	1	NA	n_ipd_ttt	178
10.1080/03007995.2022.2030112	results	1	NA	ess_ttt	178
10.1080/03007995.2022.2030112	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/03007995.2022.2030112	results	1	NA	list_covariates_yn	Yes
10.1080/03007995.2022.2030112	results	1	NA	n_covariates	7
10.1080/03007995.2022.2030112	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)
10.1080/03007995.2022.2030112	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2022.2030112	results	1	NA	unadjusted_effect	-0.3
10.1080/03007995.2022.2030112	results	1	NA	unadjusted_pval_char	NA
10.1080/03007995.2022.2030112	results	1	NA	adjusted_effect	-1.6
10.1080/03007995.2022.2030112	results	1	NA	adjusted_pval_char	[-5.3;2.2]
10.1080/03007995.2022.2030112	results	1	NA	geographical region	No
10.1080/03007995.2022.2030112	results	1	NA	n_ipd_total	NA
10.1080/03007995.2022.2030112	results	1	NA	ess_total	NA
10.1080/03007995.2022.2030112	results	1	NA	n_nonipd_total	NA
10.1080/03007995.2022.2030112	results	1	NA	n_nonipd_anchor	255
10.1080/03007995.2022.2030112	results	1	NA	n_ipd_anchor	179
10.1080/03007995.2022.2030112	results	1	NA	ess_anchor	179
10.1080/03007995.2022.2030112	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/03007995.2022.2030112	results	1	NA	effect_cutoff	0
10.1080/03007995.2022.2030112	results	1	NA	adjusted_lb_ci	-5.3
10.1080/03007995.2022.2030112	results	1	NA	adjusted_ub_ci	2.2
10.1080/03007995.2022.2030112	results	1	NA	adjusted_significant	FALSE
10.1080/03007995.2022.2030112	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2022.2030112	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2022.2030112	study_information	NA	1	EudraCT (only for clinical trials registered on clinicaltrialsregister.eu	2019-000751-13
10.1080/03007995.2022.2030112	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	poland
10.1080/03007995.2022.2030112	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2022.2030112	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2022.2030112	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2022.2030112	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2022.2030112	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00558428
10.1080/03007995.2022.2030112	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2022.2030112	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2022.2030112	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	general_information	NA	NA	Medical Condition of Interest Name	moderate-to-severe plaque psoriasis
10.1080/09546634.2020.1747592	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/09546634.2020.1747592	general_information	NA	NA	Countries of last author affiliations	germany
10.1080/09546634.2020.1747592	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1080/09546634.2020.1747592	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1080/09546634.2020.1747592	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/09546634.2020.1747592	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/09546634.2020.1747592	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/09546634.2020.1747592	methodology	1	NA	primary_outcome_name	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	1	NA	outcome_short_name	PASI 75 Responders Rate
10.1080/09546634.2020.1747592	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	1	NA	Treatment name 1	ixekizumab
10.1080/09546634.2020.1747592	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3
10.1080/09546634.2020.1747592	methodology	1	NA	Treatment name 2	guselkumab
10.1080/09546634.2020.1747592	methodology	1	NA	Study 'number(s)' for treatment 2	5
10.1080/09546634.2020.1747592	methodology	1	NA	paitc_type	MAIC
10.1080/09546634.2020.1747592	methodology	1	NA	anchored_yn	Yes
10.1080/09546634.2020.1747592	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	1	NA	prognostic_factors_yn	Yes
10.1080/09546634.2020.1747592	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1080/09546634.2020.1747592	methodology	1	NA	weights_model_yn	No
10.1080/09546634.2020.1747592	methodology	1	NA	scale_choice_yn	No
10.1080/09546634.2020.1747592	methodology	2	NA	primary_outcome_name	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	2	NA	outcome_short_name	PASI 75 Responders Rate
10.1080/09546634.2020.1747592	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	2	NA	Treatment name 1	ixekizumab
10.1080/09546634.2020.1747592	methodology	2	NA	Study 'number(s)' for treatment 1	1;2;3
10.1080/09546634.2020.1747592	methodology	2	NA	Treatment name 2	tildrakizumab 100mg
10.1080/09546634.2020.1747592	methodology	2	NA	Study 'number(s)' for treatment 2	6;7
10.1080/09546634.2020.1747592	methodology	2	NA	paitc_type	MAIC
10.1080/09546634.2020.1747592	methodology	2	NA	anchored_yn	Yes
10.1080/09546634.2020.1747592	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	2	NA	prognostic_factors_yn	Yes
10.1080/09546634.2020.1747592	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1080/09546634.2020.1747592	methodology	2	NA	weights_model_yn	No
10.1080/09546634.2020.1747592	methodology	2	NA	scale_choice_yn	No
10.1080/09546634.2020.1747592	methodology	3	NA	primary_outcome_name	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	3	NA	outcome_short_name	PASI 75 Responders Rate
10.1080/09546634.2020.1747592	methodology	3	NA	primary_outcome_type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	3	NA	Treatment name 1	ixekizumab
10.1080/09546634.2020.1747592	methodology	3	NA	Study 'number(s)' for treatment 1	1;2;3
10.1080/09546634.2020.1747592	methodology	3	NA	Treatment name 2	tildrakizumab 200mg
10.1080/09546634.2020.1747592	methodology	3	NA	Study 'number(s)' for treatment 2	6;7
10.1080/09546634.2020.1747592	methodology	3	NA	paitc_type	MAIC
10.1080/09546634.2020.1747592	methodology	3	NA	anchored_yn	Yes
10.1080/09546634.2020.1747592	methodology	3	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	3	NA	prognostic_factors_yn	Yes
10.1080/09546634.2020.1747592	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.1080/09546634.2020.1747592	methodology	3	NA	weights_model_yn	No
10.1080/09546634.2020.1747592	methodology	3	NA	scale_choice_yn	No
10.1080/09546634.2020.1747592	methodology	4	NA	primary_outcome_name	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	4	NA	outcome_short_name	PASI 75 Responders Rate
10.1080/09546634.2020.1747592	methodology	4	NA	primary_outcome_type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	4	NA	Treatment name 1	ixekizumab
10.1080/09546634.2020.1747592	methodology	4	NA	Study 'number(s)' for treatment 1	2;3
10.1080/09546634.2020.1747592	methodology	4	NA	Treatment name 2	tildrakizumab 100mg
10.1080/09546634.2020.1747592	methodology	4	NA	Study 'number(s)' for treatment 2	6;7
10.1080/09546634.2020.1747592	methodology	4	NA	paitc_type	MAIC
10.1080/09546634.2020.1747592	methodology	4	NA	anchored_yn	Yes
10.1080/09546634.2020.1747592	methodology	4	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	4	NA	variables_justification	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	4	NA	prognostic_factors_yn	Yes
10.1080/09546634.2020.1747592	methodology	4	NA	ttt_effect_modifiers_yn	Yes
10.1080/09546634.2020.1747592	methodology	4	NA	weights_model_yn	No
10.1080/09546634.2020.1747592	methodology	4	NA	scale_choice_yn	No
10.1080/09546634.2020.1747592	methodology	5	NA	primary_outcome_name	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	5	NA	outcome_short_name	PASI 75 Responders Rate
10.1080/09546634.2020.1747592	methodology	5	NA	primary_outcome_type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	5	NA	Treatment name 1	ixekizumab
10.1080/09546634.2020.1747592	methodology	5	NA	Study 'number(s)' for treatment 1	2;3
10.1080/09546634.2020.1747592	methodology	5	NA	Treatment name 2	tildrakizumab 200mg
10.1080/09546634.2020.1747592	methodology	5	NA	Study 'number(s)' for treatment 2	6;7
10.1080/09546634.2020.1747592	methodology	5	NA	paitc_type	MAIC
10.1080/09546634.2020.1747592	methodology	5	NA	anchored_yn	Yes
10.1080/09546634.2020.1747592	methodology	5	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	5	NA	variables_justification	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	5	NA	prognostic_factors_yn	Yes
10.1080/09546634.2020.1747592	methodology	5	NA	ttt_effect_modifiers_yn	Yes
10.1080/09546634.2020.1747592	methodology	5	NA	weights_model_yn	No
10.1080/09546634.2020.1747592	methodology	5	NA	scale_choice_yn	No
10.1080/09546634.2020.1747592	methodology	6	NA	primary_outcome_name	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	6	NA	outcome_short_name	PASI 75 Responders Rate
10.1080/09546634.2020.1747592	methodology	6	NA	primary_outcome_type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	6	NA	Treatment name 1	ixekizumab
10.1080/09546634.2020.1747592	methodology	6	NA	Study 'number(s)' for treatment 1	1;2;3
10.1080/09546634.2020.1747592	methodology	6	NA	Treatment name 2	risankizumab
10.1080/09546634.2020.1747592	methodology	6	NA	Study 'number(s)' for treatment 2	8
10.1080/09546634.2020.1747592	methodology	6	NA	paitc_type	MAIC
10.1080/09546634.2020.1747592	methodology	6	NA	anchored_yn	Yes
10.1080/09546634.2020.1747592	methodology	6	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	6	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	6	NA	variables_justification	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	6	NA	prognostic_factors_yn	Yes
10.1080/09546634.2020.1747592	methodology	6	NA	ttt_effect_modifiers_yn	Yes
10.1080/09546634.2020.1747592	methodology	6	NA	weights_model_yn	No
10.1080/09546634.2020.1747592	methodology	6	NA	scale_choice_yn	No
10.1080/09546634.2020.1747592	methodology	7	NA	primary_outcome_name	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	7	NA	outcome_short_name	PASI 75 Responders Rate
10.1080/09546634.2020.1747592	methodology	7	NA	primary_outcome_type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	7	NA	Treatment name 1	ixekizumab
10.1080/09546634.2020.1747592	methodology	7	NA	Study 'number(s)' for treatment 1	4
10.1080/09546634.2020.1747592	methodology	7	NA	Treatment name 2	risankizumab
10.1080/09546634.2020.1747592	methodology	7	NA	Study 'number(s)' for treatment 2	8;9
10.1080/09546634.2020.1747592	methodology	7	NA	paitc_type	MAIC
10.1080/09546634.2020.1747592	methodology	7	NA	anchored_yn	Yes
10.1080/09546634.2020.1747592	methodology	7	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	7	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	7	NA	variables_justification	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	7	NA	prognostic_factors_yn	Yes
10.1080/09546634.2020.1747592	methodology	7	NA	ttt_effect_modifiers_yn	Yes
10.1080/09546634.2020.1747592	methodology	7	NA	weights_model_yn	No
10.1080/09546634.2020.1747592	methodology	7	NA	scale_choice_yn	No
10.1080/09546634.2020.1747592	results	1	NA	contrast	Risk difference
10.1080/09546634.2020.1747592	results	1	NA	direction_benefit	superior
10.1080/09546634.2020.1747592	results	1	NA	n_nonipd_ttt	NA
10.1080/09546634.2020.1747592	results	1	NA	n_ipd_ttt	NA
10.1080/09546634.2020.1747592	results	1	NA	ess_ttt	NA
10.1080/09546634.2020.1747592	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/09546634.2020.1747592	results	1	NA	list_covariates_yn	Yes
10.1080/09546634.2020.1747592	results	1	NA	n_covariates	8
10.1080/09546634.2020.1747592	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1080/09546634.2020.1747592	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	1	NA	unadjusted_effect	8.3
10.1080/09546634.2020.1747592	results	1	NA	unadjusted_pval_char	[2.4;14.2] p<0.01
10.1080/09546634.2020.1747592	results	1	NA	adjusted_effect	8
10.1080/09546634.2020.1747592	results	1	NA	adjusted_pval_char	[2.0;14.1] p<0.01
10.1080/09546634.2020.1747592	results	1	NA	geographical region	No
10.1080/09546634.2020.1747592	results	1	NA	n_ipd_total	1952
10.1080/09546634.2020.1747592	results	1	NA	ess_total	1717
10.1080/09546634.2020.1747592	results	1	NA	n_nonipd_total	503
10.1080/09546634.2020.1747592	results	1	NA	n_nonipd_anchor	NA
10.1080/09546634.2020.1747592	results	1	NA	n_ipd_anchor	NA
10.1080/09546634.2020.1747592	results	1	NA	ess_anchor	NA
10.1080/09546634.2020.1747592	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/09546634.2020.1747592	results	1	NA	effect_cutoff	0
10.1080/09546634.2020.1747592	results	1	NA	unadjusted_lb_ci	2.4
10.1080/09546634.2020.1747592	results	1	NA	unadjusted_ub_ci	14.2
10.1080/09546634.2020.1747592	results	1	NA	unadjusted_pval	<0.01
10.1080/09546634.2020.1747592	results	1	NA	unadjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	1	NA	adjusted_lb_ci	2
10.1080/09546634.2020.1747592	results	1	NA	adjusted_ub_ci	14.1
10.1080/09546634.2020.1747592	results	1	NA	adjusted_pval	<0.01
10.1080/09546634.2020.1747592	results	1	NA	adjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	2	NA	contrast	Risk difference
10.1080/09546634.2020.1747592	results	2	NA	direction_benefit	superior
10.1080/09546634.2020.1747592	results	2	NA	n_nonipd_ttt	NA
10.1080/09546634.2020.1747592	results	2	NA	n_ipd_ttt	NA
10.1080/09546634.2020.1747592	results	2	NA	ess_ttt	NA
10.1080/09546634.2020.1747592	results	2	NA	weights_evaluation_yn	Not mentioned
10.1080/09546634.2020.1747592	results	2	NA	list_covariates_yn	Yes
10.1080/09546634.2020.1747592	results	2	NA	n_covariates	5
10.1080/09546634.2020.1747592	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/09546634.2020.1747592	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	2	NA	unadjusted_effect	27.7
10.1080/09546634.2020.1747592	results	2	NA	unadjusted_pval_char	[22.5;32.8] p<0.001
10.1080/09546634.2020.1747592	results	2	NA	adjusted_effect	27
10.1080/09546634.2020.1747592	results	2	NA	adjusted_pval_char	[21.6;32.3] p<0.001
10.1080/09546634.2020.1747592	results	2	NA	geographical region	NA
10.1080/09546634.2020.1747592	results	2	NA	n_ipd_total	1952
10.1080/09546634.2020.1747592	results	2	NA	ess_total	1565
10.1080/09546634.2020.1747592	results	2	NA	n_nonipd_total	927
10.1080/09546634.2020.1747592	results	2	NA	n_nonipd_anchor	NA
10.1080/09546634.2020.1747592	results	2	NA	n_ipd_anchor	NA
10.1080/09546634.2020.1747592	results	2	NA	ess_anchor	NA
10.1080/09546634.2020.1747592	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/09546634.2020.1747592	results	2	NA	effect_cutoff	0
10.1080/09546634.2020.1747592	results	2	NA	unadjusted_lb_ci	22.5
10.1080/09546634.2020.1747592	results	2	NA	unadjusted_ub_ci	32.8
10.1080/09546634.2020.1747592	results	2	NA	unadjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	2	NA	unadjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	2	NA	adjusted_lb_ci	21.6
10.1080/09546634.2020.1747592	results	2	NA	adjusted_ub_ci	32.3
10.1080/09546634.2020.1747592	results	2	NA	adjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	2	NA	adjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	3	NA	contrast	Risk difference
10.1080/09546634.2020.1747592	results	3	NA	direction_benefit	superior
10.1080/09546634.2020.1747592	results	3	NA	n_nonipd_ttt	NA
10.1080/09546634.2020.1747592	results	3	NA	n_ipd_ttt	NA
10.1080/09546634.2020.1747592	results	3	NA	ess_ttt	NA
10.1080/09546634.2020.1747592	results	3	NA	weights_evaluation_yn	Not mentioned
10.1080/09546634.2020.1747592	results	3	NA	list_covariates_yn	Yes
10.1080/09546634.2020.1747592	results	3	NA	n_covariates	5
10.1080/09546634.2020.1747592	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/09546634.2020.1747592	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	3	NA	unadjusted_effect	26.4
10.1080/09546634.2020.1747592	results	3	NA	unadjusted_pval_char	[21.3;31.5] p<0.001
10.1080/09546634.2020.1747592	results	3	NA	adjusted_effect	25.7
10.1080/09546634.2020.1747592	results	3	NA	adjusted_pval_char	[20.4;31.0] p<0.001
10.1080/09546634.2020.1747592	results	3	NA	geographical region	NA
10.1080/09546634.2020.1747592	results	3	NA	n_ipd_total	1952
10.1080/09546634.2020.1747592	results	3	NA	ess_total	1588
10.1080/09546634.2020.1747592	results	3	NA	n_nonipd_total	927
10.1080/09546634.2020.1747592	results	3	NA	n_nonipd_anchor	NA
10.1080/09546634.2020.1747592	results	3	NA	n_ipd_anchor	NA
10.1080/09546634.2020.1747592	results	3	NA	ess_anchor	NA
10.1080/09546634.2020.1747592	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/09546634.2020.1747592	results	3	NA	effect_cutoff	0
10.1080/09546634.2020.1747592	results	3	NA	unadjusted_lb_ci	21.3
10.1080/09546634.2020.1747592	results	3	NA	unadjusted_ub_ci	31.5
10.1080/09546634.2020.1747592	results	3	NA	unadjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	3	NA	unadjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	3	NA	adjusted_lb_ci	20.4
10.1080/09546634.2020.1747592	results	3	NA	adjusted_ub_ci	31
10.1080/09546634.2020.1747592	results	3	NA	adjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	3	NA	adjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	4	NA	contrast	Risk difference
10.1080/09546634.2020.1747592	results	4	NA	direction_benefit	superior
10.1080/09546634.2020.1747592	results	4	NA	n_nonipd_ttt	NA
10.1080/09546634.2020.1747592	results	4	NA	n_ipd_ttt	NA
10.1080/09546634.2020.1747592	results	4	NA	ess_ttt	NA
10.1080/09546634.2020.1747592	results	4	NA	weights_evaluation_yn	Not mentioned
10.1080/09546634.2020.1747592	results	4	NA	list_covariates_yn	Yes
10.1080/09546634.2020.1747592	results	4	NA	n_covariates	5
10.1080/09546634.2020.1747592	results	4	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/09546634.2020.1747592	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	4	NA	unadjusted_effect	28.1
10.1080/09546634.2020.1747592	results	4	NA	unadjusted_pval_char	[19.2;37.0] p<0.001
10.1080/09546634.2020.1747592	results	4	NA	adjusted_effect	25.7
10.1080/09546634.2020.1747592	results	4	NA	adjusted_pval_char	[16.5;34.9] p<0.001
10.1080/09546634.2020.1747592	results	4	NA	geographical region	NA
10.1080/09546634.2020.1747592	results	4	NA	n_ipd_total	1470
10.1080/09546634.2020.1747592	results	4	NA	ess_total	1108
10.1080/09546634.2020.1747592	results	4	NA	n_nonipd_total	463
10.1080/09546634.2020.1747592	results	4	NA	n_nonipd_anchor	NA
10.1080/09546634.2020.1747592	results	4	NA	n_ipd_anchor	NA
10.1080/09546634.2020.1747592	results	4	NA	ess_anchor	NA
10.1080/09546634.2020.1747592	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/09546634.2020.1747592	results	4	NA	effect_cutoff	0
10.1080/09546634.2020.1747592	results	4	NA	unadjusted_lb_ci	19.2
10.1080/09546634.2020.1747592	results	4	NA	unadjusted_ub_ci	37
10.1080/09546634.2020.1747592	results	4	NA	unadjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	4	NA	unadjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	4	NA	adjusted_lb_ci	16.5
10.1080/09546634.2020.1747592	results	4	NA	adjusted_ub_ci	34.9
10.1080/09546634.2020.1747592	results	4	NA	adjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	4	NA	adjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	5	NA	contrast	Risk difference
10.1080/09546634.2020.1747592	results	5	NA	direction_benefit	superior
10.1080/09546634.2020.1747592	results	5	NA	n_nonipd_ttt	NA
10.1080/09546634.2020.1747592	results	5	NA	n_ipd_ttt	NA
10.1080/09546634.2020.1747592	results	5	NA	ess_ttt	NA
10.1080/09546634.2020.1747592	results	5	NA	weights_evaluation_yn	Not mentioned
10.1080/09546634.2020.1747592	results	5	NA	list_covariates_yn	Yes
10.1080/09546634.2020.1747592	results	5	NA	n_covariates	5
10.1080/09546634.2020.1747592	results	5	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/09546634.2020.1747592	results	5	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	5	NA	unadjusted_effect	24.1
10.1080/09546634.2020.1747592	results	5	NA	unadjusted_pval_char	[15.3;32.9] p<0.001
10.1080/09546634.2020.1747592	results	5	NA	adjusted_effect	21.7
10.1080/09546634.2020.1747592	results	5	NA	adjusted_pval_char	[12.7;30.7] p<0.001
10.1080/09546634.2020.1747592	results	5	NA	geographical region	NA
10.1080/09546634.2020.1747592	results	5	NA	n_ipd_total	1470
10.1080/09546634.2020.1747592	results	5	NA	ess_total	1163
10.1080/09546634.2020.1747592	results	5	NA	n_nonipd_total	470
10.1080/09546634.2020.1747592	results	5	NA	n_nonipd_anchor	NA
10.1080/09546634.2020.1747592	results	5	NA	n_ipd_anchor	NA
10.1080/09546634.2020.1747592	results	5	NA	ess_anchor	NA
10.1080/09546634.2020.1747592	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/09546634.2020.1747592	results	5	NA	effect_cutoff	0
10.1080/09546634.2020.1747592	results	5	NA	unadjusted_lb_ci	15.3
10.1080/09546634.2020.1747592	results	5	NA	unadjusted_ub_ci	32.9
10.1080/09546634.2020.1747592	results	5	NA	unadjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	5	NA	unadjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	5	NA	adjusted_lb_ci	12.7
10.1080/09546634.2020.1747592	results	5	NA	adjusted_ub_ci	30.7
10.1080/09546634.2020.1747592	results	5	NA	adjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	5	NA	adjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	6	NA	contrast	Risk difference
10.1080/09546634.2020.1747592	results	6	NA	direction_benefit	superior
10.1080/09546634.2020.1747592	results	6	NA	n_nonipd_ttt	NA
10.1080/09546634.2020.1747592	results	6	NA	n_ipd_ttt	NA
10.1080/09546634.2020.1747592	results	6	NA	ess_ttt	NA
10.1080/09546634.2020.1747592	results	6	NA	weights_evaluation_yn	Not mentioned
10.1080/09546634.2020.1747592	results	6	NA	list_covariates_yn	Yes
10.1080/09546634.2020.1747592	results	6	NA	n_covariates	8
10.1080/09546634.2020.1747592	results	6	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1080/09546634.2020.1747592	results	6	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	6	NA	unadjusted_effect	5.5
10.1080/09546634.2020.1747592	results	6	NA	unadjusted_pval_char	[0.2;10.8] p<0.05
10.1080/09546634.2020.1747592	results	6	NA	adjusted_effect	5.5
10.1080/09546634.2020.1747592	results	6	NA	adjusted_pval_char	[-0.1;11.0]
10.1080/09546634.2020.1747592	results	6	NA	geographical region	No
10.1080/09546634.2020.1747592	results	6	NA	n_ipd_total	1952
10.1080/09546634.2020.1747592	results	6	NA	ess_total	1398
10.1080/09546634.2020.1747592	results	6	NA	n_nonipd_total	798
10.1080/09546634.2020.1747592	results	6	NA	n_nonipd_anchor	NA
10.1080/09546634.2020.1747592	results	6	NA	n_ipd_anchor	NA
10.1080/09546634.2020.1747592	results	6	NA	ess_anchor	NA
10.1080/09546634.2020.1747592	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/09546634.2020.1747592	results	6	NA	effect_cutoff	0
10.1080/09546634.2020.1747592	results	6	NA	unadjusted_lb_ci	0.2
10.1080/09546634.2020.1747592	results	6	NA	unadjusted_ub_ci	10.8
10.1080/09546634.2020.1747592	results	6	NA	unadjusted_pval	<0.05
10.1080/09546634.2020.1747592	results	6	NA	unadjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	6	NA	adjusted_lb_ci	-0.1
10.1080/09546634.2020.1747592	results	6	NA	adjusted_ub_ci	11
10.1080/09546634.2020.1747592	results	6	NA	adjusted_significant	FALSE
10.1080/09546634.2020.1747592	results	7	NA	contrast	Risk difference
10.1080/09546634.2020.1747592	results	7	NA	direction_benefit	superior
10.1080/09546634.2020.1747592	results	7	NA	n_nonipd_ttt	NA
10.1080/09546634.2020.1747592	results	7	NA	n_ipd_ttt	NA
10.1080/09546634.2020.1747592	results	7	NA	ess_ttt	NA
10.1080/09546634.2020.1747592	results	7	NA	weights_evaluation_yn	Not mentioned
10.1080/09546634.2020.1747592	results	7	NA	list_covariates_yn	Yes
10.1080/09546634.2020.1747592	results	7	NA	n_covariates	8
10.1080/09546634.2020.1747592	results	7	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1080/09546634.2020.1747592	results	7	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	7	NA	unadjusted_effect	0.8
10.1080/09546634.2020.1747592	results	7	NA	unadjusted_pval_char	[-10.9;12.6]
10.1080/09546634.2020.1747592	results	7	NA	adjusted_effect	7.8
10.1080/09546634.2020.1747592	results	7	NA	adjusted_pval_char	[-6.7;22.3]
10.1080/09546634.2020.1747592	results	7	NA	geographical region	No
10.1080/09546634.2020.1747592	results	7	NA	n_ipd_total	256
10.1080/09546634.2020.1747592	results	7	NA	ess_total	116
10.1080/09546634.2020.1747592	results	7	NA	n_nonipd_total	797
10.1080/09546634.2020.1747592	results	7	NA	n_nonipd_anchor	NA
10.1080/09546634.2020.1747592	results	7	NA	n_ipd_anchor	NA
10.1080/09546634.2020.1747592	results	7	NA	ess_anchor	NA
10.1080/09546634.2020.1747592	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/09546634.2020.1747592	results	7	NA	effect_cutoff	0
10.1080/09546634.2020.1747592	results	7	NA	unadjusted_lb_ci	-10.9
10.1080/09546634.2020.1747592	results	7	NA	unadjusted_ub_ci	12.6
10.1080/09546634.2020.1747592	results	7	NA	unadjusted_significant	FALSE
10.1080/09546634.2020.1747592	results	7	NA	adjusted_lb_ci	-6.7
10.1080/09546634.2020.1747592	results	7	NA	adjusted_ub_ci	22.3
10.1080/09546634.2020.1747592	results	7	NA	adjusted_significant	FALSE
10.1080/09546634.2020.1747592	study_information	NA	1	Patient-level data used	Yes
10.1080/09546634.2020.1747592	study_information	NA	1	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01474512
10.1080/09546634.2020.1747592	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/09546634.2020.1747592	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	2	Patient-level data used	Yes
10.1080/09546634.2020.1747592	study_information	NA	2	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01597245
10.1080/09546634.2020.1747592	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/09546634.2020.1747592	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	3	Patient-level data used	Yes
10.1080/09546634.2020.1747592	study_information	NA	3	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01646177
10.1080/09546634.2020.1747592	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/09546634.2020.1747592	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	4	Patient-level data used	Yes
10.1080/09546634.2020.1747592	study_information	NA	4	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02561806
10.1080/09546634.2020.1747592	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/09546634.2020.1747592	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	5	Patient-level data used	No
10.1080/09546634.2020.1747592	study_information	NA	5	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02207244
10.1080/09546634.2020.1747592	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/09546634.2020.1747592	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	6	Patient-level data used	No
10.1080/09546634.2020.1747592	study_information	NA	6	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01722331
10.1080/09546634.2020.1747592	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	7	Patient-level data used	No
10.1080/09546634.2020.1747592	study_information	NA	7	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01729754
10.1080/09546634.2020.1747592	study_information	NA	7	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	8	Patient-level data used	No
10.1080/09546634.2020.1747592	study_information	NA	8	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02684370
10.1080/09546634.2020.1747592	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	9	Patient-level data used	No
10.1080/09546634.2020.1747592	study_information	NA	9	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02684357
10.1080/09546634.2020.1747592	study_information	NA	9	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2019.1675881	general_information	NA	NA	Medical Condition of Interest Name	transplant ineligible multiple myeloma
10.1080/10428194.2019.1675881	general_information	NA	NA	Countries of first author affiliations	spain
10.1080/10428194.2019.1675881	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/10428194.2019.1675881	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/10428194.2019.1675881	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/10428194.2019.1675881	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/10428194.2019.1675881	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/10428194.2019.1675881	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/10428194.2019.1675881	methodology	1	NA	primary_outcome_name	progression-free survival
10.1080/10428194.2019.1675881	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2019.1675881	methodology	1	NA	primary_outcome_type	Time-to-event
10.1080/10428194.2019.1675881	methodology	1	NA	Treatment name 1	vmp (bortezomib/melphalan/prednisone)
10.1080/10428194.2019.1675881	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2019.1675881	methodology	1	NA	Treatment name 2	modified vmp schedule
10.1080/10428194.2019.1675881	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1080/10428194.2019.1675881	methodology	1	NA	paitc_type	MAIC
10.1080/10428194.2019.1675881	methodology	1	NA	anchored_yn	No
10.1080/10428194.2019.1675881	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/10428194.2019.1675881	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2019.1675881	methodology	1	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/10428194.2019.1675881	methodology	1	NA	prognostic_factors_yn	Yes
10.1080/10428194.2019.1675881	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1080/10428194.2019.1675881	methodology	1	NA	weights_model_yn	No
10.1080/10428194.2019.1675881	methodology	1	NA	scale_choice_yn	No
10.1080/10428194.2019.1675881	results	1	NA	contrast	HR
10.1080/10428194.2019.1675881	results	1	NA	direction_benefit	inferior
10.1080/10428194.2019.1675881	results	1	NA	n_nonipd_ttt	547
10.1080/10428194.2019.1675881	results	1	NA	n_ipd_ttt	344
10.1080/10428194.2019.1675881	results	1	NA	ess_ttt	114
10.1080/10428194.2019.1675881	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1080/10428194.2019.1675881	results	1	NA	list_covariates_yn	Yes
10.1080/10428194.2019.1675881	results	1	NA	n_covariates	8
10.1080/10428194.2019.1675881	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2019.1675881	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2019.1675881	results	1	NA	unadjusted_effect	0.911
10.1080/10428194.2019.1675881	results	1	NA	unadjusted_pval_char	0.326
10.1080/10428194.2019.1675881	results	1	NA	adjusted_effect	0.991
10.1080/10428194.2019.1675881	results	1	NA	adjusted_pval_char	0.935
10.1080/10428194.2019.1675881	results	1	NA	geographical region	NA
10.1080/10428194.2019.1675881	results	1	NA	n_ipd_total	NA
10.1080/10428194.2019.1675881	results	1	NA	ess_total	NA
10.1080/10428194.2019.1675881	results	1	NA	n_nonipd_total	NA
10.1080/10428194.2019.1675881	results	1	NA	n_nonipd_anchor	NA
10.1080/10428194.2019.1675881	results	1	NA	n_ipd_anchor	NA
10.1080/10428194.2019.1675881	results	1	NA	ess_anchor	NA
10.1080/10428194.2019.1675881	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/10428194.2019.1675881	results	1	NA	effect_cutoff	1
10.1080/10428194.2019.1675881	results	1	NA	unadjusted_pval	0.326
10.1080/10428194.2019.1675881	results	1	NA	unadjusted_num_pval	0.326
10.1080/10428194.2019.1675881	results	1	NA	unadjusted_significant	FALSE
10.1080/10428194.2019.1675881	results	1	NA	adjusted_pval	0.935
10.1080/10428194.2019.1675881	results	1	NA	adjusted_num_pval	0.935
10.1080/10428194.2019.1675881	results	1	NA	adjusted_significant	FALSE
10.1080/10428194.2019.1675881	study_information	NA	1	Patient-level data used	Yes
10.1080/10428194.2019.1675881	study_information	NA	1	Clinical Trial	Yes
10.1080/10428194.2019.1675881	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00111319
10.1080/10428194.2019.1675881	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/10428194.2019.1675881	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2019.1675881	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2019.1675881	study_information	NA	2	Patient-level data used	No
10.1080/10428194.2019.1675881	study_information	NA	2	Clinical Trial	Yes
10.1080/10428194.2019.1675881	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02195479
10.1080/10428194.2019.1675881	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2019.1675881	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2019.1675881	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2019.1675881	study_information	NA	3	Patient-level data used	No
10.1080/10428194.2019.1675881	study_information	NA	3	Clinical Trial	Yes
10.1080/10428194.2019.1675881	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01063179
10.1080/10428194.2019.1675881	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.1080/10428194.2019.1675881	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2019.1675881	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2019.1682571	general_information	NA	NA	Medical Condition of Interest Name	multiple myeloma
10.1080/10428194.2019.1682571	general_information	NA	NA	Countries of first author affiliations	greece
10.1080/10428194.2019.1682571	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/10428194.2019.1682571	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/10428194.2019.1682571	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/10428194.2019.1682571	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/10428194.2019.1682571	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/10428194.2019.1682571	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/10428194.2019.1682571	methodology	1	NA	primary_outcome_name	overall survival
10.1080/10428194.2019.1682571	methodology	1	NA	outcome_short_name	Overall Survival
10.1080/10428194.2019.1682571	methodology	1	NA	primary_outcome_type	Time-to-event
10.1080/10428194.2019.1682571	methodology	1	NA	Treatment name 1	daratumumabbortezomibmelphalanprednisone
10.1080/10428194.2019.1682571	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2019.1682571	methodology	1	NA	Treatment name 2	lenalidomidedexamethasone continuous
10.1080/10428194.2019.1682571	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2019.1682571	methodology	1	NA	paitc_type	MAIC
10.1080/10428194.2019.1682571	methodology	1	NA	anchored_yn	No
10.1080/10428194.2019.1682571	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2019.1682571	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2019.1682571	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1080/10428194.2019.1682571	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2019.1682571	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2019.1682571	methodology	1	NA	weights_model_yn	No
10.1080/10428194.2019.1682571	methodology	1	NA	scale_choice_yn	No
10.1080/10428194.2019.1682571	methodology	2	NA	primary_outcome_name	overall survival
10.1080/10428194.2019.1682571	methodology	2	NA	outcome_short_name	Overall Survival
10.1080/10428194.2019.1682571	methodology	2	NA	primary_outcome_type	Time-to-event
10.1080/10428194.2019.1682571	methodology	2	NA	Treatment name 1	daratumumabbortezomibmelphalanprednisone
10.1080/10428194.2019.1682571	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2019.1682571	methodology	2	NA	Treatment name 2	lenalidomidedexamethasone 18 months (rd18)
10.1080/10428194.2019.1682571	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2019.1682571	methodology	2	NA	paitc_type	MAIC
10.1080/10428194.2019.1682571	methodology	2	NA	anchored_yn	No
10.1080/10428194.2019.1682571	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2019.1682571	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2019.1682571	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.1080/10428194.2019.1682571	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2019.1682571	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2019.1682571	methodology	2	NA	weights_model_yn	No
10.1080/10428194.2019.1682571	methodology	2	NA	scale_choice_yn	No
10.1080/10428194.2019.1682571	methodology	3	NA	primary_outcome_name	overall survival
10.1080/10428194.2019.1682571	methodology	3	NA	outcome_short_name	Overall Survival
10.1080/10428194.2019.1682571	methodology	3	NA	primary_outcome_type	Time-to-event
10.1080/10428194.2019.1682571	methodology	3	NA	Treatment name 1	daratumumabbortezomibmelphalanprednisone
10.1080/10428194.2019.1682571	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2019.1682571	methodology	3	NA	Treatment name 2	melphalanprednisonethalidomide
10.1080/10428194.2019.1682571	methodology	3	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2019.1682571	methodology	3	NA	paitc_type	MAIC
10.1080/10428194.2019.1682571	methodology	3	NA	anchored_yn	No
10.1080/10428194.2019.1682571	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2019.1682571	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2019.1682571	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.1080/10428194.2019.1682571	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2019.1682571	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2019.1682571	methodology	3	NA	weights_model_yn	No
10.1080/10428194.2019.1682571	methodology	3	NA	scale_choice_yn	No
10.1080/10428194.2019.1682571	results	1	NA	contrast	HR
10.1080/10428194.2019.1682571	results	1	NA	direction_benefit	inferior
10.1080/10428194.2019.1682571	results	1	NA	n_nonipd_ttt	535
10.1080/10428194.2019.1682571	results	1	NA	n_ipd_ttt	350
10.1080/10428194.2019.1682571	results	1	NA	ess_ttt	248
10.1080/10428194.2019.1682571	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/10428194.2019.1682571	results	1	NA	list_covariates_yn	Yes
10.1080/10428194.2019.1682571	results	1	NA	n_covariates	7
10.1080/10428194.2019.1682571	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2019.1682571	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2019.1682571	results	1	NA	unadjusted_effect	0.88
10.1080/10428194.2019.1682571	results	1	NA	unadjusted_pval_char	0.51
10.1080/10428194.2019.1682571	results	1	NA	adjusted_effect	0.68
10.1080/10428194.2019.1682571	results	1	NA	adjusted_pval_char	0.086
10.1080/10428194.2019.1682571	results	1	NA	geographical region	NA
10.1080/10428194.2019.1682571	results	1	NA	n_ipd_total	NA
10.1080/10428194.2019.1682571	results	1	NA	ess_total	NA
10.1080/10428194.2019.1682571	results	1	NA	n_nonipd_total	NA
10.1080/10428194.2019.1682571	results	1	NA	n_nonipd_anchor	NA
10.1080/10428194.2019.1682571	results	1	NA	n_ipd_anchor	NA
10.1080/10428194.2019.1682571	results	1	NA	ess_anchor	NA
10.1080/10428194.2019.1682571	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/10428194.2019.1682571	results	1	NA	effect_cutoff	1
10.1080/10428194.2019.1682571	results	1	NA	unadjusted_pval	0.51
10.1080/10428194.2019.1682571	results	1	NA	unadjusted_num_pval	0.51
10.1080/10428194.2019.1682571	results	1	NA	unadjusted_significant	FALSE
10.1080/10428194.2019.1682571	results	1	NA	adjusted_pval	0.086
10.1080/10428194.2019.1682571	results	1	NA	adjusted_num_pval	0.086
10.1080/10428194.2019.1682571	results	1	NA	adjusted_significant	FALSE
10.1080/10428194.2019.1682571	results	2	NA	contrast	HR
10.1080/10428194.2019.1682571	results	2	NA	direction_benefit	inferior
10.1080/10428194.2019.1682571	results	2	NA	n_nonipd_ttt	541
10.1080/10428194.2019.1682571	results	2	NA	n_ipd_ttt	350
10.1080/10428194.2019.1682571	results	2	NA	ess_ttt	246
10.1080/10428194.2019.1682571	results	2	NA	weights_evaluation_yn	Not mentioned
10.1080/10428194.2019.1682571	results	2	NA	list_covariates_yn	Yes
10.1080/10428194.2019.1682571	results	2	NA	n_covariates	7
10.1080/10428194.2019.1682571	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2019.1682571	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2019.1682571	results	2	NA	unadjusted_effect	0.78
10.1080/10428194.2019.1682571	results	2	NA	unadjusted_pval_char	0.16
10.1080/10428194.2019.1682571	results	2	NA	adjusted_effect	0.6
10.1080/10428194.2019.1682571	results	2	NA	adjusted_pval_char	0.02
10.1080/10428194.2019.1682571	results	2	NA	geographical region	NA
10.1080/10428194.2019.1682571	results	2	NA	n_ipd_total	NA
10.1080/10428194.2019.1682571	results	2	NA	ess_total	NA
10.1080/10428194.2019.1682571	results	2	NA	n_nonipd_total	NA
10.1080/10428194.2019.1682571	results	2	NA	n_nonipd_anchor	NA
10.1080/10428194.2019.1682571	results	2	NA	n_ipd_anchor	NA
10.1080/10428194.2019.1682571	results	2	NA	ess_anchor	NA
10.1080/10428194.2019.1682571	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/10428194.2019.1682571	results	2	NA	effect_cutoff	1
10.1080/10428194.2019.1682571	results	2	NA	unadjusted_pval	0.16
10.1080/10428194.2019.1682571	results	2	NA	unadjusted_num_pval	0.16
10.1080/10428194.2019.1682571	results	2	NA	unadjusted_significant	FALSE
10.1080/10428194.2019.1682571	results	2	NA	adjusted_pval	0.02
10.1080/10428194.2019.1682571	results	2	NA	adjusted_num_pval	0.02
10.1080/10428194.2019.1682571	results	2	NA	adjusted_significant	TRUE
10.1080/10428194.2019.1682571	results	3	NA	contrast	HR
10.1080/10428194.2019.1682571	results	3	NA	direction_benefit	inferior
10.1080/10428194.2019.1682571	results	3	NA	n_nonipd_ttt	547
10.1080/10428194.2019.1682571	results	3	NA	n_ipd_ttt	350
10.1080/10428194.2019.1682571	results	3	NA	ess_ttt	248
10.1080/10428194.2019.1682571	results	3	NA	weights_evaluation_yn	Not mentioned
10.1080/10428194.2019.1682571	results	3	NA	list_covariates_yn	Yes
10.1080/10428194.2019.1682571	results	3	NA	n_covariates	7
10.1080/10428194.2019.1682571	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2019.1682571	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2019.1682571	results	3	NA	unadjusted_effect	0.68
10.1080/10428194.2019.1682571	results	3	NA	unadjusted_pval_char	0.024
10.1080/10428194.2019.1682571	results	3	NA	adjusted_effect	0.53
10.1080/10428194.2019.1682571	results	3	NA	adjusted_pval_char	0.003
10.1080/10428194.2019.1682571	results	3	NA	geographical region	NA
10.1080/10428194.2019.1682571	results	3	NA	n_ipd_total	NA
10.1080/10428194.2019.1682571	results	3	NA	ess_total	NA
10.1080/10428194.2019.1682571	results	3	NA	n_nonipd_total	NA
10.1080/10428194.2019.1682571	results	3	NA	n_nonipd_anchor	NA
10.1080/10428194.2019.1682571	results	3	NA	n_ipd_anchor	NA
10.1080/10428194.2019.1682571	results	3	NA	ess_anchor	NA
10.1080/10428194.2019.1682571	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/10428194.2019.1682571	results	3	NA	effect_cutoff	1
10.1080/10428194.2019.1682571	results	3	NA	unadjusted_pval	0.024
10.1080/10428194.2019.1682571	results	3	NA	unadjusted_num_pval	0.024
10.1080/10428194.2019.1682571	results	3	NA	unadjusted_significant	TRUE
10.1080/10428194.2019.1682571	results	3	NA	adjusted_pval	0.003
10.1080/10428194.2019.1682571	results	3	NA	adjusted_num_pval	0.003
10.1080/10428194.2019.1682571	results	3	NA	adjusted_significant	TRUE
10.1080/10428194.2019.1682571	study_information	NA	1	Patient-level data used	Yes
10.1080/10428194.2019.1682571	study_information	NA	1	Clinical Trial	Yes
10.1080/10428194.2019.1682571	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02195479
10.1080/10428194.2019.1682571	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2019.1682571	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2019.1682571	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2019.1682571	study_information	NA	2	Patient-level data used	No
10.1080/10428194.2019.1682571	study_information	NA	2	Clinical Trial	Yes
10.1080/10428194.2019.1682571	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00689936
10.1080/10428194.2019.1682571	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2019.1682571	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2019.1682571	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2021.1913143	general_information	NA	NA	Medical Condition of Interest Name	relapsed and refractory multiple myeloma
10.1080/10428194.2021.1913143	general_information	NA	NA	Countries of first author affiliations	spain
10.1080/10428194.2021.1913143	general_information	NA	NA	Countries of last author affiliations	switzerland
10.1080/10428194.2021.1913143	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/10428194.2021.1913143	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/10428194.2021.1913143	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/10428194.2021.1913143	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/10428194.2021.1913143	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/10428194.2021.1913143	methodology	1	NA	primary_outcome_name	overall response rate
10.1080/10428194.2021.1913143	methodology	1	NA	outcome_short_name	Overall Response Rate
10.1080/10428194.2021.1913143	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1080/10428194.2021.1913143	methodology	1	NA	Treatment name 1	idecabtagene vicleucel
10.1080/10428194.2021.1913143	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913143	methodology	1	NA	Treatment name 2	selinexor + dexamethasone
10.1080/10428194.2021.1913143	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2021.1913143	methodology	1	NA	paitc_type	MAIC
10.1080/10428194.2021.1913143	methodology	1	NA	anchored_yn	No
10.1080/10428194.2021.1913143	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913143	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913143	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/10428194.2021.1913143	methodology	1	NA	prognostic_factors_yn	Yes
10.1080/10428194.2021.1913143	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913143	methodology	1	NA	weights_model_yn	No
10.1080/10428194.2021.1913143	methodology	1	NA	scale_choice_yn	No
10.1080/10428194.2021.1913143	methodology	2	NA	primary_outcome_name	overall response rate
10.1080/10428194.2021.1913143	methodology	2	NA	outcome_short_name	Overall Response Rate
10.1080/10428194.2021.1913143	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1080/10428194.2021.1913143	methodology	2	NA	Treatment name 1	idecabtagene + vicleucel
10.1080/10428194.2021.1913143	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913143	methodology	2	NA	Treatment name 2	belantamab mafodotin
10.1080/10428194.2021.1913143	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1080/10428194.2021.1913143	methodology	2	NA	paitc_type	MAIC
10.1080/10428194.2021.1913143	methodology	2	NA	anchored_yn	No
10.1080/10428194.2021.1913143	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913143	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913143	methodology	2	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/10428194.2021.1913143	methodology	2	NA	prognostic_factors_yn	Yes
10.1080/10428194.2021.1913143	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913143	methodology	2	NA	weights_model_yn	No
10.1080/10428194.2021.1913143	methodology	2	NA	scale_choice_yn	No
10.1080/10428194.2021.1913143	results	1	NA	contrast	OR
10.1080/10428194.2021.1913143	results	1	NA	direction_benefit	superior
10.1080/10428194.2021.1913143	results	1	NA	n_nonipd_ttt	122
10.1080/10428194.2021.1913143	results	1	NA	n_ipd_ttt	128
10.1080/10428194.2021.1913143	results	1	NA	ess_ttt	56
10.1080/10428194.2021.1913143	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/10428194.2021.1913143	results	1	NA	list_covariates_yn	Yes
10.1080/10428194.2021.1913143	results	1	NA	n_covariates	6
10.1080/10428194.2021.1913143	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/10428194.2021.1913143	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913143	results	1	NA	unadjusted_effect	7.78
10.1080/10428194.2021.1913143	results	1	NA	unadjusted_pval_char	[4.43;13.65]
10.1080/10428194.2021.1913143	results	1	NA	adjusted_effect	7.74
10.1080/10428194.2021.1913143	results	1	NA	adjusted_pval_char	NA
10.1080/10428194.2021.1913143	results	1	NA	geographical region	NA
10.1080/10428194.2021.1913143	results	1	NA	n_ipd_total	NA
10.1080/10428194.2021.1913143	results	1	NA	ess_total	NA
10.1080/10428194.2021.1913143	results	1	NA	n_nonipd_total	NA
10.1080/10428194.2021.1913143	results	1	NA	n_nonipd_anchor	NA
10.1080/10428194.2021.1913143	results	1	NA	n_ipd_anchor	NA
10.1080/10428194.2021.1913143	results	1	NA	ess_anchor	NA
10.1080/10428194.2021.1913143	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	[3.83;15.62]
10.1080/10428194.2021.1913143	results	1	NA	effect_cutoff	1
10.1080/10428194.2021.1913143	results	1	NA	unadjusted_lb_ci	4.43
10.1080/10428194.2021.1913143	results	1	NA	unadjusted_ub_ci	13.65
10.1080/10428194.2021.1913143	results	1	NA	unadjusted_significant	TRUE
10.1080/10428194.2021.1913143	results	2	NA	contrast	OR
10.1080/10428194.2021.1913143	results	2	NA	direction_benefit	superior
10.1080/10428194.2021.1913143	results	2	NA	n_nonipd_ttt	97
10.1080/10428194.2021.1913143	results	2	NA	n_ipd_ttt	128
10.1080/10428194.2021.1913143	results	2	NA	ess_ttt	45
10.1080/10428194.2021.1913143	results	2	NA	weights_evaluation_yn	Not mentioned
10.1080/10428194.2021.1913143	results	2	NA	list_covariates_yn	Yes
10.1080/10428194.2021.1913143	results	2	NA	n_covariates	6
10.1080/10428194.2021.1913143	results	2	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/10428194.2021.1913143	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913143	results	2	NA	unadjusted_effect	6.17
10.1080/10428194.2021.1913143	results	2	NA	unadjusted_pval_char	[3.45;11.05]
10.1080/10428194.2021.1913143	results	2	NA	adjusted_effect	5.12
10.1080/10428194.2021.1913143	results	2	NA	adjusted_pval_char	NA
10.1080/10428194.2021.1913143	results	2	NA	geographical region	NA
10.1080/10428194.2021.1913143	results	2	NA	n_ipd_total	NA
10.1080/10428194.2021.1913143	results	2	NA	ess_total	NA
10.1080/10428194.2021.1913143	results	2	NA	n_nonipd_total	NA
10.1080/10428194.2021.1913143	results	2	NA	n_nonipd_anchor	NA
10.1080/10428194.2021.1913143	results	2	NA	n_ipd_anchor	NA
10.1080/10428194.2021.1913143	results	2	NA	ess_anchor	NA
10.1080/10428194.2021.1913143	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	[2.35;11.13]
10.1080/10428194.2021.1913143	results	2	NA	effect_cutoff	1
10.1080/10428194.2021.1913143	results	2	NA	unadjusted_lb_ci	3.45
10.1080/10428194.2021.1913143	results	2	NA	unadjusted_ub_ci	11.05
10.1080/10428194.2021.1913143	results	2	NA	unadjusted_significant	TRUE
10.1080/10428194.2021.1913143	study_information	NA	1	Patient-level data used	Yes
10.1080/10428194.2021.1913143	study_information	NA	1	Clinical Trial	Yes
10.1080/10428194.2021.1913143	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03361748
10.1080/10428194.2021.1913143	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.1913143	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1080/10428194.2021.1913143	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/10428194.2021.1913143	study_information	NA	2	Patient-level data used	No
10.1080/10428194.2021.1913143	study_information	NA	2	Clinical Trial	Yes
10.1080/10428194.2021.1913143	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02336815
10.1080/10428194.2021.1913143	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.1913143	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1080/10428194.2021.1913143	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1080/10428194.2021.1913143	study_information	NA	3	Patient-level data used	No
10.1080/10428194.2021.1913143	study_information	NA	3	Clinical Trial	Yes
10.1080/10428194.2021.1913143	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03525678
10.1080/10428194.2021.1913143	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.1913143	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.1080/10428194.2021.1913143	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1080/10428194.2021.1913144	general_information	NA	NA	Medical Condition of Interest Name	chronic lymphocytic leukemia
10.1080/10428194.2021.1913144	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/10428194.2021.1913144	general_information	NA	NA	Countries of last author affiliations	uk
10.1080/10428194.2021.1913144	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1080/10428194.2021.1913144	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1080/10428194.2021.1913144	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/10428194.2021.1913144	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/10428194.2021.1913144	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/10428194.2021.1913144	methodology	1	NA	primary_outcome_name	progression-free survival
10.1080/10428194.2021.1913144	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2021.1913144	methodology	1	NA	primary_outcome_type	Time-to-event
10.1080/10428194.2021.1913144	methodology	1	NA	Treatment name 1	acalabrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913144	methodology	1	NA	Treatment name 2	ibrutinib
10.1080/10428194.2021.1913144	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2021.1913144	methodology	1	NA	paitc_type	MAIC
10.1080/10428194.2021.1913144	methodology	1	NA	anchored_yn	No
10.1080/10428194.2021.1913144	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	1	NA	weights_model_yn	No
10.1080/10428194.2021.1913144	methodology	1	NA	scale_choice_yn	No
10.1080/10428194.2021.1913144	methodology	2	NA	primary_outcome_name	progression-free survival
10.1080/10428194.2021.1913144	methodology	2	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2021.1913144	methodology	2	NA	primary_outcome_type	Time-to-event
10.1080/10428194.2021.1913144	methodology	2	NA	Treatment name 1	acalabrutinib
10.1080/10428194.2021.1913144	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913144	methodology	2	NA	Treatment name 2	ibrutinib
10.1080/10428194.2021.1913144	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2021.1913144	methodology	2	NA	paitc_type	MAIC
10.1080/10428194.2021.1913144	methodology	2	NA	anchored_yn	No
10.1080/10428194.2021.1913144	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	2	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	2	NA	weights_model_yn	No
10.1080/10428194.2021.1913144	methodology	2	NA	scale_choice_yn	No
10.1080/10428194.2021.1913144	methodology	3	NA	primary_outcome_name	progression-free survival
10.1080/10428194.2021.1913144	methodology	3	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2021.1913144	methodology	3	NA	primary_outcome_type	Time-to-event
10.1080/10428194.2021.1913144	methodology	3	NA	Treatment name 1	acalabrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913144	methodology	3	NA	Treatment name 2	ibrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	3	NA	Study 'number(s)' for treatment 2	3
10.1080/10428194.2021.1913144	methodology	3	NA	paitc_type	MAIC
10.1080/10428194.2021.1913144	methodology	3	NA	anchored_yn	No
10.1080/10428194.2021.1913144	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	3	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	3	NA	weights_model_yn	No
10.1080/10428194.2021.1913144	methodology	3	NA	scale_choice_yn	No
10.1080/10428194.2021.1913144	methodology	4	NA	primary_outcome_name	progression-free survival
10.1080/10428194.2021.1913144	methodology	4	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2021.1913144	methodology	4	NA	primary_outcome_type	Time-to-event
10.1080/10428194.2021.1913144	methodology	4	NA	Treatment name 1	acalabrutinib
10.1080/10428194.2021.1913144	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913144	methodology	4	NA	Treatment name 2	ibrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	4	NA	Study 'number(s)' for treatment 2	3
10.1080/10428194.2021.1913144	methodology	4	NA	paitc_type	MAIC
10.1080/10428194.2021.1913144	methodology	4	NA	anchored_yn	No
10.1080/10428194.2021.1913144	methodology	4	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	4	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	4	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	4	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	4	NA	weights_model_yn	No
10.1080/10428194.2021.1913144	methodology	4	NA	scale_choice_yn	No
10.1080/10428194.2021.1913144	methodology	5	NA	primary_outcome_name	progression-free survival
10.1080/10428194.2021.1913144	methodology	5	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2021.1913144	methodology	5	NA	primary_outcome_type	Time-to-event
10.1080/10428194.2021.1913144	methodology	5	NA	Treatment name 1	acalabrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913144	methodology	5	NA	Treatment name 2	venetoclax + obinutuzumab
10.1080/10428194.2021.1913144	methodology	5	NA	Study 'number(s)' for treatment 2	4
10.1080/10428194.2021.1913144	methodology	5	NA	paitc_type	MAIC
10.1080/10428194.2021.1913144	methodology	5	NA	anchored_yn	No
10.1080/10428194.2021.1913144	methodology	5	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	5	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	5	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	5	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	5	NA	weights_model_yn	No
10.1080/10428194.2021.1913144	methodology	5	NA	scale_choice_yn	No
10.1080/10428194.2021.1913144	methodology	6	NA	primary_outcome_name	progression-free survival
10.1080/10428194.2021.1913144	methodology	6	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2021.1913144	methodology	6	NA	primary_outcome_type	Time-to-event
10.1080/10428194.2021.1913144	methodology	6	NA	Treatment name 1	acalabrutinib
10.1080/10428194.2021.1913144	methodology	6	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913144	methodology	6	NA	Treatment name 2	venetoclax + obinutuzumab
10.1080/10428194.2021.1913144	methodology	6	NA	Study 'number(s)' for treatment 2	4
10.1080/10428194.2021.1913144	methodology	6	NA	paitc_type	MAIC
10.1080/10428194.2021.1913144	methodology	6	NA	anchored_yn	No
10.1080/10428194.2021.1913144	methodology	6	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	6	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	6	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	6	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	6	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	6	NA	weights_model_yn	No
10.1080/10428194.2021.1913144	methodology	6	NA	scale_choice_yn	No
10.1080/10428194.2021.1913144	results	1	NA	contrast	HR
10.1080/10428194.2021.1913144	results	1	NA	direction_benefit	inferior
10.1080/10428194.2021.1913144	results	1	NA	n_nonipd_ttt	136
10.1080/10428194.2021.1913144	results	1	NA	n_ipd_ttt	126
10.1080/10428194.2021.1913144	results	1	NA	ess_ttt	59
10.1080/10428194.2021.1913144	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	1	NA	list_covariates_yn	Yes
10.1080/10428194.2021.1913144	results	1	NA	n_covariates	12
10.1080/10428194.2021.1913144	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	1	NA	unadjusted_effect	NA
10.1080/10428194.2021.1913144	results	1	NA	unadjusted_pval_char	NA
10.1080/10428194.2021.1913144	results	1	NA	adjusted_effect	0.61
10.1080/10428194.2021.1913144	results	1	NA	adjusted_pval_char	0.3
10.1080/10428194.2021.1913144	results	1	NA	geographical region	No
10.1080/10428194.2021.1913144	results	1	NA	n_ipd_total	NA
10.1080/10428194.2021.1913144	results	1	NA	ess_total	NA
10.1080/10428194.2021.1913144	results	1	NA	n_nonipd_total	NA
10.1080/10428194.2021.1913144	results	1	NA	n_nonipd_anchor	NA
10.1080/10428194.2021.1913144	results	1	NA	n_ipd_anchor	NA
10.1080/10428194.2021.1913144	results	1	NA	ess_anchor	NA
10.1080/10428194.2021.1913144	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/10428194.2021.1913144	results	1	NA	effect_cutoff	1
10.1080/10428194.2021.1913144	results	1	NA	adjusted_pval	0.3
10.1080/10428194.2021.1913144	results	1	NA	adjusted_num_pval	0.3
10.1080/10428194.2021.1913144	results	1	NA	adjusted_significant	FALSE
10.1080/10428194.2021.1913144	results	2	NA	contrast	HR
10.1080/10428194.2021.1913144	results	2	NA	direction_benefit	inferior
10.1080/10428194.2021.1913144	results	2	NA	n_nonipd_ttt	136
10.1080/10428194.2021.1913144	results	2	NA	n_ipd_ttt	136
10.1080/10428194.2021.1913144	results	2	NA	ess_ttt	79
10.1080/10428194.2021.1913144	results	2	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	2	NA	list_covariates_yn	Yes
10.1080/10428194.2021.1913144	results	2	NA	n_covariates	12
10.1080/10428194.2021.1913144	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	2	NA	unadjusted_effect	NA
10.1080/10428194.2021.1913144	results	2	NA	unadjusted_pval_char	NA
10.1080/10428194.2021.1913144	results	2	NA	adjusted_effect	0.92
10.1080/10428194.2021.1913144	results	2	NA	adjusted_pval_char	0.83
10.1080/10428194.2021.1913144	results	2	NA	geographical region	No
10.1080/10428194.2021.1913144	results	2	NA	n_ipd_total	NA
10.1080/10428194.2021.1913144	results	2	NA	ess_total	NA
10.1080/10428194.2021.1913144	results	2	NA	n_nonipd_total	NA
10.1080/10428194.2021.1913144	results	2	NA	n_nonipd_anchor	NA
10.1080/10428194.2021.1913144	results	2	NA	n_ipd_anchor	NA
10.1080/10428194.2021.1913144	results	2	NA	ess_anchor	NA
10.1080/10428194.2021.1913144	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/10428194.2021.1913144	results	2	NA	effect_cutoff	1
10.1080/10428194.2021.1913144	results	2	NA	adjusted_pval	0.83
10.1080/10428194.2021.1913144	results	2	NA	adjusted_num_pval	0.83
10.1080/10428194.2021.1913144	results	2	NA	adjusted_significant	FALSE
10.1080/10428194.2021.1913144	results	3	NA	contrast	HR
10.1080/10428194.2021.1913144	results	3	NA	direction_benefit	inferior
10.1080/10428194.2021.1913144	results	3	NA	n_nonipd_ttt	113
10.1080/10428194.2021.1913144	results	3	NA	n_ipd_ttt	113
10.1080/10428194.2021.1913144	results	3	NA	ess_ttt	97
10.1080/10428194.2021.1913144	results	3	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	3	NA	list_covariates_yn	Yes
10.1080/10428194.2021.1913144	results	3	NA	n_covariates	12
10.1080/10428194.2021.1913144	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	3	NA	unadjusted_effect	NA
10.1080/10428194.2021.1913144	results	3	NA	unadjusted_pval_char	NA
10.1080/10428194.2021.1913144	results	3	NA	adjusted_effect	0.55
10.1080/10428194.2021.1913144	results	3	NA	adjusted_pval_char	0.11
10.1080/10428194.2021.1913144	results	3	NA	geographical region	No
10.1080/10428194.2021.1913144	results	3	NA	n_ipd_total	NA
10.1080/10428194.2021.1913144	results	3	NA	ess_total	NA
10.1080/10428194.2021.1913144	results	3	NA	n_nonipd_total	NA
10.1080/10428194.2021.1913144	results	3	NA	n_nonipd_anchor	NA
10.1080/10428194.2021.1913144	results	3	NA	n_ipd_anchor	NA
10.1080/10428194.2021.1913144	results	3	NA	ess_anchor	NA
10.1080/10428194.2021.1913144	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/10428194.2021.1913144	results	3	NA	effect_cutoff	1
10.1080/10428194.2021.1913144	results	3	NA	adjusted_pval	0.11
10.1080/10428194.2021.1913144	results	3	NA	adjusted_num_pval	0.11
10.1080/10428194.2021.1913144	results	3	NA	adjusted_significant	FALSE
10.1080/10428194.2021.1913144	results	4	NA	contrast	HR
10.1080/10428194.2021.1913144	results	4	NA	direction_benefit	inferior
10.1080/10428194.2021.1913144	results	4	NA	n_nonipd_ttt	113
10.1080/10428194.2021.1913144	results	4	NA	n_ipd_ttt	114
10.1080/10428194.2021.1913144	results	4	NA	ess_ttt	97
10.1080/10428194.2021.1913144	results	4	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	4	NA	list_covariates_yn	Yes
10.1080/10428194.2021.1913144	results	4	NA	n_covariates	12
10.1080/10428194.2021.1913144	results	4	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	4	NA	unadjusted_effect	NA
10.1080/10428194.2021.1913144	results	4	NA	unadjusted_pval_char	NA
10.1080/10428194.2021.1913144	results	4	NA	adjusted_effect	0.53
10.1080/10428194.2021.1913144	results	4	NA	adjusted_pval_char	0.08
10.1080/10428194.2021.1913144	results	4	NA	geographical region	No
10.1080/10428194.2021.1913144	results	4	NA	n_ipd_total	NA
10.1080/10428194.2021.1913144	results	4	NA	ess_total	NA
10.1080/10428194.2021.1913144	results	4	NA	n_nonipd_total	NA
10.1080/10428194.2021.1913144	results	4	NA	n_nonipd_anchor	NA
10.1080/10428194.2021.1913144	results	4	NA	n_ipd_anchor	NA
10.1080/10428194.2021.1913144	results	4	NA	ess_anchor	NA
10.1080/10428194.2021.1913144	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/10428194.2021.1913144	results	4	NA	effect_cutoff	1
10.1080/10428194.2021.1913144	results	4	NA	adjusted_pval	0.08
10.1080/10428194.2021.1913144	results	4	NA	adjusted_num_pval	0.08
10.1080/10428194.2021.1913144	results	4	NA	adjusted_significant	FALSE
10.1080/10428194.2021.1913144	results	5	NA	contrast	HR
10.1080/10428194.2021.1913144	results	5	NA	direction_benefit	inferior
10.1080/10428194.2021.1913144	results	5	NA	n_nonipd_ttt	216
10.1080/10428194.2021.1913144	results	5	NA	n_ipd_ttt	83
10.1080/10428194.2021.1913144	results	5	NA	ess_ttt	43
10.1080/10428194.2021.1913144	results	5	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	5	NA	list_covariates_yn	Yes
10.1080/10428194.2021.1913144	results	5	NA	n_covariates	12
10.1080/10428194.2021.1913144	results	5	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	5	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	5	NA	unadjusted_effect	NA
10.1080/10428194.2021.1913144	results	5	NA	unadjusted_pval_char	NA
10.1080/10428194.2021.1913144	results	5	NA	adjusted_effect	0.78
10.1080/10428194.2021.1913144	results	5	NA	adjusted_pval_char	0.57
10.1080/10428194.2021.1913144	results	5	NA	geographical region	No
10.1080/10428194.2021.1913144	results	5	NA	n_ipd_total	NA
10.1080/10428194.2021.1913144	results	5	NA	ess_total	NA
10.1080/10428194.2021.1913144	results	5	NA	n_nonipd_total	NA
10.1080/10428194.2021.1913144	results	5	NA	n_nonipd_anchor	NA
10.1080/10428194.2021.1913144	results	5	NA	n_ipd_anchor	NA
10.1080/10428194.2021.1913144	results	5	NA	ess_anchor	NA
10.1080/10428194.2021.1913144	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/10428194.2021.1913144	results	5	NA	effect_cutoff	1
10.1080/10428194.2021.1913144	results	5	NA	adjusted_pval	0.57
10.1080/10428194.2021.1913144	results	5	NA	adjusted_num_pval	0.57
10.1080/10428194.2021.1913144	results	5	NA	adjusted_significant	FALSE
10.1080/10428194.2021.1913144	results	6	NA	contrast	HR
10.1080/10428194.2021.1913144	results	6	NA	direction_benefit	inferior
10.1080/10428194.2021.1913144	results	6	NA	n_nonipd_ttt	216
10.1080/10428194.2021.1913144	results	6	NA	n_ipd_ttt	96
10.1080/10428194.2021.1913144	results	6	NA	ess_ttt	51
10.1080/10428194.2021.1913144	results	6	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	6	NA	list_covariates_yn	Yes
10.1080/10428194.2021.1913144	results	6	NA	n_covariates	12
10.1080/10428194.2021.1913144	results	6	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	6	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	6	NA	unadjusted_effect	NA
10.1080/10428194.2021.1913144	results	6	NA	unadjusted_pval_char	NA
10.1080/10428194.2021.1913144	results	6	NA	adjusted_effect	1.24
10.1080/10428194.2021.1913144	results	6	NA	adjusted_pval_char	0.59
10.1080/10428194.2021.1913144	results	6	NA	geographical region	No
10.1080/10428194.2021.1913144	results	6	NA	n_ipd_total	NA
10.1080/10428194.2021.1913144	results	6	NA	ess_total	NA
10.1080/10428194.2021.1913144	results	6	NA	n_nonipd_total	NA
10.1080/10428194.2021.1913144	results	6	NA	n_nonipd_anchor	NA
10.1080/10428194.2021.1913144	results	6	NA	n_ipd_anchor	NA
10.1080/10428194.2021.1913144	results	6	NA	ess_anchor	NA
10.1080/10428194.2021.1913144	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/10428194.2021.1913144	results	6	NA	effect_cutoff	1
10.1080/10428194.2021.1913144	results	6	NA	adjusted_pval	0.59
10.1080/10428194.2021.1913144	results	6	NA	adjusted_num_pval	0.59
10.1080/10428194.2021.1913144	results	6	NA	adjusted_significant	FALSE
10.1080/10428194.2021.1913144	study_information	NA	1	Patient-level data used	Yes
10.1080/10428194.2021.1913144	study_information	NA	1	Clinical Trial	Yes
10.1080/10428194.2021.1913144	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02475681
10.1080/10428194.2021.1913144	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.1913144	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2021.1913144	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2021.1913144	study_information	NA	2	Patient-level data used	No
10.1080/10428194.2021.1913144	study_information	NA	2	Clinical Trial	Yes
10.1080/10428194.2021.1913144	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01722487
10.1080/10428194.2021.1913144	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.1913144	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2021.1913144	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2021.1913144	study_information	NA	3	Patient-level data used	No
10.1080/10428194.2021.1913144	study_information	NA	3	Clinical Trial	Yes
10.1080/10428194.2021.1913144	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02264574
10.1080/10428194.2021.1913144	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.1913144	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2021.1913144	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2021.1913144	study_information	NA	4	Patient-level data used	No
10.1080/10428194.2021.1913144	study_information	NA	4	Clinical Trial	Yes
10.1080/10428194.2021.1913144	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02242942
10.1080/10428194.2021.1913144	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.1913144	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2021.1913144	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2021.2010069	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory large b-cell lymphomas
10.1080/10428194.2021.2010069	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/10428194.2021.2010069	general_information	NA	NA	Countries of last author affiliations	netherlands
10.1080/10428194.2021.2010069	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/10428194.2021.2010069	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/10428194.2021.2010069	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/10428194.2021.2010069	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/10428194.2021.2010069	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/10428194.2021.2010069	methodology	1	NA	primary_outcome_name	overall response rate
10.1080/10428194.2021.2010069	methodology	1	NA	outcome_short_name	Overall Response Rate
10.1080/10428194.2021.2010069	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1080/10428194.2021.2010069	methodology	1	NA	Treatment name 1	tisagenlecleucel
10.1080/10428194.2021.2010069	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.2010069	methodology	1	NA	Treatment name 2	lisocabtagene
10.1080/10428194.2021.2010069	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2021.2010069	methodology	1	NA	paitc_type	MAIC
10.1080/10428194.2021.2010069	methodology	1	NA	anchored_yn	No
10.1080/10428194.2021.2010069	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.2010069	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.2010069	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/10428194.2021.2010069	methodology	1	NA	prognostic_factors_yn	Yes
10.1080/10428194.2021.2010069	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.2010069	methodology	1	NA	weights_model_yn	No
10.1080/10428194.2021.2010069	methodology	1	NA	scale_choice_yn	No
10.1080/10428194.2021.2010069	results	1	NA	contrast	Rate difference
10.1080/10428194.2021.2010069	results	1	NA	direction_benefit	superior
10.1080/10428194.2021.2010069	results	1	NA	n_nonipd_ttt	256
10.1080/10428194.2021.2010069	results	1	NA	n_ipd_ttt	106
10.1080/10428194.2021.2010069	results	1	NA	ess_ttt	29
10.1080/10428194.2021.2010069	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/10428194.2021.2010069	results	1	NA	list_covariates_yn	Yes
10.1080/10428194.2021.2010069	results	1	NA	n_covariates	12
10.1080/10428194.2021.2010069	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.2010069	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.2010069	results	1	NA	unadjusted_effect	-15.50
10.1080/10428194.2021.2010069	results	1	NA	unadjusted_pval_char	<0.01
10.1080/10428194.2021.2010069	results	1	NA	adjusted_effect	-9.70
10.1080/10428194.2021.2010069	results	1	NA	adjusted_pval_char	0.07
10.1080/10428194.2021.2010069	results	1	NA	geographical region	NA
10.1080/10428194.2021.2010069	results	1	NA	n_ipd_total	NA
10.1080/10428194.2021.2010069	results	1	NA	ess_total	NA
10.1080/10428194.2021.2010069	results	1	NA	n_nonipd_total	NA
10.1080/10428194.2021.2010069	results	1	NA	n_nonipd_anchor	NA
10.1080/10428194.2021.2010069	results	1	NA	n_ipd_anchor	NA
10.1080/10428194.2021.2010069	results	1	NA	ess_anchor	NA
10.1080/10428194.2021.2010069	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/10428194.2021.2010069	results	1	NA	effect_cutoff	0
10.1080/10428194.2021.2010069	results	1	NA	unadjusted_pval	<0.01
10.1080/10428194.2021.2010069	results	1	NA	unadjusted_significant	TRUE
10.1080/10428194.2021.2010069	results	1	NA	adjusted_pval	0.07
10.1080/10428194.2021.2010069	results	1	NA	adjusted_num_pval	0.07
10.1080/10428194.2021.2010069	results	1	NA	adjusted_significant	FALSE
10.1080/10428194.2021.2010069	study_information	NA	1	Patient-level data used	Yes
10.1080/10428194.2021.2010069	study_information	NA	1	Clinical Trial	Yes
10.1080/10428194.2021.2010069	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02445248
10.1080/10428194.2021.2010069	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.2010069	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1080/10428194.2021.2010069	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/10428194.2021.2010069	study_information	NA	2	Patient-level data used	No
10.1080/10428194.2021.2010069	study_information	NA	2	Clinical Trial	Yes
10.1080/10428194.2021.2010069	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02631044
10.1080/10428194.2021.2010069	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/10428194.2021.2010069	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1
10.1080/10428194.2021.2010069	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1080/10428194.2022.2047962	general_information	NA	NA	Medical Condition of Interest Name	multiple myeloma
10.1080/10428194.2022.2047962	general_information	NA	NA	Countries of first author affiliations	germany
10.1080/10428194.2022.2047962	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/10428194.2022.2047962	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1080/10428194.2022.2047962	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/10428194.2022.2047962	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/10428194.2022.2047962	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/10428194.2022.2047962	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/10428194.2022.2047962	methodology	1	NA	primary_outcome_name	progression-free survival
10.1080/10428194.2022.2047962	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2022.2047962	methodology	1	NA	primary_outcome_type	Time-to-event
10.1080/10428194.2022.2047962	methodology	1	NA	Treatment name 1	carfizomib + dexamethasone+daratumumab
10.1080/10428194.2022.2047962	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2022.2047962	methodology	1	NA	Treatment name 2	daratumumab + velcade+dexamethasone
10.1080/10428194.2022.2047962	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2022.2047962	methodology	1	NA	paitc_type	MAIC
10.1080/10428194.2022.2047962	methodology	1	NA	anchored_yn	No
10.1080/10428194.2022.2047962	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2022.2047962	methodology	1	NA	primary_outcome_yn	Yes
10.1080/10428194.2022.2047962	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2022.2047962	methodology	1	NA	prognostic_factors_yn	Yes
10.1080/10428194.2022.2047962	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2022.2047962	methodology	1	NA	weights_model_yn	No
10.1080/10428194.2022.2047962	methodology	1	NA	scale_choice_yn	No
10.1080/10428194.2022.2047962	results	1	NA	contrast	HR
10.1080/10428194.2022.2047962	results	1	NA	direction_benefit	inferior
10.1080/10428194.2022.2047962	results	1	NA	n_nonipd_ttt	251
10.1080/10428194.2022.2047962	results	1	NA	n_ipd_ttt	198
10.1080/10428194.2022.2047962	results	1	NA	ess_ttt	82
10.1080/10428194.2022.2047962	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/10428194.2022.2047962	results	1	NA	list_covariates_yn	Yes
10.1080/10428194.2022.2047962	results	1	NA	n_covariates	10
10.1080/10428194.2022.2047962	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)
10.1080/10428194.2022.2047962	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2022.2047962	results	1	NA	unadjusted_effect	0.54
10.1080/10428194.2022.2047962	results	1	NA	unadjusted_pval_char	[0.41;0.70]
10.1080/10428194.2022.2047962	results	1	NA	adjusted_effect	0.64
10.1080/10428194.2022.2047962	results	1	NA	adjusted_pval_char	[0.46;0.90]
10.1080/10428194.2022.2047962	results	1	NA	geographical region	No
10.1080/10428194.2022.2047962	results	1	NA	n_ipd_total	NA
10.1080/10428194.2022.2047962	results	1	NA	ess_total	NA
10.1080/10428194.2022.2047962	results	1	NA	n_nonipd_total	NA
10.1080/10428194.2022.2047962	results	1	NA	n_nonipd_anchor	NA
10.1080/10428194.2022.2047962	results	1	NA	n_ipd_anchor	NA
10.1080/10428194.2022.2047962	results	1	NA	ess_anchor	NA
10.1080/10428194.2022.2047962	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/10428194.2022.2047962	results	1	NA	effect_cutoff	1
10.1080/10428194.2022.2047962	results	1	NA	unadjusted_lb_ci	0.41
10.1080/10428194.2022.2047962	results	1	NA	unadjusted_ub_ci	0.7
10.1080/10428194.2022.2047962	results	1	NA	unadjusted_significant	TRUE
10.1080/10428194.2022.2047962	results	1	NA	adjusted_lb_ci	0.46
10.1080/10428194.2022.2047962	results	1	NA	adjusted_ub_ci	0.9
10.1080/10428194.2022.2047962	results	1	NA	adjusted_significant	TRUE
10.1080/10428194.2022.2047962	study_information	NA	1	Patient-level data used	Yes
10.1080/10428194.2022.2047962	study_information	NA	1	Clinical Trial	Yes
10.1080/10428194.2022.2047962	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03158688
10.1080/10428194.2022.2047962	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2022.2047962	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2022.2047962	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2022.2047962	study_information	NA	2	Patient-level data used	No
10.1080/10428194.2022.2047962	study_information	NA	2	Clinical Trial	Yes
10.1080/10428194.2022.2047962	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02136134
10.1080/10428194.2022.2047962	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2022.2047962	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2022.2047962	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/13696998.2018.1443111	general_information	NA	NA	Medical Condition of Interest Name	(ALK)-positive metastatic non-small cell lung cancer
10.1080/13696998.2018.1443111	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/13696998.2018.1443111	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/13696998.2018.1443111	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1080/13696998.2018.1443111	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/13696998.2018.1443111	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/13696998.2018.1443111	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/13696998.2018.1443111	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/13696998.2018.1443111	methodology	1	NA	primary_outcome_name	progression-free survival
10.1080/13696998.2018.1443111	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1080/13696998.2018.1443111	methodology	1	NA	primary_outcome_type	Time-to-event
10.1080/13696998.2018.1443111	methodology	1	NA	Treatment name 1	ceritinib
10.1080/13696998.2018.1443111	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/13696998.2018.1443111	methodology	1	NA	Treatment name 2	crizotinib
10.1080/13696998.2018.1443111	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/13696998.2018.1443111	methodology	1	NA	paitc_type	MAIC
10.1080/13696998.2018.1443111	methodology	1	NA	anchored_yn	No
10.1080/13696998.2018.1443111	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/13696998.2018.1443111	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/13696998.2018.1443111	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1080/13696998.2018.1443111	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/13696998.2018.1443111	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/13696998.2018.1443111	methodology	1	NA	weights_model_yn	No
10.1080/13696998.2018.1443111	methodology	1	NA	scale_choice_yn	No
10.1080/13696998.2018.1443111	results	1	NA	contrast	HR
10.1080/13696998.2018.1443111	results	1	NA	direction_benefit	inferior
10.1080/13696998.2018.1443111	results	1	NA	n_nonipd_ttt	NA
10.1080/13696998.2018.1443111	results	1	NA	n_ipd_ttt	NA
10.1080/13696998.2018.1443111	results	1	NA	ess_ttt	NA
10.1080/13696998.2018.1443111	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/13696998.2018.1443111	results	1	NA	list_covariates_yn	No
10.1080/13696998.2018.1443111	results	1	NA	n_covariates	NA
10.1080/13696998.2018.1443111	results	1	NA	list_covariates	NA
10.1080/13696998.2018.1443111	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/13696998.2018.1443111	results	1	NA	unadjusted_effect	NA
10.1080/13696998.2018.1443111	results	1	NA	unadjusted_pval_char	NA
10.1080/13696998.2018.1443111	results	1	NA	adjusted_effect	0.64
10.1080/13696998.2018.1443111	results	1	NA	adjusted_pval_char	[0.47;0.87]
10.1080/13696998.2018.1443111	results	1	NA	geographical region	NA
10.1080/13696998.2018.1443111	results	1	NA	n_ipd_total	NA
10.1080/13696998.2018.1443111	results	1	NA	ess_total	NA
10.1080/13696998.2018.1443111	results	1	NA	n_nonipd_total	NA
10.1080/13696998.2018.1443111	results	1	NA	n_nonipd_anchor	NA
10.1080/13696998.2018.1443111	results	1	NA	n_ipd_anchor	NA
10.1080/13696998.2018.1443111	results	1	NA	ess_anchor	NA
10.1080/13696998.2018.1443111	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/13696998.2018.1443111	results	1	NA	effect_cutoff	1
10.1080/13696998.2018.1443111	results	1	NA	adjusted_lb_ci	0.47
10.1080/13696998.2018.1443111	results	1	NA	adjusted_ub_ci	0.87
10.1080/13696998.2018.1443111	results	1	NA	adjusted_significant	TRUE
10.1080/13696998.2018.1443111	study_information	NA	1	Patient-level data used	Yes
10.1080/13696998.2018.1443111	study_information	NA	1	Clinical Trial	Yes
10.1080/13696998.2018.1443111	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01828099
10.1080/13696998.2018.1443111	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/13696998.2018.1443111	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/13696998.2018.1443111	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/13696998.2018.1443111	study_information	NA	2	Patient-level data used	No
10.1080/13696998.2018.1443111	study_information	NA	2	Clinical Trial	Yes
10.1080/13696998.2018.1443111	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01154140
10.1080/13696998.2018.1443111	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/13696998.2018.1443111	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/13696998.2018.1443111	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/13696998.2020.1722139	general_information	NA	NA	Medical Condition of Interest Name	plaque psoriasis
10.1080/13696998.2020.1722139	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/13696998.2020.1722139	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/13696998.2020.1722139	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1080/13696998.2020.1722139	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1080/13696998.2020.1722139	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/13696998.2020.1722139	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/13696998.2020.1722139	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/13696998.2020.1722139	methodology	1	NA	primary_outcome_name	physician's global assessment treatment success
10.1080/13696998.2020.1722139	methodology	1	NA	outcome_short_name	PGA responders Rate
10.1080/13696998.2020.1722139	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1080/13696998.2020.1722139	methodology	1	NA	Treatment name 1	calcipotriene 0.005/betamethasone dipropionate 0.064% foam
10.1080/13696998.2020.1722139	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3
10.1080/13696998.2020.1722139	methodology	1	NA	Treatment name 2	halobetasol 0.01/tazarotene 0.045%
10.1080/13696998.2020.1722139	methodology	1	NA	Study 'number(s)' for treatment 2	4;5
10.1080/13696998.2020.1722139	methodology	1	NA	paitc_type	MAIC
10.1080/13696998.2020.1722139	methodology	1	NA	anchored_yn	Yes
10.1080/13696998.2020.1722139	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/13696998.2020.1722139	methodology	1	NA	primary_outcome_yn	Yes
10.1080/13696998.2020.1722139	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/13696998.2020.1722139	methodology	1	NA	prognostic_factors_yn	No
10.1080/13696998.2020.1722139	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1080/13696998.2020.1722139	methodology	1	NA	weights_model_yn	No
10.1080/13696998.2020.1722139	methodology	1	NA	scale_choice_yn	No
10.1080/13696998.2020.1722139	results	1	NA	contrast	Rate difference
10.1080/13696998.2020.1722139	results	1	NA	direction_benefit	superior
10.1080/13696998.2020.1722139	results	1	NA	n_nonipd_ttt	276
10.1080/13696998.2020.1722139	results	1	NA	n_ipd_ttt	649
10.1080/13696998.2020.1722139	results	1	NA	ess_ttt	NA
10.1080/13696998.2020.1722139	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/13696998.2020.1722139	results	1	NA	list_covariates_yn	Yes
10.1080/13696998.2020.1722139	results	1	NA	n_covariates	4
10.1080/13696998.2020.1722139	results	1	NA	list_covariates	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1080/13696998.2020.1722139	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/13696998.2020.1722139	results	1	NA	unadjusted_effect	NA
10.1080/13696998.2020.1722139	results	1	NA	unadjusted_pval_char	NA
10.1080/13696998.2020.1722139	results	1	NA	adjusted_effect	20.7
10.1080/13696998.2020.1722139	results	1	NA	adjusted_pval_char	<0.001
10.1080/13696998.2020.1722139	results	1	NA	geographical region	NA
10.1080/13696998.2020.1722139	results	1	NA	n_ipd_total	848
10.1080/13696998.2020.1722139	results	1	NA	ess_total	586
10.1080/13696998.2020.1722139	results	1	NA	n_nonipd_total	418
10.1080/13696998.2020.1722139	results	1	NA	n_nonipd_anchor	142
10.1080/13696998.2020.1722139	results	1	NA	n_ipd_anchor	199
10.1080/13696998.2020.1722139	results	1	NA	ess_anchor	NA
10.1080/13696998.2020.1722139	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/13696998.2020.1722139	results	1	NA	effect_cutoff	0
10.1080/13696998.2020.1722139	results	1	NA	adjusted_pval	<0.001
10.1080/13696998.2020.1722139	results	1	NA	adjusted_significant	TRUE
10.1080/13696998.2020.1722139	study_information	NA	1	Patient-level data used	Yes
10.1080/13696998.2020.1722139	study_information	NA	1	Clinical Trial	Yes
10.1080/13696998.2020.1722139	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01866163
10.1080/13696998.2020.1722139	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/13696998.2020.1722139	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/13696998.2020.1722139	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/13696998.2020.1722139	study_information	NA	2	Patient-level data used	Yes
10.1080/13696998.2020.1722139	study_information	NA	2	Clinical Trial	Yes
10.1080/13696998.2020.1722139	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02132936
10.1080/13696998.2020.1722139	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.1080/13696998.2020.1722139	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/13696998.2020.1722139	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/13696998.2020.1722139	study_information	NA	3	Patient-level data used	Yes
10.1080/13696998.2020.1722139	study_information	NA	3	Clinical Trial	Yes
10.1080/13696998.2020.1722139	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01536886
10.1080/13696998.2020.1722139	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/13696998.2020.1722139	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.1080/13696998.2020.1722139	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/13696998.2020.1722139	study_information	NA	4	Patient-level data used	No
10.1080/13696998.2020.1722139	study_information	NA	4	Clinical Trial	Yes
10.1080/13696998.2020.1722139	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02462070
10.1080/13696998.2020.1722139	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/13696998.2020.1722139	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1080/13696998.2020.1722139	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1080/13696998.2020.1722139	study_information	NA	5	Patient-level data used	No
10.1080/13696998.2020.1722139	study_information	NA	5	Clinical Trial	Yes
10.1080/13696998.2020.1722139	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02462122
10.1080/13696998.2020.1722139	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/13696998.2020.1722139	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1080/13696998.2020.1722139	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1080/14656566.2020.1811850	general_information	NA	NA	Medical Condition of Interest Name	amyloidosis with polyneuropathy
10.1080/14656566.2020.1811850	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/14656566.2020.1811850	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/14656566.2020.1811850	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/14656566.2020.1811850	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/14656566.2020.1811850	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/14656566.2020.1811850	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/14656566.2020.1811850	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/14656566.2020.1811850	methodology	1	NA	primary_outcome_name	15-month changes from baseline in mnis+7ionis (modified neuropathy impairment score +7)
10.1080/14656566.2020.1811850	methodology	1	NA	outcome_short_name	Modified neuropathy impairment score
10.1080/14656566.2020.1811850	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1080/14656566.2020.1811850	methodology	1	NA	Treatment name 1	patisiran
10.1080/14656566.2020.1811850	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/14656566.2020.1811850	methodology	1	NA	Treatment name 2	inotersen
10.1080/14656566.2020.1811850	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/14656566.2020.1811850	methodology	1	NA	paitc_type	MAIC
10.1080/14656566.2020.1811850	methodology	1	NA	anchored_yn	Yes
10.1080/14656566.2020.1811850	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/14656566.2020.1811850	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/14656566.2020.1811850	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1080/14656566.2020.1811850	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/14656566.2020.1811850	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/14656566.2020.1811850	methodology	1	NA	weights_model_yn	No
10.1080/14656566.2020.1811850	methodology	1	NA	scale_choice_yn	No
10.1080/14656566.2020.1811850	results	1	NA	contrast	Means difference
10.1080/14656566.2020.1811850	results	1	NA	direction_benefit	inferior
10.1080/14656566.2020.1811850	results	1	NA	n_nonipd_ttt	112
10.1080/14656566.2020.1811850	results	1	NA	n_ipd_ttt	148
10.1080/14656566.2020.1811850	results	1	NA	ess_ttt	90
10.1080/14656566.2020.1811850	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/14656566.2020.1811850	results	1	NA	list_covariates_yn	Yes
10.1080/14656566.2020.1811850	results	1	NA	n_covariates	9
10.1080/14656566.2020.1811850	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1080/14656566.2020.1811850	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/14656566.2020.1811850	results	1	NA	unadjusted_effect	-16.2
10.1080/14656566.2020.1811850	results	1	NA	unadjusted_pval_char	0.001
10.1080/14656566.2020.1811850	results	1	NA	adjusted_effect	-12.3
10.1080/14656566.2020.1811850	results	1	NA	adjusted_pval_char	0.007
10.1080/14656566.2020.1811850	results	1	NA	geographical region	No
10.1080/14656566.2020.1811850	results	1	NA	n_ipd_total	NA
10.1080/14656566.2020.1811850	results	1	NA	ess_total	NA
10.1080/14656566.2020.1811850	results	1	NA	n_nonipd_total	NA
10.1080/14656566.2020.1811850	results	1	NA	n_nonipd_anchor	60
10.1080/14656566.2020.1811850	results	1	NA	n_ipd_anchor	77
10.1080/14656566.2020.1811850	results	1	NA	ess_anchor	47
10.1080/14656566.2020.1811850	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/14656566.2020.1811850	results	1	NA	effect_cutoff	0
10.1080/14656566.2020.1811850	results	1	NA	unadjusted_pval	0.001
10.1080/14656566.2020.1811850	results	1	NA	unadjusted_num_pval	0.001
10.1080/14656566.2020.1811850	results	1	NA	unadjusted_significant	TRUE
10.1080/14656566.2020.1811850	results	1	NA	adjusted_pval	0.007
10.1080/14656566.2020.1811850	results	1	NA	adjusted_num_pval	0.007
10.1080/14656566.2020.1811850	results	1	NA	adjusted_significant	TRUE
10.1080/14656566.2020.1811850	study_information	NA	1	Patient-level data used	Yes
10.1080/14656566.2020.1811850	study_information	NA	1	Clinical Trial	Yes
10.1080/14656566.2020.1811850	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01960348
10.1080/14656566.2020.1811850	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/14656566.2020.1811850	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/14656566.2020.1811850	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/14656566.2020.1811850	study_information	NA	2	Patient-level data used	No
10.1080/14656566.2020.1811850	study_information	NA	2	Clinical Trial	Yes
10.1080/14656566.2020.1811850	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01737398
10.1080/14656566.2020.1811850	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/14656566.2020.1811850	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3
10.1080/14656566.2020.1811850	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/14760584.2021.1994858	general_information	NA	NA	Medical Condition of Interest Name	pneumococcal disease
10.1080/14760584.2021.1994858	general_information	NA	NA	Countries of first author affiliations	switzerland
10.1080/14760584.2021.1994858	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/14760584.2021.1994858	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry
10.1080/14760584.2021.1994858	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/14760584.2021.1994858	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/14760584.2021.1994858	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/14760584.2021.1994858	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/14760584.2021.1994858	methodology	1	NA	primary_outcome_name	30 days post-vaccination serotype-specific opa (opsonophagocytic activity)
10.1080/14760584.2021.1994858	methodology	1	NA	outcome_short_name	Serotype-specific opsonophagocytic activity
10.1080/14760584.2021.1994858	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1080/14760584.2021.1994858	methodology	1	NA	Treatment name 1	15-valent pneumococcal conjugate vaccine
10.1080/14760584.2021.1994858	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3
10.1080/14760584.2021.1994858	methodology	1	NA	Treatment name 2	20-valent pneumococcal conjugate vaccine
10.1080/14760584.2021.1994858	methodology	1	NA	Study 'number(s)' for treatment 2	4
10.1080/14760584.2021.1994858	methodology	1	NA	paitc_type	MAIC
10.1080/14760584.2021.1994858	methodology	1	NA	anchored_yn	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/14760584.2021.1994858	methodology	1	NA	primary_outcome_yn	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/14760584.2021.1994858	methodology	1	NA	prognostic_factors_yn	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	weights_model_yn	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	scale_choice_yn	Yes
10.1080/14760584.2021.1994858	results	1	NA	contrast	Means Ratio
10.1080/14760584.2021.1994858	results	1	NA	direction_benefit	superior
10.1080/14760584.2021.1994858	results	1	NA	n_nonipd_ttt	1507
10.1080/14760584.2021.1994858	results	1	NA	n_ipd_ttt	2196
10.1080/14760584.2021.1994858	results	1	NA	ess_ttt	NA
10.1080/14760584.2021.1994858	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/14760584.2021.1994858	results	1	NA	list_covariates_yn	Yes
10.1080/14760584.2021.1994858	results	1	NA	n_covariates	2
10.1080/14760584.2021.1994858	results	1	NA	list_covariates	Age, Sex
10.1080/14760584.2021.1994858	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1080/14760584.2021.1994858	results	1	NA	unadjusted_effect	0.89
10.1080/14760584.2021.1994858	results	1	NA	unadjusted_pval_char	[0.74;1.07]
10.1080/14760584.2021.1994858	results	1	NA	adjusted_effect	0.91
10.1080/14760584.2021.1994858	results	1	NA	adjusted_pval_char	[0.76;1.10]
10.1080/14760584.2021.1994858	results	1	NA	geographical region	NA
10.1080/14760584.2021.1994858	results	1	NA	n_ipd_total	3033
10.1080/14760584.2021.1994858	results	1	NA	ess_total	1710
10.1080/14760584.2021.1994858	results	1	NA	n_nonipd_total	2997
10.1080/14760584.2021.1994858	results	1	NA	n_nonipd_anchor	1490
10.1080/14760584.2021.1994858	results	1	NA	n_ipd_anchor	843
10.1080/14760584.2021.1994858	results	1	NA	ess_anchor	NA
10.1080/14760584.2021.1994858	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/14760584.2021.1994858	results	1	NA	effect_cutoff	1
10.1080/14760584.2021.1994858	results	1	NA	unadjusted_lb_ci	0.74
10.1080/14760584.2021.1994858	results	1	NA	unadjusted_ub_ci	1.07
10.1080/14760584.2021.1994858	results	1	NA	unadjusted_significant	FALSE
10.1080/14760584.2021.1994858	results	1	NA	adjusted_lb_ci	0.76
10.1080/14760584.2021.1994858	results	1	NA	adjusted_ub_ci	1.1
10.1080/14760584.2021.1994858	results	1	NA	adjusted_significant	FALSE
10.1080/14760584.2021.1994858	study_information	NA	1	Patient-level data used	Yes
10.1080/14760584.2021.1994858	study_information	NA	1	Clinical Trial	Yes
10.1080/14760584.2021.1994858	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03950622
10.1080/14760584.2021.1994858	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/14760584.2021.1994858	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/14760584.2021.1994858	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/14760584.2021.1994858	study_information	NA	2	Patient-level data used	Yes
10.1080/14760584.2021.1994858	study_information	NA	2	Clinical Trial	Yes
10.1080/14760584.2021.1994858	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03480763
10.1080/14760584.2021.1994858	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/14760584.2021.1994858	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/14760584.2021.1994858	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/14760584.2021.1994858	study_information	NA	3	Patient-level data used	Yes
10.1080/14760584.2021.1994858	study_information	NA	3	Clinical Trial	Yes
10.1080/14760584.2021.1994858	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03950856
10.1080/14760584.2021.1994858	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/14760584.2021.1994858	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/14760584.2021.1994858	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/14760584.2021.1994858	study_information	NA	4	Patient-level data used	No
10.1080/14760584.2021.1994858	study_information	NA	4	Clinical Trial	Yes
10.1080/14760584.2021.1994858	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03760146
10.1080/14760584.2021.1994858	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/14760584.2021.1994858	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1080/14760584.2021.1994858	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1080/17474086.2018.1475226	general_information	NA	NA	Medical Condition of Interest Name	relapsed and refractory classical hodgkins lymphoma
10.1080/17474086.2018.1475226	general_information	NA	NA	Countries of first author affiliations	canada
10.1080/17474086.2018.1475226	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/17474086.2018.1475226	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1080/17474086.2018.1475226	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/17474086.2018.1475226	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/17474086.2018.1475226	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/17474086.2018.1475226	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/17474086.2018.1475226	methodology	1	NA	primary_outcome_name	progression-free survival
10.1080/17474086.2018.1475226	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1080/17474086.2018.1475226	methodology	1	NA	primary_outcome_type	Time-to-event
10.1080/17474086.2018.1475226	methodology	1	NA	Treatment name 1	pembrolizumab
10.1080/17474086.2018.1475226	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/17474086.2018.1475226	methodology	1	NA	Treatment name 2	st + ard of care
10.1080/17474086.2018.1475226	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/17474086.2018.1475226	methodology	1	NA	paitc_type	STC
10.1080/17474086.2018.1475226	methodology	1	NA	anchored_yn	No
10.1080/17474086.2018.1475226	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1080/17474086.2018.1475226	methodology	1	NA	primary_outcome_yn	Yes
10.1080/17474086.2018.1475226	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/17474086.2018.1475226	methodology	1	NA	prognostic_factors_yn	Yes
10.1080/17474086.2018.1475226	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/17474086.2018.1475226	methodology	1	NA	weights_model_yn	Yes
10.1080/17474086.2018.1475226	methodology	1	NA	scale_choice_yn	No
10.1080/17474086.2018.1475226	results	1	NA	contrast	HR
10.1080/17474086.2018.1475226	results	1	NA	direction_benefit	inferior
10.1080/17474086.2018.1475226	results	1	NA	n_nonipd_ttt	83
10.1080/17474086.2018.1475226	results	1	NA	n_ipd_ttt	175
10.1080/17474086.2018.1475226	results	1	NA	ess_ttt	175
10.1080/17474086.2018.1475226	results	1	NA	weights_evaluation_yn	Not mentioned
10.1080/17474086.2018.1475226	results	1	NA	list_covariates_yn	Yes
10.1080/17474086.2018.1475226	results	1	NA	n_covariates	7
10.1080/17474086.2018.1475226	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1080/17474086.2018.1475226	results	1	NA	effect_direction	Denominator if ratio, or rightside if difference
10.1080/17474086.2018.1475226	results	1	NA	unadjusted_effect	5
10.1080/17474086.2018.1475226	results	1	NA	unadjusted_pval_char	[3.56;7.01]
10.1080/17474086.2018.1475226	results	1	NA	adjusted_effect	6.35
10.1080/17474086.2018.1475226	results	1	NA	adjusted_pval_char	[4.04;9.98]
10.1080/17474086.2018.1475226	results	1	NA	geographical region	NA
10.1080/17474086.2018.1475226	results	1	NA	n_ipd_total	NA
10.1080/17474086.2018.1475226	results	1	NA	ess_total	NA
10.1080/17474086.2018.1475226	results	1	NA	n_nonipd_total	NA
10.1080/17474086.2018.1475226	results	1	NA	n_nonipd_anchor	NA
10.1080/17474086.2018.1475226	results	1	NA	n_ipd_anchor	NA
10.1080/17474086.2018.1475226	results	1	NA	ess_anchor	NA
10.1080/17474086.2018.1475226	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1080/17474086.2018.1475226	results	1	NA	effect_cutoff	1
10.1080/17474086.2018.1475226	results	1	NA	unadjusted_lb_ci	3.56
10.1080/17474086.2018.1475226	results	1	NA	unadjusted_ub_ci	7.01
10.1080/17474086.2018.1475226	results	1	NA	unadjusted_significant	TRUE
10.1080/17474086.2018.1475226	results	1	NA	adjusted_lb_ci	4.04
10.1080/17474086.2018.1475226	results	1	NA	adjusted_ub_ci	9.98
10.1080/17474086.2018.1475226	results	1	NA	adjusted_significant	TRUE
10.1080/17474086.2018.1475226	study_information	NA	1	Patient-level data used	Yes
10.1080/17474086.2018.1475226	study_information	NA	1	Clinical Trial	Yes
10.1080/17474086.2018.1475226	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02453594
10.1080/17474086.2018.1475226	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1080/17474086.2018.1475226	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/17474086.2018.1475226	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1080/17474086.2018.1475226	study_information	NA	2	Patient-level data used	No
10.1080/17474086.2018.1475226	study_information	NA	2	Clinical Trial	No
10.1080/17474086.2018.1475226	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	cheah et al., 2016
10.1080/17474086.2018.1475226	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1093/europace/euy160	general_information	NA	NA	Medical Condition of Interest Name	non-valvular atrial fibrillation
10.1093/europace/euy160	general_information	NA	NA	Countries of first author affiliations	uk
10.1093/europace/euy160	general_information	NA	NA	Countries of last author affiliations	canada
10.1093/europace/euy160	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1093/europace/euy160	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1093/europace/euy160	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1093/europace/euy160	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1093/europace/euy160	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1093/europace/euy160	methodology	1	NA	primary_outcome_name	treatment-emergent adjudicated major bleeding
10.1093/europace/euy160	methodology	1	NA	outcome_short_name	Major Bleeding
10.1093/europace/euy160	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1093/europace/euy160	methodology	1	NA	Treatment name 1	rivaroxaban
10.1093/europace/euy160	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1093/europace/euy160	methodology	1	NA	Treatment name 2	rivaroxaban
10.1093/europace/euy160	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1093/europace/euy160	methodology	1	NA	paitc_type	MAIC
10.1093/europace/euy160	methodology	1	NA	anchored_yn	No
10.1093/europace/euy160	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1093/europace/euy160	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1093/europace/euy160	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1093/europace/euy160	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1093/europace/euy160	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1093/europace/euy160	methodology	1	NA	weights_model_yn	No
10.1093/europace/euy160	methodology	1	NA	scale_choice_yn	No
10.1093/europace/euy160	results	1	NA	contrast	RR
10.1093/europace/euy160	results	1	NA	direction_benefit	inferior
10.1093/europace/euy160	results	1	NA	n_nonipd_ttt	7061
10.1093/europace/euy160	results	1	NA	n_ipd_ttt	4020
10.1093/europace/euy160	results	1	NA	ess_ttt	2492
10.1093/europace/euy160	results	1	NA	weights_evaluation_yn	Not mentioned
10.1093/europace/euy160	results	1	NA	list_covariates_yn	Yes
10.1093/europace/euy160	results	1	NA	n_covariates	2
10.1093/europace/euy160	results	1	NA	list_covariates	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1093/europace/euy160	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1093/europace/euy160	results	1	NA	unadjusted_effect	NA
10.1093/europace/euy160	results	1	NA	unadjusted_pval_char	NA
10.1093/europace/euy160	results	1	NA	adjusted_effect	0.86
10.1093/europace/euy160	results	1	NA	adjusted_pval_char	[0.67;1.12]
10.1093/europace/euy160	results	1	NA	geographical region	NA
10.1093/europace/euy160	results	1	NA	n_ipd_total	NA
10.1093/europace/euy160	results	1	NA	ess_total	NA
10.1093/europace/euy160	results	1	NA	n_nonipd_total	NA
10.1093/europace/euy160	results	1	NA	n_nonipd_anchor	NA
10.1093/europace/euy160	results	1	NA	n_ipd_anchor	NA
10.1093/europace/euy160	results	1	NA	ess_anchor	NA
10.1093/europace/euy160	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1093/europace/euy160	results	1	NA	effect_cutoff	1
10.1093/europace/euy160	results	1	NA	adjusted_lb_ci	0.67
10.1093/europace/euy160	results	1	NA	adjusted_ub_ci	1.12
10.1093/europace/euy160	results	1	NA	adjusted_significant	FALSE
10.1093/europace/euy160	study_information	NA	1	Patient-level data used	Yes
10.1093/europace/euy160	study_information	NA	1	Clinical Trial	No
10.1093/europace/euy160	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01606995
10.1093/europace/euy160	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1093/europace/euy160	study_information	NA	2	Patient-level data used	No
10.1093/europace/euy160	study_information	NA	2	Clinical Trial	Yes
10.1093/europace/euy160	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00403767
10.1093/europace/euy160	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1093/europace/euy160	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1093/europace/euy160	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1093/jnci/djab071	general_information	NA	NA	Medical Condition of Interest Name	nonmetastatic castration-resistant prostate cancer
10.1093/jnci/djab071	general_information	NA	NA	Countries of first author affiliations	usa
10.1093/jnci/djab071	general_information	NA	NA	Countries of last author affiliations	usa
10.1093/jnci/djab071	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic
10.1093/jnci/djab071	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1093/jnci/djab071	general_information	NA	NA	Mentioned sources of funding	Public grants, Pharmaceutical Industry
10.1093/jnci/djab071	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1093/jnci/djab071	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1093/jnci/djab071	methodology	1	NA	primary_outcome_name	metastasis-free survival
10.1093/jnci/djab071	methodology	1	NA	outcome_short_name	Metastasis-free Survival
10.1093/jnci/djab071	methodology	1	NA	primary_outcome_type	Time-to-event
10.1093/jnci/djab071	methodology	1	NA	Treatment name 1	abiraterone acetate
10.1093/jnci/djab071	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1093/jnci/djab071	methodology	1	NA	Treatment name 2	placebo
10.1093/jnci/djab071	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1093/jnci/djab071	methodology	1	NA	paitc_type	MAIC
10.1093/jnci/djab071	methodology	1	NA	anchored_yn	No
10.1093/jnci/djab071	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1093/jnci/djab071	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1093/jnci/djab071	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1093/jnci/djab071	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1093/jnci/djab071	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1093/jnci/djab071	methodology	1	NA	weights_model_yn	No
10.1093/jnci/djab071	methodology	1	NA	scale_choice_yn	No
10.1093/jnci/djab071	results	1	NA	contrast	HR
10.1093/jnci/djab071	results	1	NA	direction_benefit	inferior
10.1093/jnci/djab071	results	1	NA	n_nonipd_ttt	1207
10.1093/jnci/djab071	results	1	NA	n_ipd_ttt	131
10.1093/jnci/djab071	results	1	NA	ess_ttt	81
10.1093/jnci/djab071	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1093/jnci/djab071	results	1	NA	list_covariates_yn	Yes
10.1093/jnci/djab071	results	1	NA	n_covariates	4
10.1093/jnci/djab071	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1093/jnci/djab071	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1093/jnci/djab071	results	1	NA	unadjusted_effect	NA
10.1093/jnci/djab071	results	1	NA	unadjusted_pval_char	NA
10.1093/jnci/djab071	results	1	NA	adjusted_effect	0.22
10.1093/jnci/djab071	results	1	NA	adjusted_pval_char	[0.12;0.41]
10.1093/jnci/djab071	results	1	NA	geographical region	NA
10.1093/jnci/djab071	results	1	NA	n_ipd_total	NA
10.1093/jnci/djab071	results	1	NA	ess_total	NA
10.1093/jnci/djab071	results	1	NA	n_nonipd_total	NA
10.1093/jnci/djab071	results	1	NA	n_nonipd_anchor	NA
10.1093/jnci/djab071	results	1	NA	n_ipd_anchor	NA
10.1093/jnci/djab071	results	1	NA	ess_anchor	NA
10.1093/jnci/djab071	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1093/jnci/djab071	results	1	NA	effect_cutoff	1
10.1093/jnci/djab071	results	1	NA	adjusted_lb_ci	0.12
10.1093/jnci/djab071	results	1	NA	adjusted_ub_ci	0.41
10.1093/jnci/djab071	results	1	NA	adjusted_significant	TRUE
10.1093/jnci/djab071	study_information	NA	1	Patient-level data used	Yes
10.1093/jnci/djab071	study_information	NA	1	Clinical Trial	Yes
10.1093/jnci/djab071	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01314118
10.1093/jnci/djab071	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1093/jnci/djab071	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1093/jnci/djab071	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1093/jnci/djab071	study_information	NA	2	Patient-level data used	No
10.1093/jnci/djab071	study_information	NA	2	Clinical Trial	Yes
10.1093/jnci/djab071	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204
10.1093/jnci/djab071	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1093/jnci/djab071	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1093/jnci/djab071	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1097/brs.0000000000002647	general_information	NA	NA	Medical Condition of Interest Name	lumbar disc degeneration
10.1097/brs.0000000000002647	general_information	NA	NA	Countries of first author affiliations	usa
10.1097/brs.0000000000002647	general_information	NA	NA	Countries of last author affiliations	canada
10.1097/brs.0000000000002647	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Private Data Analysis Company
10.1097/brs.0000000000002647	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1097/brs.0000000000002647	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1097/brs.0000000000002647	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1097/brs.0000000000002647	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1097/brs.0000000000002647	methodology	1	NA	primary_outcome_name	5-year change in radiographic adjacent-level degeneration
10.1097/brs.0000000000002647	methodology	1	NA	outcome_short_name	Radiographic degeneration
10.1097/brs.0000000000002647	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1097/brs.0000000000002647	methodology	1	NA	Treatment name 1	total disc replacement
10.1097/brs.0000000000002647	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1097/brs.0000000000002647	methodology	1	NA	Treatment name 2	fusion
10.1097/brs.0000000000002647	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1097/brs.0000000000002647	methodology	1	NA	paitc_type	MAIC
10.1097/brs.0000000000002647	methodology	1	NA	anchored_yn	No
10.1097/brs.0000000000002647	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1097/brs.0000000000002647	methodology	1	NA	primary_outcome_yn	Yes
10.1097/brs.0000000000002647	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1097/brs.0000000000002647	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1097/brs.0000000000002647	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1097/brs.0000000000002647	methodology	1	NA	weights_model_yn	No
10.1097/brs.0000000000002647	methodology	1	NA	scale_choice_yn	No
10.1097/brs.0000000000002647	results	1	NA	contrast	OR
10.1097/brs.0000000000002647	results	1	NA	direction_benefit	inferior
10.1097/brs.0000000000002647	results	1	NA	n_nonipd_ttt	43
10.1097/brs.0000000000002647	results	1	NA	n_ipd_ttt	175
10.1097/brs.0000000000002647	results	1	NA	ess_ttt	139
10.1097/brs.0000000000002647	results	1	NA	weights_evaluation_yn	Not mentioned
10.1097/brs.0000000000002647	results	1	NA	list_covariates_yn	Yes
10.1097/brs.0000000000002647	results	1	NA	n_covariates	7
10.1097/brs.0000000000002647	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1097/brs.0000000000002647	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1097/brs.0000000000002647	results	1	NA	unadjusted_effect	0.28
10.1097/brs.0000000000002647	results	1	NA	unadjusted_pval_char	[0.12;0.63]
10.1097/brs.0000000000002647	results	1	NA	adjusted_effect	0.32
10.1097/brs.0000000000002647	results	1	NA	adjusted_pval_char	[0.13;0.76]
10.1097/brs.0000000000002647	results	1	NA	geographical region	No
10.1097/brs.0000000000002647	results	1	NA	n_ipd_total	NA
10.1097/brs.0000000000002647	results	1	NA	ess_total	NA
10.1097/brs.0000000000002647	results	1	NA	n_nonipd_total	NA
10.1097/brs.0000000000002647	results	1	NA	n_nonipd_anchor	NA
10.1097/brs.0000000000002647	results	1	NA	n_ipd_anchor	NA
10.1097/brs.0000000000002647	results	1	NA	ess_anchor	NA
10.1097/brs.0000000000002647	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1097/brs.0000000000002647	results	1	NA	effect_cutoff	1
10.1097/brs.0000000000002647	results	1	NA	unadjusted_lb_ci	0.12
10.1097/brs.0000000000002647	results	1	NA	unadjusted_ub_ci	0.63
10.1097/brs.0000000000002647	results	1	NA	unadjusted_significant	TRUE
10.1097/brs.0000000000002647	results	1	NA	adjusted_lb_ci	0.13
10.1097/brs.0000000000002647	results	1	NA	adjusted_ub_ci	0.76
10.1097/brs.0000000000002647	results	1	NA	adjusted_significant	TRUE
10.1097/brs.0000000000002647	study_information	NA	1	Patient-level data used	Yes
10.1097/brs.0000000000002647	study_information	NA	1	Clinical Trial	Yes
10.1097/brs.0000000000002647	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00589797
10.1097/brs.0000000000002647	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1097/brs.0000000000002647	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1097/brs.0000000000002647	study_information	NA	2	Patient-level data used	No
10.1097/brs.0000000000002647	study_information	NA	2	Clinical Trial	Yes
10.1097/brs.0000000000002647	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00295009
10.1097/brs.0000000000002647	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1097/brs.0000000000002647	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1097/ju.0000000000001767	general_information	NA	NA	Medical Condition of Interest Name	nonmetastatic castration-resistant prostate cancer
10.1097/ju.0000000000001767	general_information	NA	NA	Countries of first author affiliations	usa
10.1097/ju.0000000000001767	general_information	NA	NA	Countries of last author affiliations	usa
10.1097/ju.0000000000001767	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1097/ju.0000000000001767	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1097/ju.0000000000001767	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1097/ju.0000000000001767	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1097/ju.0000000000001767	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1097/ju.0000000000001767	methodology	1	NA	primary_outcome_name	Risk of fall
10.1097/ju.0000000000001767	methodology	1	NA	outcome_short_name	Risk of fall
10.1097/ju.0000000000001767	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1097/ju.0000000000001767	methodology	1	NA	Treatment name 1	darolutamide
10.1097/ju.0000000000001767	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1097/ju.0000000000001767	methodology	1	NA	Treatment name 2	apalutamide
10.1097/ju.0000000000001767	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1097/ju.0000000000001767	methodology	1	NA	paitc_type	MAIC
10.1097/ju.0000000000001767	methodology	1	NA	anchored_yn	Yes
10.1097/ju.0000000000001767	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1097/ju.0000000000001767	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1097/ju.0000000000001767	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1097/ju.0000000000001767	methodology	1	NA	prognostic_factors_yn	No
10.1097/ju.0000000000001767	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1097/ju.0000000000001767	methodology	1	NA	weights_model_yn	No
10.1097/ju.0000000000001767	methodology	1	NA	scale_choice_yn	No
10.1097/ju.0000000000001767	methodology	2	NA	primary_outcome_name	Risk of fall
10.1097/ju.0000000000001767	methodology	2	NA	outcome_short_name	Risk of fall
10.1097/ju.0000000000001767	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1097/ju.0000000000001767	methodology	2	NA	Treatment name 1	darolutamide
10.1097/ju.0000000000001767	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1097/ju.0000000000001767	methodology	2	NA	Treatment name 2	enzalutamide
10.1097/ju.0000000000001767	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1097/ju.0000000000001767	methodology	2	NA	paitc_type	MAIC
10.1097/ju.0000000000001767	methodology	2	NA	anchored_yn	Yes
10.1097/ju.0000000000001767	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1097/ju.0000000000001767	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1097/ju.0000000000001767	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.1097/ju.0000000000001767	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1097/ju.0000000000001767	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1097/ju.0000000000001767	methodology	2	NA	weights_model_yn	No
10.1097/ju.0000000000001767	methodology	2	NA	scale_choice_yn	No
10.1097/ju.0000000000001767	results	1	NA	contrast	Risk difference
10.1097/ju.0000000000001767	results	1	NA	direction_benefit	inferior
10.1097/ju.0000000000001767	results	1	NA	n_nonipd_ttt	806
10.1097/ju.0000000000001767	results	1	NA	n_ipd_ttt	943
10.1097/ju.0000000000001767	results	1	NA	ess_ttt	604
10.1097/ju.0000000000001767	results	1	NA	weights_evaluation_yn	Not mentioned
10.1097/ju.0000000000001767	results	1	NA	list_covariates_yn	Yes
10.1097/ju.0000000000001767	results	1	NA	n_covariates	7
10.1097/ju.0000000000001767	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1097/ju.0000000000001767	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1097/ju.0000000000001767	results	1	NA	unadjusted_effect	NA
10.1097/ju.0000000000001767	results	1	NA	unadjusted_pval_char	NA
10.1097/ju.0000000000001767	results	1	NA	adjusted_effect	-6.3
10.1097/ju.0000000000001767	results	1	NA	adjusted_pval_char	0.043
10.1097/ju.0000000000001767	results	1	NA	geographical region	NA
10.1097/ju.0000000000001767	results	1	NA	n_ipd_total	NA
10.1097/ju.0000000000001767	results	1	NA	ess_total	NA
10.1097/ju.0000000000001767	results	1	NA	n_nonipd_total	NA
10.1097/ju.0000000000001767	results	1	NA	n_nonipd_anchor	401
10.1097/ju.0000000000001767	results	1	NA	n_ipd_anchor	553
10.1097/ju.0000000000001767	results	1	NA	ess_anchor	391
10.1097/ju.0000000000001767	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1097/ju.0000000000001767	results	1	NA	effect_cutoff	0
10.1097/ju.0000000000001767	results	1	NA	adjusted_pval	0.043
10.1097/ju.0000000000001767	results	1	NA	adjusted_num_pval	0.043
10.1097/ju.0000000000001767	results	1	NA	adjusted_significant	TRUE
10.1097/ju.0000000000001767	results	2	NA	contrast	Risk difference
10.1097/ju.0000000000001767	results	2	NA	direction_benefit	inferior
10.1097/ju.0000000000001767	results	2	NA	n_nonipd_ttt	933
10.1097/ju.0000000000001767	results	2	NA	n_ipd_ttt	943
10.1097/ju.0000000000001767	results	2	NA	ess_ttt	580
10.1097/ju.0000000000001767	results	2	NA	weights_evaluation_yn	Not mentioned
10.1097/ju.0000000000001767	results	2	NA	list_covariates_yn	Yes
10.1097/ju.0000000000001767	results	2	NA	n_covariates	8
10.1097/ju.0000000000001767	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1097/ju.0000000000001767	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1097/ju.0000000000001767	results	2	NA	unadjusted_effect	NA
10.1097/ju.0000000000001767	results	2	NA	unadjusted_pval_char	NA
10.1097/ju.0000000000001767	results	2	NA	adjusted_effect	-6.3
10.1097/ju.0000000000001767	results	2	NA	adjusted_pval_char	0.004
10.1097/ju.0000000000001767	results	2	NA	geographical region	Yes
10.1097/ju.0000000000001767	results	2	NA	n_ipd_total	NA
10.1097/ju.0000000000001767	results	2	NA	ess_total	NA
10.1097/ju.0000000000001767	results	2	NA	n_nonipd_total	NA
10.1097/ju.0000000000001767	results	2	NA	n_nonipd_anchor	468
10.1097/ju.0000000000001767	results	2	NA	n_ipd_anchor	553
10.1097/ju.0000000000001767	results	2	NA	ess_anchor	395
10.1097/ju.0000000000001767	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1097/ju.0000000000001767	results	2	NA	effect_cutoff	0
10.1097/ju.0000000000001767	results	2	NA	adjusted_pval	0.004
10.1097/ju.0000000000001767	results	2	NA	adjusted_num_pval	0.004
10.1097/ju.0000000000001767	results	2	NA	adjusted_significant	TRUE
10.1097/ju.0000000000001767	study_information	NA	1	Patient-level data used	Yes
10.1097/ju.0000000000001767	study_information	NA	1	Clinical Trial	Yes
10.1097/ju.0000000000001767	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02200614
10.1097/ju.0000000000001767	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1097/ju.0000000000001767	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1097/ju.0000000000001767	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1097/ju.0000000000001767	study_information	NA	2	Patient-level data used	No
10.1097/ju.0000000000001767	study_information	NA	2	Clinical Trial	Yes
10.1097/ju.0000000000001767	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204
10.1097/ju.0000000000001767	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1097/ju.0000000000001767	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1097/ju.0000000000001767	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1097/ju.0000000000001767	study_information	NA	3	Patient-level data used	No
10.1097/ju.0000000000001767	study_information	NA	3	Clinical Trial	Yes
10.1097/ju.0000000000001767	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02003924
10.1097/ju.0000000000001767	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1097/ju.0000000000001767	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1097/ju.0000000000001767	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	general_information	NA	NA	Medical Condition of Interest Name	moderate-to-severe plaque psoriasis
10.1111/bjd.16140	general_information	NA	NA	Countries of first author affiliations	uk
10.1111/bjd.16140	general_information	NA	NA	Countries of last author affiliations	germany
10.1111/bjd.16140	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1111/bjd.16140	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1111/bjd.16140	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1111/bjd.16140	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1111/bjd.16140	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1111/bjd.16140	methodology	3	NA	primary_outcome_name	psoriasis area severity index 75 response rate at week 12
10.1111/bjd.16140	methodology	3	NA	outcome_short_name	PASI 75 Responders Rate
10.1111/bjd.16140	methodology	3	NA	primary_outcome_type	Binary (eg rates)
10.1111/bjd.16140	methodology	3	NA	Treatment name 1	ixekizumab
10.1111/bjd.16140	methodology	3	NA	Study 'number(s)' for treatment 1	2;3
10.1111/bjd.16140	methodology	3	NA	Treatment name 2	secukinumab
10.1111/bjd.16140	methodology	3	NA	Study 'number(s)' for treatment 2	5
10.1111/bjd.16140	methodology	3	NA	paitc_type	MAIC
10.1111/bjd.16140	methodology	3	NA	anchored_yn	Yes
10.1111/bjd.16140	methodology	3	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/bjd.16140	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/bjd.16140	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.1111/bjd.16140	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/bjd.16140	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.1111/bjd.16140	methodology	3	NA	weights_model_yn	No
10.1111/bjd.16140	methodology	3	NA	scale_choice_yn	No
10.1111/bjd.16140	methodology	5	NA	primary_outcome_name	psoriasis area severity index 75 response rate at week 12
10.1111/bjd.16140	methodology	5	NA	outcome_short_name	PASI 75 Responders Rate
10.1111/bjd.16140	methodology	5	NA	primary_outcome_type	Binary (eg rates)
10.1111/bjd.16140	methodology	5	NA	Treatment name 1	ixekizumab
10.1111/bjd.16140	methodology	5	NA	Study 'number(s)' for treatment 1	4
10.1111/bjd.16140	methodology	5	NA	Treatment name 2	secukinumab
10.1111/bjd.16140	methodology	5	NA	Study 'number(s)' for treatment 2	9
10.1111/bjd.16140	methodology	5	NA	paitc_type	MAIC
10.1111/bjd.16140	methodology	5	NA	anchored_yn	Yes
10.1111/bjd.16140	methodology	5	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1111/bjd.16140	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/bjd.16140	methodology	5	NA	variables_justification	Nothing mentioned, not reported
10.1111/bjd.16140	methodology	5	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/bjd.16140	methodology	5	NA	ttt_effect_modifiers_yn	Yes
10.1111/bjd.16140	methodology	5	NA	weights_model_yn	No
10.1111/bjd.16140	methodology	5	NA	scale_choice_yn	No
10.1111/bjd.16140	results	3	NA	contrast	Risk difference
10.1111/bjd.16140	results	3	NA	direction_benefit	superior
10.1111/bjd.16140	results	3	NA	n_nonipd_ttt	653
10.1111/bjd.16140	results	3	NA	n_ipd_ttt	1465
10.1111/bjd.16140	results	3	NA	ess_ttt	989
10.1111/bjd.16140	results	3	NA	weights_evaluation_yn	Not mentioned
10.1111/bjd.16140	results	3	NA	list_covariates_yn	Yes
10.1111/bjd.16140	results	3	NA	n_covariates	7
10.1111/bjd.16140	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1111/bjd.16140	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/bjd.16140	results	3	NA	unadjusted_effect	NA
10.1111/bjd.16140	results	3	NA	unadjusted_pval_char	0.1
10.1111/bjd.16140	results	3	NA	adjusted_effect	NA
10.1111/bjd.16140	results	3	NA	adjusted_pval_char	0.7
10.1111/bjd.16140	results	3	NA	geographical region	No
10.1111/bjd.16140	results	3	NA	n_ipd_total	1465
10.1111/bjd.16140	results	3	NA	ess_total	989
10.1111/bjd.16140	results	3	NA	n_nonipd_total	653
10.1111/bjd.16140	results	3	NA	n_nonipd_anchor	NA
10.1111/bjd.16140	results	3	NA	n_ipd_anchor	NA
10.1111/bjd.16140	results	3	NA	ess_anchor	NA
10.1111/bjd.16140	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/bjd.16140	results	3	NA	effect_cutoff	0
10.1111/bjd.16140	results	3	NA	unadjusted_pval	0.1
10.1111/bjd.16140	results	3	NA	unadjusted_num_pval	0.1
10.1111/bjd.16140	results	3	NA	unadjusted_significant	FALSE
10.1111/bjd.16140	results	3	NA	adjusted_pval	0.7
10.1111/bjd.16140	results	3	NA	adjusted_num_pval	0.7
10.1111/bjd.16140	results	3	NA	adjusted_significant	FALSE
10.1111/bjd.16140	results	5	NA	contrast	Risk difference
10.1111/bjd.16140	results	5	NA	direction_benefit	superior
10.1111/bjd.16140	results	5	NA	n_nonipd_ttt	676
10.1111/bjd.16140	results	5	NA	n_ipd_ttt	259
10.1111/bjd.16140	results	5	NA	ess_ttt	122
10.1111/bjd.16140	results	5	NA	weights_evaluation_yn	Not mentioned
10.1111/bjd.16140	results	5	NA	list_covariates_yn	Yes
10.1111/bjd.16140	results	5	NA	n_covariates	8
10.1111/bjd.16140	results	5	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1111/bjd.16140	results	5	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/bjd.16140	results	5	NA	unadjusted_effect	NA
10.1111/bjd.16140	results	5	NA	unadjusted_pval_char	0.21
10.1111/bjd.16140	results	5	NA	adjusted_effect	NA
10.1111/bjd.16140	results	5	NA	adjusted_pval_char	0.26
10.1111/bjd.16140	results	5	NA	geographical region	No
10.1111/bjd.16140	results	5	NA	n_ipd_total	259
10.1111/bjd.16140	results	5	NA	ess_total	122
10.1111/bjd.16140	results	5	NA	n_nonipd_total	676
10.1111/bjd.16140	results	5	NA	n_nonipd_anchor	NA
10.1111/bjd.16140	results	5	NA	n_ipd_anchor	NA
10.1111/bjd.16140	results	5	NA	ess_anchor	NA
10.1111/bjd.16140	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/bjd.16140	results	5	NA	effect_cutoff	0
10.1111/bjd.16140	results	5	NA	unadjusted_pval	0.21
10.1111/bjd.16140	results	5	NA	unadjusted_num_pval	0.21
10.1111/bjd.16140	results	5	NA	unadjusted_significant	FALSE
10.1111/bjd.16140	results	5	NA	adjusted_pval	0.26
10.1111/bjd.16140	results	5	NA	adjusted_num_pval	0.26
10.1111/bjd.16140	results	5	NA	adjusted_significant	FALSE
10.1111/bjd.16140	study_information	NA	1	Patient-level data used	Yes
10.1111/bjd.16140	study_information	NA	1	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01474512
10.1111/bjd.16140	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	2	Patient-level data used	Yes
10.1111/bjd.16140	study_information	NA	2	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01597245
10.1111/bjd.16140	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	3	Patient-level data used	Yes
10.1111/bjd.16140	study_information	NA	3	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01646177
10.1111/bjd.16140	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	4	Patient-level data used	Yes
10.1111/bjd.16140	study_information	NA	4	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02561806
10.1111/bjd.16140	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	5	Patient-level data used	No
10.1111/bjd.16140	study_information	NA	5	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01358578
10.1111/bjd.16140	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	6	Patient-level data used	No
10.1111/bjd.16140	study_information	NA	6	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01365455
10.1111/bjd.16140	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	7	Patient-level data used	No
10.1111/bjd.16140	study_information	NA	7	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01555125
10.1111/bjd.16140	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	7	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	8	Patient-level data used	No
10.1111/bjd.16140	study_information	NA	8	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01636687
10.1111/bjd.16140	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	9	Patient-level data used	No
10.1111/bjd.16140	study_information	NA	9	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02074982
10.1111/bjd.16140	study_information	NA	9	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	9	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more
10.1111/cea.13561	general_information	NA	NA	Medical Condition of Interest Name	asthma
10.1111/cea.13561	general_information	NA	NA	Countries of first author affiliations	france
10.1111/cea.13561	general_information	NA	NA	Countries of last author affiliations	usa
10.1111/cea.13561	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1111/cea.13561	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1111/cea.13561	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1111/cea.13561	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1111/cea.13561	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1111/cea.13561	methodology	1	NA	primary_outcome_name	ocs (oral corticosteroids) dosage reduction from baseline to week 24
10.1111/cea.13561	methodology	1	NA	outcome_short_name	Oral corticosteriods dosage reduction
10.1111/cea.13561	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1111/cea.13561	methodology	1	NA	Treatment name 1	benralizumab
10.1111/cea.13561	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1111/cea.13561	methodology	1	NA	Treatment name 2	mepolizumab
10.1111/cea.13561	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1111/cea.13561	methodology	1	NA	paitc_type	MAIC
10.1111/cea.13561	methodology	1	NA	anchored_yn	Yes
10.1111/cea.13561	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1111/cea.13561	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/cea.13561	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/cea.13561	methodology	1	NA	prognostic_factors_yn	No
10.1111/cea.13561	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1111/cea.13561	methodology	1	NA	weights_model_yn	No
10.1111/cea.13561	methodology	1	NA	scale_choice_yn	No
10.1111/cea.13561	methodology	2	NA	primary_outcome_name	ocs (oral corticosteroids) dosage reduction from baseline to week 24
10.1111/cea.13561	methodology	2	NA	outcome_short_name	Oral corticosteriods dosage reduction
10.1111/cea.13561	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1111/cea.13561	methodology	2	NA	Treatment name 1	benralizumab
10.1111/cea.13561	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1111/cea.13561	methodology	2	NA	Treatment name 2	dupilumab
10.1111/cea.13561	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1111/cea.13561	methodology	2	NA	paitc_type	MAIC
10.1111/cea.13561	methodology	2	NA	anchored_yn	Yes
10.1111/cea.13561	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1111/cea.13561	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/cea.13561	methodology	2	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/cea.13561	methodology	2	NA	prognostic_factors_yn	No
10.1111/cea.13561	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1111/cea.13561	methodology	2	NA	weights_model_yn	No
10.1111/cea.13561	methodology	2	NA	scale_choice_yn	No
10.1111/cea.13561	results	1	NA	contrast	Means difference
10.1111/cea.13561	results	1	NA	direction_benefit	superior
10.1111/cea.13561	results	1	NA	n_nonipd_ttt	NA
10.1111/cea.13561	results	1	NA	n_ipd_ttt	NA
10.1111/cea.13561	results	1	NA	ess_ttt	NA
10.1111/cea.13561	results	1	NA	weights_evaluation_yn	Not mentioned
10.1111/cea.13561	results	1	NA	list_covariates_yn	Yes
10.1111/cea.13561	results	1	NA	n_covariates	5
10.1111/cea.13561	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1111/cea.13561	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/cea.13561	results	1	NA	unadjusted_effect	20.1
10.1111/cea.13561	results	1	NA	unadjusted_pval_char	0.1584
10.1111/cea.13561	results	1	NA	adjusted_effect	6.08
10.1111/cea.13561	results	1	NA	adjusted_pval_char	0.67
10.1111/cea.13561	results	1	NA	geographical region	No
10.1111/cea.13561	results	1	NA	n_ipd_total	148
10.1111/cea.13561	results	1	NA	ess_total	72
10.1111/cea.13561	results	1	NA	n_nonipd_total	135
10.1111/cea.13561	results	1	NA	n_nonipd_anchor	NA
10.1111/cea.13561	results	1	NA	n_ipd_anchor	NA
10.1111/cea.13561	results	1	NA	ess_anchor	NA
10.1111/cea.13561	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/cea.13561	results	1	NA	effect_cutoff	0
10.1111/cea.13561	results	1	NA	unadjusted_pval	0.1584
10.1111/cea.13561	results	1	NA	unadjusted_num_pval	0.1584
10.1111/cea.13561	results	1	NA	unadjusted_significant	FALSE
10.1111/cea.13561	results	1	NA	adjusted_pval	0.67
10.1111/cea.13561	results	1	NA	adjusted_num_pval	0.67
10.1111/cea.13561	results	1	NA	adjusted_significant	FALSE
10.1111/cea.13561	results	2	NA	contrast	Means difference
10.1111/cea.13561	results	2	NA	direction_benefit	superior
10.1111/cea.13561	results	2	NA	n_nonipd_ttt	NA
10.1111/cea.13561	results	2	NA	n_ipd_ttt	NA
10.1111/cea.13561	results	2	NA	ess_ttt	NA
10.1111/cea.13561	results	2	NA	weights_evaluation_yn	Not mentioned
10.1111/cea.13561	results	2	NA	list_covariates_yn	Yes
10.1111/cea.13561	results	2	NA	n_covariates	5
10.1111/cea.13561	results	2	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1111/cea.13561	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/cea.13561	results	2	NA	unadjusted_effect	8.1
10.1111/cea.13561	results	2	NA	unadjusted_pval_char	0.46
10.1111/cea.13561	results	2	NA	adjusted_effect	-0.71
10.1111/cea.13561	results	2	NA	adjusted_pval_char	0.94
10.1111/cea.13561	results	2	NA	geographical region	No
10.1111/cea.13561	results	2	NA	n_ipd_total	148
10.1111/cea.13561	results	2	NA	ess_total	36
10.1111/cea.13561	results	2	NA	n_nonipd_total	210
10.1111/cea.13561	results	2	NA	n_nonipd_anchor	NA
10.1111/cea.13561	results	2	NA	n_ipd_anchor	NA
10.1111/cea.13561	results	2	NA	ess_anchor	NA
10.1111/cea.13561	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/cea.13561	results	2	NA	effect_cutoff	0
10.1111/cea.13561	results	2	NA	unadjusted_pval	0.46
10.1111/cea.13561	results	2	NA	unadjusted_num_pval	0.46
10.1111/cea.13561	results	2	NA	unadjusted_significant	FALSE
10.1111/cea.13561	results	2	NA	adjusted_pval	0.94
10.1111/cea.13561	results	2	NA	adjusted_num_pval	0.94
10.1111/cea.13561	results	2	NA	adjusted_significant	FALSE
10.1111/cea.13561	study_information	NA	1	Patient-level data used	Yes
10.1111/cea.13561	study_information	NA	1	Clinical Trial	Yes
10.1111/cea.13561	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02075255
10.1111/cea.13561	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/cea.13561	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1111/cea.13561	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1111/cea.13561	study_information	NA	2	Patient-level data used	No
10.1111/cea.13561	study_information	NA	2	Clinical Trial	Yes
10.1111/cea.13561	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01691508
10.1111/cea.13561	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/cea.13561	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1111/cea.13561	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1111/cea.13561	study_information	NA	3	Patient-level data used	No
10.1111/cea.13561	study_information	NA	3	Clinical Trial	Yes
10.1111/cea.13561	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02528214
10.1111/cea.13561	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/cea.13561	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1111/cea.13561	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1111/dom.14497	general_information	NA	NA	Medical Condition of Interest Name	type 2 diabetes
10.1111/dom.14497	general_information	NA	NA	Countries of first author affiliations	usa
10.1111/dom.14497	general_information	NA	NA	Countries of last author affiliations	denmark
10.1111/dom.14497	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1111/dom.14497	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1111/dom.14497	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1111/dom.14497	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1111/dom.14497	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1111/dom.14497	methodology	1	NA	primary_outcome_name	change from baseline in hba1c
10.1111/dom.14497	methodology	1	NA	outcome_short_name	HbA1C
10.1111/dom.14497	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1111/dom.14497	methodology	1	NA	Treatment name 1	semaglutide 1.0mg
10.1111/dom.14497	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1111/dom.14497	methodology	1	NA	Treatment name 2	dulaglutide 3.0mg
10.1111/dom.14497	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1111/dom.14497	methodology	1	NA	paitc_type	MAIC
10.1111/dom.14497	methodology	1	NA	anchored_yn	Yes
10.1111/dom.14497	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1111/dom.14497	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/dom.14497	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1111/dom.14497	methodology	1	NA	prognostic_factors_yn	No
10.1111/dom.14497	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1111/dom.14497	methodology	1	NA	weights_model_yn	Yes
10.1111/dom.14497	methodology	1	NA	scale_choice_yn	No
10.1111/dom.14497	methodology	2	NA	primary_outcome_name	change from baseline in hba1c
10.1111/dom.14497	methodology	2	NA	outcome_short_name	HbA1C
10.1111/dom.14497	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1111/dom.14497	methodology	2	NA	Treatment name 1	semaglutide 1.0mg
10.1111/dom.14497	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1111/dom.14497	methodology	2	NA	Treatment name 2	dulaglutide 4.5mg
10.1111/dom.14497	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1111/dom.14497	methodology	2	NA	paitc_type	MAIC
10.1111/dom.14497	methodology	2	NA	anchored_yn	Yes
10.1111/dom.14497	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1111/dom.14497	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/dom.14497	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.1111/dom.14497	methodology	2	NA	prognostic_factors_yn	No
10.1111/dom.14497	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1111/dom.14497	methodology	2	NA	weights_model_yn	Yes
10.1111/dom.14497	methodology	2	NA	scale_choice_yn	No
10.1111/dom.14497	results	1	NA	contrast	Means difference
10.1111/dom.14497	results	1	NA	direction_benefit	inferior
10.1111/dom.14497	results	1	NA	n_nonipd_ttt	616
10.1111/dom.14497	results	1	NA	n_ipd_ttt	300
10.1111/dom.14497	results	1	NA	ess_ttt	NA
10.1111/dom.14497	results	1	NA	weights_evaluation_yn	Not mentioned
10.1111/dom.14497	results	1	NA	list_covariates_yn	Yes
10.1111/dom.14497	results	1	NA	n_covariates	3
10.1111/dom.14497	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)
10.1111/dom.14497	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/dom.14497	results	1	NA	unadjusted_effect	-0.24
10.1111/dom.14497	results	1	NA	unadjusted_pval_char	0.016
10.1111/dom.14497	results	1	NA	adjusted_effect	-0.25
10.1111/dom.14497	results	1	NA	adjusted_pval_char	0.037
10.1111/dom.14497	results	1	NA	geographical region	No
10.1111/dom.14497	results	1	NA	n_ipd_total	NA
10.1111/dom.14497	results	1	NA	ess_total	NA
10.1111/dom.14497	results	1	NA	n_nonipd_total	NA
10.1111/dom.14497	results	1	NA	n_nonipd_anchor	612
10.1111/dom.14497	results	1	NA	n_ipd_anchor	299
10.1111/dom.14497	results	1	NA	ess_anchor	NA
10.1111/dom.14497	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/dom.14497	results	1	NA	effect_cutoff	0
10.1111/dom.14497	results	1	NA	unadjusted_pval	0.016
10.1111/dom.14497	results	1	NA	unadjusted_num_pval	0.016
10.1111/dom.14497	results	1	NA	unadjusted_significant	TRUE
10.1111/dom.14497	results	1	NA	adjusted_pval	0.037
10.1111/dom.14497	results	1	NA	adjusted_num_pval	0.037
10.1111/dom.14497	results	1	NA	adjusted_significant	TRUE
10.1111/dom.14497	results	2	NA	contrast	Means difference
10.1111/dom.14497	results	2	NA	direction_benefit	inferior
10.1111/dom.14497	results	2	NA	n_nonipd_ttt	614
10.1111/dom.14497	results	2	NA	n_ipd_ttt	300
10.1111/dom.14497	results	2	NA	ess_ttt	NA
10.1111/dom.14497	results	2	NA	weights_evaluation_yn	Not mentioned
10.1111/dom.14497	results	2	NA	list_covariates_yn	Yes
10.1111/dom.14497	results	2	NA	n_covariates	3
10.1111/dom.14497	results	2	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1111/dom.14497	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/dom.14497	results	2	NA	unadjusted_effect	-0.07
10.1111/dom.14497	results	2	NA	unadjusted_pval_char	0.484
10.1111/dom.14497	results	2	NA	adjusted_effect	-0.08
10.1111/dom.14497	results	2	NA	adjusted_pval_char	0.523
10.1111/dom.14497	results	2	NA	geographical region	No
10.1111/dom.14497	results	2	NA	n_ipd_total	NA
10.1111/dom.14497	results	2	NA	ess_total	NA
10.1111/dom.14497	results	2	NA	n_nonipd_total	NA
10.1111/dom.14497	results	2	NA	n_nonipd_anchor	612
10.1111/dom.14497	results	2	NA	n_ipd_anchor	299
10.1111/dom.14497	results	2	NA	ess_anchor	NA
10.1111/dom.14497	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/dom.14497	results	2	NA	effect_cutoff	0
10.1111/dom.14497	results	2	NA	unadjusted_pval	0.484
10.1111/dom.14497	results	2	NA	unadjusted_num_pval	0.484
10.1111/dom.14497	results	2	NA	unadjusted_significant	FALSE
10.1111/dom.14497	results	2	NA	adjusted_pval	0.523
10.1111/dom.14497	results	2	NA	adjusted_num_pval	0.523
10.1111/dom.14497	results	2	NA	adjusted_significant	FALSE
10.1111/dom.14497	study_information	NA	1	Patient-level data used	Yes
10.1111/dom.14497	study_information	NA	1	Clinical Trial	Yes
10.1111/dom.14497	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02648204
10.1111/dom.14497	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/dom.14497	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1111/dom.14497	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1111/dom.14497	study_information	NA	2	Patient-level data used	No
10.1111/dom.14497	study_information	NA	2	Clinical Trial	Yes
10.1111/dom.14497	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03495102
10.1111/dom.14497	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/dom.14497	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1111/dom.14497	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1111/dom.14497	study_information	NA	3	Patient-level data used	xx
10.1111/dom.14497	study_information	NA	3	Clinical Trial	xx
10.1111/dom.14497	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	xx
10.1111/dom.14497	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	xx
10.1111/dom.14497	study_information	NA	3	Phase of the clinical trial (clinical trial only)	xx
10.1111/dom.14497	study_information	NA	3	Number of treatment arms (clinical trial only)	xx
10.1111/head.14128	general_information	NA	NA	Medical Condition of Interest Name	migraine
10.1111/head.14128	general_information	NA	NA	Countries of first author affiliations	canada
10.1111/head.14128	general_information	NA	NA	Countries of last author affiliations	usa
10.1111/head.14128	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1111/head.14128	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1111/head.14128	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1111/head.14128	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1111/head.14128	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1111/head.14128	methodology	1	NA	primary_outcome_name	change in midas (migraine disability assessment) from baseline to 12 weeks
10.1111/head.14128	methodology	1	NA	outcome_short_name	Migraine disability assessment Test
10.1111/head.14128	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1111/head.14128	methodology	1	NA	Treatment name 1	rimegepant
10.1111/head.14128	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1111/head.14128	methodology	1	NA	Treatment name 2	placebo
10.1111/head.14128	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1111/head.14128	methodology	1	NA	paitc_type	MAIC
10.1111/head.14128	methodology	1	NA	anchored_yn	No
10.1111/head.14128	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/head.14128	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/head.14128	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1111/head.14128	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/head.14128	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/head.14128	methodology	1	NA	weights_model_yn	Yes
10.1111/head.14128	methodology	1	NA	scale_choice_yn	No
10.1111/head.14128	methodology	2	NA	primary_outcome_name	change in midas (migraine disability assessment) from baseline to 12 weeks
10.1111/head.14128	methodology	2	NA	outcome_short_name	Migraine disability assessment Test
10.1111/head.14128	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1111/head.14128	methodology	2	NA	Treatment name 1	rimegepant
10.1111/head.14128	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1111/head.14128	methodology	2	NA	Treatment name 2	galcanezumab
10.1111/head.14128	methodology	2	NA	Study 'number(s)' for treatment 2	2;3
10.1111/head.14128	methodology	2	NA	paitc_type	MAIC
10.1111/head.14128	methodology	2	NA	anchored_yn	No
10.1111/head.14128	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/head.14128	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/head.14128	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.1111/head.14128	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/head.14128	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/head.14128	methodology	2	NA	weights_model_yn	Yes
10.1111/head.14128	methodology	2	NA	scale_choice_yn	No
10.1111/head.14128	methodology	3	NA	primary_outcome_name	change in midas (migraine disability assessment) from baseline to 12 weeks
10.1111/head.14128	methodology	3	NA	outcome_short_name	Migraine disability assessment Test
10.1111/head.14128	methodology	3	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1111/head.14128	methodology	3	NA	Treatment name 1	rimegepant
10.1111/head.14128	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1111/head.14128	methodology	3	NA	Treatment name 2	placebo
10.1111/head.14128	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.1111/head.14128	methodology	3	NA	paitc_type	MAIC
10.1111/head.14128	methodology	3	NA	anchored_yn	No
10.1111/head.14128	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1111/head.14128	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/head.14128	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.1111/head.14128	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/head.14128	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/head.14128	methodology	3	NA	weights_model_yn	Yes
10.1111/head.14128	methodology	3	NA	scale_choice_yn	No
10.1111/head.14128	methodology	4	NA	primary_outcome_name	change in midas (migraine disability assessment) from baseline to 12 weeks
10.1111/head.14128	methodology	4	NA	outcome_short_name	Migraine disability assessment Test
10.1111/head.14128	methodology	4	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1111/head.14128	methodology	4	NA	Treatment name 1	rimegepant
10.1111/head.14128	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1111/head.14128	methodology	4	NA	Treatment name 2	erenumab
10.1111/head.14128	methodology	4	NA	Study 'number(s)' for treatment 2	4
10.1111/head.14128	methodology	4	NA	paitc_type	MAIC
10.1111/head.14128	methodology	4	NA	anchored_yn	No
10.1111/head.14128	methodology	4	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1111/head.14128	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/head.14128	methodology	4	NA	variables_justification	Nothing mentioned, not reported
10.1111/head.14128	methodology	4	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/head.14128	methodology	4	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/head.14128	methodology	4	NA	weights_model_yn	Yes
10.1111/head.14128	methodology	4	NA	scale_choice_yn	No
10.1111/head.14128	results	1	NA	contrast	Means difference
10.1111/head.14128	results	1	NA	direction_benefit	inferior
10.1111/head.14128	results	1	NA	n_nonipd_ttt	1773
10.1111/head.14128	results	1	NA	n_ipd_ttt	257
10.1111/head.14128	results	1	NA	ess_ttt	169
10.1111/head.14128	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1111/head.14128	results	1	NA	list_covariates_yn	Yes
10.1111/head.14128	results	1	NA	n_covariates	6
10.1111/head.14128	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1111/head.14128	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/head.14128	results	1	NA	unadjusted_effect	-5.54
10.1111/head.14128	results	1	NA	unadjusted_pval_char	0.026
10.1111/head.14128	results	1	NA	adjusted_effect	-7.37
10.1111/head.14128	results	1	NA	adjusted_pval_char	0.009
10.1111/head.14128	results	1	NA	geographical region	NA
10.1111/head.14128	results	1	NA	n_ipd_total	NA
10.1111/head.14128	results	1	NA	ess_total	NA
10.1111/head.14128	results	1	NA	n_nonipd_total	NA
10.1111/head.14128	results	1	NA	n_nonipd_anchor	NA
10.1111/head.14128	results	1	NA	n_ipd_anchor	NA
10.1111/head.14128	results	1	NA	ess_anchor	NA
10.1111/head.14128	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/head.14128	results	1	NA	effect_cutoff	0
10.1111/head.14128	results	1	NA	unadjusted_pval	0.026
10.1111/head.14128	results	1	NA	unadjusted_num_pval	0.026
10.1111/head.14128	results	1	NA	unadjusted_significant	TRUE
10.1111/head.14128	results	1	NA	adjusted_pval	0.009
10.1111/head.14128	results	1	NA	adjusted_num_pval	0.009
10.1111/head.14128	results	1	NA	adjusted_significant	TRUE
10.1111/head.14128	results	2	NA	contrast	Means difference
10.1111/head.14128	results	2	NA	direction_benefit	inferior
10.1111/head.14128	results	2	NA	n_nonipd_ttt	NA
10.1111/head.14128	results	2	NA	n_ipd_ttt	257
10.1111/head.14128	results	2	NA	ess_ttt	169
10.1111/head.14128	results	2	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1111/head.14128	results	2	NA	list_covariates_yn	Yes
10.1111/head.14128	results	2	NA	n_covariates	6
10.1111/head.14128	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1111/head.14128	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/head.14128	results	2	NA	unadjusted_effect	1.75
10.1111/head.14128	results	2	NA	unadjusted_pval_char	0.528
10.1111/head.14128	results	2	NA	adjusted_effect	-0.09
10.1111/head.14128	results	2	NA	adjusted_pval_char	0.979
10.1111/head.14128	results	2	NA	geographical region	NA
10.1111/head.14128	results	2	NA	n_ipd_total	NA
10.1111/head.14128	results	2	NA	ess_total	NA
10.1111/head.14128	results	2	NA	n_nonipd_total	NA
10.1111/head.14128	results	2	NA	n_nonipd_anchor	NA
10.1111/head.14128	results	2	NA	n_ipd_anchor	NA
10.1111/head.14128	results	2	NA	ess_anchor	NA
10.1111/head.14128	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/head.14128	results	2	NA	effect_cutoff	0
10.1111/head.14128	results	2	NA	unadjusted_pval	0.528
10.1111/head.14128	results	2	NA	unadjusted_num_pval	0.528
10.1111/head.14128	results	2	NA	unadjusted_significant	FALSE
10.1111/head.14128	results	2	NA	adjusted_pval	0.979
10.1111/head.14128	results	2	NA	adjusted_num_pval	0.979
10.1111/head.14128	results	2	NA	adjusted_significant	FALSE
10.1111/head.14128	results	3	NA	contrast	Means difference
10.1111/head.14128	results	3	NA	direction_benefit	inferior
10.1111/head.14128	results	3	NA	n_nonipd_ttt	NA
10.1111/head.14128	results	3	NA	n_ipd_ttt	257
10.1111/head.14128	results	3	NA	ess_ttt	214
10.1111/head.14128	results	3	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1111/head.14128	results	3	NA	list_covariates_yn	Yes
10.1111/head.14128	results	3	NA	n_covariates	4
10.1111/head.14128	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1111/head.14128	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/head.14128	results	3	NA	unadjusted_effect	-3.94
10.1111/head.14128	results	3	NA	unadjusted_pval_char	0.121
10.1111/head.14128	results	3	NA	adjusted_effect	-5.67
10.1111/head.14128	results	3	NA	adjusted_pval_char	0.025
10.1111/head.14128	results	3	NA	geographical region	NA
10.1111/head.14128	results	3	NA	n_ipd_total	NA
10.1111/head.14128	results	3	NA	ess_total	NA
10.1111/head.14128	results	3	NA	n_nonipd_total	NA
10.1111/head.14128	results	3	NA	n_nonipd_anchor	NA
10.1111/head.14128	results	3	NA	n_ipd_anchor	NA
10.1111/head.14128	results	3	NA	ess_anchor	NA
10.1111/head.14128	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/head.14128	results	3	NA	effect_cutoff	0
10.1111/head.14128	results	3	NA	unadjusted_pval	0.121
10.1111/head.14128	results	3	NA	unadjusted_num_pval	0.121
10.1111/head.14128	results	3	NA	unadjusted_significant	FALSE
10.1111/head.14128	results	3	NA	adjusted_pval	0.025
10.1111/head.14128	results	3	NA	adjusted_num_pval	0.025
10.1111/head.14128	results	3	NA	adjusted_significant	TRUE
10.1111/head.14128	results	4	NA	contrast	Means difference
10.1111/head.14128	results	4	NA	direction_benefit	inferior
10.1111/head.14128	results	4	NA	n_nonipd_ttt	NA
10.1111/head.14128	results	4	NA	n_ipd_ttt	257
10.1111/head.14128	results	4	NA	ess_ttt	214
10.1111/head.14128	results	4	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1111/head.14128	results	4	NA	list_covariates_yn	Yes
10.1111/head.14128	results	4	NA	n_covariates	4
10.1111/head.14128	results	4	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1111/head.14128	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/head.14128	results	4	NA	unadjusted_effect	3.48
10.1111/head.14128	results	4	NA	unadjusted_pval_char	0.172
10.1111/head.14128	results	4	NA	adjusted_effect	1.75
10.1111/head.14128	results	4	NA	adjusted_pval_char	0.501
10.1111/head.14128	results	4	NA	geographical region	NA
10.1111/head.14128	results	4	NA	n_ipd_total	NA
10.1111/head.14128	results	4	NA	ess_total	NA
10.1111/head.14128	results	4	NA	n_nonipd_total	NA
10.1111/head.14128	results	4	NA	n_nonipd_anchor	NA
10.1111/head.14128	results	4	NA	n_ipd_anchor	NA
10.1111/head.14128	results	4	NA	ess_anchor	NA
10.1111/head.14128	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/head.14128	results	4	NA	effect_cutoff	0
10.1111/head.14128	results	4	NA	unadjusted_pval	0.172
10.1111/head.14128	results	4	NA	unadjusted_num_pval	0.172
10.1111/head.14128	results	4	NA	unadjusted_significant	FALSE
10.1111/head.14128	results	4	NA	adjusted_pval	0.501
10.1111/head.14128	results	4	NA	adjusted_num_pval	0.501
10.1111/head.14128	results	4	NA	adjusted_significant	FALSE
10.1111/head.14128	study_information	NA	1	Patient-level data used	Yes
10.1111/head.14128	study_information	NA	1	Clinical Trial	Yes
10.1111/head.14128	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03266588
10.1111/head.14128	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1111/head.14128	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2, 3
10.1111/head.14128	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1111/head.14128	study_information	NA	2	Patient-level data used	No
10.1111/head.14128	study_information	NA	2	Clinical Trial	Yes
10.1111/head.14128	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02614183
10.1111/head.14128	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/head.14128	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1111/head.14128	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1111/head.14128	study_information	NA	3	Patient-level data used	No
10.1111/head.14128	study_information	NA	3	Clinical Trial	Yes
10.1111/head.14128	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02614196
10.1111/head.14128	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/head.14128	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1111/head.14128	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1111/head.14128	study_information	NA	4	Patient-level data used	No
10.1111/head.14128	study_information	NA	4	Clinical Trial	Yes
10.1111/head.14128	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02456740
10.1111/head.14128	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/head.14128	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1111/head.14128	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Medical Condition of Interest Name	non-squamous non-small cell lung cancer
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Countries of first author affiliations	taiwan
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Countries of last author affiliations	switzerland
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	primary_outcome_name	progression-free survival
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	primary_outcome_type	Time-to-event
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Treatment name 1	bevacizumab + cisplatin
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Treatment name 2	pemetrexed + cisplatin
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	paitc_type	Other kind of ""Matching-Adjusted Indirect Comparison""
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	anchored_yn	No
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	primary_outcome_yn	Yes
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier)
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	prognostic_factors_yn	Yes
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	weights_model_yn	No
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	scale_choice_yn	No
10.1111/j.1743-7563.2011.01400.x	results	1	NA	contrast	Median difference
10.1111/j.1743-7563.2011.01400.x	results	1	NA	direction_benefit	superior
10.1111/j.1743-7563.2011.01400.x	results	1	NA	n_nonipd_ttt	67
10.1111/j.1743-7563.2011.01400.x	results	1	NA	n_ipd_ttt	72
10.1111/j.1743-7563.2011.01400.x	results	1	NA	ess_ttt	46
10.1111/j.1743-7563.2011.01400.x	results	1	NA	weights_evaluation_yn	Not mentioned
10.1111/j.1743-7563.2011.01400.x	results	1	NA	list_covariates_yn	Yes
10.1111/j.1743-7563.2011.01400.x	results	1	NA	n_covariates	2
10.1111/j.1743-7563.2011.01400.x	results	1	NA	list_covariates	Sex, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1111/j.1743-7563.2011.01400.x	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/j.1743-7563.2011.01400.x	results	1	NA	unadjusted_effect	NA
10.1111/j.1743-7563.2011.01400.x	results	1	NA	unadjusted_pval_char	NA
10.1111/j.1743-7563.2011.01400.x	results	1	NA	adjusted_effect	1
10.1111/j.1743-7563.2011.01400.x	results	1	NA	adjusted_pval_char	NA
10.1111/j.1743-7563.2011.01400.x	results	1	NA	geographical region	NA
10.1111/j.1743-7563.2011.01400.x	results	1	NA	n_ipd_total	72
10.1111/j.1743-7563.2011.01400.x	results	1	NA	ess_total	46
10.1111/j.1743-7563.2011.01400.x	results	1	NA	n_nonipd_total	67
10.1111/j.1743-7563.2011.01400.x	results	1	NA	n_nonipd_anchor	NA
10.1111/j.1743-7563.2011.01400.x	results	1	NA	n_ipd_anchor	NA
10.1111/j.1743-7563.2011.01400.x	results	1	NA	ess_anchor	NA
10.1111/j.1743-7563.2011.01400.x	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/j.1743-7563.2011.01400.x	results	1	NA	effect_cutoff	0
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Patient-level data used	Yes
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Clinical Trial	Yes
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451906
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Phase of the clinical trial (clinical trial only)	4
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Patient-level data used	No
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Clinical Trial	Yes
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	yang et al. (2010)
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1111/jdv.15369	general_information	NA	NA	Medical Condition of Interest Name	plaque psoriasis
10.1111/jdv.15369	general_information	NA	NA	Countries of first author affiliations	uk
10.1111/jdv.15369	general_information	NA	NA	Countries of last author affiliations	usa
10.1111/jdv.15369	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1111/jdv.15369	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1111/jdv.15369	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1111/jdv.15369	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1111/jdv.15369	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1111/jdv.15369	methodology	1	NA	primary_outcome_name	physician global assessment (pga) 0/1 responders rate
10.1111/jdv.15369	methodology	1	NA	outcome_short_name	PGA responders Rate
10.1111/jdv.15369	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1111/jdv.15369	methodology	1	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam
10.1111/jdv.15369	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3;4
10.1111/jdv.15369	methodology	1	NA	Treatment name 2	apremilast
10.1111/jdv.15369	methodology	1	NA	Study 'number(s)' for treatment 2	5
10.1111/jdv.15369	methodology	1	NA	paitc_type	MAIC
10.1111/jdv.15369	methodology	1	NA	anchored_yn	No
10.1111/jdv.15369	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/jdv.15369	methodology	1	NA	primary_outcome_yn	Yes
10.1111/jdv.15369	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/jdv.15369	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/jdv.15369	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/jdv.15369	methodology	1	NA	weights_model_yn	No
10.1111/jdv.15369	methodology	1	NA	scale_choice_yn	No
10.1111/jdv.15369	methodology	2	NA	primary_outcome_name	psoriasis area severity index (pasi) 75 responders rate
10.1111/jdv.15369	methodology	2	NA	outcome_short_name	PASI 75 Responders Rate
10.1111/jdv.15369	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1111/jdv.15369	methodology	2	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam
10.1111/jdv.15369	methodology	2	NA	Study 'number(s)' for treatment 1	1;2;3;4
10.1111/jdv.15369	methodology	2	NA	Treatment name 2	methotrexate
10.1111/jdv.15369	methodology	2	NA	Study 'number(s)' for treatment 2	6
10.1111/jdv.15369	methodology	2	NA	paitc_type	MAIC
10.1111/jdv.15369	methodology	2	NA	anchored_yn	No
10.1111/jdv.15369	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/jdv.15369	methodology	2	NA	primary_outcome_yn	Yes
10.1111/jdv.15369	methodology	2	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/jdv.15369	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/jdv.15369	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/jdv.15369	methodology	2	NA	weights_model_yn	No
10.1111/jdv.15369	methodology	2	NA	scale_choice_yn	No
10.1111/jdv.15369	methodology	3	NA	primary_outcome_name	psoriasis area severity index (pasi) 75 responders rate
10.1111/jdv.15369	methodology	3	NA	outcome_short_name	PASI 75 Responders Rate
10.1111/jdv.15369	methodology	3	NA	primary_outcome_type	Binary (eg rates)
10.1111/jdv.15369	methodology	3	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam
10.1111/jdv.15369	methodology	3	NA	Study 'number(s)' for treatment 1	1;2;3;4
10.1111/jdv.15369	methodology	3	NA	Treatment name 2	acitretin
10.1111/jdv.15369	methodology	3	NA	Study 'number(s)' for treatment 2	7
10.1111/jdv.15369	methodology	3	NA	paitc_type	MAIC
10.1111/jdv.15369	methodology	3	NA	anchored_yn	No
10.1111/jdv.15369	methodology	3	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/jdv.15369	methodology	3	NA	primary_outcome_yn	Yes
10.1111/jdv.15369	methodology	3	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/jdv.15369	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/jdv.15369	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/jdv.15369	methodology	3	NA	weights_model_yn	No
10.1111/jdv.15369	methodology	3	NA	scale_choice_yn	No
10.1111/jdv.15369	methodology	4	NA	primary_outcome_name	psoriasis area severity index (pasi) 75 responders rate
10.1111/jdv.15369	methodology	4	NA	outcome_short_name	PASI 75 Responders Rate
10.1111/jdv.15369	methodology	4	NA	primary_outcome_type	Binary (eg rates)
10.1111/jdv.15369	methodology	4	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam
10.1111/jdv.15369	methodology	4	NA	Study 'number(s)' for treatment 1	1;2;3;4
10.1111/jdv.15369	methodology	4	NA	Treatment name 2	fumaric acid esters
10.1111/jdv.15369	methodology	4	NA	Study 'number(s)' for treatment 2	8
10.1111/jdv.15369	methodology	4	NA	paitc_type	MAIC
10.1111/jdv.15369	methodology	4	NA	anchored_yn	No
10.1111/jdv.15369	methodology	4	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/jdv.15369	methodology	4	NA	primary_outcome_yn	Yes
10.1111/jdv.15369	methodology	4	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/jdv.15369	methodology	4	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/jdv.15369	methodology	4	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/jdv.15369	methodology	4	NA	weights_model_yn	No
10.1111/jdv.15369	methodology	4	NA	scale_choice_yn	No
10.1111/jdv.15369	results	1	NA	contrast	Proportions difference
10.1111/jdv.15369	results	1	NA	direction_benefit	superior
10.1111/jdv.15369	results	1	NA	n_nonipd_ttt	148
10.1111/jdv.15369	results	1	NA	n_ipd_ttt	748
10.1111/jdv.15369	results	1	NA	ess_ttt	640
10.1111/jdv.15369	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1111/jdv.15369	results	1	NA	list_covariates_yn	Yes
10.1111/jdv.15369	results	1	NA	n_covariates	3
10.1111/jdv.15369	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1111/jdv.15369	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/jdv.15369	results	1	NA	unadjusted_effect	NA
10.1111/jdv.15369	results	1	NA	unadjusted_pval_char	NA
10.1111/jdv.15369	results	1	NA	adjusted_effect	22.3
10.1111/jdv.15369	results	1	NA	adjusted_pval_char	<0.001
10.1111/jdv.15369	results	1	NA	geographical region	No
10.1111/jdv.15369	results	1	NA	n_ipd_total	NA
10.1111/jdv.15369	results	1	NA	ess_total	NA
10.1111/jdv.15369	results	1	NA	n_nonipd_total	NA
10.1111/jdv.15369	results	1	NA	n_nonipd_anchor	NA
10.1111/jdv.15369	results	1	NA	n_ipd_anchor	NA
10.1111/jdv.15369	results	1	NA	ess_anchor	NA
10.1111/jdv.15369	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/jdv.15369	results	1	NA	effect_cutoff	0
10.1111/jdv.15369	results	1	NA	adjusted_pval	<0.001
10.1111/jdv.15369	results	1	NA	adjusted_significant	TRUE
10.1111/jdv.15369	results	2	NA	contrast	Proportions difference
10.1111/jdv.15369	results	2	NA	direction_benefit	superior
10.1111/jdv.15369	results	2	NA	n_nonipd_ttt	218
10.1111/jdv.15369	results	2	NA	n_ipd_ttt	749
10.1111/jdv.15369	results	2	NA	ess_ttt	633
10.1111/jdv.15369	results	2	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1111/jdv.15369	results	2	NA	list_covariates_yn	Yes
10.1111/jdv.15369	results	2	NA	n_covariates	2
10.1111/jdv.15369	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1111/jdv.15369	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/jdv.15369	results	2	NA	unadjusted_effect	NA
10.1111/jdv.15369	results	2	NA	unadjusted_pval_char	NA
10.1111/jdv.15369	results	2	NA	adjusted_effect	17.3
10.1111/jdv.15369	results	2	NA	adjusted_pval_char	<0.001
10.1111/jdv.15369	results	2	NA	geographical region	NA
10.1111/jdv.15369	results	2	NA	n_ipd_total	NA
10.1111/jdv.15369	results	2	NA	ess_total	NA
10.1111/jdv.15369	results	2	NA	n_nonipd_total	NA
10.1111/jdv.15369	results	2	NA	n_nonipd_anchor	NA
10.1111/jdv.15369	results	2	NA	n_ipd_anchor	NA
10.1111/jdv.15369	results	2	NA	ess_anchor	NA
10.1111/jdv.15369	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/jdv.15369	results	2	NA	effect_cutoff	0
10.1111/jdv.15369	results	2	NA	adjusted_pval	<0.001
10.1111/jdv.15369	results	2	NA	adjusted_significant	TRUE
10.1111/jdv.15369	results	3	NA	contrast	Proportions difference
10.1111/jdv.15369	results	3	NA	direction_benefit	superior
10.1111/jdv.15369	results	3	NA	n_nonipd_ttt	41
10.1111/jdv.15369	results	3	NA	n_ipd_ttt	748
10.1111/jdv.15369	results	3	NA	ess_ttt	102
10.1111/jdv.15369	results	3	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1111/jdv.15369	results	3	NA	list_covariates_yn	Yes
10.1111/jdv.15369	results	3	NA	n_covariates	4
10.1111/jdv.15369	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1111/jdv.15369	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/jdv.15369	results	3	NA	unadjusted_effect	NA
10.1111/jdv.15369	results	3	NA	unadjusted_pval_char	NA
10.1111/jdv.15369	results	3	NA	adjusted_effect	19.2
10.1111/jdv.15369	results	3	NA	adjusted_pval_char	0.009
10.1111/jdv.15369	results	3	NA	geographical region	No
10.1111/jdv.15369	results	3	NA	n_ipd_total	NA
10.1111/jdv.15369	results	3	NA	ess_total	NA
10.1111/jdv.15369	results	3	NA	n_nonipd_total	NA
10.1111/jdv.15369	results	3	NA	n_nonipd_anchor	NA
10.1111/jdv.15369	results	3	NA	n_ipd_anchor	NA
10.1111/jdv.15369	results	3	NA	ess_anchor	NA
10.1111/jdv.15369	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/jdv.15369	results	3	NA	effect_cutoff	0
10.1111/jdv.15369	results	3	NA	adjusted_pval	0.009
10.1111/jdv.15369	results	3	NA	adjusted_num_pval	0.009
10.1111/jdv.15369	results	3	NA	adjusted_significant	TRUE
10.1111/jdv.15369	results	4	NA	contrast	Proportions difference
10.1111/jdv.15369	results	4	NA	direction_benefit	superior
10.1111/jdv.15369	results	4	NA	n_nonipd_ttt	115
10.1111/jdv.15369	results	4	NA	n_ipd_ttt	749
10.1111/jdv.15369	results	4	NA	ess_ttt	224
10.1111/jdv.15369	results	4	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1111/jdv.15369	results	4	NA	list_covariates_yn	Yes
10.1111/jdv.15369	results	4	NA	n_covariates	2
10.1111/jdv.15369	results	4	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1111/jdv.15369	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.1111/jdv.15369	results	4	NA	unadjusted_effect	NA
10.1111/jdv.15369	results	4	NA	unadjusted_pval_char	NA
10.1111/jdv.15369	results	4	NA	adjusted_effect	-4.4
10.1111/jdv.15369	results	4	NA	adjusted_pval_char	0.451
10.1111/jdv.15369	results	4	NA	geographical region	NA
10.1111/jdv.15369	results	4	NA	n_ipd_total	NA
10.1111/jdv.15369	results	4	NA	ess_total	NA
10.1111/jdv.15369	results	4	NA	n_nonipd_total	NA
10.1111/jdv.15369	results	4	NA	n_nonipd_anchor	NA
10.1111/jdv.15369	results	4	NA	n_ipd_anchor	NA
10.1111/jdv.15369	results	4	NA	ess_anchor	NA
10.1111/jdv.15369	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1111/jdv.15369	results	4	NA	effect_cutoff	0
10.1111/jdv.15369	results	4	NA	adjusted_pval	0.451
10.1111/jdv.15369	results	4	NA	adjusted_num_pval	0.451
10.1111/jdv.15369	results	4	NA	adjusted_significant	FALSE
10.1111/jdv.15369	study_information	NA	1	Patient-level data used	Yes
10.1111/jdv.15369	study_information	NA	1	Clinical Trial	Yes
10.1111/jdv.15369	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02132936
10.1111/jdv.15369	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.1111/jdv.15369	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1111/jdv.15369	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1111/jdv.15369	study_information	NA	2	Patient-level data used	Yes
10.1111/jdv.15369	study_information	NA	2	Clinical Trial	Yes
10.1111/jdv.15369	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01866163
10.1111/jdv.15369	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1111/jdv.15369	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1111/jdv.15369	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1111/jdv.15369	study_information	NA	3	Patient-level data used	Yes
10.1111/jdv.15369	study_information	NA	3	Clinical Trial	Yes
10.1111/jdv.15369	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01536886
10.1111/jdv.15369	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1111/jdv.15369	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.1111/jdv.15369	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1111/jdv.15369	study_information	NA	4	Patient-level data used	Yes
10.1111/jdv.15369	study_information	NA	4	Clinical Trial	Yes
10.1111/jdv.15369	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01536938
10.1111/jdv.15369	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1111/jdv.15369	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.1111/jdv.15369	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1111/jdv.15369	study_information	NA	5	Patient-level data used	No
10.1111/jdv.15369	study_information	NA	5	Clinical Trial	Yes
10.1111/jdv.15369	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02425826
10.1111/jdv.15369	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1111/jdv.15369	study_information	NA	5	Phase of the clinical trial (clinical trial only)	4
10.1111/jdv.15369	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1111/jdv.15369	study_information	NA	6	Patient-level data used	No
10.1111/jdv.15369	study_information	NA	6	Clinical Trial	No
10.1111/jdv.15369	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	zurita et al., (2017)
10.1111/jdv.15369	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	spain
10.1111/jdv.15369	study_information	NA	7	Patient-level data used	No
10.1111/jdv.15369	study_information	NA	7	Clinical Trial	No
10.1111/jdv.15369	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	chiricozzi et al. (2016)
10.1111/jdv.15369	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.1111/jdv.15369	study_information	NA	8	Patient-level data used	No
10.1111/jdv.15369	study_information	NA	8	Clinical Trial	No
10.1111/jdv.15369	study_information	NA	8	Data source name (only if observational study or clinical trial without NCT)	inzinger et al. (2013)
10.1111/jdv.15369	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	austria
10.1136/rmdopen-2019-001131	general_information	NA	NA	Medical Condition of Interest Name	rheumatoid arthritis
10.1136/rmdopen-2019-001131	general_information	NA	NA	Countries of first author affiliations	france
10.1136/rmdopen-2019-001131	general_information	NA	NA	Countries of last author affiliations	usa
10.1136/rmdopen-2019-001131	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1136/rmdopen-2019-001131	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1136/rmdopen-2019-001131	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1136/rmdopen-2019-001131	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1136/rmdopen-2019-001131	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1136/rmdopen-2019-001131	methodology	1	NA	primary_outcome_name	change in pain (vas scale) from baseline to 6 months
10.1136/rmdopen-2019-001131	methodology	1	NA	outcome_short_name	Visual Analogic Pain Scale
10.1136/rmdopen-2019-001131	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1136/rmdopen-2019-001131	methodology	1	NA	Treatment name 1	baricitinib
10.1136/rmdopen-2019-001131	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1136/rmdopen-2019-001131	methodology	1	NA	Treatment name 2	adalimumab
10.1136/rmdopen-2019-001131	methodology	1	NA	Study 'number(s)' for treatment 2	5
10.1136/rmdopen-2019-001131	methodology	1	NA	paitc_type	MAIC
10.1136/rmdopen-2019-001131	methodology	1	NA	anchored_yn	Yes
10.1136/rmdopen-2019-001131	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1136/rmdopen-2019-001131	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1136/rmdopen-2019-001131	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1136/rmdopen-2019-001131	methodology	1	NA	prognostic_factors_yn	No
10.1136/rmdopen-2019-001131	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1136/rmdopen-2019-001131	methodology	1	NA	weights_model_yn	No
10.1136/rmdopen-2019-001131	methodology	1	NA	scale_choice_yn	No
10.1136/rmdopen-2019-001131	methodology	2	NA	primary_outcome_name	change in pain (vas scale) from baseline to 6 months
10.1136/rmdopen-2019-001131	methodology	2	NA	outcome_short_name	Visual Analogic Pain Scale
10.1136/rmdopen-2019-001131	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1136/rmdopen-2019-001131	methodology	2	NA	Treatment name 1	baricitinib
10.1136/rmdopen-2019-001131	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1136/rmdopen-2019-001131	methodology	2	NA	Treatment name 2	tocilizumab
10.1136/rmdopen-2019-001131	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1136/rmdopen-2019-001131	methodology	2	NA	paitc_type	MAIC
10.1136/rmdopen-2019-001131	methodology	2	NA	anchored_yn	Yes
10.1136/rmdopen-2019-001131	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1136/rmdopen-2019-001131	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1136/rmdopen-2019-001131	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.1136/rmdopen-2019-001131	methodology	2	NA	prognostic_factors_yn	No
10.1136/rmdopen-2019-001131	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1136/rmdopen-2019-001131	methodology	2	NA	weights_model_yn	No
10.1136/rmdopen-2019-001131	methodology	2	NA	scale_choice_yn	No
10.1136/rmdopen-2019-001131	methodology	3	NA	primary_outcome_name	change in pain (vas scale) from baseline to 6 months
10.1136/rmdopen-2019-001131	methodology	3	NA	outcome_short_name	Visual Analogic Pain Scale
10.1136/rmdopen-2019-001131	methodology	3	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1136/rmdopen-2019-001131	methodology	3	NA	Treatment name 1	baricitinib
10.1136/rmdopen-2019-001131	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1136/rmdopen-2019-001131	methodology	3	NA	Treatment name 2	tofacitinib
10.1136/rmdopen-2019-001131	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.1136/rmdopen-2019-001131	methodology	3	NA	paitc_type	MAIC
10.1136/rmdopen-2019-001131	methodology	3	NA	anchored_yn	Yes
10.1136/rmdopen-2019-001131	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1136/rmdopen-2019-001131	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1136/rmdopen-2019-001131	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.1136/rmdopen-2019-001131	methodology	3	NA	prognostic_factors_yn	No
10.1136/rmdopen-2019-001131	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.1136/rmdopen-2019-001131	methodology	3	NA	weights_model_yn	No
10.1136/rmdopen-2019-001131	methodology	3	NA	scale_choice_yn	No
10.1136/rmdopen-2019-001131	results	1	NA	contrast	Means difference
10.1136/rmdopen-2019-001131	results	1	NA	direction_benefit	inferior
10.1136/rmdopen-2019-001131	results	1	NA	n_nonipd_ttt	274
10.1136/rmdopen-2019-001131	results	1	NA	n_ipd_ttt	159
10.1136/rmdopen-2019-001131	results	1	NA	ess_ttt	151.5
10.1136/rmdopen-2019-001131	results	1	NA	weights_evaluation_yn	Not mentioned
10.1136/rmdopen-2019-001131	results	1	NA	list_covariates_yn	Yes
10.1136/rmdopen-2019-001131	results	1	NA	n_covariates	5
10.1136/rmdopen-2019-001131	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1136/rmdopen-2019-001131	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1136/rmdopen-2019-001131	results	1	NA	unadjusted_effect	-12.1
10.1136/rmdopen-2019-001131	results	1	NA	unadjusted_pval_char	<0.001
10.1136/rmdopen-2019-001131	results	1	NA	adjusted_effect	-12.3
10.1136/rmdopen-2019-001131	results	1	NA	adjusted_pval_char	<0.001
10.1136/rmdopen-2019-001131	results	1	NA	geographical region	No
10.1136/rmdopen-2019-001131	results	1	NA	n_ipd_total	NA
10.1136/rmdopen-2019-001131	results	1	NA	ess_total	NA
10.1136/rmdopen-2019-001131	results	1	NA	n_nonipd_total	NA
10.1136/rmdopen-2019-001131	results	1	NA	n_nonipd_anchor	257
10.1136/rmdopen-2019-001131	results	1	NA	n_ipd_anchor	210
10.1136/rmdopen-2019-001131	results	1	NA	ess_anchor	181.4
10.1136/rmdopen-2019-001131	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1136/rmdopen-2019-001131	results	1	NA	effect_cutoff	0
10.1136/rmdopen-2019-001131	results	1	NA	unadjusted_pval	<0.001
10.1136/rmdopen-2019-001131	results	1	NA	unadjusted_significant	TRUE
10.1136/rmdopen-2019-001131	results	1	NA	adjusted_pval	<0.001
10.1136/rmdopen-2019-001131	results	1	NA	adjusted_significant	TRUE
10.1136/rmdopen-2019-001131	results	2	NA	contrast	Means difference
10.1136/rmdopen-2019-001131	results	2	NA	direction_benefit	inferior
10.1136/rmdopen-2019-001131	results	2	NA	n_nonipd_ttt	292
10.1136/rmdopen-2019-001131	results	2	NA	n_ipd_ttt	159
10.1136/rmdopen-2019-001131	results	2	NA	ess_ttt	NA
10.1136/rmdopen-2019-001131	results	2	NA	weights_evaluation_yn	Not mentioned
10.1136/rmdopen-2019-001131	results	2	NA	list_covariates_yn	Yes
10.1136/rmdopen-2019-001131	results	2	NA	n_covariates	5
10.1136/rmdopen-2019-001131	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1136/rmdopen-2019-001131	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1136/rmdopen-2019-001131	results	2	NA	unadjusted_effect	-8.7
10.1136/rmdopen-2019-001131	results	2	NA	unadjusted_pval_char	<=0.05
10.1136/rmdopen-2019-001131	results	2	NA	adjusted_effect	-7.3
10.1136/rmdopen-2019-001131	results	2	NA	adjusted_pval_char	<=0.05
10.1136/rmdopen-2019-001131	results	2	NA	geographical region	No
10.1136/rmdopen-2019-001131	results	2	NA	n_ipd_total	369
10.1136/rmdopen-2019-001131	results	2	NA	ess_total	331
10.1136/rmdopen-2019-001131	results	2	NA	n_nonipd_total	NA
10.1136/rmdopen-2019-001131	results	2	NA	n_nonipd_anchor	287
10.1136/rmdopen-2019-001131	results	2	NA	n_ipd_anchor	210
10.1136/rmdopen-2019-001131	results	2	NA	ess_anchor	NA
10.1136/rmdopen-2019-001131	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1136/rmdopen-2019-001131	results	2	NA	effect_cutoff	0
10.1136/rmdopen-2019-001131	results	2	NA	unadjusted_pval	<=0.05
10.1136/rmdopen-2019-001131	results	2	NA	unadjusted_significant	TRUE
10.1136/rmdopen-2019-001131	results	2	NA	adjusted_pval	<=0.05
10.1136/rmdopen-2019-001131	results	2	NA	adjusted_significant	TRUE
10.1136/rmdopen-2019-001131	results	3	NA	contrast	Means difference
10.1136/rmdopen-2019-001131	results	3	NA	direction_benefit	inferior
10.1136/rmdopen-2019-001131	results	3	NA	n_nonipd_ttt	373
10.1136/rmdopen-2019-001131	results	3	NA	n_ipd_ttt	159
10.1136/rmdopen-2019-001131	results	3	NA	ess_ttt	146.5
10.1136/rmdopen-2019-001131	results	3	NA	weights_evaluation_yn	Not mentioned
10.1136/rmdopen-2019-001131	results	3	NA	list_covariates_yn	Yes
10.1136/rmdopen-2019-001131	results	3	NA	n_covariates	5
10.1136/rmdopen-2019-001131	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1136/rmdopen-2019-001131	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1136/rmdopen-2019-001131	results	3	NA	unadjusted_effect	-7.1
10.1136/rmdopen-2019-001131	results	3	NA	unadjusted_pval_char	<=0.05
10.1136/rmdopen-2019-001131	results	3	NA	adjusted_effect	-5.4
10.1136/rmdopen-2019-001131	results	3	NA	adjusted_pval_char	>0.05
10.1136/rmdopen-2019-001131	results	3	NA	geographical region	No
10.1136/rmdopen-2019-001131	results	3	NA	n_ipd_total	NA
10.1136/rmdopen-2019-001131	results	3	NA	ess_total	NA
10.1136/rmdopen-2019-001131	results	3	NA	n_nonipd_total	NA
10.1136/rmdopen-2019-001131	results	3	NA	n_nonipd_anchor	186
10.1136/rmdopen-2019-001131	results	3	NA	n_ipd_anchor	210
10.1136/rmdopen-2019-001131	results	3	NA	ess_anchor	177.8
10.1136/rmdopen-2019-001131	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1136/rmdopen-2019-001131	results	3	NA	effect_cutoff	0
10.1136/rmdopen-2019-001131	results	3	NA	unadjusted_pval	<=0.05
10.1136/rmdopen-2019-001131	results	3	NA	unadjusted_significant	TRUE
10.1136/rmdopen-2019-001131	results	3	NA	adjusted_pval	>0.05
10.1136/rmdopen-2019-001131	study_information	NA	1	Patient-level data used	Yes
10.1136/rmdopen-2019-001131	study_information	NA	1	Clinical Trial	Yes
10.1136/rmdopen-2019-001131	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01711359
10.1136/rmdopen-2019-001131	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1136/rmdopen-2019-001131	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1136/rmdopen-2019-001131	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1136/rmdopen-2019-001131	study_information	NA	2	Patient-level data used	No
10.1136/rmdopen-2019-001131	study_information	NA	2	Clinical Trial	Yes
10.1136/rmdopen-2019-001131	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00109408
10.1136/rmdopen-2019-001131	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1136/rmdopen-2019-001131	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1136/rmdopen-2019-001131	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1136/rmdopen-2019-001131	study_information	NA	3	Patient-level data used	No
10.1136/rmdopen-2019-001131	study_information	NA	3	Clinical Trial	Yes
10.1136/rmdopen-2019-001131	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01007435
10.1136/rmdopen-2019-001131	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1136/rmdopen-2019-001131	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1136/rmdopen-2019-001131	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1136/rmdopen-2019-001131	study_information	NA	4	Patient-level data used	No
10.1136/rmdopen-2019-001131	study_information	NA	4	Clinical Trial	Yes
10.1136/rmdopen-2019-001131	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01039688
10.1136/rmdopen-2019-001131	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1136/rmdopen-2019-001131	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1136/rmdopen-2019-001131	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1136/rmdopen-2019-001131	study_information	NA	5	Patient-level data used	No
10.1136/rmdopen-2019-001131	study_information	NA	5	Clinical Trial	Yes
10.1136/rmdopen-2019-001131	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00195663
10.1136/rmdopen-2019-001131	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1136/rmdopen-2019-001131	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1136/rmdopen-2019-001131	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1155/2017/6121760	general_information	NA	NA	Medical Condition of Interest Name	basal cell carcinoma
10.1155/2017/6121760	general_information	NA	NA	Countries of first author affiliations	usa
10.1155/2017/6121760	general_information	NA	NA	Countries of last author affiliations	usa
10.1155/2017/6121760	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1155/2017/6121760	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1155/2017/6121760	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1155/2017/6121760	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1155/2017/6121760	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1155/2017/6121760	methodology	1	NA	primary_outcome_name	objective response rate
10.1155/2017/6121760	methodology	1	NA	outcome_short_name	Objective Response Rate
10.1155/2017/6121760	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1155/2017/6121760	methodology	1	NA	Treatment name 1	sonidegib
10.1155/2017/6121760	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1155/2017/6121760	methodology	1	NA	Treatment name 2	vismodegib
10.1155/2017/6121760	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1155/2017/6121760	methodology	1	NA	paitc_type	MAIC
10.1155/2017/6121760	methodology	1	NA	anchored_yn	No
10.1155/2017/6121760	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1155/2017/6121760	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1155/2017/6121760	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1155/2017/6121760	methodology	1	NA	prognostic_factors_yn	Yes
10.1155/2017/6121760	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1155/2017/6121760	methodology	1	NA	weights_model_yn	No
10.1155/2017/6121760	methodology	1	NA	scale_choice_yn	No
10.1155/2017/6121760	results	1	NA	contrast	NA
10.1155/2017/6121760	results	1	NA	direction_benefit	superior
10.1155/2017/6121760	results	1	NA	n_nonipd_ttt	63
10.1155/2017/6121760	results	1	NA	n_ipd_ttt	66
10.1155/2017/6121760	results	1	NA	ess_ttt	NA
10.1155/2017/6121760	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1155/2017/6121760	results	1	NA	list_covariates_yn	Yes
10.1155/2017/6121760	results	1	NA	n_covariates	2
10.1155/2017/6121760	results	1	NA	list_covariates	Past treatments for the disease of interest
10.1155/2017/6121760	results	1	NA	effect_direction	NA
10.1155/2017/6121760	results	1	NA	unadjusted_effect	NA
10.1155/2017/6121760	results	1	NA	unadjusted_pval_char	NA
10.1155/2017/6121760	results	1	NA	adjusted_effect	NA
10.1155/2017/6121760	results	1	NA	adjusted_pval_char	NA
10.1155/2017/6121760	results	1	NA	geographical region	NA
10.1155/2017/6121760	results	1	NA	n_ipd_total	NA
10.1155/2017/6121760	results	1	NA	ess_total	NA
10.1155/2017/6121760	results	1	NA	n_nonipd_total	NA
10.1155/2017/6121760	results	1	NA	n_nonipd_anchor	NA
10.1155/2017/6121760	results	1	NA	n_ipd_anchor	NA
10.1155/2017/6121760	results	1	NA	ess_anchor	NA
10.1155/2017/6121760	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1155/2017/6121760	results	1	NA	effect_cutoff	NA
10.1155/2017/6121760	study_information	NA	1	Patient-level data used	Yes
10.1155/2017/6121760	study_information	NA	1	Clinical Trial	Yes
10.1155/2017/6121760	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01327053
10.1155/2017/6121760	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1155/2017/6121760	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1155/2017/6121760	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1155/2017/6121760	study_information	NA	2	Patient-level data used	No
10.1155/2017/6121760	study_information	NA	2	Clinical Trial	Yes
10.1155/2017/6121760	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00833417
10.1155/2017/6121760	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1155/2017/6121760	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1155/2017/6121760	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1177/1756286420975916	general_information	NA	NA	Medical Condition of Interest Name	relapsing multiple sclerosis
10.1177/1756286420975916	general_information	NA	NA	Countries of first author affiliations	usa
10.1177/1756286420975916	general_information	NA	NA	Countries of last author affiliations	usa
10.1177/1756286420975916	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1177/1756286420975916	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1177/1756286420975916	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1177/1756286420975916	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1177/1756286420975916	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1177/1756286420975916	methodology	1	NA	primary_outcome_name	annualized relapse rate (arr) at 1 year
10.1177/1756286420975916	methodology	1	NA	outcome_short_name	Annualized Relapse Rate
10.1177/1756286420975916	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1177/1756286420975916	methodology	1	NA	Treatment name 1	peginterferon beta-1a
10.1177/1756286420975916	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1177/1756286420975916	methodology	1	NA	Treatment name 2	glatiramer acetate
10.1177/1756286420975916	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1177/1756286420975916	methodology	1	NA	paitc_type	MAIC
10.1177/1756286420975916	methodology	1	NA	anchored_yn	No
10.1177/1756286420975916	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1177/1756286420975916	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1177/1756286420975916	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1177/1756286420975916	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1177/1756286420975916	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1177/1756286420975916	methodology	1	NA	weights_model_yn	No
10.1177/1756286420975916	methodology	1	NA	scale_choice_yn	No
10.1177/1756286420975916	results	1	NA	contrast	Rate difference
10.1177/1756286420975916	results	1	NA	direction_benefit	inferior
10.1177/1756286420975916	results	1	NA	n_nonipd_ttt	834
10.1177/1756286420975916	results	1	NA	n_ipd_ttt	407
10.1177/1756286420975916	results	1	NA	ess_ttt	276
10.1177/1756286420975916	results	1	NA	weights_evaluation_yn	Not mentioned
10.1177/1756286420975916	results	1	NA	list_covariates_yn	Yes
10.1177/1756286420975916	results	1	NA	n_covariates	5
10.1177/1756286420975916	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1177/1756286420975916	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1177/1756286420975916	results	1	NA	unadjusted_effect	NA
10.1177/1756286420975916	results	1	NA	unadjusted_pval_char	NA
10.1177/1756286420975916	results	1	NA	adjusted_effect	-0.04
10.1177/1756286420975916	results	1	NA	adjusted_pval_char	0.375
10.1177/1756286420975916	results	1	NA	geographical region	Yes
10.1177/1756286420975916	results	1	NA	n_ipd_total	NA
10.1177/1756286420975916	results	1	NA	ess_total	NA
10.1177/1756286420975916	results	1	NA	n_nonipd_total	NA
10.1177/1756286420975916	results	1	NA	n_nonipd_anchor	NA
10.1177/1756286420975916	results	1	NA	n_ipd_anchor	NA
10.1177/1756286420975916	results	1	NA	ess_anchor	NA
10.1177/1756286420975916	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1177/1756286420975916	results	1	NA	effect_cutoff	0
10.1177/1756286420975916	results	1	NA	adjusted_pval	0.375
10.1177/1756286420975916	results	1	NA	adjusted_num_pval	0.375
10.1177/1756286420975916	results	1	NA	adjusted_significant	FALSE
10.1177/1756286420975916	study_information	NA	1	Patient-level data used	Yes
10.1177/1756286420975916	study_information	NA	1	Clinical Trial	Yes
10.1177/1756286420975916	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00906399
10.1177/1756286420975916	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1177/1756286420975916	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1177/1756286420975916	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1177/1756286420975916	study_information	NA	2	Patient-level data used	No
10.1177/1756286420975916	study_information	NA	2	Clinical Trial	Yes
10.1177/1756286420975916	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01067521
10.1177/1756286420975916	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1177/1756286420975916	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1177/1756286420975916	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1177/17588359211049639	general_information	NA	NA	Medical Condition of Interest Name	advanced ovarian cancer
10.1177/17588359211049639	general_information	NA	NA	Countries of first author affiliations	uk
10.1177/17588359211049639	general_information	NA	NA	Countries of last author affiliations	uk
10.1177/17588359211049639	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1177/17588359211049639	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1177/17588359211049639	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1177/17588359211049639	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1177/17588359211049639	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1177/17588359211049639	methodology	1	NA	primary_outcome_name	progression-free survival
10.1177/17588359211049639	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1177/17588359211049639	methodology	1	NA	primary_outcome_type	Time-to-event
10.1177/17588359211049639	methodology	1	NA	Treatment name 1	olaparib + bevacizumab
10.1177/17588359211049639	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1177/17588359211049639	methodology	1	NA	Treatment name 2	niraparib
10.1177/17588359211049639	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1177/17588359211049639	methodology	1	NA	paitc_type	MAIC
10.1177/17588359211049639	methodology	1	NA	anchored_yn	No
10.1177/17588359211049639	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1177/17588359211049639	methodology	1	NA	primary_outcome_yn	Yes
10.1177/17588359211049639	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1177/17588359211049639	methodology	1	NA	prognostic_factors_yn	Yes
10.1177/17588359211049639	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1177/17588359211049639	methodology	1	NA	weights_model_yn	No
10.1177/17588359211049639	methodology	1	NA	scale_choice_yn	No
10.1177/17588359211049639	methodology	2	NA	primary_outcome_name	progression-free survival
10.1177/17588359211049639	methodology	2	NA	outcome_short_name	Progression-free Survival
10.1177/17588359211049639	methodology	2	NA	primary_outcome_type	Time-to-event
10.1177/17588359211049639	methodology	2	NA	Treatment name 1	bevacizumab + placebo
10.1177/17588359211049639	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1177/17588359211049639	methodology	2	NA	Treatment name 2	niraparib
10.1177/17588359211049639	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1177/17588359211049639	methodology	2	NA	paitc_type	MAIC
10.1177/17588359211049639	methodology	2	NA	anchored_yn	No
10.1177/17588359211049639	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1177/17588359211049639	methodology	2	NA	primary_outcome_yn	Yes
10.1177/17588359211049639	methodology	2	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1177/17588359211049639	methodology	2	NA	prognostic_factors_yn	Yes
10.1177/17588359211049639	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1177/17588359211049639	methodology	2	NA	weights_model_yn	No
10.1177/17588359211049639	methodology	2	NA	scale_choice_yn	No
10.1177/17588359211049639	methodology	3	NA	primary_outcome_name	progression-free survival
10.1177/17588359211049639	methodology	3	NA	outcome_short_name	Progression-free Survival
10.1177/17588359211049639	methodology	3	NA	primary_outcome_type	Time-to-event
10.1177/17588359211049639	methodology	3	NA	Treatment name 1	olaparib + bevacizumab
10.1177/17588359211049639	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1177/17588359211049639	methodology	3	NA	Treatment name 2	placebo
10.1177/17588359211049639	methodology	3	NA	Study 'number(s)' for treatment 2	2
10.1177/17588359211049639	methodology	3	NA	paitc_type	MAIC
10.1177/17588359211049639	methodology	3	NA	anchored_yn	No
10.1177/17588359211049639	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1177/17588359211049639	methodology	3	NA	primary_outcome_yn	Yes
10.1177/17588359211049639	methodology	3	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1177/17588359211049639	methodology	3	NA	prognostic_factors_yn	Yes
10.1177/17588359211049639	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.1177/17588359211049639	methodology	3	NA	weights_model_yn	No
10.1177/17588359211049639	methodology	3	NA	scale_choice_yn	No
10.1177/17588359211049639	methodology	4	NA	primary_outcome_name	progression-free survival
10.1177/17588359211049639	methodology	4	NA	outcome_short_name	Progression-free Survival
10.1177/17588359211049639	methodology	4	NA	primary_outcome_type	Time-to-event
10.1177/17588359211049639	methodology	4	NA	Treatment name 1	placebo + bevacizumab
10.1177/17588359211049639	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1177/17588359211049639	methodology	4	NA	Treatment name 2	placebo
10.1177/17588359211049639	methodology	4	NA	Study 'number(s)' for treatment 2	2
10.1177/17588359211049639	methodology	4	NA	paitc_type	MAIC
10.1177/17588359211049639	methodology	4	NA	anchored_yn	No
10.1177/17588359211049639	methodology	4	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1177/17588359211049639	methodology	4	NA	primary_outcome_yn	Yes
10.1177/17588359211049639	methodology	4	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1177/17588359211049639	methodology	4	NA	prognostic_factors_yn	Yes
10.1177/17588359211049639	methodology	4	NA	ttt_effect_modifiers_yn	Yes
10.1177/17588359211049639	methodology	4	NA	weights_model_yn	No
10.1177/17588359211049639	methodology	4	NA	scale_choice_yn	No
10.1177/17588359211049639	results	1	NA	contrast	HR
10.1177/17588359211049639	results	1	NA	direction_benefit	inferior
10.1177/17588359211049639	results	1	NA	n_nonipd_ttt	487
10.1177/17588359211049639	results	1	NA	n_ipd_ttt	399
10.1177/17588359211049639	results	1	NA	ess_ttt	358
10.1177/17588359211049639	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1177/17588359211049639	results	1	NA	list_covariates_yn	Yes
10.1177/17588359211049639	results	1	NA	n_covariates	8
10.1177/17588359211049639	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1177/17588359211049639	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1177/17588359211049639	results	1	NA	unadjusted_effect	NA
10.1177/17588359211049639	results	1	NA	unadjusted_pval_char	NA
10.1177/17588359211049639	results	1	NA	adjusted_effect	0.57
10.1177/17588359211049639	results	1	NA	adjusted_pval_char	[0.47;0.69]
10.1177/17588359211049639	results	1	NA	geographical region	NA
10.1177/17588359211049639	results	1	NA	n_ipd_total	NA
10.1177/17588359211049639	results	1	NA	ess_total	NA
10.1177/17588359211049639	results	1	NA	n_nonipd_total	NA
10.1177/17588359211049639	results	1	NA	n_nonipd_anchor	NA
10.1177/17588359211049639	results	1	NA	n_ipd_anchor	NA
10.1177/17588359211049639	results	1	NA	ess_anchor	NA
10.1177/17588359211049639	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1177/17588359211049639	results	1	NA	effect_cutoff	1
10.1177/17588359211049639	results	1	NA	adjusted_lb_ci	0.47
10.1177/17588359211049639	results	1	NA	adjusted_ub_ci	0.69
10.1177/17588359211049639	results	1	NA	adjusted_significant	TRUE
10.1177/17588359211049639	results	2	NA	contrast	HR
10.1177/17588359211049639	results	2	NA	direction_benefit	inferior
10.1177/17588359211049639	results	2	NA	n_nonipd_ttt	487
10.1177/17588359211049639	results	2	NA	n_ipd_ttt	196
10.1177/17588359211049639	results	2	NA	ess_ttt	174
10.1177/17588359211049639	results	2	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1177/17588359211049639	results	2	NA	list_covariates_yn	Yes
10.1177/17588359211049639	results	2	NA	n_covariates	8
10.1177/17588359211049639	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1177/17588359211049639	results	2	NA	effect_direction	Denominator if ratio, or rightside if difference
10.1177/17588359211049639	results	2	NA	unadjusted_effect	NA
10.1177/17588359211049639	results	2	NA	unadjusted_pval_char	NA
10.1177/17588359211049639	results	2	NA	adjusted_effect	1.07
10.1177/17588359211049639	results	2	NA	adjusted_pval_char	[0.87;1.32]
10.1177/17588359211049639	results	2	NA	geographical region	NA
10.1177/17588359211049639	results	2	NA	n_ipd_total	NA
10.1177/17588359211049639	results	2	NA	ess_total	NA
10.1177/17588359211049639	results	2	NA	n_nonipd_total	NA
10.1177/17588359211049639	results	2	NA	n_nonipd_anchor	NA
10.1177/17588359211049639	results	2	NA	n_ipd_anchor	NA
10.1177/17588359211049639	results	2	NA	ess_anchor	NA
10.1177/17588359211049639	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1177/17588359211049639	results	2	NA	effect_cutoff	1
10.1177/17588359211049639	results	2	NA	adjusted_lb_ci	0.87
10.1177/17588359211049639	results	2	NA	adjusted_ub_ci	1.32
10.1177/17588359211049639	results	2	NA	adjusted_significant	FALSE
10.1177/17588359211049639	results	3	NA	contrast	HR
10.1177/17588359211049639	results	3	NA	direction_benefit	inferior
10.1177/17588359211049639	results	3	NA	n_nonipd_ttt	246
10.1177/17588359211049639	results	3	NA	n_ipd_ttt	399
10.1177/17588359211049639	results	3	NA	ess_ttt	358
10.1177/17588359211049639	results	3	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1177/17588359211049639	results	3	NA	list_covariates_yn	Yes
10.1177/17588359211049639	results	3	NA	n_covariates	8
10.1177/17588359211049639	results	3	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1177/17588359211049639	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1177/17588359211049639	results	3	NA	unadjusted_effect	NA
10.1177/17588359211049639	results	3	NA	unadjusted_pval_char	NA
10.1177/17588359211049639	results	3	NA	adjusted_effect	0.33
10.1177/17588359211049639	results	3	NA	adjusted_pval_char	[0.26;0.42]
10.1177/17588359211049639	results	3	NA	geographical region	NA
10.1177/17588359211049639	results	3	NA	n_ipd_total	NA
10.1177/17588359211049639	results	3	NA	ess_total	NA
10.1177/17588359211049639	results	3	NA	n_nonipd_total	NA
10.1177/17588359211049639	results	3	NA	n_nonipd_anchor	NA
10.1177/17588359211049639	results	3	NA	n_ipd_anchor	NA
10.1177/17588359211049639	results	3	NA	ess_anchor	NA
10.1177/17588359211049639	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1177/17588359211049639	results	3	NA	effect_cutoff	1
10.1177/17588359211049639	results	3	NA	adjusted_lb_ci	0.26
10.1177/17588359211049639	results	3	NA	adjusted_ub_ci	0.42
10.1177/17588359211049639	results	3	NA	adjusted_significant	TRUE
10.1177/17588359211049639	results	4	NA	contrast	HR
10.1177/17588359211049639	results	4	NA	direction_benefit	inferior
10.1177/17588359211049639	results	4	NA	n_nonipd_ttt	246
10.1177/17588359211049639	results	4	NA	n_ipd_ttt	196
10.1177/17588359211049639	results	4	NA	ess_ttt	174
10.1177/17588359211049639	results	4	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1177/17588359211049639	results	4	NA	list_covariates_yn	Yes
10.1177/17588359211049639	results	4	NA	n_covariates	8
10.1177/17588359211049639	results	4	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1177/17588359211049639	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.1177/17588359211049639	results	4	NA	unadjusted_effect	NA
10.1177/17588359211049639	results	4	NA	unadjusted_pval_char	NA
10.1177/17588359211049639	results	4	NA	adjusted_effect	0.55
10.1177/17588359211049639	results	4	NA	adjusted_pval_char	[0.43;0.70]
10.1177/17588359211049639	results	4	NA	geographical region	NA
10.1177/17588359211049639	results	4	NA	n_ipd_total	NA
10.1177/17588359211049639	results	4	NA	ess_total	NA
10.1177/17588359211049639	results	4	NA	n_nonipd_total	NA
10.1177/17588359211049639	results	4	NA	n_nonipd_anchor	NA
10.1177/17588359211049639	results	4	NA	n_ipd_anchor	NA
10.1177/17588359211049639	results	4	NA	ess_anchor	NA
10.1177/17588359211049639	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1177/17588359211049639	results	4	NA	effect_cutoff	1
10.1177/17588359211049639	results	4	NA	adjusted_lb_ci	0.43
10.1177/17588359211049639	results	4	NA	adjusted_ub_ci	0.7
10.1177/17588359211049639	results	4	NA	adjusted_significant	TRUE
10.1177/17588359211049639	study_information	NA	1	Patient-level data used	Yes
10.1177/17588359211049639	study_information	NA	1	Clinical Trial	Yes
10.1177/17588359211049639	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02477644
10.1177/17588359211049639	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1177/17588359211049639	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1177/17588359211049639	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1177/17588359211049639	study_information	NA	2	Patient-level data used	No
10.1177/17588359211049639	study_information	NA	2	Clinical Trial	Yes
10.1177/17588359211049639	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02655016
10.1177/17588359211049639	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1177/17588359211049639	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1177/17588359211049639	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1183/13993003.01393-2018	general_information	NA	NA	Medical Condition of Interest Name	severe uncontrolled asthma
10.1183/13993003.01393-2018	general_information	NA	NA	Countries of first author affiliations	france
10.1183/13993003.01393-2018	general_information	NA	NA	Countries of last author affiliations	usa
10.1183/13993003.01393-2018	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1183/13993003.01393-2018	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1183/13993003.01393-2018	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1183/13993003.01393-2018	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1183/13993003.01393-2018	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1183/13993003.01393-2018	methodology	1	NA	primary_outcome_name	annual rate of clinically significant exacerbations
10.1183/13993003.01393-2018	methodology	1	NA	outcome_short_name	Exacerbations annual Rate
10.1183/13993003.01393-2018	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1183/13993003.01393-2018	methodology	1	NA	Treatment name 1	benralizumab
10.1183/13993003.01393-2018	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1183/13993003.01393-2018	methodology	1	NA	Treatment name 2	mepolizumab
10.1183/13993003.01393-2018	methodology	1	NA	Study 'number(s)' for treatment 2	3;4
10.1183/13993003.01393-2018	methodology	1	NA	paitc_type	MAIC
10.1183/13993003.01393-2018	methodology	1	NA	anchored_yn	Yes
10.1183/13993003.01393-2018	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1183/13993003.01393-2018	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1183/13993003.01393-2018	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1183/13993003.01393-2018	methodology	1	NA	prognostic_factors_yn	No
10.1183/13993003.01393-2018	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1183/13993003.01393-2018	methodology	1	NA	weights_model_yn	No
10.1183/13993003.01393-2018	methodology	1	NA	scale_choice_yn	No
10.1183/13993003.01393-2018	results	1	NA	contrast	RR
10.1183/13993003.01393-2018	results	1	NA	direction_benefit	inferior
10.1183/13993003.01393-2018	results	1	NA	n_nonipd_ttt	538
10.1183/13993003.01393-2018	results	1	NA	n_ipd_ttt	NA
10.1183/13993003.01393-2018	results	1	NA	ess_ttt	NA
10.1183/13993003.01393-2018	results	1	NA	weights_evaluation_yn	Not mentioned
10.1183/13993003.01393-2018	results	1	NA	list_covariates_yn	Yes
10.1183/13993003.01393-2018	results	1	NA	n_covariates	7
10.1183/13993003.01393-2018	results	1	NA	list_covariates	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1183/13993003.01393-2018	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1183/13993003.01393-2018	results	1	NA	unadjusted_effect	1.06
10.1183/13993003.01393-2018	results	1	NA	unadjusted_pval_char	0.5553
10.1183/13993003.01393-2018	results	1	NA	adjusted_effect	0.94
10.1183/13993003.01393-2018	results	1	NA	adjusted_pval_char	0.5207
10.1183/13993003.01393-2018	results	1	NA	geographical region	No
10.1183/13993003.01393-2018	results	1	NA	n_ipd_total	959
10.1183/13993003.01393-2018	results	1	NA	ess_total	639
10.1183/13993003.01393-2018	results	1	NA	n_nonipd_total	884
10.1183/13993003.01393-2018	results	1	NA	n_nonipd_anchor	346
10.1183/13993003.01393-2018	results	1	NA	n_ipd_anchor	NA
10.1183/13993003.01393-2018	results	1	NA	ess_anchor	NA
10.1183/13993003.01393-2018	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1183/13993003.01393-2018	results	1	NA	effect_cutoff	1
10.1183/13993003.01393-2018	results	1	NA	unadjusted_pval	0.5553
10.1183/13993003.01393-2018	results	1	NA	unadjusted_num_pval	0.5553
10.1183/13993003.01393-2018	results	1	NA	unadjusted_significant	FALSE
10.1183/13993003.01393-2018	results	1	NA	adjusted_pval	0.5207
10.1183/13993003.01393-2018	results	1	NA	adjusted_num_pval	0.5207
10.1183/13993003.01393-2018	results	1	NA	adjusted_significant	FALSE
10.1183/13993003.01393-2018	study_information	NA	1	Patient-level data used	Yes
10.1183/13993003.01393-2018	study_information	NA	1	Clinical Trial	Yes
10.1183/13993003.01393-2018	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01928771
10.1183/13993003.01393-2018	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1183/13993003.01393-2018	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1183/13993003.01393-2018	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1183/13993003.01393-2018	study_information	NA	2	Patient-level data used	Yes
10.1183/13993003.01393-2018	study_information	NA	2	Clinical Trial	Yes
10.1183/13993003.01393-2018	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01914757
10.1183/13993003.01393-2018	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1183/13993003.01393-2018	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1183/13993003.01393-2018	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1183/13993003.01393-2018	study_information	NA	3	Patient-level data used	No
10.1183/13993003.01393-2018	study_information	NA	3	Clinical Trial	Yes
10.1183/13993003.01393-2018	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01691521
10.1183/13993003.01393-2018	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1183/13993003.01393-2018	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1183/13993003.01393-2018	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1183/13993003.01393-2018	study_information	NA	4	Patient-level data used	No
10.1183/13993003.01393-2018	study_information	NA	4	Clinical Trial	Yes
10.1183/13993003.01393-2018	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01000506
10.1183/13993003.01393-2018	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1183/13993003.01393-2018	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.1183/13993003.01393-2018	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1185/03007995.2011.576238	general_information	NA	NA	Medical Condition of Interest Name	chronic myeloid leukemia
10.1185/03007995.2011.576238	general_information	NA	NA	Countries of first author affiliations	usa
10.1185/03007995.2011.576238	general_information	NA	NA	Countries of last author affiliations	usa
10.1185/03007995.2011.576238	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1185/03007995.2011.576238	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1185/03007995.2011.576238	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1185/03007995.2011.576238	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1185/03007995.2011.576238	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1185/03007995.2011.576238	methodology	1	NA	primary_outcome_name	major molecular response by 12 months
10.1185/03007995.2011.576238	methodology	1	NA	outcome_short_name	Major Molecular Response
10.1185/03007995.2011.576238	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1185/03007995.2011.576238	methodology	1	NA	Treatment name 1	nilotinib
10.1185/03007995.2011.576238	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1185/03007995.2011.576238	methodology	1	NA	Treatment name 2	dasatinib
10.1185/03007995.2011.576238	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1185/03007995.2011.576238	methodology	1	NA	paitc_type	MAIC
10.1185/03007995.2011.576238	methodology	1	NA	anchored_yn	No
10.1185/03007995.2011.576238	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2011.576238	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1185/03007995.2011.576238	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1185/03007995.2011.576238	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1185/03007995.2011.576238	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1185/03007995.2011.576238	methodology	1	NA	weights_model_yn	No
10.1185/03007995.2011.576238	methodology	1	NA	scale_choice_yn	No
10.1185/03007995.2011.576238	results	1	NA	contrast	Rate difference
10.1185/03007995.2011.576238	results	1	NA	direction_benefit	superior
10.1185/03007995.2011.576238	results	1	NA	n_nonipd_ttt	259
10.1185/03007995.2011.576238	results	1	NA	n_ipd_ttt	273
10.1185/03007995.2011.576238	results	1	NA	ess_ttt	NA
10.1185/03007995.2011.576238	results	1	NA	weights_evaluation_yn	Not mentioned
10.1185/03007995.2011.576238	results	1	NA	list_covariates_yn	Yes
10.1185/03007995.2011.576238	results	1	NA	n_covariates	6
10.1185/03007995.2011.576238	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1185/03007995.2011.576238	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1185/03007995.2011.576238	results	1	NA	unadjusted_effect	9.4
10.1185/03007995.2011.576238	results	1	NA	unadjusted_pval_char	0.03
10.1185/03007995.2011.576238	results	1	NA	adjusted_effect	10.8
10.1185/03007995.2011.576238	results	1	NA	adjusted_pval_char	0.014
10.1185/03007995.2011.576238	results	1	NA	geographical region	NA
10.1185/03007995.2011.576238	results	1	NA	n_ipd_total	NA
10.1185/03007995.2011.576238	results	1	NA	ess_total	NA
10.1185/03007995.2011.576238	results	1	NA	n_nonipd_total	NA
10.1185/03007995.2011.576238	results	1	NA	n_nonipd_anchor	NA
10.1185/03007995.2011.576238	results	1	NA	n_ipd_anchor	NA
10.1185/03007995.2011.576238	results	1	NA	ess_anchor	NA
10.1185/03007995.2011.576238	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1185/03007995.2011.576238	results	1	NA	effect_cutoff	0
10.1185/03007995.2011.576238	results	1	NA	unadjusted_pval	0.03
10.1185/03007995.2011.576238	results	1	NA	unadjusted_num_pval	0.03
10.1185/03007995.2011.576238	results	1	NA	unadjusted_significant	TRUE
10.1185/03007995.2011.576238	results	1	NA	adjusted_pval	0.014
10.1185/03007995.2011.576238	results	1	NA	adjusted_num_pval	0.014
10.1185/03007995.2011.576238	results	1	NA	adjusted_significant	TRUE
10.1185/03007995.2011.576238	study_information	NA	1	Patient-level data used	Yes
10.1185/03007995.2011.576238	study_information	NA	1	Clinical Trial	Yes
10.1185/03007995.2011.576238	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00471497
10.1185/03007995.2011.576238	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1185/03007995.2011.576238	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1185/03007995.2011.576238	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1185/03007995.2011.576238	study_information	NA	2	Patient-level data used	No
10.1185/03007995.2011.576238	study_information	NA	2	Clinical Trial	Yes
10.1185/03007995.2011.576238	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00481247
10.1185/03007995.2011.576238	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1185/03007995.2011.576238	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1185/03007995.2011.576238	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1185/03007995.2014.977992	general_information	NA	NA	Medical Condition of Interest Name	chronic myeloid leukemia in chronic phase
10.1185/03007995.2014.977992	general_information	NA	NA	Countries of first author affiliations	usa
10.1185/03007995.2014.977992	general_information	NA	NA	Countries of last author affiliations	usa
10.1185/03007995.2014.977992	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1185/03007995.2014.977992	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1185/03007995.2014.977992	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1185/03007995.2014.977992	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1185/03007995.2014.977992	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1185/03007995.2014.977992	methodology	1	NA	primary_outcome_name	major molecular response by 12 months
10.1185/03007995.2014.977992	methodology	1	NA	outcome_short_name	Major Molecular Response
10.1185/03007995.2014.977992	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1185/03007995.2014.977992	methodology	1	NA	Treatment name 1	nilotinib
10.1185/03007995.2014.977992	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1185/03007995.2014.977992	methodology	1	NA	Treatment name 2	dasatinib
10.1185/03007995.2014.977992	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1185/03007995.2014.977992	methodology	1	NA	paitc_type	MAIC
10.1185/03007995.2014.977992	methodology	1	NA	anchored_yn	Yes
10.1185/03007995.2014.977992	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2014.977992	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1185/03007995.2014.977992	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1185/03007995.2014.977992	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1185/03007995.2014.977992	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1185/03007995.2014.977992	methodology	1	NA	weights_model_yn	No
10.1185/03007995.2014.977992	methodology	1	NA	scale_choice_yn	No
10.1185/03007995.2014.977992	results	1	NA	contrast	Rate difference
10.1185/03007995.2014.977992	results	1	NA	direction_benefit	superior
10.1185/03007995.2014.977992	results	1	NA	n_nonipd_ttt	259
10.1185/03007995.2014.977992	results	1	NA	n_ipd_ttt	278
10.1185/03007995.2014.977992	results	1	NA	ess_ttt	NA
10.1185/03007995.2014.977992	results	1	NA	weights_evaluation_yn	Not mentioned
10.1185/03007995.2014.977992	results	1	NA	list_covariates_yn	Yes
10.1185/03007995.2014.977992	results	1	NA	n_covariates	5
10.1185/03007995.2014.977992	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1185/03007995.2014.977992	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1185/03007995.2014.977992	results	1	NA	unadjusted_effect	NA
10.1185/03007995.2014.977992	results	1	NA	unadjusted_pval_char	NA
10.1185/03007995.2014.977992	results	1	NA	adjusted_effect	11.70
10.1185/03007995.2014.977992	results	1	NA	adjusted_pval_char	0.045
10.1185/03007995.2014.977992	results	1	NA	geographical region	NA
10.1185/03007995.2014.977992	results	1	NA	n_ipd_total	NA
10.1185/03007995.2014.977992	results	1	NA	ess_total	NA
10.1185/03007995.2014.977992	results	1	NA	n_nonipd_total	NA
10.1185/03007995.2014.977992	results	1	NA	n_nonipd_anchor	260
10.1185/03007995.2014.977992	results	1	NA	n_ipd_anchor	282
10.1185/03007995.2014.977992	results	1	NA	ess_anchor	NA
10.1185/03007995.2014.977992	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1185/03007995.2014.977992	results	1	NA	effect_cutoff	0
10.1185/03007995.2014.977992	results	1	NA	adjusted_pval	0.045
10.1185/03007995.2014.977992	results	1	NA	adjusted_num_pval	0.045
10.1185/03007995.2014.977992	results	1	NA	adjusted_significant	TRUE
10.1185/03007995.2014.977992	study_information	NA	1	Patient-level data used	Yes
10.1185/03007995.2014.977992	study_information	NA	1	Clinical Trial	Yes
10.1185/03007995.2014.977992	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00471497
10.1185/03007995.2014.977992	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1185/03007995.2014.977992	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1185/03007995.2014.977992	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1185/03007995.2014.977992	study_information	NA	2	Patient-level data used	No
10.1185/03007995.2014.977992	study_information	NA	2	Clinical Trial	Yes
10.1185/03007995.2014.977992	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00481247
10.1185/03007995.2014.977992	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1185/03007995.2014.977992	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1185/03007995.2014.977992	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1185/03007995.2015.1106934	general_information	NA	NA	Medical Condition of Interest Name	genotype 4 hepatitis c virus (hcv) infection
10.1185/03007995.2015.1106934	general_information	NA	NA	Countries of first author affiliations	belgium
10.1185/03007995.2015.1106934	general_information	NA	NA	Countries of last author affiliations	uk
10.1185/03007995.2015.1106934	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1185/03007995.2015.1106934	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1185/03007995.2015.1106934	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1185/03007995.2015.1106934	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1185/03007995.2015.1106934	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1185/03007995.2015.1106934	methodology	1	NA	primary_outcome_name	sustained viral response
10.1185/03007995.2015.1106934	methodology	1	NA	outcome_short_name	SVR rate
10.1185/03007995.2015.1106934	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	1	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1185/03007995.2015.1106934	methodology	1	NA	Treatment name 2	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1185/03007995.2015.1106934	methodology	1	NA	paitc_type	MAIC
10.1185/03007995.2015.1106934	methodology	1	NA	anchored_yn	No
10.1185/03007995.2015.1106934	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	1	NA	primary_outcome_yn	Yes
10.1185/03007995.2015.1106934	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	1	NA	prognostic_factors_yn	No
10.1185/03007995.2015.1106934	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1185/03007995.2015.1106934	methodology	1	NA	weights_model_yn	No
10.1185/03007995.2015.1106934	methodology	1	NA	scale_choice_yn	No
10.1185/03007995.2015.1106934	methodology	2	NA	primary_outcome_name	sustained viral response
10.1185/03007995.2015.1106934	methodology	2	NA	outcome_short_name	SVR rate
10.1185/03007995.2015.1106934	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	2	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1185/03007995.2015.1106934	methodology	2	NA	Treatment name 2	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1185/03007995.2015.1106934	methodology	2	NA	paitc_type	MAIC
10.1185/03007995.2015.1106934	methodology	2	NA	anchored_yn	No
10.1185/03007995.2015.1106934	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	2	NA	primary_outcome_yn	Yes
10.1185/03007995.2015.1106934	methodology	2	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	2	NA	prognostic_factors_yn	No
10.1185/03007995.2015.1106934	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1185/03007995.2015.1106934	methodology	2	NA	weights_model_yn	No
10.1185/03007995.2015.1106934	methodology	2	NA	scale_choice_yn	No
10.1185/03007995.2015.1106934	methodology	3	NA	primary_outcome_name	sustained viral response
10.1185/03007995.2015.1106934	methodology	3	NA	outcome_short_name	SVR rate
10.1185/03007995.2015.1106934	methodology	3	NA	primary_outcome_type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	3	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1185/03007995.2015.1106934	methodology	3	NA	Treatment name 2	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.1185/03007995.2015.1106934	methodology	3	NA	paitc_type	MAIC
10.1185/03007995.2015.1106934	methodology	3	NA	anchored_yn	No
10.1185/03007995.2015.1106934	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	3	NA	primary_outcome_yn	Yes
10.1185/03007995.2015.1106934	methodology	3	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	3	NA	prognostic_factors_yn	No
10.1185/03007995.2015.1106934	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.1185/03007995.2015.1106934	methodology	3	NA	weights_model_yn	No
10.1185/03007995.2015.1106934	methodology	3	NA	scale_choice_yn	No
10.1185/03007995.2015.1106934	methodology	4	NA	primary_outcome_name	sustained viral response
10.1185/03007995.2015.1106934	methodology	4	NA	outcome_short_name	SVR rate
10.1185/03007995.2015.1106934	methodology	4	NA	primary_outcome_type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	4	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1185/03007995.2015.1106934	methodology	4	NA	Treatment name 2	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	4	NA	Study 'number(s)' for treatment 2	5
10.1185/03007995.2015.1106934	methodology	4	NA	paitc_type	MAIC
10.1185/03007995.2015.1106934	methodology	4	NA	anchored_yn	No
10.1185/03007995.2015.1106934	methodology	4	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	4	NA	primary_outcome_yn	Yes
10.1185/03007995.2015.1106934	methodology	4	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	4	NA	prognostic_factors_yn	No
10.1185/03007995.2015.1106934	methodology	4	NA	ttt_effect_modifiers_yn	Yes
10.1185/03007995.2015.1106934	methodology	4	NA	weights_model_yn	No
10.1185/03007995.2015.1106934	methodology	4	NA	scale_choice_yn	No
10.1185/03007995.2015.1106934	methodology	5	NA	primary_outcome_name	sustained viral response
10.1185/03007995.2015.1106934	methodology	5	NA	outcome_short_name	SVR rate
10.1185/03007995.2015.1106934	methodology	5	NA	primary_outcome_type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	5	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.1185/03007995.2015.1106934	methodology	5	NA	Treatment name 2	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	5	NA	Study 'number(s)' for treatment 2	6
10.1185/03007995.2015.1106934	methodology	5	NA	paitc_type	MAIC
10.1185/03007995.2015.1106934	methodology	5	NA	anchored_yn	No
10.1185/03007995.2015.1106934	methodology	5	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	5	NA	primary_outcome_yn	Yes
10.1185/03007995.2015.1106934	methodology	5	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	5	NA	prognostic_factors_yn	No
10.1185/03007995.2015.1106934	methodology	5	NA	ttt_effect_modifiers_yn	Yes
10.1185/03007995.2015.1106934	methodology	5	NA	weights_model_yn	No
10.1185/03007995.2015.1106934	methodology	5	NA	scale_choice_yn	No
10.1185/03007995.2015.1106934	results	1	NA	contrast	OR
10.1185/03007995.2015.1106934	results	1	NA	direction_benefit	superior
10.1185/03007995.2015.1106934	results	1	NA	n_nonipd_ttt	30
10.1185/03007995.2015.1106934	results	1	NA	n_ipd_ttt	35
10.1185/03007995.2015.1106934	results	1	NA	ess_ttt	29
10.1185/03007995.2015.1106934	results	1	NA	weights_evaluation_yn	Not mentioned
10.1185/03007995.2015.1106934	results	1	NA	list_covariates_yn	Yes
10.1185/03007995.2015.1106934	results	1	NA	n_covariates	5
10.1185/03007995.2015.1106934	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1185/03007995.2015.1106934	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	1	NA	unadjusted_effect	NA
10.1185/03007995.2015.1106934	results	1	NA	unadjusted_pval_char	NA
10.1185/03007995.2015.1106934	results	1	NA	adjusted_effect	3.28
10.1185/03007995.2015.1106934	results	1	NA	adjusted_pval_char	NA
10.1185/03007995.2015.1106934	results	1	NA	geographical region	No
10.1185/03007995.2015.1106934	results	1	NA	n_ipd_total	NA
10.1185/03007995.2015.1106934	results	1	NA	ess_total	NA
10.1185/03007995.2015.1106934	results	1	NA	n_nonipd_total	NA
10.1185/03007995.2015.1106934	results	1	NA	n_nonipd_anchor	NA
10.1185/03007995.2015.1106934	results	1	NA	n_ipd_anchor	NA
10.1185/03007995.2015.1106934	results	1	NA	ess_anchor	NA
10.1185/03007995.2015.1106934	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1185/03007995.2015.1106934	results	1	NA	effect_cutoff	1
10.1185/03007995.2015.1106934	results	2	NA	contrast	OR
10.1185/03007995.2015.1106934	results	2	NA	direction_benefit	superior
10.1185/03007995.2015.1106934	results	2	NA	n_nonipd_ttt	18
10.1185/03007995.2015.1106934	results	2	NA	n_ipd_ttt	35
10.1185/03007995.2015.1106934	results	2	NA	ess_ttt	15
10.1185/03007995.2015.1106934	results	2	NA	weights_evaluation_yn	Not mentioned
10.1185/03007995.2015.1106934	results	2	NA	list_covariates_yn	Yes
10.1185/03007995.2015.1106934	results	2	NA	n_covariates	5
10.1185/03007995.2015.1106934	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1185/03007995.2015.1106934	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	2	NA	unadjusted_effect	NA
10.1185/03007995.2015.1106934	results	2	NA	unadjusted_pval_char	NA
10.1185/03007995.2015.1106934	results	2	NA	adjusted_effect	4.26
10.1185/03007995.2015.1106934	results	2	NA	adjusted_pval_char	NA
10.1185/03007995.2015.1106934	results	2	NA	geographical region	No
10.1185/03007995.2015.1106934	results	2	NA	n_ipd_total	NA
10.1185/03007995.2015.1106934	results	2	NA	ess_total	NA
10.1185/03007995.2015.1106934	results	2	NA	n_nonipd_total	NA
10.1185/03007995.2015.1106934	results	2	NA	n_nonipd_anchor	NA
10.1185/03007995.2015.1106934	results	2	NA	n_ipd_anchor	NA
10.1185/03007995.2015.1106934	results	2	NA	ess_anchor	NA
10.1185/03007995.2015.1106934	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1185/03007995.2015.1106934	results	2	NA	effect_cutoff	1
10.1185/03007995.2015.1106934	results	3	NA	contrast	OR
10.1185/03007995.2015.1106934	results	3	NA	direction_benefit	superior
10.1185/03007995.2015.1106934	results	3	NA	n_nonipd_ttt	95
10.1185/03007995.2015.1106934	results	3	NA	n_ipd_ttt	30
10.1185/03007995.2015.1106934	results	3	NA	ess_ttt	14
10.1185/03007995.2015.1106934	results	3	NA	weights_evaluation_yn	Not mentioned
10.1185/03007995.2015.1106934	results	3	NA	list_covariates_yn	Yes
10.1185/03007995.2015.1106934	results	3	NA	n_covariates	2
10.1185/03007995.2015.1106934	results	3	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1185/03007995.2015.1106934	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	3	NA	unadjusted_effect	NA
10.1185/03007995.2015.1106934	results	3	NA	unadjusted_pval_char	NA
10.1185/03007995.2015.1106934	results	3	NA	adjusted_effect	10.02
10.1185/03007995.2015.1106934	results	3	NA	adjusted_pval_char	NA
10.1185/03007995.2015.1106934	results	3	NA	geographical region	NA
10.1185/03007995.2015.1106934	results	3	NA	n_ipd_total	NA
10.1185/03007995.2015.1106934	results	3	NA	ess_total	NA
10.1185/03007995.2015.1106934	results	3	NA	n_nonipd_total	NA
10.1185/03007995.2015.1106934	results	3	NA	n_nonipd_anchor	NA
10.1185/03007995.2015.1106934	results	3	NA	n_ipd_anchor	NA
10.1185/03007995.2015.1106934	results	3	NA	ess_anchor	NA
10.1185/03007995.2015.1106934	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1185/03007995.2015.1106934	results	3	NA	effect_cutoff	1
10.1185/03007995.2015.1106934	results	4	NA	contrast	OR
10.1185/03007995.2015.1106934	results	4	NA	direction_benefit	superior
10.1185/03007995.2015.1106934	results	4	NA	n_nonipd_ttt	40
10.1185/03007995.2015.1106934	results	4	NA	n_ipd_ttt	35
10.1185/03007995.2015.1106934	results	4	NA	ess_ttt	26
10.1185/03007995.2015.1106934	results	4	NA	weights_evaluation_yn	Not mentioned
10.1185/03007995.2015.1106934	results	4	NA	list_covariates_yn	Yes
10.1185/03007995.2015.1106934	results	4	NA	n_covariates	2
10.1185/03007995.2015.1106934	results	4	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1185/03007995.2015.1106934	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	4	NA	unadjusted_effect	NA
10.1185/03007995.2015.1106934	results	4	NA	unadjusted_pval_char	NA
10.1185/03007995.2015.1106934	results	4	NA	adjusted_effect	6.69
10.1185/03007995.2015.1106934	results	4	NA	adjusted_pval_char	NA
10.1185/03007995.2015.1106934	results	4	NA	geographical region	NA
10.1185/03007995.2015.1106934	results	4	NA	n_ipd_total	NA
10.1185/03007995.2015.1106934	results	4	NA	ess_total	NA
10.1185/03007995.2015.1106934	results	4	NA	n_nonipd_total	NA
10.1185/03007995.2015.1106934	results	4	NA	n_nonipd_anchor	NA
10.1185/03007995.2015.1106934	results	4	NA	n_ipd_anchor	NA
10.1185/03007995.2015.1106934	results	4	NA	ess_anchor	NA
10.1185/03007995.2015.1106934	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1185/03007995.2015.1106934	results	4	NA	effect_cutoff	1
10.1185/03007995.2015.1106934	results	5	NA	contrast	OR
10.1185/03007995.2015.1106934	results	5	NA	direction_benefit	superior
10.1185/03007995.2015.1106934	results	5	NA	n_nonipd_ttt	109
10.1185/03007995.2015.1106934	results	5	NA	n_ipd_ttt	19
10.1185/03007995.2015.1106934	results	5	NA	ess_ttt	17
10.1185/03007995.2015.1106934	results	5	NA	weights_evaluation_yn	Not mentioned
10.1185/03007995.2015.1106934	results	5	NA	list_covariates_yn	Yes
10.1185/03007995.2015.1106934	results	5	NA	n_covariates	2
10.1185/03007995.2015.1106934	results	5	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1185/03007995.2015.1106934	results	5	NA	effect_direction	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	5	NA	unadjusted_effect	NA
10.1185/03007995.2015.1106934	results	5	NA	unadjusted_pval_char	NA
10.1185/03007995.2015.1106934	results	5	NA	adjusted_effect	5.43
10.1185/03007995.2015.1106934	results	5	NA	adjusted_pval_char	NA
10.1185/03007995.2015.1106934	results	5	NA	geographical region	NA
10.1185/03007995.2015.1106934	results	5	NA	n_ipd_total	NA
10.1185/03007995.2015.1106934	results	5	NA	ess_total	NA
10.1185/03007995.2015.1106934	results	5	NA	n_nonipd_total	NA
10.1185/03007995.2015.1106934	results	5	NA	n_nonipd_anchor	NA
10.1185/03007995.2015.1106934	results	5	NA	n_ipd_anchor	NA
10.1185/03007995.2015.1106934	results	5	NA	ess_anchor	NA
10.1185/03007995.2015.1106934	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1185/03007995.2015.1106934	results	5	NA	effect_cutoff	1
10.1185/03007995.2015.1106934	study_information	NA	1	Patient-level data used	Yes
10.1185/03007995.2015.1106934	study_information	NA	1	Clinical Trial	Yes
10.1185/03007995.2015.1106934	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01567735
10.1185/03007995.2015.1106934	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1185/03007995.2015.1106934	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1185/03007995.2015.1106934	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1185/03007995.2015.1106934	study_information	NA	2	Patient-level data used	No
10.1185/03007995.2015.1106934	study_information	NA	2	Clinical Trial	Yes
10.1185/03007995.2015.1106934	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	varghese et al. (2009)
10.1185/03007995.2015.1106934	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	kuwait
10.1185/03007995.2015.1106934	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1185/03007995.2015.1106934	study_information	NA	3	Patient-level data used	No
10.1185/03007995.2015.1106934	study_information	NA	3	Clinical Trial	Yes
10.1185/03007995.2015.1106934	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	rumi et al. (2010)
10.1185/03007995.2015.1106934	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.1185/03007995.2015.1106934	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1185/03007995.2015.1106934	study_information	NA	4	Patient-level data used	No
10.1185/03007995.2015.1106934	study_information	NA	4	Clinical Trial	Yes
10.1185/03007995.2015.1106934	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	el makhzangy et al. (2009)
10.1185/03007995.2015.1106934	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	egypt
10.1185/03007995.2015.1106934	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.1185/03007995.2015.1106934	study_information	NA	5	Patient-level data used	No
10.1185/03007995.2015.1106934	study_information	NA	5	Clinical Trial	Yes
10.1185/03007995.2015.1106934	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00421434
10.1185/03007995.2015.1106934	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	egypt
10.1185/03007995.2015.1106934	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2, 3
10.1185/03007995.2015.1106934	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1185/03007995.2015.1106934	study_information	NA	6	Patient-level data used	No
10.1185/03007995.2015.1106934	study_information	NA	6	Clinical Trial	Yes
10.1185/03007995.2015.1106934	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00502099
10.1185/03007995.2015.1106934	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	egypt
10.1185/03007995.2015.1106934	study_information	NA	6	Phase of the clinical trial (clinical trial only)	4
10.1185/03007995.2015.1106934	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.1186/2162-3619-2-32	general_information	NA	NA	Medical Condition of Interest Name	advanced pancreatic neuroendocrine tumor
10.1186/2162-3619-2-32	general_information	NA	NA	Countries of first author affiliations	usa
10.1186/2162-3619-2-32	general_information	NA	NA	Countries of last author affiliations	canada
10.1186/2162-3619-2-32	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1186/2162-3619-2-32	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1186/2162-3619-2-32	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1186/2162-3619-2-32	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1186/2162-3619-2-32	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1186/2162-3619-2-32	methodology	1	NA	primary_outcome_name	overall survival
10.1186/2162-3619-2-32	methodology	1	NA	outcome_short_name	Overall Survival
10.1186/2162-3619-2-32	methodology	1	NA	primary_outcome_type	Time-to-event
10.1186/2162-3619-2-32	methodology	1	NA	Treatment name 1	everolimus
10.1186/2162-3619-2-32	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1186/2162-3619-2-32	methodology	1	NA	Treatment name 2	sunitinib
10.1186/2162-3619-2-32	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1186/2162-3619-2-32	methodology	1	NA	paitc_type	MAIC
10.1186/2162-3619-2-32	methodology	1	NA	anchored_yn	No
10.1186/2162-3619-2-32	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1186/2162-3619-2-32	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/2162-3619-2-32	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1186/2162-3619-2-32	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1186/2162-3619-2-32	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/2162-3619-2-32	methodology	1	NA	weights_model_yn	No
10.1186/2162-3619-2-32	methodology	1	NA	scale_choice_yn	No
10.1186/2162-3619-2-32	methodology	2	NA	primary_outcome_name	overall survival
10.1186/2162-3619-2-32	methodology	2	NA	outcome_short_name	Overall Survival
10.1186/2162-3619-2-32	methodology	2	NA	primary_outcome_type	Time-to-event
10.1186/2162-3619-2-32	methodology	2	NA	Treatment name 1	everolimus
10.1186/2162-3619-2-32	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1186/2162-3619-2-32	methodology	2	NA	Treatment name 2	placebo
10.1186/2162-3619-2-32	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1186/2162-3619-2-32	methodology	2	NA	paitc_type	MAIC
10.1186/2162-3619-2-32	methodology	2	NA	anchored_yn	No
10.1186/2162-3619-2-32	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1186/2162-3619-2-32	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/2162-3619-2-32	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.1186/2162-3619-2-32	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1186/2162-3619-2-32	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/2162-3619-2-32	methodology	2	NA	weights_model_yn	No
10.1186/2162-3619-2-32	methodology	2	NA	scale_choice_yn	No
10.1186/2162-3619-2-32	methodology	3	NA	primary_outcome_name	progression-free survival
10.1186/2162-3619-2-32	methodology	3	NA	outcome_short_name	Progression-free Survival
10.1186/2162-3619-2-32	methodology	3	NA	primary_outcome_type	Time-to-event
10.1186/2162-3619-2-32	methodology	3	NA	Treatment name 1	everolimus
10.1186/2162-3619-2-32	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1186/2162-3619-2-32	methodology	3	NA	Treatment name 2	sunitinib
10.1186/2162-3619-2-32	methodology	3	NA	Study 'number(s)' for treatment 2	2
10.1186/2162-3619-2-32	methodology	3	NA	paitc_type	MAIC
10.1186/2162-3619-2-32	methodology	3	NA	anchored_yn	Yes
10.1186/2162-3619-2-32	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1186/2162-3619-2-32	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/2162-3619-2-32	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.1186/2162-3619-2-32	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1186/2162-3619-2-32	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/2162-3619-2-32	methodology	3	NA	weights_model_yn	No
10.1186/2162-3619-2-32	methodology	3	NA	scale_choice_yn	No
10.1186/2162-3619-2-32	results	1	NA	contrast	HR
10.1186/2162-3619-2-32	results	1	NA	direction_benefit	inferior
10.1186/2162-3619-2-32	results	1	NA	n_nonipd_ttt	86
10.1186/2162-3619-2-32	results	1	NA	n_ipd_ttt	207
10.1186/2162-3619-2-32	results	1	NA	ess_ttt	NA
10.1186/2162-3619-2-32	results	1	NA	weights_evaluation_yn	Not mentioned
10.1186/2162-3619-2-32	results	1	NA	list_covariates_yn	Yes
10.1186/2162-3619-2-32	results	1	NA	n_covariates	8
10.1186/2162-3619-2-32	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1186/2162-3619-2-32	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1186/2162-3619-2-32	results	1	NA	unadjusted_effect	0.69
10.1186/2162-3619-2-32	results	1	NA	unadjusted_pval_char	0.087
10.1186/2162-3619-2-32	results	1	NA	adjusted_effect	0.81
10.1186/2162-3619-2-32	results	1	NA	adjusted_pval_char	0.383
10.1186/2162-3619-2-32	results	1	NA	geographical region	NA
10.1186/2162-3619-2-32	results	1	NA	n_ipd_total	NA
10.1186/2162-3619-2-32	results	1	NA	ess_total	NA
10.1186/2162-3619-2-32	results	1	NA	n_nonipd_total	NA
10.1186/2162-3619-2-32	results	1	NA	n_nonipd_anchor	NA
10.1186/2162-3619-2-32	results	1	NA	n_ipd_anchor	NA
10.1186/2162-3619-2-32	results	1	NA	ess_anchor	NA
10.1186/2162-3619-2-32	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1186/2162-3619-2-32	results	1	NA	effect_cutoff	1
10.1186/2162-3619-2-32	results	1	NA	unadjusted_pval	0.087
10.1186/2162-3619-2-32	results	1	NA	unadjusted_num_pval	0.087
10.1186/2162-3619-2-32	results	1	NA	unadjusted_significant	FALSE
10.1186/2162-3619-2-32	results	1	NA	adjusted_pval	0.383
10.1186/2162-3619-2-32	results	1	NA	adjusted_num_pval	0.383
10.1186/2162-3619-2-32	results	1	NA	adjusted_significant	FALSE
10.1186/2162-3619-2-32	results	2	NA	contrast	HR
10.1186/2162-3619-2-32	results	2	NA	direction_benefit	inferior
10.1186/2162-3619-2-32	results	2	NA	n_nonipd_ttt	85
10.1186/2162-3619-2-32	results	2	NA	n_ipd_ttt	207
10.1186/2162-3619-2-32	results	2	NA	ess_ttt	NA
10.1186/2162-3619-2-32	results	2	NA	weights_evaluation_yn	Not mentioned
10.1186/2162-3619-2-32	results	2	NA	list_covariates_yn	Yes
10.1186/2162-3619-2-32	results	2	NA	n_covariates	8
10.1186/2162-3619-2-32	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1186/2162-3619-2-32	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1186/2162-3619-2-32	results	2	NA	unadjusted_effect	0.53
10.1186/2162-3619-2-32	results	2	NA	unadjusted_pval_char	0.002
10.1186/2162-3619-2-32	results	2	NA	adjusted_effect	0.61
10.1186/2162-3619-2-32	results	2	NA	adjusted_pval_char	0.042
10.1186/2162-3619-2-32	results	2	NA	geographical region	NA
10.1186/2162-3619-2-32	results	2	NA	n_ipd_total	NA
10.1186/2162-3619-2-32	results	2	NA	ess_total	NA
10.1186/2162-3619-2-32	results	2	NA	n_nonipd_total	NA
10.1186/2162-3619-2-32	results	2	NA	n_nonipd_anchor	NA
10.1186/2162-3619-2-32	results	2	NA	n_ipd_anchor	NA
10.1186/2162-3619-2-32	results	2	NA	ess_anchor	NA
10.1186/2162-3619-2-32	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1186/2162-3619-2-32	results	2	NA	effect_cutoff	1
10.1186/2162-3619-2-32	results	2	NA	unadjusted_pval	0.002
10.1186/2162-3619-2-32	results	2	NA	unadjusted_num_pval	0.002
10.1186/2162-3619-2-32	results	2	NA	unadjusted_significant	TRUE
10.1186/2162-3619-2-32	results	2	NA	adjusted_pval	0.042
10.1186/2162-3619-2-32	results	2	NA	adjusted_num_pval	0.042
10.1186/2162-3619-2-32	results	2	NA	adjusted_significant	TRUE
10.1186/2162-3619-2-32	results	3	NA	contrast	HR
10.1186/2162-3619-2-32	results	3	NA	direction_benefit	inferior
10.1186/2162-3619-2-32	results	3	NA	n_nonipd_ttt	86
10.1186/2162-3619-2-32	results	3	NA	n_ipd_ttt	207
10.1186/2162-3619-2-32	results	3	NA	ess_ttt	NA
10.1186/2162-3619-2-32	results	3	NA	weights_evaluation_yn	Not mentioned
10.1186/2162-3619-2-32	results	3	NA	list_covariates_yn	Yes
10.1186/2162-3619-2-32	results	3	NA	n_covariates	8
10.1186/2162-3619-2-32	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1186/2162-3619-2-32	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.1186/2162-3619-2-32	results	3	NA	unadjusted_effect	0.9
10.1186/2162-3619-2-32	results	3	NA	unadjusted_pval_char	0.695
10.1186/2162-3619-2-32	results	3	NA	adjusted_effect	0.84
10.1186/2162-3619-2-32	results	3	NA	adjusted_pval_char	0.578
10.1186/2162-3619-2-32	results	3	NA	geographical region	NA
10.1186/2162-3619-2-32	results	3	NA	n_ipd_total	394
10.1186/2162-3619-2-32	results	3	NA	ess_total	NA
10.1186/2162-3619-2-32	results	3	NA	n_nonipd_total	NA
10.1186/2162-3619-2-32	results	3	NA	n_nonipd_anchor	85
10.1186/2162-3619-2-32	results	3	NA	n_ipd_anchor	203
10.1186/2162-3619-2-32	results	3	NA	ess_anchor	NA
10.1186/2162-3619-2-32	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1186/2162-3619-2-32	results	3	NA	effect_cutoff	1
10.1186/2162-3619-2-32	results	3	NA	unadjusted_pval	0.695
10.1186/2162-3619-2-32	results	3	NA	unadjusted_num_pval	0.695
10.1186/2162-3619-2-32	results	3	NA	unadjusted_significant	FALSE
10.1186/2162-3619-2-32	results	3	NA	adjusted_pval	0.578
10.1186/2162-3619-2-32	results	3	NA	adjusted_num_pval	0.578
10.1186/2162-3619-2-32	results	3	NA	adjusted_significant	FALSE
10.1186/2162-3619-2-32	study_information	NA	1	Patient-level data used	Yes
10.1186/2162-3619-2-32	study_information	NA	1	Clinical Trial	Yes
10.1186/2162-3619-2-32	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00510068
10.1186/2162-3619-2-32	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1186/2162-3619-2-32	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1186/2162-3619-2-32	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1186/2162-3619-2-32	study_information	NA	2	Patient-level data used	No
10.1186/2162-3619-2-32	study_information	NA	2	Clinical Trial	Yes
10.1186/2162-3619-2-32	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00428597
10.1186/2162-3619-2-32	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1186/2162-3619-2-32	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1186/2162-3619-2-32	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1186/s12885-018-5157-0	general_information	NA	NA	Medical Condition of Interest Name	metastatic renal cell carcinoma
10.1186/s12885-018-5157-0	general_information	NA	NA	Countries of first author affiliations	canada
10.1186/s12885-018-5157-0	general_information	NA	NA	Countries of last author affiliations	uk
10.1186/s12885-018-5157-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1186/s12885-018-5157-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1186/s12885-018-5157-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1186/s12885-018-5157-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1186/s12885-018-5157-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1186/s12885-018-5157-0	methodology	1	NA	primary_outcome_name	progression-free survival
10.1186/s12885-018-5157-0	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1186/s12885-018-5157-0	methodology	1	NA	primary_outcome_type	Time-to-event
10.1186/s12885-018-5157-0	methodology	1	NA	Treatment name 1	axitinib
10.1186/s12885-018-5157-0	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1186/s12885-018-5157-0	methodology	1	NA	Treatment name 2	cabozantinib
10.1186/s12885-018-5157-0	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1186/s12885-018-5157-0	methodology	1	NA	paitc_type	MAIC
10.1186/s12885-018-5157-0	methodology	1	NA	anchored_yn	No
10.1186/s12885-018-5157-0	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1186/s12885-018-5157-0	methodology	1	NA	primary_outcome_yn	Yes
10.1186/s12885-018-5157-0	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.1186/s12885-018-5157-0	methodology	1	NA	prognostic_factors_yn	Yes
10.1186/s12885-018-5157-0	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/s12885-018-5157-0	methodology	1	NA	weights_model_yn	No
10.1186/s12885-018-5157-0	methodology	1	NA	scale_choice_yn	No
10.1186/s12885-018-5157-0	methodology	2	NA	primary_outcome_name	progression-free survival
10.1186/s12885-018-5157-0	methodology	2	NA	outcome_short_name	Progression-free Survival
10.1186/s12885-018-5157-0	methodology	2	NA	primary_outcome_type	Time-to-event
10.1186/s12885-018-5157-0	methodology	2	NA	Treatment name 1	axitinib
10.1186/s12885-018-5157-0	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1186/s12885-018-5157-0	methodology	2	NA	Treatment name 2	everolimus
10.1186/s12885-018-5157-0	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1186/s12885-018-5157-0	methodology	2	NA	paitc_type	MAIC
10.1186/s12885-018-5157-0	methodology	2	NA	anchored_yn	No
10.1186/s12885-018-5157-0	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1186/s12885-018-5157-0	methodology	2	NA	primary_outcome_yn	Yes
10.1186/s12885-018-5157-0	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.1186/s12885-018-5157-0	methodology	2	NA	prognostic_factors_yn	Yes
10.1186/s12885-018-5157-0	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/s12885-018-5157-0	methodology	2	NA	weights_model_yn	No
10.1186/s12885-018-5157-0	methodology	2	NA	scale_choice_yn	No
10.1186/s12885-018-5157-0	results	1	NA	contrast	HR
10.1186/s12885-018-5157-0	results	1	NA	direction_benefit	inferior
10.1186/s12885-018-5157-0	results	1	NA	n_nonipd_ttt	135
10.1186/s12885-018-5157-0	results	1	NA	n_ipd_ttt	194
10.1186/s12885-018-5157-0	results	1	NA	ess_ttt	104
10.1186/s12885-018-5157-0	results	1	NA	weights_evaluation_yn	Not mentioned
10.1186/s12885-018-5157-0	results	1	NA	list_covariates_yn	Yes
10.1186/s12885-018-5157-0	results	1	NA	n_covariates	9
10.1186/s12885-018-5157-0	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1186/s12885-018-5157-0	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1186/s12885-018-5157-0	results	1	NA	unadjusted_effect	NA
10.1186/s12885-018-5157-0	results	1	NA	unadjusted_pval_char	NA
10.1186/s12885-018-5157-0	results	1	NA	adjusted_effect	1.15
10.1186/s12885-018-5157-0	results	1	NA	adjusted_pval_char	0.423
10.1186/s12885-018-5157-0	results	1	NA	geographical region	Yes
10.1186/s12885-018-5157-0	results	1	NA	n_ipd_total	NA
10.1186/s12885-018-5157-0	results	1	NA	ess_total	NA
10.1186/s12885-018-5157-0	results	1	NA	n_nonipd_total	NA
10.1186/s12885-018-5157-0	results	1	NA	n_nonipd_anchor	NA
10.1186/s12885-018-5157-0	results	1	NA	n_ipd_anchor	NA
10.1186/s12885-018-5157-0	results	1	NA	ess_anchor	NA
10.1186/s12885-018-5157-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1186/s12885-018-5157-0	results	1	NA	effect_cutoff	1
10.1186/s12885-018-5157-0	results	1	NA	adjusted_pval	0.423
10.1186/s12885-018-5157-0	results	1	NA	adjusted_num_pval	0.423
10.1186/s12885-018-5157-0	results	1	NA	adjusted_significant	FALSE
10.1186/s12885-018-5157-0	results	2	NA	contrast	HR
10.1186/s12885-018-5157-0	results	2	NA	direction_benefit	inferior
10.1186/s12885-018-5157-0	results	2	NA	n_nonipd_ttt	132
10.1186/s12885-018-5157-0	results	2	NA	n_ipd_ttt	194
10.1186/s12885-018-5157-0	results	2	NA	ess_ttt	61
10.1186/s12885-018-5157-0	results	2	NA	weights_evaluation_yn	Not mentioned
10.1186/s12885-018-5157-0	results	2	NA	list_covariates_yn	Yes
10.1186/s12885-018-5157-0	results	2	NA	n_covariates	9
10.1186/s12885-018-5157-0	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1186/s12885-018-5157-0	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1186/s12885-018-5157-0	results	2	NA	unadjusted_effect	NA
10.1186/s12885-018-5157-0	results	2	NA	unadjusted_pval_char	NA
10.1186/s12885-018-5157-0	results	2	NA	adjusted_effect	0.53
10.1186/s12885-018-5157-0	results	2	NA	adjusted_pval_char	0.002
10.1186/s12885-018-5157-0	results	2	NA	geographical region	Yes
10.1186/s12885-018-5157-0	results	2	NA	n_ipd_total	NA
10.1186/s12885-018-5157-0	results	2	NA	ess_total	NA
10.1186/s12885-018-5157-0	results	2	NA	n_nonipd_total	NA
10.1186/s12885-018-5157-0	results	2	NA	n_nonipd_anchor	NA
10.1186/s12885-018-5157-0	results	2	NA	n_ipd_anchor	NA
10.1186/s12885-018-5157-0	results	2	NA	ess_anchor	NA
10.1186/s12885-018-5157-0	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1186/s12885-018-5157-0	results	2	NA	effect_cutoff	1
10.1186/s12885-018-5157-0	results	2	NA	adjusted_pval	0.002
10.1186/s12885-018-5157-0	results	2	NA	adjusted_num_pval	0.002
10.1186/s12885-018-5157-0	results	2	NA	adjusted_significant	TRUE
10.1186/s12885-018-5157-0	study_information	NA	1	Patient-level data used	Yes
10.1186/s12885-018-5157-0	study_information	NA	1	Clinical Trial	Yes
10.1186/s12885-018-5157-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00678392
10.1186/s12885-018-5157-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1186/s12885-018-5157-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1186/s12885-018-5157-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1186/s12885-018-5157-0	study_information	NA	2	Patient-level data used	No
10.1186/s12885-018-5157-0	study_information	NA	2	Clinical Trial	Yes
10.1186/s12885-018-5157-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01865747
10.1186/s12885-018-5157-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1186/s12885-018-5157-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1186/s12885-018-5157-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1186/s13045-021-01144-9	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory large b cell lymphoma
10.1186/s13045-021-01144-9	general_information	NA	NA	Countries of first author affiliations	usa
10.1186/s13045-021-01144-9	general_information	NA	NA	Countries of last author affiliations	france
10.1186/s13045-021-01144-9	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1186/s13045-021-01144-9	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1186/s13045-021-01144-9	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1186/s13045-021-01144-9	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1186/s13045-021-01144-9	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1186/s13045-021-01144-9	methodology	1	NA	primary_outcome_name	objective response rate (orr)
10.1186/s13045-021-01144-9	methodology	1	NA	outcome_short_name	Objective Response Rate
10.1186/s13045-021-01144-9	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1186/s13045-021-01144-9	methodology	1	NA	Treatment name 1	lisocabtagene maraleucel
10.1186/s13045-021-01144-9	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1186/s13045-021-01144-9	methodology	1	NA	Treatment name 2	axicabtagene ciloleucel
10.1186/s13045-021-01144-9	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1186/s13045-021-01144-9	methodology	1	NA	paitc_type	MAIC
10.1186/s13045-021-01144-9	methodology	1	NA	anchored_yn	No
10.1186/s13045-021-01144-9	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1186/s13045-021-01144-9	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/s13045-021-01144-9	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1186/s13045-021-01144-9	methodology	1	NA	prognostic_factors_yn	Yes
10.1186/s13045-021-01144-9	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1186/s13045-021-01144-9	methodology	1	NA	weights_model_yn	No
10.1186/s13045-021-01144-9	methodology	1	NA	scale_choice_yn	No
10.1186/s13045-021-01144-9	results	1	NA	contrast	OR
10.1186/s13045-021-01144-9	results	1	NA	direction_benefit	superior
10.1186/s13045-021-01144-9	results	1	NA	n_nonipd_ttt	101
10.1186/s13045-021-01144-9	results	1	NA	n_ipd_ttt	110
10.1186/s13045-021-01144-9	results	1	NA	ess_ttt	42.1
10.1186/s13045-021-01144-9	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1186/s13045-021-01144-9	results	1	NA	list_covariates_yn	Yes
10.1186/s13045-021-01144-9	results	1	NA	n_covariates	10
10.1186/s13045-021-01144-9	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1186/s13045-021-01144-9	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1186/s13045-021-01144-9	results	1	NA	unadjusted_effect	0.92
10.1186/s13045-021-01144-9	results	1	NA	unadjusted_pval_char	0.753
10.1186/s13045-021-01144-9	results	1	NA	adjusted_effect	1.4
10.1186/s13045-021-01144-9	results	1	NA	adjusted_pval_char	0.476
10.1186/s13045-021-01144-9	results	1	NA	geographical region	No
10.1186/s13045-021-01144-9	results	1	NA	n_ipd_total	NA
10.1186/s13045-021-01144-9	results	1	NA	ess_total	NA
10.1186/s13045-021-01144-9	results	1	NA	n_nonipd_total	NA
10.1186/s13045-021-01144-9	results	1	NA	n_nonipd_anchor	NA
10.1186/s13045-021-01144-9	results	1	NA	n_ipd_anchor	NA
10.1186/s13045-021-01144-9	results	1	NA	ess_anchor	NA
10.1186/s13045-021-01144-9	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1186/s13045-021-01144-9	results	1	NA	effect_cutoff	1
10.1186/s13045-021-01144-9	results	1	NA	unadjusted_pval	0.753
10.1186/s13045-021-01144-9	results	1	NA	unadjusted_num_pval	0.753
10.1186/s13045-021-01144-9	results	1	NA	unadjusted_significant	FALSE
10.1186/s13045-021-01144-9	results	1	NA	adjusted_pval	0.476
10.1186/s13045-021-01144-9	results	1	NA	adjusted_num_pval	0.476
10.1186/s13045-021-01144-9	results	1	NA	adjusted_significant	FALSE
10.1186/s13045-021-01144-9	study_information	NA	1	Patient-level data used	Yes
10.1186/s13045-021-01144-9	study_information	NA	1	Clinical Trial	Yes
10.1186/s13045-021-01144-9	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02631044
10.1186/s13045-021-01144-9	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1186/s13045-021-01144-9	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.1186/s13045-021-01144-9	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1186/s13045-021-01144-9	study_information	NA	2	Patient-level data used	No
10.1186/s13045-021-01144-9	study_information	NA	2	Clinical Trial	Yes
10.1186/s13045-021-01144-9	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02348216
10.1186/s13045-021-01144-9	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1186/s13045-021-01144-9	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1, 2
10.1186/s13045-021-01144-9	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1186/s40164-022-00268-z	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory aggressive large b-cell lymphomas
10.1186/s40164-022-00268-z	general_information	NA	NA	Countries of first author affiliations	france
10.1186/s40164-022-00268-z	general_information	NA	NA	Countries of last author affiliations	canada
10.1186/s40164-022-00268-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Private Data Analysis Company, Pharmaceutical Industry
10.1186/s40164-022-00268-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1186/s40164-022-00268-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1186/s40164-022-00268-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1186/s40164-022-00268-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1186/s40164-022-00268-z	methodology	1	NA	primary_outcome_name	objective response rate
10.1186/s40164-022-00268-z	methodology	1	NA	outcome_short_name	Objective Response Rate
10.1186/s40164-022-00268-z	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1186/s40164-022-00268-z	methodology	1	NA	Treatment name 1	lisocabtagene maraleucel
10.1186/s40164-022-00268-z	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1186/s40164-022-00268-z	methodology	1	NA	Treatment name 2	tisagenlecleucel
10.1186/s40164-022-00268-z	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1186/s40164-022-00268-z	methodology	1	NA	paitc_type	MAIC
10.1186/s40164-022-00268-z	methodology	1	NA	anchored_yn	No
10.1186/s40164-022-00268-z	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1186/s40164-022-00268-z	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/s40164-022-00268-z	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1186/s40164-022-00268-z	methodology	1	NA	prognostic_factors_yn	Yes
10.1186/s40164-022-00268-z	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1186/s40164-022-00268-z	methodology	1	NA	weights_model_yn	No
10.1186/s40164-022-00268-z	methodology	1	NA	scale_choice_yn	No
10.1186/s40164-022-00268-z	results	1	NA	contrast	OR
10.1186/s40164-022-00268-z	results	1	NA	direction_benefit	superior
10.1186/s40164-022-00268-z	results	1	NA	n_nonipd_ttt	111
10.1186/s40164-022-00268-z	results	1	NA	n_ipd_ttt	256
10.1186/s40164-022-00268-z	results	1	NA	ess_ttt	164
10.1186/s40164-022-00268-z	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1186/s40164-022-00268-z	results	1	NA	list_covariates_yn	Yes
10.1186/s40164-022-00268-z	results	1	NA	n_covariates	6
10.1186/s40164-022-00268-z	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1186/s40164-022-00268-z	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1186/s40164-022-00268-z	results	1	NA	unadjusted_effect	2.49
10.1186/s40164-022-00268-z	results	1	NA	unadjusted_pval_char	[1.52;4.07]
10.1186/s40164-022-00268-z	results	1	NA	adjusted_effect	2.78
10.1186/s40164-022-00268-z	results	1	NA	adjusted_pval_char	[1.63;4.74]
10.1186/s40164-022-00268-z	results	1	NA	geographical region	NA
10.1186/s40164-022-00268-z	results	1	NA	n_ipd_total	NA
10.1186/s40164-022-00268-z	results	1	NA	ess_total	NA
10.1186/s40164-022-00268-z	results	1	NA	n_nonipd_total	NA
10.1186/s40164-022-00268-z	results	1	NA	n_nonipd_anchor	NA
10.1186/s40164-022-00268-z	results	1	NA	n_ipd_anchor	NA
10.1186/s40164-022-00268-z	results	1	NA	ess_anchor	NA
10.1186/s40164-022-00268-z	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1186/s40164-022-00268-z	results	1	NA	effect_cutoff	1
10.1186/s40164-022-00268-z	results	1	NA	unadjusted_lb_ci	1.52
10.1186/s40164-022-00268-z	results	1	NA	unadjusted_ub_ci	4.07
10.1186/s40164-022-00268-z	results	1	NA	unadjusted_significant	TRUE
10.1186/s40164-022-00268-z	results	1	NA	adjusted_lb_ci	1.63
10.1186/s40164-022-00268-z	results	1	NA	adjusted_ub_ci	4.74
10.1186/s40164-022-00268-z	results	1	NA	adjusted_significant	TRUE
10.1186/s40164-022-00268-z	study_information	NA	1	Patient-level data used	Yes
10.1186/s40164-022-00268-z	study_information	NA	1	Clinical Trial	Yes
10.1186/s40164-022-00268-z	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02631044
10.1186/s40164-022-00268-z	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.1186/s40164-022-00268-z	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1186/s40164-022-00268-z	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1186/s40164-022-00268-z	study_information	NA	2	Patient-level data used	No
10.1186/s40164-022-00268-z	study_information	NA	2	Clinical Trial	Yes
10.1186/s40164-022-00268-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02445248
10.1186/s40164-022-00268-z	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1186/s40164-022-00268-z	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1186/s40164-022-00268-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1186/s40734-017-0051-5	general_information	NA	NA	Medical Condition of Interest Name	huntington disease
10.1186/s40734-017-0051-5	general_information	NA	NA	Countries of first author affiliations	usa
10.1186/s40734-017-0051-5	general_information	NA	NA	Countries of last author affiliations	usa
10.1186/s40734-017-0051-5	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1186/s40734-017-0051-5	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1186/s40734-017-0051-5	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1186/s40734-017-0051-5	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1186/s40734-017-0051-5	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1186/s40734-017-0051-5	methodology	1	NA	primary_outcome_name	overall adverse events
10.1186/s40734-017-0051-5	methodology	1	NA	outcome_short_name	Adverse Event
10.1186/s40734-017-0051-5	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.1186/s40734-017-0051-5	methodology	1	NA	Treatment name 1	deutetrabenazine
10.1186/s40734-017-0051-5	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1186/s40734-017-0051-5	methodology	1	NA	Treatment name 2	tetrabenazine
10.1186/s40734-017-0051-5	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1186/s40734-017-0051-5	methodology	1	NA	paitc_type	MAIC
10.1186/s40734-017-0051-5	methodology	1	NA	anchored_yn	Yes
10.1186/s40734-017-0051-5	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.1186/s40734-017-0051-5	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/s40734-017-0051-5	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1186/s40734-017-0051-5	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1186/s40734-017-0051-5	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/s40734-017-0051-5	methodology	1	NA	weights_model_yn	No
10.1186/s40734-017-0051-5	methodology	1	NA	scale_choice_yn	No
10.1186/s40734-017-0051-5	results	1	NA	contrast	Risk difference
10.1186/s40734-017-0051-5	results	1	NA	direction_benefit	inferior
10.1186/s40734-017-0051-5	results	1	NA	n_nonipd_ttt	54
10.1186/s40734-017-0051-5	results	1	NA	n_ipd_ttt	45
10.1186/s40734-017-0051-5	results	1	NA	ess_ttt	NA
10.1186/s40734-017-0051-5	results	1	NA	weights_evaluation_yn	Not mentioned
10.1186/s40734-017-0051-5	results	1	NA	list_covariates_yn	Yes
10.1186/s40734-017-0051-5	results	1	NA	n_covariates	3
10.1186/s40734-017-0051-5	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1186/s40734-017-0051-5	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1186/s40734-017-0051-5	results	1	NA	unadjusted_effect	-20.70
10.1186/s40734-017-0051-5	results	1	NA	unadjusted_pval_char	0.135
10.1186/s40734-017-0051-5	results	1	NA	adjusted_effect	-35.30
10.1186/s40734-017-0051-5	results	1	NA	adjusted_pval_char	0.063
10.1186/s40734-017-0051-5	results	1	NA	geographical region	NA
10.1186/s40734-017-0051-5	results	1	NA	n_ipd_total	NA
10.1186/s40734-017-0051-5	results	1	NA	ess_total	NA
10.1186/s40734-017-0051-5	results	1	NA	n_nonipd_total	NA
10.1186/s40734-017-0051-5	results	1	NA	n_nonipd_anchor	30
10.1186/s40734-017-0051-5	results	1	NA	n_ipd_anchor	45
10.1186/s40734-017-0051-5	results	1	NA	ess_anchor	NA
10.1186/s40734-017-0051-5	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1186/s40734-017-0051-5	results	1	NA	effect_cutoff	0
10.1186/s40734-017-0051-5	results	1	NA	unadjusted_pval	0.135
10.1186/s40734-017-0051-5	results	1	NA	unadjusted_num_pval	0.135
10.1186/s40734-017-0051-5	results	1	NA	unadjusted_significant	FALSE
10.1186/s40734-017-0051-5	results	1	NA	adjusted_pval	0.063
10.1186/s40734-017-0051-5	results	1	NA	adjusted_num_pval	0.063
10.1186/s40734-017-0051-5	results	1	NA	adjusted_significant	FALSE
10.1186/s40734-017-0051-5	study_information	NA	1	Patient-level data used	Yes
10.1186/s40734-017-0051-5	study_information	NA	1	Clinical Trial	Yes
10.1186/s40734-017-0051-5	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01795859
10.1186/s40734-017-0051-5	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1186/s40734-017-0051-5	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1186/s40734-017-0051-5	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1186/s40734-017-0051-5	study_information	NA	2	Patient-level data used	No
10.1186/s40734-017-0051-5	study_information	NA	2	Clinical Trial	Yes
10.1186/s40734-017-0051-5	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00219804
10.1186/s40734-017-0051-5	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1186/s40734-017-0051-5	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1186/s40734-017-0051-5	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1210/clinem/dgab905	general_information	NA	NA	Medical Condition of Interest Name	type 2 diabetes
10.1210/clinem/dgab905	general_information	NA	NA	Countries of first author affiliations	usa
10.1210/clinem/dgab905	general_information	NA	NA	Countries of last author affiliations	usa
10.1210/clinem/dgab905	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1210/clinem/dgab905	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1210/clinem/dgab905	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1210/clinem/dgab905	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1210/clinem/dgab905	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1210/clinem/dgab905	methodology	1	NA	primary_outcome_name	change from baseline in hba1c
10.1210/clinem/dgab905	methodology	1	NA	outcome_short_name	HbA1C
10.1210/clinem/dgab905	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1210/clinem/dgab905	methodology	1	NA	Treatment name 1	semaglutide 2.0 mg
10.1210/clinem/dgab905	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1210/clinem/dgab905	methodology	1	NA	Treatment name 2	dulaglutide 3.0 mg
10.1210/clinem/dgab905	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.1210/clinem/dgab905	methodology	1	NA	paitc_type	Multilevel network meta-regression
10.1210/clinem/dgab905	methodology	1	NA	anchored_yn	Yes
10.1210/clinem/dgab905	methodology	1	NA	paitc_form	Larger network (ie involving more than 2 studies)
10.1210/clinem/dgab905	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1210/clinem/dgab905	methodology	1	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1210/clinem/dgab905	methodology	1	NA	prognostic_factors_yn	No
10.1210/clinem/dgab905	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.1210/clinem/dgab905	methodology	1	NA	weights_model_yn	No
10.1210/clinem/dgab905	methodology	1	NA	scale_choice_yn	No
10.1210/clinem/dgab905	methodology	2	NA	primary_outcome_name	change from baseline in hba1c
10.1210/clinem/dgab905	methodology	2	NA	outcome_short_name	HbA1C
10.1210/clinem/dgab905	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.1210/clinem/dgab905	methodology	2	NA	Treatment name 1	semaglutide 2.0 mg
10.1210/clinem/dgab905	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1210/clinem/dgab905	methodology	2	NA	Treatment name 2	dulaglutide 4.5 mg
10.1210/clinem/dgab905	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1210/clinem/dgab905	methodology	2	NA	paitc_type	Multilevel network meta-regression
10.1210/clinem/dgab905	methodology	2	NA	anchored_yn	Yes
10.1210/clinem/dgab905	methodology	2	NA	paitc_form	Larger network (ie involving more than 2 studies)
10.1210/clinem/dgab905	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1210/clinem/dgab905	methodology	2	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1210/clinem/dgab905	methodology	2	NA	prognostic_factors_yn	No
10.1210/clinem/dgab905	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.1210/clinem/dgab905	methodology	2	NA	weights_model_yn	No
10.1210/clinem/dgab905	methodology	2	NA	scale_choice_yn	No
10.1210/clinem/dgab905	results	1	NA	contrast	Means difference
10.1210/clinem/dgab905	results	1	NA	direction_benefit	inferior
10.1210/clinem/dgab905	results	1	NA	n_nonipd_ttt	616
10.1210/clinem/dgab905	results	1	NA	n_ipd_ttt	480
10.1210/clinem/dgab905	results	1	NA	ess_ttt	480
10.1210/clinem/dgab905	results	1	NA	weights_evaluation_yn	NA
10.1210/clinem/dgab905	results	1	NA	list_covariates_yn	Yes
10.1210/clinem/dgab905	results	1	NA	n_covariates	3
10.1210/clinem/dgab905	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1210/clinem/dgab905	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1210/clinem/dgab905	results	1	NA	unadjusted_effect	-0.47
10.1210/clinem/dgab905	results	1	NA	unadjusted_pval_char	[-0.69;-0.23]
10.1210/clinem/dgab905	results	1	NA	adjusted_effect	-0.44
10.1210/clinem/dgab905	results	1	NA	adjusted_pval_char	[-0.68;-0.19]
10.1210/clinem/dgab905	results	1	NA	geographical region	No
10.1210/clinem/dgab905	results	1	NA	n_ipd_total	NA
10.1210/clinem/dgab905	results	1	NA	ess_total	NA
10.1210/clinem/dgab905	results	1	NA	n_nonipd_total	NA
10.1210/clinem/dgab905	results	1	NA	n_nonipd_anchor	612
10.1210/clinem/dgab905	results	1	NA	n_ipd_anchor	481
10.1210/clinem/dgab905	results	1	NA	ess_anchor	481
10.1210/clinem/dgab905	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1210/clinem/dgab905	results	1	NA	effect_cutoff	0
10.1210/clinem/dgab905	results	1	NA	unadjusted_lb_ci	-0.69
10.1210/clinem/dgab905	results	1	NA	unadjusted_ub_ci	-0.23
10.1210/clinem/dgab905	results	1	NA	unadjusted_significant	TRUE
10.1210/clinem/dgab905	results	1	NA	adjusted_lb_ci	-0.68
10.1210/clinem/dgab905	results	1	NA	adjusted_ub_ci	-0.19
10.1210/clinem/dgab905	results	1	NA	adjusted_significant	TRUE
10.1210/clinem/dgab905	results	2	NA	contrast	Means difference
10.1210/clinem/dgab905	results	2	NA	direction_benefit	inferior
10.1210/clinem/dgab905	results	2	NA	n_nonipd_ttt	614
10.1210/clinem/dgab905	results	2	NA	n_ipd_ttt	480
10.1210/clinem/dgab905	results	2	NA	ess_ttt	480
10.1210/clinem/dgab905	results	2	NA	weights_evaluation_yn	NA
10.1210/clinem/dgab905	results	2	NA	list_covariates_yn	Yes
10.1210/clinem/dgab905	results	2	NA	n_covariates	3
10.1210/clinem/dgab905	results	2	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1210/clinem/dgab905	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1210/clinem/dgab905	results	2	NA	unadjusted_effect	-0.31
10.1210/clinem/dgab905	results	2	NA	unadjusted_pval_char	[-0.53;-0.08]
10.1210/clinem/dgab905	results	2	NA	adjusted_effect	-0.28
10.1210/clinem/dgab905	results	2	NA	adjusted_pval_char	[-0.52;-0.03]
10.1210/clinem/dgab905	results	2	NA	geographical region	No
10.1210/clinem/dgab905	results	2	NA	n_ipd_total	NA
10.1210/clinem/dgab905	results	2	NA	ess_total	NA
10.1210/clinem/dgab905	results	2	NA	n_nonipd_total	NA
10.1210/clinem/dgab905	results	2	NA	n_nonipd_anchor	612
10.1210/clinem/dgab905	results	2	NA	n_ipd_anchor	481
10.1210/clinem/dgab905	results	2	NA	ess_anchor	481
10.1210/clinem/dgab905	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1210/clinem/dgab905	results	2	NA	effect_cutoff	0
10.1210/clinem/dgab905	results	2	NA	unadjusted_lb_ci	-0.53
10.1210/clinem/dgab905	results	2	NA	unadjusted_ub_ci	-0.08
10.1210/clinem/dgab905	results	2	NA	unadjusted_significant	TRUE
10.1210/clinem/dgab905	results	2	NA	adjusted_lb_ci	-0.52
10.1210/clinem/dgab905	results	2	NA	adjusted_ub_ci	-0.03
10.1210/clinem/dgab905	results	2	NA	adjusted_significant	TRUE
10.1210/clinem/dgab905	study_information	NA	1	Patient-level data used	Yes
10.1210/clinem/dgab905	study_information	NA	1	Clinical Trial	Yes
10.1210/clinem/dgab905	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03989232
10.1210/clinem/dgab905	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1210/clinem/dgab905	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1210/clinem/dgab905	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1210/clinem/dgab905	study_information	NA	3	Patient-level data used	No
10.1210/clinem/dgab905	study_information	NA	3	Clinical Trial	Yes
10.1210/clinem/dgab905	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03495102
10.1210/clinem/dgab905	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1210/clinem/dgab905	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1210/clinem/dgab905	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1634/theoncologist.2017-0103	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory multiple myeloma
10.1634/theoncologist.2017-0103	general_information	NA	NA	Countries of first author affiliations	belgium
10.1634/theoncologist.2017-0103	general_information	NA	NA	Countries of last author affiliations	spain
10.1634/theoncologist.2017-0103	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1634/theoncologist.2017-0103	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1634/theoncologist.2017-0103	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1634/theoncologist.2017-0103	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1634/theoncologist.2017-0103	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1634/theoncologist.2017-0103	methodology	1	NA	primary_outcome_name	overall survival
10.1634/theoncologist.2017-0103	methodology	1	NA	outcome_short_name	Overall Survival
10.1634/theoncologist.2017-0103	methodology	1	NA	primary_outcome_type	Time-to-event
10.1634/theoncologist.2017-0103	methodology	1	NA	Treatment name 1	daratumumab
10.1634/theoncologist.2017-0103	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1634/theoncologist.2017-0103	methodology	1	NA	Treatment name 2	pomalidomide + low-dose dexamethasone
10.1634/theoncologist.2017-0103	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.1634/theoncologist.2017-0103	methodology	1	NA	paitc_type	MAIC
10.1634/theoncologist.2017-0103	methodology	1	NA	anchored_yn	No
10.1634/theoncologist.2017-0103	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1634/theoncologist.2017-0103	methodology	1	NA	primary_outcome_yn	Yes
10.1634/theoncologist.2017-0103	methodology	1	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1634/theoncologist.2017-0103	methodology	1	NA	prognostic_factors_yn	Yes
10.1634/theoncologist.2017-0103	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1634/theoncologist.2017-0103	methodology	1	NA	weights_model_yn	No
10.1634/theoncologist.2017-0103	methodology	1	NA	scale_choice_yn	No
10.1634/theoncologist.2017-0103	methodology	2	NA	primary_outcome_name	overall survival
10.1634/theoncologist.2017-0103	methodology	2	NA	outcome_short_name	Overall Survival
10.1634/theoncologist.2017-0103	methodology	2	NA	primary_outcome_type	Time-to-event
10.1634/theoncologist.2017-0103	methodology	2	NA	Treatment name 1	daratumumab
10.1634/theoncologist.2017-0103	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.1634/theoncologist.2017-0103	methodology	2	NA	Treatment name 2	pomalidomide + low-dose dexamethasone
10.1634/theoncologist.2017-0103	methodology	2	NA	Study 'number(s)' for treatment 2	4
10.1634/theoncologist.2017-0103	methodology	2	NA	paitc_type	MAIC
10.1634/theoncologist.2017-0103	methodology	2	NA	anchored_yn	No
10.1634/theoncologist.2017-0103	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1634/theoncologist.2017-0103	methodology	2	NA	primary_outcome_yn	Yes
10.1634/theoncologist.2017-0103	methodology	2	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1634/theoncologist.2017-0103	methodology	2	NA	prognostic_factors_yn	Yes
10.1634/theoncologist.2017-0103	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1634/theoncologist.2017-0103	methodology	2	NA	weights_model_yn	No
10.1634/theoncologist.2017-0103	methodology	2	NA	scale_choice_yn	No
10.1634/theoncologist.2017-0103	results	1	NA	contrast	HR
10.1634/theoncologist.2017-0103	results	1	NA	direction_benefit	inferior
10.1634/theoncologist.2017-0103	results	1	NA	n_nonipd_ttt	302
10.1634/theoncologist.2017-0103	results	1	NA	n_ipd_ttt	136
10.1634/theoncologist.2017-0103	results	1	NA	ess_ttt	55
10.1634/theoncologist.2017-0103	results	1	NA	weights_evaluation_yn	Not mentioned
10.1634/theoncologist.2017-0103	results	1	NA	list_covariates_yn	Yes
10.1634/theoncologist.2017-0103	results	1	NA	n_covariates	10
10.1634/theoncologist.2017-0103	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1634/theoncologist.2017-0103	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.1634/theoncologist.2017-0103	results	1	NA	unadjusted_effect	0.61
10.1634/theoncologist.2017-0103	results	1	NA	unadjusted_pval_char	0.0005
10.1634/theoncologist.2017-0103	results	1	NA	adjusted_effect	0.56
10.1634/theoncologist.2017-0103	results	1	NA	adjusted_pval_char	0.0041
10.1634/theoncologist.2017-0103	results	1	NA	geographical region	NA
10.1634/theoncologist.2017-0103	results	1	NA	n_ipd_total	NA
10.1634/theoncologist.2017-0103	results	1	NA	ess_total	NA
10.1634/theoncologist.2017-0103	results	1	NA	n_nonipd_total	NA
10.1634/theoncologist.2017-0103	results	1	NA	n_nonipd_anchor	NA
10.1634/theoncologist.2017-0103	results	1	NA	n_ipd_anchor	NA
10.1634/theoncologist.2017-0103	results	1	NA	ess_anchor	NA
10.1634/theoncologist.2017-0103	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1634/theoncologist.2017-0103	results	1	NA	effect_cutoff	1
10.1634/theoncologist.2017-0103	results	1	NA	unadjusted_pval	0.0005
10.1634/theoncologist.2017-0103	results	1	NA	unadjusted_num_pval	5e-04
10.1634/theoncologist.2017-0103	results	1	NA	unadjusted_significant	TRUE
10.1634/theoncologist.2017-0103	results	1	NA	adjusted_pval	0.0041
10.1634/theoncologist.2017-0103	results	1	NA	adjusted_num_pval	0.0041
10.1634/theoncologist.2017-0103	results	1	NA	adjusted_significant	TRUE
10.1634/theoncologist.2017-0103	results	2	NA	contrast	HR
10.1634/theoncologist.2017-0103	results	2	NA	direction_benefit	inferior
10.1634/theoncologist.2017-0103	results	2	NA	n_nonipd_ttt	682
10.1634/theoncologist.2017-0103	results	2	NA	n_ipd_ttt	148
10.1634/theoncologist.2017-0103	results	2	NA	ess_ttt	95
10.1634/theoncologist.2017-0103	results	2	NA	weights_evaluation_yn	Not mentioned
10.1634/theoncologist.2017-0103	results	2	NA	list_covariates_yn	Yes
10.1634/theoncologist.2017-0103	results	2	NA	n_covariates	7
10.1634/theoncologist.2017-0103	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1634/theoncologist.2017-0103	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.1634/theoncologist.2017-0103	results	2	NA	unadjusted_effect	0.55
10.1634/theoncologist.2017-0103	results	2	NA	unadjusted_pval_char	<0.0001
10.1634/theoncologist.2017-0103	results	2	NA	adjusted_effect	0.51
10.1634/theoncologist.2017-0103	results	2	NA	adjusted_pval_char	<0.0001
10.1634/theoncologist.2017-0103	results	2	NA	geographical region	NA
10.1634/theoncologist.2017-0103	results	2	NA	n_ipd_total	NA
10.1634/theoncologist.2017-0103	results	2	NA	ess_total	NA
10.1634/theoncologist.2017-0103	results	2	NA	n_nonipd_total	NA
10.1634/theoncologist.2017-0103	results	2	NA	n_nonipd_anchor	NA
10.1634/theoncologist.2017-0103	results	2	NA	n_ipd_anchor	NA
10.1634/theoncologist.2017-0103	results	2	NA	ess_anchor	NA
10.1634/theoncologist.2017-0103	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.1634/theoncologist.2017-0103	results	2	NA	effect_cutoff	1
10.1634/theoncologist.2017-0103	results	2	NA	unadjusted_pval	<0.0001
10.1634/theoncologist.2017-0103	results	2	NA	unadjusted_significant	TRUE
10.1634/theoncologist.2017-0103	results	2	NA	adjusted_pval	<0.0001
10.1634/theoncologist.2017-0103	results	2	NA	adjusted_significant	TRUE
10.1634/theoncologist.2017-0103	study_information	NA	1	Patient-level data used	Yes
10.1634/theoncologist.2017-0103	study_information	NA	1	Clinical Trial	Yes
10.1634/theoncologist.2017-0103	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00574288
10.1634/theoncologist.2017-0103	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1634/theoncologist.2017-0103	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1634/theoncologist.2017-0103	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1634/theoncologist.2017-0103	study_information	NA	2	Patient-level data used	Yes
10.1634/theoncologist.2017-0103	study_information	NA	2	Clinical Trial	Yes
10.1634/theoncologist.2017-0103	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01985126
10.1634/theoncologist.2017-0103	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1634/theoncologist.2017-0103	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1634/theoncologist.2017-0103	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1634/theoncologist.2017-0103	study_information	NA	3	Patient-level data used	No
10.1634/theoncologist.2017-0103	study_information	NA	3	Clinical Trial	Yes
10.1634/theoncologist.2017-0103	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01311687
10.1634/theoncologist.2017-0103	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1634/theoncologist.2017-0103	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1634/theoncologist.2017-0103	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1634/theoncologist.2017-0103	study_information	NA	4	Patient-level data used	No
10.1634/theoncologist.2017-0103	study_information	NA	4	Clinical Trial	Yes
10.1634/theoncologist.2017-0103	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01712789
10.1634/theoncologist.2017-0103	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1634/theoncologist.2017-0103	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1634/theoncologist.2017-0103	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2147/ceor.s203482	general_information	NA	NA	Medical Condition of Interest Name	acute myeloid leukemia
10.2147/ceor.s203482	general_information	NA	NA	Countries of first author affiliations	usa
10.2147/ceor.s203482	general_information	NA	NA	Countries of last author affiliations	uk
10.2147/ceor.s203482	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/ceor.s203482	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/ceor.s203482	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/ceor.s203482	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/ceor.s203482	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2147/ceor.s203482	methodology	1	NA	primary_outcome_name	overall survival
10.2147/ceor.s203482	methodology	1	NA	outcome_short_name	Overall Survival
10.2147/ceor.s203482	methodology	1	NA	primary_outcome_type	Time-to-event
10.2147/ceor.s203482	methodology	1	NA	Treatment name 1	glasdegib + low-dose cytarabine
10.2147/ceor.s203482	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2147/ceor.s203482	methodology	1	NA	Treatment name 2	azacitidine
10.2147/ceor.s203482	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2147/ceor.s203482	methodology	1	NA	paitc_type	STC
10.2147/ceor.s203482	methodology	1	NA	anchored_yn	Yes
10.2147/ceor.s203482	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/ceor.s203482	methodology	1	NA	primary_outcome_yn	Yes
10.2147/ceor.s203482	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2147/ceor.s203482	methodology	1	NA	prognostic_factors_yn	Yes
10.2147/ceor.s203482	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.2147/ceor.s203482	methodology	1	NA	weights_model_yn	No
10.2147/ceor.s203482	methodology	1	NA	scale_choice_yn	No
10.2147/ceor.s203482	methodology	2	NA	primary_outcome_name	overall survival
10.2147/ceor.s203482	methodology	2	NA	outcome_short_name	Overall Survival
10.2147/ceor.s203482	methodology	2	NA	primary_outcome_type	Time-to-event
10.2147/ceor.s203482	methodology	2	NA	Treatment name 1	glasdegib + low-dose cytarabine
10.2147/ceor.s203482	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2147/ceor.s203482	methodology	2	NA	Treatment name 2	decitabine
10.2147/ceor.s203482	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.2147/ceor.s203482	methodology	2	NA	paitc_type	STC
10.2147/ceor.s203482	methodology	2	NA	anchored_yn	Yes
10.2147/ceor.s203482	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/ceor.s203482	methodology	2	NA	primary_outcome_yn	Yes
10.2147/ceor.s203482	methodology	2	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2147/ceor.s203482	methodology	2	NA	prognostic_factors_yn	Yes
10.2147/ceor.s203482	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.2147/ceor.s203482	methodology	2	NA	weights_model_yn	No
10.2147/ceor.s203482	methodology	2	NA	scale_choice_yn	No
10.2147/ceor.s203482	results	1	NA	contrast	HR
10.2147/ceor.s203482	results	1	NA	direction_benefit	inferior
10.2147/ceor.s203482	results	1	NA	n_nonipd_ttt	241
10.2147/ceor.s203482	results	1	NA	n_ipd_ttt	78
10.2147/ceor.s203482	results	1	NA	ess_ttt	78
10.2147/ceor.s203482	results	1	NA	weights_evaluation_yn	NA
10.2147/ceor.s203482	results	1	NA	list_covariates_yn	Yes
10.2147/ceor.s203482	results	1	NA	n_covariates	3
10.2147/ceor.s203482	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2147/ceor.s203482	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/ceor.s203482	results	1	NA	unadjusted_effect	0.514
10.2147/ceor.s203482	results	1	NA	unadjusted_pval_char	[0.310;0.852]
10.2147/ceor.s203482	results	1	NA	adjusted_effect	0.424
10.2147/ceor.s203482	results	1	NA	adjusted_pval_char	[0.228;0.789]
10.2147/ceor.s203482	results	1	NA	geographical region	NA
10.2147/ceor.s203482	results	1	NA	n_ipd_total	NA
10.2147/ceor.s203482	results	1	NA	ess_total	NA
10.2147/ceor.s203482	results	1	NA	n_nonipd_total	NA
10.2147/ceor.s203482	results	1	NA	n_nonipd_anchor	158
10.2147/ceor.s203482	results	1	NA	n_ipd_anchor	38
10.2147/ceor.s203482	results	1	NA	ess_anchor	38
10.2147/ceor.s203482	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/ceor.s203482	results	1	NA	effect_cutoff	1
10.2147/ceor.s203482	results	1	NA	unadjusted_lb_ci	0.31
10.2147/ceor.s203482	results	1	NA	unadjusted_ub_ci	0.852
10.2147/ceor.s203482	results	1	NA	unadjusted_significant	TRUE
10.2147/ceor.s203482	results	1	NA	adjusted_lb_ci	0.228
10.2147/ceor.s203482	results	1	NA	adjusted_ub_ci	0.789
10.2147/ceor.s203482	results	1	NA	adjusted_significant	TRUE
10.2147/ceor.s203482	results	2	NA	contrast	HR
10.2147/ceor.s203482	results	2	NA	direction_benefit	inferior
10.2147/ceor.s203482	results	2	NA	n_nonipd_ttt	242
10.2147/ceor.s203482	results	2	NA	n_ipd_ttt	78
10.2147/ceor.s203482	results	2	NA	ess_ttt	78
10.2147/ceor.s203482	results	2	NA	weights_evaluation_yn	NA
10.2147/ceor.s203482	results	2	NA	list_covariates_yn	Yes
10.2147/ceor.s203482	results	2	NA	n_covariates	5
10.2147/ceor.s203482	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.2147/ceor.s203482	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/ceor.s203482	results	2	NA	unadjusted_effect	0.565
10.2147/ceor.s203482	results	2	NA	unadjusted_pval_char	[0.351;0.909]
10.2147/ceor.s203482	results	2	NA	adjusted_effect	0.505
10.2147/ceor.s203482	results	2	NA	adjusted_pval_char	[0.269;0.949]
10.2147/ceor.s203482	results	2	NA	geographical region	NA
10.2147/ceor.s203482	results	2	NA	n_ipd_total	NA
10.2147/ceor.s203482	results	2	NA	ess_total	NA
10.2147/ceor.s203482	results	2	NA	n_nonipd_total	NA
10.2147/ceor.s203482	results	2	NA	n_nonipd_anchor	215
10.2147/ceor.s203482	results	2	NA	n_ipd_anchor	38
10.2147/ceor.s203482	results	2	NA	ess_anchor	38
10.2147/ceor.s203482	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/ceor.s203482	results	2	NA	effect_cutoff	1
10.2147/ceor.s203482	results	2	NA	unadjusted_lb_ci	0.351
10.2147/ceor.s203482	results	2	NA	unadjusted_ub_ci	0.909
10.2147/ceor.s203482	results	2	NA	unadjusted_significant	TRUE
10.2147/ceor.s203482	results	2	NA	adjusted_lb_ci	0.269
10.2147/ceor.s203482	results	2	NA	adjusted_ub_ci	0.949
10.2147/ceor.s203482	results	2	NA	adjusted_significant	TRUE
10.2147/ceor.s203482	study_information	NA	1	Patient-level data used	Yes
10.2147/ceor.s203482	study_information	NA	1	Clinical Trial	Yes
10.2147/ceor.s203482	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01546038
10.2147/ceor.s203482	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/ceor.s203482	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.2147/ceor.s203482	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/ceor.s203482	study_information	NA	2	Patient-level data used	No
10.2147/ceor.s203482	study_information	NA	2	Clinical Trial	Yes
10.2147/ceor.s203482	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01074047
10.2147/ceor.s203482	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/ceor.s203482	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2147/ceor.s203482	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2147/ceor.s203482	study_information	NA	3	Patient-level data used	No
10.2147/ceor.s203482	study_information	NA	3	Clinical Trial	Yes
10.2147/ceor.s203482	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00260832
10.2147/ceor.s203482	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/ceor.s203482	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2147/ceor.s203482	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2147/cmar.s163478	general_information	NA	NA	Medical Condition of Interest Name	hr+, her2- advanced breast cancer
10.2147/cmar.s163478	general_information	NA	NA	Countries of first author affiliations	usa
10.2147/cmar.s163478	general_information	NA	NA	Countries of last author affiliations	usa
10.2147/cmar.s163478	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2147/cmar.s163478	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/cmar.s163478	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/cmar.s163478	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/cmar.s163478	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2147/cmar.s163478	methodology	1	NA	primary_outcome_name	progression-free survival
10.2147/cmar.s163478	methodology	1	NA	outcome_short_name	Progression-free Survival
10.2147/cmar.s163478	methodology	1	NA	primary_outcome_type	Time-to-event
10.2147/cmar.s163478	methodology	1	NA	Treatment name 1	ribociclib
10.2147/cmar.s163478	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2147/cmar.s163478	methodology	1	NA	Treatment name 2	palbociclib
10.2147/cmar.s163478	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2147/cmar.s163478	methodology	1	NA	paitc_type	MAIC
10.2147/cmar.s163478	methodology	1	NA	anchored_yn	Yes
10.2147/cmar.s163478	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/cmar.s163478	methodology	1	NA	primary_outcome_yn	Yes
10.2147/cmar.s163478	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2147/cmar.s163478	methodology	1	NA	prognostic_factors_yn	Yes
10.2147/cmar.s163478	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/cmar.s163478	methodology	1	NA	weights_model_yn	No
10.2147/cmar.s163478	methodology	1	NA	scale_choice_yn	No
10.2147/cmar.s163478	results	1	NA	contrast	HR
10.2147/cmar.s163478	results	1	NA	direction_benefit	inferior
10.2147/cmar.s163478	results	1	NA	n_nonipd_ttt	444
10.2147/cmar.s163478	results	1	NA	n_ipd_ttt	227
10.2147/cmar.s163478	results	1	NA	ess_ttt	220
10.2147/cmar.s163478	results	1	NA	weights_evaluation_yn	Not mentioned
10.2147/cmar.s163478	results	1	NA	list_covariates_yn	Yes
10.2147/cmar.s163478	results	1	NA	n_covariates	9
10.2147/cmar.s163478	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.2147/cmar.s163478	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/cmar.s163478	results	1	NA	unadjusted_effect	0.959
10.2147/cmar.s163478	results	1	NA	unadjusted_pval_char	[0.681;1.350]
10.2147/cmar.s163478	results	1	NA	adjusted_effect	0.904
10.2147/cmar.s163478	results	1	NA	adjusted_pval_char	[0.644;1.268]
10.2147/cmar.s163478	results	1	NA	geographical region	Yes
10.2147/cmar.s163478	results	1	NA	n_ipd_total	NA
10.2147/cmar.s163478	results	1	NA	ess_total	NA
10.2147/cmar.s163478	results	1	NA	n_nonipd_total	NA
10.2147/cmar.s163478	results	1	NA	n_nonipd_anchor	222
10.2147/cmar.s163478	results	1	NA	n_ipd_anchor	244
10.2147/cmar.s163478	results	1	NA	ess_anchor	237
10.2147/cmar.s163478	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/cmar.s163478	results	1	NA	effect_cutoff	1
10.2147/cmar.s163478	results	1	NA	unadjusted_lb_ci	0.681
10.2147/cmar.s163478	results	1	NA	unadjusted_ub_ci	1.35
10.2147/cmar.s163478	results	1	NA	unadjusted_significant	FALSE
10.2147/cmar.s163478	results	1	NA	adjusted_lb_ci	0.644
10.2147/cmar.s163478	results	1	NA	adjusted_ub_ci	1.268
10.2147/cmar.s163478	results	1	NA	adjusted_significant	FALSE
10.2147/cmar.s163478	study_information	NA	1	Patient-level data used	Yes
10.2147/cmar.s163478	study_information	NA	1	Clinical Trial	Yes
10.2147/cmar.s163478	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01958021
10.2147/cmar.s163478	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/cmar.s163478	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2147/cmar.s163478	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/cmar.s163478	study_information	NA	2	Patient-level data used	No
10.2147/cmar.s163478	study_information	NA	2	Clinical Trial	Yes
10.2147/cmar.s163478	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01740427
10.2147/cmar.s163478	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/cmar.s163478	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2147/cmar.s163478	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2147/cmar.s325043	general_information	NA	NA	Medical Condition of Interest Name	hr+/her2? advanced breast cancer
10.2147/cmar.s325043	general_information	NA	NA	Countries of first author affiliations	germany
10.2147/cmar.s325043	general_information	NA	NA	Countries of last author affiliations	usa
10.2147/cmar.s325043	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/cmar.s325043	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/cmar.s325043	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/cmar.s325043	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/cmar.s325043	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2147/cmar.s325043	methodology	1	NA	primary_outcome_name	progression-free survival
10.2147/cmar.s325043	methodology	1	NA	outcome_short_name	Progression-free Survival
10.2147/cmar.s325043	methodology	1	NA	primary_outcome_type	Time-to-event
10.2147/cmar.s325043	methodology	1	NA	Treatment name 1	ribociclib + fulvestrant
10.2147/cmar.s325043	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2147/cmar.s325043	methodology	1	NA	Treatment name 2	palbociclib + letrozole
10.2147/cmar.s325043	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2147/cmar.s325043	methodology	1	NA	paitc_type	MAIC
10.2147/cmar.s325043	methodology	1	NA	anchored_yn	No
10.2147/cmar.s325043	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/cmar.s325043	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/cmar.s325043	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2147/cmar.s325043	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/cmar.s325043	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/cmar.s325043	methodology	1	NA	weights_model_yn	No
10.2147/cmar.s325043	methodology	1	NA	scale_choice_yn	No
10.2147/cmar.s325043	methodology	2	NA	primary_outcome_name	progression-free survival
10.2147/cmar.s325043	methodology	2	NA	outcome_short_name	Progression-free Survival
10.2147/cmar.s325043	methodology	2	NA	primary_outcome_type	Time-to-event
10.2147/cmar.s325043	methodology	2	NA	Treatment name 1	placebo + fulvestrant
10.2147/cmar.s325043	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2147/cmar.s325043	methodology	2	NA	Treatment name 2	letrozole
10.2147/cmar.s325043	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.2147/cmar.s325043	methodology	2	NA	paitc_type	MAIC
10.2147/cmar.s325043	methodology	2	NA	anchored_yn	No
10.2147/cmar.s325043	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/cmar.s325043	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/cmar.s325043	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.2147/cmar.s325043	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/cmar.s325043	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/cmar.s325043	methodology	2	NA	weights_model_yn	No
10.2147/cmar.s325043	methodology	2	NA	scale_choice_yn	No
10.2147/cmar.s325043	results	1	NA	contrast	HR
10.2147/cmar.s325043	results	1	NA	direction_benefit	inferior
10.2147/cmar.s325043	results	1	NA	n_nonipd_ttt	84
10.2147/cmar.s325043	results	1	NA	n_ipd_ttt	329
10.2147/cmar.s325043	results	1	NA	ess_ttt	221
10.2147/cmar.s325043	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.2147/cmar.s325043	results	1	NA	list_covariates_yn	Yes
10.2147/cmar.s325043	results	1	NA	n_covariates	7
10.2147/cmar.s325043	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2147/cmar.s325043	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/cmar.s325043	results	1	NA	unadjusted_effect	0.83
10.2147/cmar.s325043	results	1	NA	unadjusted_pval_char	0.2838
10.2147/cmar.s325043	results	1	NA	adjusted_effect	0.77
10.2147/cmar.s325043	results	1	NA	adjusted_pval_char	0.1553
10.2147/cmar.s325043	results	1	NA	geographical region	NA
10.2147/cmar.s325043	results	1	NA	n_ipd_total	NA
10.2147/cmar.s325043	results	1	NA	ess_total	NA
10.2147/cmar.s325043	results	1	NA	n_nonipd_total	NA
10.2147/cmar.s325043	results	1	NA	n_nonipd_anchor	NA
10.2147/cmar.s325043	results	1	NA	n_ipd_anchor	NA
10.2147/cmar.s325043	results	1	NA	ess_anchor	NA
10.2147/cmar.s325043	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/cmar.s325043	results	1	NA	effect_cutoff	1
10.2147/cmar.s325043	results	1	NA	unadjusted_pval	0.2838
10.2147/cmar.s325043	results	1	NA	unadjusted_num_pval	0.2838
10.2147/cmar.s325043	results	1	NA	unadjusted_significant	FALSE
10.2147/cmar.s325043	results	1	NA	adjusted_pval	0.1553
10.2147/cmar.s325043	results	1	NA	adjusted_num_pval	0.1553
10.2147/cmar.s325043	results	1	NA	adjusted_significant	FALSE
10.2147/cmar.s325043	results	2	NA	contrast	HR
10.2147/cmar.s325043	results	2	NA	direction_benefit	inferior
10.2147/cmar.s325043	results	2	NA	n_nonipd_ttt	81
10.2147/cmar.s325043	results	2	NA	n_ipd_ttt	178
10.2147/cmar.s325043	results	2	NA	ess_ttt	117
10.2147/cmar.s325043	results	2	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.2147/cmar.s325043	results	2	NA	list_covariates_yn	Yes
10.2147/cmar.s325043	results	2	NA	n_covariates	7
10.2147/cmar.s325043	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2147/cmar.s325043	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/cmar.s325043	results	2	NA	unadjusted_effect	0.66
10.2147/cmar.s325043	results	2	NA	unadjusted_pval_char	0.0094
10.2147/cmar.s325043	results	2	NA	adjusted_effect	0.58
10.2147/cmar.s325043	results	2	NA	adjusted_pval_char	0.0019
10.2147/cmar.s325043	results	2	NA	geographical region	NA
10.2147/cmar.s325043	results	2	NA	n_ipd_total	NA
10.2147/cmar.s325043	results	2	NA	ess_total	NA
10.2147/cmar.s325043	results	2	NA	n_nonipd_total	NA
10.2147/cmar.s325043	results	2	NA	n_nonipd_anchor	NA
10.2147/cmar.s325043	results	2	NA	n_ipd_anchor	NA
10.2147/cmar.s325043	results	2	NA	ess_anchor	NA
10.2147/cmar.s325043	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/cmar.s325043	results	2	NA	effect_cutoff	1
10.2147/cmar.s325043	results	2	NA	unadjusted_pval	0.0094
10.2147/cmar.s325043	results	2	NA	unadjusted_num_pval	0.0094
10.2147/cmar.s325043	results	2	NA	unadjusted_significant	TRUE
10.2147/cmar.s325043	results	2	NA	adjusted_pval	0.0019
10.2147/cmar.s325043	results	2	NA	adjusted_num_pval	0.0019
10.2147/cmar.s325043	results	2	NA	adjusted_significant	TRUE
10.2147/cmar.s325043	study_information	NA	1	Patient-level data used	Yes
10.2147/cmar.s325043	study_information	NA	1	Clinical Trial	Yes
10.2147/cmar.s325043	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02422615
10.2147/cmar.s325043	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/cmar.s325043	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2147/cmar.s325043	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/cmar.s325043	study_information	NA	2	Patient-level data used	No
10.2147/cmar.s325043	study_information	NA	2	Clinical Trial	Yes
10.2147/cmar.s325043	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00721409
10.2147/cmar.s325043	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/cmar.s325043	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.2147/cmar.s325043	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s104074	general_information	NA	NA	Medical Condition of Interest Name	severe hemophilia a
10.2147/jbm.s104074	general_information	NA	NA	Countries of first author affiliations	usa
10.2147/jbm.s104074	general_information	NA	NA	Countries of last author affiliations	usa
10.2147/jbm.s104074	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s104074	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/jbm.s104074	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/jbm.s104074	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/jbm.s104074	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2147/jbm.s104074	methodology	1	NA	primary_outcome_name	square root transformed abr : annualized bleed rates at 1 year (all bleed)
10.2147/jbm.s104074	methodology	1	NA	outcome_short_name	Annualized bleeding Rate
10.2147/jbm.s104074	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2147/jbm.s104074	methodology	1	NA	Treatment name 1	bay 81-8973 (recombinant factor viii)
10.2147/jbm.s104074	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2147/jbm.s104074	methodology	1	NA	Treatment name 2	rahf-pfm
10.2147/jbm.s104074	methodology	1	NA	Study 'number(s)' for treatment 2	4
10.2147/jbm.s104074	methodology	1	NA	paitc_type	MAIC
10.2147/jbm.s104074	methodology	1	NA	anchored_yn	No
10.2147/jbm.s104074	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2147/jbm.s104074	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s104074	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2147/jbm.s104074	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s104074	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s104074	methodology	1	NA	weights_model_yn	No
10.2147/jbm.s104074	methodology	1	NA	scale_choice_yn	No
10.2147/jbm.s104074	methodology	2	NA	primary_outcome_name	annualized bleed rates for all bleeds (1-year)
10.2147/jbm.s104074	methodology	2	NA	outcome_short_name	Annualized bleeding Rate
10.2147/jbm.s104074	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2147/jbm.s104074	methodology	2	NA	Treatment name 1	bay 81-8973 (recombinant factor viii)
10.2147/jbm.s104074	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.2147/jbm.s104074	methodology	2	NA	Treatment name 2	rahf-pfm
10.2147/jbm.s104074	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.2147/jbm.s104074	methodology	2	NA	paitc_type	MAIC
10.2147/jbm.s104074	methodology	2	NA	anchored_yn	No
10.2147/jbm.s104074	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2147/jbm.s104074	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s104074	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.2147/jbm.s104074	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s104074	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s104074	methodology	2	NA	weights_model_yn	No
10.2147/jbm.s104074	methodology	2	NA	scale_choice_yn	No
10.2147/jbm.s104074	methodology	3	NA	primary_outcome_name	annualized bleed rates for all bleeds (1-year)
10.2147/jbm.s104074	methodology	3	NA	outcome_short_name	Annualized bleeding Rate
10.2147/jbm.s104074	methodology	3	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2147/jbm.s104074	methodology	3	NA	Treatment name 1	bay 81-8973 (recombinant factor viii)
10.2147/jbm.s104074	methodology	3	NA	Study 'number(s)' for treatment 1	1;2
10.2147/jbm.s104074	methodology	3	NA	Treatment name 2	turoctocog alfa
10.2147/jbm.s104074	methodology	3	NA	Study 'number(s)' for treatment 2	5
10.2147/jbm.s104074	methodology	3	NA	paitc_type	MAIC
10.2147/jbm.s104074	methodology	3	NA	anchored_yn	No
10.2147/jbm.s104074	methodology	3	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2147/jbm.s104074	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s104074	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.2147/jbm.s104074	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s104074	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s104074	methodology	3	NA	weights_model_yn	No
10.2147/jbm.s104074	methodology	3	NA	scale_choice_yn	No
10.2147/jbm.s104074	results	1	NA	contrast	Means difference
10.2147/jbm.s104074	results	1	NA	direction_benefit	inferior
10.2147/jbm.s104074	results	1	NA	n_nonipd_ttt	66
10.2147/jbm.s104074	results	1	NA	n_ipd_ttt	121
10.2147/jbm.s104074	results	1	NA	ess_ttt	NA
10.2147/jbm.s104074	results	1	NA	weights_evaluation_yn	Not mentioned
10.2147/jbm.s104074	results	1	NA	list_covariates_yn	Yes
10.2147/jbm.s104074	results	1	NA	n_covariates	2
10.2147/jbm.s104074	results	1	NA	list_covariates	Age, Race/ethnicity
10.2147/jbm.s104074	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s104074	results	1	NA	unadjusted_effect	0.1
10.2147/jbm.s104074	results	1	NA	unadjusted_pval_char	[-0.3;0.4]
10.2147/jbm.s104074	results	1	NA	adjusted_effect	0.1
10.2147/jbm.s104074	results	1	NA	adjusted_pval_char	[-0.3;0.4]
10.2147/jbm.s104074	results	1	NA	geographical region	NA
10.2147/jbm.s104074	results	1	NA	n_ipd_total	NA
10.2147/jbm.s104074	results	1	NA	ess_total	NA
10.2147/jbm.s104074	results	1	NA	n_nonipd_total	NA
10.2147/jbm.s104074	results	1	NA	n_nonipd_anchor	NA
10.2147/jbm.s104074	results	1	NA	n_ipd_anchor	NA
10.2147/jbm.s104074	results	1	NA	ess_anchor	NA
10.2147/jbm.s104074	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/jbm.s104074	results	1	NA	effect_cutoff	0
10.2147/jbm.s104074	results	1	NA	unadjusted_lb_ci	-0.3
10.2147/jbm.s104074	results	1	NA	unadjusted_ub_ci	0.4
10.2147/jbm.s104074	results	1	NA	unadjusted_significant	FALSE
10.2147/jbm.s104074	results	1	NA	adjusted_lb_ci	-0.3
10.2147/jbm.s104074	results	1	NA	adjusted_ub_ci	0.4
10.2147/jbm.s104074	results	1	NA	adjusted_significant	FALSE
10.2147/jbm.s104074	results	2	NA	contrast	Means difference
10.2147/jbm.s104074	results	2	NA	direction_benefit	inferior
10.2147/jbm.s104074	results	2	NA	n_nonipd_ttt	107
10.2147/jbm.s104074	results	2	NA	n_ipd_ttt	121
10.2147/jbm.s104074	results	2	NA	ess_ttt	NA
10.2147/jbm.s104074	results	2	NA	weights_evaluation_yn	Not mentioned
10.2147/jbm.s104074	results	2	NA	list_covariates_yn	Yes
10.2147/jbm.s104074	results	2	NA	n_covariates	2
10.2147/jbm.s104074	results	2	NA	list_covariates	Age, Race/ethnicity
10.2147/jbm.s104074	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s104074	results	2	NA	unadjusted_effect	-1.9
10.2147/jbm.s104074	results	2	NA	unadjusted_pval_char	[-3.5;-0.4] p<0.05
10.2147/jbm.s104074	results	2	NA	adjusted_effect	-1.5
10.2147/jbm.s104074	results	2	NA	adjusted_pval_char	[-3.7;-0.7] p=0.18
10.2147/jbm.s104074	results	2	NA	geographical region	NA
10.2147/jbm.s104074	results	2	NA	n_ipd_total	NA
10.2147/jbm.s104074	results	2	NA	ess_total	NA
10.2147/jbm.s104074	results	2	NA	n_nonipd_total	NA
10.2147/jbm.s104074	results	2	NA	n_nonipd_anchor	NA
10.2147/jbm.s104074	results	2	NA	n_ipd_anchor	NA
10.2147/jbm.s104074	results	2	NA	ess_anchor	NA
10.2147/jbm.s104074	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/jbm.s104074	results	2	NA	effect_cutoff	0
10.2147/jbm.s104074	results	2	NA	unadjusted_lb_ci	-3.5
10.2147/jbm.s104074	results	2	NA	unadjusted_ub_ci	-0.4
10.2147/jbm.s104074	results	2	NA	unadjusted_pval	<0.05
10.2147/jbm.s104074	results	2	NA	unadjusted_significant	TRUE
10.2147/jbm.s104074	results	2	NA	adjusted_lb_ci	-3.7
10.2147/jbm.s104074	results	2	NA	adjusted_ub_ci	-0.7
10.2147/jbm.s104074	results	2	NA	adjusted_pval	=0.18
10.2147/jbm.s104074	results	2	NA	adjusted_significant	TRUE
10.2147/jbm.s104074	results	3	NA	contrast	Means difference
10.2147/jbm.s104074	results	3	NA	direction_benefit	inferior
10.2147/jbm.s104074	results	3	NA	n_nonipd_ttt	150
10.2147/jbm.s104074	results	3	NA	n_ipd_ttt	121
10.2147/jbm.s104074	results	3	NA	ess_ttt	NA
10.2147/jbm.s104074	results	3	NA	weights_evaluation_yn	Not mentioned
10.2147/jbm.s104074	results	3	NA	list_covariates_yn	Yes
10.2147/jbm.s104074	results	3	NA	n_covariates	3
10.2147/jbm.s104074	results	3	NA	list_covariates	Age, Race/ethnicity, Other(s)
10.2147/jbm.s104074	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s104074	results	3	NA	unadjusted_effect	-2.1
10.2147/jbm.s104074	results	3	NA	unadjusted_pval_char	[-3.3;-1.0] p<0.01
10.2147/jbm.s104074	results	3	NA	adjusted_effect	-2.2
10.2147/jbm.s104074	results	3	NA	adjusted_pval_char	[-3.4;-1.0] p<0.05
10.2147/jbm.s104074	results	3	NA	geographical region	No
10.2147/jbm.s104074	results	3	NA	n_ipd_total	NA
10.2147/jbm.s104074	results	3	NA	ess_total	NA
10.2147/jbm.s104074	results	3	NA	n_nonipd_total	NA
10.2147/jbm.s104074	results	3	NA	n_nonipd_anchor	NA
10.2147/jbm.s104074	results	3	NA	n_ipd_anchor	NA
10.2147/jbm.s104074	results	3	NA	ess_anchor	NA
10.2147/jbm.s104074	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/jbm.s104074	results	3	NA	effect_cutoff	0
10.2147/jbm.s104074	results	3	NA	unadjusted_lb_ci	-3.3
10.2147/jbm.s104074	results	3	NA	unadjusted_ub_ci	-1
10.2147/jbm.s104074	results	3	NA	unadjusted_pval	<0.01
10.2147/jbm.s104074	results	3	NA	unadjusted_significant	TRUE
10.2147/jbm.s104074	results	3	NA	adjusted_lb_ci	-3.4
10.2147/jbm.s104074	results	3	NA	adjusted_ub_ci	-1
10.2147/jbm.s104074	results	3	NA	adjusted_pval	<0.05
10.2147/jbm.s104074	results	3	NA	adjusted_significant	TRUE
10.2147/jbm.s104074	study_information	NA	1	Patient-level data used	Yes
10.2147/jbm.s104074	study_information	NA	1	Clinical Trial	Yes
10.2147/jbm.s104074	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01029340
10.2147/jbm.s104074	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s104074	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s104074	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s104074	study_information	NA	2	Patient-level data used	Yes
10.2147/jbm.s104074	study_information	NA	2	Clinical Trial	Yes
10.2147/jbm.s104074	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01233258
10.2147/jbm.s104074	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s104074	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s104074	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s104074	study_information	NA	3	Patient-level data used	No
10.2147/jbm.s104074	study_information	NA	3	Clinical Trial	Yes
10.2147/jbm.s104074	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	tarantino et al. (2004)
10.2147/jbm.s104074	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s104074	study_information	NA	4	Patient-level data used	No
10.2147/jbm.s104074	study_information	NA	4	Clinical Trial	Yes
10.2147/jbm.s104074	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00243386
10.2147/jbm.s104074	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s104074	study_information	NA	4	Phase of the clinical trial (clinical trial only)	4
10.2147/jbm.s104074	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2147/jbm.s104074	study_information	NA	5	Patient-level data used	No
10.2147/jbm.s104074	study_information	NA	5	Clinical Trial	Yes
10.2147/jbm.s104074	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00840086
10.2147/jbm.s104074	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s104074	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s104074	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.2147/jbm.s206806	general_information	NA	NA	Medical Condition of Interest Name	severe hemophilia a
10.2147/jbm.s206806	general_information	NA	NA	Countries of first author affiliations	usa
10.2147/jbm.s206806	general_information	NA	NA	Countries of last author affiliations	germany
10.2147/jbm.s206806	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s206806	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/jbm.s206806	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/jbm.s206806	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/jbm.s206806	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2147/jbm.s206806	methodology	1	NA	primary_outcome_name	annualized bleeding rate
10.2147/jbm.s206806	methodology	1	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s206806	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2147/jbm.s206806	methodology	1	NA	Treatment name 1	bay 94-9027
10.2147/jbm.s206806	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s206806	methodology	1	NA	Treatment name 2	rfviiifc
10.2147/jbm.s206806	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2147/jbm.s206806	methodology	1	NA	paitc_type	MAIC
10.2147/jbm.s206806	methodology	1	NA	anchored_yn	No
10.2147/jbm.s206806	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s206806	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s206806	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2147/jbm.s206806	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s206806	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s206806	methodology	1	NA	weights_model_yn	No
10.2147/jbm.s206806	methodology	1	NA	scale_choice_yn	No
10.2147/jbm.s206806	methodology	2	NA	primary_outcome_name	annualized bleeding rate
10.2147/jbm.s206806	methodology	2	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s206806	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2147/jbm.s206806	methodology	2	NA	Treatment name 1	bay 94-9027
10.2147/jbm.s206806	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s206806	methodology	2	NA	Treatment name 2	bax 855
10.2147/jbm.s206806	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.2147/jbm.s206806	methodology	2	NA	paitc_type	MAIC
10.2147/jbm.s206806	methodology	2	NA	anchored_yn	No
10.2147/jbm.s206806	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s206806	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s206806	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.2147/jbm.s206806	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s206806	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s206806	methodology	2	NA	weights_model_yn	No
10.2147/jbm.s206806	methodology	2	NA	scale_choice_yn	No
10.2147/jbm.s206806	methodology	3	NA	primary_outcome_name	annualized bleeding rate
10.2147/jbm.s206806	methodology	3	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s206806	methodology	3	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2147/jbm.s206806	methodology	3	NA	Treatment name 1	bay 94-9027
10.2147/jbm.s206806	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s206806	methodology	3	NA	Treatment name 2	rahf-pfm 2004
10.2147/jbm.s206806	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.2147/jbm.s206806	methodology	3	NA	paitc_type	MAIC
10.2147/jbm.s206806	methodology	3	NA	anchored_yn	No
10.2147/jbm.s206806	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s206806	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s206806	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.2147/jbm.s206806	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s206806	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s206806	methodology	3	NA	weights_model_yn	No
10.2147/jbm.s206806	methodology	3	NA	scale_choice_yn	No
10.2147/jbm.s206806	methodology	4	NA	primary_outcome_name	annualized bleeding rate
10.2147/jbm.s206806	methodology	4	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s206806	methodology	4	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2147/jbm.s206806	methodology	4	NA	Treatment name 1	bay 94-9027
10.2147/jbm.s206806	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s206806	methodology	4	NA	Treatment name 2	rahf-pfm 2012
10.2147/jbm.s206806	methodology	4	NA	Study 'number(s)' for treatment 2	5
10.2147/jbm.s206806	methodology	4	NA	paitc_type	MAIC
10.2147/jbm.s206806	methodology	4	NA	anchored_yn	No
10.2147/jbm.s206806	methodology	4	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s206806	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s206806	methodology	4	NA	variables_justification	Nothing mentioned, not reported
10.2147/jbm.s206806	methodology	4	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s206806	methodology	4	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s206806	methodology	4	NA	weights_model_yn	No
10.2147/jbm.s206806	methodology	4	NA	scale_choice_yn	No
10.2147/jbm.s206806	results	1	NA	contrast	Means difference
10.2147/jbm.s206806	results	1	NA	direction_benefit	inferior
10.2147/jbm.s206806	results	1	NA	n_nonipd_ttt	140
10.2147/jbm.s206806	results	1	NA	n_ipd_ttt	103
10.2147/jbm.s206806	results	1	NA	ess_ttt	44.6
10.2147/jbm.s206806	results	1	NA	weights_evaluation_yn	Not mentioned
10.2147/jbm.s206806	results	1	NA	list_covariates_yn	Yes
10.2147/jbm.s206806	results	1	NA	n_covariates	7
10.2147/jbm.s206806	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2147/jbm.s206806	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s206806	results	1	NA	unadjusted_effect	0.17
10.2147/jbm.s206806	results	1	NA	unadjusted_pval_char	[-1.35;1.70]
10.2147/jbm.s206806	results	1	NA	adjusted_effect	-0.12
10.2147/jbm.s206806	results	1	NA	adjusted_pval_char	[-1.62;1.37]
10.2147/jbm.s206806	results	1	NA	geographical region	Yes
10.2147/jbm.s206806	results	1	NA	n_ipd_total	NA
10.2147/jbm.s206806	results	1	NA	ess_total	NA
10.2147/jbm.s206806	results	1	NA	n_nonipd_total	NA
10.2147/jbm.s206806	results	1	NA	n_nonipd_anchor	NA
10.2147/jbm.s206806	results	1	NA	n_ipd_anchor	NA
10.2147/jbm.s206806	results	1	NA	ess_anchor	NA
10.2147/jbm.s206806	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/jbm.s206806	results	1	NA	effect_cutoff	0
10.2147/jbm.s206806	results	1	NA	unadjusted_lb_ci	-1.35
10.2147/jbm.s206806	results	1	NA	unadjusted_ub_ci	1.7
10.2147/jbm.s206806	results	1	NA	unadjusted_significant	FALSE
10.2147/jbm.s206806	results	1	NA	adjusted_lb_ci	-1.62
10.2147/jbm.s206806	results	1	NA	adjusted_ub_ci	1.37
10.2147/jbm.s206806	results	1	NA	adjusted_significant	FALSE
10.2147/jbm.s206806	results	2	NA	contrast	Means difference
10.2147/jbm.s206806	results	2	NA	direction_benefit	inferior
10.2147/jbm.s206806	results	2	NA	n_nonipd_ttt	101
10.2147/jbm.s206806	results	2	NA	n_ipd_ttt	104
10.2147/jbm.s206806	results	2	NA	ess_ttt	78.3
10.2147/jbm.s206806	results	2	NA	weights_evaluation_yn	Not mentioned
10.2147/jbm.s206806	results	2	NA	list_covariates_yn	Yes
10.2147/jbm.s206806	results	2	NA	n_covariates	5
10.2147/jbm.s206806	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2147/jbm.s206806	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s206806	results	2	NA	unadjusted_effect	0.35
10.2147/jbm.s206806	results	2	NA	unadjusted_pval_char	[-1.00;1.70]
10.2147/jbm.s206806	results	2	NA	adjusted_effect	0.25
10.2147/jbm.s206806	results	2	NA	adjusted_pval_char	[-1.19;1.70]
10.2147/jbm.s206806	results	2	NA	geographical region	Yes
10.2147/jbm.s206806	results	2	NA	n_ipd_total	NA
10.2147/jbm.s206806	results	2	NA	ess_total	NA
10.2147/jbm.s206806	results	2	NA	n_nonipd_total	NA
10.2147/jbm.s206806	results	2	NA	n_nonipd_anchor	NA
10.2147/jbm.s206806	results	2	NA	n_ipd_anchor	NA
10.2147/jbm.s206806	results	2	NA	ess_anchor	NA
10.2147/jbm.s206806	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/jbm.s206806	results	2	NA	effect_cutoff	0
10.2147/jbm.s206806	results	2	NA	unadjusted_lb_ci	-1
10.2147/jbm.s206806	results	2	NA	unadjusted_ub_ci	1.7
10.2147/jbm.s206806	results	2	NA	unadjusted_significant	FALSE
10.2147/jbm.s206806	results	2	NA	adjusted_lb_ci	-1.19
10.2147/jbm.s206806	results	2	NA	adjusted_ub_ci	1.7
10.2147/jbm.s206806	results	2	NA	adjusted_significant	FALSE
10.2147/jbm.s206806	results	3	NA	contrast	Means difference
10.2147/jbm.s206806	results	3	NA	direction_benefit	inferior
10.2147/jbm.s206806	results	3	NA	n_nonipd_ttt	66
10.2147/jbm.s206806	results	3	NA	n_ipd_ttt	104
10.2147/jbm.s206806	results	3	NA	ess_ttt	25.32
10.2147/jbm.s206806	results	3	NA	weights_evaluation_yn	Not mentioned
10.2147/jbm.s206806	results	3	NA	list_covariates_yn	Yes
10.2147/jbm.s206806	results	3	NA	n_covariates	3
10.2147/jbm.s206806	results	3	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.2147/jbm.s206806	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s206806	results	3	NA	unadjusted_effect	-2.25
10.2147/jbm.s206806	results	3	NA	unadjusted_pval_char	[-3.64;-0.85]
10.2147/jbm.s206806	results	3	NA	adjusted_effect	-2.02
10.2147/jbm.s206806	results	3	NA	adjusted_pval_char	[-4.35;0.30]
10.2147/jbm.s206806	results	3	NA	geographical region	NA
10.2147/jbm.s206806	results	3	NA	n_ipd_total	NA
10.2147/jbm.s206806	results	3	NA	ess_total	NA
10.2147/jbm.s206806	results	3	NA	n_nonipd_total	NA
10.2147/jbm.s206806	results	3	NA	n_nonipd_anchor	NA
10.2147/jbm.s206806	results	3	NA	n_ipd_anchor	NA
10.2147/jbm.s206806	results	3	NA	ess_anchor	NA
10.2147/jbm.s206806	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/jbm.s206806	results	3	NA	effect_cutoff	0
10.2147/jbm.s206806	results	3	NA	unadjusted_lb_ci	-3.64
10.2147/jbm.s206806	results	3	NA	unadjusted_ub_ci	-0.85
10.2147/jbm.s206806	results	3	NA	unadjusted_significant	TRUE
10.2147/jbm.s206806	results	3	NA	adjusted_lb_ci	-4.35
10.2147/jbm.s206806	results	3	NA	adjusted_ub_ci	0.3
10.2147/jbm.s206806	results	3	NA	adjusted_significant	FALSE
10.2147/jbm.s206806	results	4	NA	contrast	Means difference
10.2147/jbm.s206806	results	4	NA	direction_benefit	inferior
10.2147/jbm.s206806	results	4	NA	n_nonipd_ttt	107
10.2147/jbm.s206806	results	4	NA	n_ipd_ttt	104
10.2147/jbm.s206806	results	4	NA	ess_ttt	55.33
10.2147/jbm.s206806	results	4	NA	weights_evaluation_yn	Not mentioned
10.2147/jbm.s206806	results	4	NA	list_covariates_yn	Yes
10.2147/jbm.s206806	results	4	NA	n_covariates	3
10.2147/jbm.s206806	results	4	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.2147/jbm.s206806	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s206806	results	4	NA	unadjusted_effect	0.03
10.2147/jbm.s206806	results	4	NA	unadjusted_pval_char	[-0.32;0.37]
10.2147/jbm.s206806	results	4	NA	adjusted_effect	0.07
10.2147/jbm.s206806	results	4	NA	adjusted_pval_char	[-0.32;0.46]
10.2147/jbm.s206806	results	4	NA	geographical region	NA
10.2147/jbm.s206806	results	4	NA	n_ipd_total	NA
10.2147/jbm.s206806	results	4	NA	ess_total	NA
10.2147/jbm.s206806	results	4	NA	n_nonipd_total	NA
10.2147/jbm.s206806	results	4	NA	n_nonipd_anchor	NA
10.2147/jbm.s206806	results	4	NA	n_ipd_anchor	NA
10.2147/jbm.s206806	results	4	NA	ess_anchor	NA
10.2147/jbm.s206806	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/jbm.s206806	results	4	NA	effect_cutoff	0
10.2147/jbm.s206806	results	4	NA	unadjusted_lb_ci	-0.32
10.2147/jbm.s206806	results	4	NA	unadjusted_ub_ci	0.37
10.2147/jbm.s206806	results	4	NA	unadjusted_significant	FALSE
10.2147/jbm.s206806	results	4	NA	adjusted_lb_ci	-0.32
10.2147/jbm.s206806	results	4	NA	adjusted_ub_ci	0.46
10.2147/jbm.s206806	results	4	NA	adjusted_significant	FALSE
10.2147/jbm.s206806	study_information	NA	1	Patient-level data used	Yes
10.2147/jbm.s206806	study_information	NA	1	Clinical Trial	Yes
10.2147/jbm.s206806	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01580293
10.2147/jbm.s206806	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s206806	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2, 3
10.2147/jbm.s206806	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s206806	study_information	NA	2	Patient-level data used	No
10.2147/jbm.s206806	study_information	NA	2	Clinical Trial	Yes
10.2147/jbm.s206806	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01181128
10.2147/jbm.s206806	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s206806	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s206806	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s206806	study_information	NA	3	Patient-level data used	No
10.2147/jbm.s206806	study_information	NA	3	Clinical Trial	Yes
10.2147/jbm.s206806	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01736475
10.2147/jbm.s206806	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s206806	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2, 3
10.2147/jbm.s206806	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s206806	study_information	NA	4	Patient-level data used	No
10.2147/jbm.s206806	study_information	NA	4	Clinical Trial	Yes
10.2147/jbm.s206806	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	tarantino et al. (2004)
10.2147/jbm.s206806	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s206806	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s206806	study_information	NA	5	Patient-level data used	No
10.2147/jbm.s206806	study_information	NA	5	Clinical Trial	Yes
10.2147/jbm.s206806	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00243386
10.2147/jbm.s206806	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s206806	study_information	NA	5	Phase of the clinical trial (clinical trial only)	4
10.2147/jbm.s206806	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s288283	general_information	NA	NA	Medical Condition of Interest Name	hemophilia a without inhibitors
10.2147/jbm.s288283	general_information	NA	NA	Countries of first author affiliations	germany
10.2147/jbm.s288283	general_information	NA	NA	Countries of last author affiliations	usa
10.2147/jbm.s288283	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s288283	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/jbm.s288283	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/jbm.s288283	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/jbm.s288283	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2147/jbm.s288283	methodology	1	NA	primary_outcome_name	mean annualized bleeding rate
10.2147/jbm.s288283	methodology	1	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s288283	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2147/jbm.s288283	methodology	1	NA	Treatment name 1	rfviiifc
10.2147/jbm.s288283	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s288283	methodology	1	NA	Treatment name 2	emicizumab every week
10.2147/jbm.s288283	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2147/jbm.s288283	methodology	1	NA	paitc_type	MAIC
10.2147/jbm.s288283	methodology	1	NA	anchored_yn	No
10.2147/jbm.s288283	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s288283	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s288283	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2147/jbm.s288283	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s288283	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s288283	methodology	1	NA	weights_model_yn	Yes
10.2147/jbm.s288283	methodology	1	NA	scale_choice_yn	No
10.2147/jbm.s288283	methodology	2	NA	primary_outcome_name	mean annualized bleeding rate
10.2147/jbm.s288283	methodology	2	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s288283	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2147/jbm.s288283	methodology	2	NA	Treatment name 1	rfviiifc
10.2147/jbm.s288283	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s288283	methodology	2	NA	Treatment name 2	emicizumab every 2 weeks
10.2147/jbm.s288283	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.2147/jbm.s288283	methodology	2	NA	paitc_type	MAIC
10.2147/jbm.s288283	methodology	2	NA	anchored_yn	No
10.2147/jbm.s288283	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s288283	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s288283	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.2147/jbm.s288283	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s288283	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s288283	methodology	2	NA	weights_model_yn	Yes
10.2147/jbm.s288283	methodology	2	NA	scale_choice_yn	No
10.2147/jbm.s288283	methodology	3	NA	primary_outcome_name	mean annualized bleeding rate
10.2147/jbm.s288283	methodology	3	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s288283	methodology	3	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2147/jbm.s288283	methodology	3	NA	Treatment name 1	rfviiifc
10.2147/jbm.s288283	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s288283	methodology	3	NA	Treatment name 2	emicizumab every 4 weeks
10.2147/jbm.s288283	methodology	3	NA	Study 'number(s)' for treatment 2	3
10.2147/jbm.s288283	methodology	3	NA	paitc_type	MAIC
10.2147/jbm.s288283	methodology	3	NA	anchored_yn	No
10.2147/jbm.s288283	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s288283	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s288283	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.2147/jbm.s288283	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s288283	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s288283	methodology	3	NA	weights_model_yn	Yes
10.2147/jbm.s288283	methodology	3	NA	scale_choice_yn	No
10.2147/jbm.s288283	results	1	NA	contrast	Incidence Rate Ratio
10.2147/jbm.s288283	results	1	NA	direction_benefit	inferior
10.2147/jbm.s288283	results	1	NA	n_nonipd_ttt	99
10.2147/jbm.s288283	results	1	NA	n_ipd_ttt	117
10.2147/jbm.s288283	results	1	NA	ess_ttt	94
10.2147/jbm.s288283	results	1	NA	weights_evaluation_yn	Not mentioned
10.2147/jbm.s288283	results	1	NA	list_covariates_yn	Yes
10.2147/jbm.s288283	results	1	NA	n_covariates	5
10.2147/jbm.s288283	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2147/jbm.s288283	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s288283	results	1	NA	unadjusted_effect	NA
10.2147/jbm.s288283	results	1	NA	unadjusted_pval_char	NA
10.2147/jbm.s288283	results	1	NA	adjusted_effect	0.93
10.2147/jbm.s288283	results	1	NA	adjusted_pval_char	[0.63;1.39]
10.2147/jbm.s288283	results	1	NA	geographical region	NA
10.2147/jbm.s288283	results	1	NA	n_ipd_total	NA
10.2147/jbm.s288283	results	1	NA	ess_total	NA
10.2147/jbm.s288283	results	1	NA	n_nonipd_total	NA
10.2147/jbm.s288283	results	1	NA	n_nonipd_anchor	NA
10.2147/jbm.s288283	results	1	NA	n_ipd_anchor	NA
10.2147/jbm.s288283	results	1	NA	ess_anchor	NA
10.2147/jbm.s288283	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/jbm.s288283	results	1	NA	effect_cutoff	1
10.2147/jbm.s288283	results	1	NA	adjusted_lb_ci	0.63
10.2147/jbm.s288283	results	1	NA	adjusted_ub_ci	1.39
10.2147/jbm.s288283	results	1	NA	adjusted_significant	FALSE
10.2147/jbm.s288283	results	2	NA	contrast	Incidence Rate Ratio
10.2147/jbm.s288283	results	2	NA	direction_benefit	inferior
10.2147/jbm.s288283	results	2	NA	n_nonipd_ttt	35
10.2147/jbm.s288283	results	2	NA	n_ipd_ttt	117
10.2147/jbm.s288283	results	2	NA	ess_ttt	19
10.2147/jbm.s288283	results	2	NA	weights_evaluation_yn	Not mentioned
10.2147/jbm.s288283	results	2	NA	list_covariates_yn	Yes
10.2147/jbm.s288283	results	2	NA	n_covariates	5
10.2147/jbm.s288283	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2147/jbm.s288283	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s288283	results	2	NA	unadjusted_effect	NA
10.2147/jbm.s288283	results	2	NA	unadjusted_pval_char	NA
10.2147/jbm.s288283	results	2	NA	adjusted_effect	0.57
10.2147/jbm.s288283	results	2	NA	adjusted_pval_char	[0.28;1.17]
10.2147/jbm.s288283	results	2	NA	geographical region	NA
10.2147/jbm.s288283	results	2	NA	n_ipd_total	NA
10.2147/jbm.s288283	results	2	NA	ess_total	NA
10.2147/jbm.s288283	results	2	NA	n_nonipd_total	NA
10.2147/jbm.s288283	results	2	NA	n_nonipd_anchor	NA
10.2147/jbm.s288283	results	2	NA	n_ipd_anchor	NA
10.2147/jbm.s288283	results	2	NA	ess_anchor	NA
10.2147/jbm.s288283	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/jbm.s288283	results	2	NA	effect_cutoff	1
10.2147/jbm.s288283	results	2	NA	adjusted_lb_ci	0.28
10.2147/jbm.s288283	results	2	NA	adjusted_ub_ci	1.17
10.2147/jbm.s288283	results	2	NA	adjusted_significant	FALSE
10.2147/jbm.s288283	results	3	NA	contrast	Incidence Rate Ratio
10.2147/jbm.s288283	results	3	NA	direction_benefit	inferior
10.2147/jbm.s288283	results	3	NA	n_nonipd_ttt	41
10.2147/jbm.s288283	results	3	NA	n_ipd_ttt	117
10.2147/jbm.s288283	results	3	NA	ess_ttt	36
10.2147/jbm.s288283	results	3	NA	weights_evaluation_yn	Not mentioned
10.2147/jbm.s288283	results	3	NA	list_covariates_yn	Yes
10.2147/jbm.s288283	results	3	NA	n_covariates	5
10.2147/jbm.s288283	results	3	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2147/jbm.s288283	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s288283	results	3	NA	unadjusted_effect	NA
10.2147/jbm.s288283	results	3	NA	unadjusted_pval_char	NA
10.2147/jbm.s288283	results	3	NA	adjusted_effect	0.61
10.2147/jbm.s288283	results	3	NA	adjusted_pval_char	[0.37;1.02]
10.2147/jbm.s288283	results	3	NA	geographical region	NA
10.2147/jbm.s288283	results	3	NA	n_ipd_total	NA
10.2147/jbm.s288283	results	3	NA	ess_total	NA
10.2147/jbm.s288283	results	3	NA	n_nonipd_total	NA
10.2147/jbm.s288283	results	3	NA	n_nonipd_anchor	NA
10.2147/jbm.s288283	results	3	NA	n_ipd_anchor	NA
10.2147/jbm.s288283	results	3	NA	ess_anchor	NA
10.2147/jbm.s288283	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/jbm.s288283	results	3	NA	effect_cutoff	1
10.2147/jbm.s288283	results	3	NA	adjusted_lb_ci	0.37
10.2147/jbm.s288283	results	3	NA	adjusted_ub_ci	1.02
10.2147/jbm.s288283	results	3	NA	adjusted_significant	FALSE
10.2147/jbm.s288283	study_information	NA	1	Patient-level data used	Yes
10.2147/jbm.s288283	study_information	NA	1	Clinical Trial	Yes
10.2147/jbm.s288283	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01181128
10.2147/jbm.s288283	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s288283	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s288283	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s288283	study_information	NA	2	Patient-level data used	No
10.2147/jbm.s288283	study_information	NA	2	Clinical Trial	Yes
10.2147/jbm.s288283	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02847637
10.2147/jbm.s288283	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s288283	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s288283	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s288283	study_information	NA	3	Patient-level data used	No
10.2147/jbm.s288283	study_information	NA	3	Clinical Trial	Yes
10.2147/jbm.s288283	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03020160
10.2147/jbm.s288283	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s288283	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s288283	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s312885	general_information	NA	NA	Medical Condition of Interest Name	hemophilia b
10.2147/jbm.s312885	general_information	NA	NA	Countries of first author affiliations	sweden
10.2147/jbm.s312885	general_information	NA	NA	Countries of last author affiliations	germany
10.2147/jbm.s312885	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s312885	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/jbm.s312885	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/jbm.s312885	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/jbm.s312885	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2147/jbm.s312885	methodology	1	NA	primary_outcome_name	annualized bleeding rate (abr)
10.2147/jbm.s312885	methodology	1	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s312885	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2147/jbm.s312885	methodology	1	NA	Treatment name 1	prior prophylaxis rfixfc
10.2147/jbm.s312885	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s312885	methodology	1	NA	Treatment name 2	prior prophylaxis rix-fp
10.2147/jbm.s312885	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2147/jbm.s312885	methodology	1	NA	paitc_type	MAIC
10.2147/jbm.s312885	methodology	1	NA	anchored_yn	No
10.2147/jbm.s312885	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s312885	methodology	1	NA	primary_outcome_yn	Yes
10.2147/jbm.s312885	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2147/jbm.s312885	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s312885	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s312885	methodology	1	NA	weights_model_yn	No
10.2147/jbm.s312885	methodology	1	NA	scale_choice_yn	No
10.2147/jbm.s312885	methodology	2	NA	primary_outcome_name	annualized bleeding rate (abr)
10.2147/jbm.s312885	methodology	2	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s312885	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2147/jbm.s312885	methodology	2	NA	Treatment name 1	prior episodic treatment rfixfc
10.2147/jbm.s312885	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s312885	methodology	2	NA	Treatment name 2	prior episodic treatment rix-fp
10.2147/jbm.s312885	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.2147/jbm.s312885	methodology	2	NA	paitc_type	MAIC
10.2147/jbm.s312885	methodology	2	NA	anchored_yn	No
10.2147/jbm.s312885	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s312885	methodology	2	NA	primary_outcome_yn	Yes
10.2147/jbm.s312885	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.2147/jbm.s312885	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s312885	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s312885	methodology	2	NA	weights_model_yn	Yes
10.2147/jbm.s312885	methodology	2	NA	scale_choice_yn	No
10.2147/jbm.s312885	results	1	NA	contrast	Incidence Rate Ratio
10.2147/jbm.s312885	results	1	NA	direction_benefit	inferior
10.2147/jbm.s312885	results	1	NA	n_nonipd_ttt	40
10.2147/jbm.s312885	results	1	NA	n_ipd_ttt	45
10.2147/jbm.s312885	results	1	NA	ess_ttt	26
10.2147/jbm.s312885	results	1	NA	weights_evaluation_yn	Not mentioned
10.2147/jbm.s312885	results	1	NA	list_covariates_yn	Yes
10.2147/jbm.s312885	results	1	NA	n_covariates	4
10.2147/jbm.s312885	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.2147/jbm.s312885	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s312885	results	1	NA	unadjusted_effect	NA
10.2147/jbm.s312885	results	1	NA	unadjusted_pval_char	NA
10.2147/jbm.s312885	results	1	NA	adjusted_effect	1.18
10.2147/jbm.s312885	results	1	NA	adjusted_pval_char	[0.67;2.10]
10.2147/jbm.s312885	results	1	NA	geographical region	No
10.2147/jbm.s312885	results	1	NA	n_ipd_total	NA
10.2147/jbm.s312885	results	1	NA	ess_total	NA
10.2147/jbm.s312885	results	1	NA	n_nonipd_total	NA
10.2147/jbm.s312885	results	1	NA	n_nonipd_anchor	NA
10.2147/jbm.s312885	results	1	NA	n_ipd_anchor	NA
10.2147/jbm.s312885	results	1	NA	ess_anchor	NA
10.2147/jbm.s312885	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/jbm.s312885	results	1	NA	effect_cutoff	1
10.2147/jbm.s312885	results	1	NA	adjusted_lb_ci	0.67
10.2147/jbm.s312885	results	1	NA	adjusted_ub_ci	2.1
10.2147/jbm.s312885	results	1	NA	adjusted_significant	FALSE
10.2147/jbm.s312885	results	2	NA	contrast	Incidence Rate Ratio
10.2147/jbm.s312885	results	2	NA	direction_benefit	inferior
10.2147/jbm.s312885	results	2	NA	n_nonipd_ttt	19
10.2147/jbm.s312885	results	2	NA	n_ipd_ttt	42
10.2147/jbm.s312885	results	2	NA	ess_ttt	10
10.2147/jbm.s312885	results	2	NA	weights_evaluation_yn	Not mentioned
10.2147/jbm.s312885	results	2	NA	list_covariates_yn	Yes
10.2147/jbm.s312885	results	2	NA	n_covariates	4
10.2147/jbm.s312885	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.2147/jbm.s312885	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s312885	results	2	NA	unadjusted_effect	NA
10.2147/jbm.s312885	results	2	NA	unadjusted_pval_char	NA
10.2147/jbm.s312885	results	2	NA	adjusted_effect	1.01
10.2147/jbm.s312885	results	2	NA	adjusted_pval_char	[0.40;2.57]
10.2147/jbm.s312885	results	2	NA	geographical region	No
10.2147/jbm.s312885	results	2	NA	n_ipd_total	NA
10.2147/jbm.s312885	results	2	NA	ess_total	NA
10.2147/jbm.s312885	results	2	NA	n_nonipd_total	NA
10.2147/jbm.s312885	results	2	NA	n_nonipd_anchor	NA
10.2147/jbm.s312885	results	2	NA	n_ipd_anchor	NA
10.2147/jbm.s312885	results	2	NA	ess_anchor	NA
10.2147/jbm.s312885	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/jbm.s312885	results	2	NA	effect_cutoff	1
10.2147/jbm.s312885	results	2	NA	adjusted_lb_ci	0.4
10.2147/jbm.s312885	results	2	NA	adjusted_ub_ci	2.57
10.2147/jbm.s312885	results	2	NA	adjusted_significant	FALSE
10.2147/jbm.s312885	study_information	NA	1	Patient-level data used	Yes
10.2147/jbm.s312885	study_information	NA	1	Clinical Trial	Yes
10.2147/jbm.s312885	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01027364
10.2147/jbm.s312885	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s312885	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s312885	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2147/jbm.s312885	study_information	NA	2	Patient-level data used	No
10.2147/jbm.s312885	study_information	NA	2	Clinical Trial	Yes
10.2147/jbm.s312885	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01496274
10.2147/jbm.s312885	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s312885	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3
10.2147/jbm.s312885	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.2147/jbm.s321288	general_information	NA	NA	Medical Condition of Interest Name	hemophilia a
10.2147/jbm.s321288	general_information	NA	NA	Countries of first author affiliations	usa
10.2147/jbm.s321288	general_information	NA	NA	Countries of last author affiliations	italy
10.2147/jbm.s321288	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s321288	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/jbm.s321288	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/jbm.s321288	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/jbm.s321288	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2147/jbm.s321288	methodology	1	NA	primary_outcome_name	mean annualized bleeding rate
10.2147/jbm.s321288	methodology	1	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s321288	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2147/jbm.s321288	methodology	1	NA	Treatment name 1	damoctocog alfa pegol (bay 94-9027)
10.2147/jbm.s321288	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s321288	methodology	1	NA	Treatment name 2	turoctocog alfa pegol (n8-gp)
10.2147/jbm.s321288	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2147/jbm.s321288	methodology	1	NA	paitc_type	MAIC
10.2147/jbm.s321288	methodology	1	NA	anchored_yn	No
10.2147/jbm.s321288	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s321288	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s321288	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2147/jbm.s321288	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s321288	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s321288	methodology	1	NA	weights_model_yn	No
10.2147/jbm.s321288	methodology	1	NA	scale_choice_yn	No
10.2147/jbm.s321288	results	1	NA	contrast	Incidence Rate Ratio
10.2147/jbm.s321288	results	1	NA	direction_benefit	inferior
10.2147/jbm.s321288	results	1	NA	n_nonipd_ttt	175
10.2147/jbm.s321288	results	1	NA	n_ipd_ttt	102
10.2147/jbm.s321288	results	1	NA	ess_ttt	61.94
10.2147/jbm.s321288	results	1	NA	weights_evaluation_yn	Not mentioned
10.2147/jbm.s321288	results	1	NA	list_covariates_yn	Yes
10.2147/jbm.s321288	results	1	NA	n_covariates	6
10.2147/jbm.s321288	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2147/jbm.s321288	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s321288	results	1	NA	unadjusted_effect	1.1
10.2147/jbm.s321288	results	1	NA	unadjusted_pval_char	0.4492
10.2147/jbm.s321288	results	1	NA	adjusted_effect	1.11
10.2147/jbm.s321288	results	1	NA	adjusted_pval_char	0.449
10.2147/jbm.s321288	results	1	NA	geographical region	No
10.2147/jbm.s321288	results	1	NA	n_ipd_total	NA
10.2147/jbm.s321288	results	1	NA	ess_total	NA
10.2147/jbm.s321288	results	1	NA	n_nonipd_total	NA
10.2147/jbm.s321288	results	1	NA	n_nonipd_anchor	NA
10.2147/jbm.s321288	results	1	NA	n_ipd_anchor	NA
10.2147/jbm.s321288	results	1	NA	ess_anchor	NA
10.2147/jbm.s321288	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/jbm.s321288	results	1	NA	effect_cutoff	1
10.2147/jbm.s321288	results	1	NA	unadjusted_pval	0.4492
10.2147/jbm.s321288	results	1	NA	unadjusted_num_pval	0.4492
10.2147/jbm.s321288	results	1	NA	unadjusted_significant	FALSE
10.2147/jbm.s321288	results	1	NA	adjusted_pval	0.449
10.2147/jbm.s321288	results	1	NA	adjusted_num_pval	0.449
10.2147/jbm.s321288	results	1	NA	adjusted_significant	FALSE
10.2147/jbm.s321288	study_information	NA	1	Patient-level data used	Yes
10.2147/jbm.s321288	study_information	NA	1	Clinical Trial	Yes
10.2147/jbm.s321288	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01580293
10.2147/jbm.s321288	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s321288	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2, 3
10.2147/jbm.s321288	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s321288	study_information	NA	2	Patient-level data used	No
10.2147/jbm.s321288	study_information	NA	2	Clinical Trial	Yes
10.2147/jbm.s321288	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01480180
10.2147/jbm.s321288	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s321288	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s321288	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.2147/ptt.s326121	general_information	NA	NA	Medical Condition of Interest Name	moderate-to-severe plaque psoriasis
10.2147/ptt.s326121	general_information	NA	NA	Countries of first author affiliations	uk
10.2147/ptt.s326121	general_information	NA	NA	Countries of last author affiliations	germany
10.2147/ptt.s326121	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.2147/ptt.s326121	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.2147/ptt.s326121	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/ptt.s326121	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/ptt.s326121	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2147/ptt.s326121	methodology	1	NA	primary_outcome_name	proportions of patients who achieved pasi 90 (psoriasis area severity index) at weeks 12
10.2147/ptt.s326121	methodology	1	NA	outcome_short_name	PASI 90 Responders Rate
10.2147/ptt.s326121	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.2147/ptt.s326121	methodology	1	NA	Treatment name 1	brodalumab
10.2147/ptt.s326121	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2147/ptt.s326121	methodology	1	NA	Treatment name 2	guselkumab
10.2147/ptt.s326121	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.2147/ptt.s326121	methodology	1	NA	paitc_type	MAIC
10.2147/ptt.s326121	methodology	1	NA	anchored_yn	No
10.2147/ptt.s326121	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2147/ptt.s326121	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/ptt.s326121	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2147/ptt.s326121	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/ptt.s326121	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/ptt.s326121	methodology	1	NA	weights_model_yn	No
10.2147/ptt.s326121	methodology	1	NA	scale_choice_yn	No
10.2147/ptt.s326121	results	1	NA	contrast	Risk difference
10.2147/ptt.s326121	results	1	NA	direction_benefit	superior
10.2147/ptt.s326121	results	1	NA	n_nonipd_ttt	135
10.2147/ptt.s326121	results	1	NA	n_ipd_ttt	121
10.2147/ptt.s326121	results	1	NA	ess_ttt	90
10.2147/ptt.s326121	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2147/ptt.s326121	results	1	NA	list_covariates_yn	Yes
10.2147/ptt.s326121	results	1	NA	n_covariates	11
10.2147/ptt.s326121	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2147/ptt.s326121	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2147/ptt.s326121	results	1	NA	unadjusted_effect	NA
10.2147/ptt.s326121	results	1	NA	unadjusted_pval_char	NA
10.2147/ptt.s326121	results	1	NA	adjusted_effect	14.6
10.2147/ptt.s326121	results	1	NA	adjusted_pval_char	0.002
10.2147/ptt.s326121	results	1	NA	geographical region	No
10.2147/ptt.s326121	results	1	NA	n_ipd_total	NA
10.2147/ptt.s326121	results	1	NA	ess_total	NA
10.2147/ptt.s326121	results	1	NA	n_nonipd_total	NA
10.2147/ptt.s326121	results	1	NA	n_nonipd_anchor	NA
10.2147/ptt.s326121	results	1	NA	n_ipd_anchor	NA
10.2147/ptt.s326121	results	1	NA	ess_anchor	NA
10.2147/ptt.s326121	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2147/ptt.s326121	results	1	NA	effect_cutoff	0
10.2147/ptt.s326121	results	1	NA	adjusted_pval	0.002
10.2147/ptt.s326121	results	1	NA	adjusted_num_pval	0.002
10.2147/ptt.s326121	results	1	NA	adjusted_significant	TRUE
10.2147/ptt.s326121	study_information	NA	1	Patient-level data used	Yes
10.2147/ptt.s326121	study_information	NA	1	Clinical Trial	Yes
10.2147/ptt.s326121	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01708603
10.2147/ptt.s326121	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/ptt.s326121	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2147/ptt.s326121	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/ptt.s326121	study_information	NA	2	Patient-level data used	Yes
10.2147/ptt.s326121	study_information	NA	2	Clinical Trial	Yes
10.2147/ptt.s326121	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01708629
10.2147/ptt.s326121	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/ptt.s326121	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2147/ptt.s326121	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2147/ptt.s326121	study_information	NA	3	Patient-level data used	No
10.2147/ptt.s326121	study_information	NA	3	Clinical Trial	Yes
10.2147/ptt.s326121	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02203032
10.2147/ptt.s326121	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/ptt.s326121	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2147/ptt.s326121	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2165/11592490-000000000-00000	general_information	NA	NA	Medical Condition of Interest Name	type 2 diabetes mellitus
10.2165/11592490-000000000-00000	general_information	NA	NA	Countries of first author affiliations	usa
10.2165/11592490-000000000-00000	general_information	NA	NA	Countries of last author affiliations	switzerland
10.2165/11592490-000000000-00000	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2165/11592490-000000000-00000	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2165/11592490-000000000-00000	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2165/11592490-000000000-00000	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2165/11592490-000000000-00000	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2165/11592490-000000000-00000	methodology	1	NA	primary_outcome_name	hba1c change from baseline to week 12
10.2165/11592490-000000000-00000	methodology	1	NA	outcome_short_name	HbA1C
10.2165/11592490-000000000-00000	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2165/11592490-000000000-00000	methodology	1	NA	Treatment name 1	vildagliptin 50 mg twice daily
10.2165/11592490-000000000-00000	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2165/11592490-000000000-00000	methodology	1	NA	Treatment name 2	sitagliptin 50 mg once daily
10.2165/11592490-000000000-00000	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.2165/11592490-000000000-00000	methodology	1	NA	paitc_type	MAIC
10.2165/11592490-000000000-00000	methodology	1	NA	anchored_yn	Yes
10.2165/11592490-000000000-00000	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2165/11592490-000000000-00000	methodology	1	NA	primary_outcome_yn	Yes
10.2165/11592490-000000000-00000	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2165/11592490-000000000-00000	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2165/11592490-000000000-00000	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2165/11592490-000000000-00000	methodology	1	NA	weights_model_yn	No
10.2165/11592490-000000000-00000	methodology	1	NA	scale_choice_yn	No
10.2165/11592490-000000000-00000	methodology	2	NA	primary_outcome_name	hba1c change from baseline to week 12
10.2165/11592490-000000000-00000	methodology	2	NA	outcome_short_name	HbA1C
10.2165/11592490-000000000-00000	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2165/11592490-000000000-00000	methodology	2	NA	Treatment name 1	vildagliptin 50 mg twice daily
10.2165/11592490-000000000-00000	methodology	2	NA	Study 'number(s)' for treatment 1	2
10.2165/11592490-000000000-00000	methodology	2	NA	Treatment name 2	sitagliptin 50 mg once daily
10.2165/11592490-000000000-00000	methodology	2	NA	Study 'number(s)' for treatment 2	4
10.2165/11592490-000000000-00000	methodology	2	NA	paitc_type	MAIC
10.2165/11592490-000000000-00000	methodology	2	NA	anchored_yn	Yes
10.2165/11592490-000000000-00000	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2165/11592490-000000000-00000	methodology	2	NA	primary_outcome_yn	Yes
10.2165/11592490-000000000-00000	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.2165/11592490-000000000-00000	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2165/11592490-000000000-00000	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2165/11592490-000000000-00000	methodology	2	NA	weights_model_yn	No
10.2165/11592490-000000000-00000	methodology	2	NA	scale_choice_yn	No
10.2165/11592490-000000000-00000	methodology	3	NA	primary_outcome_name	hba1c change from baseline to week 12
10.2165/11592490-000000000-00000	methodology	3	NA	outcome_short_name	HbA1C
10.2165/11592490-000000000-00000	methodology	3	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2165/11592490-000000000-00000	methodology	3	NA	Treatment name 1	vildagliptin 50 mg twice daily
10.2165/11592490-000000000-00000	methodology	3	NA	Study 'number(s)' for treatment 1	2
10.2165/11592490-000000000-00000	methodology	3	NA	Treatment name 2	sitagliptin 100 mg once daily
10.2165/11592490-000000000-00000	methodology	3	NA	Study 'number(s)' for treatment 2	4;5
10.2165/11592490-000000000-00000	methodology	3	NA	paitc_type	MAIC
10.2165/11592490-000000000-00000	methodology	3	NA	anchored_yn	Yes
10.2165/11592490-000000000-00000	methodology	3	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2165/11592490-000000000-00000	methodology	3	NA	primary_outcome_yn	Yes
10.2165/11592490-000000000-00000	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.2165/11592490-000000000-00000	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2165/11592490-000000000-00000	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2165/11592490-000000000-00000	methodology	3	NA	weights_model_yn	No
10.2165/11592490-000000000-00000	methodology	3	NA	scale_choice_yn	No
10.2165/11592490-000000000-00000	results	1	NA	contrast	Means difference
10.2165/11592490-000000000-00000	results	1	NA	direction_benefit	inferior
10.2165/11592490-000000000-00000	results	1	NA	n_nonipd_ttt	163
10.2165/11592490-000000000-00000	results	1	NA	n_ipd_ttt	188
10.2165/11592490-000000000-00000	results	1	NA	ess_ttt	NA
10.2165/11592490-000000000-00000	results	1	NA	weights_evaluation_yn	Not mentioned
10.2165/11592490-000000000-00000	results	1	NA	list_covariates_yn	Yes
10.2165/11592490-000000000-00000	results	1	NA	n_covariates	7
10.2165/11592490-000000000-00000	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2165/11592490-000000000-00000	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2165/11592490-000000000-00000	results	1	NA	unadjusted_effect	-0.17
10.2165/11592490-000000000-00000	results	1	NA	unadjusted_pval_char	0.024
10.2165/11592490-000000000-00000	results	1	NA	adjusted_effect	-0.2
10.2165/11592490-000000000-00000	results	1	NA	adjusted_pval_char	0.009
10.2165/11592490-000000000-00000	results	1	NA	geographical region	No
10.2165/11592490-000000000-00000	results	1	NA	n_ipd_total	NA
10.2165/11592490-000000000-00000	results	1	NA	ess_total	NA
10.2165/11592490-000000000-00000	results	1	NA	n_nonipd_total	NA
10.2165/11592490-000000000-00000	results	1	NA	n_nonipd_anchor	156
10.2165/11592490-000000000-00000	results	1	NA	n_ipd_anchor	192
10.2165/11592490-000000000-00000	results	1	NA	ess_anchor	NA
10.2165/11592490-000000000-00000	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2165/11592490-000000000-00000	results	1	NA	effect_cutoff	0
10.2165/11592490-000000000-00000	results	1	NA	unadjusted_pval	0.024
10.2165/11592490-000000000-00000	results	1	NA	unadjusted_num_pval	0.024
10.2165/11592490-000000000-00000	results	1	NA	unadjusted_significant	TRUE
10.2165/11592490-000000000-00000	results	1	NA	adjusted_pval	0.009
10.2165/11592490-000000000-00000	results	1	NA	adjusted_num_pval	0.009
10.2165/11592490-000000000-00000	results	1	NA	adjusted_significant	TRUE
10.2165/11592490-000000000-00000	results	2	NA	contrast	Means difference
10.2165/11592490-000000000-00000	results	2	NA	direction_benefit	inferior
10.2165/11592490-000000000-00000	results	2	NA	n_nonipd_ttt	72
10.2165/11592490-000000000-00000	results	2	NA	n_ipd_ttt	76
10.2165/11592490-000000000-00000	results	2	NA	ess_ttt	NA
10.2165/11592490-000000000-00000	results	2	NA	weights_evaluation_yn	Not mentioned
10.2165/11592490-000000000-00000	results	2	NA	list_covariates_yn	Yes
10.2165/11592490-000000000-00000	results	2	NA	n_covariates	6
10.2165/11592490-000000000-00000	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2165/11592490-000000000-00000	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2165/11592490-000000000-00000	results	2	NA	unadjusted_effect	-0.2
10.2165/11592490-000000000-00000	results	2	NA	unadjusted_pval_char	0.133
10.2165/11592490-000000000-00000	results	2	NA	adjusted_effect	-0.56
10.2165/11592490-000000000-00000	results	2	NA	adjusted_pval_char	<0.001
10.2165/11592490-000000000-00000	results	2	NA	geographical region	No
10.2165/11592490-000000000-00000	results	2	NA	n_ipd_total	NA
10.2165/11592490-000000000-00000	results	2	NA	ess_total	NA
10.2165/11592490-000000000-00000	results	2	NA	n_nonipd_total	NA
10.2165/11592490-000000000-00000	results	2	NA	n_nonipd_anchor	73
10.2165/11592490-000000000-00000	results	2	NA	n_ipd_anchor	72
10.2165/11592490-000000000-00000	results	2	NA	ess_anchor	NA
10.2165/11592490-000000000-00000	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2165/11592490-000000000-00000	results	2	NA	effect_cutoff	0
10.2165/11592490-000000000-00000	results	2	NA	unadjusted_pval	0.133
10.2165/11592490-000000000-00000	results	2	NA	unadjusted_num_pval	0.133
10.2165/11592490-000000000-00000	results	2	NA	unadjusted_significant	FALSE
10.2165/11592490-000000000-00000	results	2	NA	adjusted_pval	<0.001
10.2165/11592490-000000000-00000	results	2	NA	adjusted_significant	TRUE
10.2165/11592490-000000000-00000	results	3	NA	contrast	Means difference
10.2165/11592490-000000000-00000	results	3	NA	direction_benefit	inferior
10.2165/11592490-000000000-00000	results	3	NA	n_nonipd_ttt	145
10.2165/11592490-000000000-00000	results	3	NA	n_ipd_ttt	76
10.2165/11592490-000000000-00000	results	3	NA	ess_ttt	NA
10.2165/11592490-000000000-00000	results	3	NA	weights_evaluation_yn	Not mentioned
10.2165/11592490-000000000-00000	results	3	NA	list_covariates_yn	Yes
10.2165/11592490-000000000-00000	results	3	NA	n_covariates	6
10.2165/11592490-000000000-00000	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2165/11592490-000000000-00000	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.2165/11592490-000000000-00000	results	3	NA	unadjusted_effect	-0.19
10.2165/11592490-000000000-00000	results	3	NA	unadjusted_pval_char	0.113
10.2165/11592490-000000000-00000	results	3	NA	adjusted_effect	-0.35
10.2165/11592490-000000000-00000	results	3	NA	adjusted_pval_char	0.013
10.2165/11592490-000000000-00000	results	3	NA	geographical region	No
10.2165/11592490-000000000-00000	results	3	NA	n_ipd_total	NA
10.2165/11592490-000000000-00000	results	3	NA	ess_total	NA
10.2165/11592490-000000000-00000	results	3	NA	n_nonipd_total	NA
10.2165/11592490-000000000-00000	results	3	NA	n_nonipd_anchor	149
10.2165/11592490-000000000-00000	results	3	NA	n_ipd_anchor	72
10.2165/11592490-000000000-00000	results	3	NA	ess_anchor	NA
10.2165/11592490-000000000-00000	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2165/11592490-000000000-00000	results	3	NA	effect_cutoff	0
10.2165/11592490-000000000-00000	results	3	NA	unadjusted_pval	0.113
10.2165/11592490-000000000-00000	results	3	NA	unadjusted_num_pval	0.113
10.2165/11592490-000000000-00000	results	3	NA	unadjusted_significant	FALSE
10.2165/11592490-000000000-00000	results	3	NA	adjusted_pval	0.013
10.2165/11592490-000000000-00000	results	3	NA	adjusted_num_pval	0.013
10.2165/11592490-000000000-00000	results	3	NA	adjusted_significant	TRUE
10.2165/11592490-000000000-00000	study_information	NA	1	Patient-level data used	Yes
10.2165/11592490-000000000-00000	study_information	NA	1	Clinical Trial	Yes
10.2165/11592490-000000000-00000	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00368134
10.2165/11592490-000000000-00000	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2165/11592490-000000000-00000	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2165/11592490-000000000-00000	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2165/11592490-000000000-00000	study_information	NA	2	Patient-level data used	Yes
10.2165/11592490-000000000-00000	study_information	NA	2	Clinical Trial	Yes
10.2165/11592490-000000000-00000	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00351832
10.2165/11592490-000000000-00000	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2165/11592490-000000000-00000	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2165/11592490-000000000-00000	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2165/11592490-000000000-00000	study_information	NA	3	Patient-level data used	No
10.2165/11592490-000000000-00000	study_information	NA	3	Clinical Trial	Yes
10.2165/11592490-000000000-00000	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00411554
10.2165/11592490-000000000-00000	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2165/11592490-000000000-00000	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2165/11592490-000000000-00000	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2165/11592490-000000000-00000	study_information	NA	4	Patient-level data used	No
10.2165/11592490-000000000-00000	study_information	NA	4	Clinical Trial	Yes
10.2165/11592490-000000000-00000	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00127192
10.2165/11592490-000000000-00000	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2165/11592490-000000000-00000	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.2165/11592490-000000000-00000	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2165/11592490-000000000-00000	study_information	NA	5	Patient-level data used	No
10.2165/11592490-000000000-00000	study_information	NA	5	Clinical Trial	Yes
10.2165/11592490-000000000-00000	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2165/11592490-000000000-00000	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2
10.2165/11592490-000000000-00000	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.2165/11592490-000000000-00000	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00371007
10.2217/cer-2016-0085	general_information	NA	NA	Medical Condition of Interest Name	relapsingremitting multiple sclerosis
10.2217/cer-2016-0085	general_information	NA	NA	Countries of first author affiliations	switzerland
10.2217/cer-2016-0085	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer-2016-0085	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.2217/cer-2016-0085	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2016-0085	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2016-0085	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2016-0085	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/cer-2016-0085	methodology	1	NA	primary_outcome_name	annualized relapse rate at 2 years
10.2217/cer-2016-0085	methodology	1	NA	outcome_short_name	Annualized Relapse Rate
10.2217/cer-2016-0085	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2217/cer-2016-0085	methodology	1	NA	Treatment name 1	delayed-release dimethyl fumarate
10.2217/cer-2016-0085	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer-2016-0085	methodology	1	NA	Treatment name 2	glatiramer acetate
10.2217/cer-2016-0085	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.2217/cer-2016-0085	methodology	1	NA	paitc_type	MAIC
10.2217/cer-2016-0085	methodology	1	NA	anchored_yn	Yes
10.2217/cer-2016-0085	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2016-0085	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2016-0085	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer-2016-0085	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2016-0085	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2016-0085	methodology	1	NA	weights_model_yn	No
10.2217/cer-2016-0085	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2016-0085	methodology	2	NA	primary_outcome_name	annualized relapse rate at 2 years
10.2217/cer-2016-0085	methodology	2	NA	outcome_short_name	Annualized Relapse Rate
10.2217/cer-2016-0085	methodology	2	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2217/cer-2016-0085	methodology	2	NA	Treatment name 1	delayed-release dimethyl fumarate
10.2217/cer-2016-0085	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer-2016-0085	methodology	2	NA	Treatment name 2	glatiramer acetate
10.2217/cer-2016-0085	methodology	2	NA	Study 'number(s)' for treatment 2	4
10.2217/cer-2016-0085	methodology	2	NA	paitc_type	MAIC
10.2217/cer-2016-0085	methodology	2	NA	anchored_yn	Yes
10.2217/cer-2016-0085	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2016-0085	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2016-0085	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer-2016-0085	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2016-0085	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2016-0085	methodology	2	NA	weights_model_yn	No
10.2217/cer-2016-0085	methodology	2	NA	scale_choice_yn	No
10.2217/cer-2016-0085	methodology	3	NA	primary_outcome_name	12-week confirmed disability progression
10.2217/cer-2016-0085	methodology	3	NA	outcome_short_name	Confirmed disability progression
10.2217/cer-2016-0085	methodology	3	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer-2016-0085	methodology	3	NA	Treatment name 1	delayed-release dimethyl fumarate
10.2217/cer-2016-0085	methodology	3	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer-2016-0085	methodology	3	NA	Treatment name 2	glatiramer acetate
10.2217/cer-2016-0085	methodology	3	NA	Study 'number(s)' for treatment 2	5
10.2217/cer-2016-0085	methodology	3	NA	paitc_type	MAIC
10.2217/cer-2016-0085	methodology	3	NA	anchored_yn	No
10.2217/cer-2016-0085	methodology	3	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2016-0085	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2016-0085	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer-2016-0085	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2016-0085	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2016-0085	methodology	3	NA	weights_model_yn	No
10.2217/cer-2016-0085	methodology	3	NA	scale_choice_yn	No
10.2217/cer-2016-0085	results	1	NA	contrast	Rate ratio
10.2217/cer-2016-0085	results	1	NA	direction_benefit	inferior
10.2217/cer-2016-0085	results	1	NA	n_nonipd_ttt	NA
10.2217/cer-2016-0085	results	1	NA	n_ipd_ttt	NA
10.2217/cer-2016-0085	results	1	NA	ess_ttt	NA
10.2217/cer-2016-0085	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2016-0085	results	1	NA	list_covariates_yn	Yes
10.2217/cer-2016-0085	results	1	NA	n_covariates	7
10.2217/cer-2016-0085	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2217/cer-2016-0085	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2016-0085	results	1	NA	unadjusted_effect	NA
10.2217/cer-2016-0085	results	1	NA	unadjusted_pval_char	NA
10.2217/cer-2016-0085	results	1	NA	adjusted_effect	NA
10.2217/cer-2016-0085	results	1	NA	adjusted_pval_char	NA
10.2217/cer-2016-0085	results	1	NA	geographical region	NA
10.2217/cer-2016-0085	results	1	NA	n_ipd_total	2651
10.2217/cer-2016-0085	results	1	NA	ess_total	1032
10.2217/cer-2016-0085	results	1	NA	n_nonipd_total	251
10.2217/cer-2016-0085	results	1	NA	n_nonipd_anchor	NA
10.2217/cer-2016-0085	results	1	NA	n_ipd_anchor	NA
10.2217/cer-2016-0085	results	1	NA	ess_anchor	NA
10.2217/cer-2016-0085	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2016-0085	results	1	NA	effect_cutoff	1
10.2217/cer-2016-0085	results	2	NA	contrast	Rate ratio
10.2217/cer-2016-0085	results	2	NA	direction_benefit	inferior
10.2217/cer-2016-0085	results	2	NA	n_nonipd_ttt	NA
10.2217/cer-2016-0085	results	2	NA	n_ipd_ttt	NA
10.2217/cer-2016-0085	results	2	NA	ess_ttt	NA
10.2217/cer-2016-0085	results	2	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2016-0085	results	2	NA	list_covariates_yn	Yes
10.2217/cer-2016-0085	results	2	NA	n_covariates	5
10.2217/cer-2016-0085	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.2217/cer-2016-0085	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2016-0085	results	2	NA	unadjusted_effect	NA
10.2217/cer-2016-0085	results	2	NA	unadjusted_pval_char	NA
10.2217/cer-2016-0085	results	2	NA	adjusted_effect	NA
10.2217/cer-2016-0085	results	2	NA	adjusted_pval_char	NA
10.2217/cer-2016-0085	results	2	NA	geographical region	NA
10.2217/cer-2016-0085	results	2	NA	n_ipd_total	2651
10.2217/cer-2016-0085	results	2	NA	ess_total	1206
10.2217/cer-2016-0085	results	2	NA	n_nonipd_total	239
10.2217/cer-2016-0085	results	2	NA	n_nonipd_anchor	NA
10.2217/cer-2016-0085	results	2	NA	n_ipd_anchor	NA
10.2217/cer-2016-0085	results	2	NA	ess_anchor	NA
10.2217/cer-2016-0085	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2016-0085	results	2	NA	effect_cutoff	1
10.2217/cer-2016-0085	results	3	NA	contrast	RR
10.2217/cer-2016-0085	results	3	NA	direction_benefit	inferior
10.2217/cer-2016-0085	results	3	NA	n_nonipd_ttt	NA
10.2217/cer-2016-0085	results	3	NA	n_ipd_ttt	NA
10.2217/cer-2016-0085	results	3	NA	ess_ttt	NA
10.2217/cer-2016-0085	results	3	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2016-0085	results	3	NA	list_covariates_yn	Yes
10.2217/cer-2016-0085	results	3	NA	n_covariates	7
10.2217/cer-2016-0085	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2217/cer-2016-0085	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2016-0085	results	3	NA	unadjusted_effect	0.73
10.2217/cer-2016-0085	results	3	NA	unadjusted_pval_char	0.015
10.2217/cer-2016-0085	results	3	NA	adjusted_effect	0.51
10.2217/cer-2016-0085	results	3	NA	adjusted_pval_char	<0.001
10.2217/cer-2016-0085	results	3	NA	geographical region	NA
10.2217/cer-2016-0085	results	3	NA	n_ipd_total	2651
10.2217/cer-2016-0085	results	3	NA	ess_total	364
10.2217/cer-2016-0085	results	3	NA	n_nonipd_total	448
10.2217/cer-2016-0085	results	3	NA	n_nonipd_anchor	NA
10.2217/cer-2016-0085	results	3	NA	n_ipd_anchor	NA
10.2217/cer-2016-0085	results	3	NA	ess_anchor	NA
10.2217/cer-2016-0085	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2016-0085	results	3	NA	effect_cutoff	1
10.2217/cer-2016-0085	results	3	NA	unadjusted_pval	0.015
10.2217/cer-2016-0085	results	3	NA	unadjusted_num_pval	0.015
10.2217/cer-2016-0085	results	3	NA	unadjusted_significant	TRUE
10.2217/cer-2016-0085	results	3	NA	adjusted_pval	<0.001
10.2217/cer-2016-0085	results	3	NA	adjusted_significant	TRUE
10.2217/cer-2016-0085	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2016-0085	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2016-0085	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212
10.2217/cer-2016-0085	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2016-0085	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2016-0085	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2016-0085	study_information	NA	2	Patient-level data used	Yes
10.2217/cer-2016-0085	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2016-0085	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451
10.2217/cer-2016-0085	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2016-0085	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2016-0085	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2016-0085	study_information	NA	3	Patient-level data used	No
10.2217/cer-2016-0085	study_information	NA	3	Clinical Trial	Yes
10.2217/cer-2016-0085	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00004814
10.2217/cer-2016-0085	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/cer-2016-0085	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2016-0085	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2016-0085	study_information	NA	4	Patient-level data used	No
10.2217/cer-2016-0085	study_information	NA	4	Clinical Trial	Yes
10.2217/cer-2016-0085	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	eur/can study
10.2217/cer-2016-0085	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2016-0085	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2016-0085	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2016-0085	study_information	NA	5	Patient-level data used	No
10.2217/cer-2016-0085	study_information	NA	5	Clinical Trial	Yes
10.2217/cer-2016-0085	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00099502
10.2217/cer-2016-0085	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2016-0085	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2016-0085	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2018-0020	general_information	NA	NA	Medical Condition of Interest Name	advanced pancreatic neuroendocrine tumors
10.2217/cer-2018-0020	general_information	NA	NA	Countries of first author affiliations	canada
10.2217/cer-2018-0020	general_information	NA	NA	Countries of last author affiliations	uk
10.2217/cer-2018-0020	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2018-0020	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2018-0020	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2018-0020	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2018-0020	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/cer-2018-0020	methodology	1	NA	primary_outcome_name	progression-free survival
10.2217/cer-2018-0020	methodology	1	NA	outcome_short_name	Progression-free Survival
10.2217/cer-2018-0020	methodology	1	NA	primary_outcome_type	Time-to-event
10.2217/cer-2018-0020	methodology	1	NA	Treatment name 1	sunitinib
10.2217/cer-2018-0020	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2018-0020	methodology	1	NA	Treatment name 2	everolimus
10.2217/cer-2018-0020	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2018-0020	methodology	1	NA	paitc_type	MAIC
10.2217/cer-2018-0020	methodology	1	NA	anchored_yn	Yes
10.2217/cer-2018-0020	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2018-0020	methodology	1	NA	primary_outcome_yn	Yes
10.2217/cer-2018-0020	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer-2018-0020	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2018-0020	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2018-0020	methodology	1	NA	weights_model_yn	No
10.2217/cer-2018-0020	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2018-0020	methodology	2	NA	primary_outcome_name	overall survival
10.2217/cer-2018-0020	methodology	2	NA	outcome_short_name	Overall Survival
10.2217/cer-2018-0020	methodology	2	NA	primary_outcome_type	Time-to-event
10.2217/cer-2018-0020	methodology	2	NA	Treatment name 1	sunitinib
10.2217/cer-2018-0020	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2018-0020	methodology	2	NA	Treatment name 2	everolimus
10.2217/cer-2018-0020	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2018-0020	methodology	2	NA	paitc_type	MAIC
10.2217/cer-2018-0020	methodology	2	NA	anchored_yn	No
10.2217/cer-2018-0020	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2018-0020	methodology	2	NA	primary_outcome_yn	Yes
10.2217/cer-2018-0020	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer-2018-0020	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2018-0020	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2018-0020	methodology	2	NA	weights_model_yn	No
10.2217/cer-2018-0020	methodology	2	NA	scale_choice_yn	No
10.2217/cer-2018-0020	results	1	NA	contrast	HR
10.2217/cer-2018-0020	results	1	NA	direction_benefit	inferior
10.2217/cer-2018-0020	results	1	NA	n_nonipd_ttt	207
10.2217/cer-2018-0020	results	1	NA	n_ipd_ttt	86
10.2217/cer-2018-0020	results	1	NA	ess_ttt	43
10.2217/cer-2018-0020	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2018-0020	results	1	NA	list_covariates_yn	Yes
10.2217/cer-2018-0020	results	1	NA	n_covariates	11
10.2217/cer-2018-0020	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/cer-2018-0020	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2018-0020	results	1	NA	unadjusted_effect	1.2
10.2217/cer-2018-0020	results	1	NA	unadjusted_pval_char	[0.72;2.01]
10.2217/cer-2018-0020	results	1	NA	adjusted_effect	0.85
10.2217/cer-2018-0020	results	1	NA	adjusted_pval_char	[0.39;1.89]
10.2217/cer-2018-0020	results	1	NA	geographical region	No
10.2217/cer-2018-0020	results	1	NA	n_ipd_total	NA
10.2217/cer-2018-0020	results	1	NA	ess_total	NA
10.2217/cer-2018-0020	results	1	NA	n_nonipd_total	NA
10.2217/cer-2018-0020	results	1	NA	n_nonipd_anchor	203
10.2217/cer-2018-0020	results	1	NA	n_ipd_anchor	85
10.2217/cer-2018-0020	results	1	NA	ess_anchor	31
10.2217/cer-2018-0020	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2018-0020	results	1	NA	effect_cutoff	1
10.2217/cer-2018-0020	results	1	NA	unadjusted_lb_ci	0.72
10.2217/cer-2018-0020	results	1	NA	unadjusted_ub_ci	2.01
10.2217/cer-2018-0020	results	1	NA	unadjusted_significant	FALSE
10.2217/cer-2018-0020	results	1	NA	adjusted_lb_ci	0.39
10.2217/cer-2018-0020	results	1	NA	adjusted_ub_ci	1.89
10.2217/cer-2018-0020	results	1	NA	adjusted_significant	FALSE
10.2217/cer-2018-0020	results	2	NA	contrast	HR
10.2217/cer-2018-0020	results	2	NA	direction_benefit	inferior
10.2217/cer-2018-0020	results	2	NA	n_nonipd_ttt	207
10.2217/cer-2018-0020	results	2	NA	n_ipd_ttt	86
10.2217/cer-2018-0020	results	2	NA	ess_ttt	43
10.2217/cer-2018-0020	results	2	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2018-0020	results	2	NA	list_covariates_yn	Yes
10.2217/cer-2018-0020	results	2	NA	n_covariates	11
10.2217/cer-2018-0020	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/cer-2018-0020	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2018-0020	results	2	NA	unadjusted_effect	1.03
10.2217/cer-2018-0020	results	2	NA	unadjusted_pval_char	[0.75;1.42]
10.2217/cer-2018-0020	results	2	NA	adjusted_effect	0.82
10.2217/cer-2018-0020	results	2	NA	adjusted_pval_char	[0.53;1.27]
10.2217/cer-2018-0020	results	2	NA	geographical region	No
10.2217/cer-2018-0020	results	2	NA	n_ipd_total	NA
10.2217/cer-2018-0020	results	2	NA	ess_total	NA
10.2217/cer-2018-0020	results	2	NA	n_nonipd_total	NA
10.2217/cer-2018-0020	results	2	NA	n_nonipd_anchor	NA
10.2217/cer-2018-0020	results	2	NA	n_ipd_anchor	NA
10.2217/cer-2018-0020	results	2	NA	ess_anchor	NA
10.2217/cer-2018-0020	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2018-0020	results	2	NA	effect_cutoff	1
10.2217/cer-2018-0020	results	2	NA	unadjusted_lb_ci	0.75
10.2217/cer-2018-0020	results	2	NA	unadjusted_ub_ci	1.42
10.2217/cer-2018-0020	results	2	NA	unadjusted_significant	FALSE
10.2217/cer-2018-0020	results	2	NA	adjusted_lb_ci	0.53
10.2217/cer-2018-0020	results	2	NA	adjusted_ub_ci	1.27
10.2217/cer-2018-0020	results	2	NA	adjusted_significant	FALSE
10.2217/cer-2018-0020	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2018-0020	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2018-0020	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00428597
10.2217/cer-2018-0020	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2018-0020	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2018-0020	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2018-0020	study_information	NA	2	Patient-level data used	No
10.2217/cer-2018-0020	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2018-0020	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00510068
10.2217/cer-2018-0020	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2018-0020	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2018-0020	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2018-0141	general_information	NA	NA	Medical Condition of Interest Name	psoriatic arthritis
10.2217/cer-2018-0141	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer-2018-0141	general_information	NA	NA	Countries of last author affiliations	uk
10.2217/cer-2018-0141	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2018-0141	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2018-0141	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2018-0141	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2018-0141	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer-2018-0141	methodology	1	NA	primary_outcome_name	american college of rheumatology (acr) responses rate at week 24
10.2217/cer-2018-0141	methodology	1	NA	outcome_short_name	ACR Response Rate
10.2217/cer-2018-0141	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer-2018-0141	methodology	1	NA	Treatment name 1	secukinumab 150mg
10.2217/cer-2018-0141	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer-2018-0141	methodology	1	NA	Treatment name 2	infliximab
10.2217/cer-2018-0141	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.2217/cer-2018-0141	methodology	1	NA	paitc_type	MAIC
10.2217/cer-2018-0141	methodology	1	NA	anchored_yn	No
10.2217/cer-2018-0141	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2018-0141	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2018-0141	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2018-0141	methodology	1	NA	prognostic_factors_yn	Yes
10.2217/cer-2018-0141	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.2217/cer-2018-0141	methodology	1	NA	weights_model_yn	No
10.2217/cer-2018-0141	methodology	1	NA	scale_choice_yn	Yes
10.2217/cer-2018-0141	methodology	2	NA	primary_outcome_name	american college of rheumatology (acr) responses at week 54
10.2217/cer-2018-0141	methodology	2	NA	outcome_short_name	ACR Response Rate
10.2217/cer-2018-0141	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer-2018-0141	methodology	2	NA	Treatment name 1	secukinumab 300mg
10.2217/cer-2018-0141	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer-2018-0141	methodology	2	NA	Treatment name 2	infliximab
10.2217/cer-2018-0141	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.2217/cer-2018-0141	methodology	2	NA	paitc_type	MAIC
10.2217/cer-2018-0141	methodology	2	NA	anchored_yn	No
10.2217/cer-2018-0141	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2018-0141	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2018-0141	methodology	2	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2018-0141	methodology	2	NA	prognostic_factors_yn	Yes
10.2217/cer-2018-0141	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.2217/cer-2018-0141	methodology	2	NA	weights_model_yn	No
10.2217/cer-2018-0141	methodology	2	NA	scale_choice_yn	Yes
10.2217/cer-2018-0141	results	1	NA	contrast	OR
10.2217/cer-2018-0141	results	1	NA	direction_benefit	superior
10.2217/cer-2018-0141	results	1	NA	n_nonipd_ttt	100
10.2217/cer-2018-0141	results	1	NA	n_ipd_ttt	238
10.2217/cer-2018-0141	results	1	NA	ess_ttt	84
10.2217/cer-2018-0141	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2018-0141	results	1	NA	list_covariates_yn	Yes
10.2217/cer-2018-0141	results	1	NA	n_covariates	11
10.2217/cer-2018-0141	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2217/cer-2018-0141	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2018-0141	results	1	NA	unadjusted_effect	NA
10.2217/cer-2018-0141	results	1	NA	unadjusted_pval_char	NA
10.2217/cer-2018-0141	results	1	NA	adjusted_effect	2.31
10.2217/cer-2018-0141	results	1	NA	adjusted_pval_char	0.008
10.2217/cer-2018-0141	results	1	NA	geographical region	No
10.2217/cer-2018-0141	results	1	NA	n_ipd_total	NA
10.2217/cer-2018-0141	results	1	NA	ess_total	NA
10.2217/cer-2018-0141	results	1	NA	n_nonipd_total	NA
10.2217/cer-2018-0141	results	1	NA	n_nonipd_anchor	NA
10.2217/cer-2018-0141	results	1	NA	n_ipd_anchor	NA
10.2217/cer-2018-0141	results	1	NA	ess_anchor	NA
10.2217/cer-2018-0141	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2018-0141	results	1	NA	effect_cutoff	1
10.2217/cer-2018-0141	results	1	NA	adjusted_pval	0.008
10.2217/cer-2018-0141	results	1	NA	adjusted_num_pval	0.008
10.2217/cer-2018-0141	results	1	NA	adjusted_significant	TRUE
10.2217/cer-2018-0141	results	2	NA	contrast	OR
10.2217/cer-2018-0141	results	2	NA	direction_benefit	superior
10.2217/cer-2018-0141	results	2	NA	n_nonipd_ttt	100
10.2217/cer-2018-0141	results	2	NA	n_ipd_ttt	239
10.2217/cer-2018-0141	results	2	NA	ess_ttt	70
10.2217/cer-2018-0141	results	2	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2018-0141	results	2	NA	list_covariates_yn	Yes
10.2217/cer-2018-0141	results	2	NA	n_covariates	11
10.2217/cer-2018-0141	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2217/cer-2018-0141	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2018-0141	results	2	NA	unadjusted_effect	NA
10.2217/cer-2018-0141	results	2	NA	unadjusted_pval_char	NA
10.2217/cer-2018-0141	results	2	NA	adjusted_effect	2.72
10.2217/cer-2018-0141	results	2	NA	adjusted_pval_char	0.006
10.2217/cer-2018-0141	results	2	NA	geographical region	No
10.2217/cer-2018-0141	results	2	NA	n_ipd_total	NA
10.2217/cer-2018-0141	results	2	NA	ess_total	NA
10.2217/cer-2018-0141	results	2	NA	n_nonipd_total	NA
10.2217/cer-2018-0141	results	2	NA	n_nonipd_anchor	NA
10.2217/cer-2018-0141	results	2	NA	n_ipd_anchor	NA
10.2217/cer-2018-0141	results	2	NA	ess_anchor	NA
10.2217/cer-2018-0141	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2018-0141	results	2	NA	effect_cutoff	1
10.2217/cer-2018-0141	results	2	NA	adjusted_pval	0.006
10.2217/cer-2018-0141	results	2	NA	adjusted_num_pval	0.006
10.2217/cer-2018-0141	results	2	NA	adjusted_significant	TRUE
10.2217/cer-2018-0141	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2018-0141	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2018-0141	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01752634
10.2217/cer-2018-0141	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2018-0141	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2018-0141	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2018-0141	study_information	NA	2	Patient-level data used	Yes
10.2217/cer-2018-0141	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2018-0141	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01989468
10.2217/cer-2018-0141	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2018-0141	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2018-0141	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2018-0141	study_information	NA	3	Patient-level data used	No
10.2217/cer-2018-0141	study_information	NA	3	Clinical Trial	Yes
10.2217/cer-2018-0141	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00051623
10.2217/cer-2018-0141	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2018-0141	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2018-0141	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.2217/cer-2019-0145	general_information	NA	NA	Medical Condition of Interest Name	advanced gastric or gastroesophageal junction cancer
10.2217/cer-2019-0145	general_information	NA	NA	Countries of first author affiliations	UK
10.2217/cer-2019-0145	general_information	NA	NA	Countries of last author affiliations	USA
10.2217/cer-2019-0145	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2019-0145	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2019-0145	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2019-0145	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2019-0145	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/cer-2019-0145	methodology	1	NA	primary_outcome_name	overall survival
10.2217/cer-2019-0145	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/cer-2019-0145	methodology	1	NA	primary_outcome_type	Time-to-event
10.2217/cer-2019-0145	methodology	1	NA	Treatment name 1	nivolumab
10.2217/cer-2019-0145	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2019-0145	methodology	1	NA	Treatment name 2	routine clinical practice
10.2217/cer-2019-0145	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2019-0145	methodology	1	NA	paitc_type	STC
10.2217/cer-2019-0145	methodology	1	NA	anchored_yn	No
10.2217/cer-2019-0145	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2019-0145	methodology	1	NA	primary_outcome_yn	Yes
10.2217/cer-2019-0145	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2019-0145	methodology	1	NA	prognostic_factors_yn	Yes
10.2217/cer-2019-0145	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.2217/cer-2019-0145	methodology	1	NA	weights_model_yn	Yes
10.2217/cer-2019-0145	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2019-0145	results	1	NA	contrast	HR
10.2217/cer-2019-0145	results	1	NA	direction_benefit	inferior
10.2217/cer-2019-0145	results	1	NA	n_nonipd_ttt	34
10.2217/cer-2019-0145	results	1	NA	n_ipd_ttt	42
10.2217/cer-2019-0145	results	1	NA	ess_ttt	42
10.2217/cer-2019-0145	results	1	NA	weights_evaluation_yn	NA
10.2217/cer-2019-0145	results	1	NA	list_covariates_yn	Yes
10.2217/cer-2019-0145	results	1	NA	n_covariates	6
10.2217/cer-2019-0145	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.2217/cer-2019-0145	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2019-0145	results	1	NA	unadjusted_effect	0.46
10.2217/cer-2019-0145	results	1	NA	unadjusted_pval_char	[0.36;0.59]
10.2217/cer-2019-0145	results	1	NA	adjusted_effect	0.5
10.2217/cer-2019-0145	results	1	NA	adjusted_pval_char	[0.36;0.68]
10.2217/cer-2019-0145	results	1	NA	geographical region	NA
10.2217/cer-2019-0145	results	1	NA	n_ipd_total	NA
10.2217/cer-2019-0145	results	1	NA	ess_total	NA
10.2217/cer-2019-0145	results	1	NA	n_nonipd_total	NA
10.2217/cer-2019-0145	results	1	NA	n_nonipd_anchor	NA
10.2217/cer-2019-0145	results	1	NA	n_ipd_anchor	NA
10.2217/cer-2019-0145	results	1	NA	ess_anchor	NA
10.2217/cer-2019-0145	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2019-0145	results	1	NA	effect_cutoff	1
10.2217/cer-2019-0145	results	1	NA	adjusted_lb_ci	0.36
10.2217/cer-2019-0145	results	1	NA	adjusted_ub_ci	0.68
10.2217/cer-2019-0145	results	1	NA	adjusted_significant	TRUE
10.2217/cer-2019-0145	results	1	NA	unadjusted_lb_ci	0.36
10.2217/cer-2019-0145	results	1	NA	unadjusted_ub_ci	0.59
10.2217/cer-2019-0145	results	1	NA	unadjusted_significant	TRUE
10.2217/cer-2019-0145	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2019-0145	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2019-0145	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01928394
10.2217/cer-2019-0145	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2019-0145	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.2217/cer-2019-0145	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2019-0145	study_information	NA	2	Patient-level data used	No
10.2217/cer-2019-0145	study_information	NA	2	Clinical Trial	No
10.2217/cer-2019-0145	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	flatiron healths electronic health record database
10.2217/cer-2019-0145	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/cer-2019-0169	general_information	NA	NA	Medical Condition of Interest Name	relapsing multiple sclerosis
10.2217/cer-2019-0169	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer-2019-0169	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer-2019-0169	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2019-0169	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2019-0169	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2019-0169	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2019-0169	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/cer-2019-0169	methodology	1	NA	primary_outcome_name	percentage of patients whose lowest hourly recorded heart rate was <45 bpm in the first 6 h after their first dose ( first-dose cardiac monitoring outcomes)
10.2217/cer-2019-0169	methodology	1	NA	outcome_short_name	Bradycardia proportion
10.2217/cer-2019-0169	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer-2019-0169	methodology	1	NA	Treatment name 1	ozanimod
10.2217/cer-2019-0169	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer-2019-0169	methodology	1	NA	Treatment name 2	fingolimod
10.2217/cer-2019-0169	methodology	1	NA	Study 'number(s)' for treatment 2	3;4;5
10.2217/cer-2019-0169	methodology	1	NA	paitc_type	MAIC
10.2217/cer-2019-0169	methodology	1	NA	anchored_yn	No
10.2217/cer-2019-0169	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2019-0169	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2019-0169	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/cer-2019-0169	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2019-0169	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2019-0169	methodology	1	NA	weights_model_yn	Yes
10.2217/cer-2019-0169	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2019-0169	methodology	2	NA	primary_outcome_name	risk of any adverse events at year 1 (1-year outcomes)
10.2217/cer-2019-0169	methodology	2	NA	outcome_short_name	Adverse Event
10.2217/cer-2019-0169	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer-2019-0169	methodology	2	NA	Treatment name 1	ozanimod
10.2217/cer-2019-0169	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer-2019-0169	methodology	2	NA	Treatment name 2	fingolimod
10.2217/cer-2019-0169	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.2217/cer-2019-0169	methodology	2	NA	paitc_type	MAIC
10.2217/cer-2019-0169	methodology	2	NA	anchored_yn	Yes
10.2217/cer-2019-0169	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2019-0169	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2019-0169	methodology	2	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/cer-2019-0169	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2019-0169	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2019-0169	methodology	2	NA	weights_model_yn	Yes
10.2217/cer-2019-0169	methodology	2	NA	scale_choice_yn	No
10.2217/cer-2019-0169	methodology	3	NA	primary_outcome_name	risk of any adverse effect at 2 years
10.2217/cer-2019-0169	methodology	3	NA	outcome_short_name	Adverse Event
10.2217/cer-2019-0169	methodology	3	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer-2019-0169	methodology	3	NA	Treatment name 1	ozanimod
10.2217/cer-2019-0169	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2019-0169	methodology	3	NA	Treatment name 2	fingolimod
10.2217/cer-2019-0169	methodology	3	NA	Study 'number(s)' for treatment 2	4;5
10.2217/cer-2019-0169	methodology	3	NA	paitc_type	MAIC
10.2217/cer-2019-0169	methodology	3	NA	anchored_yn	No
10.2217/cer-2019-0169	methodology	3	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2019-0169	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2019-0169	methodology	3	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/cer-2019-0169	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2019-0169	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2019-0169	methodology	3	NA	weights_model_yn	Yes
10.2217/cer-2019-0169	methodology	3	NA	scale_choice_yn	No
10.2217/cer-2019-0169	results	1	NA	contrast	Risk difference
10.2217/cer-2019-0169	results	1	NA	direction_benefit	inferior
10.2217/cer-2019-0169	results	1	NA	n_nonipd_ttt	1212
10.2217/cer-2019-0169	results	1	NA	n_ipd_ttt	1773
10.2217/cer-2019-0169	results	1	NA	ess_ttt	597
10.2217/cer-2019-0169	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2019-0169	results	1	NA	list_covariates_yn	Yes
10.2217/cer-2019-0169	results	1	NA	n_covariates	11
10.2217/cer-2019-0169	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)
10.2217/cer-2019-0169	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2019-0169	results	1	NA	unadjusted_effect	NA
10.2217/cer-2019-0169	results	1	NA	unadjusted_pval_char	NA
10.2217/cer-2019-0169	results	1	NA	adjusted_effect	-1.4
10.2217/cer-2019-0169	results	1	NA	adjusted_pval_char	<0.001
10.2217/cer-2019-0169	results	1	NA	geographical region	No
10.2217/cer-2019-0169	results	1	NA	n_ipd_total	NA
10.2217/cer-2019-0169	results	1	NA	ess_total	NA
10.2217/cer-2019-0169	results	1	NA	n_nonipd_total	NA
10.2217/cer-2019-0169	results	1	NA	n_nonipd_anchor	NA
10.2217/cer-2019-0169	results	1	NA	n_ipd_anchor	NA
10.2217/cer-2019-0169	results	1	NA	ess_anchor	NA
10.2217/cer-2019-0169	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2019-0169	results	1	NA	effect_cutoff	0
10.2217/cer-2019-0169	results	1	NA	adjusted_pval	<0.001
10.2217/cer-2019-0169	results	1	NA	adjusted_significant	TRUE
10.2217/cer-2019-0169	results	2	NA	contrast	Risk difference
10.2217/cer-2019-0169	results	2	NA	direction_benefit	inferior
10.2217/cer-2019-0169	results	2	NA	n_nonipd_ttt	429
10.2217/cer-2019-0169	results	2	NA	n_ipd_ttt	882
10.2217/cer-2019-0169	results	2	NA	ess_ttt	276
10.2217/cer-2019-0169	results	2	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2019-0169	results	2	NA	list_covariates_yn	Yes
10.2217/cer-2019-0169	results	2	NA	n_covariates	9
10.2217/cer-2019-0169	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.2217/cer-2019-0169	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2019-0169	results	2	NA	unadjusted_effect	NA
10.2217/cer-2019-0169	results	2	NA	unadjusted_pval_char	NA
10.2217/cer-2019-0169	results	2	NA	adjusted_effect	-9.9
10.2217/cer-2019-0169	results	2	NA	adjusted_pval_char	<0.05
10.2217/cer-2019-0169	results	2	NA	geographical region	No
10.2217/cer-2019-0169	results	2	NA	n_ipd_total	NA
10.2217/cer-2019-0169	results	2	NA	ess_total	NA
10.2217/cer-2019-0169	results	2	NA	n_nonipd_total	NA
10.2217/cer-2019-0169	results	2	NA	n_nonipd_anchor	431
10.2217/cer-2019-0169	results	2	NA	n_ipd_anchor	885
10.2217/cer-2019-0169	results	2	NA	ess_anchor	317
10.2217/cer-2019-0169	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2019-0169	results	2	NA	effect_cutoff	0
10.2217/cer-2019-0169	results	2	NA	adjusted_pval	<0.05
10.2217/cer-2019-0169	results	2	NA	adjusted_significant	TRUE
10.2217/cer-2019-0169	results	3	NA	contrast	Risk difference
10.2217/cer-2019-0169	results	3	NA	direction_benefit	inferior
10.2217/cer-2019-0169	results	3	NA	n_nonipd_ttt	783
10.2217/cer-2019-0169	results	3	NA	n_ipd_ttt	434
10.2217/cer-2019-0169	results	3	NA	ess_ttt	158
10.2217/cer-2019-0169	results	3	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2019-0169	results	3	NA	list_covariates_yn	Yes
10.2217/cer-2019-0169	results	3	NA	n_covariates	8
10.2217/cer-2019-0169	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.2217/cer-2019-0169	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2019-0169	results	3	NA	unadjusted_effect	NA
10.2217/cer-2019-0169	results	3	NA	unadjusted_pval_char	NA
10.2217/cer-2019-0169	results	3	NA	adjusted_effect	-22.7
10.2217/cer-2019-0169	results	3	NA	adjusted_pval_char	<0.001
10.2217/cer-2019-0169	results	3	NA	geographical region	NA
10.2217/cer-2019-0169	results	3	NA	n_ipd_total	NA
10.2217/cer-2019-0169	results	3	NA	ess_total	NA
10.2217/cer-2019-0169	results	3	NA	n_nonipd_total	NA
10.2217/cer-2019-0169	results	3	NA	n_nonipd_anchor	NA
10.2217/cer-2019-0169	results	3	NA	n_ipd_anchor	NA
10.2217/cer-2019-0169	results	3	NA	ess_anchor	NA
10.2217/cer-2019-0169	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2019-0169	results	3	NA	effect_cutoff	0
10.2217/cer-2019-0169	results	3	NA	adjusted_pval	<0.001
10.2217/cer-2019-0169	results	3	NA	adjusted_significant	TRUE
10.2217/cer-2019-0169	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2019-0169	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2019-0169	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02047734
10.2217/cer-2019-0169	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2019-0169	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2019-0169	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2019-0169	study_information	NA	2	Patient-level data used	Yes
10.2217/cer-2019-0169	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2019-0169	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02294058
10.2217/cer-2019-0169	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2019-0169	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2019-0169	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2019-0169	study_information	NA	3	Patient-level data used	No
10.2217/cer-2019-0169	study_information	NA	3	Clinical Trial	Yes
10.2217/cer-2019-0169	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00340834
10.2217/cer-2019-0169	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2019-0169	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2019-0169	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2019-0169	study_information	NA	4	Patient-level data used	No
10.2217/cer-2019-0169	study_information	NA	4	Clinical Trial	Yes
10.2217/cer-2019-0169	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00289978
10.2217/cer-2019-0169	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2019-0169	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2019-0169	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2019-0169	study_information	NA	5	Patient-level data used	No
10.2217/cer-2019-0169	study_information	NA	5	Clinical Trial	Yes
10.2217/cer-2019-0169	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00355134
10.2217/cer-2019-0169	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2019-0169	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2019-0169	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0063	general_information	NA	NA	Medical Condition of Interest Name	non-small cell lung cancer
10.2217/cer-2020-0063	general_information	NA	NA	Countries of first author affiliations	switzerland
10.2217/cer-2020-0063	general_information	NA	NA	Countries of last author affiliations	switzerland
10.2217/cer-2020-0063	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0063	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2020-0063	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2020-0063	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2020-0063	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer-2020-0063	methodology	1	NA	primary_outcome_name	overall survival
10.2217/cer-2020-0063	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0063	methodology	1	NA	primary_outcome_type	Time-to-event
10.2217/cer-2020-0063	methodology	1	NA	Treatment name 1	entrectinib
10.2217/cer-2020-0063	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3
10.2217/cer-2020-0063	methodology	1	NA	Treatment name 2	crizotinib
10.2217/cer-2020-0063	methodology	1	NA	Study 'number(s)' for treatment 2	4
10.2217/cer-2020-0063	methodology	1	NA	paitc_type	MAIC
10.2217/cer-2020-0063	methodology	1	NA	anchored_yn	No
10.2217/cer-2020-0063	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2020-0063	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0063	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer-2020-0063	methodology	1	NA	prognostic_factors_yn	Yes
10.2217/cer-2020-0063	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.2217/cer-2020-0063	methodology	1	NA	weights_model_yn	No
10.2217/cer-2020-0063	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2020-0063	methodology	2	NA	primary_outcome_name	overall survival
10.2217/cer-2020-0063	methodology	2	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0063	methodology	2	NA	primary_outcome_type	Time-to-event
10.2217/cer-2020-0063	methodology	2	NA	Treatment name 1	entrectinib
10.2217/cer-2020-0063	methodology	2	NA	Study 'number(s)' for treatment 1	1;2;3
10.2217/cer-2020-0063	methodology	2	NA	Treatment name 2	pemetrexed + platinum followed by pemetrexed maintenance
10.2217/cer-2020-0063	methodology	2	NA	Study 'number(s)' for treatment 2	5
10.2217/cer-2020-0063	methodology	2	NA	paitc_type	MAIC
10.2217/cer-2020-0063	methodology	2	NA	anchored_yn	No
10.2217/cer-2020-0063	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2020-0063	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0063	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer-2020-0063	methodology	2	NA	prognostic_factors_yn	Yes
10.2217/cer-2020-0063	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.2217/cer-2020-0063	methodology	2	NA	weights_model_yn	No
10.2217/cer-2020-0063	methodology	2	NA	scale_choice_yn	No
10.2217/cer-2020-0063	methodology	3	NA	primary_outcome_name	overall survival
10.2217/cer-2020-0063	methodology	3	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0063	methodology	3	NA	primary_outcome_type	Time-to-event
10.2217/cer-2020-0063	methodology	3	NA	Treatment name 1	entrectinib
10.2217/cer-2020-0063	methodology	3	NA	Study 'number(s)' for treatment 1	1;2;3
10.2217/cer-2020-0063	methodology	3	NA	Treatment name 2	pemetrexed/docetaxel
10.2217/cer-2020-0063	methodology	3	NA	Study 'number(s)' for treatment 2	6
10.2217/cer-2020-0063	methodology	3	NA	paitc_type	MAIC
10.2217/cer-2020-0063	methodology	3	NA	anchored_yn	No
10.2217/cer-2020-0063	methodology	3	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2020-0063	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0063	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer-2020-0063	methodology	3	NA	prognostic_factors_yn	Yes
10.2217/cer-2020-0063	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.2217/cer-2020-0063	methodology	3	NA	weights_model_yn	No
10.2217/cer-2020-0063	methodology	3	NA	scale_choice_yn	No
10.2217/cer-2020-0063	results	1	NA	contrast	HR
10.2217/cer-2020-0063	results	1	NA	direction_benefit	inferior
10.2217/cer-2020-0063	results	1	NA	n_nonipd_ttt	53
10.2217/cer-2020-0063	results	1	NA	n_ipd_ttt	53
10.2217/cer-2020-0063	results	1	NA	ess_ttt	34.18
10.2217/cer-2020-0063	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2020-0063	results	1	NA	list_covariates_yn	Yes
10.2217/cer-2020-0063	results	1	NA	n_covariates	6
10.2217/cer-2020-0063	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2217/cer-2020-0063	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0063	results	1	NA	unadjusted_effect	NA
10.2217/cer-2020-0063	results	1	NA	unadjusted_pval_char	NA
10.2217/cer-2020-0063	results	1	NA	adjusted_effect	0.471
10.2217/cer-2020-0063	results	1	NA	adjusted_pval_char	[0.112;1.034]
10.2217/cer-2020-0063	results	1	NA	geographical region	NA
10.2217/cer-2020-0063	results	1	NA	n_ipd_total	NA
10.2217/cer-2020-0063	results	1	NA	ess_total	NA
10.2217/cer-2020-0063	results	1	NA	n_nonipd_total	NA
10.2217/cer-2020-0063	results	1	NA	n_nonipd_anchor	NA
10.2217/cer-2020-0063	results	1	NA	n_ipd_anchor	NA
10.2217/cer-2020-0063	results	1	NA	ess_anchor	NA
10.2217/cer-2020-0063	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2020-0063	results	1	NA	effect_cutoff	1
10.2217/cer-2020-0063	results	1	NA	adjusted_lb_ci	0.112
10.2217/cer-2020-0063	results	1	NA	adjusted_ub_ci	1.034
10.2217/cer-2020-0063	results	1	NA	adjusted_significant	FALSE
10.2217/cer-2020-0063	results	2	NA	contrast	HR
10.2217/cer-2020-0063	results	2	NA	direction_benefit	inferior
10.2217/cer-2020-0063	results	2	NA	n_nonipd_ttt	187
10.2217/cer-2020-0063	results	2	NA	n_ipd_ttt	53
10.2217/cer-2020-0063	results	2	NA	ess_ttt	47.5
10.2217/cer-2020-0063	results	2	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2020-0063	results	2	NA	list_covariates_yn	Yes
10.2217/cer-2020-0063	results	2	NA	n_covariates	5
10.2217/cer-2020-0063	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2217/cer-2020-0063	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0063	results	2	NA	unadjusted_effect	NA
10.2217/cer-2020-0063	results	2	NA	unadjusted_pval_char	NA
10.2217/cer-2020-0063	results	2	NA	adjusted_effect	0.478
10.2217/cer-2020-0063	results	2	NA	adjusted_pval_char	[0.167;0.918]
10.2217/cer-2020-0063	results	2	NA	geographical region	NA
10.2217/cer-2020-0063	results	2	NA	n_ipd_total	NA
10.2217/cer-2020-0063	results	2	NA	ess_total	NA
10.2217/cer-2020-0063	results	2	NA	n_nonipd_total	NA
10.2217/cer-2020-0063	results	2	NA	n_nonipd_anchor	NA
10.2217/cer-2020-0063	results	2	NA	n_ipd_anchor	NA
10.2217/cer-2020-0063	results	2	NA	ess_anchor	NA
10.2217/cer-2020-0063	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2020-0063	results	2	NA	effect_cutoff	1
10.2217/cer-2020-0063	results	2	NA	adjusted_lb_ci	0.167
10.2217/cer-2020-0063	results	2	NA	adjusted_ub_ci	0.918
10.2217/cer-2020-0063	results	2	NA	adjusted_significant	TRUE
10.2217/cer-2020-0063	results	3	NA	contrast	HR
10.2217/cer-2020-0063	results	3	NA	direction_benefit	inferior
10.2217/cer-2020-0063	results	3	NA	n_nonipd_ttt	174
10.2217/cer-2020-0063	results	3	NA	n_ipd_ttt	53
10.2217/cer-2020-0063	results	3	NA	ess_ttt	36.09
10.2217/cer-2020-0063	results	3	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2020-0063	results	3	NA	list_covariates_yn	Yes
10.2217/cer-2020-0063	results	3	NA	n_covariates	5
10.2217/cer-2020-0063	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2217/cer-2020-0063	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0063	results	3	NA	unadjusted_effect	NA
10.2217/cer-2020-0063	results	3	NA	unadjusted_pval_char	NA
10.2217/cer-2020-0063	results	3	NA	adjusted_effect	0.434
10.2217/cer-2020-0063	results	3	NA	adjusted_pval_char	[0.157;0.755]
10.2217/cer-2020-0063	results	3	NA	geographical region	NA
10.2217/cer-2020-0063	results	3	NA	n_ipd_total	NA
10.2217/cer-2020-0063	results	3	NA	ess_total	NA
10.2217/cer-2020-0063	results	3	NA	n_nonipd_total	NA
10.2217/cer-2020-0063	results	3	NA	n_nonipd_anchor	NA
10.2217/cer-2020-0063	results	3	NA	n_ipd_anchor	NA
10.2217/cer-2020-0063	results	3	NA	ess_anchor	NA
10.2217/cer-2020-0063	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2020-0063	results	3	NA	effect_cutoff	1
10.2217/cer-2020-0063	results	3	NA	adjusted_lb_ci	0.157
10.2217/cer-2020-0063	results	3	NA	adjusted_ub_ci	0.755
10.2217/cer-2020-0063	results	3	NA	adjusted_significant	TRUE
10.2217/cer-2020-0063	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2020-0063	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2020-0063	study_information	NA	1	EudraCT (only for clinical trials registered on clinicaltrialsregister.eu	2012-000148-88
10.2217/cer-2020-0063	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.2217/cer-2020-0063	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.2217/cer-2020-0063	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0063	study_information	NA	2	Patient-level data used	Yes
10.2217/cer-2020-0063	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2020-0063	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02097810
10.2217/cer-2020-0063	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0063	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1
10.2217/cer-2020-0063	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0063	study_information	NA	3	Patient-level data used	Yes
10.2217/cer-2020-0063	study_information	NA	3	Clinical Trial	Yes
10.2217/cer-2020-0063	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02568267
10.2217/cer-2020-0063	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0063	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.2217/cer-2020-0063	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0063	study_information	NA	4	Patient-level data used	No
10.2217/cer-2020-0063	study_information	NA	4	Clinical Trial	Yes
10.2217/cer-2020-0063	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00585195
10.2217/cer-2020-0063	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0063	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1
10.2217/cer-2020-0063	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0063	study_information	NA	5	Patient-level data used	No
10.2217/cer-2020-0063	study_information	NA	5	Clinical Trial	Yes
10.2217/cer-2020-0063	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01828099
10.2217/cer-2020-0063	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0063	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2020-0063	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0063	study_information	NA	6	Patient-level data used	No
10.2217/cer-2020-0063	study_information	NA	6	Clinical Trial	Yes
10.2217/cer-2020-0063	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00932893
10.2217/cer-2020-0063	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0063	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2020-0063	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0069	general_information	NA	NA	Medical Condition of Interest Name	pediatric relapsed/refractory acute lymphoblastic leukemia
10.2217/cer-2020-0069	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer-2020-0069	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer-2020-0069	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0069	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2020-0069	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2020-0069	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2020-0069	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer-2020-0069	methodology	1	NA	primary_outcome_name	overall survival
10.2217/cer-2020-0069	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0069	methodology	1	NA	primary_outcome_type	Time-to-event
10.2217/cer-2020-0069	methodology	1	NA	Treatment name 1	tisagenlecleucel
10.2217/cer-2020-0069	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0069	methodology	1	NA	Treatment name 2	blinatumomab
10.2217/cer-2020-0069	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2020-0069	methodology	1	NA	paitc_type	MAIC
10.2217/cer-2020-0069	methodology	1	NA	anchored_yn	No
10.2217/cer-2020-0069	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0069	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	1	NA	weights_model_yn	No
10.2217/cer-2020-0069	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2020-0069	methodology	2	NA	primary_outcome_name	overall survival
10.2217/cer-2020-0069	methodology	2	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0069	methodology	2	NA	primary_outcome_type	Time-to-event
10.2217/cer-2020-0069	methodology	2	NA	Treatment name 1	tisagenlecleucel
10.2217/cer-2020-0069	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0069	methodology	2	NA	Treatment name 2	clofarabine
10.2217/cer-2020-0069	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.2217/cer-2020-0069	methodology	2	NA	paitc_type	MAIC
10.2217/cer-2020-0069	methodology	2	NA	anchored_yn	No
10.2217/cer-2020-0069	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0069	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	2	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	2	NA	weights_model_yn	No
10.2217/cer-2020-0069	methodology	2	NA	scale_choice_yn	No
10.2217/cer-2020-0069	methodology	3	NA	primary_outcome_name	overall survival
10.2217/cer-2020-0069	methodology	3	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0069	methodology	3	NA	primary_outcome_type	Time-to-event
10.2217/cer-2020-0069	methodology	3	NA	Treatment name 1	tisagenlecleucel
10.2217/cer-2020-0069	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0069	methodology	3	NA	Treatment name 2	clofarabine + etoposide plus cyclophosphamide
10.2217/cer-2020-0069	methodology	3	NA	Study 'number(s)' for treatment 2	4;5;6
10.2217/cer-2020-0069	methodology	3	NA	paitc_type	MAIC
10.2217/cer-2020-0069	methodology	3	NA	anchored_yn	No
10.2217/cer-2020-0069	methodology	3	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2020-0069	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	3	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	3	NA	weights_model_yn	No
10.2217/cer-2020-0069	methodology	3	NA	scale_choice_yn	No
10.2217/cer-2020-0069	methodology	4	NA	primary_outcome_name	overall survival
10.2217/cer-2020-0069	methodology	4	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0069	methodology	4	NA	primary_outcome_type	Time-to-event
10.2217/cer-2020-0069	methodology	4	NA	Treatment name 1	tisagenlecleucel
10.2217/cer-2020-0069	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0069	methodology	4	NA	Treatment name 2	polychemotherapy/high-dose single-agent regimens/stem-cell transplantation (salvage-1)
10.2217/cer-2020-0069	methodology	4	NA	Study 'number(s)' for treatment 2	7
10.2217/cer-2020-0069	methodology	4	NA	paitc_type	MAIC
10.2217/cer-2020-0069	methodology	4	NA	anchored_yn	No
10.2217/cer-2020-0069	methodology	4	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0069	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	4	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	4	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	4	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	4	NA	weights_model_yn	No
10.2217/cer-2020-0069	methodology	4	NA	scale_choice_yn	No
10.2217/cer-2020-0069	methodology	5	NA	primary_outcome_name	overall survival
10.2217/cer-2020-0069	methodology	5	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0069	methodology	5	NA	primary_outcome_type	Time-to-event
10.2217/cer-2020-0069	methodology	5	NA	Treatment name 1	tisagenlecleucel
10.2217/cer-2020-0069	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0069	methodology	5	NA	Treatment name 2	palliative therapy/salvage therapy  second stem-cell transplantation (salvage-2)
10.2217/cer-2020-0069	methodology	5	NA	Study 'number(s)' for treatment 2	8
10.2217/cer-2020-0069	methodology	5	NA	paitc_type	MAIC
10.2217/cer-2020-0069	methodology	5	NA	anchored_yn	No
10.2217/cer-2020-0069	methodology	5	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0069	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	5	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	5	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	5	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	5	NA	weights_model_yn	No
10.2217/cer-2020-0069	methodology	5	NA	scale_choice_yn	No
10.2217/cer-2020-0069	results	1	NA	contrast	HR
10.2217/cer-2020-0069	results	1	NA	direction_benefit	inferior
10.2217/cer-2020-0069	results	1	NA	n_nonipd_ttt	70
10.2217/cer-2020-0069	results	1	NA	n_ipd_ttt	79
10.2217/cer-2020-0069	results	1	NA	ess_ttt	28.7
10.2217/cer-2020-0069	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2020-0069	results	1	NA	list_covariates_yn	Yes
10.2217/cer-2020-0069	results	1	NA	n_covariates	9
10.2217/cer-2020-0069	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.2217/cer-2020-0069	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	1	NA	unadjusted_effect	0.28
10.2217/cer-2020-0069	results	1	NA	unadjusted_pval_char	<0.0001
10.2217/cer-2020-0069	results	1	NA	adjusted_effect	0.32
10.2217/cer-2020-0069	results	1	NA	adjusted_pval_char	0.0015
10.2217/cer-2020-0069	results	1	NA	geographical region	Yes
10.2217/cer-2020-0069	results	1	NA	n_ipd_total	NA
10.2217/cer-2020-0069	results	1	NA	ess_total	NA
10.2217/cer-2020-0069	results	1	NA	n_nonipd_total	NA
10.2217/cer-2020-0069	results	1	NA	n_nonipd_anchor	NA
10.2217/cer-2020-0069	results	1	NA	n_ipd_anchor	NA
10.2217/cer-2020-0069	results	1	NA	ess_anchor	NA
10.2217/cer-2020-0069	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2020-0069	results	1	NA	effect_cutoff	1
10.2217/cer-2020-0069	results	1	NA	unadjusted_pval	<0.0001
10.2217/cer-2020-0069	results	1	NA	unadjusted_significant	TRUE
10.2217/cer-2020-0069	results	1	NA	adjusted_pval	0.0015
10.2217/cer-2020-0069	results	1	NA	adjusted_num_pval	0.0015
10.2217/cer-2020-0069	results	1	NA	adjusted_significant	TRUE
10.2217/cer-2020-0069	results	2	NA	contrast	HR
10.2217/cer-2020-0069	results	2	NA	direction_benefit	inferior
10.2217/cer-2020-0069	results	2	NA	n_nonipd_ttt	61
10.2217/cer-2020-0069	results	2	NA	n_ipd_ttt	79
10.2217/cer-2020-0069	results	2	NA	ess_ttt	43
10.2217/cer-2020-0069	results	2	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2020-0069	results	2	NA	list_covariates_yn	Yes
10.2217/cer-2020-0069	results	2	NA	n_covariates	5
10.2217/cer-2020-0069	results	2	NA	list_covariates	Age, Sex, Race/ethnicity, Past treatments for the disease of interest
10.2217/cer-2020-0069	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	2	NA	unadjusted_effect	0.17
10.2217/cer-2020-0069	results	2	NA	unadjusted_pval_char	<0.0001
10.2217/cer-2020-0069	results	2	NA	adjusted_effect	0.24
10.2217/cer-2020-0069	results	2	NA	adjusted_pval_char	<0.0001
10.2217/cer-2020-0069	results	2	NA	geographical region	NA
10.2217/cer-2020-0069	results	2	NA	n_ipd_total	NA
10.2217/cer-2020-0069	results	2	NA	ess_total	NA
10.2217/cer-2020-0069	results	2	NA	n_nonipd_total	NA
10.2217/cer-2020-0069	results	2	NA	n_nonipd_anchor	NA
10.2217/cer-2020-0069	results	2	NA	n_ipd_anchor	NA
10.2217/cer-2020-0069	results	2	NA	ess_anchor	NA
10.2217/cer-2020-0069	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2020-0069	results	2	NA	effect_cutoff	1
10.2217/cer-2020-0069	results	2	NA	unadjusted_pval	<0.0001
10.2217/cer-2020-0069	results	2	NA	unadjusted_significant	TRUE
10.2217/cer-2020-0069	results	2	NA	adjusted_pval	<0.0001
10.2217/cer-2020-0069	results	2	NA	adjusted_significant	TRUE
10.2217/cer-2020-0069	results	3	NA	contrast	HR
10.2217/cer-2020-0069	results	3	NA	direction_benefit	inferior
10.2217/cer-2020-0069	results	3	NA	n_nonipd_ttt	74
10.2217/cer-2020-0069	results	3	NA	n_ipd_ttt	79
10.2217/cer-2020-0069	results	3	NA	ess_ttt	53.5
10.2217/cer-2020-0069	results	3	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2020-0069	results	3	NA	list_covariates_yn	Yes
10.2217/cer-2020-0069	results	3	NA	n_covariates	2
10.2217/cer-2020-0069	results	3	NA	list_covariates	Sex, Past treatments for the disease of interest
10.2217/cer-2020-0069	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	3	NA	unadjusted_effect	0.22
10.2217/cer-2020-0069	results	3	NA	unadjusted_pval_char	<0.0001
10.2217/cer-2020-0069	results	3	NA	adjusted_effect	0.26
10.2217/cer-2020-0069	results	3	NA	adjusted_pval_char	<0.0001
10.2217/cer-2020-0069	results	3	NA	geographical region	NA
10.2217/cer-2020-0069	results	3	NA	n_ipd_total	NA
10.2217/cer-2020-0069	results	3	NA	ess_total	NA
10.2217/cer-2020-0069	results	3	NA	n_nonipd_total	NA
10.2217/cer-2020-0069	results	3	NA	n_nonipd_anchor	NA
10.2217/cer-2020-0069	results	3	NA	n_ipd_anchor	NA
10.2217/cer-2020-0069	results	3	NA	ess_anchor	NA
10.2217/cer-2020-0069	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2020-0069	results	3	NA	effect_cutoff	1
10.2217/cer-2020-0069	results	3	NA	unadjusted_pval	<0.0001
10.2217/cer-2020-0069	results	3	NA	unadjusted_significant	TRUE
10.2217/cer-2020-0069	results	3	NA	adjusted_pval	<0.0001
10.2217/cer-2020-0069	results	3	NA	adjusted_significant	TRUE
10.2217/cer-2020-0069	results	4	NA	contrast	HR
10.2217/cer-2020-0069	results	4	NA	direction_benefit	inferior
10.2217/cer-2020-0069	results	4	NA	n_nonipd_ttt	51
10.2217/cer-2020-0069	results	4	NA	n_ipd_ttt	79
10.2217/cer-2020-0069	results	4	NA	ess_ttt	75
10.2217/cer-2020-0069	results	4	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2020-0069	results	4	NA	list_covariates_yn	Yes
10.2217/cer-2020-0069	results	4	NA	n_covariates	3
10.2217/cer-2020-0069	results	4	NA	list_covariates	Age, Sex, Past treatments for the disease of interest
10.2217/cer-2020-0069	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	4	NA	unadjusted_effect	0.14
10.2217/cer-2020-0069	results	4	NA	unadjusted_pval_char	<0.0001
10.2217/cer-2020-0069	results	4	NA	adjusted_effect	0.15
10.2217/cer-2020-0069	results	4	NA	adjusted_pval_char	<0.0001
10.2217/cer-2020-0069	results	4	NA	geographical region	NA
10.2217/cer-2020-0069	results	4	NA	n_ipd_total	NA
10.2217/cer-2020-0069	results	4	NA	ess_total	NA
10.2217/cer-2020-0069	results	4	NA	n_nonipd_total	NA
10.2217/cer-2020-0069	results	4	NA	n_nonipd_anchor	NA
10.2217/cer-2020-0069	results	4	NA	n_ipd_anchor	NA
10.2217/cer-2020-0069	results	4	NA	ess_anchor	NA
10.2217/cer-2020-0069	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2020-0069	results	4	NA	effect_cutoff	1
10.2217/cer-2020-0069	results	4	NA	unadjusted_pval	<0.0001
10.2217/cer-2020-0069	results	4	NA	unadjusted_significant	TRUE
10.2217/cer-2020-0069	results	4	NA	adjusted_pval	<0.0001
10.2217/cer-2020-0069	results	4	NA	adjusted_significant	TRUE
10.2217/cer-2020-0069	results	5	NA	contrast	HR
10.2217/cer-2020-0069	results	5	NA	direction_benefit	inferior
10.2217/cer-2020-0069	results	5	NA	n_nonipd_ttt	242
10.2217/cer-2020-0069	results	5	NA	n_ipd_ttt	79
10.2217/cer-2020-0069	results	5	NA	ess_ttt	36.2
10.2217/cer-2020-0069	results	5	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2020-0069	results	5	NA	list_covariates_yn	Yes
10.2217/cer-2020-0069	results	5	NA	n_covariates	3
10.2217/cer-2020-0069	results	5	NA	list_covariates	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/cer-2020-0069	results	5	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	5	NA	unadjusted_effect	0.28
10.2217/cer-2020-0069	results	5	NA	unadjusted_pval_char	<0.0001
10.2217/cer-2020-0069	results	5	NA	adjusted_effect	0.27
10.2217/cer-2020-0069	results	5	NA	adjusted_pval_char	<0.0001
10.2217/cer-2020-0069	results	5	NA	geographical region	NA
10.2217/cer-2020-0069	results	5	NA	n_ipd_total	NA
10.2217/cer-2020-0069	results	5	NA	ess_total	NA
10.2217/cer-2020-0069	results	5	NA	n_nonipd_total	NA
10.2217/cer-2020-0069	results	5	NA	n_nonipd_anchor	NA
10.2217/cer-2020-0069	results	5	NA	n_ipd_anchor	NA
10.2217/cer-2020-0069	results	5	NA	ess_anchor	NA
10.2217/cer-2020-0069	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2020-0069	results	5	NA	effect_cutoff	1
10.2217/cer-2020-0069	results	5	NA	unadjusted_pval	<0.0001
10.2217/cer-2020-0069	results	5	NA	unadjusted_significant	TRUE
10.2217/cer-2020-0069	results	5	NA	adjusted_pval	<0.0001
10.2217/cer-2020-0069	results	5	NA	adjusted_significant	TRUE
10.2217/cer-2020-0069	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2020-0069	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2020-0069	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02435849
10.2217/cer-2020-0069	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0069	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.2217/cer-2020-0069	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0069	study_information	NA	2	Patient-level data used	No
10.2217/cer-2020-0069	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2020-0069	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01471782
10.2217/cer-2020-0069	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0069	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1, 2
10.2217/cer-2020-0069	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0069	study_information	NA	3	Patient-level data used	No
10.2217/cer-2020-0069	study_information	NA	3	Clinical Trial	Yes
10.2217/cer-2020-0069	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	jeha et al. (2006)
10.2217/cer-2020-0069	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.2217/cer-2020-0069	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0069	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/cer-2020-0069	study_information	NA	4	Patient-level data used	No
10.2217/cer-2020-0069	study_information	NA	4	Clinical Trial	Yes
10.2217/cer-2020-0069	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00315705
10.2217/cer-2020-0069	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/cer-2020-0069	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1, 2
10.2217/cer-2020-0069	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0069	study_information	NA	5	Patient-level data used	No
10.2217/cer-2020-0069	study_information	NA	5	Clinical Trial	Yes
10.2217/cer-2020-0069	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	locatelli et al. (2017)
10.2217/cer-2020-0069	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2
10.2217/cer-2020-0069	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0069	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.2217/cer-2020-0069	study_information	NA	6	Patient-level data used	No
10.2217/cer-2020-0069	study_information	NA	6	Clinical Trial	No
10.2217/cer-2020-0069	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	miano et al. (2012)
10.2217/cer-2020-0069	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.2217/cer-2020-0069	study_information	NA	6	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0069	study_information	NA	7	Patient-level data used	No
10.2217/cer-2020-0069	study_information	NA	7	Clinical Trial	No
10.2217/cer-2020-0069	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	von stackelbeg et al. (2010)
10.2217/cer-2020-0069	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	germany
10.2217/cer-2020-0069	study_information	NA	8	Patient-level data used	No
10.2217/cer-2020-0069	study_information	NA	8	Clinical Trial	No
10.2217/cer-2020-0069	study_information	NA	8	Data source name (only if observational study or clinical trial without NCT)	all-sct-bfm 2003 & all-sct-bfm
10.2217/cer-2020-0069	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0236	general_information	NA	NA	Medical Condition of Interest Name	advanced hepatocellular carcinoma
10.2217/cer-2020-0236	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer-2020-0236	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer-2020-0236	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0236	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2020-0236	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2020-0236	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2020-0236	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer-2020-0236	methodology	1	NA	primary_outcome_name	overall survival
10.2217/cer-2020-0236	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0236	methodology	1	NA	primary_outcome_type	Time-to-event
10.2217/cer-2020-0236	methodology	1	NA	Treatment name 1	nivolumab + ipilimumab
10.2217/cer-2020-0236	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0236	methodology	1	NA	Treatment name 2	placebo
10.2217/cer-2020-0236	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2020-0236	methodology	1	NA	paitc_type	MAIC
10.2217/cer-2020-0236	methodology	1	NA	anchored_yn	No
10.2217/cer-2020-0236	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0236	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0236	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.2217/cer-2020-0236	methodology	1	NA	prognostic_factors_yn	Yes
10.2217/cer-2020-0236	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0236	methodology	1	NA	weights_model_yn	No
10.2217/cer-2020-0236	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2020-0236	results	1	NA	contrast	HR
10.2217/cer-2020-0236	results	1	NA	direction_benefit	inferior
10.2217/cer-2020-0236	results	1	NA	n_nonipd_ttt	237
10.2217/cer-2020-0236	results	1	NA	n_ipd_ttt	50
10.2217/cer-2020-0236	results	1	NA	ess_ttt	NA
10.2217/cer-2020-0236	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2020-0236	results	1	NA	list_covariates_yn	Yes
10.2217/cer-2020-0236	results	1	NA	n_covariates	6
10.2217/cer-2020-0236	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/cer-2020-0236	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0236	results	1	NA	unadjusted_effect	NA
10.2217/cer-2020-0236	results	1	NA	unadjusted_pval_char	NA
10.2217/cer-2020-0236	results	1	NA	adjusted_effect	0.35
10.2217/cer-2020-0236	results	1	NA	adjusted_pval_char	[0.21;0.58]
10.2217/cer-2020-0236	results	1	NA	geographical region	NA
10.2217/cer-2020-0236	results	1	NA	n_ipd_total	NA
10.2217/cer-2020-0236	results	1	NA	ess_total	NA
10.2217/cer-2020-0236	results	1	NA	n_nonipd_total	NA
10.2217/cer-2020-0236	results	1	NA	n_nonipd_anchor	NA
10.2217/cer-2020-0236	results	1	NA	n_ipd_anchor	NA
10.2217/cer-2020-0236	results	1	NA	ess_anchor	NA
10.2217/cer-2020-0236	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2020-0236	results	1	NA	effect_cutoff	1
10.2217/cer-2020-0236	results	1	NA	adjusted_lb_ci	0.21
10.2217/cer-2020-0236	results	1	NA	adjusted_ub_ci	0.58
10.2217/cer-2020-0236	results	1	NA	adjusted_significant	TRUE
10.2217/cer-2020-0236	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2020-0236	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2020-0236	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01658878
10.2217/cer-2020-0236	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0236	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.2217/cer-2020-0236	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0236	study_information	NA	2	Patient-level data used	No
10.2217/cer-2020-0236	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2020-0236	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01908426
10.2217/cer-2020-0236	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0236	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2020-0236	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0272	general_information	NA	NA	Medical Condition of Interest Name	hr+/her2- advanced breast cancer
10.2217/cer-2020-0272	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer-2020-0272	general_information	NA	NA	Countries of last author affiliations	canada
10.2217/cer-2020-0272	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0272	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2020-0272	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2020-0272	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2020-0272	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/cer-2020-0272	methodology	1	NA	primary_outcome_name	overall survival
10.2217/cer-2020-0272	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0272	methodology	1	NA	primary_outcome_type	Time-to-event
10.2217/cer-2020-0272	methodology	1	NA	Treatment name 1	palbociclib + fulvestrant
10.2217/cer-2020-0272	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0272	methodology	1	NA	Treatment name 2	abemaciclib + fulvestrant
10.2217/cer-2020-0272	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2020-0272	methodology	1	NA	paitc_type	MAIC
10.2217/cer-2020-0272	methodology	1	NA	anchored_yn	Yes
10.2217/cer-2020-0272	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0272	methodology	1	NA	primary_outcome_yn	Yes
10.2217/cer-2020-0272	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0272	methodology	1	NA	prognostic_factors_yn	No
10.2217/cer-2020-0272	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.2217/cer-2020-0272	methodology	1	NA	weights_model_yn	No
10.2217/cer-2020-0272	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2020-0272	methodology	2	NA	primary_outcome_name	overall survival
10.2217/cer-2020-0272	methodology	2	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0272	methodology	2	NA	primary_outcome_type	Time-to-event
10.2217/cer-2020-0272	methodology	2	NA	Treatment name 1	palbociclib + fulvestrant
10.2217/cer-2020-0272	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0272	methodology	2	NA	Treatment name 2	ribociclib + fulvestrant
10.2217/cer-2020-0272	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.2217/cer-2020-0272	methodology	2	NA	paitc_type	MAIC
10.2217/cer-2020-0272	methodology	2	NA	anchored_yn	Yes
10.2217/cer-2020-0272	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0272	methodology	2	NA	primary_outcome_yn	Yes
10.2217/cer-2020-0272	methodology	2	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0272	methodology	2	NA	prognostic_factors_yn	No
10.2217/cer-2020-0272	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.2217/cer-2020-0272	methodology	2	NA	weights_model_yn	No
10.2217/cer-2020-0272	methodology	2	NA	scale_choice_yn	No
10.2217/cer-2020-0272	results	1	NA	contrast	HR
10.2217/cer-2020-0272	results	1	NA	direction_benefit	inferior
10.2217/cer-2020-0272	results	1	NA	n_nonipd_ttt	NA
10.2217/cer-2020-0272	results	1	NA	n_ipd_ttt	183
10.2217/cer-2020-0272	results	1	NA	ess_ttt	NA
10.2217/cer-2020-0272	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2020-0272	results	1	NA	list_covariates_yn	Yes
10.2217/cer-2020-0272	results	1	NA	n_covariates	12
10.2217/cer-2020-0272	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.2217/cer-2020-0272	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0272	results	1	NA	unadjusted_effect	1.02
10.2217/cer-2020-0272	results	1	NA	unadjusted_pval_char	[0.69;1.52]
10.2217/cer-2020-0272	results	1	NA	adjusted_effect	0.87
10.2217/cer-2020-0272	results	1	NA	adjusted_pval_char	[0.54;1.40]
10.2217/cer-2020-0272	results	1	NA	geographical region	Yes
10.2217/cer-2020-0272	results	1	NA	n_ipd_total	280
10.2217/cer-2020-0272	results	1	NA	ess_total	135
10.2217/cer-2020-0272	results	1	NA	n_nonipd_total	669
10.2217/cer-2020-0272	results	1	NA	n_nonipd_anchor	NA
10.2217/cer-2020-0272	results	1	NA	n_ipd_anchor	97
10.2217/cer-2020-0272	results	1	NA	ess_anchor	NA
10.2217/cer-2020-0272	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2020-0272	results	1	NA	effect_cutoff	1
10.2217/cer-2020-0272	results	1	NA	unadjusted_lb_ci	0.69
10.2217/cer-2020-0272	results	1	NA	unadjusted_ub_ci	1.52
10.2217/cer-2020-0272	results	1	NA	unadjusted_significant	FALSE
10.2217/cer-2020-0272	results	1	NA	adjusted_lb_ci	0.54
10.2217/cer-2020-0272	results	1	NA	adjusted_ub_ci	1.4
10.2217/cer-2020-0272	results	1	NA	adjusted_significant	FALSE
10.2217/cer-2020-0272	results	2	NA	contrast	HR
10.2217/cer-2020-0272	results	2	NA	direction_benefit	inferior
10.2217/cer-2020-0272	results	2	NA	n_nonipd_ttt	NA
10.2217/cer-2020-0272	results	2	NA	n_ipd_ttt	142
10.2217/cer-2020-0272	results	2	NA	ess_ttt	NA
10.2217/cer-2020-0272	results	2	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2020-0272	results	2	NA	list_covariates_yn	Yes
10.2217/cer-2020-0272	results	2	NA	n_covariates	8
10.2217/cer-2020-0272	results	2	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2217/cer-2020-0272	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0272	results	2	NA	unadjusted_effect	1.09
10.2217/cer-2020-0272	results	2	NA	unadjusted_pval_char	[0.70;1.69]
10.2217/cer-2020-0272	results	2	NA	adjusted_effect	0.89
10.2217/cer-2020-0272	results	2	NA	adjusted_pval_char	[0.48;1.63]
10.2217/cer-2020-0272	results	2	NA	geographical region	Yes
10.2217/cer-2020-0272	results	2	NA	n_ipd_total	217
10.2217/cer-2020-0272	results	2	NA	ess_total	64
10.2217/cer-2020-0272	results	2	NA	n_nonipd_total	726
10.2217/cer-2020-0272	results	2	NA	n_nonipd_anchor	NA
10.2217/cer-2020-0272	results	2	NA	n_ipd_anchor	75
10.2217/cer-2020-0272	results	2	NA	ess_anchor	NA
10.2217/cer-2020-0272	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2020-0272	results	2	NA	effect_cutoff	1
10.2217/cer-2020-0272	results	2	NA	unadjusted_lb_ci	0.7
10.2217/cer-2020-0272	results	2	NA	unadjusted_ub_ci	1.69
10.2217/cer-2020-0272	results	2	NA	unadjusted_significant	FALSE
10.2217/cer-2020-0272	results	2	NA	adjusted_lb_ci	0.48
10.2217/cer-2020-0272	results	2	NA	adjusted_ub_ci	1.63
10.2217/cer-2020-0272	results	2	NA	adjusted_significant	FALSE
10.2217/cer-2020-0272	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2020-0272	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2020-0272	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01942135
10.2217/cer-2020-0272	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0272	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2020-0272	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0272	study_information	NA	2	Patient-level data used	No
10.2217/cer-2020-0272	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2020-0272	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02107703
10.2217/cer-2020-0272	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0272	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2020-0272	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0272	study_information	NA	3	Patient-level data used	No
10.2217/cer-2020-0272	study_information	NA	3	Clinical Trial	Yes
10.2217/cer-2020-0272	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02422615
10.2217/cer-2020-0272	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0272	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2020-0272	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0280	general_information	NA	NA	Medical Condition of Interest Name	acute myeloid leukemia
10.2217/cer-2020-0280	general_information	NA	NA	Countries of first author affiliations	canada
10.2217/cer-2020-0280	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer-2020-0280	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0280	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2020-0280	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2020-0280	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2020-0280	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/cer-2020-0280	methodology	1	NA	primary_outcome_name	overall survival
10.2217/cer-2020-0280	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0280	methodology	1	NA	primary_outcome_type	Time-to-event
10.2217/cer-2020-0280	methodology	1	NA	Treatment name 1	glasdegib + low-dose cytarabine
10.2217/cer-2020-0280	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0280	methodology	1	NA	Treatment name 2	venetoclax + low-dose cytarabine
10.2217/cer-2020-0280	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2020-0280	methodology	1	NA	paitc_type	STC
10.2217/cer-2020-0280	methodology	1	NA	anchored_yn	Yes
10.2217/cer-2020-0280	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0280	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0280	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0280	methodology	1	NA	prognostic_factors_yn	Yes
10.2217/cer-2020-0280	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.2217/cer-2020-0280	methodology	1	NA	weights_model_yn	Yes
10.2217/cer-2020-0280	methodology	1	NA	scale_choice_yn	Yes
10.2217/cer-2020-0280	results	1	NA	contrast	HR
10.2217/cer-2020-0280	results	1	NA	direction_benefit	inferior
10.2217/cer-2020-0280	results	1	NA	n_nonipd_ttt	143
10.2217/cer-2020-0280	results	1	NA	n_ipd_ttt	78
10.2217/cer-2020-0280	results	1	NA	ess_ttt	78
10.2217/cer-2020-0280	results	1	NA	weights_evaluation_yn	NA
10.2217/cer-2020-0280	results	1	NA	list_covariates_yn	Yes
10.2217/cer-2020-0280	results	1	NA	n_covariates	6
10.2217/cer-2020-0280	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.2217/cer-2020-0280	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0280	results	1	NA	unadjusted_effect	0.66
10.2217/cer-2020-0280	results	1	NA	unadjusted_pval_char	[0.38;1.15]
10.2217/cer-2020-0280	results	1	NA	adjusted_effect	0.56
10.2217/cer-2020-0280	results	1	NA	adjusted_pval_char	[0.24;1.32]
10.2217/cer-2020-0280	results	1	NA	geographical region	NA
10.2217/cer-2020-0280	results	1	NA	n_ipd_total	NA
10.2217/cer-2020-0280	results	1	NA	ess_total	NA
10.2217/cer-2020-0280	results	1	NA	n_nonipd_total	NA
10.2217/cer-2020-0280	results	1	NA	n_nonipd_anchor	68
10.2217/cer-2020-0280	results	1	NA	n_ipd_anchor	38
10.2217/cer-2020-0280	results	1	NA	ess_anchor	38
10.2217/cer-2020-0280	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2020-0280	results	1	NA	effect_cutoff	1
10.2217/cer-2020-0280	results	1	NA	unadjusted_lb_ci	0.38
10.2217/cer-2020-0280	results	1	NA	unadjusted_ub_ci	1.15
10.2217/cer-2020-0280	results	1	NA	unadjusted_significant	FALSE
10.2217/cer-2020-0280	results	1	NA	adjusted_lb_ci	0.24
10.2217/cer-2020-0280	results	1	NA	adjusted_ub_ci	1.32
10.2217/cer-2020-0280	results	1	NA	adjusted_significant	FALSE
10.2217/cer-2020-0280	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2020-0280	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2020-0280	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01546038
10.2217/cer-2020-0280	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0280	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.2217/cer-2020-0280	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0280	study_information	NA	2	Patient-level data used	No
10.2217/cer-2020-0280	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2020-0280	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03069352
10.2217/cer-2020-0280	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0280	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2020-0280	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2021-0178	general_information	NA	NA	Medical Condition of Interest Name	parkinson's disease
10.2217/cer-2021-0178	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer-2021-0178	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer-2021-0178	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2021-0178	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2021-0178	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2021-0178	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2021-0178	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer-2021-0178	methodology	1	NA	primary_outcome_name	the mean change in the updrs part iii score at week 12 from predose to the following timepoints postdose: 15 (apomorphine sublingual film) or 20 (levodopa),30 and 60 min.
10.2217/cer-2021-0178	methodology	1	NA	outcome_short_name	UPDRS part III score at week 12
10.2217/cer-2021-0178	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2217/cer-2021-0178	methodology	1	NA	Treatment name 1	apomorphine sublingual film
10.2217/cer-2021-0178	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2021-0178	methodology	1	NA	Treatment name 2	levodopa inhalation powder
10.2217/cer-2021-0178	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2021-0178	methodology	1	NA	paitc_type	MAIC
10.2217/cer-2021-0178	methodology	1	NA	anchored_yn	Yes
10.2217/cer-2021-0178	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2021-0178	methodology	1	NA	primary_outcome_yn	Yes
10.2217/cer-2021-0178	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/cer-2021-0178	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2021-0178	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.2217/cer-2021-0178	methodology	1	NA	weights_model_yn	No
10.2217/cer-2021-0178	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2021-0178	results	1	NA	contrast	Means difference
10.2217/cer-2021-0178	results	1	NA	direction_benefit	inferior
10.2217/cer-2021-0178	results	1	NA	n_nonipd_ttt	114
10.2217/cer-2021-0178	results	1	NA	n_ipd_ttt	44
10.2217/cer-2021-0178	results	1	NA	ess_ttt	NA
10.2217/cer-2021-0178	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/cer-2021-0178	results	1	NA	list_covariates_yn	Yes
10.2217/cer-2021-0178	results	1	NA	n_covariates	4
10.2217/cer-2021-0178	results	1	NA	list_covariates	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/cer-2021-0178	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2021-0178	results	1	NA	unadjusted_effect	0.57
10.2217/cer-2021-0178	results	1	NA	unadjusted_pval_char	0.818
10.2217/cer-2021-0178	results	1	NA	adjusted_effect	0.15
10.2217/cer-2021-0178	results	1	NA	adjusted_pval_char	0.953
10.2217/cer-2021-0178	results	1	NA	geographical region	NA
10.2217/cer-2021-0178	results	1	NA	n_ipd_total	NA
10.2217/cer-2021-0178	results	1	NA	ess_total	NA
10.2217/cer-2021-0178	results	1	NA	n_nonipd_total	NA
10.2217/cer-2021-0178	results	1	NA	n_nonipd_anchor	112
10.2217/cer-2021-0178	results	1	NA	n_ipd_anchor	37
10.2217/cer-2021-0178	results	1	NA	ess_anchor	NA
10.2217/cer-2021-0178	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2021-0178	results	1	NA	effect_cutoff	0
10.2217/cer-2021-0178	results	1	NA	unadjusted_pval	0.818
10.2217/cer-2021-0178	results	1	NA	unadjusted_num_pval	0.818
10.2217/cer-2021-0178	results	1	NA	unadjusted_significant	FALSE
10.2217/cer-2021-0178	results	1	NA	adjusted_pval	0.953
10.2217/cer-2021-0178	results	1	NA	adjusted_num_pval	0.953
10.2217/cer-2021-0178	results	1	NA	adjusted_significant	FALSE
10.2217/cer-2021-0178	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2021-0178	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2021-0178	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02469090
10.2217/cer-2021-0178	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0178	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2021-0178	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2021-0178	study_information	NA	2	Patient-level data used	No
10.2217/cer-2021-0178	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2021-0178	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0178	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2021-0178	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2021-0178	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02240030
10.2217/cer-2021-0216	general_information	NA	NA	Medical Condition of Interest Name	spinal muscular atrophy
10.2217/cer-2021-0216	general_information	NA	NA	Countries of first author affiliations	switzerland
10.2217/cer-2021-0216	general_information	NA	NA	Countries of last author affiliations	uk
10.2217/cer-2021-0216	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2021-0216	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2021-0216	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2021-0216	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2021-0216	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer-2021-0216	methodology	1	NA	primary_outcome_name	event-free survival
10.2217/cer-2021-0216	methodology	1	NA	outcome_short_name	Event-free Survival
10.2217/cer-2021-0216	methodology	1	NA	primary_outcome_type	Time-to-event
10.2217/cer-2021-0216	methodology	1	NA	Treatment name 1	risdiplam
10.2217/cer-2021-0216	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2021-0216	methodology	1	NA	Treatment name 2	nusinersen
10.2217/cer-2021-0216	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.2217/cer-2021-0216	methodology	1	NA	paitc_type	MAIC
10.2217/cer-2021-0216	methodology	1	NA	anchored_yn	No
10.2217/cer-2021-0216	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2021-0216	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2021-0216	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2021-0216	methodology	1	NA	prognostic_factors_yn	Yes
10.2217/cer-2021-0216	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.2217/cer-2021-0216	methodology	1	NA	weights_model_yn	Yes
10.2217/cer-2021-0216	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2021-0216	methodology	2	NA	primary_outcome_name	event-free survival
10.2217/cer-2021-0216	methodology	2	NA	outcome_short_name	Event-free Survival
10.2217/cer-2021-0216	methodology	2	NA	primary_outcome_type	Time-to-event
10.2217/cer-2021-0216	methodology	2	NA	Treatment name 1	risdiplam
10.2217/cer-2021-0216	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2021-0216	methodology	2	NA	Treatment name 2	onasemnogene abeparvovec
10.2217/cer-2021-0216	methodology	2	NA	Study 'number(s)' for treatment 2	5
10.2217/cer-2021-0216	methodology	2	NA	paitc_type	STC
10.2217/cer-2021-0216	methodology	2	NA	anchored_yn	No
10.2217/cer-2021-0216	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2021-0216	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2021-0216	methodology	2	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2021-0216	methodology	2	NA	prognostic_factors_yn	Yes
10.2217/cer-2021-0216	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.2217/cer-2021-0216	methodology	2	NA	weights_model_yn	No
10.2217/cer-2021-0216	methodology	2	NA	scale_choice_yn	No
10.2217/cer-2021-0216	methodology	3	NA	primary_outcome_name	the 12-month rulm (revised upper limb module) score change from baseline
10.2217/cer-2021-0216	methodology	3	NA	outcome_short_name	Revised Upper Limb Module
10.2217/cer-2021-0216	methodology	3	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2217/cer-2021-0216	methodology	3	NA	Treatment name 1	risdiplam
10.2217/cer-2021-0216	methodology	3	NA	Study 'number(s)' for treatment 1	2
10.2217/cer-2021-0216	methodology	3	NA	Treatment name 2	nusinersen
10.2217/cer-2021-0216	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.2217/cer-2021-0216	methodology	3	NA	paitc_type	MAIC
10.2217/cer-2021-0216	methodology	3	NA	anchored_yn	Yes
10.2217/cer-2021-0216	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2021-0216	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2021-0216	methodology	3	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2021-0216	methodology	3	NA	prognostic_factors_yn	Yes
10.2217/cer-2021-0216	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.2217/cer-2021-0216	methodology	3	NA	weights_model_yn	Yes
10.2217/cer-2021-0216	methodology	3	NA	scale_choice_yn	No
10.2217/cer-2021-0216	results	1	NA	contrast	HR
10.2217/cer-2021-0216	results	1	NA	direction_benefit	inferior
10.2217/cer-2021-0216	results	1	NA	n_nonipd_ttt	121
10.2217/cer-2021-0216	results	1	NA	n_ipd_ttt	58
10.2217/cer-2021-0216	results	1	NA	ess_ttt	36.5
10.2217/cer-2021-0216	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.2217/cer-2021-0216	results	1	NA	list_covariates_yn	Yes
10.2217/cer-2021-0216	results	1	NA	n_covariates	3
10.2217/cer-2021-0216	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/cer-2021-0216	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2021-0216	results	1	NA	unadjusted_effect	0.24
10.2217/cer-2021-0216	results	1	NA	unadjusted_pval_char	[0.09;0.46]
10.2217/cer-2021-0216	results	1	NA	adjusted_effect	0.2
10.2217/cer-2021-0216	results	1	NA	adjusted_pval_char	[0.06;0.42]
10.2217/cer-2021-0216	results	1	NA	geographical region	NA
10.2217/cer-2021-0216	results	1	NA	n_ipd_total	NA
10.2217/cer-2021-0216	results	1	NA	ess_total	NA
10.2217/cer-2021-0216	results	1	NA	n_nonipd_total	NA
10.2217/cer-2021-0216	results	1	NA	n_nonipd_anchor	NA
10.2217/cer-2021-0216	results	1	NA	n_ipd_anchor	NA
10.2217/cer-2021-0216	results	1	NA	ess_anchor	NA
10.2217/cer-2021-0216	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2021-0216	results	1	NA	effect_cutoff	1
10.2217/cer-2021-0216	results	1	NA	unadjusted_lb_ci	0.09
10.2217/cer-2021-0216	results	1	NA	unadjusted_ub_ci	0.46
10.2217/cer-2021-0216	results	1	NA	unadjusted_significant	TRUE
10.2217/cer-2021-0216	results	1	NA	adjusted_lb_ci	0.06
10.2217/cer-2021-0216	results	1	NA	adjusted_ub_ci	0.42
10.2217/cer-2021-0216	results	1	NA	adjusted_significant	TRUE
10.2217/cer-2021-0216	results	2	NA	contrast	HR
10.2217/cer-2021-0216	results	2	NA	direction_benefit	inferior
10.2217/cer-2021-0216	results	2	NA	n_nonipd_ttt	22
10.2217/cer-2021-0216	results	2	NA	n_ipd_ttt	58
10.2217/cer-2021-0216	results	2	NA	ess_ttt	58
10.2217/cer-2021-0216	results	2	NA	weights_evaluation_yn	NA
10.2217/cer-2021-0216	results	2	NA	list_covariates_yn	Yes
10.2217/cer-2021-0216	results	2	NA	n_covariates	2
10.2217/cer-2021-0216	results	2	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/cer-2021-0216	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2021-0216	results	2	NA	unadjusted_effect	1.532
10.2217/cer-2021-0216	results	2	NA	unadjusted_pval_char	[0.721;2.665]
10.2217/cer-2021-0216	results	2	NA	adjusted_effect	0.936
10.2217/cer-2021-0216	results	2	NA	adjusted_pval_char	[0.033;4.064]
10.2217/cer-2021-0216	results	2	NA	geographical region	NA
10.2217/cer-2021-0216	results	2	NA	n_ipd_total	NA
10.2217/cer-2021-0216	results	2	NA	ess_total	NA
10.2217/cer-2021-0216	results	2	NA	n_nonipd_total	NA
10.2217/cer-2021-0216	results	2	NA	n_nonipd_anchor	NA
10.2217/cer-2021-0216	results	2	NA	n_ipd_anchor	NA
10.2217/cer-2021-0216	results	2	NA	ess_anchor	NA
10.2217/cer-2021-0216	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2021-0216	results	2	NA	effect_cutoff	1
10.2217/cer-2021-0216	results	2	NA	unadjusted_lb_ci	0.721
10.2217/cer-2021-0216	results	2	NA	unadjusted_ub_ci	2.665
10.2217/cer-2021-0216	results	2	NA	unadjusted_significant	FALSE
10.2217/cer-2021-0216	results	2	NA	adjusted_lb_ci	0.033
10.2217/cer-2021-0216	results	2	NA	adjusted_ub_ci	4.064
10.2217/cer-2021-0216	results	2	NA	adjusted_significant	FALSE
10.2217/cer-2021-0216	results	3	NA	contrast	Means difference
10.2217/cer-2021-0216	results	3	NA	direction_benefit	superior
10.2217/cer-2021-0216	results	3	NA	n_nonipd_ttt	126
10.2217/cer-2021-0216	results	3	NA	n_ipd_ttt	43
10.2217/cer-2021-0216	results	3	NA	ess_ttt	28.3
10.2217/cer-2021-0216	results	3	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.2217/cer-2021-0216	results	3	NA	list_covariates_yn	Yes
10.2217/cer-2021-0216	results	3	NA	n_covariates	3
10.2217/cer-2021-0216	results	3	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/cer-2021-0216	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2021-0216	results	3	NA	unadjusted_effect	-0.6
10.2217/cer-2021-0216	results	3	NA	unadjusted_pval_char	[-2.24;1.22]
10.2217/cer-2021-0216	results	3	NA	adjusted_effect	-0.49
10.2217/cer-2021-0216	results	3	NA	adjusted_pval_char	[-3.33;2.53]
10.2217/cer-2021-0216	results	3	NA	geographical region	NA
10.2217/cer-2021-0216	results	3	NA	n_ipd_total	NA
10.2217/cer-2021-0216	results	3	NA	ess_total	NA
10.2217/cer-2021-0216	results	3	NA	n_nonipd_total	NA
10.2217/cer-2021-0216	results	3	NA	n_nonipd_anchor	126
10.2217/cer-2021-0216	results	3	NA	n_ipd_anchor	25
10.2217/cer-2021-0216	results	3	NA	ess_anchor	8.8
10.2217/cer-2021-0216	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2021-0216	results	3	NA	effect_cutoff	0
10.2217/cer-2021-0216	results	3	NA	unadjusted_lb_ci	-2.24
10.2217/cer-2021-0216	results	3	NA	unadjusted_ub_ci	1.22
10.2217/cer-2021-0216	results	3	NA	unadjusted_significant	FALSE
10.2217/cer-2021-0216	results	3	NA	adjusted_lb_ci	-3.33
10.2217/cer-2021-0216	results	3	NA	adjusted_ub_ci	2.53
10.2217/cer-2021-0216	results	3	NA	adjusted_significant	FALSE
10.2217/cer-2021-0216	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2021-0216	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2021-0216	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02913482
10.2217/cer-2021-0216	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0216	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2, 3
10.2217/cer-2021-0216	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/cer-2021-0216	study_information	NA	2	Patient-level data used	Yes
10.2217/cer-2021-0216	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2021-0216	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02908685
10.2217/cer-2021-0216	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0216	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3
10.2217/cer-2021-0216	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2021-0216	study_information	NA	3	Patient-level data used	No
10.2217/cer-2021-0216	study_information	NA	3	Clinical Trial	Yes
10.2217/cer-2021-0216	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02193074
10.2217/cer-2021-0216	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0216	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2021-0216	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2021-0216	study_information	NA	4	Patient-level data used	No
10.2217/cer-2021-0216	study_information	NA	4	Clinical Trial	Yes
10.2217/cer-2021-0216	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02292537
10.2217/cer-2021-0216	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0216	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2021-0216	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2021-0216	study_information	NA	5	Patient-level data used	No
10.2217/cer-2021-0216	study_information	NA	5	Clinical Trial	Yes
10.2217/cer-2021-0216	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03306277
10.2217/cer-2021-0216	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/cer-2021-0216	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2021-0216	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.2217/cer-2021-0221	general_information	NA	NA	Medical Condition of Interest Name	hr+/her2- advanced breast cancer
10.2217/cer-2021-0221	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer-2021-0221	general_information	NA	NA	Countries of last author affiliations	canada
10.2217/cer-2021-0221	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2021-0221	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2021-0221	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2021-0221	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2021-0221	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/cer-2021-0221	methodology	1	NA	primary_outcome_name	global quality of life (european organisation for research and treatment of cancerquality of life questionnaire core 30 items) change from baseline
10.2217/cer-2021-0221	methodology	1	NA	outcome_short_name	Global Quality of Life
10.2217/cer-2021-0221	methodology	1	NA	primary_outcome_type	Continuous (count, mean, ...)
10.2217/cer-2021-0221	methodology	1	NA	Treatment name 1	palbociclib + fulvestrant
10.2217/cer-2021-0221	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2021-0221	methodology	1	NA	Treatment name 2	abemaciclib + fulvestrant
10.2217/cer-2021-0221	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2021-0221	methodology	1	NA	paitc_type	MAIC
10.2217/cer-2021-0221	methodology	1	NA	anchored_yn	Yes
10.2217/cer-2021-0221	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2021-0221	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2021-0221	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2021-0221	methodology	1	NA	prognostic_factors_yn	No
10.2217/cer-2021-0221	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.2217/cer-2021-0221	methodology	1	NA	weights_model_yn	No
10.2217/cer-2021-0221	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2021-0221	results	1	NA	contrast	Means difference
10.2217/cer-2021-0221	results	1	NA	direction_benefit	superior
10.2217/cer-2021-0221	results	1	NA	n_nonipd_ttt	NA
10.2217/cer-2021-0221	results	1	NA	n_ipd_ttt	180
10.2217/cer-2021-0221	results	1	NA	ess_ttt	NA
10.2217/cer-2021-0221	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.2217/cer-2021-0221	results	1	NA	list_covariates_yn	Yes
10.2217/cer-2021-0221	results	1	NA	n_covariates	11
10.2217/cer-2021-0221	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.2217/cer-2021-0221	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2021-0221	results	1	NA	unadjusted_effect	4.6
10.2217/cer-2021-0221	results	1	NA	unadjusted_pval_char	0.016
10.2217/cer-2021-0221	results	1	NA	adjusted_effect	6.95
10.2217/cer-2021-0221	results	1	NA	adjusted_pval_char	0.004
10.2217/cer-2021-0221	results	1	NA	geographical region	Yes
10.2217/cer-2021-0221	results	1	NA	n_ipd_total	270
10.2217/cer-2021-0221	results	1	NA	ess_total	NA
10.2217/cer-2021-0221	results	1	NA	n_nonipd_total	669
10.2217/cer-2021-0221	results	1	NA	n_nonipd_anchor	NA
10.2217/cer-2021-0221	results	1	NA	n_ipd_anchor	90
10.2217/cer-2021-0221	results	1	NA	ess_anchor	NA
10.2217/cer-2021-0221	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer-2021-0221	results	1	NA	effect_cutoff	0
10.2217/cer-2021-0221	results	1	NA	unadjusted_pval	0.016
10.2217/cer-2021-0221	results	1	NA	unadjusted_num_pval	0.016
10.2217/cer-2021-0221	results	1	NA	unadjusted_significant	TRUE
10.2217/cer-2021-0221	results	1	NA	adjusted_pval	0.004
10.2217/cer-2021-0221	results	1	NA	adjusted_num_pval	0.004
10.2217/cer-2021-0221	results	1	NA	adjusted_significant	TRUE
10.2217/cer-2021-0221	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2021-0221	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2021-0221	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01942135
10.2217/cer-2021-0221	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0221	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2021-0221	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2021-0221	study_information	NA	2	Patient-level data used	No
10.2217/cer-2021-0221	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2021-0221	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02107703
10.2217/cer-2021-0221	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0221	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2021-0221	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	general_information	NA	NA	Medical Condition of Interest Name	chronic genotype 1b hepatitis c
10.2217/cer.15.33	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer.15.33	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer.15.33	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer.15.33	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer.15.33	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer.15.33	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer.15.33	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer.15.33	methodology	1	NA	primary_outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	1	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer.15.33	methodology	1	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	1	NA	Study 'number(s)' for treatment 1	2;3
10.2217/cer.15.33	methodology	1	NA	Treatment name 2	telaprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	1	NA	Study 'number(s)' for treatment 2	4;5;6
10.2217/cer.15.33	methodology	1	NA	paitc_type	MAIC
10.2217/cer.15.33	methodology	1	NA	anchored_yn	No
10.2217/cer.15.33	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	1	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	1	NA	weights_model_yn	No
10.2217/cer.15.33	methodology	1	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	2	NA	primary_outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	2	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer.15.33	methodology	2	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	2	NA	Study 'number(s)' for treatment 1	2;3
10.2217/cer.15.33	methodology	2	NA	Treatment name 2	boceprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	2	NA	Study 'number(s)' for treatment 2	8
10.2217/cer.15.33	methodology	2	NA	paitc_type	MAIC
10.2217/cer.15.33	methodology	2	NA	anchored_yn	No
10.2217/cer.15.33	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	2	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	2	NA	weights_model_yn	No
10.2217/cer.15.33	methodology	2	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	3	NA	primary_outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	3	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	3	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer.15.33	methodology	3	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	3	NA	Study 'number(s)' for treatment 1	2;3
10.2217/cer.15.33	methodology	3	NA	Treatment name 2	simeprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	3	NA	Study 'number(s)' for treatment 2	10;11
10.2217/cer.15.33	methodology	3	NA	paitc_type	MAIC
10.2217/cer.15.33	methodology	3	NA	anchored_yn	No
10.2217/cer.15.33	methodology	3	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	3	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	3	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	3	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	3	NA	weights_model_yn	No
10.2217/cer.15.33	methodology	3	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	4	NA	primary_outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	4	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	4	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer.15.33	methodology	4	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	4	NA	Study 'number(s)' for treatment 1	2;3
10.2217/cer.15.33	methodology	4	NA	Treatment name 2	sofosbuvir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	4	NA	Study 'number(s)' for treatment 2	13
10.2217/cer.15.33	methodology	4	NA	paitc_type	MAIC
10.2217/cer.15.33	methodology	4	NA	anchored_yn	No
10.2217/cer.15.33	methodology	4	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	4	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	4	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	4	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	4	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	4	NA	weights_model_yn	No
10.2217/cer.15.33	methodology	4	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	5	NA	primary_outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	5	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	5	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer.15.33	methodology	5	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	5	NA	Study 'number(s)' for treatment 1	2;3
10.2217/cer.15.33	methodology	5	NA	Treatment name 2	peginterferon- + ribavirin
10.2217/cer.15.33	methodology	5	NA	Study 'number(s)' for treatment 2	4;8;10;11
10.2217/cer.15.33	methodology	5	NA	paitc_type	MAIC
10.2217/cer.15.33	methodology	5	NA	anchored_yn	No
10.2217/cer.15.33	methodology	5	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	5	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	5	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	5	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	5	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	5	NA	weights_model_yn	No
10.2217/cer.15.33	methodology	5	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	6	NA	primary_outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	6	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	6	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer.15.33	methodology	6	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	6	NA	Study 'number(s)' for treatment 1	1;2;3
10.2217/cer.15.33	methodology	6	NA	Treatment name 2	telaprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	6	NA	Study 'number(s)' for treatment 2	7
10.2217/cer.15.33	methodology	6	NA	paitc_type	MAIC
10.2217/cer.15.33	methodology	6	NA	anchored_yn	No
10.2217/cer.15.33	methodology	6	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	6	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	6	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	6	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	6	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	6	NA	weights_model_yn	No
10.2217/cer.15.33	methodology	6	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	7	NA	primary_outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	7	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	7	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer.15.33	methodology	7	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	7	NA	Study 'number(s)' for treatment 1	1;2;3
10.2217/cer.15.33	methodology	7	NA	Treatment name 2	boceprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	7	NA	Study 'number(s)' for treatment 2	9
10.2217/cer.15.33	methodology	7	NA	paitc_type	MAIC
10.2217/cer.15.33	methodology	7	NA	anchored_yn	No
10.2217/cer.15.33	methodology	7	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	7	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	7	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	7	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	7	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	7	NA	weights_model_yn	No
10.2217/cer.15.33	methodology	7	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	8	NA	primary_outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	8	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	8	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer.15.33	methodology	8	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	8	NA	Study 'number(s)' for treatment 1	1;2;3
10.2217/cer.15.33	methodology	8	NA	Treatment name 2	simeprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	8	NA	Study 'number(s)' for treatment 2	12
10.2217/cer.15.33	methodology	8	NA	paitc_type	MAIC
10.2217/cer.15.33	methodology	8	NA	anchored_yn	No
10.2217/cer.15.33	methodology	8	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	8	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	8	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	8	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	8	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	8	NA	weights_model_yn	No
10.2217/cer.15.33	methodology	8	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	9	NA	primary_outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	9	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	9	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer.15.33	methodology	9	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	9	NA	Study 'number(s)' for treatment 1	1;2;3
10.2217/cer.15.33	methodology	9	NA	Treatment name 2	peginterferon- + ribavirin
10.2217/cer.15.33	methodology	9	NA	Study 'number(s)' for treatment 2	9;12
10.2217/cer.15.33	methodology	9	NA	paitc_type	MAIC
10.2217/cer.15.33	methodology	9	NA	anchored_yn	No
10.2217/cer.15.33	methodology	9	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	9	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	9	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	9	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	9	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	9	NA	weights_model_yn	No
10.2217/cer.15.33	methodology	9	NA	scale_choice_yn	No
10.2217/cer.15.33	results	1	NA	contrast	Rate difference
10.2217/cer.15.33	results	1	NA	direction_benefit	superior
10.2217/cer.15.33	results	1	NA	n_nonipd_ttt	1643
10.2217/cer.15.33	results	1	NA	n_ipd_ttt	324
10.2217/cer.15.33	results	1	NA	ess_ttt	NA
10.2217/cer.15.33	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/cer.15.33	results	1	NA	list_covariates_yn	No
10.2217/cer.15.33	results	1	NA	n_covariates	NA
10.2217/cer.15.33	results	1	NA	list_covariates	NA
10.2217/cer.15.33	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	1	NA	unadjusted_effect	NA
10.2217/cer.15.33	results	1	NA	unadjusted_pval_char	NA
10.2217/cer.15.33	results	1	NA	adjusted_effect	8.7
10.2217/cer.15.33	results	1	NA	adjusted_pval_char	[0.2;17.3]
10.2217/cer.15.33	results	1	NA	geographical region	NA
10.2217/cer.15.33	results	1	NA	n_ipd_total	NA
10.2217/cer.15.33	results	1	NA	ess_total	NA
10.2217/cer.15.33	results	1	NA	n_nonipd_total	NA
10.2217/cer.15.33	results	1	NA	n_nonipd_anchor	NA
10.2217/cer.15.33	results	1	NA	n_ipd_anchor	NA
10.2217/cer.15.33	results	1	NA	ess_anchor	NA
10.2217/cer.15.33	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer.15.33	results	1	NA	effect_cutoff	0
10.2217/cer.15.33	results	1	NA	adjusted_lb_ci	0.2
10.2217/cer.15.33	results	1	NA	adjusted_ub_ci	17.3
10.2217/cer.15.33	results	1	NA	adjusted_significant	TRUE
10.2217/cer.15.33	results	2	NA	contrast	Rate difference
10.2217/cer.15.33	results	2	NA	direction_benefit	superior
10.2217/cer.15.33	results	2	NA	n_nonipd_ttt	368
10.2217/cer.15.33	results	2	NA	n_ipd_ttt	324
10.2217/cer.15.33	results	2	NA	ess_ttt	NA
10.2217/cer.15.33	results	2	NA	weights_evaluation_yn	Not mentioned
10.2217/cer.15.33	results	2	NA	list_covariates_yn	No
10.2217/cer.15.33	results	2	NA	n_covariates	NA
10.2217/cer.15.33	results	2	NA	list_covariates	NA
10.2217/cer.15.33	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	2	NA	unadjusted_effect	NA
10.2217/cer.15.33	results	2	NA	unadjusted_pval_char	NA
10.2217/cer.15.33	results	2	NA	adjusted_effect	16.5
10.2217/cer.15.33	results	2	NA	adjusted_pval_char	[2.5;30.5]
10.2217/cer.15.33	results	2	NA	geographical region	NA
10.2217/cer.15.33	results	2	NA	n_ipd_total	NA
10.2217/cer.15.33	results	2	NA	ess_total	NA
10.2217/cer.15.33	results	2	NA	n_nonipd_total	NA
10.2217/cer.15.33	results	2	NA	n_nonipd_anchor	NA
10.2217/cer.15.33	results	2	NA	n_ipd_anchor	NA
10.2217/cer.15.33	results	2	NA	ess_anchor	NA
10.2217/cer.15.33	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer.15.33	results	2	NA	effect_cutoff	0
10.2217/cer.15.33	results	2	NA	adjusted_lb_ci	2.5
10.2217/cer.15.33	results	2	NA	adjusted_ub_ci	30.5
10.2217/cer.15.33	results	2	NA	adjusted_significant	TRUE
10.2217/cer.15.33	results	3	NA	contrast	Rate difference
10.2217/cer.15.33	results	3	NA	direction_benefit	superior
10.2217/cer.15.33	results	3	NA	n_nonipd_ttt	521
10.2217/cer.15.33	results	3	NA	n_ipd_ttt	324
10.2217/cer.15.33	results	3	NA	ess_ttt	NA
10.2217/cer.15.33	results	3	NA	weights_evaluation_yn	Not mentioned
10.2217/cer.15.33	results	3	NA	list_covariates_yn	No
10.2217/cer.15.33	results	3	NA	n_covariates	NA
10.2217/cer.15.33	results	3	NA	list_covariates	NA
10.2217/cer.15.33	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	3	NA	unadjusted_effect	NA
10.2217/cer.15.33	results	3	NA	unadjusted_pval_char	NA
10.2217/cer.15.33	results	3	NA	adjusted_effect	0.4
10.2217/cer.15.33	results	3	NA	adjusted_pval_char	[-8.9;9.7]
10.2217/cer.15.33	results	3	NA	geographical region	NA
10.2217/cer.15.33	results	3	NA	n_ipd_total	NA
10.2217/cer.15.33	results	3	NA	ess_total	NA
10.2217/cer.15.33	results	3	NA	n_nonipd_total	NA
10.2217/cer.15.33	results	3	NA	n_nonipd_anchor	NA
10.2217/cer.15.33	results	3	NA	n_ipd_anchor	NA
10.2217/cer.15.33	results	3	NA	ess_anchor	NA
10.2217/cer.15.33	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer.15.33	results	3	NA	effect_cutoff	0
10.2217/cer.15.33	results	3	NA	adjusted_lb_ci	-8.9
10.2217/cer.15.33	results	3	NA	adjusted_ub_ci	9.7
10.2217/cer.15.33	results	3	NA	adjusted_significant	FALSE
10.2217/cer.15.33	results	4	NA	contrast	Rate difference
10.2217/cer.15.33	results	4	NA	direction_benefit	superior
10.2217/cer.15.33	results	4	NA	n_nonipd_ttt	327
10.2217/cer.15.33	results	4	NA	n_ipd_ttt	324
10.2217/cer.15.33	results	4	NA	ess_ttt	NA
10.2217/cer.15.33	results	4	NA	weights_evaluation_yn	Not mentioned
10.2217/cer.15.33	results	4	NA	list_covariates_yn	No
10.2217/cer.15.33	results	4	NA	n_covariates	NA
10.2217/cer.15.33	results	4	NA	list_covariates	NA
10.2217/cer.15.33	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	4	NA	unadjusted_effect	NA
10.2217/cer.15.33	results	4	NA	unadjusted_pval_char	NA
10.2217/cer.15.33	results	4	NA	adjusted_effect	3
10.2217/cer.15.33	results	4	NA	adjusted_pval_char	[-21.2;27.1]
10.2217/cer.15.33	results	4	NA	geographical region	NA
10.2217/cer.15.33	results	4	NA	n_ipd_total	NA
10.2217/cer.15.33	results	4	NA	ess_total	NA
10.2217/cer.15.33	results	4	NA	n_nonipd_total	NA
10.2217/cer.15.33	results	4	NA	n_nonipd_anchor	NA
10.2217/cer.15.33	results	4	NA	n_ipd_anchor	NA
10.2217/cer.15.33	results	4	NA	ess_anchor	NA
10.2217/cer.15.33	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer.15.33	results	4	NA	effect_cutoff	0
10.2217/cer.15.33	results	4	NA	adjusted_lb_ci	-21.2
10.2217/cer.15.33	results	4	NA	adjusted_ub_ci	27.1
10.2217/cer.15.33	results	4	NA	adjusted_significant	FALSE
10.2217/cer.15.33	results	5	NA	contrast	Rate difference
10.2217/cer.15.33	results	5	NA	direction_benefit	superior
10.2217/cer.15.33	results	5	NA	n_nonipd_ttt	988
10.2217/cer.15.33	results	5	NA	n_ipd_ttt	324
10.2217/cer.15.33	results	5	NA	ess_ttt	NA
10.2217/cer.15.33	results	5	NA	weights_evaluation_yn	Not mentioned
10.2217/cer.15.33	results	5	NA	list_covariates_yn	No
10.2217/cer.15.33	results	5	NA	n_covariates	NA
10.2217/cer.15.33	results	5	NA	list_covariates	NA
10.2217/cer.15.33	results	5	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	5	NA	unadjusted_effect	NA
10.2217/cer.15.33	results	5	NA	unadjusted_pval_char	NA
10.2217/cer.15.33	results	5	NA	adjusted_effect	39.6
10.2217/cer.15.33	results	5	NA	adjusted_pval_char	[30.3;48.9]
10.2217/cer.15.33	results	5	NA	geographical region	NA
10.2217/cer.15.33	results	5	NA	n_ipd_total	NA
10.2217/cer.15.33	results	5	NA	ess_total	NA
10.2217/cer.15.33	results	5	NA	n_nonipd_total	NA
10.2217/cer.15.33	results	5	NA	n_nonipd_anchor	NA
10.2217/cer.15.33	results	5	NA	n_ipd_anchor	NA
10.2217/cer.15.33	results	5	NA	ess_anchor	NA
10.2217/cer.15.33	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer.15.33	results	5	NA	effect_cutoff	0
10.2217/cer.15.33	results	5	NA	adjusted_lb_ci	30.3
10.2217/cer.15.33	results	5	NA	adjusted_ub_ci	48.9
10.2217/cer.15.33	results	5	NA	adjusted_significant	TRUE
10.2217/cer.15.33	results	6	NA	contrast	Rate difference
10.2217/cer.15.33	results	6	NA	direction_benefit	superior
10.2217/cer.15.33	results	6	NA	n_nonipd_ttt	266
10.2217/cer.15.33	results	6	NA	n_ipd_ttt	314
10.2217/cer.15.33	results	6	NA	ess_ttt	NA
10.2217/cer.15.33	results	6	NA	weights_evaluation_yn	Not mentioned
10.2217/cer.15.33	results	6	NA	list_covariates_yn	No
10.2217/cer.15.33	results	6	NA	n_covariates	NA
10.2217/cer.15.33	results	6	NA	list_covariates	NA
10.2217/cer.15.33	results	6	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	6	NA	unadjusted_effect	NA
10.2217/cer.15.33	results	6	NA	unadjusted_pval_char	NA
10.2217/cer.15.33	results	6	NA	adjusted_effect	17
10.2217/cer.15.33	results	6	NA	adjusted_pval_char	[5.3;28.7]
10.2217/cer.15.33	results	6	NA	geographical region	NA
10.2217/cer.15.33	results	6	NA	n_ipd_total	NA
10.2217/cer.15.33	results	6	NA	ess_total	NA
10.2217/cer.15.33	results	6	NA	n_nonipd_total	NA
10.2217/cer.15.33	results	6	NA	n_nonipd_anchor	NA
10.2217/cer.15.33	results	6	NA	n_ipd_anchor	NA
10.2217/cer.15.33	results	6	NA	ess_anchor	NA
10.2217/cer.15.33	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer.15.33	results	6	NA	effect_cutoff	0
10.2217/cer.15.33	results	6	NA	adjusted_lb_ci	5.3
10.2217/cer.15.33	results	6	NA	adjusted_ub_ci	28.7
10.2217/cer.15.33	results	6	NA	adjusted_significant	TRUE
10.2217/cer.15.33	results	7	NA	contrast	Rate difference
10.2217/cer.15.33	results	7	NA	direction_benefit	superior
10.2217/cer.15.33	results	7	NA	n_nonipd_ttt	162
10.2217/cer.15.33	results	7	NA	n_ipd_ttt	314
10.2217/cer.15.33	results	7	NA	ess_ttt	NA
10.2217/cer.15.33	results	7	NA	weights_evaluation_yn	Not mentioned
10.2217/cer.15.33	results	7	NA	list_covariates_yn	No
10.2217/cer.15.33	results	7	NA	n_covariates	NA
10.2217/cer.15.33	results	7	NA	list_covariates	NA
10.2217/cer.15.33	results	7	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	7	NA	unadjusted_effect	NA
10.2217/cer.15.33	results	7	NA	unadjusted_pval_char	NA
10.2217/cer.15.33	results	7	NA	adjusted_effect	22.8
10.2217/cer.15.33	results	7	NA	adjusted_pval_char	[6.9;38.7]
10.2217/cer.15.33	results	7	NA	geographical region	NA
10.2217/cer.15.33	results	7	NA	n_ipd_total	NA
10.2217/cer.15.33	results	7	NA	ess_total	NA
10.2217/cer.15.33	results	7	NA	n_nonipd_total	NA
10.2217/cer.15.33	results	7	NA	n_nonipd_anchor	NA
10.2217/cer.15.33	results	7	NA	n_ipd_anchor	NA
10.2217/cer.15.33	results	7	NA	ess_anchor	NA
10.2217/cer.15.33	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer.15.33	results	7	NA	effect_cutoff	0
10.2217/cer.15.33	results	7	NA	adjusted_lb_ci	6.9
10.2217/cer.15.33	results	7	NA	adjusted_ub_ci	38.7
10.2217/cer.15.33	results	7	NA	adjusted_significant	TRUE
10.2217/cer.15.33	results	8	NA	contrast	Rate difference
10.2217/cer.15.33	results	8	NA	direction_benefit	superior
10.2217/cer.15.33	results	8	NA	n_nonipd_ttt	260
10.2217/cer.15.33	results	8	NA	n_ipd_ttt	314
10.2217/cer.15.33	results	8	NA	ess_ttt	NA
10.2217/cer.15.33	results	8	NA	weights_evaluation_yn	Not mentioned
10.2217/cer.15.33	results	8	NA	list_covariates_yn	No
10.2217/cer.15.33	results	8	NA	n_covariates	NA
10.2217/cer.15.33	results	8	NA	list_covariates	NA
10.2217/cer.15.33	results	8	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	8	NA	unadjusted_effect	NA
10.2217/cer.15.33	results	8	NA	unadjusted_pval_char	NA
10.2217/cer.15.33	results	8	NA	adjusted_effect	10.3
10.2217/cer.15.33	results	8	NA	adjusted_pval_char	[1.1;19.5]
10.2217/cer.15.33	results	8	NA	geographical region	NA
10.2217/cer.15.33	results	8	NA	n_ipd_total	NA
10.2217/cer.15.33	results	8	NA	ess_total	NA
10.2217/cer.15.33	results	8	NA	n_nonipd_total	NA
10.2217/cer.15.33	results	8	NA	n_nonipd_anchor	NA
10.2217/cer.15.33	results	8	NA	n_ipd_anchor	NA
10.2217/cer.15.33	results	8	NA	ess_anchor	NA
10.2217/cer.15.33	results	8	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer.15.33	results	8	NA	effect_cutoff	0
10.2217/cer.15.33	results	8	NA	adjusted_lb_ci	1.1
10.2217/cer.15.33	results	8	NA	adjusted_ub_ci	19.5
10.2217/cer.15.33	results	8	NA	adjusted_significant	TRUE
10.2217/cer.15.33	results	9	NA	contrast	Rate difference
10.2217/cer.15.33	results	9	NA	direction_benefit	superior
10.2217/cer.15.33	results	9	NA	n_nonipd_ttt	213
10.2217/cer.15.33	results	9	NA	n_ipd_ttt	314
10.2217/cer.15.33	results	9	NA	ess_ttt	NA
10.2217/cer.15.33	results	9	NA	weights_evaluation_yn	Not mentioned
10.2217/cer.15.33	results	9	NA	list_covariates_yn	No
10.2217/cer.15.33	results	9	NA	n_covariates	NA
10.2217/cer.15.33	results	9	NA	list_covariates	NA
10.2217/cer.15.33	results	9	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	9	NA	unadjusted_effect	NA
10.2217/cer.15.33	results	9	NA	unadjusted_pval_char	NA
10.2217/cer.15.33	results	9	NA	adjusted_effect	57.7
10.2217/cer.15.33	results	9	NA	adjusted_pval_char	[44.0;71.4]
10.2217/cer.15.33	results	9	NA	geographical region	NA
10.2217/cer.15.33	results	9	NA	n_ipd_total	NA
10.2217/cer.15.33	results	9	NA	ess_total	NA
10.2217/cer.15.33	results	9	NA	n_nonipd_total	NA
10.2217/cer.15.33	results	9	NA	n_nonipd_anchor	NA
10.2217/cer.15.33	results	9	NA	n_ipd_anchor	NA
10.2217/cer.15.33	results	9	NA	ess_anchor	NA
10.2217/cer.15.33	results	9	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer.15.33	results	9	NA	effect_cutoff	0
10.2217/cer.15.33	results	9	NA	adjusted_lb_ci	44
10.2217/cer.15.33	results	9	NA	adjusted_ub_ci	71.4
10.2217/cer.15.33	results	9	NA	adjusted_significant	TRUE
10.2217/cer.15.33	study_information	NA	1	Patient-level data used	Yes
10.2217/cer.15.33	study_information	NA	1	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01497834
10.2217/cer.15.33	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2217/cer.15.33	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/cer.15.33	study_information	NA	10	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	10	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	10	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01289782
10.2217/cer.15.33	study_information	NA	10	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	10	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	10	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	11	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	11	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	11	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01290679
10.2217/cer.15.33	study_information	NA	11	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	11	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	11	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	12	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	12	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	12	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01281839
10.2217/cer.15.33	study_information	NA	12	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	12	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	12	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	13	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	13	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	13	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01641640
10.2217/cer.15.33	study_information	NA	13	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/cer.15.33	study_information	NA	13	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	13	Number of treatment arms (clinical trial only)	1
10.2217/cer.15.33	study_information	NA	2	Patient-level data used	Yes
10.2217/cer.15.33	study_information	NA	2	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01581203
10.2217/cer.15.33	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	3	Patient-level data used	Yes
10.2217/cer.15.33	study_information	NA	3	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01718145
10.2217/cer.15.33	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2217/cer.15.33	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	4	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	4	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00627926
10.2217/cer.15.33	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	5	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	5	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01241760
10.2217/cer.15.33	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	6	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	6	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00758043
10.2217/cer.15.33	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	7	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	7	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00703118
10.2217/cer.15.33	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	7	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	8	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	8	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00705432
10.2217/cer.15.33	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.2217/cer.15.33	study_information	NA	9	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	9	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00708500
10.2217/cer.15.33	study_information	NA	9	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	9	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.2217/cer.15.49	general_information	NA	NA	Medical Condition of Interest Name	hepatitis c genotype 3
10.2217/cer.15.49	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer.15.49	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer.15.49	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer.15.49	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer.15.49	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer.15.49	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer.15.49	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer.15.49	methodology	1	NA	primary_outcome_name	sustained virologic response at week 12 post-treatment (svr12)
10.2217/cer.15.49	methodology	1	NA	outcome_short_name	SVR rate
10.2217/cer.15.49	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer.15.49	methodology	1	NA	Treatment name 1	daclatasvir + sofosbuvir
10.2217/cer.15.49	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer.15.49	methodology	1	NA	Treatment name 2	sofosbuvir + ribavirin
10.2217/cer.15.49	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer.15.49	methodology	1	NA	paitc_type	MAIC
10.2217/cer.15.49	methodology	1	NA	anchored_yn	No
10.2217/cer.15.49	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer.15.49	methodology	1	NA	primary_outcome_yn	Yes
10.2217/cer.15.49	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer.15.49	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.49	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.49	methodology	1	NA	weights_model_yn	No
10.2217/cer.15.49	methodology	1	NA	scale_choice_yn	No
10.2217/cer.15.49	methodology	2	NA	primary_outcome_name	rate of svr12 in patients treated with dcv + sof (study 1). the rate of svr24 in patients treated with a/r (studies 3 and 4)
10.2217/cer.15.49	methodology	2	NA	outcome_short_name	SVR rate
10.2217/cer.15.49	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer.15.49	methodology	2	NA	Treatment name 1	daclatasvir + sofosbuvir
10.2217/cer.15.49	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2217/cer.15.49	methodology	2	NA	Treatment name 2	peginterferon-alfa + ribavirin
10.2217/cer.15.49	methodology	2	NA	Study 'number(s)' for treatment 2	3;4
10.2217/cer.15.49	methodology	2	NA	paitc_type	MAIC
10.2217/cer.15.49	methodology	2	NA	anchored_yn	No
10.2217/cer.15.49	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.49	methodology	2	NA	primary_outcome_yn	Yes
10.2217/cer.15.49	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer.15.49	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.49	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.49	methodology	2	NA	weights_model_yn	No
10.2217/cer.15.49	methodology	2	NA	scale_choice_yn	No
10.2217/cer.15.49	results	1	NA	contrast	Rate difference
10.2217/cer.15.49	results	1	NA	direction_benefit	superior
10.2217/cer.15.49	results	1	NA	n_nonipd_ttt	250
10.2217/cer.15.49	results	1	NA	n_ipd_ttt	144
10.2217/cer.15.49	results	1	NA	ess_ttt	NA
10.2217/cer.15.49	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/cer.15.49	results	1	NA	list_covariates_yn	Yes
10.2217/cer.15.49	results	1	NA	n_covariates	11
10.2217/cer.15.49	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2217/cer.15.49	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.49	results	1	NA	unadjusted_effect	4.40
10.2217/cer.15.49	results	1	NA	unadjusted_pval_char	0.216
10.2217/cer.15.49	results	1	NA	adjusted_effect	3.60
10.2217/cer.15.49	results	1	NA	adjusted_pval_char	0.537
10.2217/cer.15.49	results	1	NA	geographical region	No
10.2217/cer.15.49	results	1	NA	n_ipd_total	NA
10.2217/cer.15.49	results	1	NA	ess_total	NA
10.2217/cer.15.49	results	1	NA	n_nonipd_total	NA
10.2217/cer.15.49	results	1	NA	n_nonipd_anchor	NA
10.2217/cer.15.49	results	1	NA	n_ipd_anchor	NA
10.2217/cer.15.49	results	1	NA	ess_anchor	NA
10.2217/cer.15.49	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer.15.49	results	1	NA	effect_cutoff	0
10.2217/cer.15.49	results	1	NA	unadjusted_pval	0.216
10.2217/cer.15.49	results	1	NA	unadjusted_num_pval	0.216
10.2217/cer.15.49	results	1	NA	unadjusted_significant	FALSE
10.2217/cer.15.49	results	1	NA	adjusted_pval	0.537
10.2217/cer.15.49	results	1	NA	adjusted_num_pval	0.537
10.2217/cer.15.49	results	1	NA	adjusted_significant	FALSE
10.2217/cer.15.49	results	2	NA	contrast	Rate difference
10.2217/cer.15.49	results	2	NA	direction_benefit	superior
10.2217/cer.15.49	results	2	NA	n_nonipd_ttt	492
10.2217/cer.15.49	results	2	NA	n_ipd_ttt	74
10.2217/cer.15.49	results	2	NA	ess_ttt	NA
10.2217/cer.15.49	results	2	NA	weights_evaluation_yn	Not mentioned
10.2217/cer.15.49	results	2	NA	list_covariates_yn	Yes
10.2217/cer.15.49	results	2	NA	n_covariates	4
10.2217/cer.15.49	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2217/cer.15.49	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.49	results	2	NA	unadjusted_effect	21.30
10.2217/cer.15.49	results	2	NA	unadjusted_pval_char	<0.001
10.2217/cer.15.49	results	2	NA	adjusted_effect	18.90
10.2217/cer.15.49	results	2	NA	adjusted_pval_char	<0.001
10.2217/cer.15.49	results	2	NA	geographical region	No
10.2217/cer.15.49	results	2	NA	n_ipd_total	NA
10.2217/cer.15.49	results	2	NA	ess_total	NA
10.2217/cer.15.49	results	2	NA	n_nonipd_total	NA
10.2217/cer.15.49	results	2	NA	n_nonipd_anchor	NA
10.2217/cer.15.49	results	2	NA	n_ipd_anchor	NA
10.2217/cer.15.49	results	2	NA	ess_anchor	NA
10.2217/cer.15.49	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer.15.49	results	2	NA	effect_cutoff	0
10.2217/cer.15.49	results	2	NA	unadjusted_pval	<0.001
10.2217/cer.15.49	results	2	NA	unadjusted_significant	TRUE
10.2217/cer.15.49	results	2	NA	adjusted_pval	<0.001
10.2217/cer.15.49	results	2	NA	adjusted_significant	TRUE
10.2217/cer.15.49	study_information	NA	1	Patient-level data used	Yes
10.2217/cer.15.49	study_information	NA	1	Clinical Trial	Yes
10.2217/cer.15.49	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02032901
10.2217/cer.15.49	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.49	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.49	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/cer.15.49	study_information	NA	2	Patient-level data used	No
10.2217/cer.15.49	study_information	NA	2	Clinical Trial	Yes
10.2217/cer.15.49	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01682720
10.2217/cer.15.49	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.49	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.49	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.49	study_information	NA	3	Patient-level data used	No
10.2217/cer.15.49	study_information	NA	3	Clinical Trial	Yes
10.2217/cer.15.49	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	ferenci et al. (2008)
10.2217/cer.15.49	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.2217/cer.15.49	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.49	study_information	NA	4	Patient-level data used	No
10.2217/cer.15.49	study_information	NA	4	Clinical Trial	Yes
10.2217/cer.15.49	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00077636
10.2217/cer.15.49	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.49	study_information	NA	4	Phase of the clinical trial (clinical trial only)	4
10.2217/cer.15.49	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2217/cer.15.69	general_information	NA	NA	Medical Condition of Interest Name	hepatitis c virus genotype 1b
10.2217/cer.15.69	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer.15.69	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer.15.69	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer.15.69	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer.15.69	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer.15.69	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer.15.69	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer.15.69	methodology	1	NA	primary_outcome_name	sustained virologic response at week 12 post-treatment
10.2217/cer.15.69	methodology	1	NA	outcome_short_name	SVR rate
10.2217/cer.15.69	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.2217/cer.15.69	methodology	1	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.69	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer.15.69	methodology	1	NA	Treatment name 2	sofosbuvir + ledipasvir
10.2217/cer.15.69	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.2217/cer.15.69	methodology	1	NA	paitc_type	MAIC
10.2217/cer.15.69	methodology	1	NA	anchored_yn	No
10.2217/cer.15.69	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer.15.69	methodology	1	NA	primary_outcome_yn	Yes
10.2217/cer.15.69	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.2217/cer.15.69	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.69	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.69	methodology	1	NA	weights_model_yn	No
10.2217/cer.15.69	methodology	1	NA	scale_choice_yn	No
10.2217/cer.15.69	results	1	NA	contrast	Rate difference
10.2217/cer.15.69	results	1	NA	direction_benefit	superior
10.2217/cer.15.69	results	1	NA	n_nonipd_ttt	171
10.2217/cer.15.69	results	1	NA	n_ipd_ttt	252
10.2217/cer.15.69	results	1	NA	ess_ttt	NA
10.2217/cer.15.69	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/cer.15.69	results	1	NA	list_covariates_yn	Yes
10.2217/cer.15.69	results	1	NA	n_covariates	11
10.2217/cer.15.69	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.2217/cer.15.69	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.69	results	1	NA	unadjusted_effect	NA
10.2217/cer.15.69	results	1	NA	unadjusted_pval_char	0.004
10.2217/cer.15.69	results	1	NA	adjusted_effect	NA
10.2217/cer.15.69	results	1	NA	adjusted_pval_char	0.398
10.2217/cer.15.69	results	1	NA	geographical region	No
10.2217/cer.15.69	results	1	NA	n_ipd_total	NA
10.2217/cer.15.69	results	1	NA	ess_total	NA
10.2217/cer.15.69	results	1	NA	n_nonipd_total	NA
10.2217/cer.15.69	results	1	NA	n_nonipd_anchor	NA
10.2217/cer.15.69	results	1	NA	n_ipd_anchor	NA
10.2217/cer.15.69	results	1	NA	ess_anchor	NA
10.2217/cer.15.69	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/cer.15.69	results	1	NA	effect_cutoff	0
10.2217/cer.15.69	results	1	NA	unadjusted_pval	0.004
10.2217/cer.15.69	results	1	NA	unadjusted_num_pval	0.004
10.2217/cer.15.69	results	1	NA	unadjusted_significant	TRUE
10.2217/cer.15.69	results	1	NA	adjusted_pval	0.398
10.2217/cer.15.69	results	1	NA	adjusted_num_pval	0.398
10.2217/cer.15.69	results	1	NA	adjusted_significant	FALSE
10.2217/cer.15.69	study_information	NA	1	Patient-level data used	Yes
10.2217/cer.15.69	study_information	NA	1	Clinical Trial	Yes
10.2217/cer.15.69	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01497834
10.2217/cer.15.69	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2217/cer.15.69	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.69	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/cer.15.69	study_information	NA	2	Patient-level data used	Yes
10.2217/cer.15.69	study_information	NA	2	Clinical Trial	Yes
10.2217/cer.15.69	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01718145
10.2217/cer.15.69	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2217/cer.15.69	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.69	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.69	study_information	NA	3	Patient-level data used	No
10.2217/cer.15.69	study_information	NA	3	Clinical Trial	Yes
10.2217/cer.15.69	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01975675
10.2217/cer.15.69	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2217/cer.15.69	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.69	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/fon-2020-0823	general_information	NA	NA	Medical Condition of Interest Name	advanced cutaneous squamous cell carcinoma
10.2217/fon-2020-0823	general_information	NA	NA	Countries of first author affiliations	canada
10.2217/fon-2020-0823	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/fon-2020-0823	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/fon-2020-0823	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/fon-2020-0823	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/fon-2020-0823	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/fon-2020-0823	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/fon-2020-0823	methodology	1	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	1	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	1	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	1	NA	Treatment name 2	erlotinib
10.2217/fon-2020-0823	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/fon-2020-0823	methodology	1	NA	paitc_type	MAIC
10.2217/fon-2020-0823	methodology	1	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	1	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	1	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	1	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	1	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	10	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	10	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	10	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	10	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	10	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	10	NA	Treatment name 2	gefitinib
10.2217/fon-2020-0823	methodology	10	NA	Study 'number(s)' for treatment 2	6
10.2217/fon-2020-0823	methodology	10	NA	paitc_type	STC
10.2217/fon-2020-0823	methodology	10	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	10	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	10	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	10	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	10	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	10	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	10	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	10	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	11	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	11	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	11	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	11	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	11	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	11	NA	Treatment name 2	dacomitinib
10.2217/fon-2020-0823	methodology	11	NA	Study 'number(s)' for treatment 2	7
10.2217/fon-2020-0823	methodology	11	NA	paitc_type	MAIC
10.2217/fon-2020-0823	methodology	11	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	11	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	11	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	11	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	11	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	11	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	11	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	11	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	12	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	12	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	12	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	12	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	12	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	12	NA	Treatment name 2	dacomitinib
10.2217/fon-2020-0823	methodology	12	NA	Study 'number(s)' for treatment 2	7
10.2217/fon-2020-0823	methodology	12	NA	paitc_type	STC
10.2217/fon-2020-0823	methodology	12	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	12	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	12	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	12	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	12	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	12	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	12	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	12	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	13	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	13	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	13	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	13	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	13	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	13	NA	Treatment name 2	panitumumab
10.2217/fon-2020-0823	methodology	13	NA	Study 'number(s)' for treatment 2	8
10.2217/fon-2020-0823	methodology	13	NA	paitc_type	MAIC
10.2217/fon-2020-0823	methodology	13	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	13	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	13	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	13	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	13	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	13	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	13	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	13	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	14	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	14	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	14	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	14	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	14	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	14	NA	Treatment name 2	panitumumab
10.2217/fon-2020-0823	methodology	14	NA	Study 'number(s)' for treatment 2	8
10.2217/fon-2020-0823	methodology	14	NA	paitc_type	STC
10.2217/fon-2020-0823	methodology	14	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	14	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	14	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	14	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	14	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	14	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	14	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	14	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	15	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	15	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	15	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	15	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	15	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	15	NA	Treatment name 2	pembrolizumab
10.2217/fon-2020-0823	methodology	15	NA	Study 'number(s)' for treatment 2	9
10.2217/fon-2020-0823	methodology	15	NA	paitc_type	MAIC
10.2217/fon-2020-0823	methodology	15	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	15	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	15	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	15	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	15	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	15	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	15	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	15	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	16	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	16	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	16	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	16	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	16	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	16	NA	Treatment name 2	pembrolizumab
10.2217/fon-2020-0823	methodology	16	NA	Study 'number(s)' for treatment 2	9
10.2217/fon-2020-0823	methodology	16	NA	paitc_type	STC
10.2217/fon-2020-0823	methodology	16	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	16	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	16	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	16	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	16	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	16	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	16	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	16	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	17	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	17	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	17	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	17	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	17	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	17	NA	Treatment name 2	pembrolizumab
10.2217/fon-2020-0823	methodology	17	NA	Study 'number(s)' for treatment 2	10
10.2217/fon-2020-0823	methodology	17	NA	paitc_type	MAIC
10.2217/fon-2020-0823	methodology	17	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	17	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	17	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	17	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	17	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	17	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	17	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	17	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	18	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	18	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	18	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	18	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	18	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	18	NA	Treatment name 2	pembrolizumab
10.2217/fon-2020-0823	methodology	18	NA	Study 'number(s)' for treatment 2	10
10.2217/fon-2020-0823	methodology	18	NA	paitc_type	STC
10.2217/fon-2020-0823	methodology	18	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	18	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	18	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	18	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	18	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	18	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	18	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	18	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	19	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	19	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	19	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	19	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	19	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	19	NA	Treatment name 2	cetuximab
10.2217/fon-2020-0823	methodology	19	NA	Study 'number(s)' for treatment 2	11
10.2217/fon-2020-0823	methodology	19	NA	paitc_type	MAIC
10.2217/fon-2020-0823	methodology	19	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	19	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	19	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	19	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	19	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	19	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	19	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	19	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	2	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	2	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	2	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	2	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	2	NA	Treatment name 2	erlotinib
10.2217/fon-2020-0823	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.2217/fon-2020-0823	methodology	2	NA	paitc_type	STC
10.2217/fon-2020-0823	methodology	2	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	2	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	2	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	2	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	2	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	20	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	20	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	20	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	20	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	20	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	20	NA	Treatment name 2	cetuximab
10.2217/fon-2020-0823	methodology	20	NA	Study 'number(s)' for treatment 2	11
10.2217/fon-2020-0823	methodology	20	NA	paitc_type	STC
10.2217/fon-2020-0823	methodology	20	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	20	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	20	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	20	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	20	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	20	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	20	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	20	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	3	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	3	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	3	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	3	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	3	NA	Treatment name 2	platinum-based chemotherapy
10.2217/fon-2020-0823	methodology	3	NA	Study 'number(s)' for treatment 2	3
10.2217/fon-2020-0823	methodology	3	NA	paitc_type	MAIC
10.2217/fon-2020-0823	methodology	3	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	3	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	3	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	3	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	3	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	3	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	4	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	4	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	4	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	4	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	4	NA	Treatment name 2	platinum-based chemotherapy
10.2217/fon-2020-0823	methodology	4	NA	Study 'number(s)' for treatment 2	3
10.2217/fon-2020-0823	methodology	4	NA	paitc_type	STC
10.2217/fon-2020-0823	methodology	4	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	4	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	4	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	4	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	4	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	4	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	4	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	5	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	5	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	5	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	5	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	5	NA	Treatment name 2	cetuximab
10.2217/fon-2020-0823	methodology	5	NA	Study 'number(s)' for treatment 2	4
10.2217/fon-2020-0823	methodology	5	NA	paitc_type	MAIC
10.2217/fon-2020-0823	methodology	5	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	5	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	5	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	5	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	5	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	5	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	5	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	6	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	6	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	6	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	6	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	6	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	6	NA	Treatment name 2	cetuximab
10.2217/fon-2020-0823	methodology	6	NA	Study 'number(s)' for treatment 2	4
10.2217/fon-2020-0823	methodology	6	NA	paitc_type	STC
10.2217/fon-2020-0823	methodology	6	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	6	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	6	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	6	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	6	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	6	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	6	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	6	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	7	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	7	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	7	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	7	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	7	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	7	NA	Treatment name 2	cetuximab
10.2217/fon-2020-0823	methodology	7	NA	Study 'number(s)' for treatment 2	5
10.2217/fon-2020-0823	methodology	7	NA	paitc_type	MAIC
10.2217/fon-2020-0823	methodology	7	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	7	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	7	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	7	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	7	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	7	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	7	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	7	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	8	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	8	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	8	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	8	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	8	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	8	NA	Treatment name 2	cetuximab
10.2217/fon-2020-0823	methodology	8	NA	Study 'number(s)' for treatment 2	5
10.2217/fon-2020-0823	methodology	8	NA	paitc_type	STC
10.2217/fon-2020-0823	methodology	8	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	8	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	8	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	8	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	8	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	8	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	8	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	8	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	9	NA	primary_outcome_name	overall survival
10.2217/fon-2020-0823	methodology	9	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	9	NA	primary_outcome_type	Time-to-event
10.2217/fon-2020-0823	methodology	9	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	9	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	9	NA	Treatment name 2	gefitinib
10.2217/fon-2020-0823	methodology	9	NA	Study 'number(s)' for treatment 2	6
10.2217/fon-2020-0823	methodology	9	NA	paitc_type	MAIC
10.2217/fon-2020-0823	methodology	9	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	9	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	9	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	9	NA	variables_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	9	NA	prognostic_factors_yn	Yes
10.2217/fon-2020-0823	methodology	9	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	9	NA	weights_model_yn	No
10.2217/fon-2020-0823	methodology	9	NA	scale_choice_yn	No
10.2217/fon-2020-0823	results	1	NA	contrast	HR
10.2217/fon-2020-0823	results	1	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	1	NA	n_nonipd_ttt	39
10.2217/fon-2020-0823	results	1	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	1	NA	ess_ttt	NA
10.2217/fon-2020-0823	results	1	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	1	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	1	NA	n_covariates	8
10.2217/fon-2020-0823	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	1	NA	unadjusted_effect	0.28
10.2217/fon-2020-0823	results	1	NA	unadjusted_pval_char	[0.16;0.50]
10.2217/fon-2020-0823	results	1	NA	adjusted_effect	0.41
10.2217/fon-2020-0823	results	1	NA	adjusted_pval_char	[0.24;0.70]
10.2217/fon-2020-0823	results	1	NA	geographical region	NA
10.2217/fon-2020-0823	results	1	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	1	NA	ess_total	NA
10.2217/fon-2020-0823	results	1	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	1	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	1	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	1	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	1	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	1	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	1	NA	unadjusted_ub_ci	0.5
10.2217/fon-2020-0823	results	1	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	1	NA	adjusted_lb_ci	0.24
10.2217/fon-2020-0823	results	1	NA	adjusted_ub_ci	0.7
10.2217/fon-2020-0823	results	1	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	10	NA	contrast	HR
10.2217/fon-2020-0823	results	10	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	10	NA	n_nonipd_ttt	40
10.2217/fon-2020-0823	results	10	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	10	NA	ess_ttt	193
10.2217/fon-2020-0823	results	10	NA	weights_evaluation_yn	NA
10.2217/fon-2020-0823	results	10	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	10	NA	n_covariates	8
10.2217/fon-2020-0823	results	10	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	10	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	10	NA	unadjusted_effect	0.27
10.2217/fon-2020-0823	results	10	NA	unadjusted_pval_char	[0.16;0.44]
10.2217/fon-2020-0823	results	10	NA	adjusted_effect	0.29
10.2217/fon-2020-0823	results	10	NA	adjusted_pval_char	[0.18;0.45]
10.2217/fon-2020-0823	results	10	NA	geographical region	NA
10.2217/fon-2020-0823	results	10	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	10	NA	ess_total	NA
10.2217/fon-2020-0823	results	10	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	10	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	10	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	10	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	10	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	10	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	10	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	10	NA	unadjusted_ub_ci	0.44
10.2217/fon-2020-0823	results	10	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	10	NA	adjusted_lb_ci	0.18
10.2217/fon-2020-0823	results	10	NA	adjusted_ub_ci	0.45
10.2217/fon-2020-0823	results	10	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	11	NA	contrast	HR
10.2217/fon-2020-0823	results	11	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	11	NA	n_nonipd_ttt	42
10.2217/fon-2020-0823	results	11	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	11	NA	ess_ttt	NA
10.2217/fon-2020-0823	results	11	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	11	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	11	NA	n_covariates	8
10.2217/fon-2020-0823	results	11	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	11	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	11	NA	unadjusted_effect	0.2
10.2217/fon-2020-0823	results	11	NA	unadjusted_pval_char	[0.13;0.33]
10.2217/fon-2020-0823	results	11	NA	adjusted_effect	0.17
10.2217/fon-2020-0823	results	11	NA	adjusted_pval_char	[0.10;0.28]
10.2217/fon-2020-0823	results	11	NA	geographical region	NA
10.2217/fon-2020-0823	results	11	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	11	NA	ess_total	NA
10.2217/fon-2020-0823	results	11	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	11	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	11	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	11	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	11	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	11	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	11	NA	unadjusted_lb_ci	0.13
10.2217/fon-2020-0823	results	11	NA	unadjusted_ub_ci	0.33
10.2217/fon-2020-0823	results	11	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	11	NA	adjusted_lb_ci	0.1
10.2217/fon-2020-0823	results	11	NA	adjusted_ub_ci	0.28
10.2217/fon-2020-0823	results	11	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	12	NA	contrast	HR
10.2217/fon-2020-0823	results	12	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	12	NA	n_nonipd_ttt	42
10.2217/fon-2020-0823	results	12	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	12	NA	ess_ttt	193
10.2217/fon-2020-0823	results	12	NA	weights_evaluation_yn	NA
10.2217/fon-2020-0823	results	12	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	12	NA	n_covariates	8
10.2217/fon-2020-0823	results	12	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	12	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	12	NA	unadjusted_effect	0.2
10.2217/fon-2020-0823	results	12	NA	unadjusted_pval_char	[0.13;0.33]
10.2217/fon-2020-0823	results	12	NA	adjusted_effect	0.07
10.2217/fon-2020-0823	results	12	NA	adjusted_pval_char	[0.04;0.13]
10.2217/fon-2020-0823	results	12	NA	geographical region	NA
10.2217/fon-2020-0823	results	12	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	12	NA	ess_total	NA
10.2217/fon-2020-0823	results	12	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	12	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	12	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	12	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	12	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	12	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	12	NA	unadjusted_lb_ci	0.13
10.2217/fon-2020-0823	results	12	NA	unadjusted_ub_ci	0.33
10.2217/fon-2020-0823	results	12	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	12	NA	adjusted_lb_ci	0.04
10.2217/fon-2020-0823	results	12	NA	adjusted_ub_ci	0.13
10.2217/fon-2020-0823	results	12	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	13	NA	contrast	HR
10.2217/fon-2020-0823	results	13	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	13	NA	n_nonipd_ttt	16
10.2217/fon-2020-0823	results	13	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	13	NA	ess_ttt	NA
10.2217/fon-2020-0823	results	13	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	13	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	13	NA	n_covariates	8
10.2217/fon-2020-0823	results	13	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	13	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	13	NA	unadjusted_effect	0.27
10.2217/fon-2020-0823	results	13	NA	unadjusted_pval_char	[0.13;0.54]
10.2217/fon-2020-0823	results	13	NA	adjusted_effect	0.52
10.2217/fon-2020-0823	results	13	NA	adjusted_pval_char	[0.26;1.01]
10.2217/fon-2020-0823	results	13	NA	geographical region	NA
10.2217/fon-2020-0823	results	13	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	13	NA	ess_total	NA
10.2217/fon-2020-0823	results	13	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	13	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	13	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	13	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	13	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	13	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	13	NA	unadjusted_lb_ci	0.13
10.2217/fon-2020-0823	results	13	NA	unadjusted_ub_ci	0.54
10.2217/fon-2020-0823	results	13	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	13	NA	adjusted_lb_ci	0.26
10.2217/fon-2020-0823	results	13	NA	adjusted_ub_ci	1.01
10.2217/fon-2020-0823	results	13	NA	adjusted_significant	FALSE
10.2217/fon-2020-0823	results	14	NA	contrast	HR
10.2217/fon-2020-0823	results	14	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	14	NA	n_nonipd_ttt	16
10.2217/fon-2020-0823	results	14	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	14	NA	ess_ttt	193
10.2217/fon-2020-0823	results	14	NA	weights_evaluation_yn	NA
10.2217/fon-2020-0823	results	14	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	14	NA	n_covariates	8
10.2217/fon-2020-0823	results	14	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	14	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	14	NA	unadjusted_effect	0.27
10.2217/fon-2020-0823	results	14	NA	unadjusted_pval_char	[0.13;0.54]
10.2217/fon-2020-0823	results	14	NA	adjusted_effect	0.36
10.2217/fon-2020-0823	results	14	NA	adjusted_pval_char	[0.18;0.70]
10.2217/fon-2020-0823	results	14	NA	geographical region	NA
10.2217/fon-2020-0823	results	14	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	14	NA	ess_total	NA
10.2217/fon-2020-0823	results	14	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	14	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	14	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	14	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	14	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	14	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	14	NA	unadjusted_lb_ci	0.13
10.2217/fon-2020-0823	results	14	NA	unadjusted_ub_ci	0.54
10.2217/fon-2020-0823	results	14	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	14	NA	adjusted_lb_ci	0.18
10.2217/fon-2020-0823	results	14	NA	adjusted_ub_ci	0.7
10.2217/fon-2020-0823	results	14	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	15	NA	contrast	HR
10.2217/fon-2020-0823	results	15	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	15	NA	n_nonipd_ttt	39
10.2217/fon-2020-0823	results	15	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	15	NA	ess_ttt	NA
10.2217/fon-2020-0823	results	15	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	15	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	15	NA	n_covariates	8
10.2217/fon-2020-0823	results	15	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	15	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	15	NA	unadjusted_effect	0.41
10.2217/fon-2020-0823	results	15	NA	unadjusted_pval_char	[0.20;0.87]
10.2217/fon-2020-0823	results	15	NA	adjusted_effect	0.39
10.2217/fon-2020-0823	results	15	NA	adjusted_pval_char	[0.17;0.86]
10.2217/fon-2020-0823	results	15	NA	geographical region	NA
10.2217/fon-2020-0823	results	15	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	15	NA	ess_total	NA
10.2217/fon-2020-0823	results	15	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	15	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	15	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	15	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	15	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	15	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	15	NA	unadjusted_lb_ci	0.2
10.2217/fon-2020-0823	results	15	NA	unadjusted_ub_ci	0.87
10.2217/fon-2020-0823	results	15	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	15	NA	adjusted_lb_ci	0.17
10.2217/fon-2020-0823	results	15	NA	adjusted_ub_ci	0.86
10.2217/fon-2020-0823	results	15	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	16	NA	contrast	HR
10.2217/fon-2020-0823	results	16	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	16	NA	n_nonipd_ttt	39
10.2217/fon-2020-0823	results	16	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	16	NA	ess_ttt	193
10.2217/fon-2020-0823	results	16	NA	weights_evaluation_yn	NA
10.2217/fon-2020-0823	results	16	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	16	NA	n_covariates	8
10.2217/fon-2020-0823	results	16	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	16	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	16	NA	unadjusted_effect	0.41
10.2217/fon-2020-0823	results	16	NA	unadjusted_pval_char	[0.20;0.87]
10.2217/fon-2020-0823	results	16	NA	adjusted_effect	0.21
10.2217/fon-2020-0823	results	16	NA	adjusted_pval_char	[0.09;0.48]
10.2217/fon-2020-0823	results	16	NA	geographical region	NA
10.2217/fon-2020-0823	results	16	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	16	NA	ess_total	NA
10.2217/fon-2020-0823	results	16	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	16	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	16	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	16	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	16	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	16	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	16	NA	unadjusted_lb_ci	0.2
10.2217/fon-2020-0823	results	16	NA	unadjusted_ub_ci	0.87
10.2217/fon-2020-0823	results	16	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	16	NA	adjusted_lb_ci	0.09
10.2217/fon-2020-0823	results	16	NA	adjusted_ub_ci	0.48
10.2217/fon-2020-0823	results	16	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	17	NA	contrast	HR
10.2217/fon-2020-0823	results	17	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	17	NA	n_nonipd_ttt	105
10.2217/fon-2020-0823	results	17	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	17	NA	ess_ttt	NA
10.2217/fon-2020-0823	results	17	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	17	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	17	NA	n_covariates	8
10.2217/fon-2020-0823	results	17	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	17	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	17	NA	unadjusted_effect	0.4
10.2217/fon-2020-0823	results	17	NA	unadjusted_pval_char	[0.25;0.63]
10.2217/fon-2020-0823	results	17	NA	adjusted_effect	0.52
10.2217/fon-2020-0823	results	17	NA	adjusted_pval_char	[0.34;0.80]
10.2217/fon-2020-0823	results	17	NA	geographical region	NA
10.2217/fon-2020-0823	results	17	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	17	NA	ess_total	NA
10.2217/fon-2020-0823	results	17	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	17	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	17	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	17	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	17	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	17	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	17	NA	unadjusted_lb_ci	0.25
10.2217/fon-2020-0823	results	17	NA	unadjusted_ub_ci	0.63
10.2217/fon-2020-0823	results	17	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	17	NA	adjusted_lb_ci	0.34
10.2217/fon-2020-0823	results	17	NA	adjusted_ub_ci	0.8
10.2217/fon-2020-0823	results	17	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	18	NA	contrast	HR
10.2217/fon-2020-0823	results	18	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	18	NA	n_nonipd_ttt	105
10.2217/fon-2020-0823	results	18	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	18	NA	ess_ttt	193
10.2217/fon-2020-0823	results	18	NA	weights_evaluation_yn	NA
10.2217/fon-2020-0823	results	18	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	18	NA	n_covariates	8
10.2217/fon-2020-0823	results	18	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	18	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	18	NA	unadjusted_effect	0.4
10.2217/fon-2020-0823	results	18	NA	unadjusted_pval_char	[0.25;0.63]
10.2217/fon-2020-0823	results	18	NA	adjusted_effect	0.26
10.2217/fon-2020-0823	results	18	NA	adjusted_pval_char	[0.16;0.42]
10.2217/fon-2020-0823	results	18	NA	geographical region	NA
10.2217/fon-2020-0823	results	18	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	18	NA	ess_total	NA
10.2217/fon-2020-0823	results	18	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	18	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	18	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	18	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	18	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	18	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	18	NA	unadjusted_lb_ci	0.25
10.2217/fon-2020-0823	results	18	NA	unadjusted_ub_ci	0.63
10.2217/fon-2020-0823	results	18	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	18	NA	adjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	18	NA	adjusted_ub_ci	0.42
10.2217/fon-2020-0823	results	18	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	19	NA	contrast	HR
10.2217/fon-2020-0823	results	19	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	19	NA	n_nonipd_ttt	58
10.2217/fon-2020-0823	results	19	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	19	NA	ess_ttt	NA
10.2217/fon-2020-0823	results	19	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	19	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	19	NA	n_covariates	8
10.2217/fon-2020-0823	results	19	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	19	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	19	NA	unadjusted_effect	0.34
10.2217/fon-2020-0823	results	19	NA	unadjusted_pval_char	[0.21;0.55]
10.2217/fon-2020-0823	results	19	NA	adjusted_effect	0.29
10.2217/fon-2020-0823	results	19	NA	adjusted_pval_char	[0.16;0.54]
10.2217/fon-2020-0823	results	19	NA	geographical region	NA
10.2217/fon-2020-0823	results	19	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	19	NA	ess_total	NA
10.2217/fon-2020-0823	results	19	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	19	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	19	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	19	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	19	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	19	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	19	NA	unadjusted_lb_ci	0.21
10.2217/fon-2020-0823	results	19	NA	unadjusted_ub_ci	0.55
10.2217/fon-2020-0823	results	19	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	19	NA	adjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	19	NA	adjusted_ub_ci	0.54
10.2217/fon-2020-0823	results	19	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	2	NA	contrast	HR
10.2217/fon-2020-0823	results	2	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	2	NA	n_nonipd_ttt	39
10.2217/fon-2020-0823	results	2	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	2	NA	ess_ttt	193
10.2217/fon-2020-0823	results	2	NA	weights_evaluation_yn	NA
10.2217/fon-2020-0823	results	2	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	2	NA	n_covariates	8
10.2217/fon-2020-0823	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	2	NA	unadjusted_effect	0.28
10.2217/fon-2020-0823	results	2	NA	unadjusted_pval_char	[0.16;0.50]
10.2217/fon-2020-0823	results	2	NA	adjusted_effect	0.23
10.2217/fon-2020-0823	results	2	NA	adjusted_pval_char	[0.14;0.39]
10.2217/fon-2020-0823	results	2	NA	geographical region	NA
10.2217/fon-2020-0823	results	2	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	2	NA	ess_total	NA
10.2217/fon-2020-0823	results	2	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	2	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	2	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	2	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	2	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	2	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	2	NA	unadjusted_ub_ci	0.5
10.2217/fon-2020-0823	results	2	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	2	NA	adjusted_lb_ci	0.14
10.2217/fon-2020-0823	results	2	NA	adjusted_ub_ci	0.39
10.2217/fon-2020-0823	results	2	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	20	NA	contrast	HR
10.2217/fon-2020-0823	results	20	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	20	NA	n_nonipd_ttt	58
10.2217/fon-2020-0823	results	20	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	20	NA	ess_ttt	193
10.2217/fon-2020-0823	results	20	NA	weights_evaluation_yn	NA
10.2217/fon-2020-0823	results	20	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	20	NA	n_covariates	8
10.2217/fon-2020-0823	results	20	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	20	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	20	NA	unadjusted_effect	0.34
10.2217/fon-2020-0823	results	20	NA	unadjusted_pval_char	[0.21;0.55]
10.2217/fon-2020-0823	results	20	NA	adjusted_effect	0.19
10.2217/fon-2020-0823	results	20	NA	adjusted_pval_char	[0.11;0.31]
10.2217/fon-2020-0823	results	20	NA	geographical region	NA
10.2217/fon-2020-0823	results	20	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	20	NA	ess_total	NA
10.2217/fon-2020-0823	results	20	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	20	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	20	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	20	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	20	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	20	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	20	NA	unadjusted_lb_ci	0.21
10.2217/fon-2020-0823	results	20	NA	unadjusted_ub_ci	0.55
10.2217/fon-2020-0823	results	20	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	20	NA	adjusted_lb_ci	0.11
10.2217/fon-2020-0823	results	20	NA	adjusted_ub_ci	0.31
10.2217/fon-2020-0823	results	20	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	3	NA	contrast	HR
10.2217/fon-2020-0823	results	3	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	3	NA	n_nonipd_ttt	18
10.2217/fon-2020-0823	results	3	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	3	NA	ess_ttt	NA
10.2217/fon-2020-0823	results	3	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	3	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	3	NA	n_covariates	4
10.2217/fon-2020-0823	results	3	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/fon-2020-0823	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	3	NA	unadjusted_effect	0.3
10.2217/fon-2020-0823	results	3	NA	unadjusted_pval_char	[0.16;0.58]
10.2217/fon-2020-0823	results	3	NA	adjusted_effect	0.19
10.2217/fon-2020-0823	results	3	NA	adjusted_pval_char	[0.10;0.39]
10.2217/fon-2020-0823	results	3	NA	geographical region	NA
10.2217/fon-2020-0823	results	3	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	3	NA	ess_total	NA
10.2217/fon-2020-0823	results	3	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	3	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	3	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	3	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	3	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	3	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	3	NA	unadjusted_ub_ci	0.58
10.2217/fon-2020-0823	results	3	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	3	NA	adjusted_lb_ci	0.1
10.2217/fon-2020-0823	results	3	NA	adjusted_ub_ci	0.39
10.2217/fon-2020-0823	results	3	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	4	NA	contrast	HR
10.2217/fon-2020-0823	results	4	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	4	NA	n_nonipd_ttt	18
10.2217/fon-2020-0823	results	4	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	4	NA	ess_ttt	193
10.2217/fon-2020-0823	results	4	NA	weights_evaluation_yn	NA
10.2217/fon-2020-0823	results	4	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	4	NA	n_covariates	4
10.2217/fon-2020-0823	results	4	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/fon-2020-0823	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	4	NA	unadjusted_effect	0.3
10.2217/fon-2020-0823	results	4	NA	unadjusted_pval_char	[0.16;0.58]
10.2217/fon-2020-0823	results	4	NA	adjusted_effect	0.17
10.2217/fon-2020-0823	results	4	NA	adjusted_pval_char	[0.09;0.33]
10.2217/fon-2020-0823	results	4	NA	geographical region	NA
10.2217/fon-2020-0823	results	4	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	4	NA	ess_total	NA
10.2217/fon-2020-0823	results	4	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	4	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	4	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	4	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	4	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	4	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	4	NA	unadjusted_ub_ci	0.58
10.2217/fon-2020-0823	results	4	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	4	NA	adjusted_lb_ci	0.09
10.2217/fon-2020-0823	results	4	NA	adjusted_ub_ci	0.33
10.2217/fon-2020-0823	results	4	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	5	NA	contrast	HR
10.2217/fon-2020-0823	results	5	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	5	NA	n_nonipd_ttt	36
10.2217/fon-2020-0823	results	5	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	5	NA	ess_ttt	NA
10.2217/fon-2020-0823	results	5	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	5	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	5	NA	n_covariates	8
10.2217/fon-2020-0823	results	5	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	5	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	5	NA	unadjusted_effect	0.25
10.2217/fon-2020-0823	results	5	NA	unadjusted_pval_char	[0.13;0.46]
10.2217/fon-2020-0823	results	5	NA	adjusted_effect	0.25
10.2217/fon-2020-0823	results	5	NA	adjusted_pval_char	[0.13;0.49]
10.2217/fon-2020-0823	results	5	NA	geographical region	NA
10.2217/fon-2020-0823	results	5	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	5	NA	ess_total	NA
10.2217/fon-2020-0823	results	5	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	5	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	5	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	5	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	5	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	5	NA	unadjusted_lb_ci	0.13
10.2217/fon-2020-0823	results	5	NA	unadjusted_ub_ci	0.46
10.2217/fon-2020-0823	results	5	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	5	NA	adjusted_lb_ci	0.13
10.2217/fon-2020-0823	results	5	NA	adjusted_ub_ci	0.49
10.2217/fon-2020-0823	results	5	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	6	NA	contrast	HR
10.2217/fon-2020-0823	results	6	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	6	NA	n_nonipd_ttt	36
10.2217/fon-2020-0823	results	6	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	6	NA	ess_ttt	193
10.2217/fon-2020-0823	results	6	NA	weights_evaluation_yn	NA
10.2217/fon-2020-0823	results	6	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	6	NA	n_covariates	8
10.2217/fon-2020-0823	results	6	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	6	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	6	NA	unadjusted_effect	0.25
10.2217/fon-2020-0823	results	6	NA	unadjusted_pval_char	[0.13;0.46]
10.2217/fon-2020-0823	results	6	NA	adjusted_effect	0.11
10.2217/fon-2020-0823	results	6	NA	adjusted_pval_char	[0.05;0.22]
10.2217/fon-2020-0823	results	6	NA	geographical region	NA
10.2217/fon-2020-0823	results	6	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	6	NA	ess_total	NA
10.2217/fon-2020-0823	results	6	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	6	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	6	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	6	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	6	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	6	NA	unadjusted_lb_ci	0.13
10.2217/fon-2020-0823	results	6	NA	unadjusted_ub_ci	0.46
10.2217/fon-2020-0823	results	6	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	6	NA	adjusted_lb_ci	0.05
10.2217/fon-2020-0823	results	6	NA	adjusted_ub_ci	0.22
10.2217/fon-2020-0823	results	6	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	7	NA	contrast	HR
10.2217/fon-2020-0823	results	7	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	7	NA	n_nonipd_ttt	31
10.2217/fon-2020-0823	results	7	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	7	NA	ess_ttt	NA
10.2217/fon-2020-0823	results	7	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	7	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	7	NA	n_covariates	8
10.2217/fon-2020-0823	results	7	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	7	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	7	NA	unadjusted_effect	0.28
10.2217/fon-2020-0823	results	7	NA	unadjusted_pval_char	[0.16;0.50]
10.2217/fon-2020-0823	results	7	NA	adjusted_effect	0.37
10.2217/fon-2020-0823	results	7	NA	adjusted_pval_char	[0.20;0.69]
10.2217/fon-2020-0823	results	7	NA	geographical region	NA
10.2217/fon-2020-0823	results	7	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	7	NA	ess_total	NA
10.2217/fon-2020-0823	results	7	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	7	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	7	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	7	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	7	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	7	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	7	NA	unadjusted_ub_ci	0.5
10.2217/fon-2020-0823	results	7	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	7	NA	adjusted_lb_ci	0.2
10.2217/fon-2020-0823	results	7	NA	adjusted_ub_ci	0.69
10.2217/fon-2020-0823	results	7	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	8	NA	contrast	HR
10.2217/fon-2020-0823	results	8	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	8	NA	n_nonipd_ttt	31
10.2217/fon-2020-0823	results	8	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	8	NA	ess_ttt	193
10.2217/fon-2020-0823	results	8	NA	weights_evaluation_yn	NA
10.2217/fon-2020-0823	results	8	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	8	NA	n_covariates	8
10.2217/fon-2020-0823	results	8	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	8	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	8	NA	unadjusted_effect	0.28
10.2217/fon-2020-0823	results	8	NA	unadjusted_pval_char	[0.16;0.50]
10.2217/fon-2020-0823	results	8	NA	adjusted_effect	0.25
10.2217/fon-2020-0823	results	8	NA	adjusted_pval_char	[0.14;0.44]
10.2217/fon-2020-0823	results	8	NA	geographical region	NA
10.2217/fon-2020-0823	results	8	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	8	NA	ess_total	NA
10.2217/fon-2020-0823	results	8	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	8	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	8	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	8	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	8	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	8	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	8	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	8	NA	unadjusted_ub_ci	0.5
10.2217/fon-2020-0823	results	8	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	8	NA	adjusted_lb_ci	0.14
10.2217/fon-2020-0823	results	8	NA	adjusted_ub_ci	0.44
10.2217/fon-2020-0823	results	8	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	9	NA	contrast	HR
10.2217/fon-2020-0823	results	9	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	9	NA	n_nonipd_ttt	40
10.2217/fon-2020-0823	results	9	NA	n_ipd_ttt	193
10.2217/fon-2020-0823	results	9	NA	ess_ttt	NA
10.2217/fon-2020-0823	results	9	NA	weights_evaluation_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	9	NA	list_covariates_yn	Yes
10.2217/fon-2020-0823	results	9	NA	n_covariates	8
10.2217/fon-2020-0823	results	9	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	9	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	9	NA	unadjusted_effect	0.27
10.2217/fon-2020-0823	results	9	NA	unadjusted_pval_char	[0.16;0.44]
10.2217/fon-2020-0823	results	9	NA	adjusted_effect	0.47
10.2217/fon-2020-0823	results	9	NA	adjusted_pval_char	[0.29;0.75]
10.2217/fon-2020-0823	results	9	NA	geographical region	NA
10.2217/fon-2020-0823	results	9	NA	n_ipd_total	NA
10.2217/fon-2020-0823	results	9	NA	ess_total	NA
10.2217/fon-2020-0823	results	9	NA	n_nonipd_total	NA
10.2217/fon-2020-0823	results	9	NA	n_nonipd_anchor	NA
10.2217/fon-2020-0823	results	9	NA	n_ipd_anchor	NA
10.2217/fon-2020-0823	results	9	NA	ess_anchor	NA
10.2217/fon-2020-0823	results	9	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2020-0823	results	9	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	9	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	9	NA	unadjusted_ub_ci	0.44
10.2217/fon-2020-0823	results	9	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	9	NA	adjusted_lb_ci	0.29
10.2217/fon-2020-0823	results	9	NA	adjusted_ub_ci	0.75
10.2217/fon-2020-0823	results	9	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	study_information	NA	1	Patient-level data used	Yes
10.2217/fon-2020-0823	study_information	NA	1	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02760498
10.2217/fon-2020-0823	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2020-0823	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/fon-2020-0823	study_information	NA	10	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	10	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	10	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03284424
10.2217/fon-2020-0823	study_information	NA	10	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2020-0823	study_information	NA	10	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	10	Number of treatment arms (clinical trial only)	1
10.2217/fon-2020-0823	study_information	NA	11	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	11	Clinical Trial	No
10.2217/fon-2020-0823	study_information	NA	11	Data source name (only if observational study or clinical trial without NCT)	peyrade et al. (2018)
10.2217/fon-2020-0823	study_information	NA	2	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	2	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01198028
10.2217/fon-2020-0823	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/fon-2020-0823	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.2217/fon-2020-0823	study_information	NA	3	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	3	Clinical Trial	No
10.2217/fon-2020-0823	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	jarkowski et al. (2016)
10.2217/fon-2020-0823	study_information	NA	4	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	4	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00240682
10.2217/fon-2020-0823	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.2217/fon-2020-0823	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2217/fon-2020-0823	study_information	NA	5	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	5	Clinical Trial	No
10.2217/fon-2020-0823	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	picard et al. (2017)
10.2217/fon-2020-0823	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.2217/fon-2020-0823	study_information	NA	6	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	6	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00054691
10.2217/fon-2020-0823	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/fon-2020-0823	study_information	NA	6	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	6	Number of treatment arms (clinical trial only)	1
10.2217/fon-2020-0823	study_information	NA	7	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	7	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02268747
10.2217/fon-2020-0823	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.2217/fon-2020-0823	study_information	NA	7	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	7	Number of treatment arms (clinical trial only)	1
10.2217/fon-2020-0823	study_information	NA	8	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	8	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	8	Data source name (only if observational study or clinical trial without NCT)	foote et al. (2014)
10.2217/fon-2020-0823	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	australia
10.2217/fon-2020-0823	study_information	NA	8	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	8	Number of treatment arms (clinical trial only)	1
10.2217/fon-2020-0823	study_information	NA	9	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	9	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02883556
10.2217/fon-2020-0823	study_information	NA	9	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.2217/fon-2020-0823	study_information	NA	9	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	9	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1102	general_information	NA	NA	Medical Condition of Interest Name	ros1-positive non-small-cell lung cancer
10.2217/fon-2021-1102	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/fon-2021-1102	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/fon-2021-1102	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/fon-2021-1102	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/fon-2021-1102	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/fon-2021-1102	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/fon-2021-1102	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/fon-2021-1102	methodology	1	NA	primary_outcome_name	objective response rate (orr)
10.2217/fon-2021-1102	methodology	1	NA	outcome_short_name	Objective Response Rate
10.2217/fon-2021-1102	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.2217/fon-2021-1102	methodology	1	NA	Treatment name 1	crizotinib
10.2217/fon-2021-1102	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2021-1102	methodology	1	NA	Treatment name 2	entrectinib
10.2217/fon-2021-1102	methodology	1	NA	Study 'number(s)' for treatment 2	2;3;4
10.2217/fon-2021-1102	methodology	1	NA	paitc_type	STC
10.2217/fon-2021-1102	methodology	1	NA	anchored_yn	No
10.2217/fon-2021-1102	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/fon-2021-1102	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2021-1102	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/fon-2021-1102	methodology	1	NA	prognostic_factors_yn	Yes
10.2217/fon-2021-1102	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.2217/fon-2021-1102	methodology	1	NA	weights_model_yn	No
10.2217/fon-2021-1102	methodology	1	NA	scale_choice_yn	No
10.2217/fon-2021-1102	methodology	2	NA	primary_outcome_name	progression-free survival
10.2217/fon-2021-1102	methodology	2	NA	outcome_short_name	Progression-free Survival
10.2217/fon-2021-1102	methodology	2	NA	primary_outcome_type	Time-to-event
10.2217/fon-2021-1102	methodology	2	NA	Treatment name 1	crizotinib
10.2217/fon-2021-1102	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2021-1102	methodology	2	NA	Treatment name 2	crizotinib
10.2217/fon-2021-1102	methodology	2	NA	Study 'number(s)' for treatment 2	5
10.2217/fon-2021-1102	methodology	2	NA	paitc_type	STC
10.2217/fon-2021-1102	methodology	2	NA	anchored_yn	No
10.2217/fon-2021-1102	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2021-1102	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2021-1102	methodology	2	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/fon-2021-1102	methodology	2	NA	prognostic_factors_yn	Yes
10.2217/fon-2021-1102	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.2217/fon-2021-1102	methodology	2	NA	weights_model_yn	No
10.2217/fon-2021-1102	methodology	2	NA	scale_choice_yn	No
10.2217/fon-2021-1102	methodology	3	NA	primary_outcome_name	overall survival
10.2217/fon-2021-1102	methodology	3	NA	outcome_short_name	Overall Survival
10.2217/fon-2021-1102	methodology	3	NA	primary_outcome_type	Time-to-event
10.2217/fon-2021-1102	methodology	3	NA	Treatment name 1	crizotinib
10.2217/fon-2021-1102	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2021-1102	methodology	3	NA	Treatment name 2	crizotinib
10.2217/fon-2021-1102	methodology	3	NA	Study 'number(s)' for treatment 2	6
10.2217/fon-2021-1102	methodology	3	NA	paitc_type	STC
10.2217/fon-2021-1102	methodology	3	NA	anchored_yn	No
10.2217/fon-2021-1102	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2021-1102	methodology	3	NA	primary_outcome_yn	Yes
10.2217/fon-2021-1102	methodology	3	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/fon-2021-1102	methodology	3	NA	prognostic_factors_yn	Yes
10.2217/fon-2021-1102	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.2217/fon-2021-1102	methodology	3	NA	weights_model_yn	No
10.2217/fon-2021-1102	methodology	3	NA	scale_choice_yn	No
10.2217/fon-2021-1102	results	1	NA	contrast	RR
10.2217/fon-2021-1102	results	1	NA	direction_benefit	superior
10.2217/fon-2021-1102	results	1	NA	n_nonipd_ttt	161
10.2217/fon-2021-1102	results	1	NA	n_ipd_ttt	53
10.2217/fon-2021-1102	results	1	NA	ess_ttt	53
10.2217/fon-2021-1102	results	1	NA	weights_evaluation_yn	NA
10.2217/fon-2021-1102	results	1	NA	list_covariates_yn	Yes
10.2217/fon-2021-1102	results	1	NA	n_covariates	4
10.2217/fon-2021-1102	results	1	NA	list_covariates	Age, Sex, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.2217/fon-2021-1102	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2021-1102	results	1	NA	unadjusted_effect	1.07
10.2217/fon-2021-1102	results	1	NA	unadjusted_pval_char	[0.88;1.31]
10.2217/fon-2021-1102	results	1	NA	adjusted_effect	1.04
10.2217/fon-2021-1102	results	1	NA	adjusted_pval_char	[0.85;1.28]
10.2217/fon-2021-1102	results	1	NA	geographical region	NA
10.2217/fon-2021-1102	results	1	NA	n_ipd_total	NA
10.2217/fon-2021-1102	results	1	NA	ess_total	NA
10.2217/fon-2021-1102	results	1	NA	n_nonipd_total	NA
10.2217/fon-2021-1102	results	1	NA	n_nonipd_anchor	NA
10.2217/fon-2021-1102	results	1	NA	n_ipd_anchor	NA
10.2217/fon-2021-1102	results	1	NA	ess_anchor	NA
10.2217/fon-2021-1102	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2021-1102	results	1	NA	effect_cutoff	1
10.2217/fon-2021-1102	results	1	NA	unadjusted_lb_ci	0.88
10.2217/fon-2021-1102	results	1	NA	unadjusted_ub_ci	1.31
10.2217/fon-2021-1102	results	1	NA	unadjusted_significant	FALSE
10.2217/fon-2021-1102	results	1	NA	adjusted_lb_ci	0.85
10.2217/fon-2021-1102	results	1	NA	adjusted_ub_ci	1.28
10.2217/fon-2021-1102	results	1	NA	adjusted_significant	FALSE
10.2217/fon-2021-1102	results	2	NA	contrast	Median difference
10.2217/fon-2021-1102	results	2	NA	direction_benefit	superior
10.2217/fon-2021-1102	results	2	NA	n_nonipd_ttt	69
10.2217/fon-2021-1102	results	2	NA	n_ipd_ttt	53
10.2217/fon-2021-1102	results	2	NA	ess_ttt	53
10.2217/fon-2021-1102	results	2	NA	weights_evaluation_yn	NA
10.2217/fon-2021-1102	results	2	NA	list_covariates_yn	Yes
10.2217/fon-2021-1102	results	2	NA	n_covariates	2
10.2217/fon-2021-1102	results	2	NA	list_covariates	Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.2217/fon-2021-1102	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2021-1102	results	2	NA	unadjusted_effect	10.8
10.2217/fon-2021-1102	results	2	NA	unadjusted_pval_char	NA
10.2217/fon-2021-1102	results	2	NA	adjusted_effect	8.3
10.2217/fon-2021-1102	results	2	NA	adjusted_pval_char	[0.26;16.94]
10.2217/fon-2021-1102	results	2	NA	geographical region	No
10.2217/fon-2021-1102	results	2	NA	n_ipd_total	NA
10.2217/fon-2021-1102	results	2	NA	ess_total	NA
10.2217/fon-2021-1102	results	2	NA	n_nonipd_total	NA
10.2217/fon-2021-1102	results	2	NA	n_nonipd_anchor	NA
10.2217/fon-2021-1102	results	2	NA	n_ipd_anchor	NA
10.2217/fon-2021-1102	results	2	NA	ess_anchor	NA
10.2217/fon-2021-1102	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2021-1102	results	2	NA	effect_cutoff	0
10.2217/fon-2021-1102	results	2	NA	adjusted_lb_ci	0.26
10.2217/fon-2021-1102	results	2	NA	adjusted_ub_ci	16.94
10.2217/fon-2021-1102	results	2	NA	adjusted_significant	TRUE
10.2217/fon-2021-1102	results	3	NA	contrast	Median difference
10.2217/fon-2021-1102	results	3	NA	direction_benefit	superior
10.2217/fon-2021-1102	results	3	NA	n_nonipd_ttt	38
10.2217/fon-2021-1102	results	3	NA	n_ipd_ttt	53
10.2217/fon-2021-1102	results	3	NA	ess_ttt	53
10.2217/fon-2021-1102	results	3	NA	weights_evaluation_yn	Not mentioned
10.2217/fon-2021-1102	results	3	NA	list_covariates_yn	Yes
10.2217/fon-2021-1102	results	3	NA	n_covariates	4
10.2217/fon-2021-1102	results	3	NA	list_covariates	Age, Sex, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2217/fon-2021-1102	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2021-1102	results	3	NA	unadjusted_effect	15.2
10.2217/fon-2021-1102	results	3	NA	unadjusted_pval_char	NA
10.2217/fon-2021-1102	results	3	NA	adjusted_effect	-10.5
10.2217/fon-2021-1102	results	3	NA	adjusted_pval_char	NA
10.2217/fon-2021-1102	results	3	NA	geographical region	No
10.2217/fon-2021-1102	results	3	NA	n_ipd_total	NA
10.2217/fon-2021-1102	results	3	NA	ess_total	NA
10.2217/fon-2021-1102	results	3	NA	n_nonipd_total	NA
10.2217/fon-2021-1102	results	3	NA	n_nonipd_anchor	NA
10.2217/fon-2021-1102	results	3	NA	n_ipd_anchor	NA
10.2217/fon-2021-1102	results	3	NA	ess_anchor	NA
10.2217/fon-2021-1102	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2021-1102	results	3	NA	effect_cutoff	0
10.2217/fon-2021-1102	study_information	NA	1	Patient-level data used	Yes
10.2217/fon-2021-1102	study_information	NA	1	Clinical Trial	Yes
10.2217/fon-2021-1102	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00585195
10.2217/fon-2021-1102	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2021-1102	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.2217/fon-2021-1102	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1102	study_information	NA	2	Patient-level data used	No
10.2217/fon-2021-1102	study_information	NA	2	Clinical Trial	Yes
10.2217/fon-2021-1102	study_information	NA	2	EudraCT (only for clinical trials registered on clinicaltrialsregister.eu	2012-000148-88
10.2217/fon-2021-1102	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.2217/fon-2021-1102	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1
10.2217/fon-2021-1102	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1102	study_information	NA	3	Patient-level data used	No
10.2217/fon-2021-1102	study_information	NA	3	Clinical Trial	Yes
10.2217/fon-2021-1102	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02097810
10.2217/fon-2021-1102	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2021-1102	study_information	NA	3	Phase of the clinical trial (clinical trial only)	1
10.2217/fon-2021-1102	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1102	study_information	NA	4	Patient-level data used	No
10.2217/fon-2021-1102	study_information	NA	4	Clinical Trial	Yes
10.2217/fon-2021-1102	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02568267
10.2217/fon-2021-1102	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2021-1102	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2021-1102	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1102	study_information	NA	5	Patient-level data used	No
10.2217/fon-2021-1102	study_information	NA	5	Clinical Trial	No
10.2217/fon-2021-1102	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	flatiron health
10.2217/fon-2021-1102	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/fon-2021-1102	study_information	NA	6	Patient-level data used	No
10.2217/fon-2021-1102	study_information	NA	6	Clinical Trial	No
10.2217/fon-2021-1102	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	ontada (oncology insights & technology)
10.2217/fon-2021-1102	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/fon-2021-1509	general_information	NA	NA	Medical Condition of Interest Name	advanced systemic mastocytosis
10.2217/fon-2021-1509	general_information	NA	NA	Countries of first author affiliations	uk
10.2217/fon-2021-1509	general_information	NA	NA	Countries of last author affiliations	switzerland
10.2217/fon-2021-1509	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/fon-2021-1509	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/fon-2021-1509	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/fon-2021-1509	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/fon-2021-1509	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/fon-2021-1509	methodology	1	NA	primary_outcome_name	overall survival
10.2217/fon-2021-1509	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/fon-2021-1509	methodology	1	NA	primary_outcome_type	Time-to-event
10.2217/fon-2021-1509	methodology	1	NA	Treatment name 1	avapritinib
10.2217/fon-2021-1509	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2217/fon-2021-1509	methodology	1	NA	Treatment name 2	midostaurin
10.2217/fon-2021-1509	methodology	1	NA	Study 'number(s)' for treatment 2	3;4
10.2217/fon-2021-1509	methodology	1	NA	paitc_type	MAIC
10.2217/fon-2021-1509	methodology	1	NA	anchored_yn	No
10.2217/fon-2021-1509	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/fon-2021-1509	methodology	1	NA	primary_outcome_yn	Yes
10.2217/fon-2021-1509	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.2217/fon-2021-1509	methodology	1	NA	prognostic_factors_yn	Yes
10.2217/fon-2021-1509	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2021-1509	methodology	1	NA	weights_model_yn	No
10.2217/fon-2021-1509	methodology	1	NA	scale_choice_yn	No
10.2217/fon-2021-1509	results	1	NA	contrast	HR
10.2217/fon-2021-1509	results	1	NA	direction_benefit	inferior
10.2217/fon-2021-1509	results	1	NA	n_nonipd_ttt	115
10.2217/fon-2021-1509	results	1	NA	n_ipd_ttt	85
10.2217/fon-2021-1509	results	1	NA	ess_ttt	NA
10.2217/fon-2021-1509	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/fon-2021-1509	results	1	NA	list_covariates_yn	Yes
10.2217/fon-2021-1509	results	1	NA	n_covariates	3
10.2217/fon-2021-1509	results	1	NA	list_covariates	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.2217/fon-2021-1509	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2021-1509	results	1	NA	unadjusted_effect	0.54
10.2217/fon-2021-1509	results	1	NA	unadjusted_pval_char	[0.32;0.92]
10.2217/fon-2021-1509	results	1	NA	adjusted_effect	0.44
10.2217/fon-2021-1509	results	1	NA	adjusted_pval_char	[0.25;0.76]
10.2217/fon-2021-1509	results	1	NA	geographical region	NA
10.2217/fon-2021-1509	results	1	NA	n_ipd_total	NA
10.2217/fon-2021-1509	results	1	NA	ess_total	NA
10.2217/fon-2021-1509	results	1	NA	n_nonipd_total	NA
10.2217/fon-2021-1509	results	1	NA	n_nonipd_anchor	NA
10.2217/fon-2021-1509	results	1	NA	n_ipd_anchor	NA
10.2217/fon-2021-1509	results	1	NA	ess_anchor	NA
10.2217/fon-2021-1509	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/fon-2021-1509	results	1	NA	effect_cutoff	1
10.2217/fon-2021-1509	results	1	NA	unadjusted_lb_ci	0.32
10.2217/fon-2021-1509	results	1	NA	unadjusted_ub_ci	0.92
10.2217/fon-2021-1509	results	1	NA	unadjusted_significant	TRUE
10.2217/fon-2021-1509	results	1	NA	adjusted_lb_ci	0.25
10.2217/fon-2021-1509	results	1	NA	adjusted_ub_ci	0.76
10.2217/fon-2021-1509	results	1	NA	adjusted_significant	TRUE
10.2217/fon-2021-1509	study_information	NA	1	Patient-level data used	Yes
10.2217/fon-2021-1509	study_information	NA	1	Clinical Trial	Yes
10.2217/fon-2021-1509	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02561988
10.2217/fon-2021-1509	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2021-1509	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.2217/fon-2021-1509	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1509	study_information	NA	2	Patient-level data used	Yes
10.2217/fon-2021-1509	study_information	NA	2	Clinical Trial	Yes
10.2217/fon-2021-1509	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03580655
10.2217/fon-2021-1509	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2021-1509	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2021-1509	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1509	study_information	NA	3	Patient-level data used	No
10.2217/fon-2021-1509	study_information	NA	3	Clinical Trial	Yes
10.2217/fon-2021-1509	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00782067
10.2217/fon-2021-1509	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2021-1509	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2021-1509	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1509	study_information	NA	4	Patient-level data used	No
10.2217/fon-2021-1509	study_information	NA	4	Clinical Trial	Yes
10.2217/fon-2021-1509	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00233454
10.2217/fon-2021-1509	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/fon-2021-1509	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2021-1509	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2217/imt-2018-0208	general_information	NA	NA	Medical Condition of Interest Name	braf-mutant advanced melanoma
10.2217/imt-2018-0208	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/imt-2018-0208	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/imt-2018-0208	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/imt-2018-0208	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/imt-2018-0208	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/imt-2018-0208	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/imt-2018-0208	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/imt-2018-0208	methodology	1	NA	primary_outcome_name	overall survival
10.2217/imt-2018-0208	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/imt-2018-0208	methodology	1	NA	primary_outcome_type	Time-to-event
10.2217/imt-2018-0208	methodology	1	NA	Treatment name 1	nivolumab + ipilimumab
10.2217/imt-2018-0208	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2217/imt-2018-0208	methodology	1	NA	Treatment name 2	dabrafenib + trametinib
10.2217/imt-2018-0208	methodology	1	NA	Study 'number(s)' for treatment 2	3;4
10.2217/imt-2018-0208	methodology	1	NA	paitc_type	MAIC
10.2217/imt-2018-0208	methodology	1	NA	anchored_yn	No
10.2217/imt-2018-0208	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/imt-2018-0208	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2018-0208	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2018-0208	methodology	1	NA	prognostic_factors_yn	Yes
10.2217/imt-2018-0208	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.2217/imt-2018-0208	methodology	1	NA	weights_model_yn	No
10.2217/imt-2018-0208	methodology	1	NA	scale_choice_yn	No
10.2217/imt-2018-0208	methodology	2	NA	primary_outcome_name	overall survival
10.2217/imt-2018-0208	methodology	2	NA	outcome_short_name	Overall Survival
10.2217/imt-2018-0208	methodology	2	NA	primary_outcome_type	Time-to-event
10.2217/imt-2018-0208	methodology	2	NA	Treatment name 1	nivolumab + ipilimumab
10.2217/imt-2018-0208	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.2217/imt-2018-0208	methodology	2	NA	Treatment name 2	vemurafenib + cobimetinib
10.2217/imt-2018-0208	methodology	2	NA	Study 'number(s)' for treatment 2	5
10.2217/imt-2018-0208	methodology	2	NA	paitc_type	MAIC
10.2217/imt-2018-0208	methodology	2	NA	anchored_yn	No
10.2217/imt-2018-0208	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/imt-2018-0208	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2018-0208	methodology	2	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2018-0208	methodology	2	NA	prognostic_factors_yn	Yes
10.2217/imt-2018-0208	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.2217/imt-2018-0208	methodology	2	NA	weights_model_yn	No
10.2217/imt-2018-0208	methodology	2	NA	scale_choice_yn	No
10.2217/imt-2018-0208	results	1	NA	contrast	HR
10.2217/imt-2018-0208	results	1	NA	direction_benefit	inferior
10.2217/imt-2018-0208	results	1	NA	n_nonipd_ttt	563
10.2217/imt-2018-0208	results	1	NA	n_ipd_ttt	124
10.2217/imt-2018-0208	results	1	NA	ess_ttt	106.3
10.2217/imt-2018-0208	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/imt-2018-0208	results	1	NA	list_covariates_yn	Yes
10.2217/imt-2018-0208	results	1	NA	n_covariates	7
10.2217/imt-2018-0208	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/imt-2018-0208	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2018-0208	results	1	NA	unadjusted_effect	0.58
10.2217/imt-2018-0208	results	1	NA	unadjusted_pval_char	0.001
10.2217/imt-2018-0208	results	1	NA	adjusted_effect	0.64
10.2217/imt-2018-0208	results	1	NA	adjusted_pval_char	0.009
10.2217/imt-2018-0208	results	1	NA	geographical region	NA
10.2217/imt-2018-0208	results	1	NA	n_ipd_total	NA
10.2217/imt-2018-0208	results	1	NA	ess_total	NA
10.2217/imt-2018-0208	results	1	NA	n_nonipd_total	NA
10.2217/imt-2018-0208	results	1	NA	n_nonipd_anchor	NA
10.2217/imt-2018-0208	results	1	NA	n_ipd_anchor	NA
10.2217/imt-2018-0208	results	1	NA	ess_anchor	NA
10.2217/imt-2018-0208	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/imt-2018-0208	results	1	NA	effect_cutoff	1
10.2217/imt-2018-0208	results	1	NA	unadjusted_pval	0.001
10.2217/imt-2018-0208	results	1	NA	unadjusted_num_pval	0.001
10.2217/imt-2018-0208	results	1	NA	unadjusted_significant	TRUE
10.2217/imt-2018-0208	results	1	NA	adjusted_pval	0.009
10.2217/imt-2018-0208	results	1	NA	adjusted_num_pval	0.009
10.2217/imt-2018-0208	results	1	NA	adjusted_significant	TRUE
10.2217/imt-2018-0208	results	2	NA	contrast	HR
10.2217/imt-2018-0208	results	2	NA	direction_benefit	inferior
10.2217/imt-2018-0208	results	2	NA	n_nonipd_ttt	247
10.2217/imt-2018-0208	results	2	NA	n_ipd_ttt	124
10.2217/imt-2018-0208	results	2	NA	ess_ttt	59.2
10.2217/imt-2018-0208	results	2	NA	weights_evaluation_yn	Not mentioned
10.2217/imt-2018-0208	results	2	NA	list_covariates_yn	Yes
10.2217/imt-2018-0208	results	2	NA	n_covariates	8
10.2217/imt-2018-0208	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.2217/imt-2018-0208	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2018-0208	results	2	NA	unadjusted_effect	0.53
10.2217/imt-2018-0208	results	2	NA	unadjusted_pval_char	<0.001
10.2217/imt-2018-0208	results	2	NA	adjusted_effect	0.56
10.2217/imt-2018-0208	results	2	NA	adjusted_pval_char	0.014
10.2217/imt-2018-0208	results	2	NA	geographical region	Yes
10.2217/imt-2018-0208	results	2	NA	n_ipd_total	NA
10.2217/imt-2018-0208	results	2	NA	ess_total	NA
10.2217/imt-2018-0208	results	2	NA	n_nonipd_total	NA
10.2217/imt-2018-0208	results	2	NA	n_nonipd_anchor	NA
10.2217/imt-2018-0208	results	2	NA	n_ipd_anchor	NA
10.2217/imt-2018-0208	results	2	NA	ess_anchor	NA
10.2217/imt-2018-0208	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/imt-2018-0208	results	2	NA	effect_cutoff	1
10.2217/imt-2018-0208	results	2	NA	unadjusted_pval	<0.001
10.2217/imt-2018-0208	results	2	NA	unadjusted_significant	TRUE
10.2217/imt-2018-0208	results	2	NA	adjusted_pval	0.014
10.2217/imt-2018-0208	results	2	NA	adjusted_num_pval	0.014
10.2217/imt-2018-0208	results	2	NA	adjusted_significant	TRUE
10.2217/imt-2018-0208	study_information	NA	1	Patient-level data used	Yes
10.2217/imt-2018-0208	study_information	NA	1	Clinical Trial	Yes
10.2217/imt-2018-0208	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01844505
10.2217/imt-2018-0208	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2018-0208	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2018-0208	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2018-0208	study_information	NA	2	Patient-level data used	Yes
10.2217/imt-2018-0208	study_information	NA	2	Clinical Trial	Yes
10.2217/imt-2018-0208	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01927419
10.2217/imt-2018-0208	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2018-0208	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.2217/imt-2018-0208	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2018-0208	study_information	NA	3	Patient-level data used	No
10.2217/imt-2018-0208	study_information	NA	3	Clinical Trial	Yes
10.2217/imt-2018-0208	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01584648
10.2217/imt-2018-0208	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2018-0208	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2018-0208	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2018-0208	study_information	NA	4	Patient-level data used	No
10.2217/imt-2018-0208	study_information	NA	4	Clinical Trial	Yes
10.2217/imt-2018-0208	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01597908
10.2217/imt-2018-0208	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2018-0208	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2018-0208	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2018-0208	study_information	NA	5	Patient-level data used	No
10.2217/imt-2018-0208	study_information	NA	5	Clinical Trial	Yes
10.2217/imt-2018-0208	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01689519
10.2217/imt-2018-0208	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2018-0208	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2018-0208	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2020-0266	general_information	NA	NA	Medical Condition of Interest Name	multiple myeloma
10.2217/imt-2020-0266	general_information	NA	NA	Countries of first author affiliations	france
10.2217/imt-2020-0266	general_information	NA	NA	Countries of last author affiliations	the netherlands
10.2217/imt-2020-0266	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/imt-2020-0266	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/imt-2020-0266	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/imt-2020-0266	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/imt-2020-0266	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/imt-2020-0266	methodology	1	NA	primary_outcome_name	progression-free survival
10.2217/imt-2020-0266	methodology	1	NA	outcome_short_name	Progression-free Survival
10.2217/imt-2020-0266	methodology	1	NA	primary_outcome_type	Time-to-event
10.2217/imt-2020-0266	methodology	1	NA	Treatment name 1	daratumumab + bortezomib + thalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/imt-2020-0266	methodology	1	NA	Treatment name 2	bortezomib + lenalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/imt-2020-0266	methodology	1	NA	paitc_type	MAIC
10.2217/imt-2020-0266	methodology	1	NA	anchored_yn	No
10.2217/imt-2020-0266	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/imt-2020-0266	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2020-0266	methodology	1	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2020-0266	methodology	1	NA	prognostic_factors_yn	Yes
10.2217/imt-2020-0266	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.2217/imt-2020-0266	methodology	1	NA	weights_model_yn	No
10.2217/imt-2020-0266	methodology	1	NA	scale_choice_yn	No
10.2217/imt-2020-0266	methodology	2	NA	primary_outcome_name	progression-free survival
10.2217/imt-2020-0266	methodology	2	NA	outcome_short_name	Progression-free Survival
10.2217/imt-2020-0266	methodology	2	NA	primary_outcome_type	Time-to-event
10.2217/imt-2020-0266	methodology	2	NA	Treatment name 1	bortezomib + thalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2217/imt-2020-0266	methodology	2	NA	Treatment name 2	bortezomib + lenalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.2217/imt-2020-0266	methodology	2	NA	paitc_type	MAIC
10.2217/imt-2020-0266	methodology	2	NA	anchored_yn	No
10.2217/imt-2020-0266	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/imt-2020-0266	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2020-0266	methodology	2	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2020-0266	methodology	2	NA	prognostic_factors_yn	Yes
10.2217/imt-2020-0266	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.2217/imt-2020-0266	methodology	2	NA	weights_model_yn	No
10.2217/imt-2020-0266	methodology	2	NA	scale_choice_yn	No
10.2217/imt-2020-0266	methodology	3	NA	primary_outcome_name	progression-free survival
10.2217/imt-2020-0266	methodology	3	NA	outcome_short_name	Progression-free Survival
10.2217/imt-2020-0266	methodology	3	NA	primary_outcome_type	Time-to-event
10.2217/imt-2020-0266	methodology	3	NA	Treatment name 1	daratumumab + bortezomib + thalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.2217/imt-2020-0266	methodology	3	NA	Treatment name 2	bortezomib + cyclophosphamide + dexamethasone
10.2217/imt-2020-0266	methodology	3	NA	Study 'number(s)' for treatment 2	3
10.2217/imt-2020-0266	methodology	3	NA	paitc_type	MAIC
10.2217/imt-2020-0266	methodology	3	NA	anchored_yn	No
10.2217/imt-2020-0266	methodology	3	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/imt-2020-0266	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2020-0266	methodology	3	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2020-0266	methodology	3	NA	prognostic_factors_yn	Yes
10.2217/imt-2020-0266	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.2217/imt-2020-0266	methodology	3	NA	weights_model_yn	No
10.2217/imt-2020-0266	methodology	3	NA	scale_choice_yn	No
10.2217/imt-2020-0266	methodology	4	NA	primary_outcome_name	progression-free survival
10.2217/imt-2020-0266	methodology	4	NA	outcome_short_name	Progression-free Survival
10.2217/imt-2020-0266	methodology	4	NA	primary_outcome_type	Time-to-event
10.2217/imt-2020-0266	methodology	4	NA	Treatment name 1	bortezomib + thalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.2217/imt-2020-0266	methodology	4	NA	Treatment name 2	bortezomib + cyclophosphamide + dexamethasone
10.2217/imt-2020-0266	methodology	4	NA	Study 'number(s)' for treatment 2	3
10.2217/imt-2020-0266	methodology	4	NA	paitc_type	MAIC
10.2217/imt-2020-0266	methodology	4	NA	anchored_yn	No
10.2217/imt-2020-0266	methodology	4	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/imt-2020-0266	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2020-0266	methodology	4	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2020-0266	methodology	4	NA	prognostic_factors_yn	Yes
10.2217/imt-2020-0266	methodology	4	NA	ttt_effect_modifiers_yn	Yes
10.2217/imt-2020-0266	methodology	4	NA	weights_model_yn	No
10.2217/imt-2020-0266	methodology	4	NA	scale_choice_yn	No
10.2217/imt-2020-0266	methodology	5	NA	primary_outcome_name	progression-free survival
10.2217/imt-2020-0266	methodology	5	NA	outcome_short_name	Progression-free Survival
10.2217/imt-2020-0266	methodology	5	NA	primary_outcome_type	Time-to-event
10.2217/imt-2020-0266	methodology	5	NA	Treatment name 1	daratumumab + bortezomib + thalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.2217/imt-2020-0266	methodology	5	NA	Treatment name 2	bortezomib + dexamethasone
10.2217/imt-2020-0266	methodology	5	NA	Study 'number(s)' for treatment 2	4
10.2217/imt-2020-0266	methodology	5	NA	paitc_type	MAIC
10.2217/imt-2020-0266	methodology	5	NA	anchored_yn	No
10.2217/imt-2020-0266	methodology	5	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/imt-2020-0266	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2020-0266	methodology	5	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2020-0266	methodology	5	NA	prognostic_factors_yn	Yes
10.2217/imt-2020-0266	methodology	5	NA	ttt_effect_modifiers_yn	Yes
10.2217/imt-2020-0266	methodology	5	NA	weights_model_yn	No
10.2217/imt-2020-0266	methodology	5	NA	scale_choice_yn	No
10.2217/imt-2020-0266	methodology	6	NA	primary_outcome_name	progression-free survival
10.2217/imt-2020-0266	methodology	6	NA	outcome_short_name	Progression-free Survival
10.2217/imt-2020-0266	methodology	6	NA	primary_outcome_type	Time-to-event
10.2217/imt-2020-0266	methodology	6	NA	Treatment name 1	bortezomib + thalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	6	NA	Study 'number(s)' for treatment 1	1
10.2217/imt-2020-0266	methodology	6	NA	Treatment name 2	bortezomib + dexamethasone
10.2217/imt-2020-0266	methodology	6	NA	Study 'number(s)' for treatment 2	4
10.2217/imt-2020-0266	methodology	6	NA	paitc_type	MAIC
10.2217/imt-2020-0266	methodology	6	NA	anchored_yn	No
10.2217/imt-2020-0266	methodology	6	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.2217/imt-2020-0266	methodology	6	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2020-0266	methodology	6	NA	variables_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2020-0266	methodology	6	NA	prognostic_factors_yn	Yes
10.2217/imt-2020-0266	methodology	6	NA	ttt_effect_modifiers_yn	Yes
10.2217/imt-2020-0266	methodology	6	NA	weights_model_yn	No
10.2217/imt-2020-0266	methodology	6	NA	scale_choice_yn	No
10.2217/imt-2020-0266	results	1	NA	contrast	HR
10.2217/imt-2020-0266	results	1	NA	direction_benefit	inferior
10.2217/imt-2020-0266	results	1	NA	n_nonipd_ttt	350
10.2217/imt-2020-0266	results	1	NA	n_ipd_ttt	543
10.2217/imt-2020-0266	results	1	NA	ess_ttt	529
10.2217/imt-2020-0266	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/imt-2020-0266	results	1	NA	list_covariates_yn	Yes
10.2217/imt-2020-0266	results	1	NA	n_covariates	4
10.2217/imt-2020-0266	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/imt-2020-0266	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2020-0266	results	1	NA	unadjusted_effect	0.48
10.2217/imt-2020-0266	results	1	NA	unadjusted_pval_char	<0.001
10.2217/imt-2020-0266	results	1	NA	adjusted_effect	0.47
10.2217/imt-2020-0266	results	1	NA	adjusted_pval_char	<0.001
10.2217/imt-2020-0266	results	1	NA	geographical region	NA
10.2217/imt-2020-0266	results	1	NA	n_ipd_total	NA
10.2217/imt-2020-0266	results	1	NA	ess_total	NA
10.2217/imt-2020-0266	results	1	NA	n_nonipd_total	NA
10.2217/imt-2020-0266	results	1	NA	n_nonipd_anchor	NA
10.2217/imt-2020-0266	results	1	NA	n_ipd_anchor	NA
10.2217/imt-2020-0266	results	1	NA	ess_anchor	NA
10.2217/imt-2020-0266	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/imt-2020-0266	results	1	NA	effect_cutoff	1
10.2217/imt-2020-0266	results	1	NA	unadjusted_pval	<0.001
10.2217/imt-2020-0266	results	1	NA	unadjusted_significant	TRUE
10.2217/imt-2020-0266	results	1	NA	adjusted_pval	<0.001
10.2217/imt-2020-0266	results	1	NA	adjusted_significant	TRUE
10.2217/imt-2020-0266	results	2	NA	contrast	HR
10.2217/imt-2020-0266	results	2	NA	direction_benefit	inferior
10.2217/imt-2020-0266	results	2	NA	n_nonipd_ttt	350
10.2217/imt-2020-0266	results	2	NA	n_ipd_ttt	542
10.2217/imt-2020-0266	results	2	NA	ess_ttt	515
10.2217/imt-2020-0266	results	2	NA	weights_evaluation_yn	Not mentioned
10.2217/imt-2020-0266	results	2	NA	list_covariates_yn	Yes
10.2217/imt-2020-0266	results	2	NA	n_covariates	4
10.2217/imt-2020-0266	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/imt-2020-0266	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2020-0266	results	2	NA	unadjusted_effect	1.07
10.2217/imt-2020-0266	results	2	NA	unadjusted_pval_char	0.655
10.2217/imt-2020-0266	results	2	NA	adjusted_effect	1.13
10.2217/imt-2020-0266	results	2	NA	adjusted_pval_char	0.419
10.2217/imt-2020-0266	results	2	NA	geographical region	NA
10.2217/imt-2020-0266	results	2	NA	n_ipd_total	NA
10.2217/imt-2020-0266	results	2	NA	ess_total	NA
10.2217/imt-2020-0266	results	2	NA	n_nonipd_total	NA
10.2217/imt-2020-0266	results	2	NA	n_nonipd_anchor	NA
10.2217/imt-2020-0266	results	2	NA	n_ipd_anchor	NA
10.2217/imt-2020-0266	results	2	NA	ess_anchor	NA
10.2217/imt-2020-0266	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/imt-2020-0266	results	2	NA	effect_cutoff	1
10.2217/imt-2020-0266	results	2	NA	unadjusted_pval	0.655
10.2217/imt-2020-0266	results	2	NA	unadjusted_num_pval	0.655
10.2217/imt-2020-0266	results	2	NA	unadjusted_significant	FALSE
10.2217/imt-2020-0266	results	2	NA	adjusted_pval	0.419
10.2217/imt-2020-0266	results	2	NA	adjusted_num_pval	0.419
10.2217/imt-2020-0266	results	2	NA	adjusted_significant	FALSE
10.2217/imt-2020-0266	results	3	NA	contrast	HR
10.2217/imt-2020-0266	results	3	NA	direction_benefit	inferior
10.2217/imt-2020-0266	results	3	NA	n_nonipd_ttt	125
10.2217/imt-2020-0266	results	3	NA	n_ipd_ttt	543
10.2217/imt-2020-0266	results	3	NA	ess_ttt	206
10.2217/imt-2020-0266	results	3	NA	weights_evaluation_yn	Not mentioned
10.2217/imt-2020-0266	results	3	NA	list_covariates_yn	Yes
10.2217/imt-2020-0266	results	3	NA	n_covariates	12
10.2217/imt-2020-0266	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.2217/imt-2020-0266	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2020-0266	results	3	NA	unadjusted_effect	0.4
10.2217/imt-2020-0266	results	3	NA	unadjusted_pval_char	<0.001
10.2217/imt-2020-0266	results	3	NA	adjusted_effect	0.35
10.2217/imt-2020-0266	results	3	NA	adjusted_pval_char	<0.001
10.2217/imt-2020-0266	results	3	NA	geographical region	No
10.2217/imt-2020-0266	results	3	NA	n_ipd_total	NA
10.2217/imt-2020-0266	results	3	NA	ess_total	NA
10.2217/imt-2020-0266	results	3	NA	n_nonipd_total	NA
10.2217/imt-2020-0266	results	3	NA	n_nonipd_anchor	NA
10.2217/imt-2020-0266	results	3	NA	n_ipd_anchor	NA
10.2217/imt-2020-0266	results	3	NA	ess_anchor	NA
10.2217/imt-2020-0266	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/imt-2020-0266	results	3	NA	effect_cutoff	1
10.2217/imt-2020-0266	results	3	NA	unadjusted_pval	<0.001
10.2217/imt-2020-0266	results	3	NA	unadjusted_significant	TRUE
10.2217/imt-2020-0266	results	3	NA	adjusted_pval	<0.001
10.2217/imt-2020-0266	results	3	NA	adjusted_significant	TRUE
10.2217/imt-2020-0266	results	4	NA	contrast	HR
10.2217/imt-2020-0266	results	4	NA	direction_benefit	inferior
10.2217/imt-2020-0266	results	4	NA	n_nonipd_ttt	126
10.2217/imt-2020-0266	results	4	NA	n_ipd_ttt	542
10.2217/imt-2020-0266	results	4	NA	ess_ttt	211
10.2217/imt-2020-0266	results	4	NA	weights_evaluation_yn	Not mentioned
10.2217/imt-2020-0266	results	4	NA	list_covariates_yn	Yes
10.2217/imt-2020-0266	results	4	NA	n_covariates	12
10.2217/imt-2020-0266	results	4	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.2217/imt-2020-0266	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2020-0266	results	4	NA	unadjusted_effect	0.89
10.2217/imt-2020-0266	results	4	NA	unadjusted_pval_char	0.549
10.2217/imt-2020-0266	results	4	NA	adjusted_effect	1
10.2217/imt-2020-0266	results	4	NA	adjusted_pval_char	0.987
10.2217/imt-2020-0266	results	4	NA	geographical region	No
10.2217/imt-2020-0266	results	4	NA	n_ipd_total	NA
10.2217/imt-2020-0266	results	4	NA	ess_total	NA
10.2217/imt-2020-0266	results	4	NA	n_nonipd_total	NA
10.2217/imt-2020-0266	results	4	NA	n_nonipd_anchor	NA
10.2217/imt-2020-0266	results	4	NA	n_ipd_anchor	NA
10.2217/imt-2020-0266	results	4	NA	ess_anchor	NA
10.2217/imt-2020-0266	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/imt-2020-0266	results	4	NA	effect_cutoff	1
10.2217/imt-2020-0266	results	4	NA	unadjusted_pval	0.549
10.2217/imt-2020-0266	results	4	NA	unadjusted_num_pval	0.549
10.2217/imt-2020-0266	results	4	NA	unadjusted_significant	FALSE
10.2217/imt-2020-0266	results	4	NA	adjusted_pval	0.987
10.2217/imt-2020-0266	results	4	NA	adjusted_num_pval	0.987
10.2217/imt-2020-0266	results	4	NA	adjusted_significant	FALSE
10.2217/imt-2020-0266	results	5	NA	contrast	HR
10.2217/imt-2020-0266	results	5	NA	direction_benefit	inferior
10.2217/imt-2020-0266	results	5	NA	n_nonipd_ttt	240
10.2217/imt-2020-0266	results	5	NA	n_ipd_ttt	543
10.2217/imt-2020-0266	results	5	NA	ess_ttt	416
10.2217/imt-2020-0266	results	5	NA	weights_evaluation_yn	Not mentioned
10.2217/imt-2020-0266	results	5	NA	list_covariates_yn	Yes
10.2217/imt-2020-0266	results	5	NA	n_covariates	7
10.2217/imt-2020-0266	results	5	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2217/imt-2020-0266	results	5	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2020-0266	results	5	NA	unadjusted_effect	0.37
10.2217/imt-2020-0266	results	5	NA	unadjusted_pval_char	<0.001
10.2217/imt-2020-0266	results	5	NA	adjusted_effect	0.42
10.2217/imt-2020-0266	results	5	NA	adjusted_pval_char	<0.001
10.2217/imt-2020-0266	results	5	NA	geographical region	No
10.2217/imt-2020-0266	results	5	NA	n_ipd_total	NA
10.2217/imt-2020-0266	results	5	NA	ess_total	NA
10.2217/imt-2020-0266	results	5	NA	n_nonipd_total	NA
10.2217/imt-2020-0266	results	5	NA	n_nonipd_anchor	NA
10.2217/imt-2020-0266	results	5	NA	n_ipd_anchor	NA
10.2217/imt-2020-0266	results	5	NA	ess_anchor	NA
10.2217/imt-2020-0266	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/imt-2020-0266	results	5	NA	effect_cutoff	1
10.2217/imt-2020-0266	results	5	NA	unadjusted_pval	<0.001
10.2217/imt-2020-0266	results	5	NA	unadjusted_significant	TRUE
10.2217/imt-2020-0266	results	5	NA	adjusted_pval	<0.001
10.2217/imt-2020-0266	results	5	NA	adjusted_significant	TRUE
10.2217/imt-2020-0266	results	6	NA	contrast	HR
10.2217/imt-2020-0266	results	6	NA	direction_benefit	inferior
10.2217/imt-2020-0266	results	6	NA	n_nonipd_ttt	240
10.2217/imt-2020-0266	results	6	NA	n_ipd_ttt	542
10.2217/imt-2020-0266	results	6	NA	ess_ttt	393
10.2217/imt-2020-0266	results	6	NA	weights_evaluation_yn	Not mentioned
10.2217/imt-2020-0266	results	6	NA	list_covariates_yn	Yes
10.2217/imt-2020-0266	results	6	NA	n_covariates	7
10.2217/imt-2020-0266	results	6	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2217/imt-2020-0266	results	6	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2020-0266	results	6	NA	unadjusted_effect	0.82
10.2217/imt-2020-0266	results	6	NA	unadjusted_pval_char	0.222
10.2217/imt-2020-0266	results	6	NA	adjusted_effect	0.94
10.2217/imt-2020-0266	results	6	NA	adjusted_pval_char	0.738
10.2217/imt-2020-0266	results	6	NA	geographical region	No
10.2217/imt-2020-0266	results	6	NA	n_ipd_total	NA
10.2217/imt-2020-0266	results	6	NA	ess_total	NA
10.2217/imt-2020-0266	results	6	NA	n_nonipd_total	NA
10.2217/imt-2020-0266	results	6	NA	n_nonipd_anchor	NA
10.2217/imt-2020-0266	results	6	NA	n_ipd_anchor	NA
10.2217/imt-2020-0266	results	6	NA	ess_anchor	NA
10.2217/imt-2020-0266	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/imt-2020-0266	results	6	NA	effect_cutoff	1
10.2217/imt-2020-0266	results	6	NA	unadjusted_pval	0.222
10.2217/imt-2020-0266	results	6	NA	unadjusted_num_pval	0.222
10.2217/imt-2020-0266	results	6	NA	unadjusted_significant	FALSE
10.2217/imt-2020-0266	results	6	NA	adjusted_pval	0.738
10.2217/imt-2020-0266	results	6	NA	adjusted_num_pval	0.738
10.2217/imt-2020-0266	results	6	NA	adjusted_significant	FALSE
10.2217/imt-2020-0266	study_information	NA	1	Patient-level data used	Yes
10.2217/imt-2020-0266	study_information	NA	1	Clinical Trial	Yes
10.2217/imt-2020-0266	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02541383
10.2217/imt-2020-0266	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2020-0266	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2020-0266	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2020-0266	study_information	NA	2	Patient-level data used	No
10.2217/imt-2020-0266	study_information	NA	2	Clinical Trial	Yes
10.2217/imt-2020-0266	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01191060
10.2217/imt-2020-0266	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.2217/imt-2020-0266	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2020-0266	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2020-0266	study_information	NA	3	Patient-level data used	No
10.2217/imt-2020-0266	study_information	NA	3	Clinical Trial	Yes
10.2217/imt-2020-0266	study_information	NA	3	EudraCT (only for clinical trials registered on clinicaltrialsregister.eu	2010-019173-16
10.2217/imt-2020-0266	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	germany
10.2217/imt-2020-0266	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2020-0266	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2020-0266	study_information	NA	4	Patient-level data used	No
10.2217/imt-2020-0266	study_information	NA	4	Clinical Trial	Yes
10.2217/imt-2020-0266	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00200681
10.2217/imt-2020-0266	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.2217/imt-2020-0266	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2020-0266	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2021-0273	general_information	NA	NA	Medical Condition of Interest Name	metastatic non-small-cell lung cancer with pd-l1
10.2217/imt-2021-0273	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/imt-2021-0273	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/imt-2021-0273	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/imt-2021-0273	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/imt-2021-0273	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/imt-2021-0273	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/imt-2021-0273	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/imt-2021-0273	methodology	1	NA	primary_outcome_name	overall survival
10.2217/imt-2021-0273	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/imt-2021-0273	methodology	1	NA	primary_outcome_type	Time-to-event
10.2217/imt-2021-0273	methodology	1	NA	Treatment name 1	pembrolizumab
10.2217/imt-2021-0273	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2217/imt-2021-0273	methodology	1	NA	Treatment name 2	nivolumab + ipilimumab
10.2217/imt-2021-0273	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.2217/imt-2021-0273	methodology	1	NA	paitc_type	MAIC
10.2217/imt-2021-0273	methodology	1	NA	anchored_yn	Yes
10.2217/imt-2021-0273	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/imt-2021-0273	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2021-0273	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/imt-2021-0273	methodology	1	NA	prognostic_factors_yn	No
10.2217/imt-2021-0273	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.2217/imt-2021-0273	methodology	1	NA	weights_model_yn	No
10.2217/imt-2021-0273	methodology	1	NA	scale_choice_yn	No
10.2217/imt-2021-0273	results	1	NA	contrast	HR
10.2217/imt-2021-0273	results	1	NA	direction_benefit	inferior
10.2217/imt-2021-0273	results	1	NA	n_nonipd_ttt	793
10.2217/imt-2021-0273	results	1	NA	n_ipd_ttt	1428
10.2217/imt-2021-0273	results	1	NA	ess_ttt	993
10.2217/imt-2021-0273	results	1	NA	weights_evaluation_yn	Not mentioned
10.2217/imt-2021-0273	results	1	NA	list_covariates_yn	Yes
10.2217/imt-2021-0273	results	1	NA	n_covariates	8
10.2217/imt-2021-0273	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.2217/imt-2021-0273	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2021-0273	results	1	NA	unadjusted_effect	0.98
10.2217/imt-2021-0273	results	1	NA	unadjusted_pval_char	NA
10.2217/imt-2021-0273	results	1	NA	adjusted_effect	1.07
10.2217/imt-2021-0273	results	1	NA	adjusted_pval_char	[0.82;1.39]
10.2217/imt-2021-0273	results	1	NA	geographical region	Yes
10.2217/imt-2021-0273	results	1	NA	n_ipd_total	1428
10.2217/imt-2021-0273	results	1	NA	ess_total	993
10.2217/imt-2021-0273	results	1	NA	n_nonipd_total	793
10.2217/imt-2021-0273	results	1	NA	n_nonipd_anchor	NA
10.2217/imt-2021-0273	results	1	NA	n_ipd_anchor	NA
10.2217/imt-2021-0273	results	1	NA	ess_anchor	NA
10.2217/imt-2021-0273	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.2217/imt-2021-0273	results	1	NA	effect_cutoff	1
10.2217/imt-2021-0273	results	1	NA	adjusted_lb_ci	0.82
10.2217/imt-2021-0273	results	1	NA	adjusted_ub_ci	1.39
10.2217/imt-2021-0273	results	1	NA	adjusted_significant	FALSE
10.2217/imt-2021-0273	study_information	NA	1	Patient-level data used	Yes
10.2217/imt-2021-0273	study_information	NA	1	Clinical Trial	Yes
10.2217/imt-2021-0273	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02142738
10.2217/imt-2021-0273	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2021-0273	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2021-0273	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2021-0273	study_information	NA	2	Patient-level data used	Yes
10.2217/imt-2021-0273	study_information	NA	2	Clinical Trial	Yes
10.2217/imt-2021-0273	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02220894
10.2217/imt-2021-0273	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2021-0273	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2021-0273	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2021-0273	study_information	NA	3	Patient-level data used	No
10.2217/imt-2021-0273	study_information	NA	3	Clinical Trial	Yes
10.2217/imt-2021-0273	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02477826
10.2217/imt-2021-0273	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2021-0273	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2021-0273	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.3111/13696998.2013.768530	general_information	NA	NA	Medical Condition of Interest Name	psoriatic arthritis
10.3111/13696998.2013.768530	general_information	NA	NA	Countries of first author affiliations	usa
10.3111/13696998.2013.768530	general_information	NA	NA	Countries of last author affiliations	usa
10.3111/13696998.2013.768530	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.3111/13696998.2013.768530	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.3111/13696998.2013.768530	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.3111/13696998.2013.768530	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.3111/13696998.2013.768530	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.3111/13696998.2013.768530	methodology	1	NA	primary_outcome_name	proportion of patients who achieved acr70 at week 12
10.3111/13696998.2013.768530	methodology	1	NA	outcome_short_name	ACR Response Rate
10.3111/13696998.2013.768530	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.3111/13696998.2013.768530	methodology	1	NA	Treatment name 1	adalimumab
10.3111/13696998.2013.768530	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.3111/13696998.2013.768530	methodology	1	NA	Treatment name 2	etanercept
10.3111/13696998.2013.768530	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.3111/13696998.2013.768530	methodology	1	NA	paitc_type	MAIC
10.3111/13696998.2013.768530	methodology	1	NA	anchored_yn	Yes
10.3111/13696998.2013.768530	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.3111/13696998.2013.768530	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.3111/13696998.2013.768530	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.3111/13696998.2013.768530	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.3111/13696998.2013.768530	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.3111/13696998.2013.768530	methodology	1	NA	weights_model_yn	No
10.3111/13696998.2013.768530	methodology	1	NA	scale_choice_yn	No
10.3111/13696998.2013.768530	methodology	2	NA	primary_outcome_name	proportion of patients who achieved acr70 at week 14
10.3111/13696998.2013.768530	methodology	2	NA	outcome_short_name	ACR Response Rate
10.3111/13696998.2013.768530	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.3111/13696998.2013.768530	methodology	2	NA	Treatment name 1	adalimumab
10.3111/13696998.2013.768530	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.3111/13696998.2013.768530	methodology	2	NA	Treatment name 2	infliximab
10.3111/13696998.2013.768530	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.3111/13696998.2013.768530	methodology	2	NA	paitc_type	MAIC
10.3111/13696998.2013.768530	methodology	2	NA	anchored_yn	Yes
10.3111/13696998.2013.768530	methodology	2	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.3111/13696998.2013.768530	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.3111/13696998.2013.768530	methodology	2	NA	variables_justification	Nothing mentioned, not reported
10.3111/13696998.2013.768530	methodology	2	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.3111/13696998.2013.768530	methodology	2	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.3111/13696998.2013.768530	methodology	2	NA	weights_model_yn	No
10.3111/13696998.2013.768530	methodology	2	NA	scale_choice_yn	No
10.3111/13696998.2013.768530	results	1	NA	contrast	Proportion difference
10.3111/13696998.2013.768530	results	1	NA	direction_benefit	superior
10.3111/13696998.2013.768530	results	1	NA	n_nonipd_ttt	101
10.3111/13696998.2013.768530	results	1	NA	n_ipd_ttt	142
10.3111/13696998.2013.768530	results	1	NA	ess_ttt	NA
10.3111/13696998.2013.768530	results	1	NA	weights_evaluation_yn	Not mentioned
10.3111/13696998.2013.768530	results	1	NA	list_covariates_yn	Yes
10.3111/13696998.2013.768530	results	1	NA	n_covariates	12
10.3111/13696998.2013.768530	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.3111/13696998.2013.768530	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.3111/13696998.2013.768530	results	1	NA	unadjusted_effect	NA
10.3111/13696998.2013.768530	results	1	NA	unadjusted_pval_char	NA
10.3111/13696998.2013.768530	results	1	NA	adjusted_effect	9.7
10.3111/13696998.2013.768530	results	1	NA	adjusted_pval_char	0.055
10.3111/13696998.2013.768530	results	1	NA	geographical region	NA
10.3111/13696998.2013.768530	results	1	NA	n_ipd_total	NA
10.3111/13696998.2013.768530	results	1	NA	ess_total	NA
10.3111/13696998.2013.768530	results	1	NA	n_nonipd_total	NA
10.3111/13696998.2013.768530	results	1	NA	n_nonipd_anchor	104
10.3111/13696998.2013.768530	results	1	NA	n_ipd_anchor	154
10.3111/13696998.2013.768530	results	1	NA	ess_anchor	NA
10.3111/13696998.2013.768530	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.3111/13696998.2013.768530	results	1	NA	effect_cutoff	0
10.3111/13696998.2013.768530	results	1	NA	adjusted_pval	0.055
10.3111/13696998.2013.768530	results	1	NA	adjusted_num_pval	0.055
10.3111/13696998.2013.768530	results	1	NA	adjusted_significant	FALSE
10.3111/13696998.2013.768530	results	2	NA	contrast	Proportion difference
10.3111/13696998.2013.768530	results	2	NA	direction_benefit	superior
10.3111/13696998.2013.768530	results	2	NA	n_nonipd_ttt	100
10.3111/13696998.2013.768530	results	2	NA	n_ipd_ttt	108
10.3111/13696998.2013.768530	results	2	NA	ess_ttt	NA
10.3111/13696998.2013.768530	results	2	NA	weights_evaluation_yn	Not mentioned
10.3111/13696998.2013.768530	results	2	NA	list_covariates_yn	Yes
10.3111/13696998.2013.768530	results	2	NA	n_covariates	17
10.3111/13696998.2013.768530	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.3111/13696998.2013.768530	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.3111/13696998.2013.768530	results	2	NA	unadjusted_effect	NA
10.3111/13696998.2013.768530	results	2	NA	unadjusted_pval_char	NA
10.3111/13696998.2013.768530	results	2	NA	adjusted_effect	18.9
10.3111/13696998.2013.768530	results	2	NA	adjusted_pval_char	0.034
10.3111/13696998.2013.768530	results	2	NA	geographical region	NA
10.3111/13696998.2013.768530	results	2	NA	n_ipd_total	NA
10.3111/13696998.2013.768530	results	2	NA	ess_total	NA
10.3111/13696998.2013.768530	results	2	NA	n_nonipd_total	NA
10.3111/13696998.2013.768530	results	2	NA	n_nonipd_anchor	100
10.3111/13696998.2013.768530	results	2	NA	n_ipd_anchor	126
10.3111/13696998.2013.768530	results	2	NA	ess_anchor	NA
10.3111/13696998.2013.768530	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.3111/13696998.2013.768530	results	2	NA	effect_cutoff	0
10.3111/13696998.2013.768530	results	2	NA	adjusted_pval	0.034
10.3111/13696998.2013.768530	results	2	NA	adjusted_num_pval	0.034
10.3111/13696998.2013.768530	results	2	NA	adjusted_significant	TRUE
10.3111/13696998.2013.768530	study_information	NA	1	Patient-level data used	Yes
10.3111/13696998.2013.768530	study_information	NA	1	Clinical Trial	Yes
10.3111/13696998.2013.768530	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00195689
10.3111/13696998.2013.768530	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.3111/13696998.2013.768530	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.3111/13696998.2013.768530	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.3111/13696998.2013.768530	study_information	NA	2	Patient-level data used	No
10.3111/13696998.2013.768530	study_information	NA	2	Clinical Trial	Yes
10.3111/13696998.2013.768530	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	mease et al. (2004)
10.3111/13696998.2013.768530	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.3111/13696998.2013.768530	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.3111/13696998.2013.768530	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.3111/13696998.2013.768530	study_information	NA	3	Patient-level data used	No
10.3111/13696998.2013.768530	study_information	NA	3	Clinical Trial	Yes
10.3111/13696998.2013.768530	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.3111/13696998.2013.768530	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.3111/13696998.2013.768530	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.3111/13696998.2013.768530	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00051623
10.3390/biom11060780	general_information	NA	NA	Medical Condition of Interest Name	metastatic pancreatic cancer
10.3390/biom11060780	general_information	NA	NA	Countries of first author affiliations	italy
10.3390/biom11060780	general_information	NA	NA	Countries of last author affiliations	italy
10.3390/biom11060780	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic
10.3390/biom11060780	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.3390/biom11060780	general_information	NA	NA	Mentioned sources of funding	No fundings
10.3390/biom11060780	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	None
10.3390/biom11060780	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.3390/biom11060780	methodology	1	NA	primary_outcome_name	overall survival (os)
10.3390/biom11060780	methodology	1	NA	outcome_short_name	Overall Survival
10.3390/biom11060780	methodology	1	NA	primary_outcome_type	Time-to-event
10.3390/biom11060780	methodology	1	NA	Treatment name 1	gemcitabine + nab-paclitaxel
10.3390/biom11060780	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.3390/biom11060780	methodology	1	NA	Treatment name 2	folfirinox
10.3390/biom11060780	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.3390/biom11060780	methodology	1	NA	paitc_type	MAIC
10.3390/biom11060780	methodology	1	NA	anchored_yn	No
10.3390/biom11060780	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.3390/biom11060780	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.3390/biom11060780	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.3390/biom11060780	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.3390/biom11060780	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.3390/biom11060780	methodology	1	NA	weights_model_yn	No
10.3390/biom11060780	methodology	1	NA	scale_choice_yn	No
10.3390/biom11060780	results	1	NA	contrast	HR
10.3390/biom11060780	results	1	NA	direction_benefit	inferior
10.3390/biom11060780	results	1	NA	n_nonipd_ttt	171
10.3390/biom11060780	results	1	NA	n_ipd_ttt	268
10.3390/biom11060780	results	1	NA	ess_ttt	NA
10.3390/biom11060780	results	1	NA	weights_evaluation_yn	Not mentioned
10.3390/biom11060780	results	1	NA	list_covariates_yn	Yes
10.3390/biom11060780	results	1	NA	n_covariates	NA
10.3390/biom11060780	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.3390/biom11060780	results	1	NA	effect_direction	Denominator if ratio, or rightside if difference
10.3390/biom11060780	results	1	NA	unadjusted_effect	NA
10.3390/biom11060780	results	1	NA	unadjusted_pval_char	NA
10.3390/biom11060780	results	1	NA	adjusted_effect	1.1
10.3390/biom11060780	results	1	NA	adjusted_pval_char	0.527
10.3390/biom11060780	results	1	NA	geographical region	NA
10.3390/biom11060780	results	1	NA	n_ipd_total	NA
10.3390/biom11060780	results	1	NA	ess_total	NA
10.3390/biom11060780	results	1	NA	n_nonipd_total	NA
10.3390/biom11060780	results	1	NA	n_nonipd_anchor	NA
10.3390/biom11060780	results	1	NA	n_ipd_anchor	NA
10.3390/biom11060780	results	1	NA	ess_anchor	NA
10.3390/biom11060780	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.3390/biom11060780	results	1	NA	effect_cutoff	1
10.3390/biom11060780	results	1	NA	adjusted_pval	0.527
10.3390/biom11060780	results	1	NA	adjusted_num_pval	0.527
10.3390/biom11060780	results	1	NA	adjusted_significant	FALSE
10.3390/biom11060780	study_information	NA	1	Patient-level data used	Yes
10.3390/biom11060780	study_information	NA	1	Clinical Trial	No
10.3390/biom11060780	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	local retrospective cohort from ehr
10.3390/biom11060780	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.3390/biom11060780	study_information	NA	2	Patient-level data used	No
10.3390/biom11060780	study_information	NA	2	Clinical Trial	Yes
10.3390/biom11060780	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00112658
10.3390/biom11060780	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.3390/biom11060780	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3
10.3390/biom11060780	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.3390/cancers12123648	general_information	NA	NA	Medical Condition of Interest Name	metastatic non small cell lung cancer
10.3390/cancers12123648	general_information	NA	NA	Countries of first author affiliations	usa
10.3390/cancers12123648	general_information	NA	NA	Countries of last author affiliations	usa
10.3390/cancers12123648	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.3390/cancers12123648	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.3390/cancers12123648	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.3390/cancers12123648	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.3390/cancers12123648	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.3390/cancers12123648	methodology	1	NA	primary_outcome_name	overall survival
10.3390/cancers12123648	methodology	1	NA	outcome_short_name	Overall Survival
10.3390/cancers12123648	methodology	1	NA	primary_outcome_type	Time-to-event
10.3390/cancers12123648	methodology	1	NA	Treatment name 1	pembrolizumab + chemotherapy
10.3390/cancers12123648	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3
10.3390/cancers12123648	methodology	1	NA	Treatment name 2	nivolumab + ipilimumab
10.3390/cancers12123648	methodology	1	NA	Study 'number(s)' for treatment 2	4
10.3390/cancers12123648	methodology	1	NA	paitc_type	MAIC
10.3390/cancers12123648	methodology	1	NA	anchored_yn	Yes
10.3390/cancers12123648	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.3390/cancers12123648	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.3390/cancers12123648	methodology	1	NA	variables_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.3390/cancers12123648	methodology	1	NA	prognostic_factors_yn	No
10.3390/cancers12123648	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.3390/cancers12123648	methodology	1	NA	weights_model_yn	No
10.3390/cancers12123648	methodology	1	NA	scale_choice_yn	No
10.3390/cancers12123648	results	1	NA	contrast	HR
10.3390/cancers12123648	results	1	NA	direction_benefit	inferior
10.3390/cancers12123648	results	1	NA	n_nonipd_ttt	NA
10.3390/cancers12123648	results	1	NA	n_ipd_ttt	NA
10.3390/cancers12123648	results	1	NA	ess_ttt	NA
10.3390/cancers12123648	results	1	NA	weights_evaluation_yn	Not mentioned
10.3390/cancers12123648	results	1	NA	list_covariates_yn	Yes
10.3390/cancers12123648	results	1	NA	n_covariates	8
10.3390/cancers12123648	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.3390/cancers12123648	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.3390/cancers12123648	results	1	NA	unadjusted_effect	0.84
10.3390/cancers12123648	results	1	NA	unadjusted_pval_char	0.218
10.3390/cancers12123648	results	1	NA	adjusted_effect	0.8
10.3390/cancers12123648	results	1	NA	adjusted_pval_char	0.152
10.3390/cancers12123648	results	1	NA	geographical region	Yes
10.3390/cancers12123648	results	1	NA	n_ipd_total	816
10.3390/cancers12123648	results	1	NA	ess_total	456
10.3390/cancers12123648	results	1	NA	n_nonipd_total	793
10.3390/cancers12123648	results	1	NA	n_nonipd_anchor	NA
10.3390/cancers12123648	results	1	NA	n_ipd_anchor	NA
10.3390/cancers12123648	results	1	NA	ess_anchor	NA
10.3390/cancers12123648	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.3390/cancers12123648	results	1	NA	effect_cutoff	1
10.3390/cancers12123648	results	1	NA	unadjusted_pval	0.218
10.3390/cancers12123648	results	1	NA	unadjusted_num_pval	0.218
10.3390/cancers12123648	results	1	NA	unadjusted_significant	FALSE
10.3390/cancers12123648	results	1	NA	adjusted_pval	0.152
10.3390/cancers12123648	results	1	NA	adjusted_num_pval	0.152
10.3390/cancers12123648	results	1	NA	adjusted_significant	FALSE
10.3390/cancers12123648	study_information	NA	1	Patient-level data used	Yes
10.3390/cancers12123648	study_information	NA	1	Clinical Trial	Yes
10.3390/cancers12123648	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02039674
10.3390/cancers12123648	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.3390/cancers12123648	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.3390/cancers12123648	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.3390/cancers12123648	study_information	NA	2	Patient-level data used	Yes
10.3390/cancers12123648	study_information	NA	2	Clinical Trial	Yes
10.3390/cancers12123648	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02578680
10.3390/cancers12123648	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.3390/cancers12123648	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.3390/cancers12123648	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.3390/cancers12123648	study_information	NA	3	Patient-level data used	Yes
10.3390/cancers12123648	study_information	NA	3	Clinical Trial	Yes
10.3390/cancers12123648	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02775435
10.3390/cancers12123648	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.3390/cancers12123648	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.3390/cancers12123648	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.3390/cancers12123648	study_information	NA	4	Patient-level data used	No
10.3390/cancers12123648	study_information	NA	4	Clinical Trial	Yes
10.3390/cancers12123648	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02477826
10.3390/cancers12123648	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.3390/cancers12123648	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.3390/cancers12123648	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.3390/cancers13102406	general_information	NA	NA	Medical Condition of Interest Name	hepatocellular carcinoma
10.3390/cancers13102406	general_information	NA	NA	Countries of first author affiliations	italy
10.3390/cancers13102406	general_information	NA	NA	Countries of last author affiliations	italy
10.3390/cancers13102406	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic
10.3390/cancers13102406	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.3390/cancers13102406	general_information	NA	NA	Mentioned sources of funding	No fundings
10.3390/cancers13102406	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	None
10.3390/cancers13102406	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.3390/cancers13102406	methodology	1	NA	primary_outcome_name	downstaging failures
10.3390/cancers13102406	methodology	1	NA	outcome_short_name	Downstaging failure
10.3390/cancers13102406	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.3390/cancers13102406	methodology	1	NA	Treatment name 1	padua surgical aggressive downstaging
10.3390/cancers13102406	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.3390/cancers13102406	methodology	1	NA	Treatment name 2	xxl protocol downstaging
10.3390/cancers13102406	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.3390/cancers13102406	methodology	1	NA	paitc_type	MAIC
10.3390/cancers13102406	methodology	1	NA	anchored_yn	No
10.3390/cancers13102406	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.3390/cancers13102406	methodology	1	NA	primary_outcome_yn	Yes
10.3390/cancers13102406	methodology	1	NA	variables_justification	Nothing mentioned, not reported
10.3390/cancers13102406	methodology	1	NA	prognostic_factors_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.3390/cancers13102406	methodology	1	NA	ttt_effect_modifiers_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.3390/cancers13102406	methodology	1	NA	weights_model_yn	No
10.3390/cancers13102406	methodology	1	NA	scale_choice_yn	No
10.3390/cancers13102406	results	1	NA	contrast	NA
10.3390/cancers13102406	results	1	NA	direction_benefit	inferior
10.3390/cancers13102406	results	1	NA	n_nonipd_ttt	74
10.3390/cancers13102406	results	1	NA	n_ipd_ttt	191
10.3390/cancers13102406	results	1	NA	ess_ttt	NA
10.3390/cancers13102406	results	1	NA	weights_evaluation_yn	Not mentioned
10.3390/cancers13102406	results	1	NA	list_covariates_yn	No
10.3390/cancers13102406	results	1	NA	n_covariates	NA
10.3390/cancers13102406	results	1	NA	list_covariates	NA
10.3390/cancers13102406	results	1	NA	effect_direction	NA
10.3390/cancers13102406	results	1	NA	unadjusted_effect	NA
10.3390/cancers13102406	results	1	NA	unadjusted_pval_char	NA
10.3390/cancers13102406	results	1	NA	adjusted_effect	NA
10.3390/cancers13102406	results	1	NA	adjusted_pval_char	NA
10.3390/cancers13102406	results	1	NA	geographical region	NA
10.3390/cancers13102406	results	1	NA	n_ipd_total	NA
10.3390/cancers13102406	results	1	NA	ess_total	NA
10.3390/cancers13102406	results	1	NA	n_nonipd_total	NA
10.3390/cancers13102406	results	1	NA	n_nonipd_anchor	NA
10.3390/cancers13102406	results	1	NA	n_ipd_anchor	NA
10.3390/cancers13102406	results	1	NA	ess_anchor	NA
10.3390/cancers13102406	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.3390/cancers13102406	results	1	NA	effect_cutoff	NA
10.3390/cancers13102406	study_information	NA	1	Patient-level data used	Yes
10.3390/cancers13102406	study_information	NA	1	Clinical Trial	No
10.3390/cancers13102406	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	retrospective cohort of patients affected by hcc who underwent surgical at the hepatobiliary surgery and liver transplantation unit, university of padua.
10.3390/cancers13102406	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.3390/cancers13102406	study_information	NA	2	Patient-level data used	No
10.3390/cancers13102406	study_information	NA	2	Clinical Trial	Yes
10.3390/cancers13102406	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01387503
10.3390/cancers13102406	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.3390/cancers13102406	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3
10.3390/cancers13102406	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.36469/jheor.2021.19008	general_information	NA	NA	Medical Condition of Interest Name	steroid-refractory acute graft-versus-host disease
10.36469/jheor.2021.19008	general_information	NA	NA	Countries of first author affiliations	usa
10.36469/jheor.2021.19008	general_information	NA	NA	Countries of last author affiliations	usa
10.36469/jheor.2021.19008	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.36469/jheor.2021.19008	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.36469/jheor.2021.19008	general_information	NA	NA	Mentioned sources of funding	None mentioned
10.36469/jheor.2021.19008	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	No such section presenting competing interest/conflict of interest
10.36469/jheor.2021.19008	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.36469/jheor.2021.19008	methodology	1	NA	primary_outcome_name	day 28 overall response rate (orr)
10.36469/jheor.2021.19008	methodology	1	NA	outcome_short_name	Overall Response Rate
10.36469/jheor.2021.19008	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.36469/jheor.2021.19008	methodology	1	NA	Treatment name 1	remestemcel-l-rknd
10.36469/jheor.2021.19008	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.36469/jheor.2021.19008	methodology	1	NA	Treatment name 2	ruxolitinib
10.36469/jheor.2021.19008	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.36469/jheor.2021.19008	methodology	1	NA	paitc_type	STC
10.36469/jheor.2021.19008	methodology	1	NA	anchored_yn	No
10.36469/jheor.2021.19008	methodology	1	NA	paitc_form	Simple (ie treatments effects extracted from two studies)
10.36469/jheor.2021.19008	methodology	1	NA	primary_outcome_yn	Yes
10.36469/jheor.2021.19008	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.36469/jheor.2021.19008	methodology	1	NA	prognostic_factors_yn	Yes
10.36469/jheor.2021.19008	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.36469/jheor.2021.19008	methodology	1	NA	weights_model_yn	No
10.36469/jheor.2021.19008	methodology	1	NA	scale_choice_yn	No
10.36469/jheor.2021.19008	results	1	NA	contrast	RR
10.36469/jheor.2021.19008	results	1	NA	direction_benefit	superior
10.36469/jheor.2021.19008	results	1	NA	n_nonipd_ttt	49
10.36469/jheor.2021.19008	results	1	NA	n_ipd_ttt	55
10.36469/jheor.2021.19008	results	1	NA	ess_ttt	55
10.36469/jheor.2021.19008	results	1	NA	weights_evaluation_yn	NA
10.36469/jheor.2021.19008	results	1	NA	list_covariates_yn	Yes
10.36469/jheor.2021.19008	results	1	NA	n_covariates	3
10.36469/jheor.2021.19008	results	1	NA	list_covariates	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.36469/jheor.2021.19008	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.36469/jheor.2021.19008	results	1	NA	unadjusted_effect	1.21
10.36469/jheor.2021.19008	results	1	NA	unadjusted_pval_char	0.21
10.36469/jheor.2021.19008	results	1	NA	adjusted_effect	1.13
10.36469/jheor.2021.19008	results	1	NA	adjusted_pval_char	0.45
10.36469/jheor.2021.19008	results	1	NA	geographical region	NA
10.36469/jheor.2021.19008	results	1	NA	n_ipd_total	NA
10.36469/jheor.2021.19008	results	1	NA	ess_total	NA
10.36469/jheor.2021.19008	results	1	NA	n_nonipd_total	NA
10.36469/jheor.2021.19008	results	1	NA	n_nonipd_anchor	NA
10.36469/jheor.2021.19008	results	1	NA	n_ipd_anchor	NA
10.36469/jheor.2021.19008	results	1	NA	ess_anchor	NA
10.36469/jheor.2021.19008	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.36469/jheor.2021.19008	results	1	NA	effect_cutoff	1
10.36469/jheor.2021.19008	results	1	NA	unadjusted_pval	0.21
10.36469/jheor.2021.19008	results	1	NA	unadjusted_num_pval	0.21
10.36469/jheor.2021.19008	results	1	NA	unadjusted_significant	FALSE
10.36469/jheor.2021.19008	results	1	NA	adjusted_pval	0.45
10.36469/jheor.2021.19008	results	1	NA	adjusted_num_pval	0.45
10.36469/jheor.2021.19008	results	1	NA	adjusted_significant	FALSE
10.36469/jheor.2021.19008	study_information	NA	1	Patient-level data used	Yes
10.36469/jheor.2021.19008	study_information	NA	1	Clinical Trial	Yes
10.36469/jheor.2021.19008	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02336230
10.36469/jheor.2021.19008	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.36469/jheor.2021.19008	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.36469/jheor.2021.19008	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.36469/jheor.2021.19008	study_information	NA	2	Patient-level data used	No
10.36469/jheor.2021.19008	study_information	NA	2	Clinical Trial	Yes
10.36469/jheor.2021.19008	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02953678
10.36469/jheor.2021.19008	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.36469/jheor.2021.19008	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.36469/jheor.2021.19008	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Medical Condition of Interest Name	ankylosing spondylitis
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Countries of first author affiliations	canada
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Countries of last author affiliations	switzerland
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.5152/eurjrheum.2018.18162	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.5152/eurjrheum.2018.18162	methodology	1	NA	primary_outcome_name	assessment of spondylarthritis international society (asas) 20 response rate at week 8
10.5152/eurjrheum.2018.18162	methodology	1	NA	outcome_short_name	ASAS 20 response rate
10.5152/eurjrheum.2018.18162	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.5152/eurjrheum.2018.18162	methodology	1	NA	Treatment name 1	secukinumab
10.5152/eurjrheum.2018.18162	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.5152/eurjrheum.2018.18162	methodology	1	NA	Treatment name 2	adalimumab
10.5152/eurjrheum.2018.18162	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.5152/eurjrheum.2018.18162	methodology	1	NA	paitc_type	MAIC
10.5152/eurjrheum.2018.18162	methodology	1	NA	anchored_yn	Yes
10.5152/eurjrheum.2018.18162	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2018.18162	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2018.18162	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2018.18162	methodology	1	NA	prognostic_factors_yn	Yes
10.5152/eurjrheum.2018.18162	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.5152/eurjrheum.2018.18162	methodology	1	NA	weights_model_yn	No
10.5152/eurjrheum.2018.18162	methodology	1	NA	scale_choice_yn	No
10.5152/eurjrheum.2018.18162	methodology	2	NA	primary_outcome_name	assessment of spondylarthritis international society (asas) 20 response rate at week 16
10.5152/eurjrheum.2018.18162	methodology	2	NA	outcome_short_name	ASAS 20 response rate
10.5152/eurjrheum.2018.18162	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.5152/eurjrheum.2018.18162	methodology	2	NA	Treatment name 1	secukinumab
10.5152/eurjrheum.2018.18162	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.5152/eurjrheum.2018.18162	methodology	2	NA	Treatment name 2	adalimumab
10.5152/eurjrheum.2018.18162	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.5152/eurjrheum.2018.18162	methodology	2	NA	paitc_type	MAIC
10.5152/eurjrheum.2018.18162	methodology	2	NA	anchored_yn	No
10.5152/eurjrheum.2018.18162	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2018.18162	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2018.18162	methodology	2	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2018.18162	methodology	2	NA	prognostic_factors_yn	Yes
10.5152/eurjrheum.2018.18162	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.5152/eurjrheum.2018.18162	methodology	2	NA	weights_model_yn	No
10.5152/eurjrheum.2018.18162	methodology	2	NA	scale_choice_yn	No
10.5152/eurjrheum.2018.18162	results	1	NA	contrast	OR
10.5152/eurjrheum.2018.18162	results	1	NA	direction_benefit	superior
10.5152/eurjrheum.2018.18162	results	1	NA	n_nonipd_ttt	208
10.5152/eurjrheum.2018.18162	results	1	NA	n_ipd_ttt	197
10.5152/eurjrheum.2018.18162	results	1	NA	ess_ttt	120
10.5152/eurjrheum.2018.18162	results	1	NA	weights_evaluation_yn	Not mentioned
10.5152/eurjrheum.2018.18162	results	1	NA	list_covariates_yn	Yes
10.5152/eurjrheum.2018.18162	results	1	NA	n_covariates	5
10.5152/eurjrheum.2018.18162	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.5152/eurjrheum.2018.18162	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2018.18162	results	1	NA	unadjusted_effect	NA
10.5152/eurjrheum.2018.18162	results	1	NA	unadjusted_pval_char	NA
10.5152/eurjrheum.2018.18162	results	1	NA	adjusted_effect	0.91
10.5152/eurjrheum.2018.18162	results	1	NA	adjusted_pval_char	0.795
10.5152/eurjrheum.2018.18162	results	1	NA	geographical region	NA
10.5152/eurjrheum.2018.18162	results	1	NA	n_ipd_total	NA
10.5152/eurjrheum.2018.18162	results	1	NA	ess_total	NA
10.5152/eurjrheum.2018.18162	results	1	NA	n_nonipd_total	NA
10.5152/eurjrheum.2018.18162	results	1	NA	n_nonipd_anchor	107
10.5152/eurjrheum.2018.18162	results	1	NA	n_ipd_anchor	196
10.5152/eurjrheum.2018.18162	results	1	NA	ess_anchor	120
10.5152/eurjrheum.2018.18162	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.5152/eurjrheum.2018.18162	results	1	NA	effect_cutoff	1
10.5152/eurjrheum.2018.18162	results	1	NA	adjusted_pval	0.795
10.5152/eurjrheum.2018.18162	results	1	NA	adjusted_num_pval	0.795
10.5152/eurjrheum.2018.18162	results	1	NA	adjusted_significant	FALSE
10.5152/eurjrheum.2018.18162	results	2	NA	contrast	OR
10.5152/eurjrheum.2018.18162	results	2	NA	direction_benefit	superior
10.5152/eurjrheum.2018.18162	results	2	NA	n_nonipd_ttt	208
10.5152/eurjrheum.2018.18162	results	2	NA	n_ipd_ttt	197
10.5152/eurjrheum.2018.18162	results	2	NA	ess_ttt	120
10.5152/eurjrheum.2018.18162	results	2	NA	weights_evaluation_yn	Not mentioned
10.5152/eurjrheum.2018.18162	results	2	NA	list_covariates_yn	Yes
10.5152/eurjrheum.2018.18162	results	2	NA	n_covariates	5
10.5152/eurjrheum.2018.18162	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.5152/eurjrheum.2018.18162	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2018.18162	results	2	NA	unadjusted_effect	NA
10.5152/eurjrheum.2018.18162	results	2	NA	unadjusted_pval_char	NA
10.5152/eurjrheum.2018.18162	results	2	NA	adjusted_effect	1.6
10.5152/eurjrheum.2018.18162	results	2	NA	adjusted_pval_char	0.047
10.5152/eurjrheum.2018.18162	results	2	NA	geographical region	NA
10.5152/eurjrheum.2018.18162	results	2	NA	n_ipd_total	NA
10.5152/eurjrheum.2018.18162	results	2	NA	ess_total	NA
10.5152/eurjrheum.2018.18162	results	2	NA	n_nonipd_total	NA
10.5152/eurjrheum.2018.18162	results	2	NA	n_nonipd_anchor	NA
10.5152/eurjrheum.2018.18162	results	2	NA	n_ipd_anchor	NA
10.5152/eurjrheum.2018.18162	results	2	NA	ess_anchor	NA
10.5152/eurjrheum.2018.18162	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.5152/eurjrheum.2018.18162	results	2	NA	effect_cutoff	1
10.5152/eurjrheum.2018.18162	results	2	NA	adjusted_pval	0.047
10.5152/eurjrheum.2018.18162	results	2	NA	adjusted_num_pval	0.047
10.5152/eurjrheum.2018.18162	results	2	NA	adjusted_significant	TRUE
10.5152/eurjrheum.2018.18162	study_information	NA	1	Patient-level data used	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	1	Clinical Trial	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01358175
10.5152/eurjrheum.2018.18162	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.5152/eurjrheum.2018.18162	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.5152/eurjrheum.2018.18162	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.5152/eurjrheum.2018.18162	study_information	NA	2	Patient-level data used	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	2	Clinical Trial	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01649375
10.5152/eurjrheum.2018.18162	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.5152/eurjrheum.2018.18162	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.5152/eurjrheum.2018.18162	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.5152/eurjrheum.2018.18162	study_information	NA	3	Patient-level data used	No
10.5152/eurjrheum.2018.18162	study_information	NA	3	Clinical Trial	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00085644
10.5152/eurjrheum.2018.18162	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.5152/eurjrheum.2018.18162	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.5152/eurjrheum.2018.18162	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Medical Condition of Interest Name	psoriatic arthritis
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Countries of first author affiliations	usa
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Countries of last author affiliations	uk
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.5152/eurjrheum.2019.19057	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.5152/eurjrheum.2019.19057	methodology	1	NA	primary_outcome_name	acr 20 (american college of rheumatology ) response rates at week 12
10.5152/eurjrheum.2019.19057	methodology	1	NA	outcome_short_name	ACR Response Rate
10.5152/eurjrheum.2019.19057	methodology	1	NA	primary_outcome_type	Binary (eg rates)
10.5152/eurjrheum.2019.19057	methodology	1	NA	Treatment name 1	secukinumab 150 mg
10.5152/eurjrheum.2019.19057	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3
10.5152/eurjrheum.2019.19057	methodology	1	NA	Treatment name 2	etanercept
10.5152/eurjrheum.2019.19057	methodology	1	NA	Study 'number(s)' for treatment 2	4
10.5152/eurjrheum.2019.19057	methodology	1	NA	paitc_type	MAIC
10.5152/eurjrheum.2019.19057	methodology	1	NA	anchored_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	1	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2019.19057	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2019.19057	methodology	1	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2019.19057	methodology	1	NA	prognostic_factors_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	1	NA	ttt_effect_modifiers_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	1	NA	weights_model_yn	No
10.5152/eurjrheum.2019.19057	methodology	1	NA	scale_choice_yn	No
10.5152/eurjrheum.2019.19057	methodology	2	NA	primary_outcome_name	acr 20 (american college of rheumatology ) response rates at week 24
10.5152/eurjrheum.2019.19057	methodology	2	NA	outcome_short_name	ACR Response Rate
10.5152/eurjrheum.2019.19057	methodology	2	NA	primary_outcome_type	Binary (eg rates)
10.5152/eurjrheum.2019.19057	methodology	2	NA	Treatment name 1	secukinumab 150 mg
10.5152/eurjrheum.2019.19057	methodology	2	NA	Study 'number(s)' for treatment 1	1;2;3
10.5152/eurjrheum.2019.19057	methodology	2	NA	Treatment name 2	etanercept
10.5152/eurjrheum.2019.19057	methodology	2	NA	Study 'number(s)' for treatment 2	4
10.5152/eurjrheum.2019.19057	methodology	2	NA	paitc_type	MAIC
10.5152/eurjrheum.2019.19057	methodology	2	NA	anchored_yn	No
10.5152/eurjrheum.2019.19057	methodology	2	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2019.19057	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2019.19057	methodology	2	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2019.19057	methodology	2	NA	prognostic_factors_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	2	NA	ttt_effect_modifiers_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	2	NA	weights_model_yn	No
10.5152/eurjrheum.2019.19057	methodology	2	NA	scale_choice_yn	No
10.5152/eurjrheum.2019.19057	methodology	3	NA	primary_outcome_name	acr 20 (american college of rheumatology ) response rates at week 12
10.5152/eurjrheum.2019.19057	methodology	3	NA	outcome_short_name	ACR Response Rate
10.5152/eurjrheum.2019.19057	methodology	3	NA	primary_outcome_type	Binary (eg rates)
10.5152/eurjrheum.2019.19057	methodology	3	NA	Treatment name 1	secukinumab 300mg
10.5152/eurjrheum.2019.19057	methodology	3	NA	Study 'number(s)' for treatment 1	1;2;3
10.5152/eurjrheum.2019.19057	methodology	3	NA	Treatment name 2	etanercept
10.5152/eurjrheum.2019.19057	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.5152/eurjrheum.2019.19057	methodology	3	NA	paitc_type	MAIC
10.5152/eurjrheum.2019.19057	methodology	3	NA	anchored_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	3	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2019.19057	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2019.19057	methodology	3	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2019.19057	methodology	3	NA	prognostic_factors_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	3	NA	ttt_effect_modifiers_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	3	NA	weights_model_yn	No
10.5152/eurjrheum.2019.19057	methodology	3	NA	scale_choice_yn	No
10.5152/eurjrheum.2019.19057	methodology	4	NA	primary_outcome_name	acr 20 (american college of rheumatology ) response rates at week 24
10.5152/eurjrheum.2019.19057	methodology	4	NA	outcome_short_name	ACR Response Rate
10.5152/eurjrheum.2019.19057	methodology	4	NA	primary_outcome_type	Binary (eg rates)
10.5152/eurjrheum.2019.19057	methodology	4	NA	Treatment name 1	secukinumab 300mg
10.5152/eurjrheum.2019.19057	methodology	4	NA	Study 'number(s)' for treatment 1	1;2;3
10.5152/eurjrheum.2019.19057	methodology	4	NA	Treatment name 2	etanercept
10.5152/eurjrheum.2019.19057	methodology	4	NA	Study 'number(s)' for treatment 2	4
10.5152/eurjrheum.2019.19057	methodology	4	NA	paitc_type	MAIC
10.5152/eurjrheum.2019.19057	methodology	4	NA	anchored_yn	No
10.5152/eurjrheum.2019.19057	methodology	4	NA	paitc_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2019.19057	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2019.19057	methodology	4	NA	variables_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2019.19057	methodology	4	NA	prognostic_factors_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	4	NA	ttt_effect_modifiers_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	4	NA	weights_model_yn	No
10.5152/eurjrheum.2019.19057	methodology	4	NA	scale_choice_yn	No
10.5152/eurjrheum.2019.19057	results	1	NA	contrast	OR
10.5152/eurjrheum.2019.19057	results	1	NA	direction_benefit	superior
10.5152/eurjrheum.2019.19057	results	1	NA	n_nonipd_ttt	101
10.5152/eurjrheum.2019.19057	results	1	NA	n_ipd_ttt	458
10.5152/eurjrheum.2019.19057	results	1	NA	ess_ttt	104
10.5152/eurjrheum.2019.19057	results	1	NA	weights_evaluation_yn	Not mentioned
10.5152/eurjrheum.2019.19057	results	1	NA	list_covariates_yn	Yes
10.5152/eurjrheum.2019.19057	results	1	NA	n_covariates	11
10.5152/eurjrheum.2019.19057	results	1	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.5152/eurjrheum.2019.19057	results	1	NA	effect_direction	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2019.19057	results	1	NA	unadjusted_effect	NA
10.5152/eurjrheum.2019.19057	results	1	NA	unadjusted_pval_char	NA
10.5152/eurjrheum.2019.19057	results	1	NA	adjusted_effect	0.57
10.5152/eurjrheum.2019.19057	results	1	NA	adjusted_pval_char	0.186
10.5152/eurjrheum.2019.19057	results	1	NA	geographical region	Yes
10.5152/eurjrheum.2019.19057	results	1	NA	n_ipd_total	NA
10.5152/eurjrheum.2019.19057	results	1	NA	ess_total	NA
10.5152/eurjrheum.2019.19057	results	1	NA	n_nonipd_total	NA
10.5152/eurjrheum.2019.19057	results	1	NA	n_nonipd_anchor	104
10.5152/eurjrheum.2019.19057	results	1	NA	n_ipd_anchor	567
10.5152/eurjrheum.2019.19057	results	1	NA	ess_anchor	159
10.5152/eurjrheum.2019.19057	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.5152/eurjrheum.2019.19057	results	1	NA	effect_cutoff	1
10.5152/eurjrheum.2019.19057	results	1	NA	adjusted_pval	0.186
10.5152/eurjrheum.2019.19057	results	1	NA	adjusted_num_pval	0.186
10.5152/eurjrheum.2019.19057	results	1	NA	adjusted_significant	FALSE
10.5152/eurjrheum.2019.19057	results	2	NA	contrast	OR
10.5152/eurjrheum.2019.19057	results	2	NA	direction_benefit	superior
10.5152/eurjrheum.2019.19057	results	2	NA	n_nonipd_ttt	101
10.5152/eurjrheum.2019.19057	results	2	NA	n_ipd_ttt	458
10.5152/eurjrheum.2019.19057	results	2	NA	ess_ttt	104
10.5152/eurjrheum.2019.19057	results	2	NA	weights_evaluation_yn	Not mentioned
10.5152/eurjrheum.2019.19057	results	2	NA	list_covariates_yn	Yes
10.5152/eurjrheum.2019.19057	results	2	NA	n_covariates	11
10.5152/eurjrheum.2019.19057	results	2	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.5152/eurjrheum.2019.19057	results	2	NA	effect_direction	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2019.19057	results	2	NA	unadjusted_effect	NA
10.5152/eurjrheum.2019.19057	results	2	NA	unadjusted_pval_char	NA
10.5152/eurjrheum.2019.19057	results	2	NA	adjusted_effect	1.47
10.5152/eurjrheum.2019.19057	results	2	NA	adjusted_pval_char	0.173
10.5152/eurjrheum.2019.19057	results	2	NA	geographical region	Yes
10.5152/eurjrheum.2019.19057	results	2	NA	n_ipd_total	NA
10.5152/eurjrheum.2019.19057	results	2	NA	ess_total	NA
10.5152/eurjrheum.2019.19057	results	2	NA	n_nonipd_total	NA
10.5152/eurjrheum.2019.19057	results	2	NA	n_nonipd_anchor	NA
10.5152/eurjrheum.2019.19057	results	2	NA	n_ipd_anchor	NA
10.5152/eurjrheum.2019.19057	results	2	NA	ess_anchor	NA
10.5152/eurjrheum.2019.19057	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.5152/eurjrheum.2019.19057	results	2	NA	effect_cutoff	1
10.5152/eurjrheum.2019.19057	results	2	NA	adjusted_pval	0.173
10.5152/eurjrheum.2019.19057	results	2	NA	adjusted_num_pval	0.173
10.5152/eurjrheum.2019.19057	results	2	NA	adjusted_significant	FALSE
10.5152/eurjrheum.2019.19057	results	3	NA	contrast	OR
10.5152/eurjrheum.2019.19057	results	3	NA	direction_benefit	superior
10.5152/eurjrheum.2019.19057	results	3	NA	n_nonipd_ttt	101
10.5152/eurjrheum.2019.19057	results	3	NA	n_ipd_ttt	461
10.5152/eurjrheum.2019.19057	results	3	NA	ess_ttt	75
10.5152/eurjrheum.2019.19057	results	3	NA	weights_evaluation_yn	Not mentioned
10.5152/eurjrheum.2019.19057	results	3	NA	list_covariates_yn	Yes
10.5152/eurjrheum.2019.19057	results	3	NA	n_covariates	11
10.5152/eurjrheum.2019.19057	results	3	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.5152/eurjrheum.2019.19057	results	3	NA	effect_direction	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2019.19057	results	3	NA	unadjusted_effect	NA
10.5152/eurjrheum.2019.19057	results	3	NA	unadjusted_pval_char	NA
10.5152/eurjrheum.2019.19057	results	3	NA	adjusted_effect	0.86
10.5152/eurjrheum.2019.19057	results	3	NA	adjusted_pval_char	0.722
10.5152/eurjrheum.2019.19057	results	3	NA	geographical region	Yes
10.5152/eurjrheum.2019.19057	results	3	NA	n_ipd_total	NA
10.5152/eurjrheum.2019.19057	results	3	NA	ess_total	NA
10.5152/eurjrheum.2019.19057	results	3	NA	n_nonipd_total	NA
10.5152/eurjrheum.2019.19057	results	3	NA	n_nonipd_anchor	104
10.5152/eurjrheum.2019.19057	results	3	NA	n_ipd_anchor	567
10.5152/eurjrheum.2019.19057	results	3	NA	ess_anchor	159
10.5152/eurjrheum.2019.19057	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.5152/eurjrheum.2019.19057	results	3	NA	effect_cutoff	1
10.5152/eurjrheum.2019.19057	results	3	NA	adjusted_pval	0.722
10.5152/eurjrheum.2019.19057	results	3	NA	adjusted_num_pval	0.722
10.5152/eurjrheum.2019.19057	results	3	NA	adjusted_significant	FALSE
10.5152/eurjrheum.2019.19057	results	4	NA	contrast	OR
10.5152/eurjrheum.2019.19057	results	4	NA	direction_benefit	superior
10.5152/eurjrheum.2019.19057	results	4	NA	n_nonipd_ttt	101
10.5152/eurjrheum.2019.19057	results	4	NA	n_ipd_ttt	461
10.5152/eurjrheum.2019.19057	results	4	NA	ess_ttt	75
10.5152/eurjrheum.2019.19057	results	4	NA	weights_evaluation_yn	Not mentioned
10.5152/eurjrheum.2019.19057	results	4	NA	list_covariates_yn	Yes
10.5152/eurjrheum.2019.19057	results	4	NA	n_covariates	11
10.5152/eurjrheum.2019.19057	results	4	NA	list_covariates	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.5152/eurjrheum.2019.19057	results	4	NA	effect_direction	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2019.19057	results	4	NA	unadjusted_effect	NA
10.5152/eurjrheum.2019.19057	results	4	NA	unadjusted_pval_char	NA
10.5152/eurjrheum.2019.19057	results	4	NA	adjusted_effect	3.28
10.5152/eurjrheum.2019.19057	results	4	NA	adjusted_pval_char	<0.001
10.5152/eurjrheum.2019.19057	results	4	NA	geographical region	Yes
10.5152/eurjrheum.2019.19057	results	4	NA	n_ipd_total	NA
10.5152/eurjrheum.2019.19057	results	4	NA	ess_total	NA
10.5152/eurjrheum.2019.19057	results	4	NA	n_nonipd_total	NA
10.5152/eurjrheum.2019.19057	results	4	NA	n_nonipd_anchor	NA
10.5152/eurjrheum.2019.19057	results	4	NA	n_ipd_anchor	NA
10.5152/eurjrheum.2019.19057	results	4	NA	ess_anchor	NA
10.5152/eurjrheum.2019.19057	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	NA
10.5152/eurjrheum.2019.19057	results	4	NA	effect_cutoff	1
10.5152/eurjrheum.2019.19057	results	4	NA	adjusted_pval	<0.001
10.5152/eurjrheum.2019.19057	results	4	NA	adjusted_significant	TRUE
10.5152/eurjrheum.2019.19057	study_information	NA	1	Patient-level data used	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	1	Clinical Trial	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01752634
10.5152/eurjrheum.2019.19057	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.5152/eurjrheum.2019.19057	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.5152/eurjrheum.2019.19057	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.5152/eurjrheum.2019.19057	study_information	NA	2	Patient-level data used	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	2	Clinical Trial	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01989468
10.5152/eurjrheum.2019.19057	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.5152/eurjrheum.2019.19057	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.5152/eurjrheum.2019.19057	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.5152/eurjrheum.2019.19057	study_information	NA	3	Patient-level data used	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	3	Clinical Trial	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02404350
10.5152/eurjrheum.2019.19057	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.5152/eurjrheum.2019.19057	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.5152/eurjrheum.2019.19057	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.5152/eurjrheum.2019.19057	study_information	NA	4	Patient-level data used	No
10.5152/eurjrheum.2019.19057	study_information	NA	4	Clinical Trial	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00317499
10.5152/eurjrheum.2019.19057	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.5152/eurjrheum.2019.19057	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.5152/eurjrheum.2019.19057	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
